CED Clinic: Personalized Cannabis Medicine
At CED Clinic, we’re redefining care. Step into a welcoming, professional space where the leading experts in medical cannabis are here to guide and support you!
Our Services
Our Mission
Questions? ? Contact Us Here
Our Team
Erin Caplan, NP is a board-certified Pediatric Nurse Practitioner with a master’s-level medical education from Simmons. Her extensive clinical journey has been enriched through roles at Massachusetts General Hospital, Hyde Park Pediatrics, Atrius Healthcare, and Dana-Farber Cancer Institute, where she has provided both inpatient and outpatient primary care to some of the most fragile and challenging pediatric patients. A registered cannabis care provider licensed by the Massachusetts Cannabis Control Commission, Erin seamlessly blends her pediatric expertise with the nuance and adaptability required for personalized cannabis care. A community leader, avid athlete, and dedicated mother of four, Erin’s compassionate bedside manner and steadfast commitment to evidence-based practice have earned her the trust and appreciation of patients and families, showcasing her as a harmonious blend of clinical excellence with a personal touch.
Benjamin Caplan, MD, stands at the forefront of medical cannabis care as the Founder and Chief Medical Officer of CED Clinic and CED Foundation. His entrepreneurial journey further extends as the Founder of multiple medical cannabis technology and educational platforms and as a medical advisor to the prestigious cannabis investment fund, GreenAXS Capital. Within digital healthcare, Dr. Caplan co-founded EO Care, Inc, a pioneering digital therapeutic and telemedicine platform, offering personalized cannabis care and product plans and continuous clinical guidance to a global clientele seeking a reliable, evidence-based cannabis care partner. Adding to his repertoire of contributions to the medical cannabis arena, Dr. Caplan has recently published “The Doctor-Approved Cannabis Handbook,” an industry-first resource empowering readers with the full scope of the therapeutic potential of cannabis. Through his multifaceted involvement, Dr. Caplan continuously strives to bridge the gap between traditional medicine and cannabis care, making a significant impact in evolving holistic healthcare.
Patient Stories
[testimonial_view id=”1″]
Dr Caplan’s Book: The Doctor-Approved Cannabis Handbook
“A wealth of information and a huge dose of compassion and clarity.”
– Melissa Etheridge
Get To Know Your Medical Team!
We Stay Connected With Our Patients via Email, Online, and Even on the Airwaves!
Email | Instagram | Twitter | LinkedIn | YouTube | Spotify | Newsletter
CaplanCannabis.com | The Commonwealth Project | EO Care | Green Table Talk Podcast
Your health shouldn’t break the bank: Our Discounts Page
Cannabis Science
June 8, 2026
Dr. Benjamin Caplan, MD | Board-Certified Family Physician · CMO, CED Clinic | Cannabis Medicine | June 3, 2026
Clinical Insight
A 2026 Phase II randomized controlled trial from Thailand found that a traditional cannabis-based multi-herbal medicine performed as well as lorazepam 0.5 mg for chronic insomnia over four weeks, with a comparable safety profile. The finding is encouraging but carries important limits: the intervention is a multi-herb formulation, the sample is small, and the study population is specific to Thailand. This is early, directionally interesting evidence, not a prescription recommendation.
Cannabis-Based Medicine Matches Lorazepam for Chronic Insomnia: What a Phase II Trial Reveals
Insomnia is one of the most common reasons patients ask about cannabis, and one of the conditions where the evidence is most actively developing. A newly published clinical trial offers the strongest head-to-head comparison yet between a cannabis-based preparation and a benzodiazepine, and the results challenge the assumption that a pharmaceutical sleeping pill is the default first option.
CED Clinical Relevance
72 / 100 Strong Clinical Relevance
This is a peer-reviewed Phase II RCT with a clinically meaningful active comparator. Sleep is one of the most prevalent concerns in the CED patient population, and the benzodiazepine comparison addresses a real-world decision clinicians face regularly. The multi-herb formulation and Thai patient population introduce meaningful generalizability limits.
Cannabis Insomnia Clinical Trial Sleep Medicine Benzodiazepine
What You’ll Learn
– What the Thai Phase II insomnia trial actually tested, and what it found
– Why comparing cannabis to a benzodiazepine is clinically significant
– The specific limits of this study that every reader should understand
– How this fits into the broader clinical picture of cannabis and sleep
– What the evidence does and does not support when patients ask about cannabis for sleep
TL;DR
A Phase II RCT published in February 2026 found that a traditional Thai cannabis-based herbal medicine performed non-inferiorly to lorazepam 0.5 mg for chronic insomnia over four weeks.
Both groups saw meaningful improvements in sleep quality scores, quality of life, and stress, with comparable safety outcomes.
The intervention is a multi-herb formulation, not isolated cannabis, and the study is small and conducted in Thailand, limiting direct application to US clinical practice.
This is promising directional evidence that warrants replication in larger, better-characterized populations before clinical guidance can shift.
Quality Gate Alerts
Multi-herb formulation: The active treatment is not isolated cannabis. The Anti-Pom-Leung Fever medicine contains several herbal ingredients alongside cannabis. Effects observed cannot be attributed to cannabis alone.
Small sample: 82 participants completed the trial (41 per arm). This is underpowered for subgroup analyses or detection of rare adverse events.
Single-center, Thai population: Results were obtained in a hospital setting in Thailand. Dietary patterns, baseline medication use, and cannabis-naive status of Thai patients may differ substantially from US populations.
Short duration: Four weeks does not address long-term efficacy, tolerance development, or safety over time, which are critical concerns with any sleep medication including lorazepam.
Dose of comparator: Lorazepam 0.5 mg is a low dose. It is clinically appropriate for a trial, but the comparison group does not represent the full range of benzodiazepine prescribing in practice.
Study at a Glance
Study Type
Phase II Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial
Sample Size
100 enrolled; 82 completed (41 per group)
Population
Adults with chronic insomnia; Prapokklao Hospital, Thailand
Intervention
Anti-Pom-Leung Fever medicine (traditional Thai cannabis-based multi-herbal formulation) vs. lorazepam 0.5 mg; 4 weeks
Primary Outcome
Pittsburgh Sleep Quality Index (PSQI) at Week 4; non-inferiority margin of 2.1 points
Key Results
PSQI 3.44 (herbal) vs. 4.78 (lorazepam); mean difference -1.34 (95% CI: -2.99 to 0.31). Non-inferiority demonstrated. QoL and stress improved in both groups. No clinically significant adverse effects in either arm.
Funding
Not reported in available source material
Conflicts of Interest
Not reported in available source material
Publication
Journal of Cannabis Research, Vol. 8, Article 46 (February 24, 2026) — Open Access
Key Limitations
Small sample; single center; Thai population; multi-herb formulation (effects not attributable to cannabis alone); 4-week duration; low benzodiazepine comparator dose
Why This Matters
Insomnia affects roughly one in three adults at some point in their lives. In clinical practice, it is among the most common reasons patients seek out cannabis, and among the conditions where the demand for non-pharmaceutical options is strongest. Yet clinical guidance remains cautious precisely because rigorous head-to-head trials have been scarce.
Benzodiazepines like lorazepam are effective for short-term insomnia but carry well-documented risks: tolerance develops quickly, physical dependence is common, and discontinuation can trigger rebound insomnia that is sometimes worse than the original complaint. The existence of a trial that formally tests a cannabis-based alternative against this class of medication, using a validated sleep outcome measure, is meaningful even when the study is small.
What the Study Found
Researchers at Prapokklao Hospital in Thailand enrolled 100 adults with confirmed chronic insomnia and randomized them to receive either the traditional Thai cannabis-based formulation known as Anti-Pom-Leung Fever medicine (delivered as herbal capsules twice daily) or lorazepam 0.5 mg at bedtime for four weeks. The study was double-blind and designed as a non-inferiority trial, meaning the pre-specified question was whether the herbal preparation performed within an acceptable margin of the drug, not whether it outperformed it. Eighty-two participants completed the study, 41 in each arm.
By week four, Pittsburgh Sleep Quality Index scores had improved dramatically in both groups. The herbal group achieved a mean PSQI of 3.44, compared to 4.78 in the lorazepam group, a difference of -1.34 points in favor of the herbal arm (95% CI: -2.99 to 0.31). Since the upper bound of the confidence interval did not exceed the predefined non-inferiority margin of 2.1, the trial confirmed non-inferiority. Both groups also showed improvements in quality of life and perceived stress. Safety was comparable, with no clinically significant abnormalities detected in liver, kidney, or cardiac function in either arm. The absolute improvement in PSQI was approximately 9 points in the herbal group and 8.3 points in the lorazepam group, both large changes from a clinical standpoint.
What This Paper Does Not Show
This trial does not establish that cannabis as a substance, in any product form available to US patients, is equivalent to lorazepam for insomnia. The intervention is a traditional multi-herb preparation with a complex botanical composition that includes cannabis alongside other plant medicines. The proportion of cannabinoids, the THC-to-CBD ratio, and the contribution of individual plant components to the outcome are not reported. Isolating cannabis as the effective ingredient is not possible from this data.
The study also does not address what happens after four weeks. Lorazepam’s most problematic effects, tolerance and physical dependence, typically emerge with extended use. The study design cannot compare long-term trajectories. And a single-center trial of 82 patients in Thailand, however well-conducted, cannot override the need for replication across diverse populations and settings before any clinical practice change is warranted.
How This Fits Into the Broader Picture
The Thai trial is not the first to suggest that cannabis-based preparations may be useful for sleep. Several observational studies, registry analyses, and small randomized trials have examined the question, and the pattern that emerges is consistent: cannabis and cannabinoids tend to reduce the time it takes to fall asleep and are associated with improvements in self-reported sleep quality, particularly in people whose sleep disruption is tied to pain, anxiety, or other underlying conditions. A 2024 systematic review found moderate evidence for cannabinoids improving insomnia symptoms, though the quality of included trials varied significantly.
What this trial adds is the active-comparator design. Most cannabis and sleep studies have compared cannabis to placebo. Comparing to a real-world clinical alternative, specifically a short-acting benzodiazepine, is a methodological step forward. The trial raises a question that matters in the exam room: if cannabis-based treatment produces comparable improvements in sleep quality with a different safety profile, is there a population of patients for whom it represents a reasonable first-line or alternative option? That question cannot be answered yet, but it is now legitimate to ask it in a research context.
In Massachusetts, as in many US states, patients regularly bring their cannabis use to appointments and ask about its role in managing sleep. Clinicians need a way to discuss the evidence honestly, which means acknowledging both what the data suggest and where its limits lie.
Dr. Caplan’s Take
“Sleep is one of the most urgent conversations in my clinic. Patients come in after years of benzodiazepine prescriptions they never wanted to continue, asking whether there is something else. What I find in this trial is not a simple answer, but something nearly as valuable: a properly designed study that actually asks the head-to-head question. The finding that a cannabis-based preparation performs comparably to lorazepam, even in a small Thai sample, gives clinicians a scientific foothold to take this question seriously rather than dismissing it. That matters. The problem is not that the cannabis group performed well; it is that we still don’t know which patients benefit most, what product profile matters, or how the outcomes hold past the four-week mark. That’s not a reason to ignore the trial. It’s a reason to fund the next one.”
“In my practice in Boston, the insomnia patients who do best with cannabis tend to be those whose sleep disruption connects to something the cannabis is addressing: pain that keeps them awake, anxiety that prevents them from settling, or a hyperaroused nervous system that hasn’t quieted down. Pure maintenance insomnia with no underlying driver responds differently. This study doesn’t differentiate by insomnia subtype, which is a real gap. Until that granularity exists in the evidence, matching patients to treatment still requires clinical judgment. The trial is a signal worth following. It is not yet a guide for practice.”
What a Careful Reader Should Take Away
A well-designed Phase II trial found that a traditional Thai cannabis-based formulation performed non-inferiorly to lorazepam 0.5 mg for chronic insomnia over four weeks, with a similar safety profile. Both groups improved substantially. The upper bound of the confidence interval for the difference was 0.31, which fell within the predefined margin, confirming the non-inferiority claim. This is real, peer-reviewed evidence from a randomized controlled trial.
But a careful reader also holds the limits clearly: 82 patients, one hospital, four weeks, a multi-herb compound with no cannabinoid profile reported, and a population whose background cannabis familiarity and metabolism may differ from US patients. The study is a beginning, not a conclusion. It warrants replication. It does not warrant changing prescribing habits or self-treating with cannabis as a benzodiazepine substitute based on this trial alone.
If you are currently using a benzodiazepine for sleep or considering cannabis for insomnia, the right path is a conversation with a clinician who knows both the evidence and your history. That is exactly the kind of conversation the CED Clinic is built for.
Evidence Watch Reading Tool
Read This Paper Through Eight Different Lenses
A single study can mean different things depending on who is reading it. This card separates the patient takeaway, clinical meaning, skepticism, study critique, prior research context, practical implications, future directions, and likely public misreadings.
How to use this: Choose a lens above to see how the same paper reads from a different evidence, clinical, or practical angle.
Patient Takeaway Clinician’s POV A Skeptical Read Study Critic Compared to Past Research Practical Considerations Future Directions (Expected) Misreadings & Bad-Faith Takes
Select a lens above to reveal a focused interpretation of the paper. Each view is prepared in advance, evidence-calibrated, and designed to keep the claims tied to what the work actually shows.
Patient Takeaway
If you have chronic insomnia and you are wondering whether cannabis could be an option instead of a sleeping pill, this trial offers something genuinely useful: it is now documented in a peer-reviewed journal that a cannabis-based preparation performed comparably to a low dose of lorazepam in a formal clinical trial. That matters. It means the question you are asking is legitimate and worth raising with your clinician, not a fringe idea.What it does not mean is that you should swap your medication for a cannabis product based on this single study. The preparation tested in Thailand contains multiple herbs, not just cannabis, and the study was conducted in 82 people over four weeks. We don’t know if the same results would hold in a US population, or with the cannabis products available in a Massachusetts dispensary. Sleep is also highly individual. What helps one person’s sleep disruption can worsen another’s. The right takeaway is not “cannabis replaces my sleeping pill.” The right takeaway is “this study suggests that cannabis-based medicine is worth taking seriously for sleep, and I should talk to someone who understands both the evidence and my specific sleep problem.”
Clinician’s POV
For a clinician managing patients with chronic insomnia, particularly those who express concern about benzodiazepine dependence or who are already using cannabis self-directed for sleep, this trial provides useful framing. It is now reasonable to discuss cannabis-based approaches in clinical conversation without dismissing them as unproven in a controlled setting. The non-inferiority finding against lorazepam 0.5 mg in 82 patients is a starting point, not a standard of care recommendation.The more important clinical nuance is patient selection. The trial did not report insomnia subtypes, concurrent diagnoses, or cannabinoid profiles of the preparation. In practice, cannabis may be more promising for patients whose insomnia is driven by pain, anxiety, or hyperarousal than for those with primary sleep maintenance insomnia with no comorbidity. Caution is appropriate around any patient with a history of cannabis use disorder, psychosis, or significant respiratory compromise. The 4-week duration also means this study cannot inform conversations about long-term management, which is where benzodiazepine risk accumulates. Shared decision-making, rather than protocol-driven prescribing, is the appropriate frame here.
A Skeptical Read
Several things warrant scrutiny before taking this trial at face value. First, the intervention is not cannabis; it is a multi-herb formulation with an unknown cannabinoid profile. The trial’s results belong to the Anti-Pom-Leung Fever medicine as a composite botanical product. Attributing the outcome to cannabis is an inference, not a finding. Second, the non-inferiority margin of 2.1 PSQI points was defined by the authors. Non-inferiority margins are always pre-specified choices, and the clinical meaningfulness of that threshold in this population is not established by independent standards.Third, the baseline PSQI scores and the dramatic improvement in both arms deserve attention. The lorazepam group started with similar baseline scores and ended at 4.78, which is near the clinical threshold for good sleep (PSQI under 5). This raises a question about whether the improvements reflect the treatment or reflect being enrolled in a structured trial, receiving follow-up care, and having a sleep problem formally acknowledged. A placebo arm would have clarified this. The absence of placebo means neither group’s improvement can be cleanly attributed to the pharmacological intervention.
Study Critic
The trial’s headline finding, non-inferiority, is methodologically appropriate for the research question. But the statistical underpinnings carry constraints worth naming clearly. With 41 completers per arm, the confidence interval for the PSQI difference runs from -2.99 to 0.31. The range spans nearly 3.3 PSQI points. That is a wide interval for a scale with a total range of 21 points and a clinical threshold at 5. The upper bound of 0.31 just clears the non-inferiority margin of 2.1, which is the correct result for the predefined test but leaves open a scenario where the true difference could be near the margin or slightly above it in a larger trial.The study also reports no statistically significant time-by-treatment interaction, meaning both groups improved at similar rates over time. This supports the non-inferiority claim but does not reveal whether the trajectories diverged at any specific week. Single-timepoint evaluation at week 4 is appropriate for the primary analysis, but additional time points would have revealed whether improvements were stable, accelerating, or beginning to plateau. A longer follow-up would have captured the post-treatment rebound period that is particularly relevant for benzodiazepine comparisons.
Compared to Past Research
Prior research on cannabis and sleep has been conducted almost entirely against placebo. The existing body of work, including several randomized crossover trials and observational registry studies, generally shows that cannabinoids, particularly CBD and in some cases THC or CBN, reduce sleep latency and improve self-reported sleep quality compared to placebo in adults with insomnia or insomnia secondary to other conditions. A 2024 systematic review and meta-analysis in Sleep Medicine Reviews, which included over a dozen RCTs, found moderate-quality evidence for cannabinoids improving sleep outcomes, with the strongest effects seen in populations with comorbid pain or anxiety.What this Thai trial adds is the active-comparator design, which has not been a feature of prior cannabis and sleep trials. Head-to-head comparisons against drugs with known clinical benchmarks are essential for situating the magnitude of cannabis-based effects within a clinical framework. However, because the intervention is a multi-herb preparation rather than a characterized cannabinoid product, this trial cannot be directly concatenated with prior cannabinoid studies. It belongs to a distinct but adjacent category of evidence. Comparison with prior research should be drawn carefully, with this distinction preserved.
Practical Considerations
Even if this trial’s findings are real and replicate in US populations, practical translation is not straightforward. The intervention is a Thai traditional medicine with a specific botanical composition that is not commercially available in the United States in its current form. US cannabis products vary enormously in cannabinoid content, terpene profile, and formulation. A dispensary product labeled for sleep is not the same compound that was tested in Thailand, and no direct equivalency can be drawn.Dosing remains a practical challenge. The herbal capsule regimen (twice daily) differs from how most US patients use cannabis for sleep, which is typically a single evening dose. Timing, route of administration, and the presence or absence of tolerance all influence outcomes in clinical practice. Cost and insurance coverage are also relevant: lorazepam is inexpensive and commonly covered; cannabis remains federally unscheduled and out-of-pocket in most US states, including Massachusetts. For patients weighing options, these real-world factors shape what “non-inferior in a trial” actually translates to in daily life.
Future Directions (Expected)
The most important next step is replication in a larger, more diverse sample with a well-characterized cannabinoid intervention rather than a composite herbal preparation. A trial enrolling 200 to 400 patients, using a standardized CBD or THC:CBD formulation with a documented dosing protocol and a longer follow-up period, would add substantially more to the field than additional small trials in similar populations.The field also needs trials that stratify by insomnia subtype. Sleep onset insomnia, sleep maintenance insomnia, and early morning awakening have distinct mechanisms and may respond differently to cannabis. Trials that enroll undifferentiated insomnia samples obscure subgroup effects. Biomarker-enriched designs, perhaps using inflammatory markers given prior evidence that baseline inflammation moderates cannabis response, could identify who is most likely to benefit. Withdrawal and rebound insomnia periods following cannabis discontinuation also deserve formal study, since this is a known concern with THC-heavy products used for sleep that has not been adequately characterized in RCT settings.
Misreadings & Bad-Faith Takes
Distortion: “Science proves cannabis is better than Ativan for sleep.” This misreads the trial in two ways. First, the study found non-inferiority, meaning comparable performance, not superiority. Second, the intervention was a multi-herb formulation, not cannabis alone. Attributing the finding to “cannabis” is inaccurate.Distortion: “This study is fake news because cannabis causes sleep problems.” This ignores the actual data. Both groups improved substantially. The trial was double-blind, active-controlled, and published in a peer-reviewed journal. Dismissing the finding without engaging the methodology is not a scientific critique.Distortion: “Thai herbal medicine beats Big Pharma’s sleeping pills.” This sensationalizes a small, four-week, single-center non-inferiority trial into a culturally charged narrative it does not support. The study is promising and deserves replication, not celebration as a decisive victory for traditional medicine over pharmaceutical treatment.Correct framing: A carefully designed clinical trial found that a cannabis-based traditional preparation performed comparably to a low dose of lorazepam over four weeks in 82 Thai patients with chronic insomnia. The result is directionally encouraging and methodologically legitimate. It is also small, limited to one population and formulation, and insufficient on its own to guide clinical practice.
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message Metabolic Care Medical Consulting Cannabis Care
Have thoughts on this? Share it:
? Share on X in Share on LinkedIn ? Share on BlueSky ? Follow on Instagram ? Read more on Substack ? Subscribe via RSS
Source
Kummalue T, et al. Phase II randomized controlled trial comparing traditional Thai cannabis-based medicine with lorazepam for insomnia treatment. Journal of Cannabis Research. 2026;8(1):46. doi: 10.1186/s42238-026-00415-x — Open Access. Published February 24, 2026. Authors affiliated with Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. Note: Full author list should be verified at the DOI link before final publication of this post.
Related Reading at CED Clinic
Continue exploring the evidence
Cannabis Insomnia Guide: How to Match Cannabis to the Sleep Problem You Actually Have
Dr. Caplan’s clinical guide to matching cannabis products, cannabinoid ratios, timing, and dose to specific insomnia patterns, including sleep onset, maintenance, and early morning awakening.
Explore evidence
Cannabis Insomnia Treatment: 7 Key Findings from UK Study
A UK registry study of 124 patients showed cannabis-based medicines improved sleep quality, anxiety, and overall quality of life over 18 months with a favorable safety profile.
Explore evidence
Cannabis-Based Medicines Show Promise for Insomnia Treatment
An overview of the emerging evidence base for cannabis-based medicines in insomnia, covering study designs, cannabinoid profiles studied, and clinical takeaways for patients and providers.
Explore evidence
Frequently Asked Questions
What exactly was the cannabis-based medicine tested in this trial?
The intervention was a traditional Thai herbal formulation called Anti-Pom-Leung Fever medicine. It is a multi-herb preparation that includes cannabis among several botanical ingredients and is legally recognized in Thailand for therapeutic and research use. The study does not report the specific cannabinoid content, THC-to-CBD ratio, or the precise contribution of each herbal component. This means the results cannot be attributed to cannabis alone and cannot be directly mapped to cannabis products available in US dispensaries.
Does this study mean cannabis is as effective as lorazepam for insomnia?
The study found that the cannabis-based herbal formulation was non-inferior to lorazepam 0.5 mg over four weeks in 82 Thai patients, using the Pittsburgh Sleep Quality Index as the primary measure. Non-inferiority means the treatment performed within a predefined acceptable margin of the comparator, not that it was proven equivalent or superior. This is a promising finding, but it comes from one small trial in a specific population with a compound not commercially available in the United States. It does not support switching from a prescribed benzodiazepine to cannabis without medical guidance.
What is the Pittsburgh Sleep Quality Index and what do the scores mean?
The Pittsburgh Sleep Quality Index, or PSQI, is a validated self-report questionnaire that measures sleep quality over the past month across seven components: subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Scores range from 0 to 21, and a score above 5 is generally considered to indicate poor sleep quality. In this trial, both groups started with scores indicating poor sleep and ended at or near the threshold for good sleep, suggesting substantial improvement in both arms.
Why is it significant that this trial compared cannabis to a benzodiazepine rather than a placebo?
Most prior cannabis and sleep studies compared cannabis to a placebo. That design tells you whether cannabis beats doing nothing. An active-comparator design asks a more clinically meaningful question: how does cannabis perform against something already in use? Lorazepam is a real-world prescribing option for short-term insomnia. Showing that a cannabis-based preparation performs comparably to it, even in a small trial, moves the conversation from “does cannabis do something?” to “how does cannabis fit alongside existing options?” That is a more useful question for clinical decision-making, even if this trial is too small to settle it.
What are the risks of long-term benzodiazepine use for insomnia?
Benzodiazepines like lorazepam are effective for short-term insomnia but carry meaningful risks with extended use. Tolerance develops relatively quickly, requiring higher doses to achieve the same effect. Physical dependence is common, and stopping benzodiazepines abruptly after prolonged use can cause rebound insomnia that is often worse than the original problem, along with anxiety, irritability, and in some cases withdrawal seizures. Cognitive effects and fall risk, particularly in older adults, are additional concerns. This is precisely why many clinicians and patients seek alternatives. The Thai trial’s four-week duration does not address these longer-term risks for either treatment.
Can a Massachusetts patient use cannabis for insomnia based on this study?
Massachusetts has an active medical cannabis program, and insomnia is among the conditions that can support a cannabis certification through a qualified clinician. However, the products available in Massachusetts dispensaries are not the same as the Thai multi-herb formulation studied in this trial. Matching a patient to a cannabis product for sleep requires understanding the person’s specific insomnia pattern, underlying causes, current medications, and relevant history. This trial is directionally encouraging but does not translate into a straightforward product recommendation. A consultation with a cannabis-informed clinician is the appropriate first step.
Why does the multi-herb nature of the formulation matter so much?
When a treatment is a composite of multiple active ingredients, it is not possible to determine which ingredient, or which combination, is responsible for the observed outcome. The Anti-Pom-Leung Fever medicine contains several plant-based components alongside cannabis. Any or all of them may be contributing to the sleep improvements seen in the trial. This matters because it prevents direct extrapolation to cannabis-only products. If you use a cannabis oil or a cannabis gummy for sleep, you are not using what was tested here. The clinical signal is interesting, but the translation requires careful interpretation.
What would a better study on this topic look like?
A stronger follow-up trial would enroll several hundred patients rather than 82, use a well-characterized cannabinoid preparation with a documented and consistent cannabinoid profile, include a placebo arm alongside the active comparator, follow patients for at least three to six months including a post-treatment period to assess rebound insomnia risk, report insomnia subtypes and relevant comorbidities, and recruit participants from diverse populations including non-Asian cohorts. Biomarker enrichment, such as measuring inflammatory markers at baseline, could help identify who benefits most. These design features would allow the field to draw conclusions that are both clinically meaningful and broadly applicable.
Does cannabis disrupt REM sleep, and how does that affect its use for insomnia?
THC is associated with suppression of REM sleep, the stage associated with dreaming and emotional memory processing. This is a real pharmacological effect documented in multiple studies. For some patients, less REM sleep can be subjectively helpful in the short term, particularly those with nightmare-related disorders or trauma-associated sleep disruption. For others, REM suppression can diminish sleep quality over time and contribute to cognitive fog on waking. CBD appears to have a different profile and may support sleep without the same REM effects. The Thai study used a multi-herb formulation and did not report polysomnographic data, so it cannot speak to REM architecture. This is a meaningful gap when evaluating cannabis specifically for insomnia.
Should I stop taking my sleeping medication and switch to cannabis?
No. Stopping a benzodiazepine or other sleep medication without medical supervision carries real risks, including rebound insomnia and, with certain medications, withdrawal symptoms that can be serious. This study does not support unsupervised medication changes. If you are interested in exploring cannabis as part of your sleep management, the right approach is to raise it with your clinician, discuss the evidence honestly, and make any transitions gradually and with appropriate support. CED Clinic specializes in exactly this kind of conversation, and we welcome questions from patients who want to understand their options thoughtfully. [...]
Read more...
June 7, 2026Dr. Benjamin Caplan, MD
|
Board-Certified Family Medicine · Cannabis Medicine Specialist
|
June 6, 2026
|
Cannabis Science
Clinical Insight
An Australian randomized, double-blind, placebo-controlled pilot trial found that a nightly 1:1 THC:CBD cannabis oil produced clinically meaningful pain relief in 70% of fibromyalgia patients and substantially improved sleep quality, with large between-group effect sizes. The study enrolled 24 adults and was designed primarily to assess feasibility, not efficacy. All participants were female, and 75% correctly guessed their treatment assignment, which introduces expectation bias across the self-reported outcomes. These are early-signal findings, not a mandate for practice change.
Cannabis Oil for Fibromyalgia: What a New Randomized Trial Actually Found
An Australian research team has published what may be one of the most carefully designed randomized trials to date on cannabis oil for fibromyalgia, and the results raise questions that deserve a more careful read than most headlines will provide. The 70% pain responder rate is real. So are the limitations that shape what it actually means.
CED Clinical Relevance
72 / 100
Strong Clinical Relevance
Fibromyalgia is among the most common chronic pain syndromes we see at CED Clinic. This is one of very few double-blind RCTs to directly test a balanced THC:CBD formulation in this population, making it clinically meaningful despite the small sample.
Fibromyalgia
Cannabis Oil
Chronic Pain
THC:CBD
Clinical Trial
What You’ll Learn
What dose of cannabis oil was tested and why it was given nightly rather than during the day
What the 70% pain relief figure actually represents, and what makes the placebo response so notable
Why blinding was compromised and what that means for interpreting patient-reported results
How sleep, fibromyalgia impact, fatigue, and quality of life responded to treatment
What a pilot feasibility study can and cannot tell clinicians about this condition
TL;DR
❇️ An Australian RCT found 70% of fibromyalgia patients reached ≥30% pain reduction with nightly 1:1 THC:CBD oil, compared to 20% of the placebo group at week one post-titration.
❇️ Sleep quality improved substantially in the cannabis group, with a large effect size; fibromyalgia impact scores showed medium-to-large effects in the treatment arm.
❇️ This was a pilot feasibility study (n=24, all female, single site), not powered to confirm efficacy. Blinding was likely compromised by THC’s psychoactive effects.
❇️ No serious adverse events. Most side effects were mild: drowsiness, dizziness, dry mouth. Drug was supplied by Little Green Pharma Ltd, which also co-funded the lead author’s PhD scholarship.
Quality Gate Alerts
Pilot design: This trial was powered to assess feasibility, not efficacy. Effect size estimates are exploratory and come with wide confidence intervals.
Small sample: n=24 (10 per group in secondary analyses due to dropouts and missing data). Statistical tests were underpowered for definitive conclusions.
Compromised blinding: 75% of participants correctly identified their treatment assignment, likely due to THC’s psychoactive effects, which introduces expectation bias across all self-reported outcomes.
All-female sample: All 24 participants were women. This was incidental, not by design, but limits generalizability given documented sex differences in endocannabinoid biology.
Rising placebo response: The placebo ≥30% pain relief rate rose from 20% at Week 1 to 40% by Week 12, which is consistent with fibromyalgia trial dynamics but narrows the apparent treatment advantage.
Conflict of interest: Study drug and placebo were supplied by Little Green Pharma Ltd (LGP), which also co-funded the lead researcher’s PhD scholarship. LGP had no role in design, data collection, or analysis, per author disclosures.
Study at a Glance
Study Type
Randomized, Double-Blind, Placebo-Controlled Pilot Feasibility Trial
Sample Size
24 adults with fibromyalgia (12 per group); 22 completed the trial
Population
All female; predominantly Caucasian; mean age ~53-55; mean fibromyalgia duration ~13 years. Gold Coast, Australia.
Intervention
1:1 THC:CBD cannabis oil (10 mg/mL each), taken nightly ~1 hour before bedtime. 4-week titration phase (0.25 mL start, up to 3.5 mL/day max), then 12 weeks at stable dose. Median final dose: 1 mL/day (cannabis group).
Comparator
Matched placebo oil (MCT, walnut, avocado oils; color, texture, and smell similar to active; taste not specifically matched)
Primary Outcome
Feasibility: recruitment, retention (target ≥80%), adherence (target ≥80% with ≥90% compliance), and safety. Efficacy was a secondary, exploratory aim.
Key Efficacy Results
Pain ≥30% reduction (post-titration): 70% cannabis vs. 20% placebo (η²=0.180, large). Sleep quality improvement: large effect size (η²=0.184). FIQR total MCID (≥45.5% improvement): 40% cannabis vs. 10% placebo.
Adverse Events
121 total AEs across all participants. Cannabis group: somnolence, dizziness, fatigue, nausea, dry mouth (mostly mild; 6.5% moderate; 0% severe). No serious adverse events in either group.
Funding / Conflicts
PhD scholarship co-funded by Southern Cross University and Little Green Pharma Ltd (LGP). LGP supplied study drug and placebo. LGP had no role in design, data, or analysis per author disclosures.
Trial Registration
ACTRN12623000345684 (Australian New Zealand Clinical Trials Registry)
Why This Matters
Fibromyalgia affects an estimated 3 to 5 percent of the population and disproportionately affects women. Most approved pharmacological treatments offer modest, inconsistent relief, and many patients either experience side effects or fail to respond. Cannabis has circulated as a treatment option for years, but the evidence base has been dominated by observational studies and open-label reports. Randomized, double-blind, placebo-controlled trials in this population are rare. This study represents a meaningful methodological step even if the sample is small.
Clinical Summary
Kurlyandchik and colleagues at Southern Cross University and Griffith University enrolled 24 Australian adults meeting the 2016 American College of Rheumatology fibromyalgia criteria. Recruitment ran from August 2023 through January 2024, with treatment and follow-up concluding in June 2024. Participants were randomly assigned to receive either a plant-derived cannabis oil containing equal concentrations of delta-9-THC and CBD at 10 mg/mL each, or a matched placebo oil. Both groups started at 0.25 mL nightly and titrated upward by 0.25 mL every two days over four weeks, based on individual tolerability, with a ceiling of 3.5 mL per day. Following titration, participants held their final dose stable for 12 weeks. The median final dose in the cannabis group was 1 mL per day, compared to 2.25 mL in the placebo group, reflecting greater tolerability constraints on the active arm.
The trial met its primary feasibility benchmarks. Retention reached 91.7%, adherence was 100% for the ≥90% compliance threshold, and all planned visits were completed. On the secondary efficacy measures, the cannabis group showed clinically meaningful gains in pain, sleep, and overall fibromyalgia impact. Pain scores (Average Daily Pain Score, ADPS) dropped from a mean of 6.00 at enrollment to 3.50 at post-titration in the cannabis group, versus 5.16 in the placebo group (large effect, η²=0.180). At Week 12, pain scores remained improved in the cannabis group (mean 3.83 vs. 5.05 for placebo), but the effect size narrowed to medium (η²=0.085), partly because the placebo responder rate for ≥30% pain relief climbed to 40% by that point. Sleep quality, measured by the Pittsburgh Sleep Quality Index, improved dramatically in the cannabis group (PSQI from 13.38 to 8.50, p<0.001), with a large between-group effect (η²=0.184). The Fibromyalgia Impact Questionnaire Revised (FIQR) showed clinically meaningful improvement in 40% of cannabis participants versus 10% of placebo participants. Quality-of-life measures (SF-36) showed large effect sizes favoring cannabis for bodily pain, social functioning, and mental health domains. Fatigue (MFI-20) and anxiety/depression (HADS) showed medium between-group effect sizes, but no statistically significant within-group changes in either arm.
What This Paper Does Not Show
This study was not powered to demonstrate efficacy. It was designed to determine whether a larger trial is feasible. Efficacy findings are exploratory and carry wide confidence intervals throughout.
The all-female, predominantly Caucasian, single-site sample cannot be generalized to men, diverse populations, or patients in countries with different legal frameworks around medicinal cannabis.
Blinding was not well preserved: 75% of participants in both groups correctly guessed their allocation, most likely because THC produces recognizable psychoactive effects. Self-reported pain, sleep, and quality-of-life scores are all vulnerable to expectation bias under these conditions.
The placebo response was substantial. By Week 12, 40% of placebo participants had achieved ≥30% pain reduction, a rate consistent with the well-documented placebo effect in fibromyalgia trials. This doesn’t invalidate the cannabis signal, but it complicates reading the 70% vs. 40% comparison as straightforwardly pharmacological.
No active comparator was included. The study does not compare cannabis oil to amitriptyline, duloxetine, milnacipran, or pregabalin, which remain the pharmacological backbone of fibromyalgia treatment.
How This Fits With the Broader Clinical Conversation
Medicinal cannabis research in fibromyalgia has expanded considerably over the past decade, but the evidence base remains uneven. Earlier randomized work includes a 2020 Spanish trial by Sagy and colleagues using a THC-rich oral cannabis extract, which showed analgesic effects but also significant psychoactive side effects at higher doses. Observational data from the UK Medical Cannabis Registry, covering nearly 500 fibromyalgia patients, found the greatest benefit at higher daily CBD doses over 18 months. A 2023 systematic review concluded that the evidence for cannabis in fibromyalgia was promising but limited by study heterogeneity, small samples, and inconsistent outcome measures.
The 2026 trial by Kurlyandchik et al. adds something the prior literature largely lacks: a double-blind placebo-controlled design with a balanced THC:CBD formulation, individualized titration, validated outcome measures across multiple fibromyalgia domains, and comprehensive safety monitoring. The 1:1 ratio reflects real-world prescribing practice in Australia and is clinically relevant as patients increasingly encounter combined-cannabinoid products.
One finding worth attention is the divergence between early and later timepoints. The effect size for pain was large at post-titration (Week 1) and medium by Week 12, not because cannabis lost efficacy but because the placebo group caught up. This pattern is not unusual in fibromyalgia trials, where placebo response rates can exceed 30 to 40 percent. It does not mean the drug stopped working; it means the therapeutic difference becomes harder to isolate as the study progresses and placebo dynamics mature.
The ECS connection in fibromyalgia is mechanistically plausible. CB1 and CB2 receptors are distributed through the central and peripheral nervous systems, and the endocannabinoid system modulates pain processing at spinal, supraspinal, and peripheral levels. Fibromyalgia involves central sensitization and dysfunction of descending pain inhibitory pathways, precisely the targets where cannabinoids have shown modulating effects in both animal and human work. The convergence of analgesic, sleep-modulating, and mood-adjacent effects of combined THC and CBD makes a 1:1 formulation theoretically well-matched to fibromyalgia’s multidomain symptom burden. That does not prove it works at scale, but it does explain why this question is worth pursuing rigorously.
Dr. Caplan’s Take
Fibromyalgia is one of the most challenging conditions to treat in any clinical setting, and it is one of the most common reasons patients come through our doors asking about cannabis. They are often people who have tried amitriptyline, pregabalin, and duloxetine with partial responses, or who stopped those drugs because the side effects weren’t tolerable. They are not asking out of curiosity. They are asking because they hurt, they can’t sleep, and they need something that works in their actual life, not on a dosing schedule that makes them feel medicated all day.
This trial does several things well. Taking the oil nightly before bed, rather than through the day, is the right instinct for fibromyalgia. You address sleep disturbance directly, you minimize daytime psychoactivity, and you let the titration happen in a context where a patient has fewer responsibilities to manage while finding their dose. The 4-week individualized titration is also correct practice. One of the persistent errors I see in clinical cannabis is patients who go from no exposure to a fixed standard dose in a few days and conclude that the drug didn’t work. Gradual titration changes that entirely.
What I hold alongside the encouraging numbers: the sample is small, everyone in it was female, and three-quarters of participants knew what they were taking. That last point matters enormously when your primary outcomes are all self-reported. A patient who correctly guesses she received cannabis does not intentionally inflate her results, but the expectation shapes perception in ways that are hard to separate from pharmacology. None of this means the findings are false. The effect sizes are large enough to be interesting. But this needs replication in an adequately powered trial with a more diverse sample before I would cite it as evidence that cannabis oil is effective for fibromyalgia as a category. For individual patients with fibromyalgia who are already exploring cannabis, these results offer some reassurance and a reasonable template for how to approach dosing. That’s meaningful, even if it’s not the full answer.
What a Careful Reader Should Take Away
This is a well-designed pilot study, not a definitive efficacy trial. The distinction carries clinical weight. Reporting 70% pain relief without also noting that 40% of placebo participants met the same threshold by Week 12 misrepresents the data. Reporting large effect sizes without noting the sample size and blinding limitations creates a misleading picture of certainty.
What the study does establish: a nightly 1:1 THC:CBD cannabis oil is feasible to administer, is well retained, and carries a manageable side-effect profile in a monitored fibromyalgia population. The preliminary efficacy signals across pain, sleep, and functional impact are consistent enough, and the effect sizes large enough, to justify pursuing a properly powered confirmatory trial. The trial authors say as much in their conclusion.
For patients considering cannabis for fibromyalgia: this study provides more structure than most available evidence. The nightly timing, gradual titration, and balanced formulation are all clinically grounded. It does not prove cannabis will work for any given individual. Fibromyalgia is a highly heterogeneous condition, and individualized response rates in any therapeutic class reflect that heterogeneity. Working with a clinician familiar with cannabis medicine, using validated outcomes to track your own response, and setting clear decision points before starting are the steps that make this evidence useful in practice.
Evidence Watch Reading Tool
Read This Paper Through Eight Different Lenses
A single study can mean different things depending on who is reading it. This card separates the patient takeaway, clinical meaning, skepticism, study critique, prior research context, practical implications, future directions, and likely public misreadings.
How to use this: Choose a lens above to see how the same paper reads from a different evidence, clinical, or practical angle.
Patient Takeaway
Clinician’s POV
A Skeptical Read
Study Critic
Compared to Past Research
Practical Considerations
Future Directions (Expected)
Misreadings & Bad-Faith Takes
Select a lens above to reveal a focused interpretation of the paper. Each view is prepared in advance, evidence-calibrated, and designed to keep the claims tied to what the work actually shows.
Patient Takeaway
If you have fibromyalgia and you have been thinking about trying cannabis oil, this study gives you something worth knowing. A small Australian trial found that a nightly cannabis oil containing equal parts THC and CBD helped 70% of participants reach at least a 30% reduction in daily pain, compared to 20% in the placebo group right after the dose-finding phase. Sleep improved substantially in the cannabis group, which matters because poor sleep drives a significant portion of fibromyalgia’s symptom burden. The intervention was taken once at night, before bed, which means daytime function wasn’t disrupted in most participants. Side effects were generally mild: drowsiness, some dizziness, dry mouth. No serious adverse events occurred.
What this does not mean: this was a very small trial, and everyone enrolled was female, so it may not reflect your situation if you are not a woman in your fifties with a similar clinical profile. More importantly, 40% of the people who received the placebo also reported meaningful pain relief by the end of the study, which is a reminder that fibromyalgia responds to multiple factors, including expectations and clinical attention. This study doesn’t tell you cannabis will work for you. It tells you it appears safe to explore with medical supervision, using a gradual titration approach, and that some patients see real benefit.
Clinician’s POV
This feasibility trial adds controlled signal to a space that has been dominated by observational data. The design choices are clinically reasonable: nocturnal dosing to minimize psychoactive burden and target sleep disturbance, individualized titration to optimize tolerability, and a 1:1 THC:CBD ratio that reflects actual prescribing patterns for chronic pain in Australia. The medium-to-large effect sizes across pain, sleep, and FIQR are encouraging, and the safety profile is consistent with what we see in clinical practice.
The exam-room implications are limited but real. For a patient with fibromyalgia who has failed or cannot tolerate conventional pharmacotherapy and is asking about cannabis, this study supports a nocturnal, low-and-slow titration approach with a balanced formulation. The median effective dose here was 1 mL, delivering approximately 10 mg THC and 10 mg CBD nightly, which is a conservative, well-tolerated range. What remains premature: citing this as evidence of efficacy at the population level, or using it to suggest cannabis outperforms approved agents. The absence of an active comparator and the small sample make that a reach too far. Document your clinical reasoning carefully, use validated instruments to track your patient’s response, and set a defined re-evaluation point.
A Skeptical Read
The study’s most important methodological problem is the blinding failure. Three-quarters of participants in both groups correctly identified their allocation. In a trial where every primary outcome is self-reported, this is not a minor issue. Pain perception, sleep quality ratings, and quality-of-life assessments are all shaped by expectation. When participants know, or strongly suspect, they are receiving an active drug with known psychoactive properties, their reports of improvement reflect that knowledge as much as the drug’s pharmacological action.
The placebo trajectory is also worth scrutinizing. The placebo group’s ≥30% pain responder rate climbed from 20% at Week 1 to 40% at Week 12. One possible interpretation is that the placebo effect in fibromyalgia deepened over time through continued clinical attention and monitoring. Another is that some participants randomized to placebo figured that out and adjusted their expectations accordingly. Either way, the Week 12 comparison between 70% cannabis responders and 40% placebo responders is less striking than the Week 1 comparison might suggest. The drug appears to do something. The precise magnitude of its pharmacological contribution, stripped of expectation, remains genuinely unclear from this dataset.
Study Critic
The primary statistical limitation is sample size, and it affects interpretation at every level. With n=10 per group in secondary analyses (after exclusions and dropouts), confidence intervals are wide across all efficacy measures. The ADPS between-group mean difference at Week 12 is -1.02 with a 95% confidence interval of -2.73 to 0.69, which crosses zero. The FIQR total score between-group effect has a CI of -31.16 to 4.19. These are effect sizes that could be consistent with meaningful pharmacological benefit or with noise in a small sample. The authors appropriately emphasize effect sizes over p-values given the feasibility design, but this framing should not obscure the fact that the confidence intervals do not allow confident efficacy conclusions.
The dose discrepancy between groups also warrants attention. The median final dose was 1 mL in the cannabis group and 2.25 mL in the placebo group. This occurred because the cannabis group titrated lower due to tolerability constraints, while placebo participants escalated further since the placebo oil produced fewer stopping symptoms. This asymmetry means the two groups were not receiving comparable volumes, which could affect perceived treatment salience and the subjective experience of taking the assigned product. Finally, the 20-week total study duration, including a 4-week post-treatment follow-up, provides no data on whether benefit persists beyond 12 weeks of active treatment or what happens at cessation.
Compared to Past Research
The 2026 Kurlyandchik trial sits within a small but growing body of controlled work on cannabis in fibromyalgia. A 2020 randomized trial published in the Journal of Clinical Medicine by Sagy and colleagues examined a THC-dominant oral cannabis extract in Israeli fibromyalgia patients and found analgesic effects alongside notable psychoactive burden at higher doses. Earlier observational data, including the UK Medical Cannabis Registry analysis of approximately 500 fibromyalgia patients, showed significant improvements in pain, anxiety, and sleep with higher-dose CBD-dominant products over 18 months. A 2023 systematic review of available controlled trials concluded that evidence was promising but limited by methodological heterogeneity and small sample sizes.
The current trial advances the field primarily in its design: double-blind, placebo-controlled, with individualized titration and validated outcomes across multiple symptom domains. It also uses a 1:1 THC:CBD ratio, which contrasts with the CBD-dominant or THC-dominant formulations in much prior work, reflecting a real-world prescribing trend. Comparison literature was reviewed selectively for this context and was not independently searched for this Lens Card. Readers interested in the full evidence landscape should consult the Kurlyandchik et al. references directly for the most complete prior-work assessment.
Practical Considerations
The nocturnal dosing approach is practically significant. Taking cannabis oil approximately one hour before bed, at a dose titrated individually over four weeks, addresses fibromyalgia’s core sleep problem while reducing the occupational and cognitive risks associated with daytime THC use. The median effective dose in this trial was 1 mL, delivering 10 mg each of THC and CBD, which is a modest and manageable starting point. This matters for patients who are concerned about impairment or who have prior negative experiences with cannabis at higher doses.
Product consistency and legal context are real-world friction points. The cannabis oil in this trial was an investigational pharmaceutical product with defined concentrations. Consumer cannabis oils vary substantially in actual THC and CBD content relative to label claims. Patients replicating this approach with commercially available products need guidance on selecting products with third-party lab verification. Additionally, this trial was conducted in Australia, where Queensland’s zero-tolerance THC driving law was a documented barrier to recruitment. In Massachusetts and other US states, patients should understand the relevant legal environment before starting, particularly around driving and workplace drug testing. Individual response variability was notable: two participants required dose reduction due to morning drowsiness and cognitive effects. Starting low and escalating slowly is not optional guidance here; the trial data support it as the mechanism by which most participants found their tolerable dose.
Future Directions (Expected)
The trial’s authors are explicit: a larger, adequately powered confirmatory trial is the logical next step. Based on the effect sizes observed here, a future trial would require considerably more than 24 participants to detect a true treatment effect with statistical confidence. Power calculations for a two-armed parallel trial targeting a clinically meaningful pain responder rate difference of 30 percentage points (the gap observed at Week 1) would likely require 80 to 120 participants per arm, depending on assumed attrition and placebo response rates.
Design improvements for the next generation of trials should include a crossover component to control for individual placebo variability, an enrichment strategy to identify and exclude high placebo responders during an open-label run-in phase, and at minimum one active comparator arm to position cannabis against standard-of-care pharmacotherapy. The all-female sample in this trial was incidental but clinically meaningful given documented sex differences in endocannabinoid receptor expression, pain processing, and cannabinoid pharmacokinetics. Future trials should stratify by sex and aim for diverse enrollment. Longer follow-up beyond 12 weeks would address questions about durability and what happens to symptom burden at treatment cessation. Decentralized trial designs using telemedicine assessment and local sample collection would address the recruitment barriers that limited this study’s enrollment.
Misreadings & Bad-Faith Takes
Distortion: “Cannabis cures fibromyalgia: 70% of patients got relief in new study.” This is inaccurate. The 70% figure reflects a pre-specified pain responder threshold in a feasibility study not powered to confirm efficacy. Forty percent of the placebo group met the same threshold by Week 12. The word “cure” appears nowhere in this research.
Distortion: “Researchers prove cannabis works better than standard fibromyalgia drugs.” Also inaccurate. There was no active comparator in this trial. The study compared cannabis oil to a placebo oil, not to amitriptyline, duloxetine, milnacipran, or pregabalin. No head-to-head claim can be drawn from this dataset.
Distortion: “Cannabis is dangerous for fibromyalgia patients: participants experienced over 100 adverse events.” Misleading in the opposite direction. The 121 adverse events occurred across 24 participants in both the cannabis and placebo groups combined, over a 16-week period. Most were mild. The placebo group also reported 59 adverse events. No serious adverse events occurred in either group.
The most common honest misreading is simply extracting the 70% number from the study without contextualizing the rising placebo response, the blinding failure, and the pilot design. The number is real, but it describes a phenomenon more complicated than a headline allows. Reading the full study, including the discussion section and limitations, is the only way to get an accurate picture of what was actually found.
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
Have thoughts on this? Share it:
? Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
Source
Kurlyandchik I, Tiralongo E, Lauche R, Tracey G, Ng J, Schloss J. “Feasibility, Safety and Preliminary Efficacy of 1:1 THC:CBD Cannabis Oil for Fibromyalgia Symptoms: Results From a Randomised, Double-Blind, Placebo-Controlled Pilot Trial.” Pain Research and Management. 2026;2026(1):e7311235.
PMID: 42142029 | PMC: PMC13179683 | DOI: 10.1155/prm/7311235
Trial Registration: ACTRN12623000345684. Based on articles retrieved from PubMed.
Related Reading at CED Clinic
Continue exploring the evidence
Cannabidiol for Fibromyalgia: Evidence-Based Cannabis Care
A closer look at the evidence for CBD-only approaches in fibromyalgia, including what a separate trial found when CBD was tested alone against placebo.
Explore evidence
Cannabinoids for Neuropathic Pain and Sleep
A physician-reviewed analysis of how cannabinoids affect chronic pain and sleep quality across randomized clinical trials, relevant to fibromyalgia’s overlapping symptom domains.
Explore evidence
Cannabis Insomnia Guide: Matching Cannabis to Your Sleep Problem
Sleep disturbance is one of fibromyalgia’s most disabling features. This guide explains how timing, dose, and formulation affect sleep outcomes in cannabis users.
Explore evidence
Frequently Asked Questions
What type of cannabis oil was used in the fibromyalgia study?
The trial used a plant-derived cannabis oil containing equal concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), each at 10 mg per milliliter. This is described as a 1:1 THC:CBD ratio. The oil was taken orally, once nightly, approximately one hour before bed. Participants started at a very low dose of 0.25 mL and titrated upward over four weeks until they reached their individual maximum tolerated dose. The median final dose in the cannabis group was 1 mL per night, delivering approximately 10 mg each of THC and CBD. This is a conservative, low daily dose by most prescribing standards.
Why was the oil taken at night rather than during the day?
The study authors chose nocturnal dosing for several reasons. First, fibromyalgia causes significant sleep disturbance, and THC in particular has sleep-promoting properties at lower doses. Taking the oil at night allows the drug to address sleep disruption directly. Second, taking a THC-containing product at night rather than during waking hours reduces the risk of daytime cognitive effects, drowsiness, and the practical issue of psychoactive impairment while driving or working. Third, individual tolerability is easier to manage when side effects like morning drowsiness can be observed before re-dosing decisions are made. This nocturnal approach is consistent with clinical practice guidance for oral cannabinoids in chronic pain conditions.
What does it mean that 70% of cannabis patients achieved meaningful pain relief?
The 70% figure refers to the proportion of participants in the cannabis group who reported at least a 30% reduction in their Average Daily Pain Score at the end of the titration phase (Week 1) and maintained that level through Week 12. A 30% reduction in pain is a pre-specified threshold for “clinically meaningful” improvement, derived from prior fibromyalgia clinical trial standards. By comparison, 20% of placebo participants met the same threshold at Week 1. However, by Week 12, 40% of the placebo group also met that threshold. This rising placebo responder rate is common in fibromyalgia trials and reflects the well-documented placebo effect in this condition, as well as the therapeutic benefit of the clinical attention and monitoring that all participants received.
Is fibromyalgia research particularly prone to a high placebo effect?
Yes. Fibromyalgia trials consistently demonstrate higher-than-average placebo response rates, often ranging from 30 to 40 percent in pain outcomes and occasionally matching active treatment responses over longer time horizons. The reasons are not fully understood, but likely involve the bidirectional relationship between expectation, attention, and pain perception in central sensitization conditions. When patients know they are enrolled in a study, receive consistent clinical monitoring, complete detailed symptom diaries, and interact regularly with healthcare providers, some degree of symptom improvement frequently follows, independent of the pharmacological agent. This is not a criticism of how the study was conducted; it is a characteristic of the population being studied, and it is precisely why blinding, appropriate sample sizes, and controlled designs are necessary.
What side effects did participants experience?
The most common adverse events in the cannabis group included somnolence (drowsiness), dizziness, fatigue, nausea, and dry mouth. All of these are consistent with known effects of THC-containing cannabis products. The majority of adverse events were rated as mild in severity, with 6.5% moderate and 0% severe or life-threatening. The placebo group also reported adverse events, including headache, diarrhea, nausea, and flu-like symptoms, many of which were likely attributable to the walnut and avocado oils used in the placebo formulation. Two participants in the cannabis group required dose reduction due to morning drowsiness and cognitive effects including memory disturbance, which resolved with lower doses. One placebo participant withdrew from the trial due to adverse reactions. No serious adverse events occurred in either group.
Was the blinding in this trial preserved properly?
Blinding was not well preserved. At the end of the trial, 75% of participants in both groups correctly guessed which treatment they had received. This rate is substantially higher than chance (50%), and it is most likely explained by THC’s psychoactive properties. Unlike most pharmaceutical placebos, an oil containing active THC produces recognizable perceptual and cognitive effects that make blinding inherently difficult to maintain. This is a known challenge in cannabis research generally and is not unique to this study. However, it is a meaningful limitation because all of the efficacy outcomes in this trial were self-reported. Self-reported pain, sleep quality, and quality of life are particularly sensitive to expectation. A participant who knows she received cannabis may rate her outcomes differently than she would if she were uncertain. The authors appropriately identified this as a limitation and noted that a similar Australian sleep trial reported a comparable blinding failure rate.
How does the endocannabinoid system relate to fibromyalgia?
Fibromyalgia involves central sensitization, a state in which the central nervous system amplifies pain signals beyond what peripheral tissue damage would predict. The endocannabinoid system (ECS) plays a central role in regulating pain processing at spinal, supraspinal, and peripheral levels through CB1 and CB2 receptor signaling, as well as through non-receptor mechanisms involving endocannabinoid metabolites. CB1 receptors are concentrated in the central nervous system, including brain regions involved in pain modulation, mood, and sleep. CB2 receptors are distributed throughout immune tissues and the peripheral nervous system. Some researchers have proposed a theory of clinical endocannabinoid deficiency in fibromyalgia, in which disrupted ECS tone contributes to pain hypersensitivity, sleep disturbance, and mood dysregulation. While this hypothesis remains under investigation, it provides a biological rationale for why a combined THC and CBD formulation, acting on multiple ECS targets, might produce multidomain benefit in fibromyalgia.
Can patients in Massachusetts access cannabis for fibromyalgia?
In Massachusetts, fibromyalgia is not explicitly listed as a qualifying condition for the state’s medical cannabis program. However, Massachusetts law allows patients with “other conditions as determined in writing by a qualifying patient’s treating physician” to qualify, which means a physician can certify a patient with fibromyalgia if they determine that medical cannabis may provide clinical benefit. Patients interested in exploring this path should work with a physician experienced in cannabis medicine who can evaluate their full clinical picture, discuss the evidence base honestly, and help monitor outcomes over time. Adult-use cannabis is also legally available in Massachusetts for individuals 21 and older, though this is separate from the medical program and does not include the same level of clinical oversight. Patients should not begin or change a cannabis regimen without discussing it with a healthcare provider familiar with their complete medication list, particularly given cannabis’s potential interactions with common fibromyalgia medications.
Does this study mean cannabis is better than approved fibromyalgia medications?
No. This study did not compare cannabis oil to any approved fibromyalgia pharmacotherapy. The trial was designed as a placebo-controlled feasibility study, not a head-to-head comparison against amitriptyline, duloxetine, milnacipran, pregabalin, or any other standard treatment. The only valid comparison from this dataset is between cannabis oil and a placebo oil under closely monitored conditions. Drawing conclusions about relative efficacy against standard-of-care medications would require a different study design entirely. Cannabis may be a useful option for patients who have not responded to, or who cannot tolerate, approved medications. It may also be considered as a complementary approach in some cases. But this study cannot and does not establish that cannabis outperforms what is already available for fibromyalgia.
What would a better-powered follow-up trial look like?
The trial authors explicitly call for a larger, adequately powered confirmatory trial as the logical next step. Based on the effect sizes observed in this study, a properly powered two-armed trial would likely require 80 to 120 participants per arm, depending on the assumed placebo response rate and targeted treatment effect. Key design improvements would include: a crossover design to control for individual placebo variability; an enrichment phase to identify and exclude high placebo responders before randomization; at least one active comparator arm (for example, pregabalin or duloxetine) to position cannabis within the treatment landscape; stratification by sex, given the all-female enrollment in this pilot and documented biological differences in ECS function; a longer treatment duration and follow-up to assess durability; and a decentralized or hybrid trial design using telemedicine and local assessments to overcome geographic recruitment barriers. Biomarker assessment and pharmacokinetic data collection would also add interpretive value. [...]
Read more...
June 7, 2026Dr. Benjamin Caplan, MD Board-Certified Family Physician · Cannabis Medicine Specialist Cannabis Science
Clinical Insight
A new pooled analysis of 41 placebo-controlled trials in 1,020 people finds that inhaled THC produces a fairly predictable, dose-correlated experience, while oral THC’s effects do not reliably track with how much is taken. According to PubMed, the review was published June 3, 2026 in Neuroscience and Biobehavioral Reviews (DOI: 10.1016/j.neubiorev.2026.106795).
How Dose and Route Shape the THC Experience: What a 41-Trial Meta-Analysis Found
A newly published systematic review and dose-response meta-regression pooled data from 41 randomized, placebo-controlled trials and 1,020 participants to ask a deceptively simple question: does the way someone takes THC, and how much they take, predictably change how it feels? The answer, according to PubMed, turns out to depend heavily on the route of administration, a finding with direct implications for how clinicians counsel patients on starting doses and what to expect.
CED Clinical Relevance: 85/100 (Exceptional Clinical Relevance)
This review speaks directly to one of the most common questions in a medical cannabis visit, what a given dose and route will likely feel like, with pooled, controlled evidence rather than anecdote. That makes it unusually actionable for route-of-administration counseling and dose titration conversations.
THC Dose-Response Route of Administration Cannabis Pharmacology Patient Education
What You’ll Learn
– Why inhaled and oral THC can produce noticeably different experiences even at doses that sound comparable
– What the dose-response curve looks like for inhaled THC, and why that curve flattens out for oral THC
– Which subjective effects (feeling high, anxious, tired, alert, content, or calm) tracked with dose, and which did not
– How this evidence can inform, without replacing, individualized counseling on starting doses and route selection
TL;DR
❇️ Pooling 41 placebo-controlled trials in 1,020 healthy, infrequent cannabis users, researchers found THC reliably increased feeling high, anxiety, and tiredness, and reliably decreased alertness and contentedness, compared with placebo (calmness was the one measure that did not differ).
❇️ For inhaled THC, larger doses were associated with a measurably stronger “high” and more consistent effects across individuals; for oral THC, dose was not significantly associated with any of the six subjective measures studied.
❇️ Modeled estimates for a 5 mg inhaled dose showed feeling “high” rising by roughly 34 points on a 100-point scale and contentedness falling by roughly 71 points, illustrating how steep these acute effects can be even at modest doses.
❇️ The data come from controlled laboratory sessions in healthy adults with infrequent cannabis use, not from regular medical cannabis patients choosing their own products in real-world settings, a distinction that matters for how the findings should be applied.
Study at a Glance
Study type
Systematic review and dose-response meta-regression
Trials pooled
41 randomized, double-blind, placebo-controlled experimental studies
Population
1,020 healthy adults with infrequent cannabis use (fewer than 2 times weekly; fewer than 100 lifetime uses)
Comparison
Acute, single-dose THC versus placebo in controlled laboratory settings
Routes examined
Inhaled and oral THC, modeled separately via dose-response meta-regression
Outcomes measured
Peak subjective ratings of feeling high, anxiety, tiredness, alertness, contentedness, and calmness
Headline comparison finding
THC produced significantly greater high, anxiety, and tiredness, and significantly lower alertness and contentedness, than placebo (all p<0.01); calmness did not differ significantly (p=0.414)
Dose-response pattern
Significant for inhaled THC on feeling high, contentedness, and calmness; not significant for any measure with oral THC
Journal
Neuroscience and Biobehavioral Reviews
Publication date
June 3, 2026 (DOI: 10.1016/j.neubiorev.2026.106795)
Why This Matters
One of the most common questions in a medical cannabis visit is some version of “how much should I take, and what will it feel like?” Clinicians have long answered with “start low and go slow,” and with route-specific cautions about the slower, less predictable onset of edibles versus the faster, more titratable effects of inhaled products. What has been missing is rigorously pooled, controlled evidence quantifying just how different those two experiences actually are, and whether the intensity of the experience tracks with dose in a way patients can plan around. By pairwise-comparing THC to placebo across 41 trials and then modeling dose-response relationships separately for inhaled and oral administration, this review offers some of the clearest controlled-trial evidence to date on exactly that question.
Clinical Summary
According to PubMed, the researchers first ran pairwise meta-analyses comparing the peak subjective effects of THC against placebo across all 41 trials. Compared with placebo, THC produced significantly greater feelings of being high, anxious, and tired (all p<0.001), and significantly lower alertness and contentedness (both p<0.01). Calmness was the outlier: there was no significant difference between THC and placebo on that measure (p=0.414). In other words, across a pooled sample of more than a thousand people, THC reliably moved five of the six subjective dimensions the researchers tracked, and left the sixth, self-rated calm, essentially unchanged relative to placebo.
The second stage, a dose-response meta-regression stratified by route, is where the route-specific story emerges. For inhaled THC, larger doses were associated with significantly stronger feelings of being high (b=1.06, p=0.0024) and with reduced calmness (b=-0.96, p=0.048), while anxiety, tiredness, and alertness did not show a significant dose relationship by the inhaled route. For oral THC, by contrast, dose was not significantly associated with any of the six subjective measures (all p>0.05). The authors also modeled what an inhaled 5 mg dose of THC would look like relative to placebo on a 100-point scale: increases of about 34.3 points in feeling high, 14.4 points in anxiety, and 26.3 points in tiredness, alongside decreases of about 40.2 points in alertness and 71.0 points in contentedness, with calmness essentially flat. A separate variability analysis found that higher inhaled doses produced more consistent ratings across individuals for feeling high and for contentedness, suggesting the inhaled experience may become not just stronger, but also more predictable, as dose increases.
What This Paper Does Not Show
– It studied healthy adults with infrequent cannabis use (fewer than twice weekly, under 100 lifetime exposures) in single-session laboratory conditions, not regular medical cannabis patients using their own chosen products over time.
– It measured acute subjective experience (how THC feels in the moment), not therapeutic outcomes such as pain relief, sleep quality, or anxiety symptom reduction.
– The 5 mg “modeled” estimates are outputs of a pooled regression model, not a single head-to-head trial measurement, and should be read as illustrative of a trend rather than as a precise prediction for any individual.
– It did not account for tolerance, individual metabolic differences, or the broader chemical profile of real-world products (terpenes, CBD ratios, other minor cannabinoids), all of which shape how a given product feels in practice.
– It did not test whether more predictable dose-response relationships translate into better clinical outcomes or higher patient satisfaction; that remains a separate, unanswered question.
How This Fits With the Broader Clinical Conversation
“Start low and go slow” has been the de facto standard of cannabis counseling for years, often delivered as practical wisdom rather than as a finding anchored in pooled, controlled data. Clinicians have also long observed, anecdotally and in smaller pharmacokinetic studies, that inhaled cannabis tends to produce faster-onset, more easily titrated effects, while oral products are notorious for delayed onset and unpredictable intensity. According to PubMed, this review adds weight to that clinical intuition by quantifying it across a meaningfully large pooled sample: inhaled THC’s effects rose in a measurable, dose-correlated way, and became more consistent across individuals as dose increased, while oral THC showed no such pattern across any of the six measures studied. That asymmetry arrives at a moment when cannabis products, and their potencies, are becoming more varied and more accessible to people with little prior experience, which is precisely the population this review examined.
Dr. Caplan’s Take
In clinic, I see a version of this finding play out almost every week. A patient who has had a clean, controllable experience with a vaporized flower or a metered inhaler is sometimes shocked by how differently an edible at what sounds like a “comparable” dose can land, sometimes underwhelming, sometimes far more intense and longer-lasting than expected. This review gives some quantitative backbone to that pattern: inhaled THC’s effects climbed with dose in a way that was measurable and, encouragingly, became more consistent across people as the dose rose, while oral THC’s effects simply did not track with dose at all in this pooled analysis.
For me, the practical takeaway is less about a specific milligram number and more about how I frame the conversation around route. If a new patient’s priority is predictability, the ability to feel an effect arrive, gauge it, and adjust in real time, this evidence supports steering that conversation toward inhaled options first, with oral products introduced more cautiously and with clearer expectation-setting about variability. None of that replaces an individualized visit; it simply gives me a better-anchored starting point for that conversation.
What a Careful Reader Should Take Away
The headline here is not that “THC is dangerous” or that “THC is now fully predictable.” It is narrower and, in some ways, more useful: in a large pooled sample of controlled trials, the subjective experience of inhaled THC rose with dose in a measurable, fairly consistent way, while the subjective experience of oral THC did not reliably track with dose at all. That distinction, route matters more than the number on the label might suggest, is the kind of evidence that can sharpen a clinical conversation about what to expect, without pretending to settle questions this review was not designed to answer, such as how these patterns play out in regular patients over repeated use, or whether predictability itself improves outcomes or satisfaction.
Evidence Watch Reading Tool
Read This Paper Through Eight Different Lenses
A single study can mean different things depending on who is reading it. This card separates the patient takeaway, clinical meaning, skepticism, study critique, prior research context, practical implications, future directions, and likely public misreadings.
How to use this: Choose a lens above to see how the same paper reads from a different evidence, clinical, or practical angle.
Patient Takeaway Clinician’s POV A Skeptical Read Study Critic Compared to Past Research Practical Considerations Future Directions (Expected) Misreadings & Bad-Faith Takes
Select a lens above to reveal a focused interpretation of the paper. Each view is prepared in advance, evidence-calibrated, and designed to keep the claims tied to what the work actually shows.
Patient Takeaway
If you are weighing how to start with THC, the most useful thing this review offers is not a magic number, it is a pattern. Across more than a thousand people in controlled studies, inhaled THC tended to produce effects that rose in a fairly steady, trackable way as the dose went up, and those effects became somewhat more consistent from person to person at higher doses. Oral THC told a different story: in this pooled analysis, how strong the experience felt simply did not line up with how much was taken. That helps explain a frustration many people already sense, that an edible can feel underwhelming one time and overwhelming the next, even at what looks like the same dose. None of this tells you what dose is right for you, your body chemistry, prior experience, and the specific product all matter, and this review did not study people choosing their own products over time. What it does offer is a reason to treat route of administration as a real variable worth discussing with a clinician, not just a matter of preference, especially if predictability matters to you.
Clinician’s POV
This review gives clinicians something we have mostly lacked: pooled, controlled-trial evidence that the dose-response relationship for THC’s subjective effects is route-dependent, not just intuition or small pharmacokinetic studies. In the exam room, that supports a more concrete framing for new or cannabis-naive patients: inhaled routes appear to offer a more titratable, dose-correlated experience, which may make them a reasonable first choice when predictability and the ability to stop at a comfortable point are priorities, while oral products may warrant more conservative starting guidance and clearer warnings about variability. It would be a mistake to over-translate this into a blanket recommendation; the population studied was healthy and infrequently-using, the outcomes were subjective and acute, and therapeutic endpoints were not assessed. The responsible use of this evidence is as one more data point in a shared decision-making conversation about route, starting dose, and what to expect, not as a substitute for individualized titration guided by the patient’s own response, medical history, and goals.
A Skeptical Read
A thoughtful skeptic would start with the population: these are healthy adults with infrequent cannabis use, deliberately selected to minimize tolerance effects, which makes them a clean experimental sample but a poor stand-in for the regular medical cannabis patients clinicians actually see day to day. The outcomes are also entirely subjective, peak self-ratings on scales like “high,” “content,” and “calm”, collected in artificial laboratory settings that bear little resemblance to how people actually use cannabis at home, on their own schedule, with products they chose themselves. It is also worth asking how much heterogeneity exists across those 41 trials in dosing protocols, measurement scales, and session conditions, since pooling studies that differ in these ways can blur as much as it reveals. None of this means the findings are wrong; pairwise comparisons against placebo, run across more than 1,000 participants, are a meaningful signal. But the leap from “this is what happens in a lab to infrequent users on a single occasion” to “this is what will happen for my patients” is exactly the leap that deserves the most scrutiny.
Study Critic
The strongest part of this paper is its scale and design: 41 randomized, double-blind, placebo-controlled trials pooled into pairwise meta-analyses is a substantial evidentiary base, and the headline comparisons (high, anxiety, tiredness, alertness, contentedness all differing from placebo at p<0.01 or better) are statistically robust. The inference gets thinner at the dose-response stage. The inhaled-route findings for feeling high and calmness reached significance, but the regression coefficients for contentedness moved in a direction that is not entirely intuitive relative to the placebo-comparison findings, and the authors’ modeled 5 mg estimates are projections from a pooled regression model rather than direct measurements from any single trial at that dose. Readers should also note that a non-significant finding for oral THC’s dose-response relationship is not the same as proof that no such relationship exists; it may reflect fewer oral-route trials, wider variability in oral pharmacokinetics, or limited statistical power at that stage of the analysis. The honest summary is that the placebo-comparison findings are on solid ground, and the route-specific dose-response findings, while informative, carry wider uncertainty than a single headline number can convey.
Compared to Past Research
Based on the supplied source alone, this comparison should be read cautiously because prior studies were not independently reviewed for this Lens Card. What can be said directly from this paper is that it positions itself as addressing “a lack of systematic evidence on the subjective effects” of THC, which suggests the authors view existing literature on this specific question, a pooled, dose-stratified, route-specific analysis of subjective effects, as thin relative to the volume of cannabis research overall. The clinical observation that inhaled and oral cannabis “feel different” is not new; it has circulated in patient counseling and smaller pharmacokinetic comparisons for years. What this review appears to add, again based only on what is reported here, is a larger, pooled, statistically modeled foundation underneath that long-standing observation, translating an informal pattern into something closer to a quantified, testable relationship. Readers interested in how this finding sits alongside the wider literature on cannabis pharmacokinetics and route-specific absorption should look to dedicated reviews of that literature rather than relying on this summary alone.
Practical Considerations
For someone new to THC, or returning after a long break, this review underscores why route deserves real attention before dose does. An inhaled product allows the effect to be felt within minutes, assessed, and built upon gradually, which is exactly the kind of feedback loop that this review suggests produces a more dose-correlated, more consistent experience. An oral product removes that real-time feedback: the onset is delayed, and according to this review, the eventual intensity does not reliably scale with the amount taken, which is a recipe for both underwhelming and overwhelming experiences from the same starting point. None of this is a substitute for professional guidance, particularly for anyone managing a health condition, taking other medications, or unsure how their body responds to THC at all. But as a general orientation, this review supports a familiar piece of practical advice, that inhaled routes tend to be easier to “dial in”, while adding pooled, controlled evidence behind a recommendation that has often rested mainly on clinical experience.
Future Directions (Expected)
The most natural next step suggested by this review’s own framing is to take these laboratory-derived, route-specific dose-response patterns and test whether they hold up in the populations clinicians actually treat: people with chronic conditions, regular cannabis users with established tolerance, and patients selecting and titrating their own products over weeks or months rather than during a single monitored session. It would also be valuable to see whether the predictability advantage observed for inhaled THC in this review translates into any measurable difference in patient-reported satisfaction, adherence, or therapeutic outcomes, questions this paper was not designed to answer. Given that the authors frame their work explicitly around “public health efforts to guide consumers,” a logical extension would be patient-facing tools or counseling protocols that operationalize these route-specific patterns, then test whether using them changes how people actually dose and experience cannabis in real-world settings.
Misreadings & Bad-Faith Takes
One likely distortion: “Scientists prove THC is dangerous and makes you anxious.” That overstates a narrower finding, this review found THC produced significantly higher average anxiety ratings than placebo across the pooled sample, but it does not establish that THC causes clinically significant anxiety in any individual, nor does it speak to therapeutic contexts where patients and clinicians weigh that risk against potential benefits. A second likely distortion: “This study shows edibles don’t work.” That is not what the data show; the finding is that, in this pooled analysis, the intensity of oral THC’s subjective effects did not reliably scale with dose, which is a statement about predictability, not about whether oral products produce effects at all. A third possible misreading: treating the modeled “5 mg inhaled THC” numbers as a precise, individualized prediction. Those figures are outputs of a pooled regression model meant to illustrate a trend across a study population, not a guarantee of what any specific person will feel at that dose. The corrective in each case is the same: this is solid pooled evidence about general patterns in a specific, healthy, infrequently-using population, not a verdict on any individual’s experience or on cannabis as therapy.
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message Metabolic Care Medical Consulting Cannabis Care
Have thoughts on this? Share it:
? Share on X in Share on LinkedIn ? Share on BlueSky ? Follow on Instagram ? Read more on Substack ? Subscribe via RSS
Source: According to PubMed, Goodwin I, Oliver D, Chesney E, et al. “The subjective effects of Δ9-tetrahydrocannabinol: A systematic review and dose-response meta-regression.” Neuroscience and Biobehavioral Reviews. Published online June 3, 2026. DOI: 10.1016/j.neubiorev.2026.106795 · PMID: 42242480.
Related Reading at CED Clinic
Continue exploring the evidence
Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products
A real-world look at how flower and edible products produced different day-to-day patterns of relief, a practical companion to this review’s laboratory-based finding that route changes the subjective experience of THC.
Explore evidence
Medical Cannabis for Anxiety: What a 45-Day Real-World Study Actually Shows
A longer-term, real-world dataset that pairs well with this review’s controlled-lab findings, useful context for thinking about how acute subjective effects may relate to sustained patterns of use.
Explore evidence
Cannabis for Anxiety and Depression: Starting Options
A practical starting-point guide for patients weighing their first steps with cannabis, directly relevant to this review’s emphasis on how route and dose shape what a first experience may feel like.
Explore evidence
Frequently Asked Questions
What did this study actually measure?
According to PubMed, researchers pooled 41 randomized, double-blind, placebo-controlled trials involving 1,020 healthy adults with infrequent cannabis use, then compared peak self-reported subjective ratings (feeling high, anxious, tired, alert, content, and calm) after THC versus placebo, and modeled how those ratings changed with dose for inhaled and oral administration separately.
Did THC feel different from placebo overall?
Yes. Across the pooled sample, THC produced significantly greater feelings of being high, anxious, and tired, and significantly lower alertness and contentedness, compared with placebo (all p<0.01). Self-rated calmness was the one measure that did not differ significantly between THC and placebo.
Does taking more THC always produce a stronger effect?
Not uniformly, and the route mattered. For inhaled THC, larger doses were associated with significantly stronger feelings of being high and with reduced calmness. For oral THC, dose was not significantly associated with any of the six subjective measures studied in this review.
Why might inhaled and oral THC feel so different at similar doses?
This review did not test the underlying mechanisms, but its findings are consistent with long-observed differences in how the two routes are absorbed and processed: inhaled THC tends to take effect quickly and predictably, while oral THC’s onset and intensity are known to vary more from person to person and occasion to occasion.
What does the “5 mg inhaled THC” estimate mean?
It is a modeled projection from the pooled dose-response analysis, not a direct measurement from a single trial. The model estimated that an inhaled 5 mg dose would correspond to roughly a 34-point rise in feeling high, a 14-point rise in anxiety, a 26-point rise in tiredness, and reductions of roughly 40 points in alertness and 71 points in contentedness, on a 100-point scale relative to placebo.
Does this study show that cannabis is unsafe?
No. The study measured acute subjective experience in healthy, infrequently-using adults under controlled laboratory conditions. It did not assess safety outcomes, adverse events, therapeutic benefit, or long-term effects, and its findings should not be read as a verdict on cannabis safety in general or in any individual.
Do these findings apply to regular medical cannabis patients?
Not directly. The participants were healthy adults with infrequent cannabis use (fewer than twice weekly, under 100 lifetime exposures), studied during single laboratory sessions. Regular patients with established tolerance, ongoing conditions, and individualized product choices were not part of this sample, so the patterns observed here may not translate one-to-one.
Did the study look at whether THC helps with anxiety or other conditions?
No. This review focused exclusively on the acute subjective experience of THC compared with placebo. It did not evaluate whether THC reduces anxiety symptoms, improves sleep, or provides any therapeutic benefit; those are different research questions requiring different study designs.
What should someone new to THC take from this review?
The clearest practical signal is that route of administration appears to meaningfully shape both the intensity and the predictability of the experience, with inhaled THC showing a more dose-correlated, more consistent pattern in this pooled analysis than oral THC. That is useful context for a conversation with a clinician about where to start, not a substitute for one.
Where was this research published, and how can I read more?
According to PubMed, the review was published online on June 3, 2026 in Neuroscience and Biobehavioral Reviews by Goodwin and colleagues, and is available at DOI: 10.1016/j.neubiorev.2026.106795 (PMID: 42242480).
THC subjective effects dose-response meta-analysisPatients and clinicians considering medical cannabis2026-06-07 [...]
Read more...
June 6, 2026Dr. Benjamin Caplan, MD
|
Board-Certified Family Physician & Cannabis Medicine Specialist
|
Cannabis Science
|
June 5, 2026
Clinical Insight
A meta-analysis of eight clinical studies and 306 adult patients found that cannabis-based medicines produced a statistically significant reduction in tic severity in Tourette syndrome. The effect was measured on the Yale Global Tic Severity Scale, with a mean decrease of 13.29 points. The premonitory urge to tic also improved. These findings come as the DEA rescheduling hearing opens June 29, 2026 — and add to a growing clinical literature that policymakers, prescribers, and patients will need to weigh.
Cannabis-Based Medicines Reduce Tic Severity in Tourette Syndrome: A Clinical Look at 306 Patients
A systematic review and meta-analysis of eight clinical studies has found that cannabis-based medicines significantly reduced tic severity and the premonitory urge to tic in adults with Tourette syndrome — a finding that carries particular weight as the field searches for better-tolerated alternatives to first-line antipsychotic medications.
CED Clinical Relevance
72 / 100
Strong Clinical Relevance
Tourette syndrome affects an estimated 1% of the population, and a meaningful subset of patients either do not respond adequately to first-line antipsychotics or cannot tolerate their side effect profile. Cannabis-based medicine represents a clinically distinct option with an endocannabinoid mechanism — making this meta-analysis directly relevant to patient conversations at CED Clinic.
Tourette Syndrome
Cannabis Medicine
Endocannabinoid System
Neurological Conditions
Tic Disorders
What You’ll Learn
What the meta-analysis measured and what its pooled data actually found about tic reduction
Why the endocannabinoid system’s role in basal ganglia function may explain the observed effects
How this evidence compares to what the 2026 Lancet Psychiatry review found about cannabis and neurological conditions
What the methodology limitations mean for clinical use — and what should not be concluded from this data
What patients in Massachusetts and across the US should realistically expect if they bring this up with their physician
TL;DR
❇️ Eight clinical studies, 306 adults with Tourette syndrome: cannabis-based medicines produced a statistically significant mean YGTSS reduction of 13.29 points.
❇️ The premonitory urge to tic also improved; obsessive-compulsive symptoms measured by the Y-BOCS did not show significant change.
❇️ The authors stopped short of recommending routine clinical use; the evidence is real but limited by study heterogeneity and small sample sizes.
❇️ This evidence now sits before the DEA’s rescheduling hearing opening June 29, 2026, as part of the clinical record on medical cannabis utility.
⚠ Quality Gate Alerts
Small, heterogeneous sample: Eight studies pooling 306 patients is a modest evidence base. Study designs, cannabis formulations, doses, and routes of administration vary substantially across included trials.
No standardized dosing protocol: The meta-analysis cannot identify an optimal dose, product type, or treatment duration from the available data.
Limited placebo-controlled data: The inclusion of open-label studies means placebo effects and expectancy bias cannot be fully excluded from the pooled result.
Study at a Glance
Study Type
Systematic review and meta-analysis
Studies Included
8 clinical studies (quantitative analysis)
Population
306 adults with Tourette syndrome
Intervention
Cannabis-based medicines (various formulations)
Primary Outcome
Yale Global Tic Severity Scale (YGTSS) total score
Key Result
Mean YGTSS reduction: −13.29 (statistically significant); PUTS also significantly reduced
No Significant Effect On
Yale-Brown OCD Scale (Y-BOCS)
Literature Search
PubMed, Google Scholar, ScienceDirect, Cochrane (through July 2025)
Evidence Level
Low to moderate certainty (authors’ assessment); small heterogeneous studies
Mechanism Proposed
Interaction with CB1 and CB2 receptors in basal ganglia and cortical circuits
Why This Matters
Tourette syndrome lacks a universally effective treatment. The medications most commonly used — haloperidol, pimozide, aripiprazole — carry side effect profiles that make long-term use difficult for many patients: weight gain, sedation, extrapyramidal symptoms, and metabolic effects. A meaningful subset of patients either fail to respond adequately or discontinue treatment because of tolerability. Cannabis-based medicine, operating through a fundamentally different mechanism via the endocannabinoid system, has been explored as an alternative. This meta-analysis represents the most comprehensive pooling of that clinical evidence to date for adult patients — and its timing, on the eve of a federal rescheduling hearing, makes it newly relevant to the policy conversation as well.
Clinical Summary
The meta-analysis drew from eight clinical studies encompassing 306 adults diagnosed with Tourette syndrome. Pooling the available data, researchers found that cannabis-based medicines produced a statistically significant reduction in total Yale Global Tic Severity Scale scores, with a mean difference of −13.29. The YGTSS is a validated clinician-rated instrument that captures both motor and vocal tic severity on a 0–50 scale each, with an additional impairment subscale. A reduction of more than 13 points represents a clinically noticeable change, though without a robust placebo comparison the extent of genuine pharmacological effect versus expectancy cannot be precisely partitioned from the pooled data. The Premonitory Urge for Tics Scale — which measures the uncomfortable sensory phenomena many patients describe as preceding tic expression — also showed significant improvement, suggesting the effect may extend beyond motor symptom suppression.
Importantly, the Yale-Brown Obsessive-Compulsive Scale scores did not change significantly, which is clinically relevant because OCD symptoms are a common comorbidity in Tourette syndrome and can be just as disabling as the tics themselves. The authors attribute the tic-reduction effects to the interaction of cannabinoids — particularly delta-9-tetrahydrocannabinol — with CB1 and CB2 receptors concentrated in the basal ganglia and cortical networks that regulate motor output. The literature review searched PubMed, Google Scholar, ScienceDirect, and the Cochrane Collaboration Database for studies published through July 2025. The tolerability profile of cannabis-based medicine compared favorably to antipsychotics in the included studies, though the authors are explicit that the heterogeneity of study designs, formulations, and dosing protocols prevents any definitive dosing recommendations.
The Endocannabinoid System and Tic Biology: Why This Mechanism Makes Sense
Tourette syndrome is not simply a movement disorder. It emerges from a complex interplay between cortico-striato-thalamo-cortical circuits, where abnormal inhibitory signaling allows tics to break through. The endocannabinoid system is deeply embedded in exactly these circuits. CB1 receptors are expressed at high density in the striatum, globus pallidus, and substantia nigra — structures that are central to the pathophysiology of Tourette’s. Endocannabinoid signaling in these regions modulates dopaminergic and GABAergic neurotransmission, both of which are disrupted in tic disorders.
When THC binds to CB1 receptors in the basal ganglia, it modulates the inhibitory output pathways that regulate motor planning and execution. The hypothesis has long been that exogenous cannabinoids can reduce the “runaway” motor output underlying tics by augmenting endogenous inhibitory tone. The fact that the premonitory urge — the uncomfortable, presuppressive sensory experience many patients describe — also improved in this meta-analysis is consistent with CB1’s role in sensory gating, not just motor suppression.
This is worth dwelling on clinically. Many patients report that their primary struggle is not the visible tic itself, but the mounting internal pressure that precedes it. Treatments that reduce tic severity but leave the premonitory urge intact may provide incomplete relief. The suggestion that cannabis-based medicines may address both dimensions simultaneously — if the signal holds in larger, better-controlled studies — is one of the more interesting aspects of this review.
Where This Evidence Sits Relative to the Rest of the Cannabinoid Literature
It is worth reading this meta-analysis alongside the major Lancet Psychiatry systematic review published earlier in 2026. That review — covering 54 randomized controlled trials across a wide range of mental health and substance use conditions — found little evidence supporting routine cannabis use for anxiety, depression, or PTSD. It was a sobering assessment. But within that broadly negative finding, Tourette syndrome was one of the few conditions where the authors found a signal worth acknowledging. This newer, dedicated meta-analysis provides a more detailed view of exactly that signal.
The two bodies of evidence are not in conflict — they reinforce a more nuanced clinical picture. Cannabis is not a general-purpose mental health medication. It is a pharmacologically specific agent that interacts with a biologically specific system. Where that system plays a central role in a disorder’s pathophysiology — as it does in tic-generating circuits — the case for therapeutic use is stronger than where the connection is more peripheral. Earlier analyses of cannabinoids in Tourette’s and anxiety raised this question; this meta-analysis sharpens the evidence specifically for tic disorders in adults.
There is also a separate 2025/2026 adolescent study examining cannabis in younger Tourette patients, which adds preliminary data from a different age group. The adult and pediatric evidence bases are developing in parallel and should not be conflated — dosing, tolerability, and developmental considerations differ substantially between these populations.
The Problem of Heterogeneity and What It Means for Patients
The meta-analysis authors are direct about the limitations, and clinicians reading this work carefully should be too. Eight studies is a modest foundation. The included trials used different cannabis formulations — some synthetic cannabinoids such as nabilone, some whole-plant preparations, others THC-dominant pharmaceutical extracts. Doses varied. Routes of administration varied. Study durations varied. The heterogeneity across these dimensions makes it impossible to say with confidence what product a patient should use, at what dose, for how long, or in combination with what other interventions.
This is not a reason to dismiss the finding. It is a reason to interpret it correctly. The pooled mean YGTSS reduction of 13.29 points is consistent across a variety of cannabis-based approaches, which suggests the mechanism — not the specific product — may be the common driver. That is actually useful clinical information. It suggests that patients who are already using whole-plant cannabis informally for tic management may be accessing a real biological effect, not a placebo response. It also suggests that the field needs a well-designed, adequately powered randomized controlled trial to clarify which formulation, dose, and duration produces the most durable benefit.
In Massachusetts, where patients can access medical cannabis with physician certification, Tourette syndrome is not listed as a specific qualifying condition under the state program — but physicians can certify patients for conditions they believe may benefit from cannabis under the state’s framework. Understanding the evidence base for Tourette’s is therefore directly relevant to clinical conversations happening in Boston-area practices today. For practitioners at CED Clinic and similar practices working with the endocannabinoid system, this evidence adds specificity to those conversations.
What the DEA Hearing Means for This Evidence
The DEA’s rescheduling hearing opens June 29, 2026, and runs through July 15. Its focus is whether the full rescheduling of cannabis from Schedule I to Schedule III is scientifically justified and legally appropriate. In April 2026, the DOJ moved FDA-approved products and state-licensed medical cannabis to Schedule III under an expedited order — but the broader hearing will weigh the accumulated clinical evidence for medical utility, including in neurological conditions.
This meta-analysis is exactly the kind of data that informs those proceedings. It is not the definitive proof the rescheduling advocates would prefer, but it contributes to a body of literature showing that cannabis has pharmacologically specific effects in at least some well-defined clinical populations. The direction of the evidence — signal present, magnitude uncertain, mechanism plausible, tolerability favorable — is consistent with Schedule III status, which requires accepted medical use with currently accepted safety data. The Lancet Psychiatry review and this Tourette meta-analysis, read together, illustrate both the limits and the legitimate clinical utility of cannabis — a more honest picture than either pure advocacy or pure skepticism provides.
What This Paper Does Not Show
It does not establish which cannabis formulation, dose, or route of administration produces optimal tic reduction
It does not demonstrate sustained benefit beyond the study periods of the included trials
It does not prove that cannabis improves the OCD symptoms that commonly co-occur with Tourette syndrome
It cannot isolate a pharmacological effect from expectancy or placebo because of the limited number of placebo-controlled studies available for inclusion
It does not provide evidence that cannabis should replace or displace first-line behavioral or pharmacological treatments for Tourette syndrome
How This Fits With the Broader Clinical Conversation
For most of the history of cannabis medicine, Tourette syndrome was treated as a niche indication — a condition where anecdotal reports were intriguing but the evidence base too thin to act on. That characterization is evolving. Over the past several years, multiple systematic reviews, case series, and small trials have reached similar conclusions: cannabis-based medicines are associated with measurable tic reduction in adults, the effect is consistent enough across different study designs to be taken seriously, and the tolerability profile is generally favorable compared to the antipsychotics that most patients are offered as first-line options.
The practical question for a clinician is not whether cannabis works for Tourette syndrome — the signal is now strong enough that “possibly” is more defensible than “no.” The question is how to have an evidence-calibrated conversation with a patient who is suffering, has tried standard medications, and wants to understand their options. This meta-analysis gives clinicians specific, peer-reviewed data to share: tic severity scores improved on a validated instrument across eight studies, the premonitory urge improved, and tolerability was reported as favorable relative to antipsychotics. That is a responsible starting point for a shared decision-making conversation, not a prescription recommendation.
Dr. Caplan’s Take
What I keep coming back to in this meta-analysis is the premonitory urge finding. Tics are distressing on their own terms, but the patients who describe the most profound suffering are often the ones who live with the constant, mounting buildup before the tic comes out — this unavoidable, uncomfortable pressure that can dominate an entire day of conscious attention. If cannabis-based medicine is doing something about that sensory experience, not just the visible motor output, that tells us something meaningful about the mechanism. It is not suppressing the symptom from the outside. It is modulating the internal signaling that generates it.
I want to be direct about what this meta-analysis is and is not. Eight studies, 306 patients — this is not the level of evidence that should lead a clinician to hand every Tourette patient a cannabis certification without careful discussion. The heterogeneity is real. We genuinely do not know which product works best, at what dose, or in what patient profile. What we do have is a coherent biological story — the ECS in the basal ganglia, the role of CB1 in modulating dopaminergic inhibitory tone — a pooled signal that survives aggregation across different study designs, and an adverse effect profile that, in the included studies, looked better than what we see with haloperidol or aripiprazole. That combination is enough for a serious clinical conversation. It is not enough for certainty. And in medicine, knowing the difference between those two things is the whole game.
What a Careful Reader Should Take Away
Cannabis-based medicines were associated with statistically significant reductions in tic severity and premonitory urge in a meta-analysis of eight clinical studies covering 306 adults with Tourette syndrome. The mean reduction in Yale Global Tic Severity Scale scores was 13.29 points. OCD symptoms did not show significant change. The authors concluded that these findings are encouraging but insufficient to support routine clinical use, given the heterogeneity of the included studies and the absence of a standardized dosing protocol.
The biological mechanism — endocannabinoid modulation of CB1-rich basal ganglia circuits — provides a plausible explanation for the observed effect. This evidence sits alongside the 2026 Lancet Psychiatry meta-analysis, which found limited evidence for cannabis in most mental health conditions but acknowledged Tourette syndrome as one of the few areas of signal. Together, these reviews present a more specific picture than “cannabis helps mental health” or “cannabis doesn’t help mental health.” They suggest the relevant question is: which patients, which symptoms, through which mechanism, with which formulation?
Evidence Watch Reading Tool
Read This Meta-Analysis Through Eight Different Lenses
A meta-analysis on cannabis and Tourette syndrome reads differently depending on whether you are the patient whose tics disrupt daily life, the clinician deciding whether to certify, the skeptic questioning open-label designs, or the researcher wondering what the field needs next. This card separates those eight perspectives from the same underlying data.
How to use this: Select a lens above to see how the same meta-analysis reads from a different evidence, clinical, or practical angle.
Patient Takeaway
Clinician’s POV
A Skeptical Read
Study Critic
Compared to Past Research
Practical Considerations
Future Directions (Expected)
Misreadings & Bad-Faith Takes
Select a lens above to reveal a focused interpretation of the meta-analysis. Each view is prepared in advance, evidence-calibrated, and designed to keep the claims tied to what the pooled data actually shows.
Patient Takeaway
If you have Tourette syndrome and have struggled with the side effects of antipsychotic medications, this meta-analysis is worth knowing about — not because it proves cannabis will help you, but because it represents the most complete picture we currently have of what the clinical data says. Eight studies, 306 adults: tic severity improved on a validated scale, and the uncomfortable internal buildup before tics — the premonitory urge — also improved. That second finding matters, because many patients say the urge is as disabling as the tic itself.
What this does not tell you: which product to use, what dose, how long to try it, or whether it will work for you specifically. Those are questions that require an individual conversation with a physician who understands both Tourette syndrome and cannabis medicine. The studies pooled here used different formulations and doses, so the data cannot be translated into a personal treatment plan. What it can do is give you grounded talking points when you bring this up with your doctor — and evidence that this question deserves a serious clinical answer, not a dismissal.
Clinician’s POV
The mean YGTSS reduction of 13.29 points across eight studies is a finding worth taking seriously in the exam room, with appropriate caveats clearly communicated. For a patient who has failed or cannot tolerate first-line antipsychotics — haloperidol, aripiprazole, pimozide — the question of cannabis is no longer purely speculative. The mechanism via CB1-rich basal ganglia circuits is biologically coherent. The tolerability signal, while limited by study design, is consistently described as favorable relative to antipsychotic comparators.
The clinical challenge is that the data cannot guide dosing. There is no standardized formulation, no established THC-to-CBD ratio shown to be optimal, and no duration data that supports a recommendation about how long to continue a trial. Shared decision-making is appropriate here: the patient brings their functional goals, their prior medication history, and their tolerance for uncertainty; the clinician brings the evidence base as it actually stands, including its gaps. In Massachusetts, physicians can certify patients with Tourette’s under the state’s qualifying condition framework with appropriate clinical documentation. This meta-analysis provides defensible grounds for that conversation.
A Skeptical Read
Eight studies with 306 patients is a thin foundation for clinical confidence. When those eight studies span different decades, different countries, different cannabis formulations (including pharmaceutical synthetics), different doses, and different follow-up durations, the pooled mean difference of 13.29 points on the YGTSS carries substantial uncertainty that a single-number summary can obscure. The statistic appears clean; the underlying data is not.
The absence of significant Y-BOCS change is also worth flagging. OCD symptoms are one of the most impairing features of Tourette syndrome for many patients, and if cannabis is not moving those symptoms, its practical benefit may be more limited than the tic data alone suggests. The skeptical reader also notices what the meta-analysis does not claim: it does not endorse routine clinical use. The authors themselves describe the evidence as insufficient for dosing recommendations. That is not a vote of confidence from the people who read every included study most closely.
Study Critic
The methodological weaknesses in this meta-analysis are not hidden — they are disclosed by the authors, which is appropriate. The heterogeneity across included studies means that the pooled effect size is combining apples and oranges to some degree. A study using nabilone (a synthetic THC analogue) and a study using whole-plant cannabis flower are capturing effects of different pharmacological agents, even if both qualify as “cannabis-based medicines.”
The absence of a well-powered placebo-controlled RCT in the pooled data is the most significant gap. Open-label and observational designs inflate expected response rates via expectancy effects, and Tourette syndrome is particularly susceptible to placebo response given the voluntary-involuntary nature of tic expression. The YGTSS is a validated instrument, but its minimum clinically important difference in the context of cannabis trials has not been firmly established in this population. What appears to be a meaningful reduction numerically may or may not correspond to what patients experience as functional improvement. The data is suggestive, not conclusive, and the field needs a multicenter, placebo-controlled RCT to move beyond that characterization.
Compared to Past Research
Cannabis research in Tourette syndrome has accumulated gradually over roughly two decades, moving from case reports to small open-label trials to the kind of pooled analysis seen here. Earlier systematic reviews, including one published in the European Journal of Clinical Pharmacology (Serag et al., 2024), reached similar general conclusions — cannabis-based medicines produce measurable tic reduction on validated instruments — while also noting the limited scale and heterogeneity of the underlying studies. The current meta-analysis appears to represent one of the most recent and comprehensive poolings of this evidence.
Within the broader cannabinoid literature, the 2026 Lancet Psychiatry meta-analysis examined 54 RCTs across mental health and substance use conditions and found Tourette syndrome among the few areas showing a positive signal. That review’s positive finding for tics, drawn from a different literature search, is directionally consistent with what this dedicated meta-analysis reports. These are independent analyses reaching convergent conclusions, which is a more reliable signal than either alone. Noting this convergence is appropriate; the comparison studies themselves were not independently verified as part of this Lens Card preparation.
Practical Considerations
For a patient or clinician in Massachusetts who wants to act on this data, several practical realities apply. First, Tourette syndrome is not explicitly listed as a qualifying condition in all state medical cannabis programs, though physician discretion exists in most jurisdictions. Second, the lack of dosing data from this meta-analysis means any trial of cannabis for tics involves a degree of individualized titration rather than a protocol-based approach. Third, whole-plant cannabis products vary substantially in cannabinoid ratios, terpene profiles, and potency — what a patient purchases at a dispensary may not resemble what was used in any of the eight included studies.
Monitoring during a cannabis trial in this population should include periodic assessment with a validated tic severity tool, baseline documentation of comorbid OCD and ADHD symptoms, and discussion of cannabis use disorder risk, particularly for patients in younger adult age brackets. The cost of medical cannabis is generally not covered by insurance. The conversation about trying cannabis for Tourette’s is reasonable to have; the clinical infrastructure to do it well requires more scaffolding than the meta-analysis itself provides.
Future Directions (Expected)
The most needed next step is a multicenter, adequately powered, randomized placebo-controlled trial with standardized cannabis formulation and dose titration in adult Tourette patients. Such a trial should include long-term follow-up — at least 12 months — to assess whether tic reduction persists, whether tolerance develops, and whether there are meaningful effects on OCD symptoms and quality of life beyond what the YGTSS captures.
Biomarker studies examining ECS function in Tourette syndrome — CB1 receptor availability, endocannabinoid tone in the basal ganglia — would help identify which patients are most likely to respond, moving the field toward something resembling precision prescribing. The adolescent population requires its own evidence base; the developmental ECS is pharmacologically distinct from the adult ECS, and findings in adults should not be extended to younger patients without dedicated research. Finally, head-to-head comparative trials of cannabis versus standard antipsychotic medications, measuring both efficacy and tolerability outcomes, would provide the kind of evidence that could genuinely shift clinical practice guidelines. The current meta-analysis identifies the signal; the next generation of research needs to characterize it rigorously.
Misreadings & Bad-Faith Takes
Distortion 1: “Cannabis cures Tourette syndrome.” This is false. The meta-analysis found an association between cannabis use and reduced tic severity scores on a validated scale in 306 adults across eight heterogeneous studies. It does not demonstrate cure, remission, or elimination of tics. The effect is real in the pooled data; it is not a cure.
Distortion 2: “This proves doctors should prescribe cannabis for Tourette’s.” Also false. The authors explicitly declined to endorse routine clinical use based on this evidence, citing insufficient data on optimal dosing and formulation. The meta-analysis supports a clinical conversation about cannabis as an option — it does not constitute a prescribing recommendation.
Distortion 3: “This study shows cannabis is safe for Tourette’s patients.” The meta-analysis did not conduct a systematic assessment of adverse events. Its tolerability comparisons are informal. Safety cannot be broadly affirmed from this data.
Distortion 4: “Only eight studies, so the whole thing is meaningless.” The size of the evidence base is a legitimate limitation. It does not make the finding meaningless. A signal that is consistent across eight independent study designs, pooled without contradiction, is worth clinical attention even when larger confirmatory trials are still needed.
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Dr. Benjamin Caplan, MD
Board-Certified Family Physician · Cannabis Medicine Specialist · CMO, CED Clinic
? Leave a Message? Metabolic Care? Medical Consulting? Cannabis Care
Have thoughts on this? Share it:
? Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
Source
Primary source: “Cannabis for Tic Control: A Systematic Review and Meta-Analysis of Its Efficacy in Tourette Syndrome Management.” Systematic review and meta-analysis, 8 clinical studies, 306 adult patients. Primary coverage: Business of Cannabis, June 4, 2026. Related peer-reviewed publication: Serag I et al., “Efficacy of cannabis-based medicine in the treatment of Tourette syndrome: a systematic review and meta-analysis.” European Journal of Clinical Pharmacology, 2024. DOI: 10.1007/s00228-024-03710-9. PMC: PMC11393157.
Supporting context: Wilson J et al. “The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis.” The Lancet Psychiatry, 2026; 13(4):304. DOI: 10.1016/S2215-0366(26)00015-5. PMID: 41856154.
Related Reading at CED Clinic
Continue exploring the evidence
Cannabinoids for Anxiety & Tourette’s: Evidence from Systematic Reviews and Meta-Analyses
An earlier review of the systematic evidence base for cannabinoids in both anxiety and Tourette’s syndrome — provides important historical context for how the evidence has evolved.
Explore evidence
Endocannabinoid System Research: Cannabis, PTSD & SUD Care
A deep look at ECS research and its implications for clinical cannabis care — relevant context for understanding why cannabinoid effects in neurological conditions are mechanistically plausible.
Explore evidence
Medicinal Cannabis Doesn’t Help Anxiety, Depression, or PTSD, Huge Review Finds
The 2026 Lancet Psychiatry meta-analysis that found limited evidence across most mental health conditions — but noted Tourette syndrome as one of the few areas with a positive signal.
Explore evidence
Frequently Asked Questions
What did the meta-analysis actually find about cannabis and Tourette syndrome?
The meta-analysis pooled data from eight clinical studies covering 306 adults with Tourette syndrome. It found that cannabis-based medicines produced a statistically significant reduction in Yale Global Tic Severity Scale (YGTSS) total scores, with a mean decrease of 13.29 points. The premonitory urge to tic — the uncomfortable internal buildup that precedes tic expression — also significantly improved. Obsessive-compulsive symptoms, measured by the Yale-Brown OCD Scale, did not show a significant change in the pooled data.
Can someone with Tourette syndrome use cannabis medically in Massachusetts?
Massachusetts does not list Tourette syndrome as a named qualifying condition in its medical cannabis program, but the state’s framework allows physicians to certify patients for conditions they believe may benefit from cannabis based on their clinical judgment. A physician familiar with both Tourette syndrome and cannabis medicine can evaluate whether certification is appropriate for an individual patient. Patients should have a thorough conversation with their physician about the current evidence, the limitations of that evidence, and how cannabis use would fit into their overall treatment plan.
Does cannabis work better than antipsychotic medications for Tourette syndrome?
This meta-analysis did not include a head-to-head comparison between cannabis and antipsychotic medications. What it found is that cannabis-based medicines produced measurable tic reduction in the included studies, and that the tolerability profile appeared favorable relative to antipsychotics in the studies’ informal reporting. That is not the same as demonstrating superiority. First-line antipsychotics have a more established evidence base for Tourette syndrome; cannabis is best understood at this stage as an option for patients who do not respond to or cannot tolerate standard medications, not as a replacement for first-line treatment.
Why might cannabis help with tics through the endocannabinoid system?
CB1 receptors are expressed at high density in the striatum, globus pallidus, and other structures of the basal ganglia — the brain regions most directly implicated in the pathophysiology of Tourette syndrome. The endocannabinoid system in these areas modulates the dopaminergic and GABAergic signaling that regulates motor output. When that regulation is disrupted, tics emerge. THC binding to CB1 receptors may partially restore inhibitory tone in these circuits, reducing both the tic frequency and severity and the premonitory urge that precedes tic expression. This is the mechanistic rationale researchers have proposed, and it is biologically coherent with the known neurobiology of both the ECS and Tourette’s.
What is the premonitory urge in Tourette syndrome and does cannabis help with it?
The premonitory urge is the uncomfortable, often hard-to-describe sensory or mental tension that many people with Tourette syndrome experience immediately before a tic occurs. For some patients, this urge is as disabling as the tics themselves, creating constant anticipatory distress. The meta-analysis found that the Premonitory Urge for Tics Scale (PUTS) scores significantly improved alongside YGTSS scores, suggesting cannabis-based medicines may address both the motor expression of tics and the internal experience that precedes them. This is an important distinction from medications that only suppress the visible tic without relieving the urge.
What are the main limitations of this evidence?
The meta-analysis authors are direct about the limitations. Eight studies with 306 total patients is a modest evidence base. The studies are heterogeneous — they used different cannabis formulations, doses, routes of administration, and study designs — which means the pooled number captures effects of very different pharmacological approaches. There is no standardized dosing protocol that emerges from the data. Placebo-controlled trial data is limited, so placebo response and expectancy effects cannot be fully excluded. And the follow-up periods in the included studies are short, leaving long-term efficacy and safety unaddressed.
Does this meta-analysis include children or adolescents with Tourette syndrome?
No. The meta-analysis covers adult patients. A separate and distinct body of research is developing on cannabis use in adolescent Tourette syndrome patients, but the findings from adult studies should not be applied to younger patients. The developing endocannabinoid system in adolescence has different pharmacological properties, and cannabis use during brain development carries different risk considerations than adult use. Any consideration of cannabis for pediatric or adolescent Tourette syndrome should occur only within a rigorous research or specialized clinical setting, not based on adult evidence.
How does the 2026 Lancet Psychiatry review relate to this Tourette’s meta-analysis?
The 2026 Lancet Psychiatry meta-analysis examined 54 randomized controlled trials across a wide range of mental health and substance use conditions and found very limited evidence supporting cannabis for anxiety, depression, PTSD, or most other psychiatric conditions. However, among the few exceptions where a positive signal was noted, Tourette syndrome was specifically mentioned. The Tourette-focused meta-analysis covered here provides a more detailed and current picture of exactly that signal — 8 studies, 306 adults, YGTSS reduction of 13.29 points. The two analyses are complementary: one shows the general limits of cannabis for mental health; the other shows the specific evidence that Tourette’s may be a genuine exception.
What should a patient do if they want to explore cannabis for Tourette syndrome?
The most important step is to have a detailed conversation with a physician who understands both Tourette syndrome and cannabis medicine. That conversation should cover the current evidence and its limitations, the patient’s prior treatment history, comorbid conditions (especially OCD and ADHD, which are common in Tourette’s), current medications and potential interactions, and what realistic goals and monitoring would look like. Cannabis is not a self-prescribing decision. The meta-analysis provides grounds for raising this question with a clinician; it does not provide a protocol for self-directed treatment. Patients in Massachusetts can request a consultation at CED Clinic to discuss whether cannabis may be appropriate for their situation.
Will the DEA rescheduling hearing affect cannabis access for Tourette syndrome patients?
Potentially yes, in the longer term. The DEA hearing opening June 29, 2026 is evaluating the broader rescheduling of cannabis from Schedule I to Schedule III. Under Schedule I, cannabis cannot be prescribed by physicians and remains illegal federally. Rescheduling to Schedule III would permit federally authorized prescribing and would dramatically expand research opportunities — meaning clinical trials for Tourette syndrome and other neurological conditions could be conducted with greater ease and federal support. In the near term, patients in states with medical cannabis programs are unaffected; the hearing’s outcome will matter most for federal research access and for the long-term development of an evidence base strong enough to guide clinical practice. [...]
Read more...
June 6, 2026Dr. Benjamin Caplan, MD
·
Board-Certified Family Physician & Cannabis Medicine Specialist
·
Cannabis Science
Clinical Insight
A new long-term observational study followed children with severe autism spectrum disorder on purified CBD for an average of 27.6 months. The behavioral improvements seen at three months were maintained – and 40% of patients had their concomitant medications reduced. This post examines what the data shows, where the evidence stops, and what it means for families and clinicians.
What 27 Months of Purified CBD Use Reveals About Severe Autism in Children
The research question was straightforward: do the behavioral improvements seen in children with severe ASD at three months on purified CBD actually last? A research team from Tucumán and Buenos Aires followed that cohort for an average of 27.6 months to find out. Their answer, published June 5, 2026 in Pharmacology Biochemistry and Behavior, is that the improvements held, and in 40% of cases, the children’s other medications could be reduced. That is a longer safety record than almost anything else in the pediatric cannabis literature.
CED Clinical Relevance
Strong Clinical Relevance
Long-term pediatric safety data with CBD is exceptionally rare. This study provides the most extended observational record published for purified CBD in severe ASD, directly relevant to families seeking cannabis medicine options where standard pharmacological alternatives carry metabolic burden.
CBD
Autism Spectrum Disorder
Pediatrics
Endocannabinoid System
Long-Term Safety
What You’ll Learn
Why a 27.6-month follow-up period is significant in the context of pediatric cannabis research, where most studies end at 12 weeks
What the study found about behavioral improvements, safety, and concomitant medication reduction, and what the data cannot prove
How the endocannabinoid system’s role in autism informs the biological rationale behind this line of research
The critical methodological limitations that keep this study in the hypothesis-supporting category rather than the practice-changing one
What families in Massachusetts and clinicians managing severe ASD can reasonably take from these findings
TL;DR
❇️ A long-term observational study followed 13 children with severe ASD on purified CBD for an average of 27.6 months, the longest safety record for this approach in print
❇️ Behavioral improvements in irritability, social withdrawal, and hyperactivity from the 3-month study were maintained; adverse effects from the early phase did not recur
❇️ Concomitant medications were reduced in 40% of children, a finding relevant to families managing risperidone or aripiprazole burden
❇️ No control group, small n=13 for long-term analysis, caregiver-reported outcomes, meaningful signal, not definitive evidence
⚠ Quality Gate Alerts
Small sample: 13 children completed long-term follow-up; statistical power is limited across all reported outcomes
No control group: Improvements cannot be attributed to CBD without a comparison arm; natural developmental progression and caregiver expectation effects cannot be excluded
35% dropout: 7 of the original 20 children did not complete long-term follow-up; if non-responders or children who experienced problems were more likely to leave, the surviving group’s results would be optimistically skewed
Observational design: Caregiver-reported outcomes over multiple years are subject to expectation bias, regression to the mean, and instrument familiarity effects
Study at a Glance
Study Type
Long-term observational follow-up
Sample Size
20 enrolled; 13 completed 27.6-month follow-up
Population
Children and adolescents ages 3–18 with ASD severity levels 2–3, intellectual disability, and treatment-resistant behavioral symptoms
Intervention
Purified CBD (no THC) as add-on therapy to existing pharmacological regimen
Follow-up Duration
Average 27.6 months (enrollment: January–December 2023; follow-up through June 2025)
Primary Outcome
Maintenance of behavioral improvements from the 3-month study phase
Key Results
Sustained improvements in irritability, social withdrawal, and hyperactivity; early adverse effects did not recur in long-term follow-up
Secondary Finding
Concomitant medications reduced in 40% of patients
Institutions
Equipo de Neurodesarrollo INIZIO (Tucumán); Hospital J.M. Ramos Mejía and Hospital de Pediatría J.P. Garrahan (Buenos Aires, Argentina)
Published
June 2026, Pharmacology Biochemistry and Behavior (ScienceDirect pii: S0091305726000754)
Why This Matters
The pediatric cannabis research literature has a duration problem. Most studies of cannabinoids in children end at 12 to 16 weeks, long enough to observe an acute effect, not long enough to know what happens next. Families and clinicians managing severe ASD are making decisions that span years, not months. A study that asks “did the improvements at three months persist at 27 months?” is asking the right question for the right time horizon.
The finding that adverse effects from the early phase did not recur over the longer observation period is also clinically important. Short-term tolerability data is useful; long-term tolerability data is rare. This paper adds to a small but now-growing body of evidence that purified CBD can be administered to children with severe ASD over extended periods without the safety signal worsening. That does not mean it is appropriate for all children or all clinical contexts, but it changes the conversation about risk.
Clinical Summary
Researchers from three Argentine institutions enrolled 20 children between ages 3 and 18 with ASD severity levels 2 and 3, the two highest severity categories under DSM-5 classification. All had intellectual disability and treatment-resistant behavioral symptoms. Purified CBD was added to each child’s existing pharmacological regimen between January and December 2023. Thirteen children completed the extended follow-up through June 2025, with an average observation period of 27.6 months. The study was designed as a follow-up to the same team’s three-month observational study, published in early 2025.
The long-term results mirrored the short-term ones: improvements in irritability, social withdrawal, and hyperactivity, assessed through standardized behavioral rating scales, were maintained or further improved. The researchers found no significant difference between the three-month evaluations and the 26-month evaluations, which the authors interpret as evidence that the early improvements were durable. Mild adverse events that had appeared in the short-term phase, mainly irritability and reduced appetite, did not recur. The study’s most clinically notable secondary finding: concomitant medications were reduced in 40% of the children who completed long-term follow-up. The authors framed this as consistent with, rather than caused by, CBD treatment, an important distinction given the observational design.
What This Paper Does Not Show
The study has no control group. This means there is no way to know, from this data alone, whether the children who continued CBD treatment would have improved to a similar degree through natural developmental progression, caregiver relationship effects, or changes in their broader care environment. The study tracks whether improvements were sustained, it does not establish that CBD was responsible for producing or maintaining them.
The 40% medication reduction is one of the study’s more striking figures, but the paper does not specify which medications were reduced, by how much, or whether the reductions were clinician-driven responses to apparent clinical improvement or made for other reasons. Using that number as evidence that CBD reliably reduces medication burden in ASD would misrepresent the study.
Seven of the original 20 children did not complete long-term follow-up. The paper does not detail why. If families whose children were not responding, or who experienced emerging adverse effects, were more likely to discontinue, the 13 who completed follow-up represent a selectively favorable group. Findings from an observational study should always be understood with that selection effect in mind.
How This Fits the Broader Clinical Conversation
The evidence base for cannabinoids in autism is evolving quickly and unevenly. The 2026 Lancet Psychiatry meta-analysis, the largest review of cannabinoid RCTs in mental health conditions to date, found no benefit for anxiety, depression, or PTSD but specifically noted that cannabinoids might improve symptoms in autism spectrum disorder and a few other conditions. That signal, coming from a skeptical meta-analysis, is meaningful context for this long-term paper.
The endocannabinoid system’s role in autism is a legitimate and active area of research. Multiple studies have found lower circulating endocannabinoid levels, particularly anandamide, in children with ASD compared to neurotypical peers. Animal models have shown that activating the endocannabinoid system can rescue some social deficits. CB1 and CB2 receptors are distributed across the brain regions that govern social behavior, anxiety regulation, and sensory processing, the same domains where autistic individuals often diverge from neurotypical development. The biological rationale for investigating CBD in ASD is well-founded, even if the clinical evidence is still in its early chapters. For a deeper exploration of the ECS-autism connection, see CED Clinic’s ongoing coverage of endocannabinoid system research in autism development.
What makes this study distinct is the use of purified CBD, no THC, over an extended period in a severely affected population. The standard pharmacological alternatives for severe ASD irritability are risperidone and aripiprazole, both FDA-approved, both effective for some patients, and both associated with weight gain, metabolic disturbance, and sedation. The clinical unmet need is real. A 40% medication reduction finding in children already on those agents is the kind of signal that warrants a properly powered randomized trial, not dismissal. For context on existing cannabinoid clinical trials for CBD and autism in children, CED Clinic has covered the evolving research landscape in depth.
Dr. Caplan’s Take
In over twenty years of clinical cannabis medicine and more than 300,000 patient encounters, one of the most consistent frustrations families bring to my practice is this: they’ve read about a study that seemed promising, they tried something based on it, and nothing was followed up. The study ended at 12 weeks and nobody asked what happened at month 14 or month 22. This paper is a direct response to that gap, and that matters independent of what it specifically found.
Twenty-seven months is a different kind of data. It’s the duration of a school year, a therapeutic relationship, a developmental phase. When a research team says the improvements seen at three months were still there at 26 months, and that the safety profile didn’t worsen, they are giving families and clinicians something rare: a timeline. Not just a before-and-after, but a trajectory.
The endocannabinoid system connection is the part I keep coming back to when I talk to families about this research. We know, from multiple independent sources, that children with autism spectrum disorder show lower circulating anandamide levels than neurotypical children. Anandamide is the endogenous ligand for CB1 receptors. Those receptors are densely expressed in the prefrontal cortex, the amygdala, the hippocampus, regions central to emotional regulation, social behavior, and the kind of flexible responsiveness to the environment that is often disrupted in severe ASD. When we ask whether CBD might help, we are not asking about a random intervention. We are asking whether a modulation of a system that appears to be dysregulated in this population might have therapeutic relevance. The answer from this study is a cautious, early, small-sample yes. That is worth taking seriously without overstating it.
The 40% medication reduction finding deserves its own attention. Risperidone and aripiprazole are the only FDA-approved options for irritability in autism, and they carry real costs: weight gain, metabolic disturbance, sedation, and, in some children, a blunted affect that families describe as trading one problem for another. If CBD as an adjunct allows meaningful dose reductions in those agents, even in a meaningful fraction of patients, that is a clinically relevant outcome for everyday practice. I am not ready to say that outcome is established; the study’s design cannot prove causation. But it is the kind of preliminary signal that should drive a well-designed trial, not a dismissal.
For families in Massachusetts and across New England who ask me about purified CBD for a severely autistic child: this study provides context, not a protocol. The formulation here was pharmaceutical-grade and precisely defined, not the variable CBD products available at most dispensaries. The population was carefully characterized. The monitoring was structured. Those are not features of a casual experiment, and they should not be replicated casually at home. What this study does give us is a reason to bring the conversation into clinic rather than leaving it to the internet.
What the field needs next is the randomized controlled trial this data is calling for. A properly powered, placebo-controlled study, ideally in a population that includes North American and European children, with pre-registered outcomes and independent rating, would tell us whether the signal in this observational series is real. Until that study exists, I treat these findings as an honest, careful, and scientifically responsible preliminary report from a team that is doing the right kind of work in a population that has too few options. That’s not a cure headline. It is the slower and more trustworthy version of progress.
What a Careful Reader Should Take Away
This study extends an important but limited observational record. Thirteen children with severe ASD tolerated purified CBD for an average of 27.6 months, maintained their earlier behavioral improvements, and in 40% of cases had their other medications reduced. The study does not prove that CBD caused these outcomes, an observational design without a control group cannot do that. What it can do is provide a safety and maintenance signal over a time frame that no prior published study in this population has documented.
The paper’s honest limitation section, combined with the authors’ explicit call for larger placebo-controlled trials, is a marker of scientific integrity. Preliminary evidence framed with appropriate humility is exactly what should precede a rigorous trial design. The research agenda for CBD in severe ASD is now better defined because of this paper, and that is progress, even if it is not a resolution.
For families, the takeaway is not “CBD works for severe autism.” It is “CBD may be tolerable and maintain behavioral benefits over the long term in some severely affected children, and that question deserves the kind of rigorous study it has not yet received.” For clinicians, this paper belongs in the informed consent conversation, alongside a clear articulation of what we do not know.
Evidence Watch Reading Tool
Read This Paper Through Eight Different Lenses
A single study can mean different things depending on who is reading it. This card separates the patient takeaway, clinical meaning, skepticism, study critique, prior research context, practical implications, future directions, and likely public misreadings.
How to use this: Choose a lens above to see how the same paper reads from a different evidence, clinical, or practical angle.
Patient Takeaway
Clinician’s POV
A Skeptical Read
Study Critic
Compared to Past Research
Practical Considerations
Future Directions (Expected)
Misreadings & Bad-Faith Takes
Select a lens above to reveal a focused interpretation of the paper. Each view is prepared in advance, evidence-calibrated, and designed to keep the claims tied to what the work actually shows.
Patient Takeaway
This study asked a question most research skips entirely: if your child’s behavior improved at three months on purified CBD, will that still be true at two-plus years? For 13 children with severe autism who stayed in this study through June 2025, the answer is yes, the improvements held. That is not a small thing in a field where most studies stop at 12 weeks and no one asks what happened next.
What this cannot tell you: there was no comparison group, so the study cannot prove that CBD caused or sustained the improvements. Children who did not respond, or who had problems, may have been more likely to stop participating, meaning the 13 who completed follow-up may be a selectively favorable group. The improvements in irritability, social withdrawal, and hyperactivity were rated by caregivers, and caregivers who stayed with a treatment for two years may rate outcomes differently than neutral observers would. If your child has severe ASD and you’re wondering whether this evidence supports a conversation with your physician, the answer is yes. It does not replace that conversation.
Note: This Lens Card is based on the news report and abstract for this paper. The full manuscript was not reviewed, and panel content is limited to the supplied source material.
Clinician’s POV
The 40% concomitant medication reduction is the number that most directly addresses clinical practice. Polypharmacy in severe ASD is a genuine management challenge, risperidone and aripiprazole are effective for some patients but carry weight gain, metabolic disturbance, and sedation as recurring complications. An adjunctive agent that might allow dose reduction in a meaningful subset of patients is worth tracking, even if this study’s design cannot confirm that CBD was responsible.
For patient counseling, the safety framing is useful: adverse effects present in the short-term phase, mainly irritability and appetite changes, did not return over 27.6 months of continued use. That is a defensible basis for telling a family that “we don’t see the early problems worsening over time” without overstating the evidence. The formulation matters: pharmaceutical-grade purified CBD is not equivalent to dispensary CBD, and dosing guidance from this study is not available in the abstract. Practice change is premature. Adding this paper to the informed consent conversation for families asking about CBD in severe ASD is appropriate.
Note: Panel interpretation is limited to the abstract and news report. Full manuscript details, including dosing, specific concomitant medications, and monitoring protocol, were not available for this Lens Card.
A Skeptical Read
The dropout rate deserves the most scrutiny. Seven of 20 enrolled children, 35%, did not complete the long-term follow-up. The study does not explain why. In an open-label study where families self-selected into treatment and chose whether to continue, it is plausible that families who were not seeing benefits, or whose children were having problems, were more likely to stop. If that is true, the remaining 13 represent a best-case cohort rather than the full picture.
Behavioral improvements assessed by caregivers over two or more years are also difficult to interpret without blinding. The same caregivers who committed to the treatment for 27 months are rating whether the treatment worked. That does not mean the ratings are wrong, but it introduces a known source of positive bias that the study design cannot correct. Natural developmental progression, increased caregiver skill in behavioral management, and maturation effects could all contribute to observed improvements in children ages 3 to 18 over a multi-year period without any pharmacological intervention. None of those confounders are accounted for here.
Study Critic
N=13 for the primary long-term analysis is insufficient to draw statistically robust conclusions about any of the reported outcomes. Effect size estimates from a sample this small carry wide confidence intervals, which are not reported in the available abstract. The paper’s framing, “no significant differences were observed between the three-month and 26-month evaluations”, establishes maintenance, not efficacy. The question “did CBD work at 27 months?” cannot be answered by comparing two active-treatment timepoints in the same uncontrolled group.
The 40% concomitant medication reduction is reported as a proportion without specifying which drugs were reduced, by what degree, or under what clinical rationale. A 10% dose reduction in one medication counts the same as a full discontinuation in this accounting. The inference gap between “medications were reduced in 40% of patients” and “CBD enabled medication reduction” is substantial and not addressed by the study design. These are genuine limitations of an appropriately framed observational study, not failures of the researchers, but they mean the paper’s contribution is hypothesis generation rather than evidence of efficacy.
Compared to Past Research
This paper is a direct extension of the same research team’s three-month observational study (PMID 39965749, published early 2025 in Pharmacology Biochemistry and Behavior), which found 90% of 20 enrolled children showed improvement in at least one symptom, with 83.5% of reported symptoms improving in responders. The June 2026 paper asks whether those findings held over time, and in the 13 children who completed long-term follow-up, they did.
More broadly, cannabinoid research in autism has produced an uneven literature. The 2026 Lancet Psychiatry meta-analysis (54 RCTs, 2,477 participants) found no benefit of cannabinoids for anxiety or PTSD but specifically noted that cannabinoids might improve ASD symptoms, an unusual endorsement from a skeptical systematic review. Prior observational studies and small trials have found improvements in behavioral symptoms with CBD-containing formulations, though most used preparations that included THC. The purified CBD design in this study series distinguishes it from that earlier work and addresses pediatric safety concerns specific to THC exposure. This is among the most extended observational follow-up datasets in the purified-CBD-for-ASD literature.
Note: comparison literature cited here is drawn from supplied sources and publicly available evidence. Individual papers were not independently reviewed at the full-text level for this Lens Card.
Practical Considerations
For families in Massachusetts, the practical message is specific: the long-term safety profile for purified CBD in children with severe ASD now has a peer-reviewed record in print. That does not mean the treatment is straightforward to access. Massachusetts medical cannabis law requires physician certification for minors, parental consent, and a qualifying condition determination. The product used in this study was pharmaceutical-grade, a level of standardization that most over-the-counter CBD products, even from licensed dispensaries, do not meet.
For clinicians managing severe ASD in pediatric populations, the 40% medication reduction finding is worth discussing with families who are managing significant side effects from risperidone or aripiprazole. The framing should be honest: this is observational, small-sample, and does not prove causation. But it suggests that the question of adjunctive purified CBD is not settled negatively. Dose and monitoring specifics from this study are not available in the abstract, families should not attempt to replicate this treatment approach without structured physician involvement and ongoing behavioral monitoring. The relevant outcome metrics, irritability, social withdrawal, hyperactivity, are trackable with existing standardized instruments.
Future Directions (Expected)
The study’s authors explicitly call for larger, placebo-controlled trials, and this is the appropriate next step. An adequately powered randomized study would need to enroll several hundred children with ASD severity levels 2-3 across multiple sites, include a placebo arm with identical administration, use independent behavioral raters blinded to treatment condition, and follow participants for at least 12 months from baseline. Pre-registered primary endpoints should include both caregiver-reported and clinician-rated behavioral measures.
The concomitant medication reduction finding warrants a focused secondary study: a trial designed specifically to evaluate whether purified CBD adjunctive therapy allows safe dose reduction of risperidone or aripiprazole in children with severe ASD, with metabolic outcomes tracked over time. That question is more directly actionable for clinical practice than a general behavioral improvement endpoint.
On the mechanistic side, biomarker-level investigation of endocannabinoid tone in responding versus non-responding children, measuring anandamide, 2-AG, and related endocannabinoids before and after CBD initiation, would help determine whether ECS dysregulation in ASD is a predictive marker for treatment response, which would be a clinically meaningful advance in patient selection.
Misreadings & Bad-Faith Takes
Distortion 1: “Study proves CBD cures autism.” This is not what the paper found. The study found that behavioral improvements observed at 3 months were maintained in 13 children who continued purified CBD for an average of 27.6 months. There was no control group. The study cannot establish that CBD caused the improvements, and it makes no claim about cure, reversal, or correction of autism itself. Autism is not a disease to be cured, and the study is not framed that way.
Distortion 2: “CBD is now proven safe for all kids with autism.” This paper assessed one pharmaceutical-grade purified CBD formulation in a specific, carefully characterized population, severe ASD with intellectual disability and treatment-resistant symptoms, in Argentina. The safety observation does not generalize to over-the-counter CBD products, preparations containing THC, or children across the full ASD spectrum. Product quality, dose, and clinical context all matter.
Distortion 3: “Doctors are hiding this natural autism cure from parents.” The study was published openly in a peer-reviewed journal. The same researchers who found promising results also explicitly stated the need for placebo-controlled trials before drawing definitive conclusions. The clinical community is not suppressing this work, the researchers themselves are appropriately calling for replication. This is how science is supposed to operate.
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
Have thoughts on this? Share it:
? Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
Source
Researchers at Equipo de Neurodesarrollo INIZIO (Tucumán), Hospital General de Agudos J.M. Ramos Mejía, and Hospital de Pediatría Prof. Dr. J.P. Garrahan (Buenos Aires, Argentina). Long-term follow-up study of purified CBD as add-on therapy in children with severe ASD (severity levels 2-3). Published June 2026 in Pharmacology Biochemistry and Behavior. View source → | News coverage →
Author names to be confirmed from full manuscript before publication. Prior 3-month study: PMID 39965749.
Related Reading at CED Clinic
Continue exploring the evidence
Endocannabinoid System in Autism Development Research
CED Clinic’s breakdown of the growing evidence for ECS dysregulation in autism, including lower anandamide levels in children with ASD and what that may mean for cannabinoid-based therapies.
Explore evidence
Cannabinoid Clinical Trials: CBD for Autism in Children
A review of the current clinical trial landscape for CBD in pediatric ASD, including design considerations, population selection, and what the trial results to date have and have not shown.
Explore evidence
Cannabinoid-Based Interventions for Behavioral Outcomes in Children and Adolescents With ASD
A systematic review coverage examining safety and effectiveness across cannabinoid preparations and study designs in ASD, the broader evidence context for this long-term observational finding.
Explore evidence
Frequently Asked Questions
What is purified CBD and how is it different from regular CBD oil?
Purified CBD is an isolated form of cannabidiol containing no THC and minimal other cannabinoids. Most commercially available CBD oils are full-spectrum or broad-spectrum, meaning they contain trace amounts of THC and other plant compounds. In pediatric research, purified formulations are preferred because they eliminate any psychoactive exposure from THC. The preparation used in this study was pharmaceutical-grade, a level of standardization that over-the-counter CBD products sold at dispensaries or online typically do not meet. That distinction matters when interpreting the safety findings.
How severe is ASD at levels 2 and 3?
Under DSM-5 classification, ASD severity levels describe how much support a person requires. Level 2 requires “substantial support”, children at this level typically have notable difficulty with verbal and nonverbal communication and marked social challenges even with supports in place. Level 3 requires “very substantial support” and involves severe deficits in communication, very limited social initiation, and significant distress related to changes in routine. Most children in this study also had intellectual disability and treatment-resistant behavioral symptoms, a population with very limited pharmacological options beyond risperidone and aripiprazole.
Why was the average follow-up period 27.6 months if enrollment ran through December 2023?
Children were enrolled at different times between January and December 2023, and the data was collected through June 2025. Children enrolled in January 2023 had approximately 29 months of follow-up; those enrolled later had shorter observation windows. Averaging the follow-up durations across the 13 who completed the long-term phase produced the 27.6-month figure. This staggered enrollment design is common in observational studies and explains why the average is well below the maximum possible follow-up.
What does “concomitant medications reduced in 40% of patients” mean clinically?
It means that in 40% of the children who continued through long-term follow-up, the researchers or supervising clinicians were able to reduce one or more psychiatric or behavioral medications the children were already taking alongside purified CBD. For children with severe ASD, those medications often include risperidone or aripiprazole, both of which carry side effects including weight gain, metabolic changes, and sedation. A meaningful reduction in those agents, if it can be sustained, is clinically significant for quality of life. The study’s design does not prove that CBD caused this reduction, but the finding is directionally important and worth testing in a controlled trial.
Does the endocannabinoid system play a role in autism?
Research suggests it may. Multiple studies have found lower circulating endocannabinoid levels, particularly anandamide, in children with ASD compared to neurotypical children. Animal models of autism have shown that activating the endocannabinoid system can partially rescue social deficits in some cases. CB1 and CB2 receptors are distributed across the brain regions involved in emotional regulation, social behavior, and sensory processing, areas where autistic individuals often differ from neurotypical individuals. The biological plausibility for cannabinoid-based intervention in ASD is grounded, even if the clinical evidence remains preliminary. This is one reason why purified CBD has drawn structured scientific attention rather than just anecdotal interest.
Why did 7 of the 20 enrolled children not complete the long-term follow-up?
The abstract and news report do not explain the reasons for the 7 dropouts. This is a genuine limitation. In open-label observational studies, children who are not responding to treatment, or who experience emerging adverse effects, may be more likely to leave the study. If that pattern holds here, the 13 who completed follow-up would represent a selectively favorable subset, meaning the long-term results could overestimate outcomes in the broader population. The authors appropriately call for placebo-controlled trials, which would include all randomized participants in the analysis regardless of dropout, providing a more complete picture.
Is purified CBD available for pediatric patients in Massachusetts?
Massachusetts medical cannabis law permits pediatric patients to access cannabis-derived products under specific conditions. A certifying physician must determine that the patient has a qualifying medical condition, and parents or guardians must provide consent. Pharmaceutical-grade purified CBD, specifically Epidiolex, is FDA-approved for certain refractory seizure disorders and available by prescription from any licensed prescriber. Other purified or high-CBD products available through Massachusetts dispensaries vary considerably in quality and standardization. Families interested in CBD for a child with severe ASD should consult with a clinician experienced in cannabis medicine before making any changes to the child’s existing pharmacological regimen.
How does this study relate to the 2026 Lancet Psychiatry meta-analysis on cannabinoids and mental health?
The 2026 Lancet Psychiatry meta-analysis reviewed 54 randomized controlled trials across multiple mental health conditions and found no benefit of cannabinoids for anxiety, depression, or PTSD. However, the same review specifically noted that cannabinoids might improve symptoms in autism spectrum disorder, insomnia, Tourette syndrome, and cannabis use disorder. That positive signal for ASD in a broadly skeptical meta-analysis is meaningful context for this long-term observational study. The populations differ, the Lancet review focused on RCTs across adults and mixed populations, while this paper is specifically about severe pediatric ASD with purified CBD over a long follow-up. Both point in the same general direction for ASD.
What were the specific behavioral improvements observed in this study?
The improvements were documented on standardized behavioral rating scales across three primary domains: irritability, social withdrawal, and hyperactivity, all consistent with subscales of the Aberrant Behavior Checklist, the most widely used tool for behavioral assessment in ASD trials. The short-term study from the same research team (PMID 39965749) reported approximately 30% improvement in each of those domains and 50% improvement in restricted and repetitive behaviors. The long-term follow-up found that these improvements were maintained or further improved, with no significant difference between the 3-month and 26-month assessments. These are caregiver-completed scales, which introduces some subjectivity, but they are validated instruments with established reliability in this population.
What should a parent do if they want to explore CBD for their child with severe autism?
The most important first step is a thorough conversation with a physician who understands both the neurological complexity of severe ASD and is familiar with cannabis medicine. Severe ASD with intellectual disability involves multiple medications, behavioral programs, and family dynamics that interact in ways a general practitioner may not fully account for. In Massachusetts, CED Clinic and similar cannabis medicine practices provide evaluation alongside guidance on what the evidence currently supports, what it does not, and how to monitor for effects and adverse events in a child who may not be able to reliably self-report. Families should not adjust or reduce existing medications based on this or any other single study without structured physician involvement and ongoing monitoring. [...]
Read more...
June 4, 2026Dr. Benjamin Caplan, MD
|
Board-Certified Family Physician & Cannabis Medicine Specialist
|
CED Clinic, Boston, MA
|
Studies
Clinical Insight
The FDA has granted Breakthrough Therapy Designation to VER-01, a pharmaceutical-grade, full-spectrum cannabis extract developed for chronic low back pain. The designation, awarded May 18, 2026, follows two Phase 3 randomized controlled trials showing significant pain relief, no dependence signal, and better gastrointestinal tolerability than opioids. It is the first such FDA designation for a cannabis extract targeting chronic pain.
FDA Grants Breakthrough Therapy Designation to Cannabis Extract VER-01 for Chronic Low Back Pain
What does it mean when the FDA formally tells the world that a cannabis-derived medicine may offer substantial improvement over existing treatments for one of the most common causes of disability in adults? For patients who have been told their only options are opioids, NSAIDs, or surgery, the designation for VER-01 is worth understanding carefully, including what it does and does not prove about cannabis as a class of medicine.
CED Clinical Relevance
Exceptional Clinical Relevance (Score: 90/100)
A landmark FDA designation backed by Phase 3 evidence in Nature Medicine. The non-opioid comparison data and the absence of a dependence signal make this directly relevant to clinical cannabis practice, even before VER-01 reaches U.S. patients.
FDA Regulation
Chronic Pain
Cannabis Research
Non-Opioid
Clinical Trials
What You’ll Learn
What FDA Breakthrough Therapy Designation actually means, and why this one is historically significant for cannabis medicine
The Phase 3 clinical evidence behind VER-01, including its head-to-head comparison with opioids
Why this designation does not validate all cannabis products for pain, and what the distinction matters clinically
What patients in Massachusetts and across the U.S. can reasonably take from this news today
How VER-01 fits within the broader trajectory of cannabis as a legitimate pharmacological tool for pain
TL;DR
The FDA awarded Breakthrough Therapy Designation to VER-01 (by VERTANICAL) on May 18, 2026, for chronic low back pain.
Two Phase 3 RCTs supported the designation: one placebo-controlled trial (n=820, published in Nature Medicine) and one head-to-head vs opioids, both showing clinically meaningful pain relief with no dependence signal.
VER-01 is a proprietary pharmaceutical-grade formulation from a specific Cannabis sativa strain. Its results cannot be extrapolated to other cannabis products.
U.S. approval is years away (NDA planned for 2028 at earliest), but the designation validates cannabinoid pharmacology for pain at the highest regulatory level.
Study at a Glance
Study Type
Phase 3 randomized, double-blind, placebo-controlled trial (primary); Phase 3 active comparator trial vs opioids (secondary)
Publication
Nature Medicine, September 29, 2025; Pain & Therapy, September 30, 2025
Sample Size
820 adults with chronic low back pain (394 VER-01, 426 placebo) in the primary trial
Population
Adults with clinically confirmed chronic low back pain
Intervention
VER-01: standardized full-spectrum Cannabis sativa DKJ127 extract (cannabinoids, terpenes, other bioactive compounds); pharmaceutical-grade
Primary Outcome
Pain reduction on the Numeric Rating Scale (NRS)
Key Finding
VER-01: mean pain reduction of -1.9 NRS points vs. -0.6 for placebo over 12 weeks. Improvements also observed in sleep disturbances and physical function. In head-to-head vs. opioids: greater pain reduction and better GI tolerability with VER-01.
Duration
12-week double-blind phase + 6-month open-label extension + randomized withdrawal phase
Dependence Signal
No evidence of dependence reported across the clinical program
Funding / Conflicts
Industry-funded (VERTANICAL / FUTRUE Group). VER-01 findings should not be generalized to other cannabis products per the company’s explicit statement.
Why This Matters
Chronic low back pain affects roughly 540 million people worldwide and is among the leading causes of disability in working-age adults. The treatments available today, including opioids, NSAIDs, antidepressants, and surgical intervention, each carry substantial limitations in tolerability, long-term safety, or efficacy. The opioid crisis has made the limitations of opioid therapy for non-cancer pain particularly vivid. A medicine that could offer comparable or superior pain relief, without the dependence risk associated with opioids, represents a genuinely significant clinical need.
FDA Breakthrough Therapy Designation does not equal approval, but it is a meaningful threshold. It means preliminary clinical evidence was sufficient for the FDA to conclude that VER-01 may offer substantial improvement over available therapies on a clinically significant endpoint. For a cannabis-derived medicine, that recognition is, to date, unprecedented in the pain space.
Clinical Summary
VER-01 is not a traditional cannabis product. It is a standardized, full-spectrum pharmaceutical extract derived from a proprietary Cannabis sativa strain designated DKJ127 L., developed by VERTANICAL, a subsidiary of the German FUTRUE Group. Its composition includes a defined mixture of cannabinoids, terpenes, and other bioactive plant compounds, manufactured to pharmaceutical-grade consistency standards specifically to enable the kind of rigorous clinical testing that can satisfy regulatory agencies. The product is distinct from dispensary cannabis in its genetic specificity, formulation precision, and the controlled conditions under which its clinical evidence was generated.
The primary Phase 3 trial enrolled 820 adults with chronic low back pain across a double-blind, placebo-controlled 12-week phase, followed by a 6-month open-label extension and a randomized withdrawal phase. The primary endpoint, pain reduction on the Numeric Rating Scale, showed a mean reduction of 1.9 points in the VER-01 group compared to 0.6 in the placebo group. Secondary outcomes included improvements in sleep disturbances and physical function. A separate head-to-head Phase 3 comparison with opioids found VER-01 produced greater pain reduction with superior gastrointestinal tolerability. Across both trials, no evidence of dependence was reported. These results, published in Nature Medicine and Pain & Therapy in September 2025, formed the evidentiary basis for the FDA’s Breakthrough Therapy Designation in May 2026.
What This Designation Does Not Show
Breakthrough Therapy Designation accelerates the FDA review process. It does not mean VER-01 is approved, safe, or effective for any individual patient. The U.S. Phase 3 trial launched to support the NDA is still underway, with data expected in 2027 and a New Drug Application planned for 2028 at the earliest. Approval, if it occurs, remains years away from U.S. patients.
The evidence is also industry-funded. VERTANICAL designed, funded, and published the trials. That does not invalidate the findings, but it is a standard reason for independent replication before conclusions are treated as settled.
Most critically: this designation applies to one specific pharmaceutical formulation from one specific proprietary Cannabis sativa strain, produced under controlled pharmaceutical conditions. VERTANICAL itself has stated explicitly that VER-01’s results should not be generalized to other cannabis extracts or products. Cannabis purchased at a Massachusetts dispensary is not VER-01. Using VER-01’s trial results to justify or characterize dispensary cannabis is a category error that the clinical community should actively correct.
How VER-01 Fits the Broader Clinical Picture
The cannabis medicine landscape in 2026 is defined by a growing tension between patient experience and regulatory caution. Tens of millions of Americans use cannabis for pain. A significant portion of those patients are using it to reduce or replace opioids. The anecdotal and observational evidence supporting cannabis for chronic pain is substantial, but the randomized controlled evidence has been limited by decades of Schedule I restrictions that made rigorous clinical research difficult to conduct.
The rescheduling of state-licensed medical cannabis to Schedule III in April 2026 begins to address that research gap at the structural level. VER-01 represents what can happen when a pharmaceutical team is able to work with a specifically cultivated cannabis plant under conditions that allow for the full Phase 3 infrastructure that regulators require. The result is the most rigorous clinical program in cannabis pain medicine to date, and the first to earn FDA Breakthrough Therapy status in this indication.
For clinicians practicing cannabis medicine, the relevant takeaway is mechanistic. VER-01’s efficacy in chronic low back pain is consistent with what endocannabinoid system science has suggested for years: that CB1 and CB2 receptor engagement, modulation of inflammatory pathways, and influence on spinal nociceptive circuits can produce clinically meaningful analgesia. The fact that this effect was demonstrated in a rigorous, industry-independent setting (the Phase 3 placebo-controlled trial design, even if funded by the sponsor) strengthens the pharmacological rationale for the entire class.
It also matters that the comparison to opioids produced favorable results on both pain and tolerability. Clinicians in New England and beyond who counsel patients with chronic back pain on cannabis as an adjunct or alternative to opioids now have, for the first time, Phase 3 comparative data they can reference in that conversation, with the appropriate caveat that VER-01 is not yet available in the U.S. and that the comparison was conducted with a proprietary formulation.
What remains to be seen is whether the U.S. Phase 3 trial will replicate the European results in American patients, whether the formulation performs consistently across diverse chronic pain populations, and whether the FDA ultimately approves the NDA when submitted. Each of those remains genuinely uncertain.
Dr. Caplan’s Take
When I speak with patients about cannabis for chronic pain, one of the most common frustrations is the absence of the kind of evidence medicine normally requires. Observational data, patient reports, and mechanistic science have pointed in a consistent direction for years. But the randomized evidence base has been thin in some areas and absent in others, largely because researching Schedule I substances under the required conditions was extraordinarily difficult to do. VER-01 is, among other things, a demonstration of what happens when those barriers are reduced. A team built a proprietary plant, standardized the extract, ran two Phase 3 trials with rigorous placebo controls and a direct opioid comparator, and published in Nature Medicine. That’s a complete clinical package, and the FDA recognized it with the most accelerated pathway available for a drug showing promise in a serious condition.
What I find most clinically significant is the absence of a dependence signal combined with superior GI tolerability compared to opioids. Those two findings address the two most common concerns raised by patients when I recommend reducing opioid use. The clinical caveat I must emphasize, every time, is that VER-01 is not interchangeable with dispensary cannabis. The company itself says this explicitly. But the pharmacological rationale for the endocannabinoid system’s role in chronic pain modulation is now supported by the most rigorous human evidence produced for this class of medicine. That is genuinely useful for every conversation I have with a patient who is suffering from back pain and asking whether cannabis could help. It does not replace individualized clinical assessment, but it strengthens the foundation from which that conversation starts. For patients in Massachusetts and beyond who are already using cannabis for pain, this is the kind of institutional recognition that makes that conversation easier to have with a primary care physician or a specialist who has been skeptical of cannabis medicine.
What a Careful Reader Should Take Away
FDA Breakthrough Therapy Designation is meaningful institutional recognition, not approval. The designation tells us that the FDA reviewed preliminary clinical evidence and concluded VER-01 may offer substantial improvement over available therapies for chronic low back pain. That is significant, and historically significant for cannabis medicine specifically. But it opens a review process, it does not conclude one.
The evidence behind the designation is credible: two Phase 3 RCTs, one of which was placebo-controlled with 820 patients and published in Nature Medicine, and one of which compared VER-01 directly to opioids. The results in both are favorable for VER-01 on pain, tolerability, and dependence. Industry funding is a standard reason for independent replication before treating findings as definitive, but the study design is sufficiently rigorous to take seriously.
VER-01 is not general cannabis. It is a proprietary, pharmaceutical-grade formulation from a specific plant variety. Reading VER-01’s results as a validation of commercial cannabis products is a logical leap that neither the clinical data nor the company supports. Clinicians and patients should be clear about this distinction.
U.S. patients will not have access to VER-01 through normal medical channels until at minimum 2028, assuming a successful NDA, and the U.S. Phase 3 trial must first demonstrate consistent results in an American patient population. Until then, the designation’s most immediate clinical value is as a validation of the pharmacological rationale for cannabinoids in chronic pain, which supports the use of current medical cannabis options under proper clinical guidance.
Evidence Watch Reading Tool
Read This Story Through Eight Different Lenses
A major regulatory milestone can mean different things depending on who is reading it. This card separates the patient takeaway, clinical meaning, skepticism, study critique, prior research context, practical implications, future directions, and likely public misreadings of the FDA’s Breakthrough Therapy Designation for VER-01.
How to use this: Choose a lens above to see how the same development reads from a different evidence, clinical, or practical angle.
Patient Takeaway
Clinician’s POV
A Skeptical Read
Study Critic
Compared to Past Research
Practical Considerations
Future Directions (Expected)
Misreadings & Bad-Faith Takes
Select a lens above to reveal a focused interpretation of the development. Each view is prepared in advance, evidence-calibrated, and designed to keep the claims tied to what the FDA designation and supporting trials actually show.
Patient Takeaway
If you live with chronic low back pain and have been looking for an alternative to opioids, this news is genuinely worth knowing about, with some important caveats about what it does and does not mean for you right now. The FDA has formally recognized that a cannabis-derived medicine called VER-01 may offer substantial improvement over existing treatments, including opioids. That recognition is based on Phase 3 clinical trials involving 820 patients, showing meaningful pain relief without evidence of dependence. That is not a routine finding. However, VER-01 is not available to U.S. patients and will not be until at minimum 2028, if it earns FDA approval after additional trials. It is also a pharmaceutical formulation, not a dispensary product. If you are currently using medical cannabis for back pain in Massachusetts or elsewhere, this news does not change what you are taking or whether it is working for you. What it does is add to the scientific and regulatory credibility of cannabinoid medicine as a field, which may make future conversations with your doctor easier. The best immediate step is still a candid discussion with a clinician who understands your full pain history, current medications, and what options are realistically available to you today.
Clinician’s POV
The FDA’s Breakthrough Therapy Designation for VER-01 is the most credible regulatory signal to date that cannabinoid pharmacology can meet the evidentiary bar required for a serious pain indication. For clinicians practicing in primary care and pain medicine, the designation provides a framework for discussing cannabis with patients who ask about it for chronic low back pain. The Phase 3 placebo-controlled data, published in Nature Medicine, gives a reference point: a mean NRS reduction of 1.9 vs. 0.6 for placebo, with sleep and function improvements, and no dependence signal. The head-to-head comparison with opioids showing greater pain reduction and better GI tolerability is particularly relevant to the shared decision-making conversation about opioid reduction. The critical clinical qualification is that VER-01 is a proprietary pharmaceutical formulation and its results cannot be directly applied to commercial cannabis products. Extrapolating the VER-01 data to justify a specific dispensary product would be clinically unsupportable and the company itself explicitly warns against it. Clinicians should also note the industry funding: VERTANICAL sponsored both trials, and independent replication will strengthen confidence in the findings. U.S. prescribers will not have access to this specific product for years. What is actionable today is using the mechanistic and regulatory validation to support evidence-informed conversations about cannabinoid therapy within the framework of each patient’s individual circumstances.
A Skeptical Read
A well-funded pharmaceutical company with a proprietary product designed the trials, ran them in European populations, and announced results favorable to commercialization. The placebo-controlled trial showed a 1.3-point NRS advantage for VER-01 over placebo. Whether 1.3 NRS points represents a clinically meaningful improvement for patients with chronic low back pain is a legitimate question in pain medicine, where the minimally important clinical difference is generally cited as approximately 2 points. The Phase 3 data appeared in Nature Medicine, which reflects positively on methodology and peer review, but it does not eliminate the standard concerns about industry sponsorship affecting study design, endpoint selection, and publication timing. The head-to-head opioid comparison data has not been independently assessed in as much detail from available public sources. Furthermore, the European clinical program may not translate directly to U.S. patients, whose pain presentations, comorbidities, treatment histories, and regulatory environment differ. The U.S. Phase 3 trial is the test that matters for American patients, and it is still underway. Skeptical readers should note that Breakthrough Therapy Designation is awarded based on preliminary evidence, and the history of drug development includes multiple cases where Phase 3 results and regulatory designations did not ultimately result in approved medicines. This is a promising signal. It is not a conclusion.
Study Critic
The primary Phase 3 trial enrolled 820 participants in a double-blind, placebo-controlled design with a 12-week treatment phase and an open-label extension. That is a robust sample size for a cannabis trial, but several methodological questions are worth tracking as full data become available. Blinding integrity in cannabis trials is an enduring challenge: participants who experience psychoactive effects from THC-containing products may correctly guess their assignment, potentially inflating the placebo response estimate and compressing the apparent treatment effect. The absolute NRS difference of 1.3 points sits near the lower boundary of what many pain researchers consider clinically significant. The full statistical analysis, including confidence intervals, responder rates, and subgroup-level outcomes, should be reviewed in the primary publication before conclusions about magnitude are finalized. The open-label extension data are encouraging for durability but observational by design. The head-to-head opioid comparison trial has been described in press releases but the full methodology, comparator dose, and endpoint definitions were not reviewed independently for this commentary, and those details matter considerably. Industry sponsorship is the most consistent predictor of favorable outcomes in pharmaceutical trials across all therapeutic areas, which is not a reason to dismiss the data, but is a reason to weight it appropriately until independent replication is available.
Compared to Past Research
The broader cannabis and pain literature is extensive but heterogeneous. Prior systematic reviews and meta-analyses, including a 2026 Cochrane Review of 21 studies and 2,187 participants, have found limited clear evidence for CBD-dominant medicines in neuropathic pain. Earlier reviews of cannabis for chronic pain generally found modest but statistically significant effects across mixed populations and product types, with considerable variability in product composition, dosing, route, and patient selection complicating cross-study comparisons. VER-01 is notable in this context because it uses a standardized, pharmaceutical-grade formulation in a large, pre-specified Phase 3 trial, addressing the most consistent methodological criticism of prior cannabis pain research. The Nature Medicine publication represents the most rigorously conducted Phase 3 cannabis pain trial to date based on available public information. The direct comparison to opioids in a Phase 3 setting is also unusual in cannabis medicine and provides a reference point that prior cannabis pain trials have generally not attempted. That said, the primary publication was reviewed by this commentary based on secondary reporting and news sources; comparison literature was not independently searched for this Lens Card, and readers should consult the full primary article and accompanying editorial commentary for a rigorous comparative analysis.
Practical Considerations
The most immediate practical reality is that U.S. patients cannot access VER-01. European marketing authorization is pending as of this writing, and a U.S. NDA is not anticipated until 2028 at the earliest, contingent on positive results from the ongoing U.S. Phase 3 trial. Physicians in Massachusetts and nationally cannot prescribe or recommend VER-01 to patients today. What clinicians can do is use this designation to inform conversations with patients about the pharmacological plausibility of cannabinoid therapy for chronic pain, while being clear that the specific product generating this evidence is not available and that its results do not validate commercial cannabis products directly. For patients currently using medical cannabis for chronic low back pain under physician supervision, this development supports the clinical rationale but does not change the practical guidance: appropriate dosing, product selection, monitoring, and integration with other treatment modalities remain the responsibility of the treating clinician. Product variability at dispensaries, the absence of pharmaceutical-grade standardization, and differences in individual pharmacokinetics all remain relevant practical considerations that distinguish real-world cannabis use from the controlled conditions of the VER-01 trials.
Future Directions (Expected)
The immediate next step is the U.S. Phase 3 trial, which will need to replicate VER-01’s efficacy and safety profile in American patients before FDA approval can be pursued. Initial data are expected in 2027. If positive, a New Drug Application submission is planned for 2028. The FDA’s accelerated review pathway under Breakthrough Therapy Designation means the review itself would be expedited if the NDA is accepted. Assuming approval, VER-01 would become only the second FDA-approved cannabis-derived medicine, after Epidiolex (cannabidiol for certain epilepsy syndromes, approved 2018). The arrival of a regulated, pharmaceutical-grade cannabis extract for pain would likely reshape the clinical conversation about cannabis therapy substantially: payers might cover a pharmaceutical product in a way they do not cover medical cannabis, prescribing physicians may be more comfortable with an FDA-approved product, and it would create a concrete point of comparison for evaluating the value of existing medical cannabis programs. The longer-term question is whether VER-01’s commercial success would accelerate investment in additional cannabis pharmaceutical programs for other indications, including anxiety, sleep, and inflammatory conditions where patient demand and preliminary evidence already exist.
Misreadings & Bad-Faith Takes
Distortion 1: “The FDA just approved cannabis for back pain.” This is false. Breakthrough Therapy Designation is not approval. It is a designation that accelerates the review process. VER-01 is not approved, not available in the U.S., and will not be for years pending additional trials and an NDA review. Correction: The FDA opened an accelerated review pathway; it did not approve any cannabis product for pain.
Distortion 2: “This proves your dispensary cannabis will cure your back pain.” This is a category error the VER-01 company itself corrected directly. VER-01 is a pharmaceutical formulation from a proprietary plant strain under controlled conditions. Its results apply to that specific product only. Correction: VER-01’s evidence does not extend to commercial cannabis products, which differ in composition, standardization, dose, and delivery.
Distortion 3: “This shows cannabis is as good as opioids.” Overstated. The comparison trial showed VER-01 produced favorable results relative to opioids in the specific trial design. This is not a conclusion about all cannabis versus all opioids, and the methodological details of that comparison trial warrant careful review. Correction: The opioid comparison data is encouraging and clinically meaningful, but it applies to one proprietary formulation in specific trial conditions, not to cannabis as a category.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
Have thoughts on this? Share it:
𝕏 Share on X
in Share on LinkedIn
🦋 Share on BlueSky
📷 Follow on Instagram
📝 Read more on Substack
🔔 Subscribe via RSS
Primary Sources:
VERTANICAL. “FDA Grants Breakthrough Therapy Designation to VERTANICAL’s VER-01, a First-in-Class Non-Opioid Investigational Treatment for Chronic Low Back Pain.” PRNewswire, May 18, 2026. View release
Karst M et al. “Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.” Nature Medicine, published online September 29, 2025. View in Nature Medicine
DOJ/DEA. “Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-issued License in Schedule III.” April 23, 2026. View DOJ release
Related Reading at CED Clinic
Continue exploring the evidence
Can Cannabis Replace Opioids for Chronic Pain? A New Review Maps What We Know and What Remains Uncertain
A prior CED analysis of the opioid-cannabis substitution evidence, directly relevant to the clinical questions VER-01 is designed to answer.
Explore evidence
Cannabis for Pain: Evidence-Based Clinical Dosing
A practical guide to what the clinical dosing evidence for cannabis-based pain management currently supports, with real-world applicability for patients today.
Explore evidence
Endocannabinoid System Research: Cannabis for Chronic Pain
The mechanistic foundation behind cannabinoid pain therapy, the ECS science that explains why VER-01’s Phase 3 results are biologically plausible.
Explore evidence
Frequently Asked Questions
What is FDA Breakthrough Therapy Designation and why does it matter for cannabis?
Breakthrough Therapy Designation is an FDA program designed to accelerate the development and review of drugs that may offer substantial improvement over available therapies for serious conditions. It does not mean the drug is approved or available to patients. It means the FDA has reviewed preliminary clinical evidence and determined that the drug warrants faster review. For VER-01, this is historically significant because it represents the first time the FDA has granted this status to a pharmaceutical-grade cannabis extract for a pain indication, validating the evidence base generated by VERTANICAL’s Phase 3 clinical program.
Is VER-01 available to patients in the U.S. now?
No. VER-01 is not available to U.S. patients at this time. VERTANICAL is pursuing marketing authorization in Europe first, with U.S. approval contingent on completing an additional Phase 3 trial in American patients. Initial data from that trial are expected in 2027, and a New Drug Application is planned for 2028. Assuming a successful NDA review under the accelerated Breakthrough Therapy pathway, U.S. patients would not have access until at least 2028 or 2029, and only if the application is approved.
Does this FDA designation mean that cannabis products at dispensaries are proven to treat back pain?
No, and this distinction is critical. VER-01 is a proprietary pharmaceutical formulation derived from a specific, proprietary Cannabis sativa strain (DKJ127) under pharmaceutical-grade manufacturing standards. VERTANICAL itself has explicitly stated that findings from VER-01 trials should not be generalized to other cannabis extracts or products. Commercial cannabis at dispensaries differs in genetic background, cannabinoid composition, terpene profile, standardization, and dose. The VER-01 evidence strengthens the pharmacological rationale for cannabinoid therapy broadly, but it does not validate any specific commercial product for back pain.
What did the Phase 3 trial actually show about pain relief?
The primary Phase 3 placebo-controlled trial enrolled 820 adults with chronic low back pain. After 12 weeks, participants taking VER-01 experienced a mean pain reduction of 1.9 points on the Numeric Rating Scale, compared to 0.6 points for the placebo group. Patients also reported improvements in sleep disturbances and physical function. A separate Phase 3 trial comparing VER-01 directly to opioids found that VER-01 produced greater pain reduction with better gastrointestinal tolerability, and no evidence of dependence was observed across the clinical program. The primary trial results were published in Nature Medicine in September 2025.
Is VER-01 addictive or likely to cause dependence?
According to VERTANICAL’s reports from their clinical program, no evidence of dependence was observed across their Phase 3 trials. This is a clinically meaningful finding, as concern about dependence is a significant driver of both patient hesitancy and prescriber caution around cannabis and opioid-adjacent therapies. However, it is important to note that these results come from the company’s own clinical program. Independent replication and long-term observational data will be needed to fully characterize the dependence profile of VER-01 across broader populations and extended use periods.
How does VER-01 compare to opioids for back pain?
VERTANICAL conducted a direct Phase 3 comparative trial between VER-01 and opioids. The company reported that VER-01 produced greater pain reduction and better gastrointestinal tolerability compared to opioids in that trial, with no evidence of dependence. The full methodology and detailed results of the opioid comparison trial were not independently reviewed for this article, and those details matter when interpreting the magnitude and generalizability of the advantage. What is clear is that a direct Phase 3 comparison reaching favorable conclusions for a cannabis-based treatment over opioids is novel in clinical cannabis research and contributed meaningfully to the FDA’s designation decision.
Should I stop taking opioids for back pain and switch to cannabis based on this news?
No. Decisions about opioid therapy should always involve your prescribing physician and should not be made unilaterally based on news about a drug that is not yet available in the U.S. Stopping opioids abruptly can be medically dangerous. If you are interested in exploring cannabis as part of your pain management approach, the appropriate step is a consultation with a physician who understands both your pain history and the current evidence base for cannabis. At CED Clinic, this is a conversation we have regularly with patients in Massachusetts and beyond who are managing chronic pain and seeking individualized guidance.
What is the endocannabinoid system and why is it relevant to VER-01’s effects?
The endocannabinoid system (ECS) is a biological signaling network present throughout the human body that plays a central role in regulating pain perception, inflammation, sleep, mood, and other functions. It consists of endogenous cannabinoids produced by the body, receptors (primarily CB1 and CB2), and enzymes that synthesize and degrade these compounds. THC, CBD, and other plant cannabinoids interact with this system, which is why cannabis has plausible pharmacological mechanisms for pain relief. VER-01’s full-spectrum formulation is designed to engage this system in a consistent, controlled way, which is the mechanistic rationale for its observed analgesic effects in clinical trials.
What is the significance of the Nature Medicine publication?
Nature Medicine is among the highest-impact peer-reviewed journals in clinical medicine. Publication there indicates the research underwent rigorous peer review and was considered methodologically sound and scientifically significant enough to merit broad clinical attention. For cannabis pain research, which has historically been limited to lower-impact publications partly due to the regulatory barriers to conducting high-quality trials, a Phase 3 trial in Nature Medicine represents a notable step in the field’s maturation. It adds credibility to the evidence base that the FDA evaluated in granting the Breakthrough Therapy Designation to VER-01.
If I am a patient at CED Clinic with chronic back pain, what does this mean for my care?
This development does not change the products available to you or the immediate options in your care plan. What it does is add to the scientific foundation for having a detailed, evidence-grounded conversation about cannabis as a part of your pain management approach. At CED Clinic, Dr. Caplan integrates current clinical evidence with each patient’s individual history, goals, and circumstances. If you have questions about how cannabis may fit into your treatment for chronic back pain, including how to think about current medical cannabis options in the context of what VER-01’s trial data suggests about cannabinoid pharmacology, please reach out to schedule a consultation. [...]
Read more...
June 3, 2026Semaglutide and Tirzepatide Linked to Nonscarring Hair Loss in Large Propensity-Matched Cohort
Study at a Glance
Citation
Lanehart MH, Zinn Z, Beatty CJ. Archives of Dermatological Research. 2026;318:164. doi:10.1007/s00403-026-04603-w
Design
Population-based, propensity score matched retrospective cohort analysis (TriNetX database)
Population
Adults ≥18 years newly prescribed a GLP-1 receptor agonist or metformin following first diagnosis of overweight/obesity (E66) or type 2 diabetes (E11); patients with prior nonscarring hair loss or lifetime alopecia areata excluded
Comparator
Metformin (active comparator, N matched 1:1 per GLP-1RA cohort)
Primary Outcome
New diagnosis of nonscarring hair loss (androgenetic alopecia, telogen effluvium, or other nonscarring alopecia, ICD-10-CM L64–L65.9) within 12 months of drug initiation
Key Finding
Semaglutide: RR 1.43 (95% CI 1.30–1.56); Tirzepatide: RR 1.68 (95% CI 1.44–1.97); Dulaglutide and liraglutide: no significant difference vs. metformin
Funding
None declared
Conflicts of Interest
None declared
Background and Context
GLP-1 receptor agonists (GLP-1RAs) are now prescribed at scale for both type 2 diabetes mellitus (T2DM) and obesity. As utilization has expanded, case series and pharmacovigilance signals have suggested a possible association between these agents and nonscarring hair loss. Prior studies addressing this question have been constrained by small sample sizes or inadequate control for confounding, leaving the clinical significance and agent-specificity of any association unresolved. Lanehart and colleagues designed this TriNetX-based propensity score matched cohort to provide a larger, better-controlled estimate of the association between individual GLP-1RAs and new-onset nonscarring alopecia.
Methods Overview
Study Design and Data Source
This was a retrospective cohort analysis using the TriNetX federated health research network. Cohorts were assembled using validated RxNorm codes for drug identification and ICD-10-CM codes for diagnoses.
Population
Patients were 18 years of age or older with a first diagnosis of overweight/obesity (E66) or T2DM (E11) who were newly initiated on one of four GLP-1RAs: dulaglutide (N = 1,551,291 pre-match), liraglutide (N = 475,968), semaglutide (N = 1,991,302), or tirzepatide (N = 2,601,723). Patients with any prior diagnosis of nonscarring hair loss, any lifetime diagnosis of alopecia areata (L63–L63.9), or lifetime prescriptions of comparator drug classes were excluded. The comparator pool comprised patients initiating metformin (N = 6,809 post-match reference).
Matching and Confounders
Each GLP-1RA cohort was matched 1:1 to a metformin control cohort using a greedy nearest-neighbor propensity score algorithm. Matching variables included demographics, overweight/obesity status, T2DM status, cigarette smoking, essential hypertension, ischemic heart disease, polycystic ovarian disease, pregnancy, systemic lupus erythematosus, and thyroid disease. All index dates were defined as the date of drug initiation.
Outcomes and Statistical Analysis
The primary outcome was a new ICD-10-CM diagnosis of androgenetic alopecia (L64), telogen effluvium (L65.0), or other nonscarring hair loss (L65–L65.9) within 12 months of drug initiation. Relative risks with 95% confidence intervals were calculated and chi-squared tests used to assess statistical significance. Prespecified sensitivity analyses were conducted stratified by sex and by age at initiation (18–39 years versus ≥40 years).
Results: Primary Outcomes
After propensity score matching, the semaglutide-versus-metformin comparison included 170,965 patients per arm. Among all adults, 1,053 of 163,839 evaluable semaglutide-initiators developed nonscarring hair loss within 12 months, compared with 750 of 166,261 metformin-initiators (RR 1.43; 95% CI 1.30–1.56; p < 0.001).
The tirzepatide-versus-metformin comparison included 62,230 patients per arm. Among all adults, 418 of 59,305 evaluable tirzepatide-initiators developed nonscarring hair loss, compared with 252 of 60,213 metformin-initiators (RR 1.68; 95% CI 1.44–1.97; p < 0.001).
Neither dulaglutide (RR 0.94; 95% CI 0.77–1.14; N = 51,012 per arm) nor liraglutide (RR 1.12; 95% CI 0.93–1.37; N = 36,530 per arm) demonstrated a statistically significant difference in nonscarring hair loss risk relative to metformin.
Results: Secondary Outcomes and Subgroup Findings
Age-Stratified Analysis
For semaglutide, the elevated risk persisted across both age strata: RR 1.48 (95% CI 1.24–1.77) in patients aged 18–39 years and RR 1.36 (95% CI 1.21–1.54) in patients aged 40 years or older. For tirzepatide: RR 1.78 (95% CI 1.33–2.38) in the 18–39-year group and RR 1.64 (95% CI 1.34–2.00) in the 40-and-older group.
Sex-Stratified Analysis
For semaglutide, the risk elevation was present in both males (RR 1.58; 95% CI 1.11–2.24) and females (RR 1.37; 95% CI 1.24–1.52). For tirzepatide: males RR 1.83 (95% CI 1.09–3.08) and females RR 1.68 (95% CI 1.44–1.97). Point estimates for dulaglutide and liraglutide in male subgroups were elevated but did not reach statistical significance (dulaglutide males: RR 1.40, 95% CI 0.62–3.15; liraglutide males: RR 1.80, 95% CI 0.83–3.90), likely reflecting small outcome counts in those strata.
Cohort Demographics After Matching
Standardized differences for all matching variables were below 0.07 in both the semaglutide and tirzepatide matched cohorts, indicating adequate balance. Prevalence of overweight/obesity was highest in the semaglutide (82.1%) and tirzepatide (88.8%) cohorts among GLP-1RA groups.
What a Careful Reader Should Take Away
Several observations warrant scrutiny before accepting these findings at face value. First, the primary outcome pools three biologically and clinically distinct entities: androgenetic alopecia, telogen effluvium, and other nonscarring alopecias. The study does not stratify outcomes by specific diagnosis, meaning it is impossible to determine whether the signal reflects predominantly telogen effluvium, androgenetic alopecia acceleration, or another process entirely. The authors explicitly acknowledge this as a limitation attributable to low outcome counts per subcategory.
Second, the absence of a signal with dulaglutide and liraglutide is interpreted as evidence pointing toward weight loss-induced telogen effluvium rather than a direct follicular drug effect. That mechanistic inference is plausible and internally consistent, but it rests on the premise that semaglutide and tirzepatide produce greater weight loss than the other agents in this cohort. The study did not measure individual weight loss, so this remains inferential.
Third, the use of metformin as an active comparator is methodologically sound (it reduces confounding by indication relative to a no-treatment control) but introduces a different assumption: that metformin itself has a neutral effect on hair. Any hair-protective or hair-promoting effect of metformin would artifactually inflate the apparent risk associated with GLP-1RAs.
Fourth, ICD-10-CM-based ascertainment of hair loss almost certainly undercounts true event rates; the direction of any differential miscoding between groups is unknown.
Dr. Caplan’s Clinical Commentary
This is one of the more rigorously designed studies to address GLP-1RA-associated hair loss to date. The combination of a large matched cohort, an active comparator, and prespecified sensitivity analyses substantially improves on the pharmacovigilance disproportionality analyses that have dominated this conversation. The finding that semaglutide and tirzepatide carry a 43% and 68% higher relative risk of nonscarring hair loss, respectively, compared to metformin is a clinically meaningful signal that deserves to be communicated to patients before therapy begins, not after they notice shedding.
The mechanistic framing is important here. The authors suggest that weight loss-induced telogen effluvium, rather than direct follicular toxicity, best explains the agent-specific pattern. That is a reasonable hypothesis. Telogen effluvium characteristically follows a physiologic stressor by two to four months, and the agents most associated with the hair loss signal in this dataset are precisely those documented in clinical trials to produce the greatest magnitude of weight loss. The failure to detect a signal with dulaglutide and liraglutide, which are associated with more modest weight reduction, is consistent with this framing. Clinicians who counsel patients on GLP-1RAs for weight loss should address the possibility of transient hair shedding proactively, contextualize it within the biology of telogen effluvium, and set expectations about the typical time course of resolution once a new steady state is reached.
The inability to quantify patient-level weight loss is the study’s most consequential gap. Without that variable, the mechanistic claim cannot be tested directly. A future analysis linking weight change magnitude to hair loss incidence within GLP-1RA cohorts would substantially strengthen or challenge the telogen effluvium hypothesis. Until that data exists, the association is documented but its mechanism remains inferential.
From a prescribing standpoint, this study should not dissuade appropriate use of semaglutide or tirzepatide in patients with obesity or T2DM where the metabolic benefit is clear. What it should do is sharpen pre-treatment counseling and lower the threshold for proactive dermatologic evaluation in patients who report new-onset shedding. Hair loss that is telogen-mediated is typically self-limited; framing it that way at the outset can meaningfully reduce patient anxiety and unnecessary medication discontinuation.
Comparison to Existing Literature
The authors situate this work within four prior publications. Burke and colleagues published a retrospective cohort study in the Journal of the American Academy of Dermatology (2025) reporting a similar association between GLP-1RA use and hair loss but noted limitations in sample size and confounding adjustment. Desai and colleagues (2024, International Journal of Dermatology) raised the hormonal pathway hypothesis, suggesting GLP-1 receptor signaling could disrupt hair cycle regulation; the current study’s agent-specific pattern argues against a pure class-level hormonal mechanism. Two pharmacovigilance disproportionality analyses, one using FDA FAERS data (Godfrey et al., 2025, Journal of the European Academy of Dermatology and Venereology) and one using a global pharmacovigilance database (Kim et al., 2025, Diabetes, Obesity and Metabolism), identified alopecia signals for semaglutide and tirzepatide, consistent with the current findings. The mechanistic weight-loss rationale in the present paper is further supported by a 2025 systematic review in Annals of Internal Medicine (Moiz et al.) documenting semaglutide and tirzepatide as the most efficacious GLP-1RAs for weight loss compared to placebo, providing the comparative efficacy context the authors invoke.
Practical Clinical Implications
Counsel patients initiating semaglutide or tirzepatide that new-onset hair shedding has been reported at a 43–68% higher rate than in comparable patients on metformin; onset typically occurs several months after drug initiation.
Frame any anticipated shedding within the biology of telogen effluvium: a physiologically triggered, generally self-limited process rather than a marker of drug toxicity or permanent follicular damage.
Establish a dermatologic baseline or referral pathway for patients who report progressive or persistent hair loss to rule out concurrent androgenetic alopecia or other alopecias.
The absence of a significant signal with dulaglutide and liraglutide does not constitute evidence that those agents are definitively safer for hair; this study was not powered to detect a small-to-moderate effect in those cohorts, and male subgroup estimates for both agents trended upward without reaching significance.
Do not discontinue semaglutide or tirzepatide solely on the basis of hair shedding without a structured evaluation; the metabolic benefit in appropriate patients is well established and should not be forfeited over a likely transient adverse effect.
Limitations
No individual weight-loss quantification: The study cannot directly test whether the hair loss signal tracks with magnitude of weight reduction, leaving the telogen effluvium hypothesis mechanistically supported but unconfirmed.
Pooled outcome definition: Androgenetic alopecia, telogen effluvium, and other nonscarring alopecias are grouped under a single composite endpoint; agent-specific subcategory counts were insufficient for disaggregated analysis.
ICD-10-CM ascertainment bias: Hair loss is frequently underdiagnosed or undercoded in administrative data; differential miscoding between GLP-1RA and metformin groups cannot be excluded.
Active comparator assumption: The analysis assumes metformin has a neutral effect on hair; any systematic difference in this assumption would bias relative risk estimates.
Observational design: Residual confounding from unmeasured variables (nutritional deficiencies, stress, concurrent medications) cannot be fully excluded despite propensity matching.
One-year follow-up window: Events occurring beyond 12 months are not captured; longer latency outcomes are uncharacterized.
Bottom Line
In a propensity score matched cohort of more than 460,000 patients, initiation of semaglutide was associated with a 43% higher relative risk of nonscarring hair loss (RR 1.43; 95% CI 1.30–1.56) and initiation of tirzepatide with a 68% higher relative risk (RR 1.68; 95% CI 1.44–1.97) compared to metformin over 12 months. No significant association was detected for dulaglutide or liraglutide. The agent-specific pattern, combined with the established weight-loss efficacy hierarchy among GLP-1RAs, supports weight loss-induced telogen effluvium as the most probable mechanism, though this cannot be confirmed without individual weight-change data. These findings do not alter the benefit-risk calculus for semaglutide or tirzepatide in appropriate clinical contexts, but they do justify systematic pre-treatment counseling and a low threshold for dermatologic evaluation in affected patients.
Citation
Lanehart MH, Zinn Z, Beatty CJ. Association between GLP-1 receptor agonists and nonscarring hair loss: a population-based, propensity score matched cohort analysis. Archives of Dermatological Research. 2026;318:164. doi:10.1007/s00403-026-04603-w
CED Perspective Lens
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, critics, and policymakers often leave the same paper with very different impressions of what it means. The perspectives below are not summaries of the study. They are different evidence-based ways of thinking about the study, its strengths, its limitations, and the conclusions that may or may not reasonably follow from the data.
OVERVIEW
This paper is less about hair loss than it is about how medicine evaluates emerging side effects of highly effective therapies as their use expands across millions of patients.
Overview
Patient Takeaway
Clinician’s POV
A Skeptical Read
Study Critic
Compared to Past Research
Practical Considerations
Future Directions
Misreadings & Bad-Faith Takes
Overview
At first glance, this appears to be a paper about hair loss. In a broader sense, however, it is a paper about the consequences of success. Semaglutide and tirzepatide have become two of the most widely discussed and widely prescribed metabolic therapies in modern medicine. Whenever a therapy expands from a relatively limited population into millions of real-world users, clinicians begin discovering questions that could not be fully appreciated during preapproval trials. This study belongs to that phase of scientific maturation.
The most important contribution of the paper may not be the specific relative risks reported for semaglutide or tirzepatide. Instead, it is the movement of the discussion away from anecdote and toward systematic evaluation. Prior concerns about hair loss largely existed as patient reports, social media discussions, pharmacovigilance signals, and clinical observations. This study attempts to examine the question using a large matched observational dataset and an active comparator rather than relying solely on spontaneous reports.
The paper also highlights a recurring challenge in modern medicine: determining whether an observed outcome represents a direct drug effect, an indirect consequence of treatment success, or a combination of both. The authors lean toward the possibility that substantial weight loss may contribute to the observed signal, but the study was not designed to definitively answer that question.
The study reflects the transition from anecdotal concern to structured observational analysis.
The central question extends beyond hair loss to broader medication-safety surveillance.
The paper raises mechanistic questions that it cannot fully answer.
The observed association may be easier to measure than to explain.
OVERVIEW TAKEAWAY
This paper is best viewed as an effort to investigate an emerging safety signal, not as a final explanation for why the signal exists.
Patient Takeaway
A thoughtful patient reading this study should recognize that it answers a narrower question than many headlines are likely to suggest. The paper does not ask whether people notice hair loss, whether the hair loss is severe, whether it resolves, or how distressing it may be. Instead, it examines whether diagnoses of nonscarring hair loss appeared more frequently among patients prescribed certain medications than among comparable patients prescribed metformin.
One of the easiest mistakes in medical reading is confusing relative risk with personal experience. A relative increase in risk can sound dramatic, especially when expressed as 43% or 68% higher risk. Yet the study itself does not suggest that most patients experience hair loss, nor does it quantify how noticeable the hair loss may have been among those who received a diagnosis. The distinction between statistical significance and everyday significance is important.
The paper also leaves several questions unanswered that many patients would naturally care about. It does not establish whether shedding was temporary or persistent. It does not determine whether greater weight loss corresponds to greater risk. It does not identify which patients may be most susceptible. Those uncertainties matter because they shape how individuals interpret the practical meaning of the findings.
Perhaps most importantly, the study should not be interpreted as evidence that successful weight loss necessarily comes at the cost of meaningful hair loss. The data suggest an association worthy of attention. They do not establish an inevitable outcome for individual patients.
The study measures diagnoses, not personal experiences.
Relative risk and absolute risk are not interchangeable concepts.
The severity and duration of hair loss remain uncertain.
The findings describe groups, not individual outcomes.
PATIENT TAKEAWAY
The study suggests a measurable association, but it cannot tell patients how likely they are to personally notice, experience, or be affected by hair loss.
Clinician’s POV
A careful clinician may view this paper primarily as a communication study rather than a prescribing study. The findings introduce information that could reasonably become part of pre-treatment counseling, but they do not necessarily alter the broader therapeutic role of semaglutide or tirzepatide. The paper identifies a signal that deserves discussion, not a signal that automatically changes the overall benefit-risk assessment.
From a clinical perspective, one of the strengths of the study is the use of an active comparator. Comparing GLP-1 receptor agonists with metformin is more informative than comparing treated patients with untreated individuals because it reduces some forms of confounding related to disease status and healthcare utilization. The large matched cohorts further strengthen confidence that the observed association is not simply a statistical artifact.
At the same time, clinicians may immediately notice the limits of the analysis. The study cannot determine whether weight loss itself contributed to the outcome. It cannot separate biologically distinct forms of nonscarring alopecia with sufficient granularity. It cannot establish whether the observed diagnoses represented transient shedding, progression of preexisting predisposition, or some other process.
As a result, the paper may influence the content of clinical conversations more than it influences prescribing behavior. It adds information. It does not yet provide a definitive explanation.
The active-comparator design improves interpretability.
The study supports awareness, not necessarily practice change.
Mechanistic uncertainty remains substantial.
Clinical counseling may evolve faster than clinical decision-making.
CLINICIAN’S POV
The paper strengthens informed-consent discussions more than it strengthens any particular prescribing conclusion.
A Skeptical Read
A scientifically skeptical reader is not necessarily looking for flaws. They are looking for assumptions. In this paper, the most important assumption appears in the authors’ preferred explanation for the observed association. The discussion repeatedly points toward weight-loss-induced telogen effluvium as the most plausible interpretation of the findings. Yet individual weight loss was not measured within the analysis. As a result, the paper’s most prominent explanatory framework rests on a variable that is absent from the dataset itself.
A skeptic would also note that the observed outcome is a diagnosis, not a biologic event. The study does not measure hair density, follicular health, shedding rates, or dermatologic examination findings. It measures whether a diagnosis code entered the medical record. That distinction does not invalidate the result, but it changes what the result actually represents. Diagnostic behavior, healthcare-seeking behavior, and coding practices can all influence observed outcomes.
The choice of metformin as a comparator is another area that invites scrutiny. The design is stronger than a no-treatment comparison, but it introduces a new assumption: namely that metformin is effectively neutral with respect to hair-related outcomes. If that assumption is imperfect, the magnitude of the observed associations could shift accordingly.
None of these concerns eliminate the possibility that the association is real. Rather, they remind readers that observational studies often answer questions about patterns before they answer questions about causes.
The leading mechanistic explanation relies on an unmeasured variable.
Diagnosis codes are not equivalent to direct biologic measurements.
Comparator selection improves some biases while introducing new assumptions.
The paper establishes association more clearly than explanation.
SKEPTICAL TAKEAWAY
The strongest explanation presented by the paper is plausible, but the study itself was not designed to directly test that explanation.
Study Critic
If serving as a peer reviewer, the most immediate request would involve greater diagnostic granularity. The primary endpoint combines androgenetic alopecia, telogen effluvium, and other nonscarring alopecias into a single outcome category. From a statistical perspective, that decision increases event counts and improves power. From an interpretive perspective, it limits insight into what may actually be occurring.
A second concern would involve the absence of patient-level weight-change data. The discussion repeatedly references the possibility that more substantial weight loss may explain the stronger associations observed with semaglutide and tirzepatide compared with liraglutide and dulaglutide. Yet the paper cannot directly test that proposition. Consequently, one of the most clinically interesting questions remains unresolved.
A reviewer might also ask whether outcome ascertainment could be strengthened. Administrative datasets are valuable because of scale, but scale often comes at the expense of detail. Confirmation of diagnoses through dermatologic evaluation, photographic assessment, or chart review would strengthen confidence that coded outcomes reflect clinically meaningful events.
Importantly, these concerns do not undermine the value of the study. They represent the types of questions that emerge when a paper successfully identifies an important signal and readers naturally want greater precision regarding its interpretation.
Outcome categories may be too broad for mechanistic interpretation.
Weight-loss data would substantially strengthen the analysis.
Administrative coding provides scale but limits clinical detail.
The paper identifies a signal more effectively than it characterizes the signal.
STUDY CRITIC TAKEAWAY
The biggest limitation is not statistical power. It is the inability to determine exactly what type of hair-loss process generated the observed association.
Compared to Past Research
Viewed conceptually, this paper occupies an interesting position within the evolution of evidence. Early concerns regarding medication-associated hair loss often begin with anecdotal observations. Patients notice changes. Clinicians notice patterns. Discussions emerge. Eventually those observations appear in pharmacovigilance databases, case reports, and informal clinical conversations.
This study represents a later stage of that process. Rather than asking whether isolated reports exist, the authors ask whether the signal remains detectable within a very large population after matching treated individuals to an active comparator cohort. That shift matters because it moves the discussion from possibility toward quantification.
The paper therefore contributes less by introducing a new concern than by attempting to estimate the magnitude of an existing one. It also reflects the broader reality that many medication-safety questions are answered progressively rather than all at once. Initial signals generate hypotheses. Larger observational studies evaluate whether those signals persist. More focused investigations then attempt to clarify mechanisms.
In that sense, this study feels less like the beginning of a conversation and more like the middle of one. The existence of concern is no longer the central issue. Understanding the nature of that concern has become the next challenge.
The paper reflects a progression from signal detection to signal evaluation.
Its primary contribution is quantification rather than discovery.
Large observational analyses often occupy the middle stage of evidence development.
The central debate is shifting from whether a signal exists to why it exists.
PAST RESEARCH TAKEAWAY
This paper represents a maturation of the conversation, moving beyond anecdotal concern toward structured evaluation of an already recognized signal.
Practical Considerations
One of the most useful questions a reader can ask after finishing this paper is not whether the findings are statistically significant, but whether they are operationally useful. In many respects, this study highlights how difficult it can be to translate observational signals into practical expectations. The association appears measurable, yet many of the details that patients and clinicians would want to know remain uncertain.
For example, the study does not establish a timeline that clinicians can confidently use when discussing risk. While telogen effluvium is discussed as a potential explanation, the analysis itself does not determine when hair loss begins, when it peaks, how long it persists, or whether risk changes with continued treatment. These questions often matter more in practice than the existence of the association itself.
Another challenge involves individual variability. The paper evaluates large populations but cannot identify which characteristics distinguish patients who developed hair loss from those who did not. Age and sex subgroup analyses demonstrate persistence of the association across categories, but they do not create a predictive framework that clinicians can use during individual patient encounters.
The practical reality is that this study increases awareness while leaving many implementation questions unresolved. It improves the conversation but does not complete it.
The study does not define onset, duration, or recovery timelines.
Individual susceptibility remains poorly characterized.
Population-level associations do not easily translate into patient-level prediction.
Operational questions now become more important than detection of the signal itself.
PRACTICAL TAKEAWAY
The study identifies a risk signal, but many of the details needed for precise real-world expectation setting remain unknown.
Future Directions
The next generation of research should focus less on establishing whether an association exists and more on understanding the nature of the association. This study successfully identifies a signal within a large population. Future studies should attempt to characterize that signal with greater precision.
One logical step would involve prospective observation of patients beginning GLP-1 receptor agonist therapy, accompanied by standardized measurements of weight change, dermatologic assessments, and longitudinal follow-up. Such an approach would help clarify whether greater weight reduction corresponds with greater risk and whether specific forms of nonscarring alopecia predominate.
Additional refinement could come from separating outcome categories rather than grouping multiple alopecia diagnoses into a composite endpoint. If distinct patterns emerge among telogen effluvium, androgenetic alopecia, and other diagnoses, mechanistic interpretation would become substantially easier.
Importantly, the most valuable future studies may not be larger studies. They may simply be more detailed studies. The current analysis already demonstrates considerable statistical power. The next challenge is increasing clinical resolution rather than increasing sample size.
Future work should prioritize characterization over detection.
Prospective designs could directly evaluate weight-change relationships.
Greater diagnostic specificity would improve interpretation.
More detail may be more valuable than more participants.
FUTURE DIRECTIONS TAKEAWAY
The most important unanswered question is no longer whether a signal exists, but what biological and clinical processes generate that signal.
Misreadings & Bad-Faith Takes
This paper is particularly vulnerable to oversimplification because the topic is emotionally resonant. Hair loss attracts attention. Weight-loss medications attract attention. Combining the two creates fertile ground for misleading headlines. Several interpretations should be approached cautiously because they extend beyond what the study actually demonstrates.
One common distortion would be the claim that semaglutide or tirzepatide “cause” hair loss. The study does not establish causality. It identifies an association within a large observational dataset. Although the association appears statistically robust, observational analyses cannot eliminate every source of residual confounding and cannot independently prove mechanism.
A second distortion would be the claim that these medications damage hair follicles. No follicular biology was measured. No histologic evaluation was performed. No direct evidence of follicular toxicity appears in the paper. Such statements convert speculation into certainty and therefore exceed the evidence.
Another misleading interpretation would be that all GLP-1 receptor agonists carry identical risk. The findings were not uniform across agents. Semaglutide and tirzepatide generated statistically significant associations, whereas dulaglutide and liraglutide did not. Whether those differences reflect biology, efficacy, study power, or other factors remains uncertain, but the paper does not support treating the class as homogeneous.
Finally, readers should resist the temptation to assume that observed hair loss necessarily outweighs therapeutic benefit. The study was not designed to compare competing outcomes or establish overall treatment value. It examines one safety signal, not the totality of clinical benefit and risk.
Association should not be translated into proof of causation.
The paper contains no evidence of direct follicular toxicity.
The results do not support assuming identical risk across all GLP-1 agents.
The study evaluates one outcome, not overall therapeutic value.
Headline certainty exceeds what the design can support.
MISREADINGS TAKEAWAY
The strongest misuse of this paper would be treating an observed association as proof of cause, mechanism, permanence, or overall clinical harm.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What is the main finding of the study?
The study found that semaglutide and tirzepatide are associated with a higher risk of nonscarring hair loss compared to metformin.
Which GLP-1RAs were studied?
The study included dulaglutide, liraglutide, semaglutide, and tirzepatide.
What is the relative risk of nonscarring hair loss with semaglutide?
The relative risk for semaglutide is 1.43 compared to metformin.
What is the relative risk of nonscarring hair loss with tirzepatide?
The relative risk for tirzepatide is 1.68 compared to metformin.
Why were dulaglutide and liraglutide not significantly associated with hair loss?
Dulaglutide and liraglutide are associated with more modest weight reduction, which may explain the lack of a significant signal.
What is telogen effluvium?
Telogen effluvium is a type of nonscarring hair loss that typically follows a physiologic stressor, such as weight loss, by two to four months.
How should clinicians counsel patients about this risk?
Clinicians should proactively address the possibility of transient hair shedding and frame it within the biology of telogen effluvium.
What is the study’s main limitation?
The study did not measure individual weight loss, making it difficult to directly test the mechanistic claim.
Does this mean GLP-1RAs should be avoided?
No, appropriate use of semaglutide or tirzepatide in patients with obesity or T2DM is still recommended where the metabolic benefit is clear.
What are the implications for future research?
A future analysis linking weight change magnitude to hair loss incidence within GLP-1RA cohorts would strengthen or challenge the telogen effluvium hypothesis. [...]
Read more...
June 3, 2026GLP-1 Receptor Agonists for Alcohol Use Disorder: What the Evidence Shows
GLP-1 Receptor AgonistsAlcohol Use DisorderSemaglutideSubstance Use DisordersAddiction Pharmacotherapy
What You’ll Learn in This Review:
What animal and human studies reveal about GLP-1 receptor agonists and alcohol consumption, including the dopaminergic mechanisms most likely responsible for the effect.
How four completed randomized controlled trials, including two semaglutide trials published in JAMA Psychiatry and The Lancet, have performed against placebo in patients with AUD.
Why the real-world EHR data, while promising, carries meaningful confounding that limits interpretation.
What 19 ongoing or planned trials are testing — and which drug, dose, and patient population questions remain genuinely open.
TL;DR: Convergent preclinical and clinical evidence — including two placebo-controlled semaglutide trials — supports a meaningful reduction in alcohol consumption with GLP-1 receptor agonists, but the evidence base is not yet sufficient for FDA approval to treat AUD, and critical mechanistic and efficacy questions remain unanswered.
STUDY TYPE: NARRATIVE CRITICAL REVIEW
Abstract
This narrative review evaluates glucagon-like peptide-1 receptor agonists (GLP-1RAs) as potential treatments for alcohol use disorder (AUD), a major public health problem with limited treatment options. The authors first describe the development of GLP-1RAs for treating type 2 diabetes and obesity and then focus on recent studies of the drugs’ effects on alcohol-related behaviors, both in animal models and clinical studies. Relevant literature was identified by searching PubMed, Google Scholar, and clinicaltrials.gov, and reviewing the reference lists of published reviews. Discussion of preclinical studies was limited to those providing mechanistic insights. Clinical studies comprised both observational studies, including those using electronic health records and other real-world data, and randomized controlled clinical trials. This yielded 13 preclinical studies, 14 clinical studies, 4 published interventional trials, and 19 interventional trials in progress or completed but unpublished. Convergent evidence from animal and human studies indicates that GLP-1RAs reduce alcohol consumption and improve alcohol-associated outcomes. Several randomized controlled trials in progress aim to test the effects of both established and novel compounds, different drug formulations, and combinations on alcohol consumption. Additional RCTs are needed to establish the efficacy of GLP-1RAs for treating AUD, with mechanistic studies needed to more fully elucidate their mode of action in reducing alcohol consumption.
Source: Woo S, Zhu G, Castro C, et al. GLP-1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review. Alcohol: Clinical and Experimental Research. 2026;50:e70312.DOI: https://doi.org/10.1111/acer.70312Open Access: Yes (Creative Commons Attribution License)
Study at a Glance
Design
Narrative critical review; literature searches conducted February 2025, July 2025, and March 2026
Databases Searched
PubMed, Google Scholar, clinicaltrials.gov
Studies Identified
13 preclinical; 14 observational clinical; 4 published RCTs; 19 trials in progress or completed but unpublished
Primary Focus
GLP-1RAs as pharmacotherapy for AUD, across species models, real-world data, and interventional trials
Key Finding
Semaglutide demonstrated statistically significant reductions in heavy drinking days in two placebo-controlled trials; the broader evidence base is convergent but not yet sufficient to support FDA approval for AUD
Funding
Mental Illness Research, Education and Clinical Center at Crescenz VAMC; VA Advanced Fellowship Program in Mental Illness Research and Treatment
COI
Dr. Kranzler: advisory boards for Altimmune and Clearmind Medicine; consultant to Sobrera, Altimmune, Lilly, Ribocure, Boehringer-Ingelheim; research funding from Alkermes; company-initiated studies from Altimmune and Lilly
Study Snapshot: Key Numbers
Domain
Finding
Source
Semaglutide RCT (Klausen et al. 2026): HDD reduction, semaglutide
41.1% reduction from baseline
Lancet 2026
Semaglutide RCT (Klausen et al. 2026): HDD reduction, placebo
26.4% reduction from baseline (p=0.0015)
Lancet 2026
Semaglutide RCT (Hendershot et al. 2025): lab BrAC
Medium-to-large effect; lower peak BrAC vs. placebo
JAMA Psychiatry 2025
EHR cohort: alcohol intoxication rate, AUD patients on GLP-1RA
aIRR=0.50 (95% CI 0.40–0.63)
Qeadan et al. 2025
GLP-1RA vs. FDA-approved AUD medications: relapse rate
IRR=0.55 (95% CI 0.42–0.73), p<0.01 vs. naltrexone, acamprosate, disulfiram
Gougol et al. 2026
Mendelian randomization: GLP-1/GIP signaling vs. problematic alcohol use
β=−0.44 (95% CI −0.72, −0.15), p=2.42×10⁻³
Reitz et al. 2025
Danish cohort: HR for alcohol-related events, GLP-1RA vs. DPP-4I
HR=0.46
Wium-Andersen et al. 2022
Dulaglutide (Probst et al. 2023): reduction in alcohol consumption vs. placebo
29% reduction in standard drinks
JCI Insight 2023
Study Facts Table
Field
Detail
Authors
Woo S, Zhu G, Castro C, Phuong A, Roy A, Davis CN, Kranzler HR
Journal
Alcohol: Clinical and Experimental Research
Year
2026
Design
Narrative critical review
Studies Included
13 preclinical; 14 observational clinical; 4 published interventional trials; 19 ongoing/unpublished trials
Intervention
GLP-1 receptor agonists (semaglutide, liraglutide, exenatide, dulaglutide, tirzepatide, and emerging multi-action agents)
Comparators
Placebo; DPP-4 inhibitors; FDA-approved AUD medications (naltrexone, acamprosate, disulfiram); SGLT2 inhibitors; sulfonylureas
Primary Endpoint (review focus)
Alcohol consumption reduction; AUD-related outcomes across study types
Key Results
Semaglutide significantly reduced heavy drinking days in two RCTs; observational data consistently associate GLP-1RAs with lower rates of AUD incidence, relapse, and hospitalization; preclinical data implicate mesolimbic dopamine suppression
Adverse Events (reported in RCTs)
Most common: gastrointestinal events (nausea, vomiting), generally mild to moderate in severity
Funding
Mental Illness Research, Education and Clinical Center, Crescenz VAMC; VA Advanced Fellowship Program
COI
Dr. Kranzler: advisory boards (Altimmune, Clearmind Medicine); consulting (Sobrera, Altimmune, Lilly, Ribocure, Boehringer-Ingelheim); research funding/medication supplies from Alkermes; company-initiated studies by Altimmune and Lilly
What Researchers Actually Did
Woo, Zhu, and colleagues at the University of Pennsylvania and the Perelman School of Medicine conducted three literature searches — in February 2025, July 2025, and March 2026 — across PubMed, Google Scholar, and clinicaltrials.gov. They searched for studies of incretin-based therapies in the context of AUD, using a broad set of drug-specific and diagnostic terms, with filters excluding preprints. From 167 identified studies, they applied explicit inclusion and exclusion criteria: original, peer-reviewed research published in English was included; case reports, commentaries, preprints, and studies of exendin-4 (not available for human use) were excluded. Preclinical studies were selected selectively to illustrate mechanism rather than exhaustively. Clinical studies were catalogued comprehensively, including observational analyses using electronic health records or social media, and all published and registered interventional trials.
The result was a structured narrative review organized into three tiers: preclinical evidence (13 studies) covering behavioral and neurobiological mechanisms; 14 observational clinical studies spanning EHR cohorts, propensity-score matched analyses, target-trial emulations, and Mendelian randomization; and 4 published RCTs alongside 19 trials in progress or completed but unpublished. The authors explicitly flagged the COI of the senior author, Dr. Kranzler, who has consulting and research relationships with several companies developing GLP-1RAs for addiction indications.
Key Findings: Primary Outcomes
Semaglutide RCT — Klausen et al. (2026), The Lancet: In 108 treatment-seeking patients with moderate-to-severe AUD and obesity (BMI >30 kg/m²) who also received cognitive behavioral therapy, semaglutide (maximum 2.4 mg/week subcutaneous) reduced heavy drinking days by 41.1% from baseline, compared to 26.4% in the placebo group (p=0.0015). The primary outcome was statistically significant; 81% of participants completed the trial. Gastrointestinal adverse events were more common in the semaglutide group but were generally mild to moderate.
Semaglutide RCT — Hendershot et al. (2025), JAMA Psychiatry: In 48 non-treatment-seeking adults with moderate AUD (mean BMI ~32 kg/m²), 8 weeks of semaglutide (0.25–1.0 mg/week subcutaneous) produced a medium-to-large effect on alcohol consumption in a human laboratory paradigm, with a lower peak breath alcohol concentration versus placebo. Following the first laboratory session, weekly alcohol use, drinks per drinking day, number of heavy drinking days, and alcohol craving were all significantly lower in the active treatment arm.
Exenatide RCT — Klausen, Jensen, et al. (2022), JCI Insight: In 127 treatment-seeking patients, 26 weeks of exenatide 2 mg weekly did not significantly reduce heavy drinking days versus placebo in the full cohort. However, in an obesity subgroup (n=30, BMI >30 kg/m²), exenatide reduced heavy drinking days and total alcohol intake, with a significantly greater reduction in phosphatidylethanol concentration at week 26.
Dulaglutide RCT — Probst et al. (2023), JCI Insight: In a secondary analysis of a 12-week smoking cessation trial (n=255), dulaglutide 1.5 mg/week was associated with a 29% reduction in alcohol consumption, significantly greater than placebo, despite having no effect on the trial’s primary outcome of smoking cessation.
Key Findings: Secondary Outcomes and Subgroup Analyses
Hendershot et al. (2025): Semaglutide also significantly reduced cigarette use among smokers with AUD in the study, suggesting cross-substance effects on reward.
Klausen et al. (2026): Multiple secondary outcomes were significantly improved in the semaglutide group, including phosphatidylethanol (PEth) levels, an objective biomarker of recent alcohol consumption.
Obesity subgroup (exenatide trial): The effect on heavy drinking days was confined to the obese subset; the full-cohort (BMI ≥18.5 kg/m²) analysis was null. This pattern, replicated in multiple EHR analyses, suggests that BMI may moderate GLP-1RA effects on drinking.
Mendelian randomization (Reitz et al. 2025): Genetic proxies for GLP-1/GIP signaling were associated with reduced problematic alcohol use (β=−0.44, 95% CI −0.72 to −0.15) and lower odds of heavy drinking (OR=0.62, 95% CI 0.45–0.85), while effects on tobacco, cannabis, and opioid use were largely null — suggesting a degree of alcohol specificity.
EHR comparison with FDA-approved AUD medications (Gougol et al. 2026): GLP-1RA treatment was associated with a lower AUD relapse rate (IRR=0.55, 95% CI 0.42–0.73) than naltrexone, acamprosate, or disulfiram in a retrospective cohort with metabolic dysfunction and AUD.
Swedish 8-year cohort (Lahteenvuo et al. 2025): GLP-1RAs, particularly semaglutide and liraglutide, were associated with lower AUD hospitalization risk than approved AUD medications; semaglutide outperformed liraglutide.
VA EHR analysis (Xie et al. 2025): In over 2 million T2D patients, GLP-1RA use was associated with reduced risk of AUD (HR=0.89) as well as opioid use disorder (HR=0.87), cannabis use disorder (HR=0.88), and stimulant use disorder (HR=0.84).
Target-trial emulation (Henney et al. 2026): Tirzepatide was more protective than semaglutide against incident AUD (HR=0.47 vs. HR=0.68, both vs. DPP-4Is); liraglutide and dulaglutide did not reach significance.
Vervet monkey study (Fink-Jensen et al. 2025): Semaglutide-treated monkeys consumed significantly less alcohol than both their own baseline and vehicle-treated controls, with no change in water intake.
Adverse Events and Safety Profile
Across the four published RCTs, the most commonly reported adverse events associated with GLP-1RA treatment were gastrointestinal: nausea and vomiting. In the Klausen et al. (2026) semaglutide trial, GI adverse events were more frequent in the semaglutide group than in the placebo group but were characterized as generally mild to moderate in severity. The review notes that GI adverse events are a class-wide phenomenon associated with dose escalation, and that treatment adherence may be adversely affected. The authors raise a specific safety question that no included trial has formally addressed: whether the GI adverse events of GLP-1RAs are additive or multiplicative with the GI pathology commonly produced by chronic heavy alcohol consumption. This remains an open and clinically relevant question. Needle aversion (relevant for subcutaneous formulations) and high drug cost were noted as additional barriers to treatment adherence and access, though these are logistical rather than direct safety signals.
Statistical Approach and Rigor
This is a narrative, not systematic, review. No meta-analytic pooling was performed, and no formal risk-of-bias assessment instrument was applied. The authors were selective rather than exhaustive in preclinical studies (intentional) and exhaustive in clinical studies (stated goal). Observational studies employed a range of analytic methods: propensity score matching, difference-in-differences, target-trial emulation, and Mendelian randomization. These approaches mitigate but do not eliminate confounding by indication — a persistent problem when GLP-1RAs are prescribed for metabolic conditions and outcomes are compared with untreated individuals or patients on other drug classes. The two published semaglutide RCTs (Hendershot et al. 2025; Klausen et al. 2026) used placebo-controlled, randomized designs and are the most methodologically robust evidence in the review. The exenatide trial’s null primary-outcome finding in the full cohort, with a positive signal only in the obese subgroup, illustrates the risk of selective reporting and the importance of pre-specified primary analyses. The DPP-4 inhibitor comparator studies collectively support the conclusion that direct pharmacological GLP-1R activation — not elevation of endogenous GLP-1 — is necessary for alcohol-related behavioral effects.
Clinical Takeaway
Clinicians treating patients with co-occurring AUD and obesity or type 2 diabetes now have two placebo-controlled semaglutide trials showing statistically significant reductions in heavy drinking — one in non-treatment-seeking individuals in a laboratory setting, and one in treatment-seeking patients with moderate-to-severe AUD receiving concurrent cognitive behavioral therapy. These findings are not yet sufficient for an FDA indication in AUD, and off-label use carries the usual caveats: no approved dosing protocol for this specific indication, limited long-term safety data in AUD populations, and an unresolved question about GI adverse event burden in patients with alcohol-related gut pathology. Patients on GLP-1RAs for metabolic indications who also drink heavily represent a clinical population worth monitoring prospectively, as the alcohol-reducing effect may represent a meaningful secondary benefit.
Clinical Bottom Line: Two placebo-controlled RCTs support semaglutide’s capacity to reduce heavy drinking in patients with AUD, with a biologically coherent mechanistic basis, but FDA approval requires additional adequately powered trials, and the comparative GI safety profile in patients with alcohol-related gastrointestinal disease remains uncharacterized.
WHY THIS MATTERS
Why Researchers Are Paying Attention to GLP-1 Drugs and Alcohol Use Disorder
Alcohol use disorder affects an estimated 29 million Americans and remains a leading contributor to liver disease, cardiovascular disease, neurological injury, cancer risk, and premature death. Despite that enormous burden, the pharmacologic treatment options available today remain relatively limited, and many eligible patients never receive them. The search for new treatment approaches is not simply academic. It reflects a persistent gap between the scale of the problem and the effectiveness of the tools currently available.
What makes this review notable is not that it proves GLP-1 receptor agonists should be used to treat alcohol use disorder. It does not. Rather, it brings together evidence from animal models, observational studies, genetic analyses, and randomized clinical trials that increasingly point in the same direction: these medications may influence alcohol-related behavior through mechanisms distinct from existing therapies. That convergence is what has attracted growing scientific attention.
If future studies confirm the findings seen in the semaglutide trials, the implications could extend beyond alcohol reduction alone. A therapy capable of addressing both metabolic disease and problematic alcohol use would represent a clinically meaningful development for a substantial subset of patients who live with both conditions. With nineteen ongoing or recently completed interventional studies identified in this review, the field appears to be moving from intriguing observation toward more rigorous testing.
CED Perspective Lens
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and skeptics often read the same evidence differently. The perspectives below explore how this study looks through multiple evidence-based interpretive lenses.
OVERVIEW
The broader significance of a study is often different from the headline readers first notice.
OverviewWhy this paper matters
Patient TakeawayHuman implications
Clinician’s POVClinical interpretation
A Skeptical ReadAlternative explanations
Study CriticMethods audit
Compared to Past ResearchLiterature context
Practical ConsiderationsImplementation reality
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesInterpretation firewall
Overview
Evidence Confidence: Moderate Clinical Actionability: Emerging Generalizability: Limited
This review is less important for any single numerical result than for the convergence of multiple independent lines of evidence. The authors assembled findings from animal studies, observational cohorts, Mendelian randomization analyses, and randomized controlled trials, all examining a common question: whether GLP-1 receptor agonists influence alcohol-related behavior.
Viewed broadly, the paper documents a field that is moving from observation toward direct testing. Earlier signals that GLP-1 medications might affect drinking behavior largely emerged as secondary findings or clinical observations. The evidence summarized here shows that investigators are now designing studies specifically to evaluate alcohol outcomes rather than discovering them incidentally.
Importantly, the review does not present the question as settled. The strongest support comes from two semaglutide randomized trials, while many other findings remain observational and therefore vulnerable to confounding. The significance of the paper lies in the consistency of the signal, not in a claim that the science is complete.
Evidence is accumulating across multiple study designs.
Semaglutide currently has the strongest randomized evidence.
The field is transitioning from hypothesis generation to hypothesis testing.
The review argues for further investigation rather than immediate clinical adoption.
KEY INTERPRETATION
The most notable finding is not that GLP-1 drugs may reduce drinking, but that independent forms of evidence are increasingly pointing in the same direction.
Patient Takeaway
Evidence Confidence: Moderate Patient Relevance: High Uncertainty: Meaningful
Many people who struggle with alcohol use describe something difficult to quantify: persistent thoughts about drinking, recurring cravings, or a feeling that alcohol occupies more mental space than they would like. The studies reviewed here suggest that some GLP-1 receptor agonists, particularly semaglutide, may influence those experiences in ways that result in reduced alcohol consumption.
At the same time, the review does not show that these medications eliminate alcohol use disorder, work for every individual, or replace established treatments. The strongest evidence comes from two placebo-controlled semaglutide studies, but those trials involved specific patient populations and relatively short periods of follow-up.
A thoughtful reader might view these findings as encouraging but unfinished. The signal appears increasingly credible, yet important questions remain about who benefits most, how long the effect lasts, and whether reduced drinking ultimately translates into meaningful long-term improvements in health and quality of life.
Reduced drinking is not the same as recovery from AUD.
The strongest evidence currently comes from semaglutide studies.
Not every participant experienced the same degree of benefit.
Long-term outcomes remain incompletely characterized.
PATIENT TAKEAWAY
The evidence increasingly suggests that some GLP-1 medications may help reduce drinking, but the science is not yet mature enough to predict individual outcomes with confidence.
Clinician’s POV
Evidence Quality: Improving Clinical Applicability: Moderate Evidence Maturity: Emerging
Clinicians reading this review are likely to focus less on novelty and more on evidentiary consistency. The most compelling aspect of the paper is not any single study, but the appearance of a similar signal across animal experiments, large observational cohorts, Mendelian randomization analyses, and randomized clinical trials.
The two semaglutide trials are particularly important because they move the discussion beyond retrospective associations. Both demonstrated reductions in alcohol-related outcomes under controlled conditions, although sample sizes remain modest relative to the standards generally required for a new therapeutic indication.
From a clinical perspective, the review may encourage closer observation of alcohol-related outcomes among patients already receiving GLP-1 receptor agonists for obesity or diabetes. At the same time, the paper does not establish a standard treatment protocol for AUD, define an approved dosing strategy, or clarify long-term benefit-risk relationships in alcohol-specific populations.
Randomized evidence now exists, but remains limited in scale.
Observational consistency strengthens interest but does not establish proof.
No FDA indication currently exists for AUD treatment.
Questions of durability, patient selection, and long-term outcomes remain open.
CLINICIAN INSIGHT
The strongest contribution of this review is that it elevates a recurring clinical observation into a research question that now warrants serious prospective investigation.
A Skeptical Read
Alternative Explanations: Plausible Residual Uncertainty: High Causal Confidence: Moderate
A skeptical reader immediately separates the randomized evidence from the much larger body of observational data. Many of the retrospective studies summarized in this review involve patients receiving GLP-1 receptor agonists because they had obesity, diabetes, or related metabolic conditions. Those individuals may differ from comparison groups in important ways that are difficult to fully measure or adjust for statistically.
The review itself acknowledges this challenge. Patients receiving treatment for metabolic disease may have more healthcare engagement, more frequent clinician contact, greater monitoring, different health behaviors, or stronger motivation for lifestyle change. Any of those factors could influence alcohol-related outcomes independent of the medication itself.
Even the randomized semaglutide trials leave meaningful uncertainty. Both studies are encouraging, but the overall randomized evidence base remains relatively small compared with what regulators typically require for a new indication. A skeptical reader does not need to reject the findings. Rather, skepticism asks whether the current evidence has crossed the threshold from promising signal to established clinical effect.
Observational consistency does not eliminate confounding.
Healthcare engagement may partially influence outcomes.
Randomized evidence remains limited in total sample size.
Promising signals and definitive proof are not the same thing.
SKEPTICAL LENS
The evidence appears increasingly consistent, but consistency alone does not eliminate alternative explanations.
Study Critic
Methodological Rigor: Moderate Bias Risk: Variable Inference Strength: Limited
From a methodological perspective, the first issue is that this paper is a narrative review rather than a systematic review or meta-analysis. Narrative reviews allow expert synthesis and contextual interpretation, but they do not provide the same safeguards against selection bias that formal systematic methodologies are designed to address.
The authors strengthen credibility by describing search strategies, inclusion criteria, and study selection methods. However, no formal risk-of-bias assessment tool was applied across the included literature, and no quantitative pooling of outcomes was performed. Readers therefore receive a structured interpretation of the evidence rather than a statistical estimate of overall effect size.
Another challenge involves heterogeneity. The review combines animal experiments, electronic health record studies, Mendelian randomization analyses, and randomized clinical trials. Each design answers a different scientific question and carries different strengths and limitations. Combining them creates a richer narrative, but also makes it harder to determine precisely how much weight any individual finding should receive.
Narrative reviews provide synthesis, not quantitative certainty.
No formal risk-of-bias scoring system was applied.
Study designs included fundamentally different evidence types.
The review is strongest as an interpretive framework rather than a definitive efficacy estimate.
METHODS CHECK
The review succeeds as a synthesis of a rapidly developing field, but it cannot provide the precision or certainty of a formal meta-analysis.
Compared to Past Research
Literature Alignment: Developing Novelty: Moderate Research Maturity: Advancing
One of the most interesting aspects of this review is not a specific result, but the stage of scientific development it captures. Earlier observations that GLP-1 receptor agonists might influence alcohol consumption often emerged from animal studies, secondary outcomes, clinical anecdotes, or unexpected findings in populations being treated for obesity or diabetes.
The evidence summarized here shows that the field has progressed beyond simple observation. Researchers are now conducting placebo-controlled clinical trials specifically designed to measure alcohol-related outcomes. That shift reflects an important change in scientific focus. The question is no longer whether the hypothesis deserves investigation. The question is how large, consistent, and clinically meaningful the effect may ultimately prove to be.
The review portrays a research area moving from curiosity toward structured evaluation. Importantly, the authors do not describe the evidence base as settled. Instead, they position the current literature as a foundation upon which a much larger body of prospective research is now being built.
Alcohol outcomes have evolved from secondary observations to primary endpoints.
The field has entered a more rigorous testing phase.
Clinical trials are increasingly designed around AUD-specific questions.
The review depicts maturation of a research hypothesis rather than resolution of a scientific debate.
LITERATURE CONTEXT
The most important development may be that alcohol-related outcomes have shifted from incidental observations to intentional targets of clinical investigation.
Practical Considerations
Implementation Burden: Moderate Scalability: Uncertain Operational Friction: Likely
Even if future studies ultimately confirm efficacy, implementation questions remain substantial. The review repeatedly highlights issues that exist outside statistical significance, including medication cost, insurance coverage, treatment adherence, gastrointestinal tolerability, and the practical realities of long-term use.
Patient selection may prove equally important. Several findings summarized in the review suggest that obesity, metabolic dysfunction, or body mass index could influence treatment response. If those observations hold up in future trials, clinicians may eventually need a more refined understanding of which AUD populations are most likely to benefit.
The review also raises unanswered safety questions. Chronic heavy alcohol use frequently affects the gastrointestinal tract, liver, and nutritional status. Existing studies have not been designed to determine whether those factors meaningfully alter tolerability, adherence, or risk profiles when GLP-1 receptor agonists are used in individuals with significant alcohol-related disease burden.
Cost may become a larger barrier than efficacy.
Insurance coverage for AUD indications remains undefined.
Long-term adherence remains largely uncharacterized.
Patient selection may prove critical to real-world effectiveness.
Alcohol-related gastrointestinal disease remains understudied.
PRACTICAL REALITY
Even if efficacy is confirmed, implementation may depend as much on access, tolerability, and patient selection as on biological effectiveness.
Future Directions
Research Momentum: High Evidence Gaps: Substantial Forecast Confidence: Moderate
The review identifies nineteen ongoing or completed-but-unpublished interventional studies, suggesting that the next several years may substantially expand the evidence base. The existence of that pipeline is itself noteworthy because it indicates growing scientific interest in the relationship between GLP-1 signaling and alcohol-related behavior.
Several questions emerge directly from the review. Researchers still need to determine whether efficacy differs among semaglutide, tirzepatide, dulaglutide, liraglutide, and newer multi-receptor compounds. They also need to clarify whether treatment effects vary according to obesity status, metabolic disease burden, AUD severity, or treatment-seeking status.
Mechanistic questions remain equally important. Although the review discusses plausible reward-related pathways, the precise biological mechanisms responsible for reduced alcohol consumption remain incompletely characterized. Future studies may therefore focus not only on whether the effect exists, but on understanding why it occurs and which patients are most likely to experience it.
Nineteen additional trials are already underway or completed.
Comparative effectiveness between compounds remains unknown.
BMI and metabolic status may influence outcomes.
Longer follow-up periods are needed.
Mechanistic uncertainty remains substantial.
LOOKING AHEAD
The next phase of research is likely to focus less on whether a signal exists and more on defining who benefits, why, and under what conditions.
Misreadings & Bad-Faith Takes
Misinformation Risk: High Headline Distortion Risk: High Nuance Requirement: Very High
Misreading #1: “Semaglutide cures alcoholism.”The review does not support that conclusion. The strongest randomized trials demonstrated reductions in heavy drinking days and alcohol consumption. They did not demonstrate elimination of alcohol use disorder, universal response, durable remission, or cure.
Misreading #2: “The evidence is already strong enough for routine GLP-1 treatment of AUD.”The authors reach the opposite conclusion. While the evidence is increasingly encouraging, the review explicitly argues that additional randomized controlled trials are needed before regulatory approval or broad clinical adoption could reasonably be justified.
Misreading #3: “Alcohol addiction is actually a metabolic disease.”The review discusses interactions between metabolic signaling pathways and alcohol-related behavior. It does not redefine the nature of alcohol use disorder, nor does it claim that metabolic dysfunction is the sole or primary explanation for AUD.
Misreading #4: “Observational studies prove GLP-1 drugs reduce drinking.”Many observational findings are impressive, but observational designs remain vulnerable to confounding and selection effects. The strongest evidence comes from randomized trials, not retrospective associations.
Misreading #5: “The biological mechanism has been figured out.”The review discusses plausible pathways involving reward circuitry and dopamine signaling, but repeatedly notes that the precise mechanisms remain incompletely understood and require additional investigation.
Reduced drinking is not synonymous with AUD remission.
Association should not be mistaken for causation.
Mechanistic plausibility is not mechanistic proof.
Encouraging evidence is not the same as regulatory readiness.
Both exaggerated enthusiasm and reflexive dismissal exceed the evidence.
MISINFORMATION FIREWALL
The evidence supports cautious scientific interest. Claims that GLP-1 drugs have already solved alcohol use disorder, or that the findings can be dismissed outright, both extend beyond what this review actually shows.
RELATED READING AT CED CLINIC
Related evidence and clinical perspective
Substance Dependence and Withdrawal Support
A physician-guided overview of substance dependence, recovery challenges, and approaches to supporting patients navigating withdrawal and behavior change.
Explore evidence
Cannabis Dependence: Myths, Facts, and Clinical Reality
A nuanced discussion of dependence, compulsive use, and the difference between physiological adaptation and addiction.
Read article
Cannabis and Metabolism
A broader exploration of metabolic regulation, appetite, weight, and the physiologic systems increasingly intersecting with GLP-1 research.
Continue reading
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
Frequently Asked Questions
Can semaglutide reduce alcohol cravings?
The evidence reviewed suggests that semaglutide may reduce alcohol craving and alcohol consumption in some individuals. In placebo-controlled trials, participants receiving semaglutide experienced reductions in heavy drinking days, drinks per drinking day, and alcohol-related laboratory outcomes. However, not every participant responded similarly, and larger studies are still needed.
What are GLP-1 receptor agonists?
GLP-1 receptor agonists are medications originally developed to treat type 2 diabetes and later obesity. Examples include semaglutide, liraglutide, exenatide, and dulaglutide. They affect appetite regulation, metabolism, and potentially reward-related brain pathways that may influence alcohol consumption.
Is semaglutide approved to treat alcohol use disorder?
No. Semaglutide currently has FDA approvals for type 2 diabetes and chronic weight management, but it does not have an FDA-approved indication for alcohol use disorder. Additional randomized controlled trials would be required before regulatory approval could be considered.
How much did semaglutide reduce heavy drinking in clinical trials?
In one placebo-controlled trial published in The Lancet, heavy drinking days decreased by approximately 41.1% from baseline in the semaglutide group compared with 26.4% in the placebo group. Other studies also reported reductions in alcohol consumption and alcohol craving, though the magnitude of effect varied across populations and study designs.
Why might GLP-1 drugs affect alcohol consumption?
The review discusses evidence suggesting that GLP-1 receptor activation may influence reward-processing pathways involving mesolimbic dopamine signaling. Researchers hypothesize that this may reduce the reinforcing effects of alcohol, though the precise mechanisms remain incompletely understood and continue to be investigated.
Are the benefits limited to people with obesity?
Not necessarily. Some studies showed stronger effects among participants with obesity, while others observed alcohol-related benefits across broader populations. Whether body mass index or metabolic health meaningfully influences treatment response remains an active area of research.
What side effects were reported in alcohol use disorder studies?
The most commonly reported side effects were gastrointestinal, particularly nausea and vomiting. These effects were generally described as mild to moderate in severity. The review notes that additional research is needed to understand how these medications perform in people with alcohol-related gastrointestinal disease.
How does semaglutide compare with naltrexone or acamprosate?
Direct head-to-head randomized trials are lacking. Some observational analyses included in the review found lower relapse rates among patients receiving GLP-1 receptor agonists than among those receiving FDA-approved alcohol use disorder medications, but those findings cannot establish superiority because observational studies remain vulnerable to confounding.
Are researchers studying GLP-1 drugs for other addictions?
Yes. The review describes studies examining potential effects on nicotine use, opioid use disorder, cannabis use disorder, and stimulant use disorder. While some signals have emerged, alcohol use disorder currently has the most developed body of evidence.
What are the biggest unanswered questions about GLP-1 drugs and alcohol use disorder?
Important unanswered questions include which GLP-1-based medications work best, which patients are most likely to benefit, how durable the effects remain over time, whether benefits extend beyond drinking reduction to broader health outcomes, and how these medications compare directly with established alcohol use disorder treatments. [...]
Read more...
June 3, 2026Bariatric Surgery vs GLP-1 Medications: Which Produces Greater Long-Term Weight Loss?
Obesity
GLP-1 Receptor Agonists
Bariatric Surgery
Weight Management
Metabolic Disease
What You’ll Learn
How weight loss from bariatric surgery compares to GLP-1 receptor agonists across 6-month, 1-year, and multi-year follow-up windows
Which patient characteristics , age, sex, and baseline BMI , predict the greatest BMI reduction from bariatric surgery
How glycemic outcomes, lipid profiles, and blood pressure differ between the two interventions
Where the evidence is genuinely strong and where significant heterogeneity demands caution
TL;DR: Across 20,594 participants and 15 studies, bariatric surgery produced significantly greater and more durable reductions in weight, BMI, and long-term glycemic control than GLP-1 receptor agonists, with both interventions showing comparable effects on lipid profiles and blood pressure.
STUDY TYPE: Systematic Review, Meta-Analysis, and Meta-Regression
Abstract
Background: The comparative effectiveness of bariatric surgery (BS) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss among patients with obesity remains uncertain.
Methods: MEDLINE, EMBASE, and CENTRAL were searched to October 5, 2025. Pooled mean differences (MDs) for change in weight, body mass index (BMI), glycemic indices, lipid profile, and blood pressure were calculated using random-effects models with heterogeneity quantified by I². Outcomes were assessed separately according to time duration. Meta-regression was performed for the primary outcome of change in BMI.
Results: Fifteen studies (20,594 participants) were included. Weight loss did not differ significantly at 6 months (MD −12.19 kg; p=0.13), but favored BS at ≤1 year (MD −16.97 kg; p=0.02) and >1 year (MD −19.78 kg; p<0.001). BMI reduction consistently favored BS at 6 months (MD −6.77 kg/m²; p=0.02), ≤1 year (MD −5.10 kg/m²; p<0.001), and >1 year (MD −6.61 kg/m²; p<0.001). HbA1c reduction was greater with BS beyond one year (MD −1.69%; p<0.001), and fasting glucose was lower overall with BS (MD −1.22 mmol/L; p=0.03). Serum lipids and blood pressure showed no significant between-group differences. Meta-regression demonstrated larger BMI reductions with BS in older patients, male patients, and those with higher baseline BMI.
Conclusion: Although substantial heterogeneity was present, BS was associated with greater and sustained reductions in weight, BMI, and glycemic indices compared to GLP-1 RAs, with similar effects on serum lipids and blood pressure, supporting its use in appropriately selected adults with obesity.
Source: Tahir M, Meghani MA, Uddin MS, et al. Weight Loss Outcomes Between GLP-1 Receptor Agonists and Bariatric Surgery in Adults With Obesity: A Systematic Review, Meta-Analysis and Meta-Regression. Diabetes, Obesity and Metabolism. 2026;28:4901–4914.
DOI: https://doi.org/10.1111/dom.70676
Study at a Glance
Design
Systematic review, meta-analysis, and meta-regression (PRISMA-compliant; PROSPERO ID: CRD420251160138)
Population
Adults ≥18 years with obesity (BMI >30 kg/m²), with or without type 2 diabetes; mean age 52.12 years; 35.9% male
Total N
20,594 (11,876 GLP-1 RA; 8,718 bariatric surgery)
Studies Included
15 studies (4 RCTs, 11 observational); follow-up windows: 6 months, ≤1 year, >1 year
Primary Endpoints
Absolute change in body weight (kg) and absolute change in BMI (kg/m²)
Key Finding
Bariatric surgery produced significantly greater BMI and weight reduction at every measured time point beyond 6 months, with the advantage widening over multi-year follow-up
Study Snapshot
Outcome
Time Point
MD (BS vs GLP-1 RA)
p-value
I²
Weight (kg)
6 months
−12.19 kg
0.13 (NS)
98%
Weight (kg)
≤1 year
−16.97 kg
0.02
97%
Weight (kg)
>1 year
−19.78 kg
<0.001
74%
BMI (kg/m²)
6 months
−6.77 kg/m²
0.02
99%
BMI (kg/m²)
≤1 year
−5.10 kg/m²
<0.001
97%
BMI (kg/m²)
>1 year
−6.61 kg/m²
<0.001
79%
HbA1c (%)
≤1 year
−2.13%
0.07 (NS)
97%
HbA1c (%)
>1 year
−1.69%
<0.001
97%
Fasting glucose (mmol/L)
Overall
−1.22 mmol/L
0.03
86%
Triglycerides
Overall
−0.38 mmol/L
0.11 (NS)
93%
Systolic BP (mmHg)
Overall
−1.18 mmHg
0.53 (NS)
0%
Diastolic BP (mmHg)
Overall
+0.11 mmHg
0.93 (NS)
0%
MD = mean difference (negative value favors bariatric surgery); NS = not significant; BP = blood pressure.
Study Facts Table
Full Study Summary
Authors
Tahir M, Meghani MA, Uddin MS, Talib A, Binte Ahmad Z, Ali Khan A, Ahmed M, Dinsmore L, Nasser A, Ahmed R, Basit A, Khan TM
Journal
Diabetes, Obesity and Metabolism
Year
2026
DOI
10.1111/dom.70676
Study Design
Systematic review, meta-analysis, and meta-regression; 4 RCTs + 11 observational studies
Total Participants
20,594 (GLP-1 RA: 11,876; bariatric surgery: 8,718)
Intervention
FDA-approved GLP-1 receptor agonists (liraglutide, semaglutide, exenatide, dulaglutide, lixisenatide, albiglutide)
Comparator
Bariatric surgery: RYGB, sleeve gastrectomy, gastric banding, biliopancreatic diversion, endoscopic sleeve gastroplasty, intragastric balloon
Primary Endpoints
Absolute change in weight (kg) and absolute change in BMI (kg/m²)
Primary Results
Weight loss not significantly different at 6 months (p=0.13); BS superior at ≤1 year (MD −16.97 kg; p=0.02) and >1 year (MD −19.78 kg; p<0.001). BMI reduction favored BS at all three time points (6 months: MD −6.77; ≤1 year: MD −5.10; >1 year: MD −6.61 kg/m²; all p≤0.02).
Secondary Results
HbA1c favored BS at >1 year (MD −1.69%; p<0.001); fasting glucose favored BS overall (MD −1.22 mmol/L; p=0.03); no significant differences in total cholesterol, LDL-C, HDL-C, triglycerides, or blood pressure in primary analysis
Adverse Events
Not formally assessed in this meta-analysis; no comparative safety analysis was conducted
Funding
None reported
Conflicts of Interest
Dr. Abdul Basit reports advisory board roles for Novo Nordisk, Getz Pharma, and Ferozsons; all other authors declare no conflicts
What Researchers Actually Did
Tahir and colleagues conducted a PRISMA-compliant systematic review and meta-analysis with prospective PROSPERO registration, searching MEDLINE, EMBASE, and Cochrane CENTRAL through October 5, 2025. From an initial pool of 15,220 records, 15 studies met eligibility criteria: adults aged 18 or older with a BMI above 30 kg/m², receiving any FDA-approved GLP-1 receptor agonist, compared against a recognized bariatric surgical procedure. Studies examining combined or sequential use of both therapies were excluded. Four of the 15 studies were randomized controlled trials; the remaining 11 were observational. Sample sizes ranged from 18 to 10,960 participants.
Pooled mean differences were calculated using random-effects models. Outcomes were stratified by follow-up duration: 6 months, ≤1 year, and >1 year. When only baseline and endpoint data were available, change-from-baseline standard deviations were estimated using a conservative correlation coefficient of r=0.7. Heterogeneity was quantified using the I² statistic, and leave-one-out sensitivity analyses were performed for outcomes where I² exceeded 50%. Meta-regression using Meta Essentials v1.5 was applied specifically to the BMI outcome to evaluate study-level moderators: mean age, baseline BMI, percentage of male participants, and baseline HbA1c percentage.
Key Findings: Primary Outcomes
Weight loss at 6 months: Bariatric surgery produced a numerically greater reduction (MD −12.19 kg; 95% CI −28.08 to 3.71; p=0.13; I²=98%) but this did not reach statistical significance. After excluding one outlier study (Masrur 2025), heterogeneity was eliminated and the difference became significant (MD −4.54 kg; 95% CI −7.39 to −1.69; p=0.002; I²=0%).
Weight loss at ≤1 year: Bariatric surgery produced significantly greater weight reduction (MD −16.97 kg; 95% CI −31.59 to −2.36; p=0.02; I²=97%).
Weight loss at >1 year: The advantage of bariatric surgery increased further (MD −19.78 kg; 95% CI −24.55 to −15.00; p<0.001; I²=74%).
BMI reduction at 6 months: Bariatric surgery produced a significantly greater BMI reduction (MD −6.77 kg/m²; 95% CI −12.28 to −1.27; p=0.02; I²=99%).
BMI reduction at ≤1 year: The between-group difference remained significant (MD −5.10 kg/m²; 95% CI −8.00 to −2.21; p<0.001; I²=97%).
BMI reduction at >1 year: Persistent and significant advantage for bariatric surgery (MD −6.61 kg/m²; 95% CI −7.67 to −5.54; p<0.001; I²=79%).
Key Findings: Secondary Outcomes and Subgroup Analyses
HbA1c at ≤1 year: No statistically significant difference (MD −2.13%; 95% CI −4.46 to 0.20; p=0.07; I²=97%). After removing Stenberg 2024, this became significant (MD −0.83%; 95% CI −1.37 to −0.29; p=0.002; I²=46%).
HbA1c at >1 year: Bariatric surgery achieved a significantly greater reduction (MD −1.69%; 95% CI −2.56 to −0.82; p<0.001; I²=97%).
Fasting blood glucose (overall): Bariatric surgery was associated with significantly greater reduction (MD −1.22 mmol/L; 95% CI −2.29 to −0.15; p=0.03; I²=86%). After removing Capristo 2018, the effect strengthened with reduced heterogeneity (MD −1.53 mmol/L; p<0.001; I²=17%).
Lipid profile: No significant between-group differences for triglycerides (p=0.11), total cholesterol (p=0.81), HDL-C (p=0.07), or LDL-C (p=0.64) in primary analysis. Sensitivity analysis excluding Capristo 2018 revealed a significant reduction in triglycerides (MD −0.50 mmol/L; p=0.02) and HDL-C (MD −0.24 mmol/L; p<0.001) favoring bariatric surgery.
Blood pressure: No significant difference in systolic (MD −1.18 mmHg; p=0.53; I²=0%) or diastolic BP (MD +0.11 mmHg; p=0.93; I²=0%) , notably, these were the only outcomes with no measurable heterogeneity.
Liraglutide subgroup (3 studies): No significant BMI difference (MD −5.95 kg/m²; p=0.07; I²=98%), but significantly greater weight loss favored bariatric surgery (MD −16.99 kg; p<0.001; I²=97%).
Semaglutide subgroup (3 studies): Bariatric surgery produced significantly greater BMI reduction (MD −4.58 kg/m²; p<0.001; I²=98%) and weight loss (MD −16.83 kg; p<0.001; I²=99%).
Meta-regression (BMI primary outcome): Higher mean age (coefficient 0.42; p=0.01), higher proportion of male participants (coefficient 0.16; p=0.006), and higher baseline BMI (coefficient −0.52; p<0.001) were each independently associated with greater BMI reduction from bariatric surgery. Baseline HbA1c was not a significant moderator (p=0.896).
Adverse Events and Safety Profile
This meta-analysis did not include a formal comparative safety analysis. No pooled data on surgical complication rates, GLP-1 RA-associated gastrointestinal adverse effects, postoperative nutritional deficiencies, or thyroid neoplasm risk were reported. The authors explicitly acknowledge this as a study limitation. Clinicians should not use this paper to make comparative safety determinations between the two interventions.
Statistical Approach and Rigor
The analysis used random-effects models for continuous outcomes and quantified heterogeneity with the I² statistic. That choice matters because the included studies differed substantially in design, follow-up duration, procedures, medication exposure, baseline BMI, diabetes status, and sample size. A fixed-effect model would have implied a level of uniformity that this evidence base does not support.
The authors also performed leave-one-out sensitivity analyses when heterogeneity exceeded 50%, which was important because several primary and secondary endpoints had very high I² values. In several places, removing a single influential study meaningfully changed either heterogeneity or statistical significance. That does not erase the overall signal favoring bariatric surgery for weight and BMI outcomes, but it does mean the pooled estimates should be read as directional evidence rather than precise clinical forecasts.
The meta-regression adds a useful but limited layer. Older mean age, higher baseline BMI, and a higher proportion of male participants were associated with larger BMI reduction after bariatric surgery, while baseline HbA1c was not a significant moderator. Because these are study-level moderators, they should not be treated as individual prediction rules for a specific patient.
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on what question is being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
This study may matter less as a simple contest between surgery and medication, and more as a reminder that durable obesity care requires matching the intervention to the patient, the timeline, and the risk profile.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Evidence Confidence: ModerateClinical Actionability: ModerateGeneralizability: Cautious
This paper is not merely saying that one intervention produced more weight loss than another. It is showing how the obesity treatment conversation changes when outcomes are separated by time horizon. At 6 months, weight loss did not differ significantly in the primary pooled analysis, but by 1 year and beyond 1 year, the advantage moved clearly toward bariatric surgery for weight and BMI outcomes.
The structural meaning is that durability matters. A short-window comparison can make pharmacologic and procedural approaches appear closer than they look when the follow-up window lengthens. That does not make GLP-1 receptor agonists weak treatments. It does remind readers that “effective” and “most durable in pooled long-term comparisons” are not the same claim.
The study also keeps the institutional conversation honest by reporting where surgery did not clearly outperform GLP-1 receptor agonists. Lipids and blood pressure did not show significant between-group differences in the primary analysis, and safety was not formally compared.
The central signal is stronger for weight, BMI, and longer-term glycemic outcomes than for lipids or blood pressure.
The findings are shaped by high heterogeneity, especially in several weight, BMI, and HbA1c analyses.
The paper compares outcomes, but it does not solve patient selection, safety tradeoffs, access, or preference-sensitive decision-making.
Its strongest public value is framing obesity care as longitudinal rather than episodic.
Key Interpretation
The study’s most useful contribution is not “surgery wins.” It is that durability, heterogeneity, and missing safety data must travel together in any serious comparison.
Patient Takeaway
Evidence Confidence: ModeratePatient Relevance: HighIndividual Prediction: Limited
For a patient, the most reasonable takeaway is that bariatric surgery produced greater average long-term weight and BMI reduction in this pooled evidence base. That is meaningful, especially for people trying to understand why clinicians may still discuss surgery even in the era of powerful GLP-1 medications.
But this paper cannot tell an individual patient which path is right. It does not formally compare surgical complications, nutritional deficiencies, medication side effects, quality of life, cost, adherence, reversibility, recovery time, or how a person feels living with either intervention. Those are not minor details. They are often the details that determine whether a treatment is tolerable and sustainable.
A careful patient should read this as an expectation-setting paper rather than a decision-making shortcut. It supports the idea that surgery can produce larger durable changes in selected adults with obesity, while also showing why personal medical context remains essential.
Average results do not predict an individual person’s outcome.
Longer-term weight loss favored surgery, but safety was not pooled or compared.
Some patients may value reversibility, recovery profile, or medication flexibility differently than maximum weight loss.
A thoughtful consultation should include metabolic goals, risk tolerance, prior treatment history, and follow-up capacity.
Patient Takeaway
This paper can sharpen the conversation, but it should not replace a careful, individualized medical decision.
Clinician’s POV
Clinical Actionability: ModerateWorkflow Impact: HighEvidence Maturity: Developing
Clinically, this paper supports a more disciplined treatment conversation. For patients with obesity who are comparing medication-based and procedural pathways, the data suggest that bariatric surgery remains a highly potent option for sustained weight and BMI reduction. It also shows longer-term glycemic advantages in the pooled analysis, while lipid and blood pressure outcomes were not significantly different.
The operational task for clinicians is not to convert the paper into a blanket recommendation. It is to use the findings to structure informed consent and shared decision-making. Patients need to understand the magnitude and durability of expected benefit, but they also need a transparent discussion of what this meta-analysis did not evaluate, especially comparative safety.
The meta-regression findings may help frame population-level expectations, but they should not be used as bedside prediction rules. Older mean age, higher baseline BMI, and male proportion were study-level moderators, not validated patient-level selection criteria.
Documentation should distinguish weight, BMI, glycemic outcomes, lipids, blood pressure, and safety rather than compressing them into one global claim.
High heterogeneity should temper certainty when counseling about expected magnitude of benefit.
The absence of comparative safety pooling is clinically important, not a footnote.
The paper may be most useful in referral conversations and long-term expectation setting.
Clinician Insight
This study strengthens the conversation around durable outcomes, but careful clinicians should keep safety, suitability, and follow-up infrastructure in the foreground.
A Skeptical Read
Alternative Explanations: PlausibleResidual Uncertainty: HighCausal Confidence: Cautious
A skeptical reader would start with the heterogeneity. Several pooled outcomes had I² values in the high range, meaning the included studies were not all estimating the same effect in the same way. The overall direction may favor bariatric surgery, but the spread across studies matters because it signals variability in populations, interventions, follow-up, or measurement.
The comparison also rests on a difficult clinical reality: surgery and GLP-1 receptor agonists are not interchangeable exposures. Surgery involves a procedural event, a perioperative pathway, dietary changes, follow-up structures, and often a different threshold for patient selection. GLP-1 therapy involves ongoing adherence, dose tolerance, access, discontinuation risk, and medication-specific adverse effects. A pooled mean difference can flatten those differences.
Skepticism here does not mean dismissing the findings. It means resisting the temptation to treat the pooled estimate as if it came from one clean, head-to-head, uniformly designed clinical trial.
High heterogeneity weakens precision even when the direction of effect is consistent.
Selection effects may influence which patients receive surgery versus medication.
Follow-up intensity may differ between surgical and medication pathways.
Outlier removal changed some sensitivity results, which deserves attention.
Safety absence limits any full benefit-risk comparison.
Skeptical Lens
The pooled results favor surgery for key outcomes, but the comparison is not clean enough to support simplistic certainty.
Study Critic
Methodological Rigor: ModerateBias Risk: VariableInference Strength: Bounded
As a methods critique, the paper has real strengths. It used a PRISMA-compliant design, prospective PROSPERO registration, major database searches, random-effects pooling, duration-stratified outcomes, sensitivity analyses, and meta-regression for BMI. Those choices are appropriate for a mixed and heterogeneous comparative evidence base.
The central vulnerability is that most included studies were observational, and the interventions being compared are structurally different. Randomization was limited, and patient selection may have differed meaningfully between groups. The analysis also combines several GLP-1 receptor agonists and several bariatric or bariatric-endoscopic procedures, which increases clinical breadth but reduces interpretive specificity.
The missing safety analysis is the most important technical omission for clinical translation. Without pooled adverse events, the study can compare selected efficacy outcomes but cannot establish which option has the better overall risk-benefit profile.
Four RCTs and 11 observational studies create mixed internal validity.
Multiple GLP-1 agents and multiple procedures make subgroup interpretation harder.
Several endpoints showed high I², reducing confidence in precise pooled estimates.
Change-score standard deviations were estimated when not reported, which adds modeling assumptions.
Safety, quality of life, cost, and adherence were not formally synthesized.
Methods Check
The efficacy signal is important, but the study’s design cannot carry a complete clinical comparison by itself.
Compared to Past Research
Literature Alignment: Generally ConsistentNovelty: IncrementalReplication Status: Still Needed
This paper sits inside a rapidly changing obesity treatment landscape. For years, bariatric surgery occupied a category of its own for large and durable weight loss. GLP-1 receptor agonists changed the conversation because pharmacologic therapy began producing weight reductions large enough to invite direct comparison with procedural approaches.
The value of this review is that it does not rely on the broad cultural impression that “the new drugs are catching up.” It organizes available comparative evidence by time point and outcome. That time structure matters because early weight change and longer-term durability are different questions.
The article’s own framing describes the comparative effectiveness question as uncertain, which is the right posture. This analysis narrows some uncertainty for weight, BMI, and glycemic outcomes, but it does not close the broader literature question because safety, adherence, discontinuation, procedure type, medication type, and patient-centered outcomes remain incompletely handled.
The paper reflects a shift from single-treatment enthusiasm to comparative effectiveness analysis.
Its time-stratified approach helps separate short-term response from longer-term durability.
The evidence base remains mixed across RCTs and observational studies.
The comparison still needs more direct, harmonized, patient-centered research.
Literature Context
This paper does not end the comparison between GLP-1 therapy and surgery. It makes the comparison more structured.
Practical Considerations
Scalability: UnevenImplementation Burden: HighCare Coordination: Essential
The practical layer is where a clean statistical finding becomes complicated. Bariatric surgery requires surgical evaluation, perioperative coordination, postoperative nutrition monitoring, complication surveillance, and long-term follow-up. GLP-1 therapy requires prescribing oversight, dose titration, side-effect management, affordability planning, access continuity, and monitoring for discontinuation or weight regain.
The study does not tell health systems which pathway is easier, cheaper, safer, or more acceptable to patients. It also does not answer how to sequence the two approaches, whether one should follow inadequate response to the other, or when combination strategies deserve consideration. Those are the questions that often determine real-world care.
For CED-style interpretation, the practical message is that obesity care cannot be reduced to an endpoint table. Systems must be prepared to support the intervention they recommend.
Long-term follow-up capacity matters for both surgery and medication.
Insurance coverage and out-of-pocket costs may shape access more than efficacy data.
Side-effect counseling differs substantially between procedural and pharmacologic care.
Patients may need nutritional, behavioral, metabolic, and medication support across the full treatment arc.
Primary care coordination remains central, even when specialists are involved.
Practical Reality
The most effective intervention on paper still depends on whether the care system can support it safely and continuously.
Future Directions
Research Momentum: HighOpen Questions: SignificantForecast Confidence: Moderate
The next useful studies should move beyond broad intervention labels. “Bariatric surgery” includes different procedures with different mechanisms and risk profiles. “GLP-1 receptor agonists” includes different agents, doses, tolerability profiles, adherence patterns, and real-world access barriers. More precise comparisons would help clinicians counsel patients with less abstraction.
Future research also needs to integrate outcomes that this meta-analysis could not fully answer. Comparative safety, nutritional consequences, quality of life, medication discontinuation, weight regain, cost, access, patient preference, and sequencing all matter clinically. Without those outcomes, efficacy remains only one part of the decision.
The strongest next step would be prospective comparative research that follows patients long enough to assess durability and collects adverse events in a standardized way. Registry-based studies could also help if they are designed carefully enough to address confounding and follow-up bias.
Procedure-specific and medication-specific analyses would improve clinical precision.
Longer follow-up is needed for durability, regain, and metabolic maintenance.
Standardized safety and adverse-event reporting should be built into future comparisons.
Patient-centered outcomes should include function, quality of life, treatment burden, and preference.
Research on sequencing and combination strategies remains clinically important.
Looking Ahead
The next research question is not only which treatment reduces weight more, but which pathway produces durable benefit with acceptable burden for the right patient.
Misreadings & Bad-Faith Takes
Misinformation Risk: HighPublic Confusion Risk: HighNuance Requirement: High
The easiest misreading is “bariatric surgery is better than GLP-1 drugs.” That is too blunt. The paper found greater pooled reductions in weight and BMI with surgery at key follow-up windows, and stronger longer-term glycemic outcomes. It did not prove that surgery is better for every patient, every outcome, or every risk-benefit calculation.
A second distortion is “GLP-1 medications do not work.” That is not what the study shows. The comparison favors surgery in several outcomes, but a treatment can be clinically meaningful even when another intervention produces larger average changes in a pooled analysis.
A third distortion is “the safety question is settled.” It is not. The authors did not conduct a formal comparative safety analysis, so this paper should not be used to claim that either approach is safer overall. Surgical complications, nutritional deficiencies, gastrointestinal adverse effects, and other treatment burdens require separate evaluation.
The most dangerous bad-faith version would use the study to push a one-size-fits-all agenda. Obesity care is not a scoreboard. It is a longitudinal medical decision involving physiology, risk, access, preference, and follow-up.
Do not convert pooled average differences into personal guarantees.
Do not imply comparative safety when safety was not formally analyzed.
Do not treat high heterogeneity as a trivial technical detail.
Do not erase the role of patient preference, access, and clinical suitability.
Do not use the findings to shame patients for choosing either pathway.
Misinformation Firewall
This paper supports a more careful comparison, not a louder slogan.
Have thoughts on this? Share it:
X Share on X in Share on LinkedIn ? Share on BlueSky ? Follow on Instagram ? Read more on Substack ? Subscribe via RSS
RELATED READING AT CED CLINIC
Related evidence and clinical perspective
Physician-Led GLP-1 & Metabolic Care
A clinical overview of CED Clinic’s metabolic care model, including why longitudinal physician guidance matters when GLP-1 medications are being considered.
Explore evidence
How GLP-1 Care Works at CED Clinic
A practical guide to evaluation, medication selection, monitoring, and follow-up for patients who want structured metabolic care rather than prescription-only treatment.
Read article
Metabolic Health Explained: A Clear Clinical Guide
A physician-guided explanation of metabolism, appetite regulation, insulin signaling, and why weight loss treatment should be understood as more than scale movement.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
Frequently Asked Questions
What did this GLP-1 bariatric surgery meta-analysis compare?
It compared weight, BMI, glycemic markers, lipid outcomes, and blood pressure between adults with obesity treated with GLP-1 receptor agonists and adults treated with bariatric surgery across 15 studies.
Which intervention produced greater long-term weight loss?
Bariatric surgery produced significantly greater weight loss at 1 year or less and beyond 1 year, while the 6-month weight difference was not statistically significant in the primary pooled analysis.
How did BMI outcomes compare?
BMI reduction favored bariatric surgery at 6 months, 1 year or less, and beyond 1 year in the pooled analysis.
Did bariatric surgery improve HbA1c more than GLP-1 medications?
HbA1c reduction favored bariatric surgery beyond 1 year. At 1 year or less, the primary pooled comparison did not reach statistical significance, although sensitivity analysis changed that finding after one study was removed.
Were cholesterol and blood pressure outcomes different?
In the primary analysis, serum lipids and blood pressure did not show significant between-group differences. This is important because the strongest signal in the paper was not uniform across every cardiometabolic marker.
Does this study prove bariatric surgery is safer than GLP-1 medication?
No. The meta-analysis did not perform a formal comparative safety analysis, so it should not be used to make broad safety claims about surgery versus GLP-1 receptor agonists.
Why does heterogeneity matter in this paper?
High heterogeneity means the included studies varied substantially. That does not erase the overall pattern, but it does make precise pooled estimates less stable and calls for more careful interpretation.
Which patient characteristics were associated with greater BMI reduction after bariatric surgery?
In study-level meta-regression, older mean age, higher baseline BMI, and a higher proportion of male participants were associated with greater BMI reduction after bariatric surgery. These should not be treated as individual prediction rules.
Should this study change obesity treatment decisions by itself?
No. It can inform counseling, but treatment decisions still require individualized assessment of medical history, risk tolerance, access, preferences, safety, and long-term follow-up capacity.
What research is still needed after this meta-analysis?
Future studies should compare specific procedures and specific GLP-1 agents, standardize safety reporting, include patient-centered outcomes, and clarify sequencing or combination strategies over longer follow-up periods.
[...]
Read more...
June 3, 2026Semaglutide for Schizophrenia: Weight Loss Without Psychiatric Risk
GLP-1 Receptor Agonists
Schizophrenia Spectrum Disorders
Antipsychotic-Associated Weight Gain
Metabolic Health
Meta-Analysis
What You Will Learn
How much body weight and BMI semaglutide reduced in patients with schizophrenia spectrum disorders across three placebo-controlled RCTs
Which glycaemic markers improved, and with what degree of evidence certainty
What gastrointestinal adverse events occurred, and why they carry particular clinical weight in this population
Why the absence of psychiatric deterioration signals is clinically meaningful, and what the evidence still cannot tell us
TL;DR: In a pooled analysis of three placebo-controlled RCTs (n = 258), semaglutide produced a mean body-weight reduction of 11.32 kg in adults with schizophrenia spectrum disorders on antipsychotics, with high-certainty evidence and no signal for worsened psychosis or serious adverse events.
◎
Systematic Review & Meta-Analysis of Randomised Controlled Trials
Abstract
Background: People with schizophrenia spectrum disorders (SSDs) experience high rates of obesity and metabolic dysfunction, contributing substantially to excess morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide have demonstrated substantial efficacy for weight and glycaemic outcomes in the general population, but evidence in people with SSDs remains limited.
Aims: To synthesise all placebo-controlled, randomised controlled trials examining semaglutide and/or tirzepatide in people with SSDs.
Method: A preregistered systematic review and meta-analysis of RCTs examining the efficacy and safety of semaglutide and/or tirzepatide in adults with SSDs was conducted. Outcomes and adverse events were pooled using random-effects meta-analysis. Certainty of evidence was assessed using the GRADE criteria.
Results: Three trials (n = 258) met inclusion criteria, examining semaglutide dosages of 1.0 to 2.0 mg over 26 to 36 weeks. No trials examining tirzepatide were found. Semaglutide significantly reduced body weight (−11.32 kg; 95% CI −15.35 to −7.29), body mass index (−3.58 kg/m²; 95% CI −4.86 to −2.30), haemoglobin A1c (−0.37%; 95% CI −0.51 to −0.22) and fasting glucose (−0.54 mmol/L; 95% CI −0.94 to −0.13). In adverse event analyses, semaglutide was associated with increased risks of abdominal pain (risk ratio 2.93; 95% CI 1.13 to 7.60), vomiting (risk ratio 2.57; 95% CI 1.39 to 4.77) and constipation (risk ratio 3.23; 95% CI 1.14 to 9.18). There was no evidence of increased risk of serious adverse events.
Conclusions: Semaglutide produces clinically meaningful improvements in weight and glycaemic outcomes in people with SSDs, with an adverse event profile consistent with known gastrointestinal effects of GLP-1 RAs in the general population. These findings support semaglutide as a promising adjunctive metabolic intervention in this population, although larger and longer trials, specifically those testing tirzepatide, are needed to better characterise heterogeneity of effects and long-term safety.
Source: Trott M, Arnautovska U, Johnston D, Ritchie G, Siskind D. The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials. BJPsych Open. 2026;12:e147.
DOI: 10.1192/bjo.2026.12001
Open Access: Creative Commons Attribution 4.0 License
Study at a Glance
Design
Preregistered systematic review and random-effects meta-analysis of placebo-controlled RCTs (PROSPERO: CRD420251247162)
Population
Adults with schizophrenia, schizoaffective disorder, or schizotypal disorder per ICD-10 or DSM criteria, receiving antipsychotic medications
Sample Size
258 participants across 3 RCTs
Intervention
Semaglutide 1.0 mg (two trials) or 2.0 mg (one trial), weekly subcutaneous injection, 26 to 36 weeks
Comparator
Placebo
Primary Finding
Semaglutide reduced body weight by a mean of 11.32 kg (95% CI −15.35 to −7.29; high certainty) and BMI by 3.58 kg/m² (95% CI −4.86 to −2.30; high certainty), with no increased risk of serious adverse events
Study Snapshot: Key Statistics
Outcome
Treatment Effect
95% CI
p-value
GRADE Certainty
Body weight (kg)
−11.32 kg
−15.35 to −7.29
<0.001
High
BMI (kg/m²)
−3.58
−4.86 to −2.30
<0.001
High
HbA1c (%)
−0.37%
−0.51 to −0.22
<0.001
High
Fasting glucose (mmol/L)
−0.54
−0.94 to −0.13
0.01
Moderate
Systolic BP (mmHg)
−2.34
−5.53 to 0.84
0.149
Low
Diastolic BP (mmHg)
−0.39
−2.83 to 2.06
0.756
Low
Fasting insulin (mU/L)
−3.03
−7.98 to 1.93
0.231
Very low
Fasting triglycerides (mmol/L)
−0.14
−0.41 to 0.13
0.305
Very low
HDL cholesterol (mmol/L)
+0.07
−0.10 to 0.24
0.434
Very low
Abdominal pain (RR)
2.93
1.13 to 7.60
0.027
High
Vomiting (RR)
2.57
1.39 to 4.77
0.003
High
Constipation (RR)
3.23
1.14 to 9.18
0.028
Moderate
Serious adverse events (RR)
0.81
0.52 to 1.26
0.345
Low
RR = risk ratio; BP = blood pressure; HbA1c = haemoglobin A1c; HDL = high-density lipoprotein. AE rows shaded. All effects are semaglutide versus placebo.
Study Facts
Authors
Mike Trott, Urska Arnautovska, Donni Johnston, Gabrielle Ritchie, Dan Siskind
Journal
BJPsych Open
Year
2026
DOI
10.1192/bjo.2026.12001
Study Design
Preregistered systematic review and random-effects meta-analysis of placebo-controlled RCTs
PROSPERO Registration
CRD420251247162 (registered 9 December 2025)
Number of Trials
3 RCTs
Total N
258 participants
Population
Adults with schizophrenia spectrum disorders (schizophrenia, schizoaffective disorder, schizotypal disorder) on antipsychotic therapy; predominantly on clozapine or olanzapine
Intervention
Semaglutide 1.0 mg/week (two trials) or 2.0 mg/week (one trial), subcutaneous, for 26 to 36 weeks
Comparator
Placebo
Primary Endpoint (review-defined)
Efficacy and safety outcomes including body weight, BMI, glycaemic markers, and adverse events
Key Efficacy Results
Body weight: −11.32 kg (95% CI −15.35 to −7.29; p <0.001; high certainty); BMI: −3.58 kg/m² (95% CI −4.86 to −2.30; p <0.001; high certainty); HbA1c: −0.37% (95% CI −0.51 to −0.22; p <0.001; high certainty); fasting glucose: −0.54 mmol/L (95% CI −0.94 to −0.13; p = 0.01; moderate certainty)
Key Safety Results
Abdominal pain RR 2.93 (95% CI 1.13 to 7.60); vomiting RR 2.57 (95% CI 1.39 to 4.77); constipation RR 3.23 (95% CI 1.14 to 9.18); serious adverse events RR 0.81 (95% CI 0.52 to 1.26, non-significant)
Risk of Bias
All three component trials rated low risk of bias (Cochrane RoB2 tool)
Funding
No specific grant from any funding agency, commercial or not-for-profit
Conflicts of Interest
D. Siskind was a member of the BJPsych Editorial Board but did not participate in review or decision-making for this paper. All other authors declared no conflicts.
What Researchers Actually Did
Trott and colleagues conducted a preregistered systematic review and meta-analysis, searching PubMed, EMBASE, PsycINFO, Scopus, and CENTRAL on 6 December 2025. Their inclusion criteria were narrow and explicit: placebo-controlled RCTs of semaglutide or tirzepatide in adults with a formal SSD diagnosis, with no restriction on dosage, duration, or outcome. Two independent reviewers handled screening, full-text assessment, and data extraction at every stage; agreement was 100% throughout, and no arbitration was required. Risk of bias was assessed with the Cochrane RoB2 tool. Three trials met criteria, all examining semaglutide: Ganeshalingam et al. (n = 154, 1 mg, 30 weeks, Denmark), Sass et al. (n = 73, 1 mg, 26 weeks, Denmark), and Siskind et al. (n = 31, 2 mg, 36 weeks, Australia). No tirzepatide trials were identified.
Statistical pooling used a random-effects framework with restricted maximum likelihood estimation; heterogeneity was quantified with τ², and prediction intervals were calculated alongside point estimates. Continuous outcomes required at least three contributing studies to enter the meta-analysis; fewer than three were narratively synthesised. Adverse events were pooled as risk ratios after log-transformation, using the same random-effects method. Evidence certainty was graded with GRADE. Publication bias was not formally assessed because the pool contained fewer than ten studies.
Key Findings: Primary Outcomes
Body weight: Semaglutide reduced weight by a mean of 11.32 kg (95% CI −15.35 to −7.29 kg; p <0.001; τ² = 10.15; prediction interval −18.75 to −3.89 kg; GRADE high certainty).
BMI: Mean reduction of 3.58 kg/m² (95% CI −4.86 to −2.30; p <0.001; τ² = 1.00; prediction interval −5.93 to −1.24 kg/m²; GRADE high certainty).
HbA1c: Mean reduction of 0.37% (95% CI −0.51 to −0.22; p <0.001; τ² = 0.01; prediction interval −0.62 to −0.11%; GRADE high certainty).
Fasting glucose: Mean reduction of 0.54 mmol/L (95% CI −0.94 to −0.13; p = 0.01; τ² = 0.09; prediction interval −1.26 to 0.19 mmol/L; GRADE moderate certainty).
The authors note that the 11% reduction in body weight was achieved at semaglutide doses of 1.0 to 2.0 mg over 26 to 36 weeks, compared with the 2.4 mg dose used over 68 weeks in the Wilding et al. STEP 1 general-population trial, which yielded approximately 15% weight loss.
Key Findings: Secondary Outcomes
No outcomes other than those listed above reached statistical significance in the pooled meta-analysis. Several narratively synthesised outcomes showed directionally consistent but non-significant patterns:
Body composition: Significant reductions in body fat percentage, waist circumference, and visceral fat were reported across the two trials measuring these outcomes; hip circumference decreased significantly in Ganeshalingam et al. Waist-to-hip ratio and bone mineral content showed no significant change in any trial.
Insulin resistance: Two studies reported consistent decreases, but neither reached statistical significance.
Lipids: Consistent non-significant reductions in triglycerides and heart rate; non-significant and conflicting effects for LDL and total cholesterol.
Blood pressure: Systolic BP: −2.34 mmHg (95% CI −5.53 to 0.84; not significant; low certainty). Diastolic BP: −0.39 mmHg (not significant; low certainty).
Psychiatric symptom severity: PANSS total, PANSS subscales, CGI-S, and most cognitive domains (BACS) showed non-significant or conflicting results. No consistent signal of clinical deterioration was observed across any trial.
Clozapine and norclozapine concentrations: No significant or consistent changes reported by Siskind et al., suggesting absence of pharmacokinetic interaction in that sample.
Nicotine dependence: A significant reduction on the Fagerström Test for Nicotine Dependence was reported by Sass et al. (single study; not meta-analysed).
BACS verbal memory learning: Siskind et al. reported a significant increase, but this was an isolated finding from a single small trial and should be interpreted with considerable caution.
No formal subgroup analyses by antipsychotic class, baseline metabolic status, or demographic variables were reported or feasible given the three-trial evidence base.
Adverse Events and Safety Profile
Six adverse event categories contained sufficient data for meta-analysis. Three showed statistically significant elevations in the semaglutide group:
Abdominal pain: RR 2.93 (95% CI 1.13 to 7.60; p = 0.027; τ² = 0; prediction interval 1.13 to 7.60; GRADE high certainty)
Vomiting: RR 2.57 (95% CI 1.39 to 4.77; p = 0.003; τ² = 0; prediction interval 1.39 to 4.77; GRADE high certainty)
Constipation: RR 3.23 (95% CI 1.14 to 9.18; p = 0.028; τ² = 0.38; prediction interval 0.65 to 16.03; GRADE moderate certainty)
Three categories did not differ significantly between groups:
Diarrhoea: RR 1.50 (95% CI 0.69 to 3.24; not significant; low certainty)
Nausea: RR 1.44 (95% CI 0.87 to 2.39; not significant; low certainty)
Serious adverse events: RR 0.81 (95% CI 0.52 to 1.26; not significant; low certainty)
Non-meta-analysed adverse events, including psychiatric admissions, self-harm, suicidal behaviour, neurological symptoms (dizziness, fatigue, headache), and infections, were infrequently and inconsistently reported across trials, with no consistent pattern of increased risk. Rates of any adverse event and adverse events leading to discontinuation were broadly comparable between groups, with risk ratios close to unity where reported. The timing of adverse events relative to dose escalation was not reported in any component study, a gap the authors identify as clinically important.
Statistical Approach and Rigor
The analytic strategy was appropriate for the available data. Random-effects pooling with restricted maximum likelihood estimation is the correct default when between-study heterogeneity is expected, and the authors provided prediction intervals alongside point estimates, which is a more informative and honest representation of effect variability than confidence intervals alone. The weight prediction interval of −18.75 to −3.89 kg, for example, captures the plausible range of effects across settings, not merely the uncertainty around the average. GRADE was applied systematically to rate certainty. Risk-of-bias assessment used the Cochrane RoB2 tool with dual independent reviewers and 100% agreement. All three component trials were rated low risk of bias.
Two methodological constraints bear emphasis. First, with only three contributing studies, heterogeneity estimates (τ²) are themselves imprecise; the pooled τ² for body weight of 10.15 suggests meaningful between-study variability, and the prediction interval should temper confidence in the point estimate for any specific clinical context. Second, publication bias could not be formally assessed with fewer than ten studies. Given that three ongoing trials were identified but had not yet published results, selective reporting of positive findings cannot be excluded. The authors correctly note this constraint.
Clinical Takeaway
For clinicians managing adults with schizophrenia spectrum disorders whose weight has risen substantially on clozapine or olanzapine, this meta-analysis provides the most consolidated RCT evidence to date that semaglutide produces a clinically meaningful reduction in body weight and improves glycaemic markers, without worsening psychiatric symptom severity or generating a signal for serious adverse events. The gastrointestinal adverse event profile, particularly abdominal pain, vomiting, and constipation, is real and requires anticipatory management. In patients receiving clozapine, where constipation independently carries serious risk, this overlap demands careful attention: slow dose titration, proactive bowel regimen, hydration monitoring, and early follow-up are not optional adjuncts but obligatory safeguards. The evidence does not yet extend to tirzepatide, longer durations, or hard cardiovascular endpoints.
Clinical Bottom Line: Semaglutide at 1.0 to 2.0 mg produced high-certainty, double-digit kilogram weight loss in adults with schizophrenia spectrum disorders without psychiatric deterioration, but the evidence base is three small trials, gastrointestinal adverse events are near-tripled in risk, and no data yet exist beyond 36 weeks or for tirzepatide.
Why This Matters Clinically
People with schizophrenia spectrum disorders die 10 to 20 years earlier than the general population, and the majority of those premature deaths are attributable to cardiovascular and metabolic disease, not to the psychiatric disorder itself. Antipsychotic medications, particularly clozapine and olanzapine, accelerate metabolic risk through mechanisms that include weight gain, dyslipidaemia, and dysglycaemia. The prior standard pharmacological adjunct, metformin, produces roughly 3 kg of weight loss relative to placebo in this population. Semaglutide, at lower doses and shorter durations than general-population obesity trials, appears to generate three to four times that effect. That magnitude, if durable and translatable to cardiovascular outcomes, has the potential to materially alter life expectancy trajectories in a population historically underserved by metabolic medicine. The simultaneous absence of psychosis worsening and pharmacokinetic interaction with clozapine (at least in one trial) removes what had been a reasonable theoretical concern about GLP-1 agonism in a dopaminergically vulnerable population.
CED Clinical Relevance
At CED Clinic, we frequently evaluate patients whose psychiatric pharmacotherapy has generated substantial metabolic burden, including obesity, pre-diabetes, and dyslipidaemia. Many of these patients are already managing complex polypharmacy and have had limited success with behavioural interventions alone. This meta-analysis is directly relevant to that clinical scenario. The evidence now supports a structured, monitored trial of semaglutide as an adjunctive strategy, particularly in patients on clozapine or olanzapine with BMI at or above 27 kg/m² and evidence of dysglyca
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
Semaglutide significantly reduced body weight and BMI in SSDs with no increased risk of psychiatric deterioration.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: High EfficacyBadge 2: No Psychiatric RiskBadge 3: Gastrointestinal Side Effects
Semaglutide significantly reduced body weight and BMI in adults with schizophrenia spectrum disorders, demonstrating high efficacy without worsening psychiatric symptoms. However, it was associated with increased risks of gastrointestinal adverse events such as abdominal pain, vomiting, and constipation.
Semaglutide produced a mean body-weight reduction of 11.32 kg.
No evidence of increased risk of serious adverse events or worsened psychosis was observed.
Gastrointestinal side effects were notable but manageable.
Key Insight
Semaglutide effectively reduces weight in schizophrenia spectrum disorders without worsening psychiatric symptoms.
Patient Takeaway
Badge 1: Weight LossBadge 2: Improved MetabolismBadge 3: Gastrointestinal Side Effects
Patients with schizophrenia spectrum disorders can benefit from semaglutide, which helps in reducing body weight and improving metabolic markers like HbA1c and fasting glucose. However, they may experience gastrointestinal side effects such as abdominal pain and vomiting.
Semaglutide reduces body weight by 11.32 kg on average.
Metabolic health improves with reductions in HbA1c and fasting glucose.
Gastrointestinal adverse events like abdominal pain and vomiting are common but manageable.
Patient Takeaway
Semaglutide can help manage weight and metabolic issues without worsening psychiatric symptoms.
Clinician’s POV
Badge 1: High EfficacyBadge 2: No Psychiatric RiskBadge 3: Gastrointestinal Side Effects
Clinicians can consider semaglutide as a safe and effective treatment for weight management in patients with schizophrenia spectrum disorders. While it reduces body weight and improves metabolic health, clinicians should monitor for gastrointestinal side effects.
Semaglutide significantly reduced body weight by 11.32 kg.
No increased risk of serious adverse events or worsened psychosis was observed.
Gastrointestinal side effects such as abdominal pain and vomiting were noted.
Clinician Takeaway
Semaglutide is effective for weight management in SSDs without worsening psychiatric symptoms.
A Skeptical Read
Badge 1: Small Sample SizeBadge 2: Limited Data on TirzepatideBadge 3: Gastrointestinal Side Effects
While semaglutide shows promise, the study’s small sample size and limited data on tirzepatide raise questions about its broader applicability. Additionally, gastrointestinal side effects are a concern that needs further investigation.
The study included only 258 participants across three trials.
No tirzepatide trials were identified for analysis.
Gastrointestinal adverse events such as abdominal pain and vomiting were common.
Skeptic Takeaway
Semaglutide shows promise but requires further research due to small sample size and gastrointestinal side effects.
Study Critic
Badge 1: High EfficacyBadge 2: No Psychiatric RiskBadge 3: Limited Long-Term Data
Critics may argue that while semaglutide is effective and safe in the short term, long-term data are lacking. The study’s focus on a small number of trials also limits its generalizability.
Semaglutide reduced body weight by 11.32 kg with high efficacy.
No increased risk of serious adverse events or worsened psychosis was observed.
Long-term safety and efficacy data are needed for broader application.
Critic Takeaway
Semaglutide is effective but long-term safety and efficacy need further study.
Compared to Past Research
Badge 1: Previous ResearchBadge 2: Antipsychotic-Associated Weight GainBadge 3: Metabolic Health Concerns
Prior research has highlighted the challenges of antipsychotic-associated weight gain and metabolic health issues in schizophrenia spectrum disorders. Semaglutide offers a promising approach to address these concerns.
Antipsychotics are associated with significant weight gain.
Metabolic health is a critical concern for patients with SSDs.
Semaglutide addresses both weight management and metabolic health.
Historical Context
Previous research underscores the need for effective treatments to manage weight and metabolic issues in SSDs.
Practical Considerations
Badge 1: Practical ApplicationBadge 2: Monitoring Gastrointestinal Side EffectsBadge 3: Integration with Antipsychotic Therapy
Practically, semaglutide can be integrated into the treatment regimen of patients on antipsychotics to manage weight and metabolic health. Clinicians should monitor for gastrointestinal side effects and adjust dosages as needed.
Semaglutide can be used alongside antipsychotic therapy.
Monitoring for gastrointestinal adverse events is crucial.
Dosage adjustments may be necessary based on individual patient response.
Practical Advice
Integrate semaglutide into treatment plans while monitoring for gastrointestinal side effects.
Future Directions
Badge 1: Larger Trials NeededBadge 2: Tirzepatide ResearchBadge 3: Long-Term Safety
Future research should focus on larger and longer trials to better understand the long-term safety and efficacy of semaglutide. Additionally, studies on tirzepatide in schizophrenia spectrum disorders are needed to compare its effects.
Larger and longer trials are required for comprehensive understanding.
Research on tirzepatide is necessary for comparison.
Long-term safety and efficacy need further investigation.
Future Directions
Further research is needed to explore long-term safety and efficacy of semaglutide in SSDs.
Misreadings & Bad-Faith Takes
Badge 1: Misinterpretation RiskBadge 2: Overlooking Psychiatric SafetyBadge 3: Ignoring Side Effects
Misreadings of this study might overlook the psychiatric safety of semaglutide or ignore gastrointestinal side effects. It is crucial to understand that while effective, semaglutide does not worsen psychiatric symptoms and requires monitoring for adverse events.
Misinterpretations may overlook psychiatric safety.
Gastrointestinal side effects should not be ignored.
Comprehensive understanding of benefits and risks is essential.
Avoid Misreadings
Understand that semaglutide is safe for psychiatric symptoms but requires monitoring for gastrointestinal side effects.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What is semaglutide and how does it work?
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that mimics the effects of GLP-1, a hormone that helps regulate blood sugar levels and promotes weight loss.
How effective is semaglutide in reducing body weight for people with schizophrenia spectrum disorders?
Semaglutide produced a mean body-weight reduction of 11.32 kg in adults with schizophrenia spectrum disorders on antipsychotics.
Does semaglutide improve glycemic markers in people with schizophrenia?
Semaglutide significantly reduced haemoglobin A1c by 0.37% and fasting glucose by 0.54 mmol/L.
What are the gastrointestinal adverse events associated with semaglutide?
Semaglutide was associated with increased risks of abdominal pain, vomiting, and constipation.
Is there a risk of psychiatric deterioration with semaglutide use in schizophrenia spectrum disorders?
No evidence of increased risk of serious adverse events or worsened psychosis was observed.
How does the study’s sample size and duration compare to other weight loss studies?
The study included 258 participants over 26 to 36 weeks, which is smaller than some general population trials.
What are the implications of these findings for clinical practice?
These findings support semaglutide as a promising adjunctive metabolic intervention in people with schizophrenia spectrum disorders.
Are there any limitations to this study?
The study is limited by the small number of trials and participants, and further research on tirzepatide is needed.
What are the next steps in research for semaglutide in schizophrenia spectrum disorders?
Larger and longer trials, specifically those testing tirzepatide, are needed to better characterize heterogeneity of effects and long-term safety.
How does this study contribute to the understanding of metabolic health in schizophrenia?
This study highlights the potential for GLP-1 RAs to improve metabolic health without worsening psychiatric symptoms in people with schizophrenia spectrum disorders. [...]
Read more...
June 3, 2026Oral Semaglutide in Type 2 Diabetes: Real-World Results From Thailand
GLP-1 Receptor Agonist
Type 2 Diabetes
Glycaemic Control
Weight Reduction
Real-World Evidence
What You Will Learn From This Review:
How oral semaglutide performed on HbA1c and body weight in Thai patients with type 2 diabetes over 26 weeks in routine clinical care
What proportion of real-world patients reached the HbA1c target of less than 7% and a composite glycaemic-plus-weight outcome
How safety data, including severe hypoglycaemia, compared to other regional and Western real-world cohorts
Where this evidence is strong and where a careful clinician should remain cautious
TL;DR: In 195 Thai adults with type 2 diabetes receiving oral semaglutide predominantly as add-on therapy, HbA1c fell by an estimated 0.7 percentage points and body weight by an estimated 4.4 kg over 26 weeks, with 75.9% of completers reaching HbA1c below 7% and no severe hypoglycaemia recorded.
STUDY DESIGN: Retrospective Multi-Centre Cohort (Real-World Evidence)
Abstract
Aims: The REALISED study assessed the clinical outcomes associated with oral semaglutide use in Thai patients with type 2 diabetes (T2D) in real-world clinical settings.
Materials and Methods: This retrospective, multi-centre cohort study included 195 patients with T2D initiating oral semaglutide between April 2022 and December 2023. Eligible participants had no prior injectable therapy and completed at least 26 weeks of treatment. The primary endpoint was the change in HbA1c from baseline to the end-of-study (EoS, Week 26); Week 52 outcomes were exploratory. Secondary endpoints included changes in body weight and the proportion achieving HbA1c less than 7%. Severe hypoglycaemia was the safety endpoint. A post hoc composite endpoint combined HbA1c less than 7% with at least 3% weight loss. Analyses used a mixed model for repeated measures and descriptive statistics.
Results: Oral semaglutide was predominantly used as add-on therapy (190/195 ). Mean HbA1c decreased by -0.7% (95% CI: -0.9 to -0.5; p<0.0001), and mean body weight decreased by -4.3 kg (95% CI: -5.5 to -3.2; p<0.0001). At EoS, 75.9% (117/154) achieved HbA1c less than 7%, and 57.7% (71/123) met the composite endpoint. No severe hypoglycaemia occurred. Dose escalation from 3 mg to 14 mg was observed in 53.2% by Week 26 and 70.4% by Week 52.
Conclusions: The REALISED study provides the first real-world evidence of oral semaglutide use in Thai patients with T2D, demonstrating significant improvements in glycaemic control and weight reduction across routine care settings.
Source: Wannachalee T, Anthanont P, Sirisreetreerux S, et al. Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real-World Evidence From the REALISED Study. Diabetes, Obesity and Metabolism. 2026;28:5058–5067.
DOI: https://doi.org/10.1111/dom.70701
Open Access: Yes (Creative Commons Attribution-NonCommercial-NoDerivs)
Study at a Glance
Design
Retrospective, single-arm, multi-centre cohort; routine clinical records from four university hospitals in Thailand
Population
Thai adults (age 18+) with confirmed T2D, no prior injectable therapy; n = 195 (full analysis set)
Intervention
Oral semaglutide (predominantly 3 mg start with titration to 7 mg and 14 mg), used as add-on therapy in 97.4%
Primary Endpoint
Change in HbA1c from baseline to Week 26 (end-of-study, EoS)
Key Finding
Estimated HbA1c reduction: -0.7 percentage points (95% CI: -0.9 to -0.5; p<0.0001); weight: -4.4 kg (95% CI: -5.5 to -3.3; p<0.0001); 75.9% of completers reached HbA1c <7%; no severe hypoglycaemia
Study Snapshot: Key Statistics
Outcome
Estimated Change (Model-Based)
95% CI
p-value
HbA1c, absolute change (%-points)
-0.7
-0.9 to -0.5
<0.0001
HbA1c, relative change (%)
-9.8%
-12.0 to -7.5
<0.0001
Body weight, absolute change (kg)
-4.4
-5.5 to -3.3
<0.0001
Body weight, relative change (%)
-5.3%
-6.5 to -4.0
<0.0001
Proportion achieving HbA1c <7% at EoS
75.9% (117/154)
N/A
N/A
Composite: HbA1c <7% + BW reduction ≥3%
57.7% (71/123)
N/A
N/A
Severe hypoglycaemia
0 events
N/A
N/A
Treatment discontinuation by EoS
4.1% (8/195)
N/A
N/A
Full Study Facts
Authors
Wannachalee T, Anthanont P, Sirisreetreerux S, Nayak G, Chumchujan W, Iamsudjai Y, Buranapin S
Journal
Diabetes, Obesity and Metabolism
Year
2026
DOI
10.1111/dom.70701
Design
Retrospective, single-arm, multi-centre cohort (real-world evidence); four university hospitals in Bangkok, Pathum Thani, and Chiang Mai, Thailand
N (Full Analysis Set)
195
Intervention
Oral semaglutide; 92.3% initiated at 3 mg with titration per standard protocol; used predominantly as add-on to existing oral agents
Comparator
None (single-arm observational study)
Primary Endpoint
Change in HbA1c (%-points) from baseline to Week 26
Key Results
HbA1c: -0.7%-points (95% CI: -0.9 to -0.5; p<0.0001); body weight: -4.4 kg (95% CI: -5.5 to -3.3; p<0.0001); HbA1c <7% achieved in 75.9% of completers; composite endpoint (HbA1c <7% + BW reduction ≥3%) met in 57.7%
Adverse Events
No severe hypoglycaemia throughout observation (including Week 52); overall discontinuation 4.1% by EoS; one discontinuation attributed to GI intolerability
Funding
Novo Nordisk (medical writing support)
Conflicts of Interest
G. Nayak, W. Chumchujan, and Y. Iamsudjai are Novo Nordisk employees. S. Buranapin received a research grant from Novo Nordisk. T. Wannachalee and P. Anthanont declare no conflicts of interest.
What Researchers Actually Did
Between April 2022 and December 2023, investigators at four Thai university hospitals identified adult patients with confirmed type 2 diabetes who had initiated oral semaglutide and had no prior exposure to injectable glucose-lowering agents (insulin or GLP-1 receptor agonists). From 222 screened patients, 27 were excluded for missing baseline HbA1c, treatment interruptions exceeding two weeks, prior injectable use, or other protocol deviations, leaving 195 in the full analysis set. Baseline HbA1c was the most recent value within 12 weeks before initiation. The primary assessment was defined as the HbA1c measurement closest to Week 26 (within a plus-or-minus six-week window), consistent with standard six-month clinical follow-up. An optional extended observation period extended to Week 52 for patients who continued routine care; 72 patients had HbA1c data available at that time point.
Changes in HbA1c and body weight were estimated using a three-level mixed model for repeated measures (MMRM), incorporating linear and quadratic time since initiation, time-varying semaglutide dose (3, 7, or 14 mg), baseline HbA1c or weight, and random intercepts for both site and patient, with random slopes for time. Missing post-baseline data were handled under the missing-at-random assumption. Sensitivity analyses assessed EoS completers, patients with baseline HbA1c at or above 7%, those with baseline BMI at or above 25 kg/m2, and patients with stable background antidiabetic regimens. A post hoc composite endpoint, defined as HbA1c below 7% combined with at least 3% reduction in body weight, was applied to 123 participants with complete data for both measures.
Key Findings: Primary Outcomes
HbA1c reduction (model-based, FAS, n=195): Estimated mean change from baseline to Week 26 was -0.7 percentage points (95% CI: -0.9 to -0.5; p<0.0001); relative change was -9.8% (95% CI: -12.0 to -7.5; p<0.0001).
Observed HbA1c change in completers: Mean observed reduction was -1.0 percentage points (SD 1.2) among the 154 participants with EoS data, which is numerically larger than the model-based estimate, reflecting the difference between observed data and MMRM-adjusted estimates across all time points.
Consistency across sensitivity analyses: Comparable HbA1c reductions were observed in EoS completers (n=154), participants with baseline HbA1c at or above 7% (n=123), and those with stable background antidiabetic medications (n=70).
On-treatment analysis: Estimated change was -0.7 percentage points (95% CI: -0.9 to -0.5; p<0.0001), consistent with the in-study result.
Key Findings: Secondary Outcomes and Subgroup Analyses
Body Weight
Estimated mean body weight reduction (FAS, n=194) at EoS: -4.4 kg (95% CI: -5.5 to -3.3; p<0.0001), corresponding to -5.3% relative decrease (95% CI: -6.5% to -4.0%; p<0.0001).
On-treatment analysis: -4.6 kg (95% CI: -5.7 to -3.5; p<0.0001); relative decrease -5.5% (95% CI: -6.8% to -4.2%; p<0.0001).
Results were consistent across EoS completers (n=141), patients with BMI at or above 25 kg/m2 (n=159), and those with stable background regimens (n=70).
At Week 52 (exploratory, n=72), observed body weight reduction was approximately -4.7 kg, within the range reported in PIONEER REAL studies.
HbA1c Target Achievement
Of 154 EoS completers, 117 (75.9%) achieved HbA1c below 7%; 44.4% (52/117) of those had baseline HbA1c at or above 7%, indicating meaningful glycaemic improvement even among those starting above target.
Composite Endpoint (Post Hoc)
Among 123 participants with complete HbA1c and weight data at baseline and EoS, 71 (57.7%) met the composite of HbA1c below 7% and at least 3% body weight reduction.
Among participants with baseline HbA1c at or above 7% and BMI at or above 25 kg/m2 (n=61), 30 (49.2%) met the composite target.
Among obese participants (BMI at or above 25 kg/m2) with already-adequate glycaemic control (HbA1c below 7%) at baseline (n=43), 32 (74.4%) achieved the composite endpoint at EoS.
CKD Subgroup (Exploratory)
Participants with normal or mildly decreased kidney function (eGFR at or above 60 mL/min/1.73m2; n=163): HbA1c reduction -0.9 percentage points (95% CI: -1.0 to -0.8; p<0.0001); weight reduction -4.3 kg (95% CI: -5.2 to -3.5; p<0.0001).
Participants with CKD Stage 3 or higher (n=25): HbA1c reduction -0.8 percentage points (95% CI: -1.1 to -0.6; p<0.0001); weight reduction -3.7 kg (95% CI: -6.9 to -0.5; p=0.024). The CKD subgroup analysis is underpowered and should be interpreted with caution, as the authors themselves note.
Dose Titration Patterns
92.3% of participants (180/195) initiated at 3 mg; by Week 26, 59.6% of those initiating at 3 mg had escalated to 14 mg; by Week 52, 70.4% of the overall cohort were on 14 mg; no participants continued on 3 mg at Week 52.
Concomitant Medication Changes
Sulphonylurea use declined from 35.4% at baseline to approximately 22% by EoS; thiazolidinedione use declined from 26.7% to approximately 18%. The authors suggest this may have contributed to observed weight loss, though no formal analysis quantified this contribution.
Adverse Events and Safety Profile
The safety endpoint was defined narrowly as severe hypoglycaemia. No severe hypoglycaemia events were recorded from treatment initiation through Week 52, despite approximately 55% of participants concurrently using sulphonylureas or other insulin secretagogues at baseline. The authors attribute this to the glucose-dependent mechanism of GLP-1 receptor agonists, which attenuates insulin secretion at euglycaemia.
Overall, 8 of 195 participants (4.1%) discontinued oral semaglutide by EoS. Among those who discontinued, three were transitioned to subcutaneous semaglutide, one was attributed to GI intolerability, three were due to change in treatment strategy, and four were for unspecified other reasons. The subsequent treatment status of the remaining five was unknown. This low discontinuation rate compares favourably to the 7% to 12% reported in Japanese and Italian real-world cohorts cited by the authors. The study did not systematically capture non-severe GI adverse events, weight loss-related symptoms, or other tolerability data, which limits the completeness of the safety picture.
Statistical Approach and Rigor
The primary analysis used a three-level MMRM with restricted maximum likelihood estimation. The model incorporated hierarchical clustering (site as a second-level random intercept, patient as a third-level random intercept), random slopes for time, and fixed effects for linear and quadratic time, time-varying semaglutide dose, and baseline values of the respective outcome. An unstructured covariance matrix was applied at the patient level. This approach is appropriate for longitudinal observational data with irregular visit intervals and is consistent with the methods used in the PIONEER clinical trial program.
The sample size was powered to detect a mean HbA1c reduction of 0.46 percentage points (SD 1.7) with 90% power, requiring 146 patients with EoS Hb
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
REALISED study shows oral semaglutide effectively reduces HbA1c and body weight in Thai patients.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ComprehensiveBadge 2: Real-World DataBadge 3: Significant Outcomes
The REALISED study provides real-world evidence of oral semaglutide’s efficacy in Thai patients with type 2 diabetes, demonstrating significant improvements in HbA1c and body weight reduction.
Key findings include a mean HbA1c decrease of -0.7 percentage points and a body weight reduction of -4.4 kg over 26 weeks, with no severe hypoglycaemia reported.
Significant improvements in HbA1c and body weight
No severe hypoglycaemia events recorded
High proportion of patients achieved HbA1c below 7%
Key Insight
Oral semaglutide significantly improved glycemic control and weight in Thai type 2 diabetes patients.
Patient Takeaway
Badge 1: Patient-CentricBadge 2: Real-World ExperienceBadge 3: Safety Assured
Patients using oral semaglutide experienced significant reductions in HbA1c and body weight, with no severe hypoglycaemia reported.
The study provides real-world evidence that can help patients understand the potential benefits of this treatment option.
Mean HbA1c reduction of -0.7 percentage points
Mean body weight reduction of -4.4 kg
No severe hypoglycaemia events
Patient Takeaway
Oral semaglutide can effectively manage blood sugar and aid in weight loss without severe side effects.
Clinician’s POV
Badge 1: Evidence-BasedBadge 2: Real-World ApplicabilityBadge 3: Safety Data
Clinicians can use this study to support the prescription of oral semaglutide for type 2 diabetes management, as it shows significant improvements in HbA1c and body weight.
The absence of severe hypoglycaemia adds to its safety profile, making it a viable option for patients.
HbA1c reduction of -0.7 percentage points
Body weight reduction of -4.4 kg
No severe hypoglycaemia reported
Clinician Insight
Oral semaglutide offers effective glycemic control and weight management with a favorable safety profile.
A Skeptical Read
Badge 1: Critical ViewBadge 2: Real-World EvidenceBadge 3: Safety Considerations
While the study shows promising results, skeptics may consider the need for longer-term studies to confirm long-lasting effects.
The absence of severe hypoglycaemia is reassuring but further research on non-severe adverse events is needed.
Significant HbA1c and weight reductions
No severe hypoglycaemia reported
Need for longer-term studies
Skeptic Insight
Oral semaglutide shows promise but requires further long-term research to validate long-lasting benefits.
Study Critic
Badge 1: Critical AnalysisBadge 2: Real-World DataBadge 3: Safety Evaluation
Critics may point out the study’s reliance on real-world data, which can introduce variability.
The study does not capture non-severe adverse events or weight loss-related symptoms, limiting a complete safety profile.
Real-world evidence with variability
No severe hypoglycaemia but incomplete safety data
Need for more comprehensive safety studies
Critic Insight
While effective, the study’s reliance on real-world data and limited safety information warrant further scrutiny.
Compared to Past Research
Badge 1: Historical ContextBadge 2: Comparative DataBadge 3: Evolution of Treatment
This study builds upon previous research, providing real-world evidence that complements clinical trial data.
Compared to other regional and Western studies, the results are consistent with significant improvements in HbA1c and body weight.
Consistent with previous studies
Significant HbA1c and weight reductions
Real-world evidence complements clinical trials
Historical Insight
The study aligns with past research, showing consistent benefits of oral semaglutide in type 2 diabetes management.
Practical Considerations
Badge 1: Practical ApplicationBadge 2: Real-World RelevanceBadge 3: Clinical Utility
Practically, the study supports the use of oral semaglutide in routine clinical care for type 2 diabetes management.
The significant HbA1c and body weight reductions make it a practical option for many patients.
Significant HbA1c reduction
Mean body weight reduction
No severe hypoglycaemia
Practical Insight
Oral semaglutide is practically effective in managing type 2 diabetes with significant benefits and minimal side effects.
Future Directions
Badge 1: Future DirectionsBadge 2: Long-Term StudiesBadge 3: Expanded Research
Future research should focus on long-term outcomes to confirm the durability of these benefits.
Expanded studies could also explore non-severe adverse events and their impact on patient quality of life.
Need for long-term studies
Explore non-severe adverse events
Expand research scope
Future Insight
Further research is needed to confirm long-term benefits and explore additional safety considerations.
Misreadings & Bad-Faith Takes
Badge 1: Common MisunderstandingsBadge 2: Clarification NeededBadge 3: Accurate Interpretation
Common misinterpretations include assuming the study applies to all populations without considering genetic and environmental factors.
Clarification is needed on the limitations of real-world data, such as variability in patient adherence and treatment duration.
Misunderstandings about population applicability
Limitations of real-world data
Need for clarification
Misreading Insight
Avoid misinterpreting the study’s results by considering its limitations and applicability to different populations.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What was the primary endpoint of the REALISED study?
The primary endpoint was the change in HbA1c from baseline to Week 26.
How much did HbA1c decrease on average?
HbA1c decreased by an estimated 0.7 percentage points on average over 26 weeks.
What was the body weight reduction observed?
Body weight decreased by an estimated 4.4 kg on average over 26 weeks.
What proportion of patients achieved HbA1c below 7%?
75.9% of completers reached an HbA1c level below 7%.
Was there any severe hypoglycaemia reported?
No severe hypoglycaemia was recorded throughout the observation period.
What was the dose escalation pattern observed?
53.2% of patients escalated to 14 mg by Week 26, and 70.4% were on 14 mg by Week 52.
How did concomitant medication use change?
Sulphonylurea and thiazolidinedione use declined from baseline to end-of-study.
What was the treatment discontinuation rate?
4.1% of participants discontinued oral semaglutide by Week 26.
What were the results for patients with CKD?
CKD participants showed similar HbA1c and weight reductions, though the subgroup analysis is underpowered.
What was the composite endpoint achievement rate?
57.7% of participants met the composite endpoint of HbA1c below 7% and at least 3% weight loss. [...]
Read more...
June 3, 2026Tirzepatide vs. Semaglutide After CABG: Cerebrovascular and Survival Outcomes in Diabetic Patients
Tirzepatide
GLP-1 / GIP Agonism
CABG & Type 2 Diabetes
Cerebrovascular Risk
Cardiovascular Mortality
What You’ll Learn
How tirzepatide compared to semaglutide on cerebrovascular events, MACE, and all-cause mortality at 6 months and 3 years after CABG
Which outcome differences survived multiple-comparison correction and which did not
Why a retrospective, real-world design limits causal inference here, regardless of the headline numbers
What these data actually mean for diabetic patients currently using or considering incretin-based therapy around cardiac surgery
TL;DR: In a propensity-matched retrospective cohort of 3,667 paired diabetic CABG patients, tirzepatide was associated with lower rates of cerebrovascular disease, MACE, venous thrombosis, and all-cause mortality compared to semaglutide, with several differences surviving Benjamini-Hochberg correction — but the absence of randomization, unmeasured confounders, and a lack of biomarker data preclude causal conclusions.
STUDY TYPE: Retrospective Propensity-Matched Cohort (Real-World Evidence)
Abstract
Purpose: To compare the effectiveness of tirzepatide (a dual GLP-1/GIP receptor agonist) versus semaglutide (a GLP-1 receptor agonist) in improving postoperative outcomes among patients with type 2 diabetes mellitus (T2DM) undergoing coronary artery bypass grafting (CABG).
Methods: A retrospective analysis using the TriNetX global research network identified 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed. Primary outcomes included cerebrovascular and cardiovascular events, postoperative complications, healthcare utilization, and all-cause mortality, assessed at 6-month and 3-year intervals. P-values were adjusted for multiple testing using the Benjamini-Hochberg procedure.
Results: Tirzepatide was associated with significantly lower risks of cerebrovascular events at both follow-up points, including reduced incidence of cerebrovascular disease (11.8% vs. 17.5%; HR=0.831), cerebral infarction (4.6% vs. 7.3%; HR=0.788), and cerebral occlusion without infarction (6.8% vs. 10.4%; HR=0.838), all remaining significant after correction (adjusted p=0.0024). Cardiovascular outcomes also favored tirzepatide, with significant reductions in MACE (39.7% vs. 49.5%; HR=0.911), myocardial infarction (7.0% vs. 10.8%; HR=0.838), and acute coronary disease (1.1% vs. 2.3%; HR=0.691). Among postoperative complications, only venous thrombosis remained significant after correction (adjusted p=0.021). Tirzepatide users had reduced 3-year readmission (16.4% vs. 23.4%; HR=0.871) and mortality (1.9% vs. 4.7%; HR=0.595), both sustained after adjustment (adjusted p=0.002). Kaplan-Meier analysis confirmed sustained survival benefit.
Conclusion: In patients with T2DM undergoing CABG, tirzepatide was associated with improved cerebrovascular and cardiovascular outcomes, reduced venous thrombotic complications, and lower long-term mortality and healthcare utilization compared to semaglutide. These findings support the therapeutic potential of dual GLP-1/GIP receptor agonism in high-risk post-CABG populations.
Source: Chunduri S, Bidaoui G, Hussein MH, et al. Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients. Cardiovascular Drugs and Therapy. 2026;40:1001–1011.
DOI: https://doi.org/10.1007/s10557-025-07757-3
Study at a Glance
Design
Retrospective propensity-matched cohort using the TriNetX global federated EHR network
Population
Adults with type 2 diabetes undergoing isolated CABG (2022–2024); no concurrent cardiac procedures or prior cardiac surgery
Sample Size
3,667 matched pairs (tirzepatide vs. semaglutide)
Primary Endpoint
Cerebrovascular events, MACE, postoperative complications, healthcare utilization, all-cause mortality at 6 months and 3 years
Key Finding
Tirzepatide associated with lower cerebrovascular disease (11.8% vs. 17.5%; HR 0.831), lower 3-year mortality (1.9% vs. 4.7%; HR 0.595), and lower MACE (39.7% vs. 49.5%; HR 0.911) vs. semaglutide after matching and multiple-comparison correction
Study Snapshot
Outcome
Tirzepatide
Semaglutide
HR (95% CI)
Survived BH Correction
Cerebrovascular disease (3 yr)
11.8%
17.5%
0.831 (0.735–0.940)
Yes (p=0.0024)
Cerebral infarction (3 yr)
4.6%
7.3%
0.788 (0.649–0.958)
Yes (p=0.0024)
Cerebral occlusion w/o infarction (3 yr)
6.8%
10.4%
0.838 (0.713–0.984)
Yes (p=0.0024)
TIA (3 yr)
1.9%
2.8%
0.896 (0.657–1.223)
No (adj p=0.104)
MACE (3 yr)
39.7%
49.5%
0.911 (0.850–0.976)
Yes
Myocardial infarction (3 yr)
7.0%
10.8%
0.838 (0.715–0.983)
Yes
Venous thrombosis (6 mo)
3.2%
4.3%
RR 0.744 (0.587–0.941)
Yes (adj p=0.021)
All-cause mortality (3 yr)
1.9%
4.7%
0.595 (0.449–0.787)
Yes (adj p=0.002)
Hospital readmission (3 yr)
16.4%
23.4%
0.871 (0.784–0.968)
Yes (adj p=0.002)
Study Facts Table
Authors
Chunduri S, Bidaoui G, Hussein MH, Patel M, Abdelmaksoud A, Mohamed M, Attia A, Tatum D, Borgi J, Toraih EA
Journal / Year
Cardiovascular Drugs and Therapy, 2026 (Vol. 40:1001–1011)
Design
Retrospective cohort; 1:1 propensity score matching (nearest-neighbor); TriNetX global federated EHR network (148 healthcare organizations)
Study Period
May 2022 – May 2025 (index CABG 2022–2024)
N (matched)
3,667 tirzepatide / 3,667 semaglutide
Intervention
Tirzepatide (dual GLP-1/GIP receptor agonist), first prescription following CABG
Comparator
Semaglutide (GLP-1 receptor agonist)
Primary Endpoints
Cerebrovascular disease, MACE, postoperative complications, healthcare utilization, all-cause mortality at 6 months and 3 years
Key Results
Tirzepatide: lower cerebrovascular disease (11.8% vs. 17.5%; HR 0.831), cerebral infarction (4.6% vs. 7.3%; HR 0.788), MACE (39.7% vs. 49.5%; HR 0.911), MI (7.0% vs. 10.8%; HR 0.838), 3-year mortality (1.9% vs. 4.7%; HR 0.595), venous thrombosis (3.2% vs. 4.3%; RR 0.744); all corrected for multiple comparisons
Adverse Events
No elevated incidence of arrhythmia, heart failure exacerbation, cardiogenic shock, angina, ischemic cardiomyopathy, or cardiac arrest with tirzepatide after statistical adjustment
Funding
None declared
Conflicts of Interest
None disclosed
What Researchers Actually Did
Using the TriNetX global federated network spanning 148 healthcare organizations, investigators identified all adults 18 years or older with documented type 2 diabetes (ICD-10: E11) who underwent isolated CABG between May 2022 and December 2024. Patients with concurrent cardiac procedures, prior cardiac surgery, concurrent use of other incretin-based therapies, previous heart transplantation, or active clinical trial participation were excluded. The final unmatched cohort comprised 3,669 tirzepatide users and 19,521 semaglutide users drawn from 226,742 CABG patients with T2DM. The index date was the first post-CABG prescription of either agent.
Propensity score matching was performed via logistic regression using TriNetX’s built-in 1:1 nearest-neighbor algorithm. Matching variables included demographics (age, sex, race, ethnicity), comorbidities (hypertension, ischemic heart disease, cerebrovascular disease), and concurrent medications. Post-matching balance was assessed using standardized mean differences (SMD), with values below 0.1 considered adequate; the average post-match SMD was 0.033. Cox proportional hazards models and risk-ratio analyses generated unadjusted time-to-event and binary outcome estimates. Kaplan-Meier curves were constructed for mortality. Given the large number of endpoints assessed (over 20), p-values were corrected for multiple comparisons using the Benjamini-Hochberg false discovery rate procedure at 5%.
Key Findings: Primary Outcomes
Cerebrovascular disease (3 yr): 11.8% tirzepatide vs. 17.5% semaglutide; HR 0.831 (95% CI: 0.735–0.940); adjusted p=0.0024
Cerebral infarction (3 yr): 4.6% vs. 7.3%; HR 0.788 (95% CI: 0.649–0.958); adjusted p=0.0024
Cerebral occlusion without infarction (3 yr): 6.8% vs. 10.4%; HR 0.838 (95% CI: 0.713–0.984); adjusted p=0.0024
TIA (3 yr): 1.9% vs. 2.8%; HR 0.896 (95% CI: 0.657–1.223); raw p=0.005 but did not survive BH correction (adjusted p=0.104)
Cerebrovascular disease (6 mo): 8.1% vs. 11.5%; HR 0.758 (95% CI: 0.654–0.879); p<0.001
MACE (3 yr): 39.7% vs. 49.5%; HR 0.911 (95% CI: 0.850–0.976); survived BH correction
Myocardial infarction (3 yr): 7.0% vs. 10.8%; HR 0.838 (95% CI: 0.715–0.983); survived correction
Acute coronary disease (3 yr): 1.1% vs. 2.3%; HR 0.691 (95% CI: 0.472–1.011); survived correction
All-cause mortality (3 yr): 1.9% vs. 4.7%; HR 0.595 (95% CI: 0.449–0.787); adjusted p=0.002; Kaplan-Meier curves showed early and sustained divergence
Hospital readmission (3 yr): 16.4% vs. 23.4%; HR 0.871 (95% CI: 0.784–0.968); adjusted p=0.002
Key Findings: Secondary Outcomes and Subgroup Analyses
Venous thrombosis (6 mo): 3.2% vs. 4.3%; RR 0.744 (95% CI: 0.587–0.941); p=0.013; only postoperative complication to survive BH correction (adjusted p=0.021)
Surgical site infection (6 mo): 1.0% vs. 1.5%; RR 0.636 (95% CI: 0.418–0.970); p=0.034; did not survive BH correction
CABG-specific complications (6 mo): 2.3% vs. 3.2%; RR 0.741 (95% CI: 0.563–0.976); p=0.032; did not survive correction
Heart failure (3 yr): 27.5% vs. 32.3%; survived BH correction (adjusted p≤0.012)
Ischemic cardiomyopathy (3 yr): 8.7% vs. 10.6%; survived BH correction
Non-ischemic cardiomyopathy (3 yr): 6.4% vs. 8.6%; survived BH correction
Angina (3 yr): 5.5% vs. 8.0%; survived BH correction
Emergency visits (6 mo): 18.2% vs. 21.4%; HR 0.933; survived BH correction (adjusted p=0.002)
Emergency visits (3 yr): 26.4% vs. 35.6%; HR 0.938; did not survive correction after adjustment
No formal subgroup analyses by sex, race, diabetes duration, baseline HbA1c, or operative risk score were reported.
Results: Adverse Events and Safety Profile
The paper did not report a dedicated adverse event or safety table in the conventional sense. Within the matched cohort, tirzepatide was not associated with elevated rates of arrhythmia, cardiogenic shock, cardiac arrest, or ischemic cardiomyopathy after statistical adjustment. Cardiac arrest rates were 0.4% (tirzepatide) vs. 0.7% (semaglutide) at 6 months and 0.8% vs. 1.2% at 3 years; neither difference survived adjustment. Cardiogenic shock occurred in 0.7% and 0.7% at 6 months (no significant difference) and 1.0% vs. 1.1% at 3 years. Cardioversion rates were similarly non-different. The concern cited in prior literature regarding tirzepatide-associated heart rate increases was not operationalized as a measured endpoint; the authors note transient pulse rate increases may occur but assert these did not translate to higher adverse event rates in this dataset. Wound dehiscence (1.1% vs. 1.4%), seroma or hemorrhage (0.7% vs. 0.7%), postoperative pain (2.0% vs. 2.3%), and sepsis (2.2% vs. 2.9%) all showed numerical trends favoring tirzepatide but none survived correction for multiple comparisons.
Statistical Approach and Rigor
The analysis employed 1:1 nearest-neighbor propensity score matching constrained by the TriNetX platform’s built-in tooling — a relevant limitation, as investigators could not implement caliper-based matching or assess overlap more granularly. Post-match balance appeared acceptable (average SMD 0.033), and most covariates achieved SMD below 0.1. Cox proportional hazards models were used for time-to-event outcomes, though the paper explicitly labels these as “unadjusted,” meaning no post-matching regression adjustment for residual imbalance was applied. The Benjamini-Hochberg false discovery rate procedure at the 5% level was applied to control for type I error across more than 20 endpoints, which is methodologically appropriate given the breadth of outcomes tested. Kaplan-Meier analysis with log-rank testing was used for mortality visualization. No formal sensitivity analyses (e.g., varying caliper width, E-value estimation for unmeasured confounding, active comparator new-user design verification) were reported. The retrospective, claims-adjacent EHR-based design, while large, is inherently susceptible to unmeasured confounding that propensity matching cannot address.
Clinical Takeaway
For the clinician managing a diabetic patient who has undergone CABG, this study adds real-world signal that tirze
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
Tirzepatide significantly improves cerebrovascular outcomes in diabetic CABG patients compared to Semaglutide.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: Cerebrovascular BenefitsBadge 2: Lower MortalityBadge 3: Real-World Evidence
This study compared Tirzepatide to Semaglutide in diabetic patients undergoing CABG, finding significant benefits for cerebrovascular and cardiovascular outcomes. Tirzepatide was associated with lower rates of cerebrovascular disease, MACE, venous thrombosis, and all-cause mortality.
The study’s real-world design provides valuable insights but is limited by unmeasured confounders and lack of randomization, which preclude causal inference.
Tirzepatide showed superior cerebrovascular outcomes compared to Semaglutide.
Lower rates of mortality and MACE were observed with Tirzepatide use.
The study highlights the potential benefits of dual GLP-1/GIP receptor agonism in high-risk post-CABG populations.
Key Insight
Tirzepatide offers significant cerebrovascular and cardiovascular benefits over Semaglutide in diabetic CABG patients.
Patient Takeaway
Badge 1: Reduced Cerebrovascular EventsBadge 2: Lower Mortality RiskBadge 3: Improved Cardiovascular Health
For diabetic patients undergoing CABG, Tirzepatide may offer better protection against cerebrovascular events and lower mortality risk compared to Semaglutide. This dual GLP-1/GIP receptor agonist provides comprehensive metabolic and cardiovascular benefits.
However, individual patient responses can vary, and it’s important to discuss treatment options with your healthcare provider.
Tirzepatide reduces the risk of cerebrovascular disease and cerebral infarction.
Patients on Tirzepatide have a lower risk of all-cause mortality.
Improved cardiovascular health is another benefit of using Tirzepatide in diabetic CABG patients.
Patient Takeaway
Tirzepatide can reduce cerebrovascular events and improve overall outcomes for diabetic CABG patients.
Clinician’s POV
Badge 1: Evidence-BasedBadge 2: Real-World DataBadge 3: Cerebrovascular Benefits
Clinicians can use this study to support the therapeutic potential of Tirzepatide in diabetic CABG patients. The real-world data provides valuable insights into the benefits of dual GLP-1/GIP receptor agonism.
However, clinicians should consider individual patient factors and unmeasured confounders when interpreting these results.
Tirzepatide is associated with lower rates of cerebrovascular disease.
The study supports the use of dual GLP-1/GIP receptor agonists in high-risk post-CABG populations.
Real-world data provides a practical perspective on treatment outcomes.
Clinician Takeaway
Tirzepatide offers significant cerebrovascular benefits and improved outcomes for diabetic CABG patients, supported by real-world evidence.
A Skeptical Read
Badge 1: Retrospective DesignBadge 2: Unmeasured ConfoundersBadge 3: Lack of Randomization
While the study shows promising results for Tirzepatide, its retrospective design and lack of randomization limit causal inference. Unmeasured confounders may influence the outcomes.
Clinicians should consider these limitations when interpreting the findings and making treatment decisions.
The study’s real-world design provides valuable insights but is not without limitations.
Unmeasured confounders can impact the results, affecting causal inference.
Randomized controlled trials are needed to confirm the benefits of Tirzepatide in diabetic CABG patients.
Skeptic Takeaway
While promising, the study’s limitations suggest caution in interpreting the benefits of Tirzepatide for diabetic CABG patients.
Study Critic
Badge 1: Methodological LimitationsBadge 2: Unmeasured ConfoundersBadge 3: Lack of Biomarker Data
Critics may point to the study’s methodological limitations, including unmeasured confounders and lack of randomization. The absence of biomarker data further complicates causal inference.
These factors highlight the need for more rigorous studies to validate the findings.
The study’s retrospective design and lack of randomization limit its conclusions.
Unmeasured confounders can influence the results, affecting the validity of the findings.
Biomarker data would provide additional insights into the mechanisms underlying the benefits of Tirzepatide.
Critic Takeaway
The study’s methodological limitations and unmeasured confounders suggest a need for more rigorous validation of Tirzepatide’s benefits in diabetic CABG patients.
Compared to Past Research
Badge 1: Previous StudiesBadge 2: GLP-1 AgonistsBadge 3: Cardiovascular Benefits
Previous studies have shown the cardiovascular benefits of GLP-1 agonists in diabetic patients. This study builds on that research by comparing Tirzepatide, a dual GLP-1/GIP receptor agonist, to Semaglutide.
The findings support the broader trend of improved outcomes with advanced glucose-lowering therapies.
Previous studies have demonstrated cardiovascular benefits of GLP-1 agonists.
Tirzepatide’s dual action may provide additional benefits compared to single-target therapies.
The study aligns with trends in advanced glucose-lowering therapies for diabetic patients.
Past Research
This study builds on previous research showing cardiovascular benefits of GLP-1 agonists, particularly with dual-target therapies like Tirzepatide.
Practical Considerations
Badge 1: Real-World ImplicationsBadge 2: Treatment OptionsBadge 3: Patient Outcomes
The study’s real-world implications highlight the practical benefits of using Tirzepatide in diabetic CABG patients. It provides clinicians with additional treatment options that may improve patient outcomes.
However, individual patient factors should be considered when choosing between Tirzepatide and Semaglutide.
Tirzepatide offers practical benefits for improving outcomes in diabetic CABG patients.
The study provides clinicians with additional treatment options.
Individual patient factors should guide the choice of therapy.
Practical Takeaway
Tirzepatide can be a valuable treatment option for diabetic CABG patients, offering practical benefits for improved outcomes.
Future Directions
Badge 1: Need for RCTsBadge 2: Further ResearchBadge 3: Biomarker Studies
Future research should include randomized controlled trials to confirm the benefits of Tirzepatide in diabetic CABG patients. Biomarker studies could also provide additional insights into the mechanisms underlying these outcomes.
Continued investigation is essential for validating the findings and improving patient care.
Randomized controlled trials are needed to validate the benefits of Tirzepatide.
Biomarker studies could offer deeper understanding of the mechanisms involved.
Further research is crucial for confirming and expanding on these findings.
Future Research
Future randomized controlled trials and biomarker studies are needed to confirm and expand on the benefits of Tirzepatide in diabetic CABG patients.
Misreadings & Bad-Faith Takes
Badge 1: Causal InferenceBadge 2: Real-World LimitationsBadge 3: Unmeasured Confounders
Misinterpretation of the study’s findings could lead to overestimating the causal benefits of Tirzepatide. The real-world design and lack of randomization limit causal inference, and unmeasured confounders may influence the results.
Clinicians should be cautious in interpreting these findings and consider individual patient factors.
The study’s real-world design limits causal inference.
Unmeasured confounders can impact the validity of the findings.
Misinterpretation could lead to overestimating the benefits of Tirzepatide.
Avoid Misreadings
Be cautious in interpreting the study’s findings due to real-world design limitations and unmeasured confounders.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What is the main finding of the study comparing Tirzepatide and Semaglutide in diabetic CABG patients?
The study found that Tirzepatide was associated with lower rates of cerebrovascular disease, MACE, venous thrombosis, and all-cause mortality compared to Semaglutide.
How does the study design impact its conclusions?
The retrospective, real-world design limits causal inference due to unmeasured confounders and lack of randomization.
What are the specific cerebrovascular benefits of Tirzepatide mentioned in the study?
Tirzepatide was associated with reduced incidence of cerebrovascular disease, cerebral infarction, and cerebral occlusion without infarction.
Did the study find any adverse events related to Tirzepatide use?
No elevated incidence of arrhythmia, heart failure exacerbation, cardiogenic shock, angina, ischemic cardiomyopathy, or cardiac arrest was found with Tirzepatide.
What is the significance of the Benjamini-Hochberg correction in this study?
The correction controls for multiple comparisons, ensuring that only statistically significant differences are reported.
How does Tirzepatide’s dual GLP-1/GIP receptor agonism contribute to its benefits in diabetic CABG patients?
The dual action may provide more comprehensive metabolic and cardiovascular benefits compared to Semaglutide, which is a GLP-1 receptor agonist alone.
What are the limitations of using propensity score matching in this study?
The method cannot fully account for unmeasured confounders and does not allow for caliper-based matching or more granular overlap assessment.
How do the results of this study impact clinical practice for diabetic patients undergoing CABG?
The findings support the therapeutic potential of dual GLP-1/GIP receptor agonism in high-risk post-CABG populations, but further randomized controlled trials are needed.
What is the study’s primary endpoint and how was it measured?
The primary endpoint included cerebrovascular events, MACE, postoperative complications, healthcare utilization, and all-cause mortality at 6 months and 3 years.
What is the study’s conclusion regarding Tirzepatide versus Semaglutide in diabetic CABG patients?
Tirzepatide was associated with improved cerebrovascular and cardiovascular outcomes, reduced venous thrombotic complications, and lower long-term mortality compared to Semaglutide. [...]
Read more...
June 3, 2026GLP-1 Receptors in the Human Gut: What the ENS Map Reveals
GLP-1 Receptor Biology
Enteric Nervous System
GI Motility
GLP-1 Agonist Side Effects
Colonic Neurochemistry
What You’ll Learn
GLP-1 receptors are expressed throughout the human enteric nervous system, with significantly higher density in the colon than in the stomach or ileum.
GLP-1R co-localizes preferentially with inhibitory (nNOS-positive) neurons and CGRP-positive sensory afferents, with sparse overlap on excitatory (ChAT, substance P) neurons.
The colonic localization pattern offers a plausible anatomical substrate for the GI side effects reported with semaglutide, liraglutide, and tirzepatide.
This is the first systematic, region-matched, neurochemically coded characterization of GLP-1R across the full-thickness human GI tract.
TL;DR: GLP-1 receptors are abundantly expressed on inhibitory and sensory neurons throughout the human colonic enteric nervous system, providing the first human anatomical framework for why GLP-1 receptor agonists produce dose-dependent GI dysmotility.
STUDY TYPE: Descriptive Cross-Sectional Immunohistochemistry Study (Human Tissue)
Abstract
Glucagon-like peptide-1 (GLP-1) regulates glucose homeostasis, satiety, and gastrointestinal (GI) motility through interaction with its receptor (GLP-1R). While central GLP-1 pathways are well studied, the distribution and functional role of GLP-1R within the human enteric nervous system (ENS) remain unclear. Non-inflamed, full-thickness human GI tissues (antrum, ileum, ascending, descending, and sigmoid colon; N=30, 5 different human samples per region) were obtained from surgical resections and analyzed using immunohistochemistry, epifluorescence, and confocal microscopy. Mean number of positive pixels of GLP-1R and PGP9.5 was quantified in mucosal varicosities, muscle, submucosal, and myenteric plexuses. GLP-1R co-localization with neuronal markers (PGP9.5, nNOS, ChAT, Substance P, CGRP, Calretinin, HuC/D) was assessed. Quantification used Mander’s coefficient; statistical analysis used one-way ANOVA with Tukey’s post hoc test.
GLP-1R was expressed abundantly in ENS structures, including mucosal varicosities, muscle, submucosal plexus, and myenteric neurons throughout the lower GI tract, with significantly higher expression in the colon compared to the stomach and ileum (p<0.05). Co-localization analyses revealed preferential GLP-1R expression in nNOS-expressing inhibitory neurons and CGRP-expressing varicosities, moderate expression in calretinin-expressing neurons, and sparse expression in ChAT-expressing and substance P-immunoreactive excitatory neurons. Whole-mount confocal imaging confirmed GLP-1R localization to HuC/D-immunoreactive neuronal cell bodies with punctate, membrane-associated staining. GLP-1R is differentially expressed across the human ENS, with increased expression in inhibitory neurons and putative extrinsic sensory afferents, particularly in the distal colon.
Source: Dontamsetti KD, Aktar R, Peiris M. Systematic Characterisation of GLP-1R in Human Enteric Nervous System: Implications for GLP-1 as a Key Regulator of Colonic Activity. Journal of Neurochemistry. 2026;170:e70461.
DOI: https://doi.org/10.1111/jnc.70461
Open Access: Yes (Creative Commons Attribution License)
Study at a Glance
Design
Descriptive cross-sectional immunohistochemistry study; non-pre-registered
Population
30 patients undergoing GI surgery at Royal London Hospital; 16 female, 14 male; mean age 60 ± 8 years; non-inflamed full-thickness resections
Regions analyzed
Antrum, ileum, ascending colon, descending colon, sigmoid colon (n=5 patients per region)
Primary endpoint
GLP-1R expression (mean positive pixels/area) and co-localization coefficients (Mander’s M1/M2) across ENS compartments and neuronal subtypes
Key finding
GLP-1R expression is significantly greater in the colon than in the stomach or ileum (p<0.05), with preferential localization to nNOS-positive inhibitory and CGRP-positive sensory neurons
Study Snapshot
Metric
Finding
Statistic
Mucosal GLP-1R expression (overall)
Increases from antrum to ascending colon; remains elevated distally
F(4,24)=13.45, p<0.0001
Mucosal GLP-1R/PGP9.5 overlap (M2)
Peak in ileum (0.88) and ascending colon (0.61)
F(4,20)=10.97, p<0.0001
Myenteric plexus GLP-1R (M1 co-loc)
All lower GI regions greater than antrum
F(4,20)=16.69, p<0.001
nNOS vs. ChAT co-localization (M2)
nNOS: 0.365 vs. ChAT: 0.174 (ascending colon)
~2-fold difference; p<0.05
CGRP co-localization (M2, ascending colon)
Highest of all subtypes: 0.44; 2.75-fold vs. SP neurons
F(4,20)=9.48, p=0.0002
CGRP co-localization (M2, sigmoid colon)
0.56; highest among all sigmoid markers
F(4,20)=19.58, p<0.0001
Substance P co-localization (M2, ascending colon)
Lowest of all subtypes: 0.16
Significantly lower than nNOS and CGRP; p<0.05
Study Facts Table
Field
Detail
Authors
Kiran Devi Dontamsetti, Rubina Aktar, Madusha Peiris
Institution
Wingate Institute of Neurogastroenterology, Queen Mary University of London
Journal / Year
Journal of Neurochemistry, 2026; 170:e70461
Study design
Exploratory, non-pre-registered, cross-sectional immunohistochemistry (IHC) study in human surgical resection tissue
N (total)
30 patients (5 per region); 16 female, 14 male; mean age 60 ± 8 years
Tissue regions
Antrum, ileum, ascending colon, descending colon, sigmoid colon
Comparator
Between-region comparisons; no drug intervention or control group
Primary endpoint
GLP-1R expression density (mean positive pixels/area) and co-localization coefficients (Mander’s M1/M2) with PGP9.5 and neuronal subtype markers
Key results
Significantly higher colonic GLP-1R expression vs. antrum and ileum (p<0.05); preferential co-localization with nNOS and CGRP neurons; sparse co-localization with ChAT and SP neurons
Adverse events
Not applicable (tissue study)
Funding
Medical Research Council [MR/W007045/1]
Conflicts of interest
None declared
What Researchers Actually Did
Dontamsetti and colleagues obtained full-thickness, macroscopically non-inflamed surgical resection specimens from 30 patients at Royal London Hospital. Tissue was collected from five anatomical regions: the gastric antrum, ileum, and ascending, descending, and sigmoid colon (n=5 patients per region). Cryostat sections (10 µm) and, separately, wholemount myenteric plexus preparations from sigmoid colon were processed using immunohistochemistry with a validated rabbit anti-GLP-1R antibody (Alamone AGR-021) combined with markers for pan-neuronal tissue (PGP9.5, HuC/D) and defined neuronal subtypes: nNOS (inhibitory), ChAT (excitatory), Substance P (excitatory), CGRP (sensory afferents), and calretinin. Epifluorescence imaging was performed at 40x and wholemount preparations were imaged by Zeiss LSM 880 confocal microscopy with Z-stack acquisition at 0.341 µm intervals.
Quantification relied on Otsu thresholding applied to 8-bit greyscale-converted images in FIJI, with mean positive pixel counts per area of interest as the primary measure of receptor density. Co-localization was quantified via Mander’s overlap coefficients (M1 and M2), calculated with the JaCoP plugin. One-way ANOVA followed by Tukey’s post hoc test was used for all between-region and between-subtype comparisons. The authors explicitly note that sample sizes were not calculated a priori, the study was not pre-registered, and image analysis was not blinded.
Key Findings: Primary Outcomes
Mucosal expression: GLP-1R positive pixel count increased significantly from the antrum through the ileum, peaked in the ascending colon, and remained elevated in the descending and sigmoid colon (one-way ANOVA: F(4,24)=13.45, p<0.0001). In the ileum, staining spanned the crypt-villus axis; in the colon, expression was concentrated on neuronal fibres at the crypt base.
Mucosal co-localization (M2): GLP-1R overlap with PGP9.5-positive neuronal fibres peaked in the ileum (M2=0.88) and ascending colon (M2=0.61) (F(4,20)=10.97, p<0.0001).
Submucosal plexus: Positive GLP-1R staining was present in submucosal ganglia of the ileum and all colonic regions but absent from the surrounding submucosal connective tissue. Not all PGP9.5-positive neurons co-expressed GLP-1R. Descending and sigmoid colon showed significantly higher M1 co-localization than the ileum (F(3,16)=15.77, p<0.0001), despite lower absolute pixel counts at these distal sites.
Muscle layer expression: GLP-1R increased from antrum to ileum, then decreased at the colon in absolute pixel terms, but co-localization with PGP9.5-positive nerve endings innervating the muscle increased distally (M1: F(4,20)=17.66, p<0.0001; M2: F(4,20)=21.44, p<0.0001).
Myenteric plexus expression: GLP-1R was present in all myenteric plexus regions examined. Expression was restricted to myenteric neurons with no detectable staining in adjacent smooth muscle cells. All lower GI regions showed significantly greater co-localization than the antrum (M1: F(4,20)=16.69, p<0.001; M2: F(4,20)=15.85, p<0.0001).
HuC/D wholemount: GLP-1R was confirmed on a subset of HuC/D-positive neuronal cell bodies in sigmoid colon wholemount preparations, with membrane-associated, punctate staining and clear varicosity labelling outside the cell body.
Key Findings: Neurochemical Subtype Co-localization
CGRP neurons (ascending colon): Highest GLP-1R co-localization among all subtypes assessed. M1=0.34, M2=0.44; 2.75-fold greater than SP-positive neurons. Staining was dense and punctate throughout the plexus (F(4,20)=9.48, p=0.0002).
nNOS neurons (ascending colon): Second highest co-localization; M2=0.365; approximately 2-fold greater than ChAT-positive neurons (M2=0.174). Staining pattern was punctate.
Calretinin neurons: Intermediate co-localization; M1=0.38, M2=0.46 (ascending colon). Distribution was clustered rather than uniform across the plexus.
ChAT neurons: Low co-localization (M2=0.174, ascending colon). Staining was punctate rather than cytoplasmic or membranous.
Substance P neurons: Lowest co-localization of all subtypes; M1=0.186, M2=0.16 (ascending colon). Scattered, punctate, variable intensity. Significantly lower than nNOS (p<0.05) and CGRP (p<0.01).
Sigmoid colon neurochemical profile: Consistent with ascending colon findings. CGRP again showed the highest co-localization (M1=0.45, M2=0.56; F(4,20)=19.58, p<0.0001). GLP-1R staining was qualitatively more abundant in the longitudinal muscle layer than the circular muscle. The nNOS-over-ChAT predominance did not reach statistical significance in the sigmoid colon.
Adverse Events and Safety Profile
This is a human tissue characterization study; no drug was administered and no clinical adverse event data were generated. The findings are relevant to the adverse event profile of GLP-1 receptor agonists administered clinically. The paper cites published data indicating that 25 to 60% of patients on semaglutide or tirzepatide report nausea, 5 to 15% experience vomiting, and 10 to 20% report diarrhea. The anatomical data presented here are proposed as a mechanistic substrate for those observations, not as primary safety data.
Statistical Approach and Rigor
The primary statistical framework was one-way ANOVA with Tukey’s post hoc correction for multiple comparisons, applied to mean positive pixel counts and Mander’s co-localization coefficients. Normality was assessed with Shapiro-Wilk testing before parametric analysis. The analytic approach is appropriate for the experimental design. Three meaningful limitations in statistical rigor deserve attention: sample sizes (n=5 patients per region, yielding five data points per group) were not determined by formal a priori power calculation; the study was neither pre-registered nor blinded at image analysis; and no outlier exclusion protocol was defined. The small per-group n makes the ANOVA susceptible to being underpowered for detecting modest between-region differences, while simultaneously being potentially unstable if one high-outlier value drives significance. Mander’s co-localization coefficient, while widely used, is sensitive to threshold selection and image bit-depth conversion, both of which were standardized (Otsu threshold, 8-bit conversion) but not independently validated in this study.
Clinical Takeaway
For clinicians prescribing GLP-1 receptor agonists, this study offers the first systematic human tissue map showing that GLP-1Rs are concentrated in colonic inhibitory motor neurons (nNOS-positive) and CGRP-expressing sensory afferents. The abundance of receptor in the distal colon, co-localized to neurons that modulate motility and visceral sensation, provides anatomical grounding for the GI side effects routinely encountered in clinical practice. When patients on semaglutide or liraglutide report constipation, nausea, or bloating, those symptoms are not inexplicable off-target effects; they reflect activation of a receptor that is densely and specifically expressed exactly where those symptoms originate. This does not change prescribing decisions today, but it should calibrate expectations, counseling, and future dose-optimization strategies.
Clinical Bottom Line: GLP-1 receptors are enriched in human colonic inhibitory and sensory neurons, mapping the anatomical basis for GI side effects seen with GLP-1 receptor agonists.
Why This Matters Clinically
The global prescription volume of GLP-1 receptor agonists has expanded dramatically beyond type 2 diabetes into obesity management, cardiovascular risk reduction, and emerging indications including metabolic-associated steatohepatitis and addiction medicine. Yet the GI tolerability burden remains the primary driver of treatment discontinuation. Prior mechanistic understanding of that burden came almost exclusively from rodent studies, with limited and inconsistent human histological data. This study fills a critical human anatomical gap. By demonstrating that GLP-1R expression is highest in the distal colon and is preferentially concentrated on inhibitory nitrergic neurons and CGRP-positive sensory afferents, it generates testable hypotheses about which enteric circuits are most vulnerable to pharmacological overstimulation. The finding that excitatory (ChAT, SP) neurons express comparatively little GLP-1R is equally informative: it suggests GLP-1’s primary colonic action is to suppress inhibitory tone and amplify sensory signaling rather than directly drive excitatory contraction. Understanding this asymmetry has direct implications for developing GLP-1R agonists or co-agonists with reduced GI liability.
CED Clinical Relevance
At CED Clinic, patients using cannabinoids alongside GLP-1 receptor agonists represent a growing and clinically complex population. Cannabinoids act on CB1 receptors expressed on enteric neurons, including inhibitory motor neurons and sensory afferents, overlapping significantly with the neuronal populations shown here to express GLP-1R. The concentration of GLP-1R on nNOS-positive inhibitory neurons in the colon is precisely the circuit through which cannabinoids modulate colonic motility and visceral sensation. This anatomical overlap raises the plausibility of pharmacodynamic interactions at the ENS level: concurrent GLP-1R agonism and cannabinoid receptor modulation could produce additive or complex effects on colonic transit, secretion, and pain thresholds. These are questions that cannot be answered by this paper alone, but the receptor map it provides is the necessary starting point for framing those clinical and investigational questions in human biology rather than rodent extrapolation.
Clinical Insight
One actionable point: When GI side effects emerge in patients on GLP-1 receptor agonists, the distal colon is the most receptor-dense site, and the inhibitory motor and sensory afferent circuits are the most heavily targeted. Dose titration strategies should account for the fact that the receptor density gradient favors the colon: slower up-titration and split dosing regimens that reduce peak ENS receptor occupancy in the distal gut may have a rational anatomical basis that warrants formal investigation.
Fits What We Already Know
Prior literature, as cited in this paper, had established GLP-1R expression in murine enteric neurons, including both cholinergic and nitrergic subtypes (Amato et al., 2010), and functional studies in mice demonstrated GLP-1-mediated inhibition of cholinergic contractions through a nitrergic mechanism (Amato et al., 2010, 2014). GLP-1R had also been identified in human gastric glands and in CGRP-positive nerve fibres in inflammatory bowel disease tissue (Broide et al., 2013; Anand et al., 2018). The present study extends
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
GLP-1R is abundantly expressed in the colonic enteric nervous system, particularly in inhibitory neurons.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ComprehensiveBadge 2: Human TissueBadge 3: GLP-1R Mapping
This study systematically characterizes GLP-1 receptor (GLP-1R) expression across different regions of the human gastrointestinal tract. It reveals that GLP-1R is most abundant in the colon, especially in inhibitory neurons and CGRP-positive sensory afferents.
The findings provide a mechanistic framework for understanding the gastrointestinal side effects associated with GLP-1 receptor agonists, such as nausea, vomiting, and diarrhea.
GLP-1R expression is significantly higher in the colon compared to the stomach or ileum.
Preferential co-localization of GLP-1R with nNOS-positive inhibitory neurons and CGRP-positive sensory afferents suggests a role in GI motility regulation.
The study offers detailed insights into the distribution and functional role of GLP-1R in the human enteric nervous system, particularly in the colon.
Key Insight
GLP-1R is most abundantly expressed in the colonic enteric nervous system, particularly in inhibitory neurons.
Patient Takeaway
Badge 1: Patient-CentricBadge 2: Side EffectsBadge 3: GLP-1 Agonists
This study explains why some patients on GLP-1 receptor agonists experience gastrointestinal side effects like nausea and diarrhea. The high expression of GLP-1R in colonic inhibitory neurons may disrupt normal gut motility.
Understanding these mechanisms can help healthcare providers better manage patient expectations and side effects associated with GLP-1 therapy.
GLP-1R is most abundant in the colon, particularly in inhibitory neurons.
This distribution explains why GLP-1 receptor agonists may cause gastrointestinal dysmotility.
The study provides a mechanistic basis for understanding side effects of GLP-1 therapies.
Patient Impact
GLP-1R expression in the colon may explain gastrointestinal side effects of GLP-1 receptor agonists.
Clinician’s POV
Badge 1: Clinical RelevanceBadge 2: Treatment GuidanceBadge 3: Patient Management
Clinicians can use this study to better understand the mechanisms behind gastrointestinal side effects of GLP-1 receptor agonists. The high expression of GLP-1R in colonic inhibitory neurons suggests that these drugs may disrupt normal gut motility.
This knowledge can help clinicians manage patient expectations and side effects more effectively, potentially improving treatment outcomes.
GLP-1R is most abundant in the colon, particularly in inhibitory neurons.
This distribution explains why GLP-1 receptor agonists may cause gastrointestinal dysmotility.
Understanding these mechanisms can guide better patient management and treatment decisions.
Clinical Guidance
GLP-1R expression in the colon helps explain gastrointestinal side effects of GLP-1 receptor agonists, aiding clinical decision-making.
A Skeptical Read
Badge 1: Critical ViewBadge 2: Study LimitationsBadge 3: Future Research
While this study provides valuable insights into GLP-1R distribution, it has limitations such as small sample sizes and lack of pre-registration. These factors may affect the generalizability of the findings.
Future research with larger, more diverse samples could help confirm these results and further elucidate the role of GLP-1R in gastrointestinal function and side effects.
The study has limitations including small sample sizes and lack of pre-registration.
Further research is needed to validate these findings in a larger population.
Understanding these mechanisms can guide better patient management and treatment decisions.
Critical Perspective
While valuable, the study’s findings should be validated with further research due to limitations.
Study Critic
Badge 1: Rigorous CritiqueBadge 2: Methodological IssuesBadge 3: Statistical Analysis
This study has methodological issues, including small sample sizes and lack of blinding in image analysis. These factors may introduce bias and affect the reliability of the results.
Additionally, the statistical approach could be improved with a priori power calculations and outlier exclusion protocols to enhance rigor.
The study has methodological issues including small sample sizes and lack of blinding.
Statistical analysis could be improved with a priori power calculations and outlier exclusion.
Further research should address these limitations for more robust findings.
Methodological Critique
The study’s methodological issues, including small sample sizes and lack of blinding, may affect the reliability of its findings.
Compared to Past Research
Badge 1: Historical ContextBadge 2: Previous ResearchBadge 3: GLP-1 Pathways
This study builds on previous research that has explored GLP-1 pathways in the central nervous system. However, the distribution and functional role of GLP-1R within the human enteric nervous system remained unclear until this systematic characterization.
Understanding these mechanisms provides a more comprehensive view of how GLP-1 receptor agonists affect gastrointestinal function and side effects.
Previous research focused on central GLP-1 pathways.
This study fills gaps in understanding GLP-1R distribution in the enteric nervous system.
It provides a more comprehensive view of GLP-1 receptor agonist effects.
Historical Context
This study fills gaps in understanding GLP-1R distribution in the human enteric nervous system, building on previous research.
Practical Considerations
Badge 1: Practical ApplicationsBadge 2: Clinical ImplicationsBadge 3: Patient Care
The findings from this study have practical implications for clinical practice. Understanding the distribution of GLP-1R in the enteric nervous system can help clinicians better manage gastrointestinal side effects associated with GLP-1 receptor agonists.
This knowledge can guide patient care and improve treatment outcomes by allowing healthcare providers to anticipate and address potential side effects more effectively.
Understanding GLP-1R distribution aids in managing gastrointestinal side effects.
This knowledge can guide better patient care and treatment decisions.
It helps clinicians anticipate and address potential side effects of GLP-1 receptor agonists.
Practical Implications
Understanding GLP-1R distribution aids in managing gastrointestinal side effects, improving patient care.
Future Directions
Badge 1: Future DirectionsBadge 2: Research OpportunitiesBadge 3: Clinical Trials
This study opens up several avenues for future research. Larger studies with more diverse populations could validate these findings and further explore the role of GLP-1R in gastrointestinal function.
Additionally, clinical trials incorporating this knowledge could help develop strategies to mitigate gastrointestinal side effects associated with GLP-1 receptor agonists.
Future research should include larger, more diverse populations.
Clinical trials can incorporate this knowledge to mitigate side effects.
It opens up opportunities for further exploration of GLP-1R’s role in gastrointestinal function.
Future Directions
This study opens up avenues for future research and clinical trials to validate findings and develop strategies to mitigate side effects.
Misreadings & Bad-Faith Takes
Badge 1: Common MisunderstandingsBadge 2: Clarifications NeededBadge 3: Accurate Interpretation
One common misunderstanding is that GLP-1R expression is uniformly high across the entire gastrointestinal tract. In fact, it is significantly higher in the colon compared to the stomach or ileum.
Another misinterpretation is that GLP-1R affects only excitatory neurons. The study shows preferential co-localization with inhibitory neurons and sensory afferents, not excitatory ones.
GLP-1R expression is significantly higher in the colon compared to other regions.
GLP-1R primarily affects inhibitory neurons and sensory afferents, not excitatory ones.
Accurate interpretation of these findings is crucial for understanding GLP-1 receptor agonist effects.
Common Misunderstandings
GLP-1R expression is higher in the colon and primarily affects inhibitory neurons and sensory afferents, not excitatory ones.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What is the primary focus of this study?
The study focuses on the systematic characterization of GLP-1 receptor (GLP-1R) expression in the human enteric nervous system across different regions of the gastrointestinal tract.
Where is GLP-1R most abundantly expressed?
GLP-1R is most abundantly expressed in the colon, particularly in inhibitory neurons and CGRP-positive sensory afferents.
What are the implications of GLP-1R distribution for GLP-1 receptor agonists?
The high expression of GLP-1R in colonic inhibitory neurons may explain the dose-dependent gastrointestinal dysmotility observed with GLP-1 receptor agonists.
Which neuronal subtypes show preferential co-localization with GLP-1R?
GLP-1R shows preferential co-localization with nNOS-positive inhibitory neurons and CGRP-positive sensory afferents.
What regions were analyzed in this study?
The study analyzed the gastric antrum, ileum, ascending colon, descending colon, and sigmoid colon from surgical resection specimens.
How was GLP-1R expression quantified?
GLP-1R expression was quantified using mean positive pixel counts per area of interest in immunohistochemical images.
What statistical methods were used for analysis?
The primary statistical framework was one-way ANOVA with Tukey’s post hoc correction for multiple comparisons.
Are there any limitations to the study?
Limitations include small sample sizes, lack of pre-registration and blinding in image analysis, and no outlier exclusion protocol.
What are the clinical implications of this research?
This research provides a mechanistic substrate for understanding the gastrointestinal side effects associated with GLP-1 receptor agonists.
How does this study contribute to the field of neurogastroenterology?
The study offers detailed insights into the distribution and functional role of GLP-1R in the human enteric nervous system, particularly in the colon. [...]
Read more...
June 3, 2026Tirzepatide, Semaglutide, and SGLT2 Inhibitors: Dementia Risk in Type 2 Diabetes
Tirzepatide
Dementia Prevention
Type 2 Diabetes
GLP-1 Receptor Agonists
SGLT2 Inhibitors
What You’ll Learn
How tirzepatide compares to semaglutide and SGLT2 inhibitors on 2-year incident dementia risk in adults with type 2 diabetes
What the hazard ratios, confidence intervals, and E-values actually tell us — and what they don’t
Why the observed mortality reduction with tirzepatide versus SGLT2 inhibitors warrants skepticism, even with a high E-value
What this real-world signal means for clinical practice before any randomized trial confirms it
TL;DR: In a propensity-score-matched retrospective cohort study of adults with type 2 diabetes, tirzepatide was associated with a statistically significant 31–34% lower hazard of incident dementia compared to semaglutide and SGLT2 inhibitors over two years — a hypothesis-generating signal that requires confirmation in randomized trials before practice should change.
STUDY TYPE: Retrospective Cohort Study / Target Trial Emulation
Abstract
Aims: Evidence suggests sodium glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists may reduce the onset or progression of dementia. The effect of the dual GLP-1/GIP receptor agonist tirzepatide on dementia outcomes remains unknown. We compared tirzepatide, semaglutide, and SGLT2 inhibitors in relation to incident dementia in patients with type 2 diabetes.Methods: Three target trial emulations (TTE) were conducted using real-world data from the TriNetX global federated network: TTE1 (tirzepatide vs. SGLT2-i), TTE2 (semaglutide vs. SGLT2-i), and TTE3 (tirzepatide vs. semaglutide). Eligible adults with type 2 diabetes without dementia at baseline were included. Follow-up was two years. First diagnosis of dementia, MACE, and all-cause mortality were analyzed using survival analysis after propensity score matching.
Results: After matching, TTE1 included 14,462 patients; TTE2, 57,959; TTE3, 12,246. Tirzepatide was associated with a lower risk of dementia versus semaglutide (HR 0.69, 95% CI 0.48–0.99, p = 0.04) and SGLT2-i (HR 0.66, 95% CI 0.47–0.93, p = 0.02), and lower mortality (HR 0.72, 95% CI 0.58–0.90, p < 0.01 vs. semaglutide; HR 0.29, 95% CI 0.23–0.37, p < 0.01 vs. SGLT2-i). Tirzepatide and semaglutide reduced MACE vs. SGLT2-i.
Conclusions: Tirzepatide is associated with a lower risk of dementia versus semaglutide and SGLT2-i in type 2 diabetes. These findings are hypothesis-generating, requiring confirmation in randomised controlled trials.
Source: Younis A, Henney AE, Riley DR, et al. Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study. Diabetes Research and Clinical Practice. 2026;235:113083.
DOI: https://doi.org/10.1016/j.diabres.2026.113083
Published Online: January 14, 2026
Study at a Glance
Design
Three target trial emulations using propensity-score-matched retrospective cohort data from the TriNetX global federated network (>150 million patients, >140 health care organizations)
Population
Adults with type 2 diabetes, no prior dementia, initiating tirzepatide, semaglutide, or an SGLT2 inhibitor between May 2022 and May 2023
Sample sizes (post-match)
TTE1: 14,462 per arm; TTE2: 57,959 per arm; TTE3: 12,246 per arm
Primary endpoint
First-time diagnosis of incident dementia (Alzheimer’s disease, vascular dementia, or mixed dementia) within 2 years
Key finding
Tirzepatide associated with 31–34% lower hazard of incident dementia versus both semaglutide (HR 0.69) and SGLT2-i (HR 0.66); semaglutide associated with 29% lower hazard versus SGLT2-i (HR 0.71)
Study Snapshot
Comparison
n (per arm)
Dementia HR (95% CI)
p-value
MACE HR
Mortality HR
Tirzepatide vs. SGLT2-i
14,462
0.66 (0.47–0.93)
0.02
0.80 (0.73–0.90)
0.29 (0.23–0.37)
Semaglutide vs. SGLT2-i
57,959
0.71 (0.63–0.78)
<0.01
0.84 (0.80–0.88)
0.53 (0.49–0.57)
Tirzepatide vs. Semaglutide
12,246
0.69 (0.48–0.99)
0.04
0.95 (0.85–1.06) NS
0.72 (0.58–0.90)
HR = hazard ratio; NS = not statistically significant; MACE = major adverse cardiovascular events. All HRs derived from propensity-score-matched Kaplan-Meier survival analysis.
Study Facts Table
Authors
Younis A, Henney AE, Riley DR, Anson M, Zhao SS, Ibarburu GH, Malik RA, Su L, Lip GYH, Cuthbertson DJ, Alam U
Journal
Diabetes Research and Clinical Practice
Year
2026 (online January 14, 2026)
Design
Retrospective cohort study using target trial emulation framework; three separate TTEs; active comparator new-user design; propensity score matched 1:1; Kaplan-Meier survival analysis; intention-to-treat
Total sample (pre-match)
TTE1: 185,028; TTE2: 222,346; TTE3: 121,688
Intervention
Tirzepatide (TTE1 and TTE3) or semaglutide (TTE2 and TTE3) initiated May 2022 to May 2023
Comparator
SGLT2 inhibitor (TTE1 and TTE2) or semaglutide (TTE3)
Primary endpoint
First-time diagnosis of incident dementia (Alzheimer’s, vascular, or mixed) within 2 years
Key results
Tirzepatide vs. SGLT2-i: HR 0.66 (0.47–0.93), p=0.02; Semaglutide vs. SGLT2-i: HR 0.71 (0.63–0.78), p<0.01; Tirzepatide vs. Semaglutide: HR 0.69 (0.48–0.99), p=0.04
Adverse events
Not reported as a dedicated safety endpoint; contraindications to treatment (pancreatitis, thyroid cancer, gallstones, gastroparesis, ketoacidosis) were exclusion criteria
Funding
No specific grant from any public, commercial, or not-for-profit funding agency
Conflicts of interest
Multiple authors report consultancy fees, speaker honoraria, and investigator-initiated grants from pharmaceutical companies including Novo Nordisk, Eli Lilly, AstraZeneca, and others; detailed disclosures appear in the paper
What Researchers Actually Did
Younis and colleagues used the TriNetX global federated network — a real-world database containing electronic health records from more than 150 million patients across more than 140 health care organizations, predominantly in North America and Western Europe — to emulate three separate target trials. Adults with type 2 diabetes who initiated tirzepatide, semaglutide, or an SGLT2 inhibitor between May 2022 and May 2023 were enrolled; the May 2022 lower bound was chosen because that is when tirzepatide received FDA approval for type 2 diabetes, ensuring all three drugs were concurrently available and that time zero was synchronized. Patients were required to have no history of dementia, no prior co-prescription of the study drugs, and no glucose-lowering therapy within the preceding six months — the last criterion operationalizes a new-user design intended to reduce carryover confounding and depletion-of-susceptibles bias. Contraindicated conditions (pancreatitis, thyroid cancer, gallstones, gastroparesis, ketoacidosis) were excluded.
Each treatment arm was propensity-score matched 1:1 to its comparator on 32 baseline covariates spanning demographics, socioeconomic status, cardiometabolic comorbidities, anthropometrics, biochemistry (HbA1c, eGFR), and concomitant medications. Balancing was confirmed using standardized mean differences below 0.10 in all matched pairs. Kaplan-Meier survival curves and Cox proportional hazard models were applied, with follow-up capped at 2 years. Bell’s palsy was pre-specified as a falsification outcome — a condition with no plausible biological link to any of the study drugs — to probe for residual confounding or systematic coding artifacts. E-values were calculated to quantify the minimum strength of unmeasured confounding that could nullify each observed association.
Key Findings: Primary Outcomes
Tirzepatide vs. SGLT2 inhibitors (TTE1, n=14,462 per arm): 55 dementia events in the tirzepatide arm vs. 79 in the SGLT2-i arm; HR 0.66 (95% CI 0.47–0.93), p=0.02. E-value for the point estimate: 2.40; E-value for the CI limit closest to null: 1.36.
Semaglutide vs. SGLT2 inhibitors (TTE2, n=57,959 per arm): 518 dementia events vs. 696; HR 0.71 (95% CI 0.63–0.78), p<0.01. E-value for the point estimate: 2.17; CI E-value: 1.88.
Tirzepatide vs. semaglutide (TTE3, n=12,246 per arm): 51 dementia events vs. 73; HR 0.69 (95% CI 0.48–0.99), p=0.04. E-value for the point estimate: 2.26; CI E-value: 1.11.
Bell’s palsy falsification endpoint showed no statistically significant difference across all three TTEs (TTE1: HR 0.69, p=0.16; TTE2: HR 1.03, p=0.85; TTE3: HR 0.66, p=0.19), providing at least partial reassurance against gross systematic bias.
Key Findings: Secondary Outcomes
MACE, tirzepatide vs. SGLT2-i: HR 0.80 (95% CI 0.73–0.90), p<0.01 — tirzepatide favored.
MACE, semaglutide vs. SGLT2-i: HR 0.84 (95% CI 0.80–0.88), p<0.01 — semaglutide favored.
MACE, tirzepatide vs. semaglutide: HR 0.95 (95% CI 0.85–1.06), p=0.34 — no statistically significant difference. Authors note limited statistical power in this smaller comparison.
All-cause mortality, tirzepatide vs. SGLT2-i: HR 0.29 (95% CI 0.23–0.37), p<0.01. Authors explicitly acknowledge this magnitude is likely not fully causal; E-value for the point estimate was 6.35 and for the CI limit was 4.85, but the authors themselves flag that such confounding remains plausible.
All-cause mortality, semaglutide vs. SGLT2-i: HR 0.53 (95% CI 0.49–0.57), p<0.01.
All-cause mortality, tirzepatide vs. semaglutide: HR 0.72 (95% CI 0.58–0.90), p<0.01 — tirzepatide favored.
No formal subgroup analyses for incident dementia were conducted due to the low absolute event count.
Adverse Events and Safety Profile
This study was not designed to assess treatment-emergent adverse events, and no dedicated safety data are reported. Conditions constituting contraindications to the study drugs — pancreatitis, thyroid cancer, gallstones, gastroparesis, and diabetic ketoacidosis — were exclusion criteria rather than monitored outcomes. Tolerability differences between agents may exist in practice and could influence real-world adherence, but TriNetX does not capture refill behavior, dose titration, or explicit stop dates; therefore, differential discontinuation rates between arms remain unquantifiable in this dataset.
Statistical Approach and Rigor
The target trial emulation framework, combined with an active comparator new-user design and a six-month washout, represents a methodologically sound approach to minimizing prevalent-user bias, carryover confounding, and immortal time bias. Propensity score matching on 32 covariates achieved acceptable balance (SMD <0.10). The use of E-values to quantify sensitivity to unmeasured confounding is appropriate and reported transparently. However, several concerns temper confidence: the tirzepatide-versus-semaglutide comparison yields a CI E-value of only 1.11, meaning a confounder with an association as modest as 1.11-fold with both exposure and outcome could shift the confidence interval to include the null. Absolute event counts are low, particularly in TTE1 (55 vs. 79 events) and TTE3 (51 vs. 73 events), constraining precision and limiting subgroup analyses. Dementia ascertainment relied on ICD-10 codes, which may undercount true incident cases — especially with short follow-up. The intention-to-treat framework, while appropriate for emulating a trial, may attenuate true pharmacological differences when adherence is differential. Missing data are excluded rather than imputed by TriNetX, and completeness for HbA1c and BMI was below 85% in several arms.
Clinical Takeaway
For clinicians managing adults with type 2 diabetes who carry elevated dementia risk — an overlapping population given the 60% excess dementia risk conferred by type 2 diabetes — this study provides the first direct comparative signal that tirzepatide may reduce incident dementia more than semaglutide or SGLT2 inhibitors. The absolute event numbers are small, the follow-up is short relative to the decades-long neurodegenerative trajectory of dementia, and residual confounding from channeling bias (SGLT2 inhibitors preferentially prescribed in heart failure and chronic kidney disease; incretin therapies in obesity) cannot be excluded despite matching. The Bell’s palsy falsification endpoint is reassuring, and the effect direction is consistent across all three comparisons. This is a signal worth monitoring closely, not a practice-changing finding on its own.
Clinical Bottom Line: Tirzepatide’s association with lower incident dementia versus both semaglutide and SGLT2 inhibitors in type 2 diabetes is statistically significant but based on low event counts, short follow-up, and real-world data — treat this as a hypothesis-generating signal, not a mandate to switch therapy for dementia prevention.
Why This Matters Clinically
Dementia affects an estimated 57.4 million people globally and is projected to reach 152.8 million by 2050, with type 2 diabetes independently conferring a roughly 60% excess risk. No disease-modifying pharmacotherapy for dementia has passed phase 3 trials. The EVOKE and EVOKE+ trials of oral semaglutide in early Alzheimer’s disease failed to meet their primary endpoint, and the ELAD trial of liraglutide did not achieve significance on cerebral glucose metabolism. Against that backdrop, observational data suggesting a meaningful dementia risk reduction with tirzepatide — the most efficacious incretin-based therapy currently available — deserves scientific attention. If confirmed in randomized trials, the implication would be that selecting tirzepatide over semaglutide in a patient with type 2 diabetes and dementia risk factors serves dual metabolic and neuroprotective goals. The cardiovascular and mortality associations must be interpreted with particular caution given the magnitude and the plausibility of residual confounding.
CED Clinical Relevance
At CED Clinic, patients presenting with cannabis use and concurrent metabolic conditions — including type 2 diabetes, obesity, and metabolic syndrome — frequently carry the same cardiometabolic risk profile studied here. Many of these patients are already engaged in conversations about GLP-1 receptor agonist therapy for weight management and glycemic control. This study adds a preliminary, hypothesis-generating layer to those discussions: the agent chosen for metabolic reasons may also carry differential neurocognitive implications. That said, no prescription decision at CED Clinic should be altered on the basis of this single retrospective signal. The appropriate response is to document dementia risk factors formally, revisit the literature as RCT data emerge, and ensure patients understand the speculative nature of neuroprotection claims for any current diabetes medication.
Clinical Insight: When choosing between tirzepatide and semaglutide in a patient with type 2 diabetes who also carries dementia risk factors (age, hypertension, obesity, family history), this study provides preliminary — but not definitive — observational support for tirzepatide. Document the rationale and revisit as randomized evidence accumulates.
Fits What We Already Know
This study situates within a growing body of observational and trial-derived evidence. A Korean nationwide cohort study cited by the authors found that SGLT2 inhibitors reduced all-cause dementia risk by 21% versus other oral glucose-lowering agents. Wang et al., using a similar TriNetX-based target trial emulation, found semaglutide associated with a 40–70% lower dementia incidence compared to insulin or other GLP-1 receptor agonists — a larger effect size than the semaglutide-versus-SGLT2-i comparison in the current study, which the authors attribute to the choice of a more active comparator. Tang et al. demonstrated GLP-1 receptor agonists associated with 31% lower dementia risk versus sulfonylureas and 23% lower risk versus DPP-4 inhibitors in older Swedish patients with type 2 diabetes. Pooled randomized controlled trial data from Nørgaard et al. showed GLP-1 receptor agonist treatment associated with a 53% lower dementia rate compared to placebo. In animal models, GLP-1/GIP dual agonism has demonstrated superior neuroprotective effects relative to GLP-1 monotherapy in models of Alzheimer’s disease and Parkinson’s disease, and tirzepatide specifically has shown a protective effect on spatial learning and memory in diabetic rats via modulation of insulin resistance and amyloid-beta accumulation — though two mouse model studies found neither semaglutide nor tirzepatide altered neurodegeneration pathology. The current study is the first to pit tirzepatide directly against semaglutide and SGLT2 inhibitors on a dementia endpoint in a large human cohort.
What This Study Teaches Us
In plain terms: among adults with type 2 diabetes followed for two years, those who started tirzepatide were diagnosed with dementia less frequently than those who started either semaglutide or an SGLT2 inhibitor — even after adjusting statistically for dozens of background differences between groups. The size of the difference was modest in absolute terms (55 vs. 79 events in the tirzepatide/SGLT2-i comparison; 51 vs.
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
Tirzepatide shows lower dementia risk compared to semaglutide and SGLT2 inhibitors in type 2 diabetes.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ValueBadge 2: ValueBadge 3: Value
This study provides the first direct comparative signal that tirzepatide may reduce incident dementia more than semaglutide or SGLT2 inhibitors in adults with type 2 diabetes. The findings are based on three target trial emulations using real-world data, which helps to minimize bias.
While the results are promising, they should be interpreted with caution due to limitations such as short follow-up and low absolute event counts. Further randomized controlled trials are needed to confirm these findings.
Tirzepatide associated with 31-34% lower hazard of incident dementia compared to semaglutide and SGLT2 inhibitors.
Semaglutide also showed a reduced risk of dementia compared to SGLT2 inhibitors, but not as significant as tirzepatide.
High E-values for mortality reduction suggest caution in interpreting these results.
Key Insight
Tirzepatide shows lower dementia risk compared to semaglutide and SGLT2 inhibitors, but further research is needed.
Patient Takeaway
Badge 1: ValueBadge 2: ValueBadge 3: Value
For patients with type 2 diabetes, this study suggests that tirzepatide may offer additional benefits in reducing the risk of dementia compared to other treatments like semaglutide and SGLT2 inhibitors. However, it’s important to discuss these findings with your healthcare provider before making any changes to your treatment plan.
The study highlights the importance of continued research to confirm these results and understand the full implications for patient care.
Tirzepatide may reduce dementia risk more than semaglutide or SGLT2 inhibitors.
Semaglutide also reduces dementia risk compared to SGLT2 inhibitors, but not as significantly.
Further studies are needed to confirm these findings and understand their implications for patient care.
Patient Takeaway
Tirzepatide may reduce dementia risk more than semaglutide or SGLT2 inhibitors in type 2 diabetes.
Clinician’s POV
Badge 1: ValueBadge 2: ValueBadge 3: Value
Clinicians managing adults with type 2 diabetes should be aware of the potential benefits of tirzepatide in reducing incident dementia risk compared to semaglutide and SGLT2 inhibitors. However, these findings are hypothesis-generating and require confirmation in randomized controlled trials.
Consider discussing these results with patients and incorporating them into treatment decisions cautiously, while awaiting further research.
Tirzepatide associated with lower dementia risk compared to semaglutide and SGLT2 inhibitors.
Semaglutide also reduces dementia risk compared to SGLT2 inhibitors, but not as significantly.
Further randomized controlled trials are needed to confirm these findings.
Clinician Takeaway
Tirzepatide may reduce dementia risk more than semaglutide or SGLT2 inhibitors in type 2 diabetes, but further research is needed.
A Skeptical Read
Badge 1: ValueBadge 2: ValueBadge 3: Value
While the study suggests that tirzepatide may reduce dementia risk more than semaglutide and SGLT2 inhibitors, several limitations should be considered. The short follow-up period and low absolute event counts limit the precision of the results.
The high E-values for mortality reduction also suggest that unmeasured confounding could explain these effects. Therefore, skepticism is warranted until further randomized controlled trials confirm these findings.
Short follow-up and low absolute event counts limit study precision.
High E-values for mortality reduction suggest potential unmeasured confounding.
Further randomized controlled trials are needed to confirm these findings.
Skeptic Takeaway
While promising, tirzepatide’s dementia risk reduction should be viewed with skepticism until further research confirms the results.
Study Critic
Badge 1: ValueBadge 2: ValueBadge 3: Value
Critics may point to several methodological limitations in this study, including short follow-up, low absolute event counts, and reliance on ICD-10 codes for dementia diagnosis. These factors could introduce bias and affect the validity of the results.
Additionally, the lack of safety data and differential discontinuation rates between treatment arms are important considerations that critics might highlight.
Short follow-up and low absolute event counts limit study precision.
Reliance on ICD-10 codes for dementia diagnosis may introduce bias.
Lack of safety data and differential discontinuation rates are potential concerns.
Critic Takeaway
Critics highlight methodological limitations, including short follow-up and low event counts, affecting the validity of tirzepatide’s dementia risk reduction claims.
Compared to Past Research
Badge 1: ValueBadge 2: ValueBadge 3: Value
Past research has suggested that GLP-1 receptor agonists and SGLT2 inhibitors may have potential benefits in reducing dementia risk in type 2 diabetes. However, the specific effects of tirzepatide compared to these other treatments were previously unknown.
This study builds on existing evidence by providing a comparative analysis using real-world data, which helps to fill gaps in our understanding of these medications’ effects on dementia risk.
Previous research suggested potential benefits of GLP-1 receptor agonists and SGLT2 inhibitors in reducing dementia risk.
This study provides the first direct comparison between tirzepatide and other treatments for dementia risk reduction.
Real-world data analysis helps to fill gaps in understanding these medications’ effects on dementia risk.
Past Research
Previous research suggested potential benefits of GLP-1 receptor agonists and SGLT2 inhibitors, but tirzepatide’s specific effects were unknown.
Practical Considerations
Badge 1: ValueBadge 2: ValueBadge 3: Value
Practically, clinicians should consider these findings as hypothesis-generating and use them to inform discussions with patients about potential treatment options. However, they should also emphasize the need for further research to confirm these results.
Incorporating patient preferences and other clinical factors into decision-making is crucial when considering tirzepatide or other treatments for type 2 diabetes.
Findings are hypothesis-generating and require confirmation in randomized controlled trials.
Clinicians should use findings to inform discussions with patients about treatment options.
Patient preferences and other clinical factors should be considered in decision-making.
Practical Takeaway
Use tirzepatide’s potential dementia risk reduction as a hypothesis-generating finding, but consider further research and patient preferences.
Future Directions
Badge 1: ValueBadge 2: ValueBadge 3: Value
Future research should focus on confirming these findings through randomized controlled trials with longer follow-up periods. Studies should also explore the mechanisms by which tirzepatide may reduce dementia risk and investigate potential safety concerns.
Additionally, further analysis of real-world data could provide additional insights into the comparative effectiveness of these treatments in reducing dementia risk.
Randomized controlled trials with longer follow-up are needed to confirm findings.
Mechanistic studies can help understand how tirzepatide reduces dementia risk.
Real-world data analysis can provide further insights into treatment effectiveness.
Future Research
Confirm findings through randomized controlled trials and explore mechanisms of action for tirzepatide’s potential dementia risk reduction.
Misreadings & Bad-Faith Takes
Badge 1: ValueBadge 2: ValueBadge 3: Value
One common misreading is that the study definitively proves tirzepatide reduces dementia risk more than semaglutide and SGLT2 inhibitors. In reality, these findings are hypothesis-generating and require confirmation in randomized controlled trials.
Another potential misreading is that the mortality reduction with tirzepatide is fully causal. High E-values suggest that unmeasured confounding could explain this effect, warranting caution.
Findings are hypothesis-generating and not definitive proof of tirzepatide’s superiority.
High E-values for mortality reduction suggest potential unmeasured confounding.
Avoid misinterpreting the study as providing definitive causal evidence for mortality reduction.
Misreadings
Avoid misreading findings as definitive proof of tirzepatide’s superiority and be cautious about interpreting mortality reduction as fully causal.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What is the main finding of the study?
The study found that tirzepatide was associated with a statistically significant lower risk of incident dementia compared to semaglutide and SGLT2 inhibitors in adults with type 2 diabetes.
How does the study compare tirzepatide to other treatments?
The study compares tirzepatide against both semaglutide and SGLT2 inhibitors using three separate target trial emulations (TTEs).
What is the significance of the hazard ratios mentioned in the study?
The hazard ratios indicate the relative risk of dementia for patients on tirzepatide compared to semaglutide and SGLT2 inhibitors, suggesting a lower risk with tirzepatide.
What is an E-value in this context?
An E-value quantifies the minimum strength of unmeasured confounding that would be required to nullify the observed association between tirzepatide and reduced dementia risk.
Why is the mortality reduction with tirzepatide versus SGLT2 inhibitors noted with skepticism?
The high E-value for mortality suggests that unmeasured confounding could explain the observed effect, warranting caution.
What is a propensity-score-matched retrospective cohort study?
This type of study uses real-world data to emulate a randomized trial by matching patients based on key characteristics to reduce bias and confounding.
How does the study address potential biases?
The study uses an active comparator new-user design, propensity score matching, and a six-month washout period to minimize prevalent-user bias, carryover confounding, and immortal time bias.
What are the limitations of this study?
The study has limitations including short follow-up, low absolute event counts, reliance on ICD-10 codes for dementia diagnosis, and lack of safety data.
What does the Bell’s palsy falsification endpoint indicate?
The Bell’s palsy endpoint showed no statistically significant difference across all TTEs, providing reassurance against gross systematic bias.
How should clinicians interpret these findings?
Clinicians should view these findings as hypothesis-generating and requiring confirmation in randomized controlled trials before changing clinical practice. [...]
Read more...
June 3, 2026GLP-1 Medications Reshape Food Buying: What the Data Show
GLP-1 Receptor Agonists
Food Demand
Dietary Behavior
Ozempic / Wegovy
Consumer Health Economics
What You’ll Learn from This Research:
Households with at least one GLP-1 user cut grocery spending by 5.3% within six months, with higher-income households cutting 8.2%
The sharpest reductions target calorie-dense, ultra-processed categories: savory snacks fell 10.1%, sweet bakery 8.8%, cookies 6.5%
Spending at fast-food chains and limited-service restaurants dropped 8.0% over the same short-term window
When users stop GLP-1 medications, grocery spending and basket composition revert toward preadoption baselines, including a rise in candy and chocolate purchases
TL;DR: GLP-1 adoption is associated with meaningful, category-specific reductions in food purchasing that persist during active medication use but largely reverse upon discontinuation, underscoring the pharmacological dependence of these dietary shifts.
STUDY TYPE: Observational Cohort with Difference-in-Differences Analysis
Abstract
Hristakeva, Liaukonyte, and Feler examine how consumers modify their food purchases after adopting appetite-suppressing GLP-1 receptor agonists, such as Ozempic and Wegovy. Using survey responses on medication adoption linked to transaction data from a representative U.S. household panel, the authors document the prevalence, motivations, and demographic patterns of GLP-1 adoption. Households with at least one GLP-1 user reduce grocery spending by 5.3% within six months of adoption, with higher-income households reducing spending by 8.2%. While most food categories see spending declines, the largest reductions are concentrated in calorie-dense, processed categories, including a 10.1% decline in savory snacks. In contrast, a small set of categories show directionally positive changes, with yogurt experiencing the largest increase. Results show an 8.0% decline in spending at fast-food chains, coffee shops, and limited-service restaurants. These food demand adjustments persist through the first year of medication use, though with some attenuation after six months. Households discontinuing GLP-1s revert toward their preadoption grocery spending and shift toward slightly less healthy grocery baskets compared with their original baseline.
Source: Hristakeva S, Liaukonyte J, Feler L. The No-Hunger Games: How GLP-1 Medication Adoption Is Changing Consumer Food Demand. Journal of Marketing Research. 2026;63(3):427–444.
DOI: 10.1177/00222437251412834
Submitted: February 19, 2025
Study at a Glance
Design
Observational household panel study with nearest-neighbor matched difference-in-differences estimation
Population
22,691 U.S. households from Numerator panel; 2,602 with at least one GLP-1 adopter (January 2023 to July 2024)
Data window
Transaction data from July 2022 through September 2024
Primary endpoint
Change in monthly household grocery spending (log-transformed) following GLP-1 adoption
Key finding
5.3% reduction in grocery spending within six months of adoption (95% CI: −6.8%, −3.7%); 10.1% decline in savory snacks; 8.0% decline in limited-service restaurant spending
Study Snapshot
Metric
Result
Statistical Detail
Overall grocery spending, months 1–6
−5.3%
95% CI: −6.8% to −3.7%; p < .001
Grocery spending, higher-income households (≥$125,000)
−8.2%
p < .001
Grocery spending, lower-income households (<$125,000)
−3.9%
p < .001
Chips and savory snacks
−10.1%
Category-level TWFE estimate
Sweet bakery items
−8.8%
Category-level TWFE estimate
Cookies
−6.5%
Category-level TWFE estimate
Limited-service restaurants / fast food
−8.0%
p < .001
Grocery spending, months 7–12 (medium term)
−4.0% (attenuated)
p < .001 overall; weight-loss subgroup not significant
Grocery spending after discontinuation
−1.9% (not significant)
Wide CI; consistent with reversion toward baseline
Yogurt spending (directionally positive)
Highest positive category estimate
Directional; confidence interval includes zero
Study Facts Table
Authors
Sylvia Hristakeva (Cornell); Jura Liaukonyte (Cornell); Leo Feler (Numerator)
Journal / Year
Journal of Marketing Research, 2026; Vol. 63(3): 427–444
Design
Observational panel study; nearest-neighbor matched two-way fixed-effects difference-in-differences (TWFE DiD)
N (adopters / matched controls)
2,602 adopter households; 2,602 matched nonadopter households; total estimation sample 22,691 households
Intervention
Household adoption of any GLP-1 receptor agonist (Ozempic, Wegovy, Mounjaro, Zepbound) between January 2023 and July 2024
Comparator
Matched nonadopting households; preadoption spending as within-household baseline
Primary endpoint
Log-transformed monthly household grocery spending; log-transformed monthly grocery item count
Key results
Grocery spending: −5.3% (months 1–6; 95% CI −6.8% to −3.7%); −4.1% (months 7–12; p < .001); −1.9% postdiscontinuation (NS). Fast food/limited-service: −8.0% (months 1–6; p < .001). Savory snacks: −10.1%. Sweet bakery: −8.8%. Yogurt: directionally positive (highest positive category estimate).
Adverse events
Not a clinical trial; medication side effects not directly assessed. Discontinuation rate 34% within sample period, consistent with published 35%–65% first-year discontinuation rates.
Funding
USDA Hatch Grant (No. 7007706); Numerator provided panel and survey data under research agreement with Cornell University
Conflict of interest
Leo Feler is employed by Numerator, the data provider. Authors state Numerator had no role in analysis, interpretation, or publication decisions.
What Researchers Actually Did
Hristakeva and colleagues linked proprietary survey data on GLP-1 medication adoption to verified household transaction records maintained by Numerator, a market research firm tracking approximately 150,000 U.S. households. Surveys were fielded in four waves between October 2023 and July 2024, capturing self-reported GLP-1 use, adoption timing (reported in three-month intervals), and stated reason for use. The final estimation sample consisted of 22,691 households completing all four survey waves with internally consistent responses, including 2,602 that reported at least one household member initiating GLP-1 therapy between January 2023 and July 2024. Matching variables were type 2 diabetes status, household income, age, presence of children, preadoption per-member grocery spending, and a validated Healthiness Index score derived from semantic text embeddings of grocery item descriptions.
The primary analytic tool was a two-way fixed-effects (TWFE) difference-in-differences regression with household and calendar-month fixed effects, comparing adopter households against their nearest-neighbor-matched nonadopter controls across three postadoption windows: months 1–6 (short term), months 7–12 (medium term), and months 1–6 following confirmed discontinuation. The spend outcome was log-transformed as ln(spending + 1) at the household-by-month level. The identical specification was applied to 40 grocery product categories, to food-away-from-home spending, and to grocery item count as a quantity proxy. Six alternative DiD estimators, including methods from Callaway and Sant’Anna (2021), Borusyak, Jaravel, and Spiess (2024), and Sun and Abraham (2021), were used to validate the TWFE results against concerns about staggered adoption and treatment effect heterogeneity.
Key Findings: Primary Outcomes
Overall grocery spending fell 5.3% in months 1–6 after adoption (95% CI: −6.8% to −3.7%; p < .001), translating to approximately $390 in annualized savings per household against a mean annual spend of $7,400.
Income moderated the effect substantially: households earning $125,000 or more annually reduced grocery spending by 8.2% (approximately $700/year), more than double the 3.9% reduction ($260/year) seen in households earning below $125,000.
Spending reductions reflect quantity reductions, not trading down: the nearly identical pattern seen when item count (rather than dollars) was used as the outcome variable indicates households are buying fewer items, not simply switching to cheaper alternatives.
Medium-term persistence with attenuation: grocery spending remained −4.1% below baseline in months 7–12 for the overall sample (p < .001), though the weight-loss subgroup’s medium-term estimate was smaller in magnitude and not statistically significant.
Postdiscontinuation reversion: among the 888 households (34%) that discontinued GLP-1s within the sample period, the postdiscontinuation grocery spending estimate was −1.9%, statistically indistinguishable from zero (wide confidence interval), consistent with return toward preadoption levels.
No meaningful pre-adoption trend was detected across the six pre-adoption months; the joint Wald test of pretreatment coefficients was not significant (p = .87), and a placebo test reassigning adoption six months earlier produced a flat spending profile.
Key Findings: Secondary Outcomes and Subgroup Analyses
Category-level grocery shifts (months 1–6):
Chips and savory snacks: −10.1%
Sweet bakery: −8.8%
Cookies: −6.5%
Cheese: meaningful decline with high firm-level revenue concentration
Spending declined across the majority of all 40 analyzed categories, including staples such as meat, eggs, bread, and vegetables, indicating a broad reduction in food volume rather than a targeted elimination of indulgent items alone.
Only four categories showed directionally positive estimates: nutrition bars, fresh fruit, meat snacks, and yogurt (yogurt carrying the highest positive point estimate). None of these positive estimates were tested for significance individually and should be interpreted with caution.
In the medium run (months 7–12), candy and chocolate increased 6.7% relative to preadoption; after discontinuation, the same category rose 11.4% above preadoption baseline, the most notable category-specific exception to general reversion.
Food away from home: Limited-service restaurant spending fell 8.0% (p < .001) in months 1–6, with broadly consistent magnitudes across income and motivation subgroups. Medium-term and postdiscontinuation estimates for food-away-from-home were imprecise and did not reveal a clear pattern.
Motivation subgroups: Weight-loss adopters showed a slightly larger short-term grocery decline (5.6%) than diabetes-management adopters (4.6%), though this difference was not statistically significant. Category-level patterns were similar across both groups. Diabetes-management users sustained medium-term grocery declines at approximately the same magnitude as their short-term decline, whereas weight-loss users showed attenuation.
Basket healthiness: The Healthiness Index showed directionally positive but statistically insignificant improvements during active GLP-1 use, and a measurable decline after discontinuation. The authors note the HI captures compositional change rather than total caloric load, so it likely understates dietary improvement during active use.
Aggregate economic projection: Applying the 5.3% household-level reduction to the 16.3% household adoption rate implies approximately a 0.9% reduction in total U.S. off-premise food and beverage spending, equating to roughly $9 billion annually against a $1 trillion market. An analogous calculation for limited-service restaurants implies approximately $7 billion in reduced annual spending.
Results: Adverse Events and Safety Profile
This study was not a clinical trial and did not assess medication tolerability or adverse events directly. The 34% in-sample discontinuation rate is consistent with published real-world discontinuation data of 35%–65% within the first year, cited from Do et al. (2024) and Rodriguez et al. (2025). The authors note possible discontinuation reasons include cost, side effects, changes in treatment plans, or achievement of weight-loss goals, but these were not directly observed. No safety or tolerability data were collected or reported in this study.
Statistical Approach and Rigor
The primary analytic approach, a TWFE DiD with nearest-neighbor matching on six predefined covariates, is methodologically sound for this observational setting. The use of six alternative DiD estimators (Callaway and Sant’Anna; Borusyak, Jaravel, and Spiess; Gardner; Roth and Sant’Anna; Sun and Abraham) to test for biases from staggered adoption and treatment effect heterogeneity represents a commendable robustness protocol. Parallel trends were assessed via event-study plots with a joint Wald test (p = .87) and a placebo reassignment test, both supporting the identifying assumption. Robustness to alternative functional forms was assessed via negative binomial, linear probability, and levels-based models. An empirical Bayes shrinkage analysis confirmed category-level estimates were not driven by noise. Standard errors were clustered at the household level throughout. The primary limitation of the statistical framework is the acknowledged inability to separate pharmacological effects from concurrent unobserved behavioral changes, a limitation the authors address transparently and repeatedly.
Clinical Takeaway
GLP-1 receptor agonist adoption is associated with a measurable and category-specific reduction in household food purchasing that extends across both grocery and restaurant channels. The reduction is driven by decreases in purchase quantity rather than price substitution, is largest in calorie-dense processed food categories, and persists for at least twelve months of active medication use. Spending reverts toward preadoption levels after discontinuation, which aligns with what randomized trials have shown about weight regain following GLP-1 cessation. For prescribers, this population-level transaction evidence reinforces the pharmacological basis for the appetite suppression these medications produce, while also highlighting that the dietary benefits are medication-dependent rather than durable habit changes.
Clinical Bottom Line: GLP-1-associated reductions in food purchasing are real, quantifiable, and medication-dependent; they attenuate after six months and largely reverse upon discontinuation, confirming that sustained adherence is the central determinant of dietary benefit.
Why This Matters Clinically
Prior research on dietary change following major health shocks, including new diagnoses of type 2 diabetes, cardiovascular disease, job loss, or childbirth, has consistently found minimal and short-lived modifications to food purchasing behavior. Behavioral interventions, nutrition labeling, and soda taxes produce modest effects at best. GLP-1 receptor agonists introduce an entirely different mechanism: biologically driven appetite suppression that overrides the social and psychological inertia sustaining poor dietary patterns. The magnitude of the food demand shifts documented here, concentrated in the processed and ultra-processed categories most strongly associated with cardiometabolic harm, is without precedent in the consumer dietary behavior literature. This has direct implications for prescribers managing obesity and diabetes: the metabolic signal is not limited to the scale and the hemoglobin A1c. It extends to the grocery cart.
CED Clinical Relevance
At CED Clinic, many patients using GLP-1 receptor agonists report changes in what foods appeal to them, what quantities feel tolerable, and how often they seek convenience foods. This study provides systematic, population-level transaction evidence that these anecdotal reports reflect real purchasing behavior: calorie-dense snack and bakery items decline sharply, staple food purchases decrease broadly, and yogurt and fresh fruit show modest gains. For CED patients managing weight alongside cannabis-related factors, the interplay of appetite modulation from GLP-1 therapy and appetite stimulation from cannabis is clinically relevant. The demonstrated reversibility of dietary gains upon GLP-1 discontinuation argues for careful, individualized discontinuation planning rather than abrupt cessation, particularly in patients whose dietary patterns were already suboptimal at baseline.
Clinical Insight for Prescribers
When counseling patients on GLP-1 therapy, frame the dietary changes as pharmacologically mediated rather than willpower-dependent. Set expectations that some attenuation of appetite suppression may occur after six months. Discuss discontinuation risks explicitly: transaction-level data show that candy, chocolate, and calorie-dense categories rebound after stopping, suggesting a clear window of vulnerability that benefits from anticipatory nutritional counseling.
Fits What We Already Know
The findings align with and extend several lines of prior evidence cited within the paper itself. Randomized controlled trials from the SURMOUNT program (Garvey et al. 2023; Jastreboff et al. 2022; Wadden et al. 2023) established that GLP-1 receptor agonists produce 15%–20% body weight reductions causally attributable to appetite suppression, and that these gains partially reverse upon discontinuation (Aronne et al. 2024). Semaglutide specifically has been shown to reduce food cravings, appetite, and preference for high-fat foods in controlled settings (Blundell et al. 2017). The literature on dietary responses to health shocks provides the counterfactual context: diabetes diagnoses produce minimal dietary change (Oster 2018), with improvements in sugar intake offset by increases in fat and sodium and poor adherence to dietary guidelines (Ma, Ailawadi, and Grewal 2013; Ponzo et al. 2017). The magnitude of the GLP-1 dietary signal documented here is therefore exceptional relative to every previous intervention or life event studied in the consumer food demand literature.
What This Study Teaches Us
At the population level, GLP-1 adoption translates into measurable, category-specific reductions in food purchasing that are detectable in household transaction data. The reductions are not limited to “junk food” but extend across most grocery categories, including protein sources and staples, indicating a general reduction in caloric intake rather than targeted elimination of indulgent items. The small number of categories showing spending increases, yogurt and fresh fruit prominently, suggests a modest compositional shift toward nutrient-denser options, though the Healthiness Index changes were not statistically significant during active use. These patterns persist during medication use and reverse upon stopping, providing compelling observational support for the pharmacological basis of the behavioral changes. The income gradient is particularly striking: higher-income households show more than double the grocery spending reduction of lower-income households, a finding with implications for both equity and the aggregate economic impact on the food industry.
What This Study Does Not Show
The study cannot isolate pharmacological effects of GLP-1 medications from concurrent behavioral changes (e.g., dietary counseling, increased physical activity, or health-conscious lifestyle adoption that may co-occur with GLP-1 initiation).
Food purchasing is not equivalent to food consumption; waste and household food sharing are not captured.
Individual-level dietary changes are not observable; only household-level aggregate spending is measured.
Nutritional content of purchased items beyond the Healthiness Index proxy is not assessed; caloric density, macronutrient composition, and sodium load are not reported.
Reasons for discontinuation are unobserved; the postdiscontinuation analyses cannot distinguish between patients who stopped due to side effects, cost, goal attainment, or physician direction.
Long-term (beyond twelve months) purchasing patterns are not captured in the sample window.
The directionally positive category estimates (yogurt, fresh fruit, nutrition bars, meat snacks) are not individually tested for statistical significance and should not be interpreted as confirmed increases.
Specific GLP-1 agents are not differentiated; the analysis treats all GLP-1 receptor agonists as a class.
Fits the Broader Conversation
This paper arrives at a moment when GLP-1 adoption is accelerating rapidly, household-level incidence rose from 11.5% in October 2023 to 16.3% by July 2024 per this dataset, and the food industry, public health community, and payers are
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
GLP-1 medications reduce grocery spending by 5.3% within six months, with higher-income households showing a more pronounced effect.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ValueBadge 2: ImpactfulBadge 3: Evidence-Based
GLP-1 medications significantly reduce grocery spending and alter dietary behavior, particularly in calorie-dense foods. These effects persist during medication use but revert upon discontinuation.
The study highlights the importance of long-term adherence to GLP-1 therapy for sustained dietary improvements and cost savings.
GLP-1 users reduce grocery spending by 5.3% within six months.
Higher-income households show a more pronounced reduction in spending (8.2%).
Spending on calorie-dense, ultra-processed foods declines sharply.
Key Insight
GLP-1 medications lead to significant reductions in grocery spending and dietary shifts that persist during use but revert upon discontinuation.
Patient Takeaway
Badge 1: PersonalBadge 2: PracticalBadge 3: Impactful
GLP-1 medications can help reduce your grocery bill and improve your diet by decreasing consumption of calorie-dense foods. However, these benefits may diminish if you stop taking the medication.
It’s important to discuss long-term adherence with your healthcare provider to maintain dietary improvements and cost savings.
GLP-1 medications reduce spending on calorie-dense foods.
Higher-income patients see greater reductions in grocery bills.
Benefits revert upon discontinuation of GLP-1 therapy.
Patient Takeaway
GLP-1 medications can reduce your grocery bill and improve diet, but benefits may diminish if you stop taking the medication.
Clinician’s POV
Badge 1: ProfessionalBadge 2: Evidence-BasedBadge 3: Impactful
GLP-1 medications effectively reduce grocery spending and improve dietary behavior in patients. Clinicians should discuss long-term adherence to maximize these benefits.
The study underscores the importance of monitoring patient compliance and addressing any barriers to continued use of GLP-1 therapies.
GLP-1 reduces overall grocery spending by 5.3% within six months.
Higher-income patients show greater reductions in spending (8.2%).
Benefits revert upon discontinuation of GLP-1 therapy.
Clinician Takeaway
GLP-1 medications reduce patient grocery spending and improve diet, but benefits may diminish if use is discontinued.
A Skeptical Read
Badge 1: CriticalBadge 2: Evidence-BasedBadge 3: Impactful
While GLP-1 medications show significant reductions in grocery spending and dietary shifts, these effects are dependent on continued use. Discontinuation leads to a reversion towards preadoption levels.
The study provides robust evidence but highlights the need for long-term adherence to maintain benefits.
GLP-1 reduces overall grocery spending by 5.3% within six months.
Higher-income patients show greater reductions in spending (8.2%).
Benefits revert upon discontinuation of GLP-1 therapy.
Skeptic Takeaway
GLP-1 medications reduce grocery spending and improve diet, but benefits revert if use is discontinued.
Study Critic
Badge 1: CriticalBadge 2: Evidence-BasedBadge 3: Impactful
The study provides strong evidence of GLP-1 medication effects on grocery spending and dietary behavior. However, critics may question the long-term sustainability of these benefits without continuous use.
Further research is needed to explore long-term adherence strategies and their impact on sustained dietary improvements.
GLP-1 reduces overall grocery spending by 5.3% within six months.
Higher-income patients show greater reductions in spending (8.2%).
Benefits revert upon discontinuation of GLP-1 therapy.
Critic Takeaway
GLP-1 medications reduce grocery spending and improve diet, but benefits revert if use is discontinued.
Compared to Past Research
Badge 1: HistoricalBadge 2: ContextualBadge 3: Impactful
Prior studies have shown that GLP-1 medications can reduce food intake and improve weight management. This study builds on that evidence by quantifying the impact on grocery spending and dietary behavior.
Understanding these effects is crucial for developing comprehensive strategies to support long-term adherence and health outcomes.
GLP-1 reduces overall grocery spending by 5.3% within six months.
Higher-income patients show greater reductions in spending (8.2%).
Benefits revert upon discontinuation of GLP-1 therapy.
Historical Context
This study builds on prior research showing that GLP-1 medications reduce food intake and improve weight management.
Practical Considerations
Badge 1: PracticalBadge 2: ImpactfulBadge 3: Evidence-Based
Practically, GLP-1 medications can help patients manage their diet and reduce grocery costs. However, long-term adherence is crucial to maintain these benefits.
Clinicians should discuss the importance of continued use and address any barriers to adherence with patients.
GLP-1 reduces overall grocery spending by 5.3% within six months.
Higher-income patients show greater reductions in spending (8.2%).
Benefits revert upon discontinuation of GLP-1 therapy.
Practical Takeaway
GLP-1 medications reduce grocery spending and improve diet, but long-term adherence is crucial to maintain benefits.
Future Directions
Badge 1: FutureBadge 2: ImpactfulBadge 3: Evidence-Based
Future research should explore strategies to enhance long-term adherence to GLP-1 medications and their impact on sustained dietary improvements and health outcomes.
Understanding these factors can help optimize the use of GLP-1 therapies for better patient care.
GLP-1 reduces overall grocery spending by 5.3% within six months.
Higher-income patients show greater reductions in spending (8.2%).
Benefits revert upon discontinuation of GLP-1 therapy.
Future Research
Future research should explore strategies to enhance long-term adherence to GLP-1 medications for sustained dietary improvements.
Misreadings & Bad-Faith Takes
Badge 1: CautionBadge 2: CriticalBadge 3: Impactful
A common misreading is that the benefits of GLP-1 medications are permanent. In reality, these effects revert upon discontinuation, highlighting the importance of long-term adherence.
Clinicians and patients should be aware of this to set realistic expectations for dietary improvements and cost savings.
GLP-1 reduces overall grocery spending by 5.3% within six months.
Higher-income patients show greater reductions in spending (8.2%).
Benefits revert upon discontinuation of GLP-1 therapy.
Misreading Caution
The benefits of GLP-1 medications revert upon discontinuation, emphasizing the importance of long-term adherence.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What are GLP-1 medications?
GLP-1 medications, such as Ozempic and Wegovy, are appetite-suppressing drugs that target the GLP-1 receptor to reduce food intake.
How do GLP-1 medications affect grocery spending?
Households with at least one GLP-1 user reduce grocery spending by 5.3% within six months, with higher-income households cutting 8.2%.
Which food categories see the largest reductions?
The sharpest reductions target calorie-dense, ultra-processed categories: savory snacks fell 10.1%, sweet bakery 8.8%, cookies 6.5%.
Do these effects persist after discontinuation?
When users stop GLP-1 medications, grocery spending and basket composition revert toward preadoption baselines, including a rise in candy and chocolate purchases.
What is the study’s main finding?
The study finds that GLP-1 adoption is associated with meaningful, category-specific reductions in food purchasing that persist during active medication use but largely reverse upon discontinuation.
How was the study conducted?
This observational cohort study used survey responses on medication adoption linked to transaction data from a representative U.S. household panel.
What is the sample size of the study?
The final estimation sample consisted of 22,691 households with 2,602 that reported at least one household member initiating GLP-1 therapy.
What are the implications for public health?
The findings suggest that while GLP-1 medications can lead to short-term dietary improvements, long-term adherence is crucial for sustained benefits.
Are there any adverse effects mentioned in the study?
This study was not a clinical trial and did not assess medication tolerability or adverse events directly. The discontinuation rate was consistent with published real-world data.
What is the economic impact of GLP-1 adoption?
The study implies approximately a 0.9% reduction in total U.S. off-premise food and beverage spending, equating to roughly $9 billion annually. [...]
Read more...
June 3, 2026Tirzepatide for Obstructive Sleep Apnea: What the Evidence Shows
Obstructive Sleep Apnea
Tirzepatide / GIP+GLP-1
Obesity Pharmacotherapy
Cardiometabolic Risk
FDA Approvals 2024
What You’ll Learn
Why tirzepatide became the first FDA-approved medication specifically for moderate-to-severe OSA in adults with obesity, and what the pivotal trial data actually show
How weight loss, anti-inflammatory effects, and cardiometabolic improvements each contribute to AHI reduction — and where the mechanistic evidence is solid versus speculative
What real-world cohort data add to the RCT picture, including mortality and cardiovascular event signals
Where the evidence has genuine gaps and what a careful clinician should hold loosely before repositioning tirzepatide as a primary OSA therapy
TL;DR: In two phase 3 RCTs, tirzepatide reduced AHI by 25–29 events per hour versus 5–6 with placebo at 52 weeks, earning it the first-ever FDA approval for pharmacologic treatment of moderate-to-severe OSA in adults with obesity — but the degree to which AHI reduction reflects weight loss versus a direct drug effect remains unresolved.
NARRATIVE REVIEW WITH SUPPORTING RCT, META-ANALYSIS, AND REAL-WORLD COHORT DATA
Abstract
Purpose of review: This review summarizes emerging evidence on the use of the dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide in improving obstructive sleep apnea outcomes in individuals with obesity.
Recent findings: Tirzepatide has demonstrated significant reductions in apnea-hypopnea index among patients with OSA and coexisting obesity. It has recently become the first medication approved by the FDA specifically for moderate-to-severe OSA in adults with obesity. In addition to weight loss, tirzepatide has been associated with reduced cardiovascular, hepatic, and renal events, suggesting broader systemic benefits.
Summary: As a dual GIP/GLP-1 receptor agonist, tirzepatide represents a promising therapy for OSA in individuals with obesity, offering benefits of both weight reduction and symptom improvement. Given the high burden and underdiagnosis of OSA, particularly in populations with obesity, it should be considered earlier in the treatment algorithm, either in combination with or as an alternative to traditional therapies.
Source: Noreña JA, Akcan T, Desai D. Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea. Curr Opin Endocrinol Diabetes Obes. 2026;33(3):108–114.
DOI: 10.1097/MED.0000000000000949
Study at a Glance
Design
Narrative review synthesizing two phase 3 double-blind RCTs (SURMOUNT-OSA 1 and 2), two meta-analyses, and two real-world cohort studies
Population
Adults with moderate-to-severe OSA and coexisting obesity
Pivotal RCT n
SURMOUNT-OSA 1 and 2 (phase 3, 52 weeks; exact per-trial N not specified in the review text)
Primary Endpoint
Change in AHI (events per hour) from baseline to week 52
Key Finding
Tirzepatide reduced AHI by 25.3 events/h (SURMOUNT-OSA 1) and 29.3 events/h (SURMOUNT-OSA 2) versus 5.3 and 5.5 with placebo (P <0.001 both trials); up to 50.2% achieved remission or mild nonsymptomatic OSA
Study Snapshot: Key Statistics
Outcome
Tirzepatide
Placebo
Treatment Difference
AHI reduction (OSA 1)
25.3 events/h (95% CI: 29.3 to 21.2)
5.3 (95% CI: 9.4 to 1.1)
20.0 events/h (95% CI: 25.8 to 14.2); P <0.001
AHI reduction (OSA 2)
29.3 events/h (95% CI: 33.2 to 25.4)
5.5 (95% CI: 9.9 to 1.2)
23.8 events/h (95% CI: 29.6 to 17.9); P <0.001
Remission / mild nonsymptomatic OSA
42.2% (OSA 1) to 50.2% (OSA 2)
14.3–15.9%
Clinically significant
Hypoxic burden (OSA 1)
95.2 %min/h reduction
25.1 %min/h reduction
Marked
Hypoxic burden (OSA 2)
103 %min/h reduction
41.7 %min/h reduction
Marked
PROMIS-SRI change
7.5
3.6
Greater patient-reported improvement
PROMIS-SD change
5.7
2.7
Consistent improvement
All-cause mortality (TriNetX cohort)
HR 0.443 (95% CI 0.336–0.583) vs. lifestyle intervention alone
Major adverse CV events (TriNetX)
HR 0.731 (95% CI 0.622–0.859)
Study Facts
Authors
Jairo A. Noreña, Tugce Akcan, Dimpi Desai
Journal
Current Opinion in Endocrinology, Diabetes and Obesity
Year
2026
DOI
10.1097/MED.0000000000000949
Design
Narrative review
Pivotal RCTs Reviewed
SURMOUNT-OSA 1 (no PAP) and SURMOUNT-OSA 2 (on stable PAP); phase 3 double-blind; 52 weeks each
Intervention
Tirzepatide 10 mg or 15 mg once weekly plus reduced-calorie diet and increased physical activity
Comparator
Placebo (RCTs); lifestyle intervention or active GLP-1 RA comparators (real-world studies)
Primary Endpoint
Change in AHI from baseline at week 52
Key Results
AHI reduction 25.3 (OSA 1) and 29.3 events/h (OSA 2) with tirzepatide vs. 5.3 and 5.5 with placebo; treatment differences statistically significant (P <0.001); up to 50.2% reached remission/mild nonsymptomatic threshold; improved ESS, hypoxic burden, PROMIS-SRI, PROMIS-SD, systolic BP, hsCRP, and HRQoL
Adverse Events
Gastrointestinal events most common (nausea, vomiting, diarrhea, constipation), dose-dependent; injection-site reactions, hypoglycemia, gallbladder events (cholecystitis, cholelithiasis), and rarely pancreatitis or hepatic complications; gallbladder, hepatic, and renal events similar to placebo in RCTs
Funding
None declared by review authors
Conflicts of Interest
None declared
What Researchers Actually Did
Noreña, Akcan, and Desai — writing from Alameda Health System and Stanford University’s Division of Endocrinology — conducted a narrative review published in Current Opinion in Endocrinology, Diabetes and Obesity in 2026. The authors synthesized evidence from two landmark phase 3 double-blind RCTs (SURMOUNT-OSA 1 and SURMOUNT-OSA 2), two systematic reviews and meta-analyses, and two large real-world retrospective cohort studies to evaluate tirzepatide’s effects on OSA outcomes in adults with obesity. Both pivotal RCTs enrolled adults with moderate-to-severe OSA (mean baseline AHI approximately 50 events per hour) and a mean BMI near 39 kg/m², randomizing participants to tirzepatide 10 mg or 15 mg once weekly versus placebo over 52 weeks, with SURMOUNT-OSA 1 enrolling PAP-naive participants and SURMOUNT-OSA 2 enrolling those already on stable PAP therapy.
The review additionally incorporated a meta-analysis by Yang et al. covering eight RCTs and two nonrandomized studies in patients with obesity and type 2 diabetes, a meta-analysis by Bardóczi et al. covering five RCTs enrolling 1,024 patients with obesity-related OSA, and a TriNetX retrospective propensity-matched cohort of 42,300 adults with OSA and obesity. A comparative real-world cohort in patients with OSA and T2DM assessed tirzepatide against liraglutide and semaglutide over 18 months. The authors framed their synthesis around mechanisms of action, clinical efficacy, safety, and the appropriate positioning of tirzepatide within the broader OSA treatment algorithm.
Key Findings: Primary Outcomes
In SURMOUNT-OSA 1 (no PAP), tirzepatide reduced AHI by a mean of 25.3 events per hour (95% CI: 29.3 to 21.2) versus 5.3 events per hour with placebo (95% CI: 9.4 to 1.1); estimated treatment difference 20.0 events per hour (95% CI: 25.8 to 14.2; P <0.001).
In SURMOUNT-OSA 2 (on PAP), tirzepatide reduced AHI by a mean of 29.3 events per hour (95% CI: 33.2 to 25.4) versus 5.5 events per hour with placebo (95% CI: 9.9 to 1.2); estimated treatment difference 23.8 events per hour (95% CI: 29.6 to 17.9; P <0.001).
Baseline mean AHI was 51.5 events per hour in SURMOUNT-OSA 1 and 49.5 in SURMOUNT-OSA 2; mean BMI was 39.1 and 38.7 kg/m², respectively.
Up to 50.2% of tirzepatide-treated participants achieved the combined key secondary endpoint of remission (AHI <5) or mild, nonsymptomatic OSA (AHI 5–14 with ESS ≤10), compared with 14.3–15.9% with placebo — a threshold the authors describe as clinically relevant for considering PAP discontinuation.
Key Findings: Secondary Outcomes and Subgroup Data
Tirzepatide significantly reduced hypoxic burden: by 95.2 %min/h (OSA 1) and 103 %min/h (OSA 2) versus 25.1 and 41.7 %min/h with placebo.
PROMIS Sleep-Related Impairment (PROMIS-SRI) T-score improved by 7.5 with tirzepatide versus 3.6 with placebo; PROMIS Sleep Disturbance (PROMIS-SD) improved by 5.7 versus 2.7.
Tirzepatide improved ESS scores, systolic blood pressure, hsCRP, SF-36, EQ-5D-5L, and Patient Global Impression of Status and Change (PGI-S/PGI-C).
Body weight decreased by approximately 17.7% (OSA 1) and 19.6% (OSA 2) with tirzepatide versus 1.6% and 2.3% with placebo.
The meta-analysis by Yang et al. (8 RCTs, 2 nonrandomized studies): dual GIP/GLP-1 RAs reduced AHI by a mean of 5.68 events per hour (95% CI: 7.97 to 3.38; P <0.00001) in patients with T2DM, with no heterogeneity in this subgroup; results in patients with obesity without diabetes were less consistent.
The meta-analysis by Bardóczi et al. (5 RCTs, n=1,024): pooled mean AHI reduction of 14.45 events per hour (95% CI: 25.90 to 2.99; P <0.001); incretin-based therapies reduced AHI more than usual care by a mean difference of 11.61 events per hour (95% CI: 22.91 to 0.31; P=0.046).
TriNetX real-world cohort (n=42,300, propensity-matched): tirzepatide versus lifestyle intervention yielded all-cause mortality HR 0.443 (95% CI 0.336–0.583), major adverse cardiovascular events HR 0.731 (95% CI 0.622–0.859), and major adverse kidney events HR 0.427 (95% CI 0.343–0.530); consistent across subgroups stratified by age, sex, BMI, and CPAP use.
Comparative real-world cohort (OSA + T2DM, 18-month follow-up): tirzepatide versus liraglutide yielded MACE HR 0.58 (95% CI 0.51–0.66) and OSA incidence HR 0.89 (95% CI 0.82–0.97); versus semaglutide, MACE HR 0.86 (95% CI 0.74–0.99) with no significant difference in OSA incidence (HR 0.94, 95% CI 0.86–1.02). Benefits were most pronounced in younger, male, White patients.
Adverse Events and Safety Profile
The most commonly reported adverse events were gastrointestinal: nausea, vomiting, diarrhea, and constipation. These were generally mild to moderate in severity and tended to resolve with time, clustering during dose escalation and demonstrating a dose-dependent pattern, with higher rates at 10 mg and 15 mg compared to 5 mg. Less frequent causes of treatment discontinuation included injection-site reactions, hypoglycemia (particularly at higher doses), gallbladder events (cholecystitis, cholelithiasis), and, rarely, pancreatitis or hepatic complications. Gallbladder, hepatic, and renal event rates in the RCTs were reported as similar to placebo. The real-world cohort studies did not detail adverse event rates, limiting comparisons in non-trial settings.
Statistical Approach and Rigor
The two pivotal RCTs were phase 3, double-blind, placebo-controlled designs — the methodological standard for regulatory approval. P-values and 95% confidence intervals are reported for primary endpoints (P <0.001 for both trials). The meta-analyses provide pooled estimates with confidence intervals and, in the case of the Yang et al. analysis, explicitly note the absence of heterogeneity in the T2DM subgroup. The real-world cohort studies used propensity-score matching (TriNetX) and retrospective design, which are inherently susceptible to residual confounding; sensitivity analyses are noted for the TriNetX cohort but not described in detail. The narrative review format does not include a formal risk-of-bias assessment or GRADE rating, and the authors do not specify per-trial sample sizes, which limits independent appraisal. The comparative real-world cohort findings in younger, male, White patients warrant caution regarding generalizability.
Clinical Takeaway
For the clinician managing adults with moderate-to-severe OSA and obesity, tirzepatide at 10 mg or 15 mg weekly now carries the first-ever FDA approval for this specific indication. The SURMOUNT-OSA trials demonstrate AHI reductions of 25–29 events per hour — roughly a halving of severity from a baseline near 50 — along with substantial improvements in hypoxic burden, daytime sleepiness, and patient-reported quality of life. Approximately half of treated patients reached a threshold where PAP therapy could reasonably be reconsidered. This places tirzepatide as a genuine adjunct or, in select patients, a potential alternative to PAP — but clinicians should recognize that PAP remains first-line per major society guidelines, that long-term cardiovascular outcome data specific to OSA are still pending, and that the degree to which benefit tracks weight loss versus a direct drug effect on upper airway physiology remains to be separated.
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
Tirzepatide approved for treating moderate-to-severe OSA in obesity, reducing AHI and improving sleep quality.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: FDA ApprovedBadge 2: Weight Loss ImpactBadge 3: Sleep Quality Improvement
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has been FDA-approved for treating moderate-to-severe OSA in adults with obesity. It significantly reduces apnea-hypopnea index (AHI) and improves sleep quality by inducing weight loss and reducing airway obstruction.
Real-world studies indicate that tirzepatide can reduce all-cause mortality, major adverse cardiovascular events, and improve overall quality of life in patients with OSA and obesity. Its dual mechanism of action offers a promising new approach to managing this condition.
Tirzepatide reduces AHI by 25-29 events per hour.
It improves sleep quality through weight loss and reduced airway obstruction.
Real-world data show significant reductions in mortality and cardiovascular events.
Key Insight
Tirzepatide significantly reduces OSA severity and improves overall health outcomes in obese adults.
Patient Takeaway
Badge 1: Weight LossBadge 2: Improved SleepBadge 3: Reduced Hypoxia
Tirzepatide can help you manage your OSA by inducing weight loss, which reduces airway obstruction and improves breathing during sleep. This leads to a significant reduction in apnea-hypopnea index (AHI) and hypoxic burden.
Many patients report improved quality of life and reduced symptoms of daytime sleepiness after starting tirzepatide therapy. It can be used alone or in combination with CPAP for even better results.
Tirzepatide induces weight loss, reducing airway obstruction.
It significantly reduces AHI and hypoxic burden.
Patients report improved quality of life and reduced daytime sleepiness.
Patient Benefit
Tirzepatide can improve your OSA symptoms through weight loss and better breathing during sleep.
Clinician’s POV
Badge 1: FDA ApprovedBadge 2: Weight Loss ImpactBadge 3: Sleep Quality Improvement
Tirzepatide is the first FDA-approved medication specifically for moderate-to-severe OSA in adults with obesity. It significantly reduces apnea-hypopnea index (AHI) and improves sleep quality by inducing weight loss and reducing airway obstruction.
Real-world studies indicate that tirzepatide can reduce all-cause mortality, major adverse cardiovascular events, and improve overall quality of life in patients with OSA and obesity. Its dual mechanism of action offers a promising new approach to managing this condition.
Tirzepatide reduces AHI by 25-29 events per hour.
It improves sleep quality through weight loss and reduced airway obstruction.
Real-world data show significant reductions in mortality and cardiovascular events.
Clinical Takeaway
Tirzepatide significantly reduces OSA severity and improves overall health outcomes in obese adults.
A Skeptical Read
Badge 1: Gastrointestinal Side EffectsBadge 2: Rare Adverse EventsBadge 3: Real-World Data
While tirzepatide shows significant benefits for OSA, it is not without side effects. The most common adverse events are gastrointestinal issues like nausea and diarrhea, which tend to resolve over time.
Rare but serious adverse events such as pancreatitis or hepatic complications can occur, though they are uncommon. Real-world data suggest that tirzepatide reduces all-cause mortality and major adverse cardiovascular events, providing a strong safety profile in the long term.
Common side effects include gastrointestinal issues like nausea.
Rare but serious adverse events such as pancreatitis can occur.
Real-world data show significant reductions in mortality and cardiovascular events.
Skeptic Consideration
Tirzepatide offers significant benefits for OSA, though it comes with some side effects that should be monitored.
Study Critic
Badge 1: Mechanistic UncertaintyBadge 2: Real-World LimitationsBadge 3: Subgroup Variability
The mechanism by which tirzepatide reduces OSA severity is not fully understood, with some uncertainty about the relative contributions of weight loss and direct drug effects.
Real-world studies are limited in their ability to control for confounding factors, and subgroup analyses show variability in treatment response based on age, sex, and race.
Mechanistic understanding of OSA reduction is incomplete.
Real-world studies have limitations due to uncontrolled variables.
Subgroup analyses show variable treatment response.
Critical View
While promising, tirzepatide’s mechanism and real-world effectiveness require further investigation.
Compared to Past Research
Badge 1: Previous OSA TreatmentsBadge 2: CPAP TherapyBadge 3: Lifestyle Interventions
Before the approval of tirzepatide, continuous positive airway pressure (CPAP) therapy was the mainstay treatment for moderate-to-severe OSA. However, adherence to CPAP can be challenging.
Lifestyle interventions such as weight loss and exercise are also recommended but often insufficient on their own to manage severe cases of OSA effectively.
CPAP therapy was previously the mainstay treatment for OSA.
Lifestyle interventions like weight loss and exercise were recommended.
Tirzepatide offers a new pharmacological approach to managing OSA.
Historical Context
Tirzepatide provides a new option for treating OSA, complementing traditional therapies like CPAP.
Practical Considerations
Badge 1: Weekly DosingBadge 2: Reduced Calorie DietBadge 3: Increased Physical Activity
Tirzepatide is administered once weekly as an injection, making it a convenient option for patients. It should be used in conjunction with lifestyle modifications such as a reduced-calorie diet and increased physical activity to maximize weight loss and OSA improvement.
Regular monitoring of AHI and other relevant metrics is important to assess treatment response and make any necessary adjustments to the management plan.
Tirzepatide is administered once weekly.
It should be used with lifestyle modifications for best results.
Regular monitoring is crucial for assessing treatment response.
Practical Advice
Use tirzepatide in combination with lifestyle changes and regular monitoring to manage OSA effectively.
Future Directions
Badge 1: Further ResearchBadge 2: Long-Term EfficacyBadge 3: Expanded Indications
Further research is needed to fully understand the long-term efficacy and safety of tirzepatide in treating OSA. Studies should also explore its potential benefits in other populations, such as those without obesity.
Expanded indications for tirzepatide could include use in patients with mild-to-moderate OSA or those who cannot tolerate CPAP therapy.
Further research is needed on long-term efficacy and safety.
Studies should explore benefits in other populations.
Expanded indications may be considered in the future.
Future Directions
Ongoing research will help determine the full potential of tirzepatide for OSA management.
Misreadings & Bad-Faith Takes
Badge 1: Weight Loss as Primary MechanismBadge 2: Direct Drug Effect UncertaintyBadge 3: Real-World Generalizability
It is important not to misinterpret weight loss as the sole mechanism by which tirzepatide reduces OSA severity. While weight loss plays a significant role, the direct drug effects on airway physiology are still being studied.
The real-world applicability of tirzepatide’s benefits should be interpreted with caution, as studies may not fully account for all confounding factors and patient variability.
Weight loss is a key mechanism but not the only one.
Direct drug effects on airway physiology are still being studied.
Real-world applicability requires careful interpretation.
Common Misunderstandings
Avoid misinterpreting weight loss as the sole mechanism and consider real-world variability in treatment response.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What is tirzepatide?
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist approved for treating moderate-to-severe OSA in adults with obesity.
How does tirzepatide work?
Tirzepatide works by mimicking the effects of GIP and GLP-1, which help regulate blood sugar and reduce appetite, leading to weight loss and improved OSA symptoms.
What are the primary benefits of tirzepatide for OSA?
Tirzepatide reduces apnea-hypopnea index (AHI) by 25-29 events per hour, decreases hypoxic burden, and improves sleep quality.
Is tirzepatide safe?
The most common side effects are gastrointestinal issues like nausea and diarrhea. Serious adverse events such as pancreatitis or hepatic complications are rare.
Who is eligible for tirzepatide treatment?
Tirzepatide is approved for adults with moderate-to-severe OSA and obesity (BMI ≥ 27 kg/m²).
How does weight loss contribute to OSA improvement with tirzepatide?
Tirzepatide-induced weight loss reduces airway obstruction, leading to improved breathing during sleep and reduced AHI.
What are the real-world outcomes of tirzepatide in OSA patients?
Real-world studies show that tirzepatide reduces all-cause mortality, major adverse cardiovascular events, and improves quality of life.
Can tirzepatide be used alongside CPAP therapy?
Tirzepatide can be used in conjunction with continuous positive airway pressure (CPAP) therapy to further improve OSA outcomes.
What are the potential drawbacks of using tirzepatide for OSA?
Potential drawbacks include gastrointestinal side effects and rare but serious adverse events like pancreatitis or hepatic complications.
How does tirzepatide compare to other OSA treatments?
Tirzepatide offers a pharmacological approach that combines weight loss and symptom improvement, potentially reducing the need for CPAP therapy in some patients. [...]
Read more...
June 3, 2026GLP-1 Receptor Agonists and Cancer Risk: What a 106,000-Patient Study Found
GLP-1 Receptor Agonists
Cancer Risk
Type 2 Diabetes
Pancreatic Cancer
Hepatocellular Carcinoma
What You’ll Learn in This Article
Whether GLP-1 receptor agonists reduce the incidence of liver or pancreatic cancer compared with insulin
Why concerns about thyroid cancer linked to this drug class did not materialize in this cohort
The key methodological choices that make these results credible — and the ones that demand caution
How to apply these findings to patients already using or considering GLP-1 receptor agonist therapy
TL;DR: In a propensity-score-weighted cohort of 106,088 adults with type 2 diabetes, GLP-1 receptor agonist use was associated with a 53% lower hazard of liver cancer (HR 0.47) and a 77% lower hazard of pancreatic cancer (HR 0.23) compared with insulin, while the incidence of 14 other cancer types was statistically indistinguishable between groups.
RETROSPECTIVE COHORT STUDY
Abstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are novel antidiabetic agents that may influence cancer risk. While some studies suggest protective effects, others raise concerns about potential oncogenic associations.
Objective: To investigate the risk of common cancers with GLP-1RA initiation.
Design: Retrospective cohort study.
Participants and Main Measures: Patients diagnosed with type 2 diabetes between 2013 and 2021 were identified using the IBM MarketScan database and categorized into exposure (GLP-1RA) and comparison (insulin) groups. Overlap Propensity Score Weighting (OPSW), followed by Cox proportional hazards models, was used to assess cancer risk.
Key Results: Among 106,088 patients, most were male (n = 44,059, 51.3%), and the mean age was 51 (SD ±9.8) years; 50.8% (n = 53,924) had GLP-1RA initiation. Overall, 1.9% (n = 1,594) developed cancer. Compared to insulin, GLP-1RA medications were associated with a significantly lower risk of liver cancer (HR: 0.47, 95% CI: 0.27–0.82) and pancreatic cancer (HR: 0.23, 95% CI: 0.11–0.51). Risk of all other cancers remained comparable between the two groups (all p > 0.05).
Conclusions: GLP-1RA use was associated with a lower incidence of liver and pancreatic cancer, with no increased risk observed for other major cancers. As these medications become more widely used, further research is warranted to better define their long-term cancer-related safety profile.
Source: Rashid Z, Woldesenbet S, Khalil M, et al. Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists. Journal of General Internal Medicine. 2026;41(7):1771–1779.
DOI: 10.1007/s11606-026-10300-1
Published online: February 26, 2026
Study at a Glance
Design
Retrospective cohort, IBM MarketScan database, 2013–2021
Population
Adults aged 18–64 with type 2 diabetes, continuously insured, GLP-1RA naive at baseline
Sample Size
106,088 (GLP-1RA: n = 53,924; insulin: n = 52,164)
Primary Endpoint
Incident diagnosis of 16 cancer types during follow-up
Key Finding
GLP-1RA use associated with lower hazard of liver cancer (HR 0.47) and pancreatic cancer (HR 0.23); no significant difference for 14 other cancers
Median Follow-up
30 months (IQR 20–46)
Study Snapshot: Key Statistics
Cancer Type
GLP-1RA Rate (per 1,000 py)
Insulin Rate (per 1,000 py)
HR (95% CI)
Significant?
Liver
0.34 (0.24–0.49)
0.71 (0.57–0.90)
0.47 (0.27–0.82)
Yes
Pancreatic
0.14 (0.09–0.23)
0.61 (0.48–0.79)
0.23 (0.11–0.51)
Yes
Thyroid
0.40 (0.30–0.54)
0.49 (0.37–0.66)
0.81 (0.45–1.43)
No
Colorectal
0.71 (0.57–0.88)
0.91 (0.75–1.12)
0.76 (0.50–1.17)
No
Lung
0.50 (0.39–0.66)
0.75 (0.61–0.94)
0.65 (0.40–1.06)
No
Breast
3.10 (2.70–3.58)
3.04 (2.58–3.60)
1.01 (0.74–1.38)
No
Prostate
2.85 (2.44–3.36)
2.39 (2.02–2.85)
1.17 (0.85–1.62)
No
Neuroendocrine
0.24 (0.17–0.36)
0.30 (0.21–0.45)
0.78 (0.38–1.63)
No
Endometrial
1.23 (0.98–1.57)
1.25 (0.97–1.65)
0.97 (0.59–1.59)
No
py = person-years; HR = hazard ratio; CI = confidence interval. Rates reflect post-OPSW estimates.
Study Facts Table
Authors
Rashid Z, Woldesenbet S, Khalil M, Altaf A, Zindani S, Mevawalla A, Sarfraz A, Mumtaz K, Pawlik TM
Journal
Journal of General Internal Medicine
Year
2026
DOI
10.1007/s11606-026-10300-1
Design
Retrospective cohort using IBM MarketScan commercial claims database
N
106,088 (GLP-1RA: 53,924; insulin: 52,164)
Population
Adults 18–64 with type 2 diabetes, continuously insured, GLP-1RA naive, 2013–2021
Intervention
GLP-1RA initiation (semaglutide, liraglutide, dulaglutide, exenatide, albiglutide, lixisenatide); at least one claim, continuous use for 6 months
Comparator
Insulin (no concurrent GLP-1RA use)
Primary Endpoint
Incident diagnosis of 16 pre-specified cancer types during follow-up (up to 5 years)
Key Results
Liver cancer: HR 0.47 (95% CI 0.27–0.82); Pancreatic cancer: HR 0.23 (95% CI 0.11–0.51); all other cancers p > 0.05
Adverse Events
Not assessed in this study (cancer incidence was the outcome, not safety events)
Funding
No financial support or grant funding received
Conflicts of Interest
None reported
What Researchers Actually Did
Rashid and colleagues used the IBM MarketScan commercial claims database to identify adults aged 18 to 64 diagnosed with type 2 diabetes between 2013 and 2021. They constructed two mutually exclusive groups: patients who initiated a GLP-1RA medication (and took no insulin) and patients who initiated insulin (and took no GLP-1RA). Pharmaceutical exposure was confirmed through national drug codes, and continuous use for at least six months from the index prescription was required. A three-month lead-in window was applied after that six-month confirmation period before cancer events were counted, and any individual with a new cancer diagnosis in the first nine months after the index prescription was excluded to reduce detection bias. Patients with a cancer diagnosis in the year preceding the index date were also excluded.
To address the substantial baseline differences between patients who receive GLP-1RAs versus insulin in clinical practice, the investigators applied Overlap Propensity Score Weighting (OPSW) across approximately 50 covariates, including age, sex, body mass index, adverse social determinants of health, personal or family cancer history, diabetes-related complications, genetic cancer predisposition, concurrent antidiabetic medications, and prior bariatric surgery. Following OPSW, standardized differences across measured covariates were reduced to less than 0.1. Cox proportional hazards models were then used to estimate hazard ratios for 16 specific cancer types, with Kaplan-Meier cumulative incidence curves generated for each. Participants were followed until cancer diagnosis, loss to follow-up, death, five years after index prescription, or end of the study period, whichever came first. Sensitivity analyses excluded patients using DPP-4 inhibitors and stratified by sex.
Key Findings: Primary Outcomes
Of 106,088 patients, 1.9% (n = 1,594) developed cancer during a median follow-up of 30 months (IQR 20–46).
Liver cancer: GLP-1RA was associated with a 53% lower hazard compared with insulin (HR 0.47, 95% CI 0.27–0.82; p < 0.05). Post-OPSW incidence rates were 0.34 per 1,000 person-years (GLP-1RA) versus 0.71 per 1,000 person-years (insulin).
Pancreatic cancer: GLP-1RA was associated with a 77% lower hazard compared with insulin (HR 0.23, 95% CI 0.11–0.51; p < 0.001). Post-OPSW incidence rates were 0.14 per 1,000 person-years (GLP-1RA) versus 0.61 per 1,000 person-years (insulin).
Overall combined cancer incidence was lower in the GLP-1RA group (6.5%, 95% CI 6.1–7.0) compared with insulin (7.7%, 95% CI 7.2–8.2).
No statistically significant difference in cancer risk was identified for thyroid, lung, breast, esophageal, gastric, biliary, small intestinal, renal, bladder, colorectal, prostate, ovarian, endometrial, or neuroendocrine cancers (all p > 0.05).
Key Findings: Secondary Outcomes and Subgroup Analyses
A sex-stratified sensitivity analysis was performed to account for sex-specific cancers; results were reported as consistent with the primary analysis, though granular sex-specific hazard ratios are not provided in the published tables.
A secondary sensitivity analysis excluding patients who received DPP-4 inhibitors produced consistent findings (Supplementary Table 2), suggesting that concurrent incretin-based therapy was not driving the observed associations.
Among cancer types with numerically lower point estimates that did not reach statistical significance, biliary cancer showed an HR of 0.32 (95% CI 0.06–1.59) and gastric cancer an HR of 0.57 (95% CI 0.21–1.54). The wide confidence intervals for these low-incidence cancers preclude any conclusion.
Small intestinal cancer showed an HR of 1.85 (95% CI 0.46–7.41) favoring insulin, though the confidence interval is extremely wide and the event count is low (n = 23 total), rendering this numerically elevated estimate uninformative.
The median duration of GLP-1RA use was 21 months (IQR 15–31) and insulin use was 23 months (IQR 15–38), indicating broadly comparable exposure durations between groups.
Adverse Events and Safety Profile
This study was designed to assess cancer incidence as an outcome, not to capture adverse events from GLP-1RA therapy. Accordingly, no structured adverse event data are reported. Notably, the study found no increased cancer signal for any of the 16 cancer types evaluated, including thyroid and neuroendocrine tumors, which have carried regulatory concern based on preclinical animal data. The absence of a thyroid cancer signal in this cohort is consistent with the study authors’ observation that clinicians may already be excluding patients with familial thyroid cancer or multiple endocrine neoplasia risk from GLP-1RA prescriptions, per FDA guidance, which would attenuate any detectable signal in a real-world claims dataset.
Statistical Approach and Rigor
The investigators used Overlap Propensity Score Weighting, a causal inference technique that assigns greater weight to individuals near the region of propensity score overlap between treatment groups. The authors cite its superiority over Inverse Probability of Treatment Weighting for achieving covariate balance without extreme weight truncation. Post-weighting standardized differences below 0.1 were achieved across all measured covariates, which is a standard threshold for balance adequacy. Cox proportional hazards models provided time-to-event estimates, and Kaplan-Meier survival analysis generated cumulative incidence curves adjusted for baseline characteristics. Cancer outcomes required either one inpatient or two outpatient ICD-9/10 diagnoses, a two-source confirmation criterion that reduces false-positive outcome misclassification. The study followed STROBE reporting guidelines. The primary statistical limitation is that OPSW, however well-executed, balances only measured covariates; residual confounding from unmeasured variables (e.g., HbA1c, smoking status, race, alcohol use) cannot be excluded. Multiple outcomes were tested across 16 cancer types without a formal correction for multiplicity, which means some null results may be underpowered and some statistically significant results may warrant additional scrutiny.
Clinical Takeaway
For the clinician managing a patient with type 2 diabetes who has elevated baseline risk for hepatocellular carcinoma or pancreatic cancer, particularly in the context of metabolic-associated steatotic liver disease or obesity, these data add to a growing body of evidence suggesting that GLP-1RA therapy may confer oncologic benefit beyond glycemic control. The association with reduced liver cancer risk is biologically plausible and directionally consistent with prior work from Wang et al. The pancreatic cancer finding is the more striking result numerically and mechanistically; the reported HR of 0.23 is large enough to warrant serious attention, though the absolute event counts (22 cases in the GLP-1RA group vs. 65 in the insulin group) are modest. Neither finding should yet redirect oncologic surveillance protocols or override individualized prescribing decisions. These are hypothesis-generating signals from an observational dataset that demand prospective confirmation.
Clinical Bottom Line: GLP-1 receptor agonists were associated with significantly lower incidence of liver and pancreatic cancer compared with insulin in a large, propensity-weighted cohort of commercially insured adults with type 2 diabetes — an observational signal that warrants prospective investigation but does not yet change screening or treatment guidelines.
Why This Matters Clinically
GLP-1 receptor agonists are now prescribed to tens of millions of patients worldwide for type 2 diabetes, obesity, and cardiovascular risk reduction. Any meaningful cancer signal in this drug class, whether protective or harmful, carries population-level implications that dwarf most single-drug oncology trials. The prior anxiety about thyroid cancer risk, which drove FDA boxed warning language for this class, was grounded largely in rodent C-cell hyperplasia data and has not been replicated in large human cohort studies, including this one. Conversely, the emerging protective signal for liver and pancreatic cancer is biologically anchored: GLP-1RAs reduce hepatic steatosis, modulate the PI3K/Akt pathway, suppress tumorigenic adipokines such as leptin, and may enhance natural killer cell cytotoxicity against hepatocellular carcinoma through IL-6/STAT3 pathway suppression. Pancreatic cancer cells also appear to have reduced or absent GLP-1 receptor expression compared with normal pancreatic cells, which may explain why receptor agonism does not promote pancreatic carcinogenesis in this dataset. These mechanistic threads do not prove causality, but they provide a rational biological framework for the observed associations. The clinical significance of a 77% hazard reduction for pancreatic cancer, a malignancy with a five-year survival rate below 15%, would be extraordinary if replicated in prospective trials.
CED Clinical Relevance
At CED Clinic, patients with type 2 diabetes often present with overlapping metabolic comorbidities, including obesity, dyslipidemia, hypertension, and metabolic-associated steatotic liver disease. These are precisely the patients at elevated baseline risk for both hepatocellular carcinoma and pancreatic adenocarcinoma. When a patient with this metabolic phenotype requires an antidiabetic agent, these data introduce a legitimate secondary consideration: the drug class choice may have cancer-related implications over a multi-year treatment horizon. This does not mean GLP-1RA therapy should be prescribed specifically for cancer prevention — the data do not support that framing. What the data do support is that patients already using GLP-1RAs for established indications can be counseled that the available evidence does not indicate an increased cancer risk for the 16 tumor types evaluated, and may
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
GLP-1RA use linked to lower liver and pancreatic cancer risk in type 2 diabetes patients.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ComprehensiveBadge 2: Large CohortBadge 3: Rigorous Methodology
This study, involving over 106,000 adults with type 2 diabetes, found that GLP-1 receptor agonist (GLP-1RA) use was associated with a significantly lower risk of liver and pancreatic cancer compared to insulin. The research used Overlap Propensity Score Weighting to balance covariates effectively.
The findings suggest that GLP-1RAs may offer oncologic benefits beyond glycemic control, particularly for patients at elevated risk for hepatocellular carcinoma or pancreatic cancer.
GLP-1RA use was associated with a 53% lower hazard of liver cancer and a 77% lower hazard of pancreatic cancer compared to insulin.
No increased risk of thyroid cancer was observed in the GLP-1RA group, contrary to some preclinical concerns.
The study relied on claims data and did not capture adverse events, which may have limitations in capturing all cancer cases.
Key Insight
GLP-1RAs are associated with a significantly lower risk of liver and pancreatic cancer compared to insulin.
Patient Takeaway
Badge 1: Patient-CentricBadge 2: Evidence-BasedBadge 3: Risk Reduction
For patients with type 2 diabetes, GLP-1 receptor agonists (GLP-1RAs) may offer additional benefits beyond controlling blood sugar levels. This study shows that GLP-1RA use is associated with a lower risk of liver and pancreatic cancer compared to insulin.
This could be particularly beneficial for patients who are at higher risk for these cancers, such as those with metabolic-associated steatotic liver disease or obesity.
GLP-1RA use was linked to a 53% lower risk of liver cancer and a 77% lower risk of pancreatic cancer compared to insulin.
The study did not find any increased risk of thyroid cancer, addressing previous concerns.
These findings suggest that GLP-1RAs may be a safer option for certain high-risk patients.
Patient Takeaway
GLP-1RAs may reduce the risk of liver and pancreatic cancer in type 2 diabetes patients.
Clinician’s POV
Badge 1: Clinically RelevantBadge 2: Evidence-BasedBadge 3: Risk Assessment
Clinicians managing patients with type 2 diabetes can consider GLP-1 receptor agonists (GLP-1RAs) not only for glycemic control but also for potential oncologic benefits. This study indicates that GLP-1RA use is associated with a lower risk of liver and pancreatic cancer compared to insulin.
These findings are particularly relevant for patients at elevated risk for hepatocellular carcinoma or pancreatic cancer, such as those with metabolic-associated steatotic liver disease or obesity.
GLP-1RA use was associated with a 53% lower hazard of liver cancer and a 77% lower hazard of pancreatic cancer compared to insulin.
No increased risk of thyroid cancer was observed, addressing previous concerns.
These findings suggest that GLP-1RAs may be a safer option for certain high-risk patients.
Clinician Takeaway
GLP-1RAs reduce liver and pancreatic cancer risk in type 2 diabetes patients.
A Skeptical Read
Badge 1: Skeptical ViewBadge 2: Critical AnalysisBadge 3: Data Scrutiny
While the study suggests that GLP-1 receptor agonists (GLP-1RAs) may reduce the risk of liver and pancreatic cancer, it is important to consider potential limitations. The research relied on claims data and did not capture adverse events, which could affect the accuracy of the findings.
Further research is needed to confirm these results and better understand the long-term safety profile of GLP-1RAs in relation to cancer risk.
The study found a 53% lower hazard of liver cancer and a 77% lower hazard of pancreatic cancer with GLP-1RA use compared to insulin.
No increased risk of thyroid cancer was observed, addressing previous concerns.
The study did not capture adverse events, which could affect the accuracy of the findings.
Skeptic Takeaway
GLP-1RAs may reduce liver and pancreatic cancer risk, but further research is needed.
Study Critic
Badge 1: Critical PerspectiveBadge 2: Data ScrutinyBadge 3: Methodological Rigor
Critics might point out that the study relied on claims data, which may not capture all cancer cases accurately. Additionally, while no increased risk of thyroid cancer was observed, this could be due to exclusion criteria that may have reduced detectable signals.
Further research with more comprehensive data collection and longer follow-up periods is necessary to fully understand the oncologic safety profile of GLP-1RAs.
The study found a 53% lower hazard of liver cancer and a 77% lower hazard of pancreatic cancer with GLP-1RA use compared to insulin.
No increased risk of thyroid cancer was observed, but this could be due to exclusion criteria.
The study relied on claims data, which may not capture all cancer cases accurately.
Critic Takeaway
GLP-1RA cancer risk findings need further validation with comprehensive data.
Compared to Past Research
Badge 1: Historical ContextBadge 2: Previous StudiesBadge 3: Research Evolution
Previous studies have suggested both protective and potentially oncogenic effects of GLP-1 receptor agonists (GLP-1RAs). This study adds to the body of evidence by providing a large, real-world cohort analysis that shows GLP-1RA use is associated with a lower risk of liver and pancreatic cancer compared to insulin.
These findings are consistent with some prior work but also address concerns raised in preclinical studies about potential oncogenic associations.
GLP-1RA use was associated with a 53% lower hazard of liver cancer and a 77% lower hazard of pancreatic cancer compared to insulin.
The study addresses previous concerns about potential oncogenic associations raised by preclinical studies.
These findings are consistent with some prior work suggesting protective effects of GLP-1RAs.
Past Research
GLP-1RA cancer risk findings align with some past research but address previous concerns.
Practical Considerations
Badge 1: Practical ImplicationsBadge 2: Clinical ApplicationBadge 3: Risk Management
Practically, these findings suggest that GLP-1 receptor agonists (GLP-1RAs) may be a safer option for patients with type 2 diabetes who are at elevated risk for liver or pancreatic cancer. Clinicians can consider GLP-1RA therapy in such cases to potentially reduce cancer risk.
However, it is important to monitor patients closely and consider individual patient factors when making treatment decisions.
GLP-1RA use was associated with a 53% lower hazard of liver cancer and a 77% lower hazard of pancreatic cancer compared to insulin.
These findings suggest that GLP-1RAs may be a safer option for certain high-risk patients.
Individual patient factors should be considered when making treatment decisions.
Practical Takeaway
GLP-1RAs reduce liver and pancreatic cancer risk in high-risk type 2 diabetes patients.
Future Directions
Badge 1: Future DirectionsBadge 2: Research NeedsBadge 3: Long-Term Studies
Future research should focus on confirming these findings with longer follow-up periods and more comprehensive data collection. It is also important to investigate the mechanisms behind the reduced cancer risk associated with GLP-1 receptor agonists (GLP-1RAs).
Additionally, studies should explore the long-term safety profile of GLP-1RAs in relation to other cancer types.
Further research is needed to confirm these findings and better understand the mechanisms behind reduced cancer risk.
Longer follow-up periods and more comprehensive data collection are required for future studies.
Investigating the long-term safety profile of GLP-1RAs in relation to other cancer types is important.
Future Research
Further research needed to confirm GLP-1RA cancer risk findings and explore mechanisms.
Misreadings & Bad-Faith Takes
Badge 1: Common MisunderstandingsBadge 2: Clarification NeededBadge 3: Data Interpretation
One common misreading of this study is that GLP-1 receptor agonists (GLP-1RAs) completely eliminate cancer risk in type 2 diabetes patients. The study shows a reduced risk of liver and pancreatic cancer but does not eliminate the risk entirely.
Another potential misunderstanding is that these findings apply to all patients with type 2 diabetes. The benefits are particularly relevant for those at elevated risk for hepatocellular carcinoma or pancreatic cancer, such as those with metabolic-associated steatotic liver disease.
GLP-1RA use was associated with a lower risk of liver and pancreatic cancer but does not eliminate the risk entirely.
The benefits are particularly relevant for patients at elevated risk for hepatocellular carcinoma or pancreatic cancer.
These findings do not apply to all type 2 diabetes patients.
Misreadings
GLP-1RA reduces liver and pancreatic cancer risk but does not eliminate it.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
Understanding the Endocannabinoid System
A physician-authored primer on ECS biology and why it matters for clinical cannabis decisions.
Explore evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program, including GLP-1 therapies and whole-person care.
Read article
Cannabis for Pain Management
A practical physician guide to cannabinoid selection and symptom matching.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What are GLP-1 receptor agonists?
GLP-1 receptor agonists (GLP-1RAs) are medications used to treat type 2 diabetes by mimicking the effects of glucagon-like peptide-1, which helps regulate blood sugar levels.
How does this study compare GLP-1RA use to insulin?
The study compared cancer incidence in patients who initiated GLP-1RAs to those who started insulin therapy, using a large cohort of over 106,000 adults with type 2 diabetes.
What were the key findings regarding liver and pancreatic cancer?
The study found that GLP-1RA use was associated with a 53% lower hazard of liver cancer and a 77% lower hazard of pancreatic cancer compared to insulin.
Was there any increased risk of thyroid cancer observed?
No increased risk of thyroid cancer was observed in the GLP-1RA group, contrary to some preclinical concerns.
What methodological approach did the researchers use to ensure accuracy?
The researchers used Overlap Propensity Score Weighting (OPSW) and Cox proportional hazards models to assess cancer risk, ensuring balance across covariates.
What are the implications of these findings for clinical practice?
These findings suggest that GLP-1RA therapy may confer oncologic benefits beyond glycemic control, particularly in patients at risk for liver or pancreatic cancer.
How long was the follow-up period in this study?
The median follow-up period was 30 months (IQR 20–46).
Were there any limitations to the study?
The study did not capture adverse events and relied on claims data, which may have limitations in capturing all cancer cases.
What is the next step for research in this area?
Further research is warranted to better define the long-term cancer-related safety profile of GLP-1RAs.
Can these findings be applied to all patients with type 2 diabetes?
The findings may be particularly relevant for patients at elevated risk for hepatocellular carcinoma or pancreatic cancer, such as those with metabolic-associated steatotic liver disease. [...]
Read more...
June 3, 2026Cannabis Policy Priorities of Elected Officials: What the Data Show
Cannabis Policy
Public Health
Youth Prevention
Local Government
Partisan Politics
What You’ll Learn
How California’s local elected officials rank cannabis policy priorities — and where public health ranks relative to revenue
Where partisan divides are sharpest, and where rare cross-party consensus actually exists on youth protection measures
Why an 84% approval rating for a health-protective packaging rule has not translated into real ordinances in the vast majority of jurisdictions
What the qualitative data reveal about how officials actually frame cannabis, from prohibition-era moralism to wellness narratives, and why that framing matters for evidence-based advocacy
TL;DR: Among California elected officials, economic priorities outrank health concerns, partisan divides govern most licensing and resource-allocation questions, and an 84% cross-party consensus on banning youth-attractive packaging has failed to materialize into actual law in more than 96% of jurisdictions that allow retail sales.
? Cross-Sectional Survey Study
Abstract
Background: Cannabis legalization has substantial impacts on public health across the United States, yet the perspectives of local elected officials who oversee regulatory environments and make decisions about cannabis business retail licensing, taxation, and marketing restrictions remain largely unstudied. Understanding how these policymakers prioritize health considerations relative to economic and other concerns is essential for developing effective public health advocacy and anticipating barriers to implementing health-protective cannabis regulations.
Methods: From September 2023 to February 2024, we conducted an online survey of 2,681 elected officials in California local government, assessing cannabis policy positions, priorities, and engagement. Descriptive statistics were calculated for all measures. Likelihood ratio tests using logistic regression assessed differences across political party affiliations (Democrat, Republican, Independent), with analyses stratified by whether respondents’ jurisdictions allowed cannabis retail. One open-ended measure was analyzed using thematic coding.
Results: Among 250 respondents (9.3% response rate), who were primarily city council members, 40% reported direct cannabis policy experience and 75% expressed interest in regulatory involvement. Top priorities were tax revenue (41%), economic development (41%), and youth cannabis use (38%), reflecting tension between fiscal and health considerations. Support for licensing adult-use retailers was significantly higher among Democrats (72%) than Republicans (39%; OR = 0.25 ) or Independents (38%; OR = 0.23 ). Republicans were significantly more likely to prioritize adverse health effects (47% vs. 22% Democrats; OR = 3.10 ). Social equity was prioritized by only 13% overall, with significant partisan variation (20% Democrats vs. 3% Republicans; OR = 0.11 ). Cross-party agreement emerged on restricting youth-attractive packaging (84%), yet fewer than 4% of California jurisdictions that allow retail to operate have implemented such protections. Qualitative responses revealed diverse framings of cannabis, from prohibition-era moral concerns to wellness narratives, suggesting policy decisions are often not evidence-based.
Conclusions: This first systematic study of U.S. elected officials’ cannabis policy positions documents a political landscape in which economic considerations predominate over health concerns and significant gaps exist between policymakers’ support for health-protective measures and actual policy implementation. These findings identify actionable opportunities for evidence-based public health advocacy, particularly in support of bipartisan youth protection measures.
Source: Whitacre R, Padon A, Simard B, Silver LD. Cannabis policy priorities and public health: a survey of elected officials in California. BMC Public Health (2026).
DOI: https://doi.org/10.1186/s12889-026-27889-x
Status: Article in Press (accepted 20 May 2026; unedited version)
PubMed: PMID not yet assigned at time of publication
Study at a Glance
Design
Online cross-sectional survey with mixed-methods (quantitative + reflexive thematic analysis)
Population
Elected officials and their staffers in California city, county, and state government
N (invited / responded)
2,681 invited; 250 responded (9.3% response rate)
Primary Endpoint
Cannabis policy priorities and positions, including health vs. economic framing and partisan variation
Key Finding
Tax revenue and economic development (each 41%) outranked health outcomes; 84% cross-party support for packaging restrictions has not translated into enforceable ordinances in over 96% of retail-allowing jurisdictions
Study Snapshot
Metric
Finding
Top policy priority #1 and #2 (tied)
Tax revenue (41%) and economic development (41%)
Top policy priority #3
Youth cannabis use (38%)
Democrats supporting adult-use retail licensing
72%
Republicans supporting adult-use retail licensing
39% (OR = 0.25 vs. Democrats)
Republicans prioritizing adverse health effects
47% vs. 22% Democrats (OR = 3.10 )
Social equity as a top priority (overall)
13% overall; 20% Democrats vs. 3% Republicans (OR = 0.11 )
Cross-party support for banning youth-attractive packaging
84%
Jurisdictions with retail that enacted such packaging rules
12 of 320 (<4%)
Republicans prioritizing law enforcement for tax revenue
71% vs. 28% Democrats (OR = 6.47 )
Officials approached by cannabis industry representatives
54% (across all parties)
Study Facts Table
Field
Detail
Authors
Ryan Whitacre, Alisa Padon, Bethany Simard, Lynn D. Silver
Journal
BMC Public Health
Year
2026 (Article in Press)
Design
Cross-sectional online survey with thematic analysis of open-ended responses
N
250 respondents from 2,681 invited (9.3% response rate); partisan analysis n = 155
Population
City council members, county supervisors, county sheriffs, district attorneys, state legislators, and their staffers in California
Intervention
Not applicable (observational survey)
Primary Endpoint
Cannabis policy priorities, positions on regulatory measures, and partisan variation in both
Key Results
Tax revenue and economic development tied as top priorities (41% each); youth use third (38%); 84% cross-party support for packaging restrictions vs. <4% implementation; significant partisan divides on licensing, equity, and tax allocation
Adverse Events
Not applicable
Funding
University of California Tobacco-Related Diseases Research Program (Agreement No. T32IR5110)
Conflicts of Interest
LDS reports financial support from the University of California Office of the President; all other authors declare no competing interests
What Researchers Actually Did
Between September 2023 and February 2024, the research team deployed an online survey to 2,681 California elected officials and their staffers — spanning city council members, county supervisors, sheriffs, district attorneys, and state legislators — whose email addresses were publicly listed on jurisdiction websites. Four reminder contacts were sent over a 19-week window. The instrument covered four domains: prior cannabis policy experience and barriers to engagement; substantive policy priorities (respondents’ own and their perception of constituents’); positions on specific regulatory measures (retail licensing, packaging, marketing, delivery, taxation, and revenue allocation); and stakeholder input received. Four items used a forced-choice “top three” format to reveal true priority ordering rather than global endorsement. Jurisdiction retail status as of January 1, 2024, was drawn from the Public Health Institute’s California Cannabis Policies database and used to stratify all logistic regression analyses.
Statistical comparisons across Democrats, Republicans, and Independents used likelihood ratio tests from logistic regression, with Bonferroni-corrected Z-tests for significant pairwise comparisons. Quasi-complete separation, encountered in several low-frequency cells, was handled with Firth penalized likelihood regression. Sixty-two respondents (25%) provided open-ended text, analyzed via reflexive thematic analysis using a hybrid deductive-inductive coding strategy aligned with Braun and Clarke’s framework. A second coder independently reviewed a subset of responses, with discrepancies resolved by consensus. The quantitative and qualitative streams were triangulated to produce the final thematic synthesis.
Key Findings: Primary Outcomes
Economic priorities dominate: Tax revenue and economic development were each named a top-three priority by 41% of respondents, tied for first. Youth cannabis use ranked third at 38%.
Partisan divide on licensing: Democrat support for adult-use retail licensing (72%) substantially exceeded Republican support (39%; OR = 0.25 ) and Independent support (38%; OR = 0.23 ). In jurisdictions already allowing retail, this gap narrowed to non-significance (D: 78%, R: 70%; OR = 0.64 ).
Republicans more likely to prioritize adverse health effects: 47% of Republicans listed adverse health or social effects of cannabis use as a top-three priority, compared with 22% of Democrats (OR = 3.10 ).
Social equity neglected across the board: Only 13% overall named social equity a top priority. The figure was 20% among Democrats and 3% among Republicans (OR = 0.11 ).
Cross-party consensus on packaging: 84% of respondents supported prohibiting packaging attractive to youth, with no statistically significant partisan difference. Despite this, only 12 of 320 California jurisdictions allowing retail had enacted regulations improving upon the state’s vague standard.
Cannabis industry access to policymakers: 54% of respondents had been approached by cannabis industry representatives — the same frequency as private citizens (56%).
General engagement: 75% of respondents expressed being somewhat or very interested in cannabis industry regulation; 59% considered cannabis policy a priority.
Key Findings: Secondary Outcomes and Subgroup Analyses
Tax Revenue Allocation by Party
Republicans prioritized directing cannabis tax revenue to law enforcement at a rate of 71%, compared with 28% among Democrats (OR = 6.47 ) and 43% among Independents (OR = 0.31 ). This disparity widened within retail-allowing jurisdictions: an estimated 95% of Republicans in those jurisdictions ranked law enforcement first, compared with 28% of Democrats (OR = 54.31 ) — a finding where the confidence interval width signals a small-cell problem and warrants interpretive caution. Democrats were more likely to prioritize supporting vulnerable youth (29% vs. 11% Republicans; OR = 0.29 ).
Youth Prevention Strategies
The two most commonly cited effective strategies for reducing youth cannabis use were limiting products mimicking candies or foods attractive to children (55%) and eliminating the illicit market (53%). Fewer than one in five respondents endorsed using tax revenue for youth programs (19%), establishing larger retailer buffer zones (16%), or education campaigns (16%). Democrats more frequently endorsed dedicating tax revenue for youth programs (28% vs. 8% Republicans; OR = 0.23 ).
Constituent Priorities vs. Officials’ Own Priorities
When asked to characterize constituent priorities, officials ranked negative health impacts of youth use first (42%), followed by eliminating the illicit market (36%) and negative community impacts of cannabis businesses (35%). Republicans were significantly more likely to identify negative health impacts of cannabis consumption (not just youth use) as a constituent priority (34%) relative to Democrats (11%; OR = 4.10 ).
Partisan Convergence in Retail-Allowing Jurisdictions
In jurisdictions where retail cannabis was already permitted, partisan differences in support for licensing medical and adult-use retailers were statistically non-significant between Democrats and Republicans. This convergence may reflect either normalization of legal retail or baseline self-selection of less divided jurisdictions into allowing retail in the first place.
Qualitative Themes
Open-ended responses revealed framings spanning prohibition-era moralism (“the dumbing down of America”; “eating away at the fabric of our community”), wellness narratives (“legal, regulated cannabis is not a dangerous drug”), informed public-health thinking (concerns about edible dosing, rising mental health diagnoses in young adults), and pragmatic market concerns (illicit market competition, over-regulation, insufficient medical access in rural communities). These framings coexisted across regions and do not track cleanly onto party affiliation.
Adverse Events and Safety Profile
Not applicable to a survey study of elected officials. No pharmacological intervention was assessed. The paper does, however, document that respondents perceived the illicit cannabis market as a safety threat, including concerns about fentanyl-contaminated products reaching youth and pesticide-laden illegal cannabis entering licensed facilities — framing these as population-level safety signals requiring regulatory action rather than clinical adverse events.
Statistical Approach and Rigor
The primary analytic strategy — likelihood ratio tests from logistic regression with Bonferroni-corrected pairwise Z-tests — is appropriate for the research questions posed. The use of Firth penalized likelihood regression to handle quasi-complete separation in sparse cells (e.g., Republicans with zero experience in certain policy areas) reflects methodological awareness; however, several resulting confidence intervals are very wide and should be treated as directional rather than precise estimates. Stratification by local retail policy adds important contextual resolution. The forced-choice “top three” format prevents artificial inflation of endorsement rates and is well-suited to priority elicitation in time-constrained official samples. The reflexive thematic analysis of open-ended responses follows an established framework (Braun and Clarke), with inter-rater reliability addressed through independent subset coding and consensus resolution. The triangulation of quantitative and qualitative findings is explicit and methodologically coherent. The cross-sectional design, 9.3% response rate, and the 36% of respondents who declined to provide party affiliation are the main threats to inferential validity.
Clinical Takeaway
The decisions that most directly shape the cannabis exposure environment — retail density, product type restrictions, packaging rules, marketing limitations — are made by local elected officials whose stated priorities are overwhelmingly fiscal, not clinical. Public health practitioners and cannabis clinicians who assume that evidence alone will move local policy are operating under a miscalculation. The data show that 84% of officials already support packaging restrictions that demonstrably reduce youth appeal; the bottleneck is not attitude, it is translation into ordinance. That gap is likely maintained by industry lobbying, competing municipal priorities, and limited regulatory technical capacity — not policymaker ignorance of the issue. Effective clinical-to-policy translation will require direct engagement with local decision-makers, not just publication of additional health outcome studies.
Clinical Bottom Line: Local cannabis regulatory environments, which directly affect patient exposure, use patterns, and health outcomes, are governed primarily by economic priorities and partisan dynamics — not by the clinical evidence that health professionals generate and publish.
Why This Matters Clinically
Research cited within this paper has established that retail outlet density near homes is associated with increased adolescent cannabis use, problematic use, and cannabis use during pregnancy; that local retail bans and longer drive times to the nearest retailer correlate with lower prevalence of psychotic disorder diagnoses in California adolescents; and that frequent adolescent use increased post-legalization specifically in communities allowing storefront retail. These are not theoretical regulatory risks — they are observed epidemiological signals with direct clinical relevance to the patients seen in cannabis medicine and general practice. The present survey reveals that the officials making the licensing, density, packaging, and taxation decisions driving these outcomes are operating primarily from fiscal frames and are reaching those decisions in a political environment where the cannabis industry has achieved access parity with private citizens. For clinicians ordering cannabis for patients with anxiety, psychosis risk, or prenatal concerns, the local regulatory environment is as clinically relevant as the pharmacology.
CED Clinic Relevance
At CED Clinic, patients and families frequently ask whether the cannabis they or their loved ones use is safe, properly labeled, appropriately dosed, and not marketed to children. This paper provides a structural answer to why those assurances are not consistently available: the local officials best positioned to enact packaging standards, marketing restrictions, and potency labeling requirements rank those protections well below revenue generation and market development. Patients residing in jurisdictions that allow retail are exposed to a product environment that has not been systematically bounded by the health-protective regulations that 84% of their own elected officials claim to support. That gap between stated preference and enacted law is the central policy failure this paper documents. For CED Clinic patients, particularly adolescents, pregnant individuals, and those with mental health comorbidities, this regulatory vacuum is clinically material — not peripheral.
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
California officials prioritize economic gains over health in cannabis policy.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ValueBadge 2: ValueBadge 3: Value
This study highlights the significant economic focus of California elected officials in cannabis policy, overshadowing health concerns. Despite a strong cross-party agreement on youth packaging bans, implementation remains largely unenforced.
The research underscores the need for evidence-based advocacy to bridge the gap between policymakers’ support and actual policy outcomes, particularly in protecting youth from cannabis use.
Economic priorities dominate over health concerns.
Cross-party consensus exists on youth packaging bans but is not implemented.
Advocacy can help align policy with public health goals.
Key Insight
Economic benefits are prioritized over health in cannabis policy, despite cross-party agreement on youth protection measures.
Patient Takeaway
Badge 1: ValueBadge 2: Value
Patients should be aware that while there is strong support for protecting youth from attractive packaging, this has not yet been implemented in most jurisdictions. This gap highlights the need for continued advocacy to ensure health-protective measures are enacted.
Understanding these priorities can help patients advocate more effectively for policies that protect public health.
Youth protection measures lack implementation.
Advocacy is crucial for policy change.
Patients can play a role in promoting evidence-based policies.
Patient Takeaway
Support for youth packaging bans exists but is not implemented, highlighting the need for continued advocacy.
Clinician’s POV
Badge 1: ValueBadge 2: Value
Clinicians can use this data to inform their advocacy efforts, focusing on evidence-based policies that protect public health. The gap between support and implementation of youth protection measures underscores the need for targeted interventions.
Understanding these priorities can help clinicians better communicate with policymakers about the importance of health-protective regulations.
Clinicians should advocate for evidence-based policies.
Youth protection measures lack enforcement.
Communication is key in policy advocacy.
Clinical Takeaway
Advocate for youth packaging bans and other health-protective measures despite current gaps in implementation.
A Skeptical Read
Badge 1: ValueBadge 2: Value
Skeptics might question the effectiveness of cross-party consensus without enforcement. This study highlights the disconnect between policy support and actual implementation, suggesting that additional measures are needed to ensure health-protective policies are enacted.
Understanding these gaps can help skeptics identify areas for reform in the legislative process.
Cross-party agreement does not guarantee policy change.
Implementation gaps exist despite consensus.
Reform is needed in legislative processes.
Skeptic Takeaway
Cross-party support for youth packaging bans exists but lacks enforcement, indicating a need for legislative reform.
Study Critic
Badge 1: ValueBadge 2: Value
Critics can point to the economic focus of policymakers as a potential conflict of interest. The study reveals that while health is a concern, it is often secondary to economic priorities, raising questions about the balance between fiscal and public health goals.
Understanding these priorities can help critics highlight areas where policy may not align with public health objectives.
Economic focus may conflict with health goals.
Health concerns are secondary to economic priorities.
Critics should address potential conflicts of interest.
Critical Takeaway
Economic priorities dominate over health, raising questions about the balance between fiscal and public health goals.
Compared to Past Research
Badge 1: ValueBadge 2: Value
Past research has often focused on the impacts of cannabis legalization but rarely examined the perspectives of local elected officials. This study fills a gap by providing insights into how policymakers prioritize health versus economic considerations.
Historical data can be compared to this new information to track changes in policy priorities over time.
Past research lacked focus on official perspectives.
This study provides unique insights into policy priorities.
Comparison with historical data is possible.
Historical Context
This study fills a gap by examining the priorities of local elected officials, providing new insights into cannabis policy.
Practical Considerations
Badge 1: ValueBadge 2: Value
Practically, this research can guide advocacy efforts to prioritize health-protective measures. The strong support for youth packaging bans suggests that targeted campaigns could be effective in pushing for implementation.
Understanding these priorities can help stakeholders align their advocacy with the most supported policies.
Advocacy should focus on evidence-based policies.
Youth protection measures have broad support.
Stakeholders can align advocacy efforts effectively.
Practical Takeaway
Focus advocacy on youth packaging bans and other health-protective measures with strong cross-party support.
Future Directions
Badge 1: ValueBadge 2: Value
Future research could explore the reasons behind the gap between policy support and implementation. Understanding these barriers can inform strategies to improve enforcement of health-protective measures.
This study sets a foundation for further investigation into the legislative process and policy outcomes.
Explore barriers to policy implementation.
Further research is needed on legislative processes.
Set a foundation for future studies.
Future Research
Investigate barriers to implementing health-protective policies to improve enforcement.
Misreadings & Bad-Faith Takes
Badge 1: ValueBadge 2: Value
A common misreading of this study might be that cross-party consensus guarantees policy change. However, the research clearly shows that support does not translate into implementation in most jurisdictions.
Understanding these gaps is crucial to avoid oversimplifying the legislative process and its challenges.
Cross-party agreement does not guarantee policy change.
Implementation gaps are significant.
Avoid oversimplifying legislative processes.
Misreading Alert
Cross-party support for youth packaging bans exists but does not translate into implementation, highlighting the complexity of legislative processes.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
Understanding the Endocannabinoid System
A physician-authored primer on ECS biology, receptor function, and why the system matters for clinical cannabis care.
Explore evidence
Cannabis for Pain Management: Smarter Ways to Match Products to Symptoms
A practical explainer on how pain timing, formulation selection, and cannabinoid ratios influence real-world outcomes.
Read article
Cannabis and Sleep: What the Evidence Actually Shows
A review of cannabinoid effects on sleep architecture, with clinical guidance for patients using cannabis for insomnia or sleep disruption.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What were the top priorities of California elected officials regarding cannabis policy?
The top priorities were tax revenue (41%), economic development (41%), and youth cannabis use (38%).
How did partisan differences affect support for adult-use retail licensing?
Support was significantly higher among Democrats (72%) than Republicans (39%) or Independents (38%).
What percentage of California jurisdictions with retail cannabis have implemented youth-attractive packaging bans?
Fewer than 4% of such jurisdictions have enacted these protections.
How did officials frame cannabis in their qualitative responses?
Responses varied from prohibition-era moral concerns to wellness narratives, indicating that policy decisions are often not evidence-based.
What was the level of cross-party agreement on restricting youth-attractive packaging?
There was an 84% cross-party support for such restrictions.
How did Republicans and Democrats differ in their prioritization of adverse health effects?
Republicans were significantly more likely to prioritize adverse health effects (47%) compared to Democrats (22%).
What percentage of officials had been approached by cannabis industry representatives?
54% of respondents reported being approached by cannabis industry representatives.
How did Republicans and Democrats differ in their prioritization of directing tax revenue to law enforcement?
Republicans prioritized directing cannabis tax revenue to law enforcement at a rate of 71%, compared with 28% among Democrats.
What were the two most commonly cited effective strategies for reducing youth cannabis use?
The two most cited strategies were limiting products mimicking candies or foods attractive to children (55%) and eliminating the illicit market (53%).
How did officials perceive constituent priorities regarding cannabis?
Officials ranked negative health impacts of youth use first, followed by eliminating the illicit market and negative community impacts of cannabis businesses. [...]
Read more...
June 3, 2026Stopping GLP-1 Drugs: Weight Regain and Heart Risks Explained
GLP-1 Receptor Agonists
Weight Regain
Cardiometabolic Risk
Obesity Pharmacotherapy
Tirzepatide / Semaglutide
What You’ll Learn From This Review
How rapidly weight and cardiometabolic markers rebound after stopping GLP-1 or dual-incretin therapy, with specific timelines drawn from STEP-1, STEP-4, and SURMOUNT-4
The biological and behavioral mechanisms — orexigenic reactivation, adaptive thermogenesis, insulin resistance re-emergence — that drive post-discontinuation relapse
What the real-world cardiovascular event data show for patients who stop therapy within the first year
A proposed five-phase multidisciplinary transition framework for clinicians managing patients who must or choose to discontinue
TL;DR: Stopping GLP-1 receptor agonists is not a neutral event — 60% to 90% of lost weight returns within one year, cardiometabolic biomarkers revert to baseline within 12 to 18 months, and early discontinuers carry significantly elevated risks of coronary artery disease and heart failure compared with patients who continue therapy.
? Narrative Review with Synthesis of RCT Extension Data, Meta-Analyses, and Real-World Cohorts
Abstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual incretin therapies produce substantial weight loss and cardiometabolic improvement, yet treatment discontinuation is common and associated with adverse metabolic consequences.
Aims: This review aims to synthesize current mechanistic and clinical evidence on metabolic trajectories following GLP-1RA discontinuation, identify predictors of relapse, and propose a multidisciplinary framework for post-treatment management.
Materials and Methods: The authors conducted a narrative review of evidence from randomized withdrawal trials (including STEP-1 extension, STEP-4, and SURMOUNT-4), systematic reviews, meta-analyses, and large real-world observational cohorts encompassing over 289,000 patients.
Results: Discontinuation is associated with substantial weight regain (60%–90% within one year) and parallel reversal of cardiometabolic benefits. Modelling studies suggest that glycaemic, blood pressure, and lipid parameters return to baseline within approximately 12 months, while HbA1c normalizes within 12–18 months. Early discontinuation (<1 year) is associated with increased risks of coronary artery disease and heart failure compared with continued therapy.
Discussion: Weight recurrence reflects biological adaptations to weight loss, including reactivation of orexigenic pathways and adaptive thermogenesis. In the absence of validated tapering strategies, structured multidisciplinary transition approaches combining pharmacological, behavioral, and psychological interventions may mitigate post-discontinuation relapse.
Conclusion: GLP-1RA discontinuation should be considered a high-risk clinical transition rather than a treatment endpoint. Structured follow-up and multidisciplinary management are essential to preserve long-term cardiometabolic benefits.
Source: Shah E, AlShiab R, Abdo A, Ozbek L, Covic A, Kanbay M. Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists. Diabetes, Obesity and Metabolism. 2026;28:4546–4558.
DOI: 10.1111/dom.70713 |
Received: 13 February 2026 | Accepted: 17 March 2026
Study at a Glance
Design
Narrative review synthesizing randomized withdrawal trials, systematic reviews, meta-analyses, and real-world cohort data
Key Data Sources
STEP-1 extension, STEP-4, SURMOUNT-4; a 2026 BMJ systematic review/meta-analysis (37 studies, 9,341 participants); a U.S. real-world cohort (n = 289,809)
Population
Adults with obesity (with and without type 2 diabetes) who discontinued GLP-1RA or dual incretin therapy
Intervention
Discontinuation of semaglutide or tirzepatide (abrupt cessation in most trial contexts)
Primary Focus
Magnitude and timeline of weight regain; reversal of cardiometabolic benefits; predictors of relapse; multidisciplinary management
Headline Finding
60%–90% of lost weight is regained within 12 months; all cardiometabolic biomarkers return to baseline within 12–18 months; early discontinuers carry elevated CAD and HF risk
Study Snapshot: Key Numbers
Metric
Finding
Source
Weight regained at 52 weeks post-semaglutide
~11.6 percentage points of body weight (~2/3 of loss)
STEP-1 extension
Weight regained at 52 weeks post-tirzepatide
14.0% (vs. additional 5.5% loss in continuers)
SURMOUNT-4
Overall proportion of weight loss regained
60%–90% within 1 year; regain begins within 8–12 weeks
Pooled withdrawal trial data
HbA1c rebound rate
~0.05 mmol/mol per month; returns to baseline in ~12–18 months
BMJ meta-analysis (2026)
Systolic BP rebound rate
~0.5 mmHg/month (initial treatment reduction: 5.8 mmHg)
BMJ meta-analysis (2026)
LDL-C / triglyceride rebound
Total cholesterol +0.05 mmol/L/month; triglycerides +0.03 mmol/L/month
BMJ meta-analysis (2026)
Real-world discontinuation rates
~30% stopped within 1 year; >50% by 2 years
U.S. cohort, n = 289,809
Post-cessation CV event rates (early discontinuers)
ACS 1.78%; CAD 17.1%; HF 10.2% at 1 year; CAD and HF risk remained elevated vs. long-term users
Tajerian et al. real-world cohort
Full Study Facts
Authors
Shah E, AlShiab R, Abdo A, Ozbek L, Covic A, Kanbay M
Journal
Diabetes, Obesity and Metabolism
Year
2026
DOI
10.1111/dom.70713
Study Design
Narrative review integrating randomized withdrawal trials, systematic reviews, meta-analyses, and large observational cohorts
Total Patients (across sources)
>289,000 (real-world cohort); 9,341 (meta-analysis); additional withdrawal trial participants
Intervention
Discontinuation of once-weekly semaglutide 2.4 mg or tirzepatide (various doses)
Comparator
Continued therapy (in randomized withdrawal trials: placebo vs. active drug continuation)
Primary Endpoint (review focus)
Weight regain magnitude and timeline; reversal of cardiometabolic biomarkers after cessation
Key Results
60%–90% weight regain within 1 year; all biomarkers return to baseline within 12–18 months; CAD and HF risk elevated in early discontinuers
Adverse Events
Not systematically reported in this review; CV outcomes referenced from real-world cohort data
Funding
Nothing reported by authors
Conflicts of Interest
None declared
What the Researchers Actually Did
Shah and colleagues conducted a narrative review synthesizing evidence from three categories of sources: randomized withdrawal and extension trials (specifically the STEP-1 extension, STEP-4, and SURMOUNT-4), a 2026 systematic review and meta-analysis that pooled 37 studies including 9,341 participants on post-cessation biomarker trajectories, and a large U.S. real-world cohort of 289,809 adults initiating semaglutide or tirzepatide. The review was organized around four domains: the physiology of post-discontinuation weight regain, clinical evidence on regain magnitude and timing, cardiometabolic consequences, and multidisciplinary management strategies.
Because this is a narrative rather than systematic review, study selection and evidence weighting were not governed by a registered protocol or formal risk-of-bias assessment. The authors drew on mechanistic literature, clinical trial data, and observational cohort analyses to construct a conceptual framework for post-discontinuation trajectories. They also propose a five-phase clinical transition protocol (summarized in Figure 3 of the paper) and compare post-pharmacotherapy weight recurrence patterns with those observed after bariatric surgery. No new primary data were generated.
Key Findings: Primary Outcomes
STEP-1 extension (semaglutide 2.4 mg): After 68 weeks of treatment followed by 52 weeks of withdrawal, approximately two-thirds of previously lost weight was regained, corresponding to a mean rebound of 11.6 percentage points of body weight. By week 120, most cardiometabolic improvements had substantially reverted toward baseline.
SURMOUNT-4 (tirzepatide): Participants who discontinued after a 36-week lead-in achieving ~21% weight loss regained a mean of 14.0% body weight over 52 weeks, versus an additional 5.5% reduction in those who continued. Nearly 90% of the weight lost during the lead-in phase was preserved only in the continuation arm.
Pooled withdrawal trial data: 60%–90% of achieved weight loss is typically regained within the first year. Regain begins within 8–12 weeks and follows a steep early trajectory.
BMJ meta-analysis (37 studies, 9,341 participants): HbA1c rose at approximately 0.05 mmol/mol per month; fasting glucose rose at ~0.06 mmol/L per month. Systolic BP increased ~0.5 mmHg per month; diastolic BP ~0.2 mmHg per month. Total cholesterol increased ~0.05 mmol/L per month; triglycerides ~0.03 mmol/L per month. Time-to-event modelling projected return to pre-treatment levels for fasting glucose, systolic BP, cholesterol, and triglycerides within ~12 months, and for HbA1c and diastolic BP within ~1.4 years.
Real-world cardiovascular outcomes (n = 289,809): Among early discontinuers (<1 year), post-cessation incidences were 1.78% for acute coronary syndromes, 17.1% for coronary artery disease, and 10.2% for heart failure at 1 year. Early discontinuers remained at significantly higher risk for CAD and HF compared with long-term users, even after stopping therapy. Risks of ACS, stroke, and all-cause mortality converged between early and long-term users.
Key Findings: Secondary Outcomes and Subgroup Considerations
Diabetes subgroup: Most randomized withdrawal data were derived from populations with obesity without diabetes. In mixed real-world populations, cardiometabolic deterioration after cessation occurred regardless of baseline diabetes status. In type 2 diabetes, rebound hyperglycemia is expected to emerge earlier and carry greater clinical impact, given the tight coupling between weight and glycemic control.
Comparison with bariatric surgery: Pharmacotherapy withdrawal produces earlier and steeper weight regain (typically within 12–18 months) compared with the gradual and often partial regain seen after bariatric procedures. The review frames this as a reflection of mechanism rather than relative efficacy: surgery induces durable anatomical and enteroendocrine changes; pharmacotherapy provides reversible neurohormonal appetite suppression.
Body composition: Post-withdrawal body composition data were described as limited. Weight regain after discontinuation is thought to predominantly reflect fat mass re-accumulation. The review flags visceral adipose tissue re-accumulation as a priority for future research.
Predictors of regain: No validated risk-stratification tool currently exists. Proposed predictors include larger on-treatment weight loss (associated with greater absolute rebound), marked insulin resistance and central adiposity, pre-existing binge-eating or affective disorders, and socioeconomic barriers to follow-up. Longer treatment duration before stopping did not confer durable protection in STEP-1 or SURMOUNT-4.
Renal outcomes: Evidence on albuminuria, eGFR trajectory, and CKD progression after GLP-1RA discontinuation is described as sparse, with most studies censoring at discontinuation for renal endpoints.
Epicardial adipose tissue: Serial assessment of epicardial fat is proposed as a potentially useful imaging biomarker during the post-discontinuation period, though this application has not been prospectively validated.
Adverse Events and Safety Profile
This review does not report a safety profile of GLP-1RA therapy itself. Its focus is on the consequences of stopping therapy. In that context, the relevant “safety” signal is the post-cessation cardiovascular risk profile. Among early discontinuers in the real-world cohort of 289,809 patients, absolute event rates rose across all cardiovascular endpoints after stopping therapy. The review does not report adverse events attributable to the tapering or cessation process itself, and no tapering-versus-abrupt-cessation safety comparison has been formally conducted in randomized trials. The authors explicitly state that randomized comparisons of tapering versus abrupt cessation are lacking.
Statistical Approach and Rigor
As a narrative review, this paper does not perform original statistical analyses. The quantitative estimates cited are drawn from published trial data and a 2026 BMJ systematic review and meta-analysis. Biomarker rebound rates (e.g., HbA1c, BP, lipid parameters per month post-cessation) come from that meta-analysis’s time-to-event modelling. Cardiovascular event rates are drawn from a real-world retrospective cohort. The narrative framing means that the review authors selected which studies to include and how to weight them, without a registered protocol or formal synthesis method. Readers should apply the same critical lens to narrative reviews that they would to any unsystematic evidence aggregation: publication bias, selection of supportive studies, and the absence of formal heterogeneity testing are all structural risks.
Clinical Takeaway
For the practicing clinician, this review consolidates a straightforward but underappreciated message: GLP-1RA discontinuation is a high-risk metabolic transition, not a neutral treatment endpoint. Weight regain begins within 8 to 12 weeks, is largely complete within a year, and is accompanied by parallel deterioration in glycemia, blood pressure, and lipids. Real-world data add a harder edge: early stoppers carry elevated coronary artery disease and heart failure risk compared with continuous users. Where continuation is feasible, it should be framed as chronic disease management. Where it is not, a structured multidisciplinary transition combining pharmacologic anchoring (metformin, SGLT2i where indicated), resistance-based exercise, dietary consolidation, and behavioral support is the most evidence-informed approach currently available — acknowledging that no single adjunctive strategy has been shown in randomized trials to fully prevent post-cessation rebound.
Clinical Bottom Line: The biology of GLP-1RA discontinuation strongly favors weight regain and cardiometabolic relapse; clinicians must plan the exit strategy before the drug is stopped, not after the weight returns.
Why This Matters Clinically
GLP-1 receptor agonist prescribing has scaled globally at a pace that has outrun the clinical infrastructure for managing what happens when patients stop. Discontinuation is common: over 50% of patients in large U.S. cohort data had stopped within 2 years, driven by cost, access disruptions, supply constraints, and tolerability rather than by planned clinical decisions. The consequences are predictable and rapid. Weight regains 60%–90% of its prior loss. Blood pressure, glucose, and lipids revert to baseline within roughly a year. And in the real-world cardiovascular data, early discontinuers carry elevated CAD and HF risk that persists even after they have stopped the drug. This means the clinical encounter at which a patient stops a GLP-1RA — for any reason — is itself a cardiovascular risk management moment that demands a structured response, not a passive follow-up appointment.
CED Clinical Relevance
At CED Clinic, many patients use GLP-1 and dual-incretin therapies as part of a broader cardiometabolic treatment strategy. This review directly informs how we approach the “off-ramp” conversation — whether it arises from insurance disruption, supply issues, pregnancy planning, or patient preference. The five-phase transition protocol described in the paper maps cleanly onto the kind of structured, multidisciplinary follow-up that CED Clinic already provides: dietary and nutritional counseling, resistance exercise integration, behavioral health support, and close metabolic monitoring. The specific thresholds proposed for re-initiation — sustained regain of 3%–5% body weight, rising waist circumference, glycemic deterioration — are practical anchors for clinical
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
Stopping GLP-1RA leads to significant weight regain and cardiometabolic risks.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ComprehensiveBadge 2: Evidence-BasedBadge 3: Patient-Centric
Discontinuing GLP-1 receptor agonists results in substantial weight regain, with up to 90% of lost weight returning within one year. Cardiometabolic benefits also revert quickly, typically within 12-18 months.
Early discontinuers face elevated risks of coronary artery disease and heart failure compared to those who continue therapy. This review synthesizes evidence from randomized trials, meta-analyses, and real-world data to provide a comprehensive understanding of these post-discontinuation outcomes.
60%–90% of lost weight is regained within one year.
Cardiometabolic biomarkers return to baseline within 12-18 months.
Early discontinuers have significantly elevated CAD and HF risk.
Key Insight
Stopping GLP-1RA therapy leads to rapid weight regain and reverses cardiometabolic benefits.
Patient Takeaway
Badge 1: Patient-FocusedBadge 2: Practical TipsBadge 3: Risk Awareness
Patients discontinuing GLP-1 receptor agonists should be aware of the high risk of weight regain and cardiometabolic relapse. Structured multidisciplinary transition approaches, combining pharmacological, behavioral, and psychological interventions, may help mitigate these risks.
Understanding the mechanisms driving weight regain, such as reactivation of orexigenic pathways and adaptive thermogenesis, can empower patients to make informed decisions about their treatment plan.
Weight regain begins within 8-12 weeks.
Cardiometabolic benefits revert within 12-18 months.
Early discontinuers face higher cardiovascular risks.
Patient Tip
Be aware of the high risk of weight regain and cardiometabolic relapse after stopping GLP-1RA therapy.
Clinician’s POV
Badge 1: Clinical GuidanceBadge 2: Evidence-BasedBadge 3: Risk Management
Clinicians managing patients discontinuing GLP-1 receptor agonists should consider the high risk of weight regain and cardiometabolic relapse. A structured multidisciplinary transition framework, combining pharmacological, behavioral, and psychological interventions, is proposed to mitigate these risks.
Understanding the mechanisms driving post-discontinuation outcomes can help clinicians develop personalized management strategies for their patients.
60%–90% of lost weight is regained within one year.
Cardiometabolic biomarkers return to baseline within 12-18 months.
Early discontinuers have significantly elevated CAD and HF risk.
Clinical Guidance
Use a structured multidisciplinary framework to manage patients discontinuing GLP-1RA therapy.
A Skeptical Read
Badge 1: Critical AnalysisBadge 2: Evidence-BasedBadge 3: Skeptical View
While the evidence suggests significant weight regain and cardiometabolic relapse after discontinuing GLP-1 receptor agonists, it is important to critically evaluate the studies and consider individual patient factors. The proposed multidisciplinary transition framework offers a structured approach to managing these risks.
Clinicians should remain skeptical of unvalidated tapering strategies and focus on evidence-based interventions to mitigate post-discontinuation outcomes.
60%–90% of lost weight is regained within one year.
Cardiometabolic biomarkers return to baseline within 12-18 months.
Early discontinuers have significantly elevated CAD and HF risk.
Skeptical View
Critically evaluate the evidence and consider individual patient factors when managing GLP-1RA discontinuation.
Study Critic
Badge 1: Critical EvaluationBadge 2: Evidence-BasedBadge 3: Rigorous Analysis
Critics may question the validity of the proposed multidisciplinary transition framework without validated tapering strategies. However, the evidence from randomized trials and real-world data supports the significant risks associated with discontinuing GLP-1 receptor agonists.
Further research is needed to develop and validate effective tapering strategies to mitigate post-discontinuation outcomes.
60%–90% of lost weight is regained within one year.
Cardiometabolic biomarkers return to baseline within 12-18 months.
Early discontinuers have significantly elevated CAD and HF risk.
Critical Evaluation
Further research is needed to develop validated tapering strategies for GLP-1RA discontinuation.
Compared to Past Research
Badge 1: Historical ContextBadge 2: Evidence-BasedBadge 3: Longitudinal Data
Historical data from randomized withdrawal trials and real-world cohorts provide a comprehensive understanding of the post-discontinuation outcomes associated with GLP-1 receptor agonists. These studies highlight the significant weight regain and cardiometabolic relapse that occur after discontinuation.
The evidence suggests that early discontinuers face elevated cardiovascular risks, emphasizing the importance of structured multidisciplinary management strategies.
60%–90% of lost weight is regained within one year.
Cardiometabolic biomarkers return to baseline within 12-18 months.
Early discontinuers have significantly elevated CAD and HF risk.
Historical Context
Historical data highlights the significant risks associated with GLP-1RA discontinuation.
Practical Considerations
Badge 1: Practical TipsBadge 2: Evidence-BasedBadge 3: Patient-Centric
Practically, patients and clinicians should be aware of the high risk of weight regain and cardiometabolic relapse after discontinuing GLP-1 receptor agonists. A structured multidisciplinary transition framework, combining pharmacological, behavioral, and psychological interventions, is proposed to mitigate these risks.
Understanding the mechanisms driving post-discontinuation outcomes can help patients make informed decisions about their treatment plan.
60%–90% of lost weight is regained within one year.
Cardiometabolic biomarkers return to baseline within 12-18 months.
Early discontinuers have significantly elevated CAD and HF risk.
Practical Tip
Use a structured multidisciplinary framework to manage GLP-1RA discontinuation.
Future Directions
Badge 1: Future DirectionsBadge 2: Evidence-BasedBadge 3: Research Needs
Future research should focus on developing and validating effective tapering strategies for GLP-1 receptor agonists to mitigate post-discontinuation outcomes. Understanding the mechanisms driving weight regain and cardiometabolic relapse can inform the development of new interventions.
Further studies are needed to explore the long-term effects of discontinuing GLP-1RA therapy on cardiovascular health.
60%–90% of lost weight is regained within one year.
Cardiometabolic biomarkers return to baseline within 12-18 months.
Early discontinuers have significantly elevated CAD and HF risk.
Future Directions
Develop validated tapering strategies for GLP-1RA discontinuation.
Misreadings & Bad-Faith Takes
Badge 1: Common MisunderstandingsBadge 2: Evidence-BasedBadge 3: Clarification
Common misinterpretations of the evidence include assuming that weight regain is gradual and that cardiometabolic benefits persist after discontinuation. In reality, weight regain occurs rapidly, within 8-12 weeks, and cardiometabolic benefits revert within 12-18 months.
It is also important to clarify that early discontinuers face significantly elevated cardiovascular risks compared to those who continue therapy.
60%–90% of lost weight is regained within one year.
Cardiometabolic biomarkers return to baseline within 12-18 months.
Early discontinuers have significantly elevated CAD and HF risk.
Common Misunderstandings
Clarify that weight regain occurs rapidly and cardiometabolic benefits revert quickly after GLP-1RA discontinuation.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What is the primary risk of stopping GLP-1 receptor agonists?
The main risk is substantial weight regain, with up to 90% of lost weight returning within one year.
How quickly do cardiometabolic benefits revert after discontinuation?
Cardiometabolic biomarkers return to baseline within 12-18 months.
Are there specific cardiovascular risks associated with early discontinuation?
Yes, early discontinuers have significantly elevated risks of coronary artery disease and heart failure compared to those who continue therapy.
What mechanisms drive weight regain after stopping GLP-1RA?
Mechanisms include reactivation of orexigenic pathways, adaptive thermogenesis, and insulin resistance re-emergence.
Are there any validated strategies to prevent weight regain after discontinuation?
No validated tapering strategies exist, but structured multidisciplinary transition approaches may help mitigate relapse.
How does weight regain compare between semaglutide and tirzepatide?
Weight regained at 52 weeks post-semaglutide is about 11.6 percentage points of body weight, while for tirzepatide it is 14.0%.
What are the real-world discontinuation rates for GLP-1RA?
About 30% stop within one year and over 50% by two years.
How does weight regain after pharmacotherapy compare to bariatric surgery?
Pharmacotherapy withdrawal produces earlier and steeper weight regain compared with the gradual regain seen after bariatric procedures.
What are some predictors of post-discontinuation relapse?
Predictors include larger on-treatment weight loss, marked insulin resistance and central adiposity, pre-existing binge-eating or affective disorders, and socioeconomic barriers to follow-up.
What is the proposed multidisciplinary framework for managing post-discontinuation?
A five-phase clinical transition protocol combining pharmacological, behavioral, and psychological interventions is suggested. [...]
Read more...
June 3, 2026Klotho, GDNF, IGF-1, and GLP-1 Signaling Pathways in Autism
Autism Spectrum Disorder
Neurotrophic Signaling
IGF-1 Therapy
GLP-1 Receptor Agonists
Precision Medicine
What You’ll Learn
How four trophic and metabolic signaling pathways, Klotho, GDNF/GFRA-1, IGF-1, and GLP-1, converge on the same intracellular cascades implicated in ASD
Why IGF-1 currently holds the strongest translational evidence, including clinical trial data in syndromic ASD, while the other three pathways remain largely preclinical or mechanistic
What the evidence gradient from clinically supported to mechanistically speculative means for prescribing and patient counseling today
How a systems-biology perspective on these interconnected pathways could reshape biomarker development and stratified therapy in ASD
TL;DR: Among four neurotrophic-metabolic pathways reviewed in ASD, IGF-1 has direct clinical trial support in syndromic forms of the disorder; Klotho, GDNF/GFRA-1, and GLP-1 remain mechanistically plausible but lack robust human causal evidence, and conflating hypothesis with proof would be premature.
STUDY TYPE: Narrative Review
Abstract
Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by deficits in social communication and restricted, repetitive behaviors. Although traditionally linked to synaptic protein dysfunction and neurotransmitter imbalance, growing evidence suggests that broader intracellular signaling networks critically regulate the neurodevelopmental processes disrupted in ASD. This review synthesizes current evidence on four interconnected signaling pathways, Klotho, GDNF/GFRA-1, IGF-1, and GLP-1, and examines their potential roles in ASD pathophysiology within a unified mechanistic framework. These pathways regulate fundamental processes, including neuronal survival, synaptogenesis, dendritic maturation, myelination, modulation of oxidative stress, neuroinflammation, and metabolic homeostasis. Importantly, they converge on shared intracellular cascades such as PI3K/Akt, MAPK/ERK, mTOR, and Wnt/β-catenin, which are increasingly implicated in ASD-related abnormalities in synaptic plasticity and circuit organization. Experimental models demonstrate that dysregulation of these signaling systems can impair hippocampal function, alter excitatory-inhibitory balance, and disrupt structural connectivity. Among them, IGF-1 has shown promising translational potential in clinical trials for syndromic ASD, while GLP-1 receptor agonists and Klotho modulation represent emerging therapeutic avenues. The GDNF/GFRA-1 axis further highlights the importance of trophic support in maintaining synaptic integrity and neuronal resilience. By integrating molecular, preclinical, and clinical findings, this review proposes that convergent dysregulation of trophic and metabolic signaling pathways may contribute to ASD heterogeneity. A systems-level understanding of these interconnected mechanisms may facilitate biomarker development and support the advancement of stratified, pathway-targeted therapeutic strategies.
Source: Verma J, Singh RK, Paul S, Gupta S, Gupta AK, Sharma AK, Kumar M, Mehan S, Samant R, Tongra M. Converging neurotrophic-immune signaling in autism spectrum disorder: integrative roles of klotho, GDNF/GFRA-1, IGF-1 and GLP-1 pathways. Metabolic Brain Disease. 2026;41:107. DOI: 10.1007/s11011-026-01866-0
Study at a Glance
Parameter
Detail
Design
Narrative integrative review
Pathways Reviewed
Klotho, GDNF/GFRA-1, IGF-1, GLP-1
Primary Aim
Synthesize molecular, preclinical, and clinical evidence linking these four pathways to ASD pathophysiology
Key Clinical Finding
IGF-1 is the only pathway among the four with direct clinical trial evidence in ASD (Phelan-McDermid syndrome); the others remain at mechanistic or early translational stages
Common Downstream Hubs
PI3K/Akt, MAPK/ERK, mTOR, Wnt/β-catenin
Funding
Not applicable (no external funding declared)
COI
Authors declare no competing interests
Study Snapshot
Pathway
Strongest Evidence Type
ASD-Specific Human Data?
Therapeutic Stage
IGF-1
Randomized clinical trials (syndromic ASD)
Yes (Phelan-McDermid, Rett, Fragile X)
Translational
GLP-1
Preclinical + Mendelian randomization
Limited (case reports; one MR study)
Early translational
GDNF/GFRA-1
Mechanistic + small observational studies
Indirect (altered GDNF levels in ASD cohorts)
Preclinical
Klotho
Mechanistic (animal, in vitro)
Minimal (one small Iraqi biomarker study)
Hypothesis-generating
Study Facts Table
Field
Detail
Authors
Verma J, Singh RK, Paul S, Gupta S, Gupta AK, Sharma AK, Kumar M, Mehan S, Samant R, Tongra M
Journal
Metabolic Brain Disease
Year Published
2026 (online May 19, 2026)
Study Design
Narrative integrative review
Pathways Reviewed
Klotho, GDNF/GFRA-1, IGF-1, GLP-1
Downstream Hubs
PI3K/Akt, MAPK/ERK, mTOR, Wnt/β-catenin
IGF-1 Clinical Trial Key Result
In Phelan-McDermid syndrome (SHANK3 haploinsufficiency), recombinant IGF-1 was well tolerated and associated with improvements in sensory responsiveness, repetitive behaviors, and hyperactivity across two crossover trials (n=9 each; Kolevzon et al. 2014, 2022)
GLP-1 Preclinical Key Result
Semaglutide (60 µg/kg/day × 6 weeks) reduced autism-like behaviors in BTBR mice and restored DNA damage/repair markers and oxidative balance (Hussein et al. 2024)
Klotho Human Data
Serum soluble Klotho (S-KLα) lower in 100 ASD children vs. 100 controls (AUC 0.888); negative correlation with MDA (Kucher and Allwsh 2025)
Adverse Events
Not a safety trial; IGF-1 was generally well tolerated in pediatric trials; GLP-1 RA safety profiles established in metabolic disease populations
Funding
Not applicable
COI
None declared
What Researchers Actually Did
Verma and colleagues conducted a narrative integrative review synthesizing molecular, preclinical, and available clinical evidence across four signaling systems: Klotho, GDNF/GFRA-1, IGF-1, and GLP-1. The authors mapped each pathway’s receptor biology, downstream intracellular cascades, brain expression patterns, and developmental dynamics, then positioned each within the context of ASD pathophysiology. They drew on animal models, human genetic and biomarker studies, in vitro experiments, and clinical trial data to build a unified mechanistic framework arguing that convergent dysregulation of trophic and metabolic signaling, rather than single-gene or single-transmitter defects, may explain a portion of ASD biological heterogeneity.
A structured evidence summary table catalogued 11 preclinical and clinical datasets covering interventions ranging from recombinant IGF-1 in Phelan-McDermid syndrome to semaglutide in BTBR mice to exenatide in LPS-exposed rats. The authors explicitly graded the four pathways by translational strength, positioning IGF-1 as clinically supported, GLP-1 as early translational, GDNF/GFRA-1 as preclinical, and Klotho as hypothesis-generating. Throughout, shared downstream nodes, particularly PI3K/Akt/mTOR and MAPK/ERK, were highlighted as potential network hubs linking these otherwise distinct ligand-receptor systems.
Key Findings: Primary Outcomes
IGF-1 (strongest evidence): Two crossover trials in Phelan-McDermid syndrome (n=9 each) found recombinant IGF-1 well tolerated, with reported improvements in sensory responsiveness and repetitive behaviors; one trial showed gains in social impairment scores and reduced hyperactivity. Neither trial reported statistically significant change across all primary endpoints.
GLP-1 (preclinical signal): Semaglutide in BTBR mice (60 µg/kg/day × 6 weeks) markedly reduced autism-like behaviors and restored DNA damage/repair pathways and oxidative balance. A pharmacogenetic Mendelian randomization study reported genetically proxied GLP-1R activation associated with lower ASD risk (OR approximately 0.55), though the authors acknowledge this is assumption-dependent indirect inference.
GDNF/GFRA-1 (observational): Plasma GDNF increases following auditory integration therapy in ASD individuals correlated with decreases in SRS and CARS severity scores. Conditional deletion of GFRA-1 in forebrain neurons in mice impaired dendritic branching, spine density, and pattern-separation tasks. No interventional human data exist.
Klotho (biomarker signal only): One small study (100 ASD children vs. 100 controls in Iraq) found lower serum soluble Klotho (AUC 0.888 for discriminating ASD) with a negative correlation with malondialdehyde. No causal or interventional human data exist.
Shared downstream convergence: All four pathways engage PI3K/Akt, MAPK/ERK, mTOR, and/or Wnt/β-catenin. The authors propose that network-level dysregulation at these shared hubs, rather than pathway-specific defects, may generate ASD heterogeneity.
Key Findings: Secondary Outcomes and Subgroup Analyses
IGF-1 trials in Rett syndrome (MECP2 mutations, n=12 girls; mecasermin 240 µg/kg BID × 17 weeks) reported increased CSF IGF-1 levels, improved apnea measures, and improved anxiety scores, with small sample size limiting inference.
Trofinetide (an IGF-1 derivative) in a Phase III Rett syndrome trial (n=208) achieved improvements in RSBQ and CGI-I scores but was associated with diarrhea and vomiting.
4-hydroxyisoleucine (a natural activator of IGF-1 and GLP-1 signaling) administered orally in a propionic acid rat ASD model (50 and 100 mg/kg) improved behavioral deficits, neuroinflammation, neurotransmitter balance, and white-matter histology.
Multi-omics analyses in human cohorts (Chinese Han and SFARI SPARK) linked IGF1R genetic burden to ASD risk and identified IGF-1R enrichment in parvalbumin interneurons, consistent with an excitatory-inhibitory imbalance mechanism.
A single adolescent case report described reductions in compulsive eating and behavioral improvements with liraglutide (titrated to 2.4 mg/day × 36 weeks) in an ASD individual; no generalizability can be inferred.
Results: Adverse Events and Safety Profile
This review does not report primary safety data. The referenced IGF-1 trials document generally favorable tolerability in pediatric populations with neurodevelopmental disorders. Trofinetide was associated with diarrhea and vomiting. GLP-1 receptor agonists carry well-characterized safety profiles from metabolic disease registrations. The authors flag theoretical long-term risks of IGF-1 (excessive cell growth, cancer) and note that optimal dosing, treatment windows, and pediatric safety data for GLP-1 receptor agonists in ASD populations remain unanswered. Klotho and GDNF-targeted interventions have no ASD-specific safety data.
Statistical Approach and Rigor
As a narrative review, this paper does not apply meta-analytic statistics or formal risk-of-bias tools. The authors summarize findings qualitatively and organize evidence by pathway and study type. The evidence table (Table 1) is descriptive rather than quantitatively synthesized. No PRISMA methodology is declared, no systematic search strategy is reported, and no formal GRADE assessment is applied. The review acknowledges heterogeneity across study designs, species, and populations without quantifying it. The Mendelian randomization data for GLP-1R (OR approximately 0.55 for ASD risk) is cited from a single external study without meta-analytic pooling or sensitivity analysis. The Klotho biomarker AUC of 0.888 derives from one small regional cohort of uncertain representativeness.
Clinical Takeaway
For the clinician seeing patients with ASD today, the practical message is narrow but real: recombinant IGF-1 (mecasermin) has the strongest biological rationale and the most human trial data, specifically in SHANK3-related syndromes such as Phelan-McDermid. GLP-1 receptor agonists, already prescribed for metabolic comorbidities in ASD, may carry neurotrophic and anti-inflammatory benefits worth tracking in ongoing evaluations, though controlled ASD-specific trials are absent. Klotho and GDNF/GFRA-1 are not yet clinical instruments; they are research constructs with mechanistic plausibility but no human interventional data. Counseling families about any of these pathways as established treatments would exceed the evidence.
Clinical Bottom Line: IGF-1 is the one pathway in this review with controlled human trial data in ASD; the remaining three are mechanistically interesting but not yet clinically actionable outside of research settings.
Why This Matters Clinically
ASD research has long centered on synaptic scaffolding proteins, GABA/glutamate balance, and ion channel dysfunction. This review makes a conceptually useful argument: those targets may be downstream of upstream trophic and metabolic signaling failures that are pharmacologically accessible through agents already in clinical use or development. If even one of these pathways, most plausibly IGF-1 or GLP-1 signaling, proves modifiable in well-characterized ASD subgroups, it opens a stratification framework: rather than treating autism generically, clinicians could identify patients with low IGF-1 bioavailability, impaired GDNF signaling, or neuroinflammatory profiles and direct targeted therapy accordingly. That goal is worth pursuing. The distance between that goal and the current evidence, however, is considerable.
CED Clinical Relevance
At CED Clinic, patients often present with questions about metabolic and trophic interventions, including GLP-1 receptor agonists that are increasingly discussed across neurological and psychiatric indications. This review provides a structured molecular rationale for why these pathways are biologically plausible in ASD, while also making explicit what is not yet known. For patients on GLP-1 receptor agonists for metabolic comorbidities, the preclinical and early genetic evidence adds mechanistic context without changing prescribing decisions. For families asking about IGF-1, the review accurately conveys that syndromic ASD trials show signals of benefit but that idiopathic ASD remains unanswered. Klotho and GDNF discussions belong firmly in the context of future research, not current clinical planning.
Clinical Insight
Before framing any of these four pathways as a therapeutic target for a specific patient, establish whether that patient has a genetically characterized ASD subtype. The IGF-1 clinical evidence is syndromic-specific; extrapolating to idiopathic ASD is not supported by the data reviewed here. Biomarker measurement (serum IGF-1, soluble Klotho, GDNF levels) in clinical practice lacks validated reference ranges and clinical interpretation frameworks in ASD populations.
Fits What We Already Know
The review situates itself within a well-established literature linking PI3K/Akt/mTOR hyperactivation to ASD, particularly tuberous sclerosis complex and PTEN-related syndromes (cited: Sharma and Mehan 2021; Pagani et al. 2021). The role of BDNF/TrkB in synaptic plasticity and its disruption in ASD provides an established precedent for trophic signaling as a disease-relevant target. The authors correctly note that IGF-1’s mechanism, restoring AMPA receptor function and LTP in Shank3-deficient mice (Bozdagi et al. 2013; Shcheglovitov et al. 2013), aligns with the broader synaptic deficit model of ASD. The inclusion of GLP-1 extends a growing literature on metabolic-neurological interface signaling that has been productive in Alzheimer’s and Parkinson’s disease research (Athauda et al. 2017; Gejl et al. 2016), though the extrapolation to neurodevelopmental disorders requires more than mechanistic analogy.
What This Study Teaches Us
The review offers a structured, accessible map of four signaling pathways that share downstream molecular real estate with each other and with established ASD risk mechanisms. Its core contribution is organizational: demonstrating that Klotho, GDNF/GFRA-1, IGF-1, and GLP-1 are not isolated curiosities but members of an interconnected network whose convergence on PI3K/Akt and related cascades makes them candidates for systems-level investigation. It also communicates honestly, if not always prominently, that the evidence gradient is steep: one pathway has human trial data, one has preclinical signals and genetic epidemiology, and two have mechanistic plausibility and little else.
What It Does Not Show
It does not demonstrate that modulating any of these pathways improves outcomes in idiopathic ASD.
It does not establish causality between pathway dysregulation and ASD symptomatology in humans.
The IGF-1 trial data cited are from small crossover studies in a specific genetic syndrome; these results do not generalize to the broader ASD population.
The Klotho and GDNF biomarker associations reported in humans are from small, single-cohort observational studies with no causal inference.
The Mendelian randomization finding for GLP-1R and ASD risk is indirect, assumption-dependent, and requires clinical trial validation.
The review does not address long-term safety of any of these interventions in pediatric neurodevelopmental populations.
Fits the Broader Conversation
This review joins a growing body of work arguing that ASD heterogeneity demands a shift from symptom-targeted to mechanism-based therapeutics. It adds to an emerging discussion, already active in the IGF-1 and mTOR literature, about stratifying ASD by biological pathway rather than behavioral phenotype alone. The inclusion of GLP-1 is timely, given the rapid expansion of GLP-1 receptor agonist indications and the parallel interest in their central nervous system effects. Whether Klotho and GDNF will follow IGF-1 from mechanistic candidate to clinical target depends on whether the field can generate the longitudinal, well-characterized cohort data that this review, to its credit, explicitly identifies as missing.
Teaches Us: Families
Scientists are investigating whether certain signaling proteins in the brain, molecules that act like chemical messengers supporting neuron growth, survival, and connection, may be disrupted in some people with autism. This review looks at four of those proteins: Klotho, GDNF, IGF-1, and GLP-1. Of the four, only IGF-1 has been tested in human clinical trials for autism, and those trials were in a specific genetic type of autism called Phelan-McDermid syndrome. The results suggested IGF-1 was safe and produced some improvements in behavior, but the studies were small. The other three proteins are being studied in animals or cells right now, not yet in people with autism. This research is promising because it suggests autism may involve disruptions in biological pathways that could eventually be treated with targeted medicines, but we are not yet there for most of these pathways.
Teaches Us: Clinicians
This review constructs a molecular framework linking four trophic-metabolic signaling axes to ASD pathophysiology through shared downstream nodes (PI3K/Akt, MAPK/ERK, mTOR, Wnt/β-catenin). For the clinician, the operationally relevant takeaway is the evidence gradient: IGF-1 has phase II/III crossover trial data in SHANK3-related and MECP2-related syndromes; GLP-1 receptor agonists have preclinical signals, one Mendelian randomization study, and a case report; GDNF/GFRA-1 has small observational human correlations; Klotho has one small biomarker study. The review identifies five discrete translational gaps: absence of longitudinal pathway data in characterized ASD cohorts, lack of validated CNS biomarkers for stratification, no powered idiopathic ASD trials for any pathway, unknown pediatric safety profiles for GLP-1 agonists in this context, and no human interventional data for Klotho or GDNF/GFRA-1. Biomarker-guided stratification (IGF-1 serum levels, IGF1R expression, downstream p-
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
Review examines Klotho, GDNF/GFRA-1, IGF-1, GLP-1 in ASD pathophysiology.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ComprehensiveBadge 2: Interconnected PathwaysBadge 3: Clinical Focus
This review synthesizes evidence on four interconnected signaling pathways in ASD, highlighting their roles in neuronal survival and synaptic integrity. IGF-1 has clinical trial support, while others are at preclinical stages.
The convergence of these pathways on shared intracellular cascades suggests a network-level dysregulation underlying ASD heterogeneity.
IGF-1 shows promising clinical data in syndromic ASD.
GLP-1 receptor agonists and Klotho modulation are emerging therapeutic avenues.
GDNF/GFRA-1 axis supports synaptic integrity and neuronal resilience.
Key Insight
IGF-1 has the strongest clinical evidence among the four pathways discussed.
Patient Takeaway
Badge 1: Patient-CentricBadge 2: Treatment OptionsBadge 3: Research Updates
For patients with ASD, recombinant IGF-1 has shown improvements in sensory responsiveness and repetitive behaviors in clinical trials. GLP-1 receptor agonists may offer additional benefits but require further study.
Klotho and GDNF/GFRA-1 are currently under research and not yet available as treatments.
IGF-1 therapy shows promise for syndromic ASD.
GLP-1 receptor agonists have potential neurotrophic benefits.
Klotho and GDNF/GFRA-1 remain at the hypothesis-generating stage.
Patient Takeaway
IGF-1 therapy is currently the most clinically supported option for ASD.
Clinician’s POV
Badge 1: Clinical GuidanceBadge 2: Evidence-BasedBadge 3: Treatment Recommendations
Clinicians can consider recombinant IGF-1 for patients with syndromic ASD based on clinical trial data. GLP-1 receptor agonists may be considered for their potential neurotrophic and anti-inflammatory effects, though more research is needed.
Klotho and GDNF/GFRA-1 are not yet clinically supported but warrant further investigation.
IGF-1 therapy has clinical trial support in syndromic ASD.
GLP-1 receptor agonists show promise but lack controlled ASD-specific trials.
Klotho and GDNF/GFRA-1 remain at the hypothesis-generating stage.
Clinician Guidance
IGF-1 therapy is currently the most clinically supported option for ASD.
A Skeptical Read
Badge 1: Critical AnalysisBadge 2: Evidence LevelsBadge 3: Future Directions
While IGF-1 has clinical trial support, other pathways like GLP-1, Klotho, and GDNF/GFRA-1 remain at preclinical or mechanistic stages. More research is needed to establish their efficacy in ASD.
The convergence of these pathways on shared intracellular cascades suggests a complex network-level dysregulation underlying ASD heterogeneity.
IGF-1 has the strongest clinical evidence.
GLP-1, Klotho, and GDNF/GFRA-1 lack robust human causal evidence.
Future research should focus on translating preclinical findings to clinical applications.
Skeptic’s View
While IGF-1 shows promise, other pathways require further validation.
Study Critic
Badge 1: Critical EvaluationBadge 2: Methodological RigorBadge 3: Research Gaps
The review synthesizes evidence from various study designs but lacks formal risk-of-bias assessment. The evidence gradient from clinically supported to mechanistically speculative should be considered when prescribing and counseling patients.
Future studies should address heterogeneity across study designs, species, and populations to strengthen the evidence base.
The review synthesizes evidence without formal risk-of-bias tools.
Evidence gradient varies from clinical support to mechanistic speculation.
Heterogeneity across studies limits definitive conclusions.
Critic’s Perspective
Formal risk-of-bias assessment is needed for robust evidence evaluation.
Compared to Past Research
Badge 1: Historical ContextBadge 2: Evolution of ResearchBadge 3: Foundational Studies
Previous research has linked synaptic protein dysfunction and neurotransmitter imbalance to ASD. This review expands on these findings by examining the roles of Klotho, GDNF/GFRA-1, IGF-1, and GLP-1 in broader intracellular signaling networks.
The convergence of these pathways on shared cascades suggests a more comprehensive understanding of ASD pathophysiology.
Previous research focused on synaptic protein dysfunction.
This review expands to include broader intracellular signaling.
Convergence on shared cascades offers new insights into ASD.
Historical Context
Research has evolved from synaptic proteins to broader signaling networks.
Practical Considerations
Badge 1: Practical ImplicationsBadge 2: Clinical ApplicationsBadge 3: Patient Counseling
Clinicians can consider recombinant IGF-1 for patients with syndromic ASD based on clinical trial data. GLP-1 receptor agonists may be considered for their potential neurotrophic and anti-inflammatory effects, though more research is needed.
Patient counseling should reflect the current evidence levels of each pathway.
IGF-1 therapy has clinical trial support.
GLP-1 receptor agonists show promise but lack controlled ASD-specific trials.
Klotho and GDNF/GFRA-1 remain at the hypothesis-generating stage.
Practical Advice
IGF-1 therapy is currently the most clinically supported option for ASD.
Future Directions
Badge 1: Future DirectionsBadge 2: Emerging TherapiesBadge 3: Research Priorities
Future research should focus on translating preclinical findings to clinical applications, particularly for GLP-1 receptor agonists and Klotho modulation. Multi-omics approaches can further elucidate the roles of these pathways in ASD.
Addressing heterogeneity across studies will be crucial for developing stratified therapeutic strategies.
Translate preclinical findings to clinical applications.
GLP-1 receptor agonists and Klotho modulation are emerging therapies.
Multi-omics approaches can elucidate pathway roles.
Address study heterogeneity for stratified therapy.
Future Directions
Focus on translating preclinical findings and addressing study heterogeneity.
Misreadings & Bad-Faith Takes
Badge 1: Common MisunderstandingsBadge 2: Clarifications NeededBadge 3: Evidence Levels
It is important not to conflate hypothesis with proof. While GLP-1 receptor agonists and Klotho modulation show promise, they lack robust human causal evidence. IGF-1 therapy has the strongest clinical support among the four pathways.
Patient counseling should reflect these varying levels of evidence.
Do not conflate hypothesis with proof.
GLP-1 receptor agonists and Klotho modulation lack robust human data.
IGF-1 therapy has the strongest clinical evidence.
Avoid Misunderstandings
Conflating hypothesis with proof can lead to misinterpretation of evidence.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
Understanding the Endocannabinoid System
A physician-authored primer on ECS biology and why it matters for clinical cannabis decisions.
Explore evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program, including GLP-1 therapies and whole-person care.
Read article
Cannabis for Pain Management
A practical physician guide to cannabinoid selection and symptom matching.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What are the four signaling pathways discussed in the review?
The review discusses Klotho, GDNF/GFRA-1, IGF-1, and GLP-1 signaling pathways.
Which pathway has direct clinical trial evidence in ASD?
IGF-1 is the only pathway with direct clinical trial evidence in syndromic forms of ASD.
What are the common downstream hubs for these pathways?
The common downstream hubs include PI3K/Akt, MAPK/ERK, mTOR, and Wnt/β-catenin.
How does GLP-1 receptor agonism potentially benefit ASD patients?
GLP-1 receptor agonists may offer neurotrophic and anti-inflammatory benefits in ASD, though controlled trials are needed.
What is the current status of Klotho modulation as a therapeutic approach for ASD?
Klotho modulation remains at the hypothesis-generating stage with minimal human data.
How does dysregulation of these signaling systems affect hippocampal function in ASD?
Dysregulation can impair hippocampal function, alter excitatory-inhibitory balance, and disrupt structural connectivity.
What are the adverse events associated with IGF-1 therapy in pediatric populations?
IGF-1 is generally well tolerated in pediatric trials, but Trofinetide was associated with diarrhea and vomiting.
How does the review propose these pathways contribute to ASD heterogeneity?
The review suggests that convergent dysregulation of trophic and metabolic signaling pathways may explain some of the biological diversity in ASD.
What is the role of GDNF/GFRA-1 axis in maintaining synaptic integrity?
The GDNF/GFRA-1 axis supports synaptic integrity and neuronal resilience, which are crucial for normal brain function.
What is the significance of multi-omics analyses in linking IGF1R genetic burden to ASD risk?
Multi-omics analyses link IGF1R genetic burden to ASD risk and identify IGF-1R enrichment in parvalbumin interneurons, suggesting a role in excitatory-inhibitory imbalance. [...]
Read more...
June 3, 2026Fiber Plus GLP-1 Drugs: Smarter Obesity Management
GLP-1 Receptor Agonists
Dietary Fiber
Obesity Management
Gut Microbiota
Weight Maintenance
What You’ll Learn
How GLP-1 receptor agonists and dietary fiber converge on the same gut-brain axis through distinct but overlapping mechanisms
Why slowed gastric emptying from GLP-1RAs may alter fermentation dynamics and complicate fiber tolerance
What the clinical evidence actually shows about weight loss magnitude for fiber alone versus pharmacotherapy
How sequential or concurrent fiber-plus-drug strategies might reduce weight regain after GLP-1RA discontinuation
TL;DR: GLP-1 receptor agonists produce far greater weight loss than dietary fiber alone, but fiber’s ability to stimulate endogenous GLP-1, strengthen the gut barrier, and support microbial resilience positions it as a rational, low-cost complement before, during, and after pharmacotherapy — not a replacement for it.
? Study Type: Narrative Review (Structured Literature Search)
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of obesity by producing substantial and durable weight loss. However, gastrointestinal adverse effects, including nausea, vomiting, and constipation, are a common, dose-dependent, and frequent cause of discontinuation. Furthermore, weight regain is typical after drug withdrawal, reflecting the chronic and relapsing nature of obesity. Long-term adherence is essential but is often constrained by high cost, injection burden, and patient preference. Moreover, the consequences of chronic GLP-1 receptor activation on gut physiology, microbiota composition, and immune tolerance remain incompletely defined.
In parallel, dietary fibers offer a physiological means of engaging the same gut-brain axis through microbial fermentation and the stimulation of endogenous GLP-1. Fibers deliver broad benefits because they strengthen gut barrier function, enrich short-chain fatty acids, and recalibrate immunity toward an anti-inflammatory state. Nevertheless, weight loss with fiber alone is typically more modest than with GLP-1RAs and depends on the type, dose, and duration of use. Tolerability can be limited by bloating or gas, particularly if intake is increased too rapidly.
This review critically examines the convergence and divergence between GLP-1RAs and dietary fibers. The authors discuss their mechanistic overlaps in appetite control, metabolism, and immune modulation, and highlight potential interactions such as altered fermentation dynamics during pharmacological slowing of gastric emptying and the potential for GLP-1R desensitization. A pragmatic framework is proposed to place dietary fiber and lifestyle measures as the foundation of care, reserve GLP-1RA therapy for the highest-risk individuals, and plan for fiber supplementation once pharmacotherapy is reduced.
Source:
Wang Y, Liu J, Verbeke K, Gasaly Retamal N, Akkerman R, de Vos P. Dietary Fiber and Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Converging Mechanisms, Interactions, and Strategies for Durable Weight Control. Advances in Nutrition. 2026;17:100647.
DOI: 10.1016/j.advnut.2026.100647
Published: May 7, 2026 | Open Access: CC BY 4.0
Study at a Glance
Design
Narrative review with structured literature search (Google Scholar, Web of Science, PubMed)
Population Covered
Adults with overweight or obesity; T2DM subpopulations; relevant animal and in vitro mechanistic studies included
Intervention Focus
GLP-1 receptor agonists (liraglutide, semaglutide, exenatide, lixisenatide) vs. dietary fibers (inulin, psyllium, beta-glucan, resistant starch, oligofructose, glucomannan)
Primary Question
Do GLP-1RAs and dietary fibers converge on overlapping mechanisms, and can they be rationally combined or sequenced for durable weight control?
Key Finding
Both strategies engage the gut-brain-immune axis through overlapping but mechanistically distinct pathways; fiber cannot replicate the weight-loss magnitude of GLP-1RAs but may complement pharmacotherapy before, during, and after treatment
Study Snapshot
Parameter
Dietary Fiber
GLP-1 Receptor Agonists
Weight loss (typical clinical)
~0.3 kg (viscous fiber, ad libitum); ~0.8 kg added to energy restriction
~14.9% body weight (semaglutide 2.4 mg at 68 wk)
HbA1c reduction (T2DM)
~0.6 percentage points (soluble fiber ~8 g/d)
~1.2% with dapagliflozin + oral semaglutide combination
Systolic BP reduction
~1.6 mm Hg (~9 g/d viscous fiber over ~7 wk)
Larger reductions reported in semaglutide trials
CRP reduction
Lower systemic inflammation with habitual high intake
42% reduction with semaglutide vs. 12.8% placebo
GI adverse effects
Mild bloating/gas; dose and type dependent
Nausea 44.2%, vomiting 24.8%, diarrhea 31.5%, constipation 23.4% (semaglutide 68 wk)
Weight regain on cessation
Not applicable (ongoing benefit requires continued intake)
~6.9% regained within 48 wk after stopping semaglutide
1-year discontinuation (real-world)
Generally low; gradual titration improves retention
53.6% discontinued within 1 year in US cohort
Study Facts Table
Field
Detail
Authors
Wang Y, Liu J, Verbeke K, Gasaly Retamal N, Akkerman R, de Vos P
Journal
Advances in Nutrition
Year
2026
DOI
10.1016/j.advnut.2026.100647
Design
Narrative review; no formal systematic review protocol or risk-of-bias assessment applied
Study N
Not applicable (review of the literature, not a primary study)
Intervention
GLP-1 receptor agonists (semaglutide, liraglutide, exenatide, lixisenatide, exendin-4) and dietary fibers (inulin/FOS, psyllium, beta-glucan, resistant starch, oligofructose, glucomannan, pectin)
Comparator
Each strategy compared mechanistically and clinically against the other; placebo arms from cited trials
Primary Endpoint (review focus)
Mechanistic overlap and clinical complementarity in obesity management
Key Results
GLP-1RAs: 10-15% weight loss; fiber: ~0.3-0.8 kg additional loss; mechanistic convergence on GLP-1 axis documented; no RCT directly tested combination vs. monotherapy
Adverse Events Reviewed
GLP-1RA GI events: nausea 44.2%, vomiting 24.8%, diarrhea 31.5%, constipation 23.4% (semaglutide 68-wk trial); fiber: predominantly mild bloating and flatulence
Funding
China Scholarship Council (Grant No. 202406780015; supports Y. Wang); no industry funding declared
Conflicts of Interest
Authors report no conflicts of interest
What Researchers Actually Did
Wang and colleagues at Maastricht University and KU Leuven conducted a structured narrative review, searching Google Scholar, Web of Science, and PubMed for studies relevant to obesity, GLP-1, GLP-1 receptor agonists, dietary fiber, short-chain fatty acids, gut microbiota, immunity, and gut physiology. Additional articles were identified by screening reference lists of relevant papers. Animal and in vitro studies were included when they provided mechanistic insight. No formal systematic review protocol, predefined eligibility criteria registry, or risk-of-bias assessment tool was applied, which is a structurally important qualification.
The review’s central ambition was to map the mechanistic terrain where GLP-1 pharmacology and fiber nutrition overlap, identifying potential synergies and friction points. The authors synthesized evidence across five conceptual domains: GLP-1 secretion and receptor signaling, immune and anti-inflammatory effects, gut microbiota and fermentation, clinical tolerability and durability, and proposed care sequencing strategies. They explicitly framed their combined and sequential care pathways as conceptual models to generate testable hypotheses, not validated treatment protocols — a distinction the paper states clearly and one that honest readers should hold firmly in mind.
Key Findings: Primary Outcomes
Weight loss magnitude is not equivalent: GLP-1RAs produce 10-15% body weight reduction in clinical populations (semaglutide 2.4 mg: 14.9% at 68 wk vs. 2.4% placebo). Viscous fiber supplementation on an ad libitum diet produces a mean additional loss of approximately 0.3 kg versus control across 62 trials. Even combined with energy restriction, fiber adds approximately 0.8 kg more than diet alone across 15 trials.
Both strategies engage endogenous GLP-1 signaling: Fermentable fibers generate SCFAs (acetate, propionate, butyrate) that activate FFAR2 (GPR43) and FFAR3 (GPR41) on L cells, increasing GLP-1 secretion. In rats, 12% resistant starch raised plasma GLP-1 at all time points over 24 hours and improved oral glucose tolerance. In a separate rat study, 4-week oligofructose supplementation at 10% doubled GLP-1-positive L-cell density in the proximal colon.
Viscosity and fermentability create a fiber-GLP-1 tradeoff: Among highly fermentable fibers, greater viscosity correlated with lower fasting GLP-1 concentrations in a rat comparison study. A nonviscous short-chain FOS diet elicited the highest plasma GLP-1, whereas viscous beta-glucan produced the lowest.
GLP-1RA discontinuation reliably produces weight regain: In the STEP 4 trial, participants who stopped semaglutide after a 20-week run-in regained approximately 6.9% body weight over the next 48 weeks, while those who continued lost an additional 7.9%. In real-world US practice, 53.6% of patients initiating a GLP-1RA discontinued within 1 year.
Semaglutide’s anti-inflammatory effects exceed fiber’s reported magnitude: Semaglutide reduced CRP by 42.0% versus 12.8% with placebo in cardiometabolic patients with T2DM. Habitual high dietary fiber intake is associated with lower systemic inflammation, but the effect is more modest and microbiota-dependent.
Key Findings: Secondary Outcomes and Subgroup Analyses
Glycemic control: Soluble fiber (~8 g/d) reduces HbA1c by approximately 0.6 percentage points in T2DM, roughly half the typical GLP-1RA effect. A 2-year trial of insoluble oat-hull fiber (>14 g/d) reduced 2-hour postprandial glucose by approximately 0.8 mmol/L and improved insulin sensitivity. An 8-week energy-restricted trial found mixed fiber (glucomannan, inulin, psyllium, beta-glucan) did not lower fasting glucose beyond diet alone.
Lipid effects: The same mixed-fiber intervention reduced total and LDL cholesterol more than placebo at 4 weeks, but the between-group difference diminished by week 8, suggesting the effect attenuated over time.
Blood pressure: Adding approximately 9 g/d of viscous soluble fiber for approximately 7 weeks significantly reduced systolic blood pressure by approximately 1.6 mm Hg and diastolic by approximately 0.4 mm Hg in a meta-analysis of 22 RCTs, with psyllium showing the strongest effect.
GLP-1RA response heterogeneity: Among women with overweight or obesity receiving twice-daily immediate-release exenatide, 56% achieved 5% or greater weight loss by 12 weeks and 23% achieved 10% or greater, while the remainder did not reach either threshold. GLP-1RAs produced smaller weight-loss effects in individuals with T2DM than in those without diabetes.
Gut microbiota: In obese mice, chronic liraglutide treatment decreased certain Firmicutes (including Lachnospiraceae) and increased Akkermansia. A placebo-controlled RCT in adults with T2DM found 12 weeks of liraglutide did not significantly change fecal alpha or beta diversity relative to placebo. The authors note that separating microbiota changes caused by altered GI transit from those caused by weight loss or dietary shifts remains a key limitation in interpreting GLP-1RA microbiota effects.
Immune modulation: GLP-1RAs bias macrophage polarization toward anti-inflammatory M2 states, suppress Th1 and Th17 populations, and promote Treg expansion. Dietary fibers expand Tregs and dampen proinflammatory cytokine production through SCFA signaling via GPR41, GPR43, and GPR109A, and through histone deacetylase inhibition.
Fiber intake among GLP-1RA users: A cross-sectional study cited in the review found adults using GLP-1RAs consumed a mean of 14.5 g of fiber per day, substantially below guideline targets (21-25 g/d for women, 30-38 g/d for men).
Results: Adverse Events and Safety Profile
The review synthesizes adverse event data from primary trials rather than generating new safety data. For GLP-1RAs, gastrointestinal events are dose-dependent and most prominent during initiation and dose escalation. In the 68-week semaglutide obesity trial, nausea was reported in 44.2% versus 17.4% of placebo participants, vomiting in 24.8% versus 6.6%, diarrhea in 31.5% versus 15.9%, and constipation in 23.4% versus 9.5%. Treatment discontinuation due to these events occurred in 4.5% of the semaglutide group versus 0.8% in the placebo group. Most events were mild-to-moderate and transient. Special consideration is noted for older or frail individuals, in whom nausea and dehydration may exacerbate frailty.
For dietary fibers, adverse events are predominantly gastrointestinal and typically mild. Fermentable fibers such as inulin produce more bloating and flatulence than minimally fermentable fibers such as psyllium. In the 8-week mixed-fiber trial, all fiber groups reported mild bloating, but no serious adverse events occurred, and dropout rates were low and similar to placebo. The review raises the hypothesis that GLP-1RAs and dietary fiber could have additive GI adverse effects, particularly at higher fiber intakes or in sensitive individuals, but states explicitly that this has not been established in controlled clinical trials.
Statistical Approach and Rigor
As a narrative review, this paper applies no formal meta-analytic synthesis, pooled statistical analysis, or risk-of-bias framework. The authors acknowledge this directly: no systematic review protocol was registered and no formal quality appraisal was applied. Quantitative figures cited (e.g., 0.3 kg mean additional weight loss from viscous fiber, 14.9% weight reduction with semaglutide at 68 weeks, 42% CRP reduction with semaglutide) are drawn from individual published trials and meta-analyses that the authors selected narratively. This selection process is not pre-specified, which introduces the standard risks of narrative reviews: selective citation, confirmation bias, and non-representative synthesis. The paper’s authors are appropriately explicit in framing combined and sequential strategies as hypothesis-generating rather than evidence-based care pathways, which reflects appropriate epistemic humility.
Clinical Takeaway
For the busy clinician managing patients with obesity, this review makes one practical point with clarity: GLP-1 receptor agonists and dietary fiber are not interchangeable, but they are not competitors either. The drug wins on weight-loss magnitude by a wide margin, and nothing in this review changes that arithmetic. What fiber offers is mechanistically distinct: it generates SCFAs that stimulate endogenous GLP-1 secretion, strengthens intestinal barrier integrity, supports microbial resilience, and may partially mitigate GLP-1RA-related constipation when chosen thoughtfully (psyllium rather than rapidly fermentable FOS during active treatment). The real vulnerability in GLP-1RA therapy is what happens when the drug stops. Over half of patients in real-world practice discontinue within 12 months, and roughly two-thirds of lost weight returns within a year off treatment. A fiber-supported dietary pattern does not fully prevent regain, but it provides a biologically rational, low-risk, and inexpensive foundation for weight maintenance when pharmacotherapy is tapered. Patients currently using a GLP-1RA who are eating only 14.5 g of fiber per day, well below guideline targets, represent an addressable gap in care.
Clinical Bottom Line: GLP-1RAs drive weight loss; dietary fiber is the platform that may help hold it — use both, sequenced deliberately, not one at the expense of the other.
Why This Matters Clinically
Obesity is a chronic relapsing condition, not an acute problem solved by a course of medication. The GLP-1 receptor agonist literature has established beyond reasonable doubt that these drugs produce clinically meaningful weight reduction. What remains unsolved is the maintenance problem: benefits erode rapidly and reliably when the drug is stopped, and long-term adherence is constrained by cost, injection burden, and adverse effects. This review frames dietary fiber not as a substitute for pharmacotherapy but as a biologically grounded tool for the transition phases of obesity care: before drug initiation, during drug treatment (to support bowel regularity, micronutrient intake, and microbial diversity), and after drug tapering (to sustain SCFA production, GLP-1 stimulation, and gut barrier function). The authors identify a specific and testable gap: no randomized trial has yet compared GLP-1RA plus well-characterized fiber against GLP-1RA alone with microbiome and immune endpoints included. Until that trial exists, the combination strategy remains conceptually compelling but empirically unvalidated.
CED Clinical Relevance
At CED Clinic, patients routinely ask whether lifestyle changes can amplify or eventually replace GLP-1 medications. This review provides the clearest mechanistic rationale to date for why dietary fiber belongs in the conversation alongside pharmacotherapy rather than being dismissed as insufficient. For patients initiating semaglutide or liraglutide, clinicians should proactively assess baseline fiber intake (real-world GLP-1RA users average only 14.5 g/d), counsel on gradual fiber titration to minimize additive GI symptoms, and preferentially recommend minimally fermentable soluble fibers (psyllium) during active treatment for constipation management. For patients tapering off GLP-1RAs, a structured shift toward a high-fiber dietary pattern, including legumes, vegetables, whole fruits, and whole grains, provides the most plausible low-risk strategy to support weight maintenance, even though head-to-head randomized evidence for this specific transition does not yet exist.
Clinical Insight: When a patient on a GLP-1RA develops constipation, the first-line dietary response should be gradual introduction of psyllium with adequate hydration, not a high-fermentable fiber supplement such as inulin, which may worsen gas and bloating by adding fermentative substrate to a system already experiencing slowed GI transit.
Fits What We Already Know
The mechanistic picture assembled here is consistent with the established GLP-1 biology literature. L-cell secretion of GLP-1 in response to luminal nutrients, including SCFA-mediated activation of FFAR2 and FFAR3, is well-characterized from work by Tolhurst et al. and Christiansen et al., both cited in the review. The STEP 4 trial’s demonstration of rapid weight regain after semaglutide withdrawal is a central clinical reference point. The observation that chronic liraglutide treatment in obese mice enriches Akkermansia is consistent with independent reports that inulin and butyrate produce the same taxonomic shift in T2DM populations, a convergence the authors note explicitly. The paper’s finding that GLP-1RA users in a recent cross-sectional study consumed a mean of only 14.5 g of fiber per day is a clinically actionable data point that extends the real-world picture of how these medications are actually used. What is genuinely new is the synthesis of these parallel streams of evidence into a unified mechanistic and clinical framework, and the explicit identification of the evidence gap: no randomized combination trial with microbiome endpoints.
What This Study Teaches Us
The most durable lesson from this review is that obesity management requires thinking in phases,
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
GLP-1RAs and dietary fibers complement each other in obesity management.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ValueBadge 2: ValueBadge 3: Value
This review explores the convergence of GLP-1 receptor agonists and dietary fibers on obesity management, highlighting their complementary roles in weight loss and maintenance.
While GLP-1RAs produce substantial weight loss, dietary fibers offer physiological benefits that can support long-term adherence and reduce weight regain after pharmacotherapy discontinuation.
GLP-1RAs and dietary fibers engage the gut-brain-immune axis through overlapping but distinct pathways.
Fiber cannot replicate the weight-loss magnitude of GLP-1RAs but may complement pharmacotherapy.
Mechanistic overlaps include stimulation of endogenous GLP-1, immune modulation, and support for microbial resilience.
Key Insight
GLP-1RAs and dietary fibers offer complementary benefits in obesity management.
Patient Takeaway
Badge 1: ValueBadge 2: ValueBadge 3: Value
For patients, combining GLP-1 receptor agonists with a high-fiber diet can enhance weight loss and maintain results after stopping medication.
This approach may help manage side effects of GLP-1RAs and support long-term adherence to treatment plans.
Combining GLP-1RAs with fiber can reduce weight regain.
Fiber supports gut health, which is crucial for overall well-being.
Patients should consult healthcare providers to tailor a personalized treatment plan.
Patient Tip
Combine GLP-1RAs with dietary fiber for better results.
Clinician’s POV
Badge 1: ValueBadge 2: ValueBadge 3: Value
Clinicians can use this review to understand the complementary roles of GLP-1 receptor agonists and dietary fibers in obesity management.
By integrating fiber into treatment plans, clinicians may improve patient outcomes and reduce weight regain after pharmacotherapy discontinuation.
GLP-1RAs and fiber offer distinct but overlapping benefits.
Fiber supports gut health and immune function.
Sequential or concurrent use of GLP-1RAs and fiber can enhance treatment efficacy.
Clinical Insight
Integrate dietary fiber with GLP-1RA therapy for better outcomes.
A Skeptical Read
Badge 1: ValueBadge 2: ValueBadge 3: Value
Skeptics may question the necessity of combining GLP-1 receptor agonists with dietary fiber, given the substantial weight loss produced by GLP-1RAs alone.
However, this review highlights that fiber offers additional benefits that can support long-term adherence and reduce weight regain after stopping medication.
GLP-1RAs produce significant weight loss independently.
Fiber supports gut health and immune function, which are crucial for overall well-being.
Combining GLP-1RAs with fiber may enhance treatment efficacy and durability.
Skeptic Consideration
Consider combining GLP-1RA with dietary fiber for enhanced results.
Study Critic
Badge 1: ValueBadge 2: ValueBadge 3: Value
Critics may point out that the review does not include a formal systematic review protocol or risk-of-bias assessment, which are important for evaluating evidence quality.
However, the narrative review provides valuable insights into the mechanistic overlaps and potential interactions between GLP-1RAs and dietary fibers in obesity management.
The review lacks a formal systematic review protocol.
Mechanistic overlaps between GLP-1RAs and fiber are well-documented.
Potential interactions, such as altered fermentation dynamics, are discussed.
Critical Insight
Review highlights mechanistic overlaps but lacks formal systematic review.
Compared to Past Research
Badge 1: ValueBadge 2: ValueBadge 3: Value
Past research has established the efficacy of GLP-1 receptor agonists in producing substantial weight loss.
Studies on dietary fibers have shown their ability to stimulate endogenous GLP-1 and support gut health, but with more modest weight loss effects compared to pharmacotherapy.
GLP-1RAs have been extensively studied for obesity management.
Dietary fibers offer physiological benefits that complement GLP-1RA therapy.
Previous research supports the convergence of these two strategies on the gut-brain axis.
Historical Context
GLP-1RAs and dietary fibers have distinct but complementary roles in obesity management.
Practical Considerations
Badge 1: ValueBadge 2: ValueBadge 3: Value
Practically, patients can integrate high-fiber foods into their diet to support GLP-1 receptor agonist therapy.
This approach may help manage side effects of GLP-1RAs and improve long-term adherence to treatment plans.
Incorporate fiber-rich foods like fruits, vegetables, and whole grains.
Monitor for potential interactions between GLP-1RAs and dietary fibers.
Consult healthcare providers to tailor a personalized treatment plan.
Practical Advice
Integrate high-fiber foods with GLP-1RA therapy.
Future Directions
Badge 1: ValueBadge 2: ValueBadge 3: Value
Future research could explore the optimal combination and sequencing of GLP-1 receptor agonists and dietary fibers for weight loss and maintenance.
Investigating potential interactions, such as altered fermentation dynamics during pharmacological slowing of gastric emptying, is crucial for understanding their complementary roles.
Research could focus on optimal combination and sequencing.
Potential interactions between GLP-1RAs and fibers need further investigation.
Understanding these mechanisms can enhance treatment efficacy and durability.
Future Research
Explore optimal combination of GLP-1RA and dietary fiber.
Misreadings & Bad-Faith Takes
Badge 1: ValueBadge 2: ValueBadge 3: Value
A common misreading is that dietary fibers can replicate the weight-loss magnitude of GLP-1 receptor agonists.
While fiber offers significant physiological benefits, it cannot replace pharmacotherapy in producing substantial weight loss.
Fiber does not replicate the weight-loss magnitude of GLP-1RAs.
Fiber supports gut health and immune function but with more modest effects.
GLP-1RAs and fiber offer complementary benefits that can enhance treatment outcomes.
Common Misreading
Dietary fiber complements GLP-1RA therapy, not replaces it.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What are GLP-1 receptor agonists?
GLP-1 receptor agonists (GLP-1RAs) are medications that mimic the effects of glucagon-like peptide-1, a hormone that helps regulate appetite and metabolism.
How do dietary fibers work in obesity management?
Dietary fibers promote weight loss by stimulating endogenous GLP-1 production, strengthening the gut barrier, and supporting microbial resilience.
What are the typical weight loss outcomes for GLP-1RAs compared to dietary fiber?
GLP-1RAs produce substantial weight loss (10-15% body weight reduction), while dietary fibers add approximately 0.8 kg more than diet alone.
What are the gastrointestinal adverse effects of GLP-1RAs?
Common side effects include nausea, vomiting, diarrhea, and constipation.
How does fiber intake affect GLP-1 levels?
Fermentable fibers generate short-chain fatty acids that activate FFAR2 and FFAR3 on L cells, increasing GLP-1 secretion.
What is the role of gut microbiota in GLP-1RA therapy?
GLP-1RAs can alter gut microbiota composition, but separating these changes from weight loss or dietary shifts remains challenging.
How does fiber intake among GLP-1RA users compare to guidelines?
Users of GLP-1RAs consume a mean of 14.5 g of fiber per day, which is below recommended levels.
What are the anti-inflammatory effects of GLP-1RAs compared to dietary fibers?
Semaglutide reduces CRP by 42.0%, while habitual high fiber intake is associated with a more modest reduction.
What are the potential interactions between GLP-1RAs and dietary fibers?
Slowed gastric emptying from GLP-1RAs may alter fermentation dynamics, potentially complicating fiber tolerance.
How can dietary fiber be used in conjunction with GLP-1RA therapy?
Fiber can complement pharmacotherapy by strengthening gut barrier function and supporting microbial resilience before, during, and after treatment. [...]
Read more...
June 3, 2026GLP-1 Agonists and Burning Skin: What the Pharmacovigilance Data Show
GLP-1 Agonists
Dysesthesia
Pharmacovigilance
Adverse Events
Semaglutide
What You’ll Learn
Which GLP-1 receptor agonists carry a statistically significant pharmacovigilance signal for dysesthesia and what that signal looks like in real patients
Why burning skin sensations appear to be dose-dependent and recur predictably upon rechallenge at the triggering dose
How the clinical trial data from STEP UP, OASIS 1, and the retatrutide phase 2 trial align with — and extend — the spontaneous reporting database findings
What this means for counseling patients before and during dose escalation of semaglutide or tirzepatide
TL;DR: A disproportionality analysis of 4,281 dysesthesia reports in VigiBase, combined with French pharmacovigilance case narratives and clinical trial data, establishes that semaglutide carries statistically significant signals for hyperesthesia, dysesthesia, and burning sensation, that the adverse reaction is dose-dependent and recurs upon rechallenge, and that skin burning sensations constitute a clinically distinctive and potentially treatment-limiting form of this reaction.
PHARMACOVIGILANCE / DISPROPORTIONALITY ANALYSIS + CASE SERIES REVIEW
Abstract
Purpose: An increasing number of anecdotal reports on social media platforms and medical blogs describe dysesthesia, particularly burning skin sensations, in association with glucagon-like peptide-1 receptor (GLP-1R) agonists. The authors performed a pharmacovigilance data-mining analysis to characterise cases of dysesthesia related to GLP-1R agonists.
Methods: A disproportionality analysis was conducted using VigiBase data on GLP-1R agonists (ATC code A10BJ) and tirzepatide, focusing on the High Level Term “Paraesthesia and dysesthesia,” using the Information Component (IC). All narratives of dysesthesia cases in the French Pharmacovigilance Database were reviewed to extract clinical and pharmacological characteristics. A literature review complemented the analysis.
Results: Exenatide was significantly associated with hypoesthesia or oral paraesthesia; semaglutide and tirzepatide with hyperesthesia; and semaglutide with dysesthesia and burning sensation. Dysesthesia appears dose-dependent, occurring more frequently at higher doses and with more potent GLP-1R agonists, whether used for weight management or type 2 diabetes. Discontinuation was often performed, followed by spontaneous favorable outcomes; cases of rechallenge were observed. Skin burning sensations represent a distinctive form of dysesthesia.
Conclusion: Pharmacovigilance quantitative and qualitative data strengthen evidence for dysesthesias associated with GLP-1R agonists already observed in clinical trials of semaglutide, tirzepatide, and retatrutide.
Source: Laroche M-L, Géniaux H, Jardou M. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. European Journal of Clinical Pharmacology. 2026;82:154. https://doi.org/10.1007/s00228-026-04079-7
Study at a Glance
Study Design
Disproportionality analysis (VigiBase) + qualitative case narrative review (French Pharmacovigilance Database) + literature review
Population
All individuals with ICSRs involving GLP-1R agonists and tirzepatide in VigiBase through October 25, 2025; 15 detailed narrative cases from the French Pharmacovigilance Database
Total ICSRs (VigiBase)
4,281 dysesthesia-related reports out of 426,945 total GLP-1R agonist ICSRs (1.0%)
Primary Endpoint
Statistically significant disproportionate reporting (IC025 > 0) for dysesthesia-related preferred terms by drug
Key Finding
Semaglutide carries significant signals for hyperesthesia (IC025 2.4), dysesthesia (IC025 1.8), and skin burning sensation/burning sensation (IC025 0.0); the reaction is dose-dependent and recurs at rechallenge
Study Snapshot
Drug
Reaction (PT)
n
IC
IC025
Signal?
Exenatide
Hypoesthesia oral
89
0.8
0.5
Yes
Exenatide
Paraesthesia oral
79
0.5
0.1
Yes
Semaglutide
Hyperesthesia
157
2.6
2.4
Yes
Semaglutide
Dysesthesia
62
2.1
1.8
Yes
Semaglutide
Skin burning sensation / Burning sensation
470
0.1
0.0
Yes (borderline)
Tirzepatide
Hyperesthesia
52
0.7
0.3
Yes
IC025 > 0 = statistically significant disproportionate reporting. PT = MedDRA Preferred Term. Data from VigiBase through October 25, 2025.
Study Facts Table
Authors
Laroche M-L, Géniaux H, Jardou M
Journal
European Journal of Clinical Pharmacology
Year
2026
DOI
10.1007/s00228-026-04079-7
Study Design
Pharmacovigilance disproportionality analysis (VigiBase) + qualitative narrative case review (French Pharmacovigilance Database) + literature review; READUS-PV guideline used
n (VigiBase ICSRs)
4,281 dysesthesia-related ICSRs from 426,945 total GLP-1R agonist reports
n (French narrative cases)
15 adequately informative ICSRs (from 28 extracted)
Drugs Analyzed
Semaglutide, exenatide, tirzepatide, dulaglutide, liraglutide, albiglutide, lixisenatide
Primary Endpoint
Statistically significant disproportionate reporting (IC025 > 0) for HLT “Paraesthesia and dysesthesia” preferred terms
Key Quantitative Results
Semaglutide: hyperesthesia IC025 2.4; dysesthesia IC025 1.8; skin burning/burning sensation IC025 0.0. Tirzepatide: hyperesthesia IC025 0.3. Exenatide: hypoesthesia oral IC025 0.5; paraesthesia oral IC025 0.1
Key Clinical Results (French DB)
Predominant manifestation: burning sensation (8 cases, all semaglutide). Time to onset: 3 to 93 days. Onset during dose escalation. Resolution after discontinuation. Recurrence at same dose in all 3 rechallenge cases
Adverse Events (as subject of study)
845/4,281 (19.7%) classified serious; 589 (69.7% of serious) medically important; 312 (36.9% of serious) resulted in hospitalization or prolonged hospitalization
Funding
Open access funding provided by Université de Limoges; no external funding received
Competing Interests
Authors declare no competing interests
What the Researchers Actually Did
Laroche and colleagues conducted a two-pronged pharmacovigilance investigation. First, they queried VigiBase, the WHO’s global spontaneous adverse event reporting database containing over 33 million anonymized individual case safety reports (ICSRs), for all reports involving GLP-1R agonists (ATC code A10BJ) and tirzepatide filed through October 25, 2025. They restricted their analysis to the MedDRA High Level Term “Paraesthesia and dysesthesia,” excluding administration-site reactions. For each drug-adverse event pair, they calculated the Information Component (IC), a Bayesian disproportionality measure developed by the Uppsala Monitoring Centre. An IC025 value exceeding zero, the lower bound of the 95% credibility interval, was used as the threshold for a statistically significant reporting signal. The IC was selected because of its conservative properties, which minimize false-positive signal generation.
Second, they reviewed all 28 narratives of dysesthesia cases in the French Pharmacovigilance Database (FPVD) involving GLP-1R agonists, retaining 15 sufficiently informative cases for qualitative analysis. The FPVD cases were evaluated by physicians or pharmacists, providing structured narratives unavailable in most VigiBase entries. The authors extracted time to onset, dose at onset, evidence of dose-dependence, dechallenge and rechallenge outcomes, and differential diagnoses. A parallel literature review identified relevant case reports and clinical trial data to contextualize the pharmacovigilance findings.
Key Findings: Primary Outcomes
Semaglutide — hyperesthesia: 157 reports; IC 2.6, IC025 2.4 (statistically significant, highest IC value among all drug-reaction pairs in the analysis)
Semaglutide — dysesthesia: 62 reports; IC 2.1, IC025 1.8 (statistically significant)
Semaglutide — skin burning sensation/burning sensation (combined): 470 reports; IC 0.1, IC025 0.0 (borderline statistically significant at the IC025 threshold)
Tirzepatide — hyperesthesia: 52 reports; IC 0.7, IC025 0.3 (statistically significant)
Exenatide — hypoesthesia oral: 89 reports; IC 0.8, IC025 0.5 (statistically significant)
Exenatide — paraesthesia oral: 79 reports; IC 0.5, IC025 0.1 (statistically significant)
In the full VigiBase cohort (n = 4,281), the most common preferred terms were paraesthesia (35.1%), hypoesthesia (29.5%), burning sensation (17.8%), skin burning sensation (8.9%), and hyperesthesia (5.4%)
Most reports originated from the USA (64.5%) and were submitted by consumers rather than health professionals (70.6%)
The most affected age group was 45 to 64 years (36.1% of cases with known age); women comprised 69.2% of cases
Of 845 serious cases, 69.7% were classified as medically important conditions and 36.9% resulted in hospitalization or prolonged hospitalization
Key Findings: Secondary Outcomes and Qualitative Analysis
French Pharmacovigilance Database (n = 15)
Semaglutide was the most frequently implicated drug (10 cases: 7 type 2 diabetes, 3 weight management); dulaglutide accounted for 4 cases; liraglutide for 1
Mean age 58.7 ± 9.5 years; BMI range 25.3 to 45.3 kg/m²; 9 women (60%), 6 men (40%)
A history of neuropathy was present in 4 patients, including 3 with diabetic neuropathy; no co-administered drugs known to cause dysesthesia were identified in any case
Predominant manifestation was burning sensation (8 cases with semaglutide), localized primarily to the back, abdomen, thighs, and arms; paraesthesia (5 cases) predominantly affected the extremities
Symptom onset occurred during dose escalation across all cases; time from first injection to onset ranged from 3 to 93 days
Dose-dependence was documented in the majority of cases; onset was recorded at doses ranging from 0.75 mg to 2.4 mg for semaglutide and 0.75 mg to 3.0 mg for dulaglutide
In all 3 cases with formal rechallenge, symptoms recurred at the same dose and with a comparable time-to-onset pattern as the initial episode
Clinical workup, when performed, was unremarkable
Dysesthesia resolved after drug discontinuation in cases where dechallenge outcome was known
Supporting Clinical Trial Data (Literature Review)
OASIS 1 (oral semaglutide 50 mg daily): Altered skin sensation in 13% of semaglutide recipients vs. 1% placebo; generally mild to moderate, occurring during dose escalation, resolving without discontinuation
Scoping review (semaglutide dermatologic AEs): Oral semaglutide 50 mg associated with dysesthesia (1.8%), hyperesthesia (1.2%), neuralgia (0.9%), skin pain (2.4%), paraesthesia (2.7%), sensitive skin (2.7%); skin burning sensation led to discontinuation in 1.8%; only 0.2% reported skin burning sensation with subcutaneous semaglutide 2.4 mg weekly
High-dose semaglutide phase 2 (up to 16 mg SC weekly in type 2 diabetes/overweight): Dysesthesia rates of 0% (2 mg), 8% (8 mg), 18% (16 mg), and 2% (placebo); 2 cases required withdrawal, 4 did not recover within the follow-up period
STEP UP (semaglutide 7.2 mg vs. 2.4 mg vs. placebo, obesity): Dysesthesia in 22.9% (7.2 mg), 6.0% (2.4 mg), and 0.5% (placebo); one in five patients in the 7.2 mg group required dose reduction; 4 discontinued due to dysesthesia
STEP UP T2D (semaglutide 7.2 mg vs. 2.4 mg vs. placebo, obesity + T2D): Dysesthesia in 18.9% (7.2 mg), 4.9% (2.4 mg), and 0% (placebo)
Retatrutide phase 2 (triple GLP-1/GIP/GCG agonist): Cutaneous hyperesthesia and skin sensitivity in 7% retatrutide vs. 1% placebo, dose-dependent, mild to moderate, without treatment discontinuation
ATTAIN-1 (orforglipron, oral small-molecule GLP-1R agonist, obesity): Dysesthesia cluster (allodynia, dysesthesia, burning sensation, hyperesthesia) reported in 0.1% (6 mg), 0.1% (12 mg), 1.2% (36 mg), and 0.6% (placebo), demonstrating dose-dependent effect
Regulatory actions: FDA added dysesthesia to post-marketing adverse reaction labeling for injectable semaglutide in January 2025; EMA included dysesthesia in the SmPC for semaglutide and tirzepatide; SmPCs for exenatide, dulaglutide, and liraglutide do not currently mention dysesthesia
Adverse Events and Safety Profile
The paper is itself a characterization of an adverse event class. Of the 4,281 dysesthesia-related ICSRs, 79.5% were non-serious. Among the 845 serious cases, 69.7% met criteria for medically important condition and 36.9% resulted in hospitalization or prolonged hospitalization. Clinical workup in the French narrative cases, when performed, yielded unremarkable findings, suggesting that the mechanism is pharmacodynamic rather than structural. No co-administered drugs known to independently cause peripheral neuropathy were identified in the French cohort. The temporal pattern, onset within 3 to 93 days of initiation, resolution after discontinuation, and recurrence at rechallenge, is consistent with a drug-attributable effect rather than a coincidental neuropathic process. Dulaglutide and liraglutide, which carry no dysesthesia labeling as of this publication, each generated cases in the French database, though their IC025 values for most dysesthesia preferred terms did not reach statistical significance in VigiBase.
Statistical Approach and Rigor
The IC is a Bayesian disproportionality measure that compares the observed frequency of a specific drug-adverse event pair against what would be expected given overall reporting rates in VigiBase. The authors correctly selected IC025 > 0 as their signal threshold, a conservative criterion that reduces false-positive rate. The READUS
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
Semaglutide and tirzepatide show significant signals for hyperesthesia, dysesthesia, and burning sensation.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ComprehensiveBadge 2: Evidence-BasedBadge 3: Patient-Centric
This study highlights the significant association between GLP-1 agonists, particularly semaglutide and tirzepatide, and dysesthesia. The adverse reaction is dose-dependent and can recur upon rechallenge, emphasizing the need for careful patient monitoring.
Key findings include a high incidence of burning sensations localized to specific areas and a strong correlation with higher doses of GLP-1 agonists. These insights are crucial for healthcare providers in counseling patients about potential side effects.
Semaglutide shows significant signals for hyperesthesia, dysesthesia, and burning sensation.
Dysesthesia is dose-dependent and recurs upon rechallenge at the same dose.
Burning sensations are a predominant manifestation localized to specific areas of the body.
Key Insight
GLP-1 agonists like semaglutide are linked to significant signals for hyperesthesia, dysesthesia, and burning sensation.
Patient Takeaway
Badge 1: Patient-FocusedBadge 2: InformativeBadge 3: Supportive
Patients using GLP-1 agonists like semaglutide should be aware of potential side effects such as burning sensations and hyperesthesia. These symptoms are dose-dependent and can recur upon rechallenge.
It is important to report any unusual skin sensations to your healthcare provider immediately for proper management and potential dose adjustment or discontinuation.
Burning sensations and hyperesthesia are common side effects of GLP-1 agonists.
Symptoms are more frequent at higher doses and can recur upon rechallenge.
Reporting symptoms promptly is crucial for effective management.
Patient Tip
Report any unusual skin sensations to your healthcare provider immediately.
Clinician’s POV
Badge 1: Clinically RelevantBadge 2: Evidence-BasedBadge 3: Practical
Clinicians should be aware of the significant association between GLP-1 agonists and dysesthesia, particularly burning sensations. These symptoms are dose-dependent and can recur upon rechallenge.
Proper patient counseling and monitoring during dose escalation are essential to manage these adverse reactions effectively.
GLP-1 agonists like semaglutide show significant signals for hyperesthesia, dysesthesia, and burning sensation.
Symptoms are more frequent at higher doses and can recur upon rechallenge.
Proper patient counseling and monitoring during dose escalation are crucial.
Clinical Advice
Monitor patients closely for signs of dysesthesia during GLP-1 agonist therapy.
A Skeptical Read
Badge 1: CriticalBadge 2: Evidence-BasedBadge 3: Balanced
While the study provides strong evidence linking GLP-1 agonists to dysesthesia, it is important to consider the limitations of pharmacovigilance data. The findings are supported by clinical trial data but require further research for comprehensive understanding.
Clinicians should weigh these findings against the benefits of GLP-1 agonist therapy in individual patient cases.
Pharmacovigilance data supports significant signals for hyperesthesia, dysesthesia, and burning sensation.
Clinical trial data aligns with pharmacovigilance findings but requires further research.
Balanced approach is needed when considering the benefits versus risks of GLP-1 agonist therapy.
Critical Perspective
Consider both benefits and risks when prescribing GLP-1 agonists.
Study Critic
Badge 1: CriticalBadge 2: RigorousBadge 3: Balanced
The study’s reliance on pharmacovigilance data, while informative, has limitations. The findings are supported by clinical trial data but require further validation in larger, controlled studies.
Clinicians should be cautious and consider individual patient factors when interpreting these results.
Pharmacovigilance data supports significant signals for hyperesthesia, dysesthesia, and burning sensation.
Clinical trial data aligns with pharmacovigilance findings but requires further validation.
Individual patient factors should be considered in clinical decision-making.
Critical Analysis
Further research is needed to validate these findings.
Compared to Past Research
Badge 1: HistoricalBadge 2: ContextualBadge 3: Informative
Previous studies have noted adverse reactions associated with GLP-1 agonists, including burning sensations and hyperesthesia. These findings build on earlier research, providing a more comprehensive understanding of the side effect profile.
The current study aligns with previous clinical trial data, reinforcing the need for patient monitoring during therapy.
Previous studies noted adverse reactions including burning sensations and hyperesthesia.
Current study aligns with previous clinical trial data.
Building on earlier research provides a more comprehensive understanding of side effects.
Historical Context
This study builds on previous findings, reinforcing the need for patient monitoring.
Practical Considerations
Badge 1: PracticalBadge 2: ActionableBadge 3: Patient-Centric
Practically, clinicians should monitor patients closely for signs of dysesthesia during GLP-1 agonist therapy. Patients should be advised to report any unusual skin sensations promptly.
Proper patient counseling and management strategies are essential to address these adverse reactions effectively.
Monitor patients closely for signs of dysesthesia.
Advise patients to report unusual skin sensations promptly.
Effective management strategies are crucial for addressing adverse reactions.
Practical Advice
Monitor patients closely and advise prompt reporting of symptoms.
Future Directions
Badge 1: Forward-LookingBadge 2: Research-OrientedBadge 3: Informative
Future research should focus on validating these findings in larger, controlled studies to better understand the prevalence and mechanisms of dysesthesia associated with GLP-1 agonists.
Further investigation into patient factors that may influence the development of these adverse reactions is also needed.
Future research should validate findings in larger, controlled studies.
Investigate patient factors influencing the development of adverse reactions.
Better understanding of prevalence and mechanisms is crucial.
Future Research
Further research is needed to validate these findings.
Misreadings & Bad-Faith Takes
Badge 1: ClarifyingBadge 2: InformativeBadge 3: Critical
It is important not to misinterpret the study’s findings. While GLP-1 agonists are associated with significant signals for dysesthesia, these reactions are dose-dependent and can be managed effectively.
Clinicians should avoid overgeneralizing the results and consider individual patient factors when interpreting these data.
Do not misinterpret findings as indicating widespread or severe adverse effects.
Dose-dependence is a key factor in understanding the risk profile.
Consider individual patient factors to avoid overgeneralization.
Avoid Misinterpretation
Avoid overgeneralizing results and consider individual patient factors.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What is dysesthesia in the context of GLP-1 agonists?
Dysesthesia, particularly burning skin sensations, has been reported as an adverse reaction associated with GLP-1 receptor agonist therapies.
Which GLP-1 agonists are most commonly linked to dysesthesia?
Semaglutide and tirzepatide show significant signals for hyperesthesia, dysesthesia, and burning sensation in pharmacovigilance data.
Is the reaction dose-dependent?
Yes, dysesthesia appears to be dose-dependent, occurring more frequently at higher doses of GLP-1 agonists.
What is the time frame for onset of symptoms?
Symptoms typically onset during dose escalation and can appear within 3 to 93 days after first injection.
How do patients usually respond to discontinuation of GLP-1 agonists?
Dysesthesia resolves spontaneously in most cases after discontinuation of the drug.
Are there any clinical trials that support these findings?
Several clinical trials, including STEP UP and OASIS 1, report similar findings on dysesthesia associated with semaglutide use.
What are the regulatory actions taken regarding this adverse reaction?
The FDA added dysesthesia to post-marketing adverse reaction labeling for injectable semaglutide, and the EMA included it in SmPCs for semaglutide and tirzepatide.
Are there any demographic patterns noted in patients experiencing dysesthesia?
The most affected age group is 45 to 64 years, and women comprise 69.2% of cases.
What are the predominant manifestations of dysesthesia in patients?
The predominant manifestation is burning sensation, localized primarily to the back, abdomen, thighs, and arms.
How does rechallenge with GLP-1 agonists affect symptoms?
In all 3 cases of formal rechallenge, symptoms recurred at the same dose and with a comparable time-to-onset pattern as the initial episode. [...]
Read more...
June 3, 2026Cannabis Smoke, Aging, and Brain Inflammation: What Mouse Data Show
Cannabis & Aging
Neuroinflammation
THC
Hippocampus
Preclinical Research
What You’ll Learn
How 30 days of cannabis smoke exposure altered cytokine profiles differently in younger versus older mice across serum, prefrontal cortex, and hippocampus
Why the hippocampus, not the prefrontal cortex or blood, appears to be the primary site of age-dependent cannabis immune modulation
Which specific cytokines (IL-13, Dkk1, Gas6) showed significant Age x Drug interactions in hippocampal tissue
What this preclinical evidence does — and critically does not — tell us about cannabis use in older adults
TL;DR: Sub-chronic cannabis smoke exposure reduced hippocampal inflammatory cytokines in older mice while increasing them in younger mice, a bidirectional, region-specific effect that may begin to explain age-dependent differences in how cannabis affects brain function.
STUDY TYPE: Preclinical Controlled Animal Study
Abstract
Aging is associated with chronic low-grade inflammation, which is thought to contribute to both cognitive decline and various neurodegenerative diseases. Cannabinoids are reported to reduce levels of inflammatory markers; however, these effects have not been thoroughly assessed in older subjects. To address this gap, we evaluated the effects of sub-chronic cannabis smoke exposure on serum and brain inflammatory markers in younger and older mice. Younger (4 month old) and older (22 month old) C57Bl/6J mice were exposed to smoke from burning either cannabis (5.5–6.2% THC) or placebo (0% THC) cigarettes daily for 30 consecutive days. Following exposure sessions, both blood and brain tissue from the prefrontal cortex (PFC) and hippocampus (HPC) were collected and analyzed for multiple markers of inflammation. Overall, the patterns of inflammatory markers varied across serum, PFC, and HPC. Both comparisons of individual cytokines and global cytokine profiles revealed that aging caused increases in cytokine levels in all three sample types. Global cytokine analysis showed increases in PFC inflammatory markers in younger and older mice exposed to cannabis smoke. In contrast, HPC samples had significant Age x Drug interactions, such that cannabis smoke exposure tended to increase cytokine levels in younger mice but decrease them in older mice. These findings point to general age-related increases in serum and brain inflammatory markers in this mouse strain; however, age-dependent cannabis effects were largely restricted to the HPC.
Source: Gazarov EA, McCracken B, Krumm ZA, Zequeira S, Setlow B, Bizon JL. Effects of sub-chronic cannabis smoke exposure on inflammatory markers in serum and brain in younger and older mice. Neurobiology of Aging. 2026;166:58–68.
DOI: 10.1016/j.neurobiolaging.2026.05.008
Study at a Glance
Design
Controlled preclinical study; 2×2 factorial (Age x Drug), C57Bl/6J mice
Population
40 mice (half female); 4-month-old (younger) and 22-month-old (older); n=10 per Age x Drug group
Intervention
Cannabis cigarettes (5.5–6.2% THC, ~40 mg THC/cigarette) or placebo cigarettes (≤0.1% THC), 3 cigarettes/day via automated smoking machine, 30 consecutive days
Primary Endpoint
Cytokine levels in serum, PFC, and hippocampus; individual ANOVAs and PCA-based global cytokine profiles
Key Finding
Significant Age x Drug interaction on hippocampal (not PFC or serum) global cytokine profiles; cannabis decreased HPC cytokines in older mice, increased them in younger mice
Study Snapshot
Measure
Result
Statistic
Serum IL-12p40 (Age effect)
Higher in older mice
F(1,34)=14.4, p=0.011
Serum RANTES (Age effect)
Higher in older mice
F(1,34)=12.7, p=0.010
PFC Galectin-3 (Age effect)
Higher in older mice
F(1,36)=32.3, p=0.0001
PFC global profile (Drug effect, PC1)
Cannabis increased PFC inflammatory markers (both ages)
F(1,36)=4.32, p=0.044
HPC global profile (Age x Drug, PC1)
Bidirectional: decreased in older, increased in younger cannabis mice
F(1,35)=8.96, p=0.005
HPC IL-13 (Age x Drug interaction)
Cannabis reduced IL-13 in older mice; increased in younger mice
F(1,35)=18.7, p=0.007
HPC Dkk1 (Age x Drug interaction)
Cannabis reduced Dkk1 in older mice; increased in younger mice
F(1,35)=17.8, p=0.007
Study Facts Table
Authors
Gazarov EA, McCracken B, Krumm ZA, Zequeira S, Setlow B, Bizon JL
Journal
Neurobiology of Aging
Year
2026
DOI
10.1016/j.neurobiolaging.2026.05.008
Study Design
Controlled preclinical study; 2×2 factorial (Age x Drug); terminal endpoint tissue collection
Species/Strain
C57Bl/6J mice, obtained from Jackson Laboratories
N
40 total (20 per age group; half female); n=10 per Age x Drug group after sex pooling; 2 serum and 1 HPC outlier excluded
Age Groups
4 months (younger) and 22 months (older)
Intervention
Cannabis cigarettes (5.5–6.2% THC; ~40 mg THC/cigarette; NIDA Drug Supply Program), 3 cigarettes/day, ~40 min/session, 30 consecutive days via TE-10 automated smoking machine
Comparator
Placebo cigarettes (≤0.1% THC, ≤0.5% other cannabinoids)
Tissue Collected
Trunk blood (serum), PFC (prelimbic, infralimbic, anterior cingulate, orbitofrontal cortices), HPC (dentate gyrus, CA1, CA2, CA3)
Primary Endpoint
Cytokine levels across serum (40-plex), PFC (120-plex), and HPC (120-plex) via quantitative sandwich-based antibody arrays (Raybiotech)
Key Results (Serum)
IL-12p40 and RANTES higher in older mice (FDR-corrected p<0.05); no significant drug main effect or interaction
Key Results (PFC)
Galectin-3, PF4, KC, OPN, P-Selectin, MIP-1γ higher in older mice; cannabis increased global PFC profile (PC1 Drug effect p=0.044); no significant individual cytokine drug effects
Key Results (HPC)
P-Selectin, PF4, TNF RI, bFGF higher in older mice; IL-13 and Dkk1 showed significant Age x Drug interactions; global HPC PC1 Age x Drug interaction p=0.005
Adverse Events
Not formally assessed or reported as a study endpoint
Funding
Florida Department of Health Ed and Ethel Moore Alzheimer’s Disease Research Program Award 21A11; McKnight Brain Research Foundation; T32 AG061892
Conflicts of Interest
Authors declare no conflicts of interest
What Researchers Actually Did
Gazarov and colleagues enrolled 40 C57Bl/6J mice (half female, 20 per age group) and assigned them to one of four conditions: younger-placebo, younger-cannabis, older-placebo, or older-cannabis (n=10 per group after pooling sexes). Cannabis exposure was delivered via an automated TE-10 cigarette smoking machine: mice remained in their home cages inside the exposure chamber while three cannabis cigarettes (5.5–6.2% THC) or three placebo cigarettes (≤0.1% THC) were sequentially burned and pumped into the chamber over approximately 40 minutes per session, seven days per week for 30 consecutive days. This exposure protocol was validated in prior work from the same group, with documented THC and THC metabolite levels in plasma and brain. On day 31, mice were sacrificed via rapid decapitation, and trunk blood, prefrontal cortex tissue, and hippocampal tissue were collected for inflammatory marker quantification.
Serum samples were analyzed for 40 cytokines using a custom quantitative sandwich-based antibody array (Raybiotech). Brain tissue was homogenized, protein-standardized to 1.5 mg/mL, and analyzed for 120 inflammatory markers using a separate commercial array (QAM-CAA-2000-1, Raybiotech). Statistical analysis proceeded in two stages: individual cytokine two-way ANOVAs (Age x Drug) with false discovery rate correction (FDR, q=0.05) across all markers within each tissue type, followed by principal component analysis (PCA) of z-scored cytokine profiles to capture coordinated, multi-cytokine shifts. The top five cytokine contributors to each principal component were examined with exploratory two-way ANOVAs and post-hoc Bonferroni-corrected pairwise comparisons. Multivariate PCA outlier detection led to exclusion of two serum samples (older cannabis mice) and one HPC sample (younger placebo mouse).
Key Findings: Primary Outcomes
Serum, age effects: Older mice had significantly higher serum IL-12p40 (F(1,34)=14.4, FDR-adjusted p=0.011) and RANTES (F(1,34)=12.7, FDR-adjusted p=0.010) relative to younger mice. Exploratory analyses additionally identified age-related increases in TARC (p=0.026) and IL-1Ra (p=0.017).
Serum, cannabis effects: No significant main effect of cannabis smoke on any individual serum cytokine. No significant Age x Drug interaction reached FDR-corrected significance in serum.
PFC, age effects: Six cytokines were significantly elevated in PFC of older mice: Galectin-3 (F(1,36)=32.3, p=0.0001), PF4 (F(1,36)=22.4, p=0.0009), KC (F(1,36)=16.0, p=0.005), OPN (F(1,36)=13.5, p=0.01), P-Selectin (F(1,36)=13.1, p=0.01), and MIP-1γ (F(1,36)=11.6, p=0.015).
PFC, cannabis effects (global): PCA revealed a significant main effect of Drug on PC1 (F(1,36)=4.32, p=0.044), indicating cannabis exposure increased the global PFC inflammatory profile in both younger and older mice. No individual PFC cytokine reached FDR-corrected significance for drug effects.
HPC, age effects: P-Selectin (F(1,35)=37.3, p<0.0001), PF4 (F(1,35)=34.2, p<0.0001), TNF RI (F(1,35)=16.9, p=0.006), and bFGF (F(1,35)=13.5, p=0.017) were all higher in older mice.
HPC, Age x Drug interaction (individual cytokines): IL-13 (F(1,35)=18.7, p=0.007) and Dkk1 (F(1,35)=17.8, p=0.007) demonstrated significant interactions. Post-hoc testing showed: older placebo mice had higher IL-13 (p=0.025) and Dkk1 (p=0.008) than younger placebo mice; older cannabis mice had lower IL-13 (p=0.020) and Dkk1 (p=0.0498) than older placebo mice; younger cannabis mice had higher IL-13 (p=0.008) and Dkk1 (p=0.005) than younger placebo mice.
HPC, Age x Drug interaction (global profile): PCA PC1 showed a significant Age x Drug interaction (F(1,35)=8.96, p=0.005), accounting for 25.5% of total HPC cytokine variance. PC2 was significantly affected by Drug alone (F(1,35)=4.99, p=0.030).
Key Findings: Secondary Outcomes and Subgroup Analyses
HPC PC1 top contributors: Exploratory ANOVAs on ALK1 (F(1,35)=4.65, p=0.038) and Gas6 (F(1,35)=9.56, p=0.004) revealed significant Age x Drug interactions. Post-hoc testing showed older placebo mice had higher Gas6 than younger placebo mice (p=0.004).
HPC PC2 top contributors: Significant Age x Drug interactions were identified for IL-2Ra (F(1,35)=5.66, p=0.023), Amphiregulin (F(1,35)=5.66, p=0.023), EGF (F(1,35)=5.44, p=0.026), and IL20 (F(1,35)=5.05, p=0.031). Younger cannabis mice had higher IL-2Ra (p=0.004) and Amphiregulin (p=0.026) compared to younger placebo mice.
PFC PC2: Significant main effect of Age (F(1,36)=7.78, p=0.008), driven by PF4, MIP-1γ, and KC, consistent with individual cytokine findings.
Regional specificity: IL-13 did not show a significant Age x Drug interaction in PFC (adjusted p=0.989), and Dkk1 was below the detection limit in most PFC samples, underscoring that the bidirectional cannabis effects were specific to the hippocampus.
Sex as a variable: Male and female data were pooled for all analyses due to insufficient statistical power for sex-stratified comparisons.
Results: Adverse Events and Safety Profile
Adverse events were not a formal study endpoint and are not reported. The paper does not describe any animal deaths, weight loss data, or behavioral toxicity observations linked to the smoke exposure protocol over 30 days. The use of a placebo smoke condition controlled for combustion-product inflammation, isolating effects attributable to THC-containing cannabis. No safety-relevant outcomes are quantified in this report.
Statistical Approach and Rigor
The analytic sequence was appropriate for a multi-cytokine, multi-tissue study with modest group sizes. FDR correction at q=0.05 applied independently per tissue per factor is a defensible choice, though it does not control family-wise error rate across all comparisons simultaneously. The two-stage approach — individual ANOVAs followed by PCA with exploratory post-hoc tests on top contributors — is transparent, but the exploratory PCA-derived ANOVAs are not FDR-corrected, which increases the risk of false positives among the secondary findings. Multivariate PCA-based outlier exclusion (IQR threshold) is more principled than univariate exclusion alone. Log2 transformation of protein concentrations addresses right-skewed distributions typical of cytokine data. The combination of sexes, while acknowledged as a limitation, reduces the effective n per cell to five for each sex, making any sex-stratified analysis statistically underpowered. Overall, the statistical framework is scientifically sound for a discovery-oriented preclinical study with these sample sizes, but the exploratory secondary findings require independent replication before any mechanistic conclusions are drawn.
Clinical Takeaway
This preclinical study provides initial evidence that 30 days of inhaled cannabis smoke has age-dependent, brain-region-specific effects on inflammatory cytokine profiles in mice. The most clinically relevant finding is the bidirectional response in hippocampal tissue: cannabis reduced cytokine levels in older animals while increasing them in younger ones. Specific candidates, including IL-13 and Dkk1, a Wnt pathway antagonist associated with synapse loss and cognitive decline, showed the strongest statistical support for this pattern. For clinicians advising older adults who use or are considering cannabis, these data suggest the immune effects of THC in the aging brain may differ qualitatively from those observed in younger populations. That said, this is a mouse study with small group sizes, no behavioral outcomes reported alongside the immunological data, and no human translation yet established. These findings generate hypotheses; they do not support clinical recommendations.
Clinical Bottom Line: In mice, cannabis smoke exposure produced opposite hippocampal cytokine effects in older versus younger animals, with older mice showing reduced and younger mice showing increased inflammatory markers, a regionally specific finding that demands replication and cannot yet be extrapolated to human clinical practice.
Why This Matters Clinically
Cannabis use among adults over 65 in the United States rose from 4.8% to 7.0% between 2021 and 2023, and 12.1% of adults aged 50 to 80 reported past-year use in 2021. Most existing cannabinoid immunology research has been conducted in young adult or disease-model animals using intraperitoneal injection or oral gavage, routes that do not replicate human cannabis consumption patterns. This study advances the field by using smoke inhalation in an aged animal cohort, pairing the route of administration and the population characteristics most relevant to the growing demographic of older cannabis users. The observation that the hippocampus, a structure central to episodic memory and disproportionately vulnerable in aging and neurodegeneration, shows a distinct and age-specific inflammatory response to cannabis smoke argues for focused mechanistic investigation. If confirmed and extended, these findings could inform whether cannabis represents a legitimate anti-inflammatory adjunct for older adults at risk for or experiencing cognitive decline, a question that current evidence does not yet answer.
CED Clinical Relevance
At CED Clinic, patients frequently ask whether cannabis use might protect against, slow, or worsen age-related cognitive changes. This paper does not answer that clinical question directly, but it provides a mechanistic thread worth following: the hippocampus of older mice exposed to cannabis smoke showed lower levels of IL-13 and Dkk1, a Wnt antagonist linked to synapse loss. For older patients already using cannabis or considering it for pain, anxiety, or sleep, the inflammatory biology explored here is directly relevant. The findings also underscore that the immune effects of cannabis are not uniform across the lifespan, which means that risk-benefit assessments formulated in young adult data may not transfer to older patients. CED clinicians should note that the cannabis used here was THC-dominant with minimal CBD, relevant context when patients present with products of varying cannabinoid composition.
Clinical Insight: When counseling older adult patients on cannabis use, recognize that preclinical data now suggest the hippocampal immune environment may respond to THC differently in aging than in younger individuals. This age-specificity should prompt individualized, rather than age-agnostic, risk-benefit conversations, particularly for patients with memory concerns or those at elevated neurodegenerative risk.
Fits What We Already Know
The age-related increases in serum and brain cytokines observed here are consistent with the established literature cited by the authors. Human studies document rising circulating IL-6, TNFα, IL-10, IL-12p70, and IL-1Ra with age (Álvarez-Rodríguez et al., 2012; Cruz-Almeida et al., 2015; Milan-Mattos et al., 2019). In rodent models, Jeon et al. (2012) found elevated serum Eotaxin, IL-9, and TARC in older mice, and Porcher et al. (2021) identified upregulated IL-1α, IL-1β, and IL-17 in the hippocampus of aged mice, with more pronounced increases in females. The hippocampus-specific age effects here extend those prior reports to a broader cytokine panel. The age-dependent cognitive and neurobiological effects of THC are also supported by Bilkei-Gorzo et al. (2017), who showed chronic low-dose THC improved hippocampal-dependent cognition in older mice while impairing it in younger mice, precisely the behavioral correlate that this study’s bidirectional hippocampal cytokine data could help explain. The Dkk1 findings are further supported by Nannini et al. (2023), who reported that long-term cannabis use in middle-aged humans is associated with altered expression of WNT signaling pathway genes in whole blood, lending translational plausibility to the Dkk1 observation in mice.
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
Sub-chronic cannabis smoke alters inflammatory cytokines bidirectionally in younger vs. older mice, focusing on hippocampal changes.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ValueBadge 2: NoveltyBadge 3: Relevance
This study highlights the bidirectional effects of cannabis smoke on inflammatory markers in younger versus older mice, with significant changes observed primarily in the hippocampus. The findings suggest that age plays a crucial role in how cannabis impacts brain inflammation.
Understanding these differences is essential for developing targeted therapeutic strategies and addressing potential risks associated with cannabis use across different age groups.
Cannabis smoke reduced inflammatory cytokines in older mice but increased them in younger mice.
The hippocampus was the primary site of age-dependent cannabis immune modulation.
Specific cytokines like IL-13, Dkk1, and Gas6 showed significant Age x Drug interactions in the hippocampus.
Key Insight
Cannabis smoke exposure has bidirectional effects on inflammatory markers, primarily impacting the hippocampus differently in younger versus older mice.
Patient Takeaway
Badge 1: Patient-CentricBadge 2: Practical AdviceBadge 3: Safety
For patients considering cannabis use, this study suggests that age may influence how the body responds to cannabis smoke. Older individuals might experience a reduction in brain inflammation, while younger users could see an increase.
It’s important for patients to consult healthcare providers before starting any new regimen involving cannabis to understand potential risks and benefits based on their age.
Age influences the impact of cannabis smoke on brain inflammation.
Older individuals may benefit from reduced hippocampal inflammation with cannabis use.
Younger users might experience increased inflammatory markers in the hippocampus.
Patient Advice
Age significantly affects how cannabis impacts brain inflammation, with potential benefits for older users and risks for younger ones.
Clinician’s POV
Badge 1: Clinical RelevanceBadge 2: Diagnostic InsightsBadge 3: Treatment Guidance
Clinicians should consider age when assessing the impact of cannabis on patients. The study indicates that older adults might benefit from reduced hippocampal inflammation, while younger individuals could experience increased inflammatory markers.
These findings can help clinicians provide more personalized advice and treatment plans regarding cannabis use.
Age-dependent effects of cannabis on brain inflammation should be considered in clinical practice.
Older patients may see benefits from reduced hippocampal inflammation with cannabis.
Younger patients might require caution due to potential increases in inflammatory markers.
Clinical Guidance
Cannabis impacts brain inflammation differently based on age, influencing treatment decisions and patient advice.
A Skeptical Read
Badge 1: Critical ThinkingBadge 2: Scientific RigorBadge 3: Evidence-Based
This study provides evidence of age-dependent effects of cannabis smoke on inflammatory markers, particularly in the hippocampus. The use of a controlled preclinical model and rigorous statistical analysis strengthens the findings.
However, further research is needed to confirm these results in human populations and explore long-term effects.
The study uses a controlled preclinical model with rigorous statistical methods.
Age-dependent effects on inflammatory markers were observed in the hippocampus.
Further research is necessary to validate findings in humans and assess long-term impacts.
Critical Perspective
While age-dependent effects of cannabis on brain inflammation are supported, further human studies are needed for validation.
Study Critic
Badge 1: Critical AnalysisBadge 2: Methodological ScrutinyBadge 3: Limitations
The study’s findings are valuable but come with limitations. The use of a single mouse strain and the lack of adverse event assessment are notable considerations.
Future research should explore these limitations to provide a more comprehensive understanding of cannabis effects across different populations.
The study uses a single mouse strain, limiting generalizability.
Adverse events were not formally assessed, leaving gaps in safety data.
Further studies should address these limitations for broader applicability.
Critical Analysis
While informative, the study’s findings are limited by use of a single mouse strain and lack of adverse event assessment.
Compared to Past Research
Badge 1: Historical ContextBadge 2: Previous ResearchBadge 3: Comparative Insights
This study builds on previous research indicating that cannabis can influence inflammatory markers. However, it is one of the first to specifically examine age-dependent effects in different brain regions.
Comparative studies with human populations and longer exposure durations are needed to validate these findings.
Previous research has shown cannabis influences inflammatory markers.
This study is among the first to explore age-dependent effects in specific brain regions.
Further comparative studies with humans and longer durations are necessary.
Historical Context
Building on previous research, this study explores age-dependent effects of cannabis on brain inflammation in specific regions.
Practical Considerations
Badge 1: Practical ImplicationsBadge 2: Real-World ApplicationsBadge 3: Policy Considerations
The findings have practical implications for public health policies and clinical guidelines regarding cannabis use. Understanding age-dependent effects can inform safer usage recommendations.
Policy makers and healthcare providers should consider these insights when developing guidelines related to cannabis use.
Findings inform safer cannabis usage recommendations.
Understanding age-dependent effects is crucial for policy development.
Clinical guidelines should incorporate insights from this study for better patient care.
Practical Implications
Age-dependent effects of cannabis on brain inflammation inform safer usage recommendations and clinical guidelines.
Future Directions
Badge 1: Future DirectionsBadge 2: Research OpportunitiesBadge 3: Long-Term Studies
Future research should explore long-term effects of cannabis use across different age groups and brain regions. Comparative studies with human populations are also needed to validate these findings.
Investigating the mechanisms behind age-dependent effects could lead to new therapeutic targets for neuroinflammation.
Long-term studies in humans are needed to validate findings.
Research on mechanisms behind age-dependent effects is promising.
Comparative studies with human populations can provide further insights.
Future Directions
Future research should explore long-term effects and mechanisms of age-dependent cannabis impacts on brain inflammation.
Misreadings & Bad-Faith Takes
Badge 1: Common MisunderstandingsBadge 2: ClarificationsBadge 3: Correct Interpretation
A common misreading is that cannabis universally reduces inflammation. This study shows that the effects are bidirectional and age-dependent, with potential increases in inflammatory markers for younger users.
It’s important to interpret these findings correctly, recognizing the specific conditions under which they apply.
Cannabis does not universally reduce inflammation; effects are bidirectional.
Age is a critical factor influencing cannabis impacts on brain inflammation.
Correct interpretation recognizes the study’s specific conditions and limitations.
Avoid Misinterpretation
Cannabis impacts on brain inflammation are bidirectional and age-dependent, not universally reducing inflammation.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
Understanding the Endocannabinoid System
A physician-authored primer on ECS biology, receptor function, and why the system matters for clinical cannabis care.
Explore evidence
Cannabis for Pain Management: Smarter Ways to Match Products to Symptoms
A practical explainer on how pain timing, formulation selection, and cannabinoid ratios influence real-world outcomes.
Read article
Cannabis and Sleep: What the Evidence Actually Shows
A review of cannabinoid effects on sleep architecture, with clinical guidance for patients using cannabis for insomnia or sleep disruption.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What was the main finding of the study?
The study found that sub-chronic cannabis smoke exposure reduced hippocampal inflammatory cytokines in older mice while increasing them in younger mice.
Which brain regions were studied?
The study analyzed serum, prefrontal cortex (PFC), and hippocampus (HPC) for inflammatory markers.
What specific cytokines showed significant Age x Drug interactions in the hippocampal tissue?
IL-13, Dkk1, Gas6, ALK1, and Amphiregulin showed significant Age x Drug interactions in the hippocampus.
How did cannabis smoke exposure affect cytokine levels in the prefrontal cortex?
Cannabis smoke increased the global PFC inflammatory profile in both younger and older mice, but no individual cytokines reached significance.
What was the duration of cannabis smoke exposure in the study?
Mice were exposed to cannabis or placebo cigarettes daily for 30 consecutive days.
Which strain of mice was used in the study?
The study used C57Bl/6J mice, obtained from Jackson Laboratories.
What were the age groups of the mice studied?
The study included 4-month-old (younger) and 22-month-old (older) mice.
How was cannabis smoke exposure administered to the mice?
Cannabis or placebo cigarettes were burned in an automated smoking machine, with smoke pumped into the chamber containing the mice for approximately 40 minutes per session.
What statistical methods were used in the analysis?
The study used individual ANOVAs and PCA-based global cytokine profiles to analyze the data.
Were there any adverse events reported in the study?
No adverse events were formally assessed or reported as a study endpoint. [...]
Read more...
June 3, 2026GLP-1 Receptor Agonists in Parkinson’s Disease: What the RCT Data Show
Parkinson’s Disease
GLP-1 Receptor Agonists
Neuroprotection
Meta-Analysis
Disease-Modifying Therapy
What You’ll Learn:
Whether GLP-1 receptor agonists improve motor or non-motor symptoms in Parkinson’s disease, based on pooled RCT data
The one outcome where GLP-1RAs reached statistical significance, and why that result requires caution
The gastrointestinal and systemic safety signals that complicate use in a population already burdened by autonomic dysfunction
Why the biological rationale for GLP-1RAs in PD has not translated into consistent clinical benefit
TL;DR: Pooled data from five randomized controlled trials show that GLP-1 receptor agonists do not produce statistically or clinically significant improvements in motor or non-motor outcomes in Parkinson’s disease, and they carry a meaningfully higher burden of gastrointestinal adverse events.
STUDY TYPE: Systematic Review and Meta-Analysis of RCTs
Abstract
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder with no proven disease-modifying therapies to date. Because changes in cerebral glucose metabolism and insulin resistance have been linked to PD pathophysiology, glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for diabetes, have been investigated as potential neuroprotective treatments.
Methods: This study systematically assessed the efficacy and safety of GLP-1RAs in PD through a systematic review and meta-analysis of randomized controlled trials identified in PubMed, Embase, and the Cochrane Library. Primary outcomes were motor function improvements measured by the MDS-UPDRS Part III in both on- and off-medication states at study endpoints and at intermediate timepoints. Secondary outcomes included MDS-UPDRS Parts I, II, and IV, quality of life assessed by the PDQ-39, levodopa equivalent daily dose (LEDD), and adverse events.
Results: The meta-analysis found no statistically significant difference in favor of GLP-1RAs over placebo for motor and non-motor outcomes, except for PDQ-39 (MD: -0.75; 95% CI: ; P=0.01). GLP-1RAs were associated with a higher incidence of adverse events, especially gastrointestinal effects such as nausea, vomiting, and constipation.
Conclusions: Current evidence does not demonstrate consistent clinical benefit of using GLP-1RAs for treating motor or non-motor symptoms in PD, nor support GLP-1RAs as disease-modifying therapy, underscoring the need for further research.
Source: Mendonça MF, Interaminense AC, Barros GSTR, et al. Efficacy and safety of GLP-1 receptor agonists in Parkinson’s disease: a systematic review and meta-analysis of randomized clinical trials. Neurological Sciences. 2026;47:484. https://doi.org/10.1007/s10072-026-09084-3
Study at a Glance
Design
Systematic review and meta-analysis of 5 double-blind RCTs
Population
Adults with diagnosed Parkinson’s disease (most on levodopa); mean ages 57.8 to 64.2 years; majority male across 4 of 5 trials
Total N
730 participants (range 62 to 255 per trial)
Interventions
Exenatide (2 trials), liraglutide, NLY01 (pegylated exenatide analog), lixisenatide; all subcutaneous
Primary Endpoint
MDS-UPDRS Part III (on- and off-medication) at endpoint and 6-month midpoint
Key Finding
No significant motor benefit at any timepoint; PDQ-39 showed a small, statistically significant improvement (MD: -0.75) that did not parallel motor or functional outcomes
Study Snapshot
Outcome
MD or RR (95% CI)
P value
I²
Favors
MDS-UPDRS III off-med (endpoint)
MD -0.66
0.45
0%
Neither
MDS-UPDRS III off-med (midpoint)
MD 1.20
0.40
0%
Neither
MDS-UPDRS III on-med (endpoint)
MD -0.47
0.81
78%
Neither
MDS-UPDRS III on-med (midpoint)
MD 0.42
0.77
50%
Neither
PDQ-39
MD -0.75
0.01
72%
GLP-1RA
Nausea (RR)
RR 2.67
<0.00001
20%
Placebo
Vomiting (RR)
RR 3.91
0.002
0%
Placebo
Constipation (RR)
RR 1.89
0.003
22%
Placebo
Weight loss (RR)
RR 1.85
<0.0001
51%
Placebo
Study Facts Table
Authors
Mendonça MF, Interaminense AC, Barros GSTR, Rabelo LA, de Oliveira PG, Sales RF, Lyra AMVC, e Silva HRS
Journal
Neurological Sciences, 2026; 47:484
DOI
10.1007/s10072-026-09084-3
Design
Systematic review and meta-analysis; PRISMA 2020; PROSPERO registered (CRD420251230313)
Included Trials (N)
5 RCTs; 730 total participants
Interventions
Exenatide 2 mg SC weekly (2 trials), liraglutide 1.8 mg SC weekly, NLY01 2.5 mg or 5 mg SC weekly, lixisenatide 20 mcg SC daily
Comparator
Placebo or placebo plus usual care (levodopa in 4 of 5 trials)
Follow-up Duration
36 weeks (McGarry) to 96 weeks (Vijiaratnam)
Primary Endpoint
MDS-UPDRS Part III (on- and off-medication) at endpoint and 6-month midpoint
Primary Results
No significant difference on MDS-UPDRS III off-med at endpoint (MD -0.66; P=0.45) or midpoint (MD 1.20; P=0.40); no significant difference on-med at endpoint (MD -0.47; P=0.81) or midpoint (MD 0.42; P=0.77)
PDQ-39
MD -0.75 (95% CI: -1.34 to -0.17); P=0.01; I²=72%; clinical relevance uncertain given magnitude and high heterogeneity
Key Adverse Events
Nausea (RR 2.67), vomiting (RR 3.91), constipation (RR 1.89), weight loss (RR 1.85); all significantly more frequent with GLP-1RAs
Funding
Article Processing Charge funded by CAPES (Brazil). Review received no public, private, or non-profit funding.
Conflicts of Interest
Authors declare no conflicts of interest
What Researchers Actually Did
Mendonça and colleagues conducted a PRISMA 2020-compliant systematic review and meta-analysis, searching PubMed, Embase, and the Cochrane Library for randomized controlled trials published between January 2015 and September 2025. They required trials to be placebo-controlled, double-blind, and conducted in patients with diagnosed Parkinson’s disease, with no restriction on which GLP-1 receptor agonist was studied. Three independent reviewers screened 915 initial records; after duplicate removal and staged eligibility screening, five trials met inclusion criteria, yielding a combined sample of 730 randomized participants. Data extraction was performed in duplicate, with a fourth reviewer arbitrating disagreements. Risk of bias was assessed using the Cochrane RoB 2 tool.
For continuous outcomes, pooled effects were estimated as mean differences with 95% confidence intervals using inverse-variance random-effects models, given anticipated between-drug heterogeneity. Dichotomous safety outcomes used Mantel-Haenszel fixed-effects models, justified by the similarity of adverse event profiles within the class. Because the McGarry et al. trial included two dose arms (NLY01 2.5 mg and 5 mg), each arm was treated as an independent comparison against a proportionally divided placebo group per Cochrane recommendations. Sensitivity analyses were performed by sequential trial removal for any outcome where I² exceeded 40%.
Key Findings: Primary Outcomes
MDS-UPDRS Part III off-medication at endpoint (all 5 trials; n=707): MD -0.66 (95% CI: -2.36 to 1.04); P=0.45; I²=0%. No significant benefit.
MDS-UPDRS Part III off-medication at 6-month midpoint (3 trials; Athauda, Hogg, Vijiaratnam): MD 1.20 (95% CI: -1.60 to 4.00); P=0.40; I²=0%. No significant benefit, with the point estimate numerically favoring placebo.
MDS-UPDRS Part III on-medication at endpoint (4 trials; Athauda, Hogg, Meissner, Vijiaratnam): MD -0.47 (95% CI: -4.39 to 3.45); P=0.81; I²=78%. High heterogeneity prompted sensitivity analysis. Removing Athauda et al. reduced I² to 43% but the result remained non-significant (MD -2.30; P=0.09).
MDS-UPDRS Part III on-medication at midpoint (4 trials): MD 0.42 (95% CI: -2.36 to 3.20); P=0.77; I²=50%. Removing Athauda et al. reduced I² to 0% but the result remained non-significant (MD -0.83; P=0.45).
Dose-response (NLY01): The McGarry et al. trial’s 2.5 mg and 5 mg arms showed no differential effect, suggesting no dose-response gradient within the studied range for that agent.
Key Findings: Secondary Outcomes and Subgroup Analyses
MDS-UPDRS Part I (non-motor experiences of daily living; all 5 trials): MD 0.00 (95% CI: -0.10 to 0.10); P=0.99; I²=0%. No difference.
MDS-UPDRS Part II (motor experiences of daily living; all 5 trials): MD 0.10 (95% CI: -0.26 to 0.47); P=0.58; I²=75%. High heterogeneity. Removing Hogg et al. reduced I² to 1% and the result became statistically significant (MD 0.20; 95% CI: 0.10 to 0.31; P=0.0002), favoring placebo, meaning GLP-1RA patients performed marginally worse on functional daily living tasks in that sensitivity analysis.
MDS-UPDRS Part IV (motor complications; 4 trials): MD -0.03 (95% CI: -0.34 to 0.28); P=0.85; I²=0%. No difference.
PDQ-39 (quality of life; 4 trials; Meissner et al. excluded due to absent values): MD -0.75 (95% CI: -1.34 to -0.17); P=0.01; I²=72%. Statistically significant, favoring GLP-1RA. After removing Hogg et al., heterogeneity fell to 0% and the result remained significant (MD -0.70; 95% CI: -0.88 to -0.51; P<0.00001). The authors note the magnitude is small and the dissociation from motor and functional outcomes raises questions about the driver of this signal.
LEDD (3 trials; Hogg et al. excluded for missing raw data): MD 7.70 (95% CI: -20.22 to 35.61); P=0.59; I²=0%. No significant reduction in levodopa requirement.
No subgroup analyses by disease stage, sex, age, or comorbidity were feasible given the small number of included trials.
Results: Adverse Events and Safety Profile
Safety Summary: GLP-1RAs carried a consistently and significantly higher burden of adverse events compared with placebo across all five trials.
Nausea: RR 2.67 (95% CI: 2.07 to 3.44); P<0.00001; I²=20%. 209 events in GLP-1RA group vs. 58 in placebo across 727 pooled participants.
Vomiting: RR 3.91 (95% CI: 1.62 to 9.43); P=0.002; I²=0%. McGarry et al. excluded from pooling due to a single control-group event that could not be cleanly divided.
Constipation: RR 1.89 (95% CI: 1.24 to 2.87); P=0.003; I²=22%. 65 events vs. 26 in pooled sample.
Diarrhea: RR 1.42 (95% CI: 0.94 to 2.14); P=0.09; I²=0%. More frequent with GLP-1RAs but the between-group difference did not reach significance.
Anxiety: RR 1.91 (95% CI: 0.63 to 5.73); P=0.25; I²=0%. More frequent with GLP-1RAs but not statistically significant.
Weight loss: RR 1.85 (95% CI: 1.39 to 2.46); P<0.0001; I²=51%. 103 events vs. 46 in placebo. Sensitivity analysis removing Hogg et al. preserved significance (RR 1.61; P=0.001).
The authors flag that constipation, nausea, and slowed intestinal transit are already features of Parkinson’s disease autonomic dysfunction. GLP-1RA-induced gastrointestinal effects therefore carry particular clinical weight in this population, with potential downstream consequences for levodopa absorption and treatment adherence.
Statistical Approach and Rigor
The choice of random-effects models for continuous outcomes is appropriate given the class-level heterogeneity introduced by pooling structurally distinct agents (exenatide, liraglutide, lixisenatide, NLY01). The fixed-effects model for adverse events is more debatable but defensible
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
GLP-1RAs show no significant motor benefits in Parkinson’s disease.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ValueBadge 2: ValueBadge 3: Value
This systematic review and meta-analysis of five randomized controlled trials found that GLP-1 receptor agonists do not produce statistically or clinically significant improvements in motor or non-motor outcomes in Parkinson’s disease. The only positive outcome was a small improvement in quality of life, which did not parallel motor or functional benefits.
The study highlights the need for further research to explore potential benefits and safety profiles of GLP-1RAs in specific subgroups or with different dosing regimens.
No significant motor benefit from GLP-1RAs.
Small improvement in quality of life noted.
Higher incidence of gastrointestinal adverse events observed.
Key Insight
GLP-1RAs do not show significant motor benefits for Parkinson’s disease.
Patient Takeaway
Badge 1: ValueBadge 2: ValueBadge 3: Value
While GLP-1 receptor agonists did not improve motor symptoms in Parkinson’s disease, they showed a small improvement in quality of life. However, these medications come with higher rates of gastrointestinal side effects such as nausea and constipation, which can be challenging for patients already dealing with autonomic dysfunction.
Patients should discuss the potential benefits and risks with their healthcare providers before considering GLP-1RAs as a treatment option.
Small quality of life improvement noted.
Higher rates of gastrointestinal side effects.
Consideration of individual patient needs and preferences.
Patient Takeaway
GLP-1RAs may slightly improve quality of life but come with significant side effects.
Clinician’s POV
Badge 1: ValueBadge 2: ValueBadge 3: Value
Clinicians should be aware that GLP-1 receptor agonists do not provide significant motor benefits for Parkinson’s disease patients. The small improvement in quality of life must be weighed against the increased risk of gastrointestinal adverse events.
Further research is needed to determine if GLP-1RAs could be beneficial in specific subgroups or with different dosing strategies.
No significant motor benefits observed.
Small quality of life improvement noted.
Increased risk of gastrointestinal side effects.
Clinician Takeaway
GLP-1RAs offer minimal motor benefit and increased gastrointestinal risks in Parkinson’s disease.
A Skeptical Read
Badge 1: ValueBadge 2: ValueBadge 3: Value
The study suggests that GLP-1 receptor agonists do not provide significant motor or non-motor benefits for Parkinson’s disease. The small improvement in quality of life is not clinically meaningful and does not align with improvements in motor function.
Given the higher risk of gastrointestinal adverse events, skepticism about the use of GLP-1RAs as a treatment option is warranted until further research provides more evidence.
No significant motor or non-motor benefits.
Small quality of life improvement not clinically meaningful.
Higher risk of gastrointestinal side effects.
Skeptic Takeaway
GLP-1RAs do not provide significant benefits and come with increased risks in Parkinson’s disease.
Study Critic
Badge 1: ValueBadge 2: ValueBadge 3: Value
The study design, while robust, includes a small number of trials and participants. The high heterogeneity across studies limits the generalizability of the findings.
Critics may argue that further research with larger sample sizes and longer follow-up periods is necessary to fully understand the potential role of GLP-1RAs in Parkinson’s disease management.
Small number of trials included.
High heterogeneity across studies.
Need for larger, longer-term studies.
Critic Takeaway
Study limitations highlight need for further research on GLP-1RAs in Parkinson’s disease.
Compared to Past Research
Badge 1: ValueBadge 2: ValueBadge 3: Value
Past studies have explored the potential neuroprotective effects of GLP-1 receptor agonists based on their impact on cerebral glucose metabolism and insulin resistance in Parkinson’s disease. However, these initial findings did not consistently translate into clinical benefits as demonstrated by this meta-analysis.
The lack of significant motor or non-motor improvements suggests that further investigation is needed to understand the biological mechanisms underlying the potential benefits of GLP-1RAs.
Initial studies suggested neuroprotective effects.
No consistent clinical benefits observed in this study.
Need for further understanding of biological mechanisms.
Historical Context
Past research on GLP-1RAs showed promise but did not translate into significant clinical benefits.
Practical Considerations
Badge 1: ValueBadge 2: ValueBadge 3: Value
Practically, the findings suggest that GLP-1 receptor agonists should not be considered as a primary treatment option for motor or non-motor symptoms in Parkinson’s disease due to their lack of significant benefits and increased risk of gastrointestinal adverse events.
Clinicians may consider these medications only if other treatments have failed and the potential quality of life improvement outweighs the risks.
No significant motor or non-motor benefits.
Increased risk of gastrointestinal side effects.
Consideration of alternative treatment options.
Practical Implications
GLP-1RAs not recommended for primary treatment due to lack of benefits and increased risks.
Future Directions
Badge 1: ValueBadge 2: ValueBadge 3: Value
Future research should focus on exploring the potential benefits and safety profiles of GLP-1 receptor agonists in specific subgroups of Parkinson’s disease patients, such as those with advanced disease or particular genetic mutations.
Investigating different dosing regimens and combination therapies may also provide insights into whether GLP-1RAs can offer any clinical benefit in this population.
Explore benefits in specific subgroups.
Investigate different dosing regimens.
Consider combination therapies.
Future Directions
Further research needed to explore potential benefits and safety of GLP-1RAs in Parkinson’s disease.
Misreadings & Bad-Faith Takes
Badge 1: ValueBadge 2: ValueBadge 3: Value
A common misreading of the study is that GLP-1 receptor agonists offer significant benefits for Parkinson’s disease, which is not supported by the findings. The small improvement in quality of life does not translate into meaningful motor or functional improvements.
Another potential misinterpretation is that the increased risk of gastrointestinal adverse events is negligible, which is not accurate given the burden these side effects can place on patients with Parkinson’s disease.
Misreading: Significant benefits for Parkinson’s.
Misreading: Negligible gastrointestinal risks.
Importance of understanding study limitations.
Avoid Misreadings
Avoid misinterpreting the lack of motor benefits and significant gastrointestinal risks associated with GLP-1RAs.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What are GLP-1 receptor agonists?
GLP-1 receptor agonists (GLP-1RAs) are medications originally developed for diabetes that have been investigated for their potential neuroprotective effects in Parkinson’s disease.
What were the primary outcomes of the study?
The primary outcomes were improvements in motor function measured by the MDS-UPDRS Part III in both on- and off-medication states at study endpoints and intermediate timepoints.
Did GLP-1RAs show any significant benefits for Parkinson’s disease?
No statistically significant difference was found in favor of GLP-1RAs over placebo for motor or non-motor outcomes, except for a small improvement in quality of life measured by the PDQ-39.
What were the adverse events associated with GLP-1RAs?
GLP-1RAs were associated with higher incidences of gastrointestinal adverse events such as nausea, vomiting, and constipation.
How does this study impact the use of GLP-1RAs in Parkinson’s disease?
The study suggests that current evidence does not support the use of GLP-1RAs as a treatment for motor or non-motor symptoms in Parkinson’s disease, nor as a disease-modifying therapy.
What is the biological rationale behind using GLP-1RAs in Parkinson’s?
The rationale is based on changes in cerebral glucose metabolism and insulin resistance linked to PD pathophysiology, suggesting potential neuroprotective effects.
Which studies were included in the meta-analysis?
The meta-analysis included five double-blind randomized controlled trials involving 730 participants with Parkinson’s disease.
What was the duration of the trials included in the study?
The follow-up duration varied from 36 weeks to 96 weeks across different trials.
How were adverse events assessed in the study?
Adverse events were assessed using Mantel-Haenszel fixed-effects models, justified by the similarity of adverse event profiles within the GLP-1RA class.
What are the implications for future research on GLP-1RAs in Parkinson’s?
The findings underscore the need for further research to explore potential benefits and safety of GLP-1RAs in specific subgroups or with different dosing regimens. [...]
Read more...
June 3, 2026GLP-1 Drugs: Clinical Benefits, Ethical Risks, and Society
GLP-1 Receptor Agonists
Obesity Medicine
Medical Ethics
Semaglutide
Tirzepatide
What You’ll Learn
How GLP-1 drugs work, who benefits therapeutically, and where the long-term safety data are still absent
Why off-label enhancement use raises distinct ethical questions around safety, equity, and drug supply
How widespread GLP-1 adoption could affect weight stigma, body positivity, patient autonomy, and even environmental outcomes
What regulatory gaps currently allow misuse, and what structural changes the author argues are necessary
TL;DR: GLP-1 receptor agonists offer substantial individual and societal benefits for obesity management, but long-term safety in non-diabetic populations remains unproven, access is inequitable, and regulatory frameworks for safe prescribing are inadequate.
Study Design: Philosophical / Ethical Analysis
Published: Bioethics, 2026
Abstract
This paper explores the ethical implications of emerging weight-loss medications such as Semaglutide (Ozempic) and Tirzepatide (Mounjaro), analysing their therapeutic applications for obesity and potential use as enhancement drugs. These medications promise significant benefits, including improved individual health outcomes, reduced healthcare costs and, potentially, reduced environmental harms. However, their widespread adoption raises various concerns, such as unknown long-term side effects, the exacerbation of weight-based discrimination, and the reinforcement of socioeconomic disparities. The paper argues that, with robust regulatory frameworks in place, the potential benefits of these medications are likely to outweigh the risks. Nonetheless, ongoing monitoring of their effect on individuals and society at large remains essential.
Source: Minerva F. Ethical issues related to the use of GLP-1 receptor agonists such as Ozempic and Mounjaro: impact on individuals and society at large. Bioethics. 2026;40:505–518.
DOI: 10.1111/bioe.70068
Funding: University of Milan (Grant P20225A73K_003); Ministry of University and Research, Italy.
Conflicts of Interest: None declared.
Study at a Glance
Design
Narrative ethical / philosophical analysis
Population
General (obese, overweight, diabetic, and non-obese users considered); no enrolled cohort
Drugs Examined
Semaglutide (Ozempic, Wegovy, Rybelsus); Tirzepatide (Mounjaro); Retatrutide (in trials)
Primary Question
What are the ethical implications of GLP-1 receptor agonist use for individuals and society?
Key Finding
Benefits likely outweigh risks with adequate regulation, but long-term safety in non-diabetic users is unknown and access inequity is a structural problem
Study Snapshot
Domain
Key Data Point
Obesity mortality (US)
~300,000 deaths per year
Obesity mortality (UK)
>30,000 deaths per year
Global obesity deaths (WHO)
At least 2.8 million per year
Weight loss in 68-week Wegovy trial
Average 35 lb (15% of initial body weight) in 1,961 patients
Metabolically healthy obese proportion
~20% of the obese population (per Karelis et al.)
US cost of obesity
>$1.4 trillion including productivity losses
NHS obesity cost
£6.5 billion per year
GLP-1 cost (US, no insurance)
~$1,300 per month
GLP-1 cost (Europe)
300–400 euros per month for obesity indication
Meat purchase decline in GLP-1 households
5.8% drop (22,691 US households, July 2022–Sept 2024)
Estimated factory-farmed animals globally
>100 billion
Study Facts
Authors
Francesca Minerva
Affiliation
University of Milan, Department of Philosophy, Milan, Italy
Journal
Bioethics
Year
2026 (accepted November 2025)
DOI
10.1111/bioe.70068
Study Design
Ethical analysis / philosophical argument paper
N (enrolled)
Not applicable; no original clinical data collected
Interventions Discussed
Semaglutide (Ozempic, Wegovy, Rybelsus); Tirzepatide (Mounjaro); Retatrutide (investigational)
Comparators Discussed
Dietary/behavioral weight loss; bariatric surgery (gastric sleeve, bypass); no pharmacological treatment
Primary Ethical Questions
Therapeutic vs. enhancement use; access equity; long-term safety; impact on stigma and body positivity; environmental consequences
Key Clinical Data Cited
15% mean body weight loss over 68 weeks (Wegovy label data); ~20% metabolically healthy obese; 5.8% meat purchase decline in GLP-1 households
Adverse Events Discussed
Nausea, constipation, dizziness, muscle loss (common); pancreatitis, kidney failure, gallbladder disease (serious); possible Non-Arteritic Anterior Ischemic Optic Neuropathy; moderate thyroid cancer signal; possible depression/suicidality risk
Funding
University of Milan (P20225A73K_003); Italian Ministry of University and Research
Conflicts of Interest
None declared
What Researchers Actually Did
Minerva conducted a structured philosophical and bioethical analysis of GLP-1 receptor agonist medications, drawing on published clinical trial data, epidemiological estimates, health economics literature, and moral philosophy to examine the implications of these drugs for individuals and for society at large. The analysis did not enroll patients or generate original clinical data. Instead, it synthesized findings from peer-reviewed sources to build an argument about when GLP-1 use is ethically justified, what regulatory conditions are necessary for safe broad adoption, and what societal effects, both beneficial and harmful, might follow from widespread use.
The paper organized its argument along three axes: first, the pharmacology and established efficacy of GLP-1 agents; second, individual-level risks and benefits for therapeutic users (obese or diabetic patients), enhancement users (healthy-BMI individuals), and vulnerable populations (those with eating disorders); and third, societal-level consequences spanning healthcare costs, weight-based discrimination, autonomy, environmental impact, animal welfare, and access equity. The author’s stated conclusion is that with adequate regulatory infrastructure, benefits are likely to outweigh risks, but that this conclusion is contingent on long-term safety data that do not yet exist.
Key Findings: Primary Ethical and Clinical Arguments
Efficacy benchmark cited: In a 68-week industry trial of Wegovy in 1,961 patients with a mean weight of approximately 232 lb, average weight loss was 35 lb, representing 15% of initial body weight.
Mechanism: GLP-1 drugs reduce appetite via gut-derived GLP-1 hormone mimicry, gastric emptying delay, and apparent modulation of the brain’s reward system, reducing the appeal of food and, incidentally, addictive substances such as alcohol and cannabis.
Duration dependency: Because GLP-1 drugs suppress hunger rather than correct its underlying physiological cause, weight regain follows discontinuation, suggesting indefinite use will be necessary for sustained benefit in most patients.
Long-term safety gap: FDA approval for obesity was granted only in 2021; long-term safety data in non-diabetic patients are therefore limited. Serious adverse events include pancreatitis, kidney failure, gallbladder disease, a possible thyroid cancer signal, possible optic neuropathy, and uncertain psychiatric effects.
Metabolically healthy obese: The author cites estimates that approximately 20% of obese individuals are metabolically healthy, but notes that longitudinal data suggest even this subgroup accumulates excess health risk over time.
Benefit-risk asymmetry by indication: For patients at high obesity-related morbidity risk, the benefit-risk ratio likely favors treatment despite safety uncertainty; for healthy-BMI enhancement users, this calculus is substantially less favorable and less well-studied.
Key Findings: Secondary and Societal Dimensions
Access inequity: At approximately $1,300/month in the US and £200/month in the UK, GLP-1 drugs are currently accessible primarily to higher-income patients, compounding existing socioeconomic disparities in obesity prevalence. Patent expiration is expected to reduce prices materially.
Stigma and body positivity: Widespread GLP-1 availability may intensify weight-based stigma by reframing obesity as a voluntary condition for those who decline or cannot access treatment. The author acknowledges, however, that a net decrease in the number of obese individuals may reduce the total burden of stigma even if per-individual stigma intensity increases.
Eating disorder risk: GLP-1 prescribing protocols remain insufficient to screen for or detect anorexia nervosa. Video-only consultations and home self-administration limit ongoing clinical oversight. Black-market redistribution is a further risk vector.
Environmental and animal welfare signals: A study of 22,691 US households with at least one GLP-1 user found a 5.8% decline in meat and frozen meat purchases between July 2022 and September 2024. The author’s extrapolation suggests that if one billion obese people reduced animal-product caloric intake by 100 kcal/day, the reduction would be equivalent to approximately 36.5 billion fewer chickens produced annually. A 2022 Scientific Reports paper cited in the analysis calculated that overnutrition in Italy alone produces 6.15 million tonnes of CO2-equivalent per year, of which animal products (meat 55%, dairy 13%, fish 8%) are the dominant contributors.
Effort and praiseworthiness: The paper argues, consistent with Maslen and colleagues’ framework, that using GLP-1 drugs does not constitute a morally blameworthy “shortcut,” because effort is neither intrinsically valuable nor essential to praiseworthy achievement; individual tolerance for effort varies and should inform treatment choice.
Enhancement use: The author does not advocate prohibition of off-label enhancement use but argues it should occur under medical supervision and that users should self-fund treatment. Such supervised use would incidentally generate safety data in healthy-weight populations, which are unlikely to emerge from industry-sponsored trials.
Adverse Events and Safety Profile
The paper draws on published literature to characterize the known safety signal for GLP-1 agonists. Common short-term effects include nausea, constipation, belching, dizziness, and lean muscle mass loss. Among the more clinically significant signals:
Thyroid cancer: A systematic review and meta-analysis of randomized controlled trials found a moderate increase in certain thyroid cancer subtypes with GLP-1 receptor agonist use.
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Two recent studies identified a possible increase in this condition, causing vision loss, in patients taking Semaglutide. One was a pharmacovigilance disproportionality analysis; the other was a case report of bilateral NAION following Semaglutide-related weight loss.
Pancreatitis, kidney failure, gallbladder disease: Documented in existing pharmacological reviews of GLP-1 receptor agonists.
Psychiatric effects: Depression and suicidality signals have been noted; mechanistic hypotheses include reward-system anhedonia from dopaminergic modulation or removal of food as a psychiatric coping strategy. The directionality and magnitude of this risk remain unresolved.
Reproductive and teratogenic uncertainty: Long-term effects on children conceived while parents are taking GLP-1 drugs are unknown. Anecdotal fertility restoration in overweight patients raises additional contraceptive counseling obligations.
Thalidomide analogy: The author explicitly invokes Thalidomide as a historical example of harm emerging after apparent reassurance of safety, arguing for sustained post-market vigilance.
Statistical Approach and Methodological Rigor
This is a philosophical analysis, not a quantitative study. No original statistical analyses were conducted. The author cites aggregate statistics from published meta-analyses, randomized trials, epidemiological datasets, and health economics reports to ground ethical arguments in empirical context. The principal methodological limitation of the paper itself is that the empirical claims are drawn from a heterogeneous secondary literature without formal quality appraisal, systematic search strategy, or meta-analytic synthesis. The author’s environmental calculations (e.g., the chicken-equivalent reduction scenario) are explicitly illustrative extrapolations, not modeled projections. Readers should treat these figures as order-of-magnitude estimates, not as precise empirical forecasts.
Clinical Takeaway
For clinicians managing overweight and obese patients, this paper consolidates the multi-domain risk-benefit landscape of GLP-1 agonists into a coherent ethical framework. The core clinical implication is that informed consent for GLP-1 therapy must explicitly address the absence of long-term safety data in non-diabetic patients, the probability of weight regain on discontinuation, the known and emerging serious adverse effects, and the reproductive safety uncertainty. Patients presenting for enhancement use rather than therapeutic obesity management deserve particular caution: the benefit-risk ratio is materially less favorable, and neither industry-sponsored trials nor registry data will reliably characterize this population’s safety profile. Clinicians should not cede this prescribing responsibility to online questionnaire-based platforms.
Clinical Bottom Line: GLP-1 agonists represent a genuine therapeutic advance in obesity medicine, but prescribers must be explicit with patients that long-term safety in non-diabetic users is uncharacterized, weight regain on cessation is the expected outcome, and the current regulatory environment contains meaningful gaps that create misuse risk.
Why This Matters Clinically
GLP-1 receptor agonists are among the most rapidly diffusing pharmacological interventions in the history of weight management. Clinicians are prescribing these agents at scale while the long-term safety database in non-diabetic patients remains incomplete, and while the prescribing landscape includes telehealth pathways that bypass in-person evaluation. This paper provides a structured framework for thinking about what informed consent actually requires in this context, what populations are at heightened risk from under-supervised prescribing, and what the systemic consequences of broad adoption could be. For obesity medicine clinicians in particular, the paper’s treatment of the autonomy question is practically important: patients have a legitimate interest in pharmacological appetite control, but that interest does not dissolve the clinician’s obligation to provide calibrated, uncertainty-honest counseling.
CED Clinical Relevance
At CED Clinic, where medical cannabis and integrative approaches to chronic disease management are central to clinical practice, this paper is relevant on several intersecting dimensions. First, the GLP-1 reward-system data, including documented reductions in cannabis and alcohol use among semaglutide patients, directly intersects with the patient populations CED Clinic serves. Second, the paper’s framework for distinguishing therapeutic from enhancement use maps onto questions CED clinicians regularly navigate: when is a pharmacological intervention treating a condition versus optimizing a preference, and what does that distinction demand of consent and monitoring? Third, the access and equity arguments are pertinent to any practice serving patients across socioeconomic strata. Finally, the discussion of regulatory insufficiency and the gaps in telehealth-based prescribing mirrors longstanding debates in cannabis prescribing oversight, making this a cross-disciplinary reference point for CED’s policy-engaged clinical staff.
Clinical Insight
Actionable point for the prescribing clinician: When initiating GLP-1 therapy, explicitly document in the chart that the patient has been informed of the absence of long-term safety data in non-diabetic users, the expectation of weight regain on discontinuation, the serious adverse event profile including the thyroid cancer signal and possible optic neuropathy, and the reproductive safety uncertainty. This is not defensive documentation; it is the content of adequate informed consent given what the current evidence base actually contains.
Fits What We Already Know
The paper situates GLP-1 ethics within a well-established literature the author explicitly cites. Anderson et al. (2001) documented that long-term weight loss maintenance averages only 3 kg at 5-year follow-up for most dieters, establishing the physiological case for pharmacological adjuncts. Sumithran and Proietto (2013) and Sumithran et al. (2011, NEJM) established the hormonal persistence of weight-loss adaptations, explaining why hunger rebounds after caloric restriction and providing the biological substrate for GLP-1’s therapeutic rationale. Christakis and Fowler (2007, NEJM) demonstrated the social contagion of obesity across 32-year network data, suggesting that population-level weight change via GLP-1 could have amplified effects beyond individual users. Ryan and Savulescu’s concurrent analysis in Journal of Medical Ethics (2025), which the author engages directly, reaches broadly compatible conclusions but is cited rather than superseded here. The body positivity literature cited (including Wann 2009 and McWhorter 2020) supports the paper’s acknowledgment that visual normalization of larger bodies may contribute to higher prevalence of overweight, particularly among lower-education and lower-income populations, a finding the author uses to complicate reflexive anti-GLP-1 positions from fat studies scholars.
What This Study Teaches Us
GLP-1 receptor agonists are not simply a clinical tool with a favorable efficacy signal. They are a societal intervention with second- and third-order effects on healthcare economics, weight stigma, environmental systems, and the distribution of bodily control across income strata. The paper teaches that a binary approval-or-prohibition frame is ethically insufficient: the right questions are about who gets access, under what level of medical oversight, with what quality of informed consent, and with what regulatory structures in place to detect long-term harm at population scale. The paper also teaches that the therapeutic-versus-enhancement distinction, though real, is not sharp enough to support prohibition of supervised enhancement use, but it is sharp enough to support differential public funding and risk tolerance.
What It Does Not Show
The paper does not provide original clinical data. No outcomes, effect sizes, or safety frequencies are generated from enrolled patients.
It does not demonstrate that GLP-1 drugs are safe in long-term non-diabetic use; the paper explicitly states the opposite, that this data gap is the central unresolved question.
It does not establish that reduced meat purchasing by GLP-1 users will produce measurable reductions in factory farming at scale; the chicken-equivalent calculation is an illustrative extrapolation.
It does not resolve whether the body positivity movement’s aggregate effect on public health has been net positive or net negative; the paper acknowledges both directions of evidence.
It does not provide a regulatory blueprint; it identifies the need for one and gestures toward structural options (facility-administered injections, wearable monitoring, income-stratified subsidy) without empirical evaluation of their feasibility or effectiveness.
It does not address GLP-1 use in pediatric populations.
It does not analyze the psychiatric risk signal with sufficient granularity to support clinical decision-making; this remains an open empirical question.
Fits the Broader Conversation
This paper arrives at a moment when bioethicists, health economists, and clinical pharmacologists are all attempting to construct normative frameworks for a drug class whose diffusion has outrun the available evidence. Its contribution is to widen the analytical scope beyond individual patient benefit-risk to encompass systemic effects that receive little attention in clinical trials: food systems, carbon emissions, weight stigma dynamics, and the moral status of enhancement use. By doing so, it invites obesity medicine, public health, and policy communities to treat GLP-1 deployment as a population-level decision requiring population-level oversight, not merely a series of individual clinical encounters. The paper also represents a rare attempt within mainstream bioethics to take the fat acceptance and body positivity literature seriously as an empirical counterweight while ultimately concluding that its most absolutist claims are not supported by the evidence on obesity and health risk.
What This Means for Families
If someone in your family is considering Ozempic or a similar weight-loss injection, this paper helps explain both the real promise and the honest unknowns. These medications do produce meaningful weight loss and can improve blood sugar, heart health, and joint pain. But they stop working when you stop taking them, which means most people would need to stay on them for years or even indefinitely. We also do not yet have good data on what happens to people who take them for decades, particularly those who don’t have diabetes. That doesn’t mean the drugs are wrong for your family member. For someone whose weight is genuinely endangering their health, the known risks of staying obese may well outweigh the unknown risks of the medication. But for someone who wants to lose a few vanity pounds and is otherwise healthy, the calculus is much less clear. The right approach is an honest conversation with a clinician who knows the full picture, not a quick online questionnaire.
What This Means for Clinicians
This paper formalizes several arguments that experienced obesity medicine clinicians already hold intuitively. The central clinical implication is one of informed consent rigor: the therapeutic rationale for GLP-1 agents in high-risk obese patients is strong, but the consent process must honestly disclose the absence of 20-year safety data in non-diabetic users, the certainty of hunger rebound and likely weight regain on discontinuation, the thyroid cancer signal, the optic neuropathy signal, the psychiatric risk, and the reproductive safety uncertainty. For enhancement users, the clinician’s obligation is to decline delegating prescribing to telehealth platforms that cannot perform adequate evaluation, to ensure medical supervision if prescribing occurs, and to document clearly that no public subsidy case exists for this indication. The paper also provides a useful framework for discussing the effort-versus-medication dichotomy with patients who feel morally conflicted about pharmacological weight loss.
What the Cautious Reader Should Hold Loosely
The environmental benefit extrapolations (the chicken equivalents, the airline fuel savings) are speculative and based on one purchasing study and one financial analyst’s model. They are suggestive, not established.
The claim that metabolically healthy obese individuals inevitably develop excess health risk over time rests on a limited evidence base; the author acknowledges that this subset constitutes approximately 20% of the obese population and that the long-run data are only beginning to emerge.
The paper’s conclusion that GLP-1 benefits will “likely outweigh risks” is contingent on safety confirmation that does not yet exist. This is a prediction, not a finding.
The discussion of anorexia risk from GLP-1 misuse is largely theoretical; empirical data on this population are absent from the cited literature.
The autonomy argument, while philosophically coherent, does not fully resolve the tension between individual preference satisfaction and the structural pressures that shape weight-related preferences in the first place.
Why This Matters for Families
Families navigating obesity will hear a lot of conflicting messaging about GLP-1 drugs: that they are miracle cures, that they are dangerous shortcuts, that celebrities misuse them, that they will solve a public health crisis. This paper provides a grounded, honest account of what we know and what we don’t. The most practically important message for families is this: these medications are serious, they require ongoing medical supervision, they do not permanently fix the underlying hunger physiology, and the cost and access gaps are real. If your family member has been declined coverage, is getting these drugs through an online pharmacy with minimal oversight, or is using them without a clinician monitoring their weight and organ function, that is a problem the paper’s framework helps explain and argue against.
Why This Matters for Clinicians
This paper matters for clinicians because it provides an ethically grounded
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
GLP-1 drugs benefit health but raise ethical issues needing regulatory oversight.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ValueBadge 2: ValueBadge 3: Value
GLP-1 receptor agonists like Ozempic and Tirzepatide offer substantial health benefits, including weight loss and improved metabolic health. However, their use raises ethical concerns related to long-term safety, access equity, and potential exacerbation of weight stigma.
The paper argues that with robust regulatory frameworks in place, the potential benefits of these medications are likely to outweigh the risks. Nonetheless, ongoing monitoring of their effect on individuals and society at large remains essential.
GLP-1 drugs promise significant health outcomes but have unknown long-term side effects.
Access to GLP-1 drugs is inequitable, primarily benefiting higher-income patients.
Widespread use may intensify weight stigma by reframing obesity as a voluntary condition.
Key Insight
GLP-1 receptor agonists offer benefits but require robust regulation to address ethical concerns.
Patient Takeaway
Badge 1: ValueBadge 2: ValueBadge 3: Value
For patients, GLP-1 receptor agonists can lead to significant weight loss and improved metabolic health. However, it is crucial to be aware of potential long-term side effects such as pancreatitis, kidney failure, and thyroid cancer.
Patient autonomy should guide the decision to use these drugs, with careful consideration of individual risk factors and benefits. Ongoing monitoring by healthcare providers is essential for safety.
GLP-1 drugs can lead to significant weight loss and improved metabolic health.
Long-term side effects include pancreatitis, kidney failure, and thyroid cancer.
Patient autonomy should guide the decision to use GLP-1 drugs.
Patient Takeaway
Consider long-term risks and benefits when deciding on GLP-1 therapy.
Clinician’s POV
Badge 1: ValueBadge 2: ValueBadge 3: Value
Clinicians play a crucial role in prescribing GLP-1 receptor agonists safely and effectively. They should consider individual patient risk factors, long-term safety data, and the potential for exacerbating weight stigma.
Screening for eating disorders and providing ongoing clinical oversight are essential to mitigate risks associated with these medications.
Clinicians must consider individual patient risk factors.
Long-term safety data is limited and requires ongoing monitoring.
Screening for eating disorders is crucial in GLP-1 prescribing.
Clinical Takeaway
Prescribe GLP-1 drugs with caution, considering long-term risks and benefits.
A Skeptical Read
Badge 1: ValueBadge 2: ValueBadge 3: Value
Skeptics may question the long-term safety and efficacy of GLP-1 receptor agonists, especially in non-diabetic populations. The limited data on long-term use raise concerns about potential adverse effects.
Access inequity is another significant issue, as these drugs are primarily accessible to higher-income patients, exacerbating existing socioeconomic disparities.
Long-term safety data for GLP-1 drugs in non-diabetic populations is limited.
Access to GLP-1 drugs is inequitable, benefiting higher-income patients.
Skepticism about long-term efficacy and safety is valid given current data gaps.
Skeptical View
Long-term safety and access equity are significant concerns for GLP-1 receptor agonists.
Study Critic
Badge 1: ValueBadge 2: ValueBadge 3: Value
Critics argue that the widespread use of GLP-1 receptor agonists may exacerbate weight stigma by reframing obesity as a voluntary condition for those who decline or cannot access treatment. This could intensify discrimination against individuals with obesity.
Off-label enhancement use raises ethical concerns about safety and equity, suggesting a need for robust regulatory frameworks to ensure safe and equitable access.
Widespread GLP-1 use may exacerbate weight stigma.
Off-label enhancement use poses ethical risks related to safety and equity.
Critics emphasize the need for robust regulatory oversight.
Critical Perspective
GLP-1 drugs may exacerbate stigma and require strict regulation.
Compared to Past Research
Badge 1: ValueBadge 2: ValueBadge 3: Value
The history of weight-loss medications, including past controversies like Thalidomide, underscores the importance of sustained post-market vigilance for GLP-1 receptor agonists. Long-term safety data is crucial to ensure these drugs do not cause unforeseen harm.
Previous studies on GLP-1 drugs have shown significant benefits in weight loss and metabolic health, but long-term effects remain uncertain.
Historical controversies highlight the need for post-market vigilance.
GLP-1 drugs have shown significant short-term benefits in clinical trials.
Long-term safety data is essential to avoid unforeseen harm.
Historical Context
Past controversies emphasize the importance of long-term safety monitoring.
Practical Considerations
Badge 1: ValueBadge 2: ValueBadge 3: Value
Practically, patients and clinicians must balance the benefits of GLP-1 receptor agonists against potential long-term risks. Ongoing monitoring and adherence to regulatory guidelines are essential for safe use.
Access inequity is a significant practical challenge; efforts to reduce drug costs and improve access are crucial to ensure equitable treatment.
Balance benefits against long-term risks.
Ongoing monitoring and adherence to guidelines are essential.
Addressing access inequity is a critical practical challenge.
Practical Advice
Balance benefits with risks and address access inequity.
Future Directions
Badge 1: ValueBadge 2: ValueBadge 3: Value
The future of GLP-1 receptor agonists depends on the development of long-term safety data and robust regulatory frameworks. Continued research is essential to understand the full impact of these drugs on individuals and society.
Advancements in drug delivery methods and cost reduction strategies could improve access and reduce stigma associated with obesity treatment.
Long-term safety data is crucial for future use.
Robust regulatory frameworks are necessary for safe adoption.
Advancements in drug delivery and cost reduction can improve access.
Future Outlook
Develop long-term safety data and robust regulation.
Misreadings & Bad-Faith Takes
Badge 1: ValueBadge 2: ValueBadge 3: Value
Misreadings of the benefits and risks associated with GLP-1 receptor agonists can lead to inappropriate use and exacerbate ethical concerns. It is crucial to understand that these drugs are primarily intended for therapeutic use in obese or diabetic patients.
Off-label enhancement use should be discouraged due to safety risks and equity concerns, emphasizing the importance of medical supervision and self-funding by users.
Misreadings can lead to inappropriate use.
GLP-1 drugs are primarily for therapeutic use in obese or diabetic patients.
Off-label enhancement use is discouraged due to safety and equity concerns.
Common Misunderstandings
Avoid misreading benefits and risks; prioritize therapeutic use.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What are the primary ethical concerns with GLP-1 receptor agonists?
The main ethical issues include long-term safety in non-diabetic populations, access inequity, and potential exacerbation of weight stigma.
How do GLP-1 drugs work to reduce appetite?
GLP-1 drugs mimic the gut-derived GLP-1 hormone, delay gastric emptying, and modulate the brain’s reward system to reduce food appeal.
What are the potential long-term side effects of GLP-1 receptor agonists?
Potential long-term side effects include pancreatitis, kidney failure, gallbladder disease, thyroid cancer, and possible psychiatric effects.
How does widespread use of GLP-1 drugs affect weight stigma?
Widespread use may intensify weight-based stigma by reframing obesity as a voluntary condition for those who decline or cannot access treatment.
What is the current cost of GLP-1 drugs, and how does it impact access?
The cost ranges from $1,300/month in the US to £200/month in the UK, primarily benefiting higher-income patients.
How might GLP-1 drugs influence environmental outcomes?
A study found a 5.8% decline in meat and frozen meat purchases in households using GLP-1 drugs, suggesting potential environmental benefits.
What are the ethical considerations regarding off-label enhancement use of GLP-1 drugs?
Off-label enhancement use raises concerns about safety and equity; it should occur under medical supervision with self-funding by users.
How does the paper address the risk of eating disorders in GLP-1 drug users?
The paper notes that current prescribing protocols are insufficient to screen for or detect anorexia nervosa, posing a risk.
What is the author’s stance on the moral blameworthiness of using GLP-1 drugs?
The author argues that using GLP-1 drugs does not constitute a morally blameworthy ‘shortcut’ because effort is neither intrinsically valuable nor essential to praiseworthy achievement.
What regulatory changes are suggested in the paper?
The paper argues for robust regulatory frameworks to ensure safe broad adoption of GLP-1 receptor agonists, including ongoing monitoring and safety data collection. [...]
Read more...
June 3, 2026GLP-1 Receptor Agonists for Substance Use Disorders: What the Evidence Actually Shows
GLP-1 Receptor Agonists
Substance Use Disorder
Alcohol Use Disorder
Semaglutide
Addiction Pharmacotherapy
What You Will Learn
How semaglutide and exenatide performed in clinical trials targeting alcohol and nicotine use disorders
What the safety and tolerability data actually show across nine qualifying studies
Why the evidence for stimulant use disorders remains thin and what that means for clinical practice
What neurobiological mechanisms drive the hypothesis, and where those mechanisms may produce treatment plateaus or rebound after discontinuation
TL;DR: A nine-study qualitative review finds that semaglutide and exenatide produce statistically significant reductions in alcohol self-administration, craving, and nicotine use, but the evidence base is small, predominantly Western, and not yet sufficient to support routine clinical adoption.
STUDY TYPE: Systematic Review (PRISMA-guided qualitative synthesis)
Abstract
Substance use disorders (SUDs) represent a major global public health challenge, and currently available pharmacological treatments remain only moderately effective. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used in the treatment of obesity and type 2 diabetes, have recently attracted attention as potential therapeutic agents in addiction medicine due to their effects on reward-related neural pathways. The aim of this review was to evaluate the efficacy and safety of GLP-1RAs in adults with substance use disorders. A total of nine studies met the inclusion criteria and were included in the qualitative analysis. The available evidence suggests that semaglutide and exenatide may reduce alcohol consumption, decrease craving, and support the maintenance of nicotine abstinence, while also contributing to weight control. In contrast, clinical data regarding stimulant use disorders remain limited. Across the analysed studies, GLP-1RAs demonstrated a favourable safety profile. The most commonly reported adverse effects were mild gastrointestinal symptoms, and no significant neuropsychiatric safety concerns were identified. Overall, GLP-1RAs may represent a promising adjunctive approach in the treatment of substance use disorders. However, potential plateau effects and rebound phenomena after treatment discontinuation suggest that long-term therapeutic strategies may be required. Further large-scale randomized clinical trials are needed to confirm these findings and to determine the optimal role of GLP-1RAs in addiction treatment.
Citation: Gwałt P, Musioł A, Nowakowski M, Rakuś M, Marzec J, Łukasz K. GLP-1 agonists in addiction therapy: review. Biul Gł Bibl Lek. 2026;386:5-16.
DOI: 10.2478/bgbl-2026-0001
License: Creative Commons Attribution-NonCommercial 4.0
Study at a Glance
Design
PRISMA-guided qualitative systematic review
Population
Adults with substance use disorders (alcohol, nicotine, stimulant)
Studies Included
9 (4 original RCTs, 4 secondary/post-hoc RCT analyses, 1 large EHR cohort)
Agents Evaluated
Semaglutide, exenatide, dulaglutide, liraglutide (referenced)
Primary Question
Efficacy and safety of GLP-1RAs in adults with SUD
Key Finding
Semaglutide and exenatide reduced alcohol consumption, craving, and cigarette use; stimulant data remain insufficient; GI adverse events were mild and transient
Study Snapshot: Key Statistics
Domain
Agent / Study
Key Result
p-value
Alcohol self-administration
Semaglutide (Phase II RCT, 9 weeks)
Significant reduction in g-ETOH and peak BrAC
p=0.01; p=0.03
Alcohol craving (PACS)
Semaglutide
Significant reduction in Penn Alcohol Craving Scale score
p=0.01
Heavy drinking days
Exenatide ER (26-week RCT)
Reduction as adjunct to standard of care
Reported significant
Phosphatidylethanol (PEth)
Exenatide ER (post-hoc)
Significant reduction in direct alcohol biomarker
Reported significant
AUD risk (real-world)
Semaglutide (TriNetX cohort)
Lower risk of incident AUD and AUD recurrence
Significant
AUD risk (meta-analysis)
GLP-1RAs (obesity/T2DM populations)
28% reduction in AUD diagnosis risk vs. other interventions
Significant
Nicotine abstinence
Exenatide + NRT (pilot RCT)
Enhanced biologically verified 7-day abstinence at week 6; reduced post-cessation weight gain
Reported significant
Daily cigarette use
Semaglutide (AUD trial, secondary)
Reduction in daily cigarette consumption
p=0.005
Cocaine self-administration
Exenatide single-dose crossover (n=13)
Reduced cocaine infusions selected; reduced subjective euphoria ratings
Reported significant
Full Study Facts
Authors
Gwałt P, Musioł A, Nowakowski M, Rakuś M, Marzec J, Łukasz K
Journal
Biuletyn Głównej Biblioteki Lekarskiej (Biul Gł Bibl Lek)
Year
2026
DOI
10.2478/bgbl-2026-0001
Study Design
PRISMA-guided systematic review (qualitative synthesis only; no meta-analysis performed)
Databases Searched
PubMed/MEDLINE, Scopus, Web of Science; search through March 3, 2026
Studies Included (n)
9 total: 4 original RCTs, 4 secondary/post-hoc RCT analyses, 1 EHR cohort
Population
Adults with formally diagnosed or clinically evident SUD (AUD, NUD, CUD)
Interventions
Semaglutide, exenatide (ER and single-dose), dulaglutide, liraglutide
Primary Endpoint
Efficacy (consumption, craving, abstinence rates) and safety of GLP-1RAs in SUD
Key Results
Semaglutide reduced g-ETOH (p=0.01), BrAC (p=0.03), PACS craving (p=0.01); exenatide reduced heavy drinking days, PEth biomarker, and nicotine abstinence failure; semaglutide reduced daily cigarette use (p=0.005); 28% reduction in AUD risk in observational meta-analysis
Adverse Events
Mild, transient gastrointestinal symptoms (nausea, less frequently emesis); no treatment-induced major depressive disorder or suicidal ideation identified
Risk of Bias Assessment
Cochrane RoB 2 (RCTs); ROBINS-I (observational studies); most studies rated moderate risk, primarily due to attrition and residual confounding
Funding
Not reported
Conflict of Interest
Authors declare no conflicts of interest
What the Researchers Actually Did
Gwałt and colleagues conducted a PRISMA-compliant systematic review of published clinical evidence evaluating GLP-1 receptor agonists in adults with substance use disorders. They searched PubMed/MEDLINE, Scopus, and Web of Science through March 3, 2026, supplementing automated retrieval with manual reference screening of identified systematic reviews and meta-analyses. Eligibility was structured around the PICOS framework: included studies required pharmacological administration of a GLP-1RA or dual agonist, adult participants with problematic substance use or a formal SUD diagnosis, and direct empirical measurement of addiction-relevant outcomes, such as consumption quantity, validated craving scores, days of abstinence, fMRI cue-reactivity, or addiction-related hospitalization rates. Preclinical studies, non-SUD obesity/diabetes trials without addiction-specific endpoints, and publications evaluating only endogenous GLP-1 changes were excluded. Six investigators independently conducted study selection. Risk of bias was assessed with Cochrane RoB 2 for RCTs and ROBINS-I for observational studies.
Nine studies met inclusion criteria: four original RCTs, four secondary or post-hoc analyses of existing RCT data, and one large retrospective cohort using the TriNetX electronic health record database. Because design heterogeneity precluded meta-analytic pooling, the authors conducted a qualitative synthesis organized by substance category: alcohol use disorder (AUD), nicotine use disorder (NUD), and stimulant use disorder (StUD). The review did not perform a formal GRADE assessment of the overall evidence, though it noted that most RCTs carried a moderate risk of bias driven primarily by participant attrition, and the observational study was limited by residual confounding inherent to retrospective analyses.
Key Findings: Primary Outcomes
Alcohol self-administration (semaglutide): In a Phase II RCT enrolling adults with moderate AUD over nine weeks, semaglutide produced a statistically significant reduction in laboratory-based alcohol self-administration (g-ETOH, p=0.01) and in peak breath alcohol concentration (peak BrAC, p=0.03).
Alcohol craving (semaglutide): The same trial reported a significant attenuation of alcohol cravings on the Penn Alcohol Craving Scale (PACS, p=0.01).
Heavy drinking days (exenatide ER): A 26-week RCT of extended-release exenatide as adjunctive therapy to standard of care demonstrated a reduction in heavy drinking days.
Phosphatidylethanol (exenatide ER, post-hoc): A secondary analysis of the exenatide RCT cohort found significant reductions in blood PEth concentrations, a direct biomarker of alcohol consumption, alongside favourable shifts in pro-inflammatory and metabolic marker profiles.
AUD risk (real-world cohort): A retrospective TriNetX database analysis found that patients prescribed semaglutide had a significantly lower risk of both incident AUD diagnoses and AUD recurrence.
AUD risk (meta-analysis cited in review): A meta-analysis of observational studies found that GLP-1RA use in patients with obesity and type 2 diabetes was associated with a statistically significant 28% reduction in the risk of an AUD diagnosis compared to other therapeutic interventions.
Key Findings: Secondary Outcomes and Subgroup Analyses
Nicotine Use Disorder
Abstinence rates: A pilot double-blind RCT integrating once-weekly exenatide into a regimen of nicotine replacement patches and behavioural counselling significantly enhanced biologically verified 7-day abstinence rates at week 6, and reduced post-cessation weight gain.
Treatment response predictors: A secondary analysis of that trial identified heterogeneous therapeutic response to exenatide, moderated by baseline body mass index, depressive symptomatology, and CHRNA5 receptor genotype, suggesting that personalized treatment selection may be feasible.
Long-term cardiovascular safety (dulaglutide): A 52-week follow-up of patients receiving dulaglutide alongside varenicline identified no cardiovascular safety signals, specifically regarding systolic blood pressure reductions, among participants maintaining abstinence.
Cross-substance effect: Participants receiving semaglutide in the AUD trial demonstrated a significant reduction in daily cigarette consumption (p=0.005), suggesting that anti-addictive effects may extend across substance classes simultaneously.
Stimulant Use Disorder
Cocaine (exenatide, crossover, n=13): Individuals with cocaine use disorder who received a single dose of exenatide three hours before a testing session showed a measurable reduction in subjective ratings of euphoria and drug-seeking intent, translating into a significant decrease in cocaine infusions selected during an operant self-administration paradigm. This represents the sole clinical data point for stimulant use disorders in this review.
Opioid Use Disorder (referenced in discussion)
The review’s discussion cites a systematic review of EHRs indicating that semaglutide initiation significantly reduced intoxication episodes and the risk of fatal overdose in patients with opioid use disorders; however, no original OUD study was included among the nine qualifying studies.
Adverse Events and Safety Profile
Across all nine appraised studies, the administration of GLP-1RAs in patients with SUD was characterized by a consistently favourable tolerability profile. The most frequently reported adverse events were gastrointestinal, primarily manifesting as mild nausea and, less frequently, emesis. These symptoms were typically transient and resolved during the initial titration phase.
No significant neuropsychiatric adverse events were identified. Specifically, no evidence of treatment-induced major depressive disorder or suicidal ideation was detected across the analysed studies. The authors frame the absence of neuropsychiatric signal as particularly clinically meaningful, given the high prevalence of comorbid psychiatric conditions in the SUD population, where such signals would constitute a substantial barrier to adoption.
One cautionary finding: the 52-week dulaglutide follow-up in smokers found that participants maintaining abstinence showed a significant increase in systolic blood pressure after dulaglutide discontinuation at week 52, which the authors interpret as consistent with a post-discontinuation rebound phenomenon rather than a direct drug toxicity signal.
Statistical Approach and Rigor
This review is a qualitative synthesis only. No pooled effect sizes, weighted means, or meta-analytic calculations were performed by the review authors. Risk of bias was formally assessed using Cochrane RoB 2 for RCTs and ROBINS-I for observational studies, with most studies rated at moderate risk of bias due to attrition (RCTs) or residual confounding (observational data). No formal GRADE evidence quality assessment was conducted. The inclusion of four secondary or post-hoc analyses derived from the same underlying RCT datasets introduces the possibility that shared-sample findings are overrepresented in the evidence base. The smallest study informing conclusions about stimulant use disorders enrolled only 13 participants, a sample size that affords negligible statistical power for subgroup inference. The review’s reliance on individual study p-values rather than pooled effect estimates limits quantitative precision and precludes dose-response inference.
Clinical Takeaway
For the clinician managing patients with alcohol or nicotine use disorders who are already on or being considered for GLP-1 receptor agonist therapy, this review provides a coherent, if preliminary, signal: semaglutide and exenatide show statistically significant reductions in alcohol consumption, craving, and nicotine relapse across multiple study designs. The safety profile is reassuring, with no neuropsychiatric signals, which distinguishes GLP-1RAs from agents such as varenicline that carry labeling warnings in certain populations. However, the evidence does not yet support prescribing GLP-1RAs as primary addiction pharmacotherapy, and the possibility of rebound phenomena after discontinuation argues against time-limited courses. Clinicians should treat these data as hypothesis-strengthening rather than practice-defining, and patients with comorbid metabolic disease and SUD represent the most defensible population in whom adjunctive use might be considered off-label today.
Clinical Bottom Line: Semaglutide and exenatide reduce alcohol self-administration and craving in randomized trials, but nine studies of heterogeneous design, predominantly at moderate risk of bias, do not constitute sufficient evidence to add GLP-1RAs to addiction treatment guidelines.
Why This Matters Clinically
Substance use disorders impose a staggering global burden, and the current pharmacological toolkit is limited in both breadth and effectiveness. Naltrexone for AUD and varenicline for NUD represent the standard, yet real-world adherence to both agents is persistently suboptimal, driven in part by adverse event profiles. GLP-1 receptor agonists occupy an unusual pharmacological niche: they are already approved, widely prescribed, and carry a well-characterized safety record from metabolic indications. If their apparent anti-addictive effects are confirmed at scale, the clinical benefit would be additive for patients who carry the common clinical phenotype of comorbid obesity, type 2 diabetes, and substance use disorder. The dual metabolic and addiction-modifying profile described in this review would address two high-mortality comorbidities with a single agent class, reducing polypharmacy burden and potentially improving overall adherence. That said, clinicians must resist the narrative compression that often follows promising early-phase data in addiction medicine.
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
GLP-1RAs reduce alcohol and nicotine use, showing potential in addiction treatment.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ValueBadge 2: Evidence-BasedBadge 3: Promising
GLP-1 receptor agonists, such as semaglutide and exenatide, show promise in reducing alcohol consumption, decreasing cravings, and supporting nicotine abstinence. These medications may offer a new approach to addiction treatment by affecting reward-related neural pathways.
However, the evidence base is small and predominantly Western, with limited data on stimulant use disorders. Future research is needed to confirm these findings and determine the optimal role of GLP-1RAs in clinical practice.
GLP-1RAs reduce alcohol self-administration and craving.
Exenatide enhances nicotine abstinence when combined with NRT.
Stimulant use disorder data are insufficient for definitive conclusions.
Key Insight
GLP-1RAs show promise in treating alcohol and nicotine addiction but require further research.
Patient Takeaway
Badge 1: Patient-CentricBadge 2: Safety-FocusedBadge 3: Evidence-Based
For patients with substance use disorders, GLP-1 receptor agonists like semaglutide and exenatide may offer new hope by reducing alcohol consumption, decreasing cravings, and supporting nicotine abstinence. These medications have a favorable safety profile, with mild gastrointestinal symptoms being the most commonly reported adverse effects.
However, more research is needed to understand their long-term effectiveness and potential for use in treating stimulant use disorders.
GLP-1RAs reduce alcohol self-administration and craving.
Exenatide enhances nicotine abstinence when combined with NRT.
Safety profile includes mild gastrointestinal symptoms.
Patient Takeaway
GLP-1RAs may help reduce alcohol and nicotine use, but more research is needed.
Clinician’s POV
Badge 1: Clinically RelevantBadge 2: Evidence-BasedBadge 3: Safety-Focused
Clinicians can consider GLP-1 receptor agonists as a potential adjunctive treatment for alcohol and nicotine use disorders. These medications have shown efficacy in reducing alcohol consumption, decreasing cravings, and supporting nicotine abstinence.
However, the evidence base is small and predominantly Western, with limited data on stimulant use disorders. Clinicians should monitor patients for gastrointestinal symptoms and consider long-term therapeutic strategies to avoid potential rebound effects.
GLP-1RAs reduce alcohol self-administration and craving.
Exenatide enhances nicotine abstinence when combined with NRT.
Safety profile includes mild gastrointestinal symptoms.
Clinician Takeaway
Consider GLP-1RAs for alcohol and nicotine addiction, monitor for side effects.
A Skeptical Read
Badge 1: Skeptical ViewBadge 2: Evidence-BasedBadge 3: Critical
While GLP-1 receptor agonists show promise in reducing alcohol consumption and cravings, as well as supporting nicotine abstinence, the evidence base is small and predominantly Western. The limited data on stimulant use disorders raise questions about their broader applicability.
Clinicians should approach these medications with caution, considering the potential for plateau effects and rebound phenomena after treatment discontinuation. Further research is needed to confirm their efficacy and determine optimal clinical use.
GLP-1RAs reduce alcohol self-administration and craving.
Exenatide enhances nicotine abstinence when combined with NRT.
Limited data on stimulant use disorders.
Skeptic Takeaway
GLP-1RAs show promise but require more research for broader clinical application.
Study Critic
Badge 1: Critical ViewBadge 2: Evidence-BasedBadge 3: Skeptical
Critics may question the efficacy and applicability of GLP-1 receptor agonists in treating substance use disorders due to the small, predominantly Western evidence base. The limited data on stimulant use disorders further complicate their clinical utility.
Additionally, potential plateau effects and rebound phenomena after treatment discontinuation raise concerns about long-term effectiveness. Critics argue that more research is needed to confirm these findings and determine the optimal role of GLP-1RAs in addiction treatment.
GLP-1RAs reduce alcohol self-administration and craving.
Exenatide enhances nicotine abstinence when combined with NRT.
Limited data on stimulant use disorders.
Critic Takeaway
Critics question GLP-1RA efficacy due to limited evidence and potential rebound effects.
Compared to Past Research
Badge 1: Historical ContextBadge 2: Evolutionary ViewBadge 3: Past Research
The use of GLP-1 receptor agonists in addiction treatment is a relatively new area of research. Previous studies focused primarily on their effects in obesity and type 2 diabetes, where they demonstrated efficacy in weight management.
Recent interest in their potential for treating substance use disorders stems from their impact on reward-related neural pathways, which may offer new therapeutic approaches to reducing cravings and consumption.
GLP-1RAs previously studied in obesity and type 2 diabetes.
Interest in addiction treatment due to effects on reward pathways.
New area of research with evolving evidence base.
Historical Takeaway
GLP-1RAs evolved from obesity studies, now being explored for addiction treatment.
Practical Considerations
Badge 1: Practical ApplicationBadge 2: Real-World UseBadge 3: Implementation
In practical terms, GLP-1 receptor agonists can be considered as an adjunctive therapy for alcohol and nicotine use disorders. They have shown efficacy in reducing alcohol consumption, decreasing cravings, and supporting nicotine abstinence.
Clinicians should monitor patients for gastrointestinal symptoms and consider long-term therapeutic strategies to avoid potential rebound effects. Real-world applications may include combining GLP-1RAs with existing treatments like behavioral counseling and nicotine replacement therapy.
GLP-1RAs reduce alcohol self-administration and craving.
Exenatide enhances nicotine abstinence when combined with NRT.
Monitor for gastrointestinal symptoms.
Practical Takeaway
Use GLP-1RAs as adjunctive therapy, monitor for side effects.
Future Directions
Badge 1: Future OutlookBadge 2: Emerging TrendsBadge 3: Research Directions
The future of GLP-1 receptor agonists in addiction treatment looks promising but requires further research. Larger-scale randomized clinical trials are needed to confirm their efficacy and determine the optimal role in clinical practice.
Emerging trends include exploring the use of GLP-1RAs for stimulant use disorders and investigating long-term therapeutic strategies to avoid potential rebound effects.
GLP-1RAs show promise but need more research.
Future studies should explore stimulant use disorders.
Investigate long-term therapeutic strategies.
Future Takeaway
More research needed to confirm GLP-1RA efficacy and determine optimal clinical use.
Misreadings & Bad-Faith Takes
Badge 1: Common MisunderstandingsBadge 2: Clarification NeededBadge 3: Misinterpretation
Common misreadings of the evidence include overestimating the efficacy of GLP-1 receptor agonists in treating stimulant use disorders, which is currently unsupported by data. Another misconception is that these medications are a standalone treatment for addiction.
GLP-1RAs should be considered as adjunctive therapies and combined with existing treatments like behavioral counseling and nicotine replacement therapy. Clinicians should also monitor patients for gastrointestinal symptoms and consider long-term therapeutic strategies to avoid potential rebound effects.
Misunderstanding of efficacy in stimulant use disorders.
GLP-1RAs are not standalone treatments.
Monitor for gastrointestinal symptoms.
Misreading Takeaway
Avoid misinterpreting GLP-1RA efficacy and consider as adjunctive therapy.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What are GLP-1 receptor agonists?
GLP-1 receptor agonists (GLP-1RAs) are medications that mimic the effects of glucagon-like peptide-1, a hormone involved in regulating metabolism and appetite.
How do GLP-1RAs work in addiction treatment?
GLP-1RAs may reduce alcohol consumption, decrease craving, and support nicotine abstinence by affecting reward-related neural pathways.
What studies have been conducted on GLP-1RAs in addiction?
Nine studies were included in the review, with four original RCTs, four secondary/post-hoc analyses, and one large EHR cohort.
What are the key findings for alcohol use disorder?
Semaglutide reduced laboratory-based alcohol self-administration and peak breath alcohol concentration. Exenatide also showed reductions in heavy drinking days.
How effective is exenatide for nicotine addiction?
A pilot RCT found that exenatide enhanced 7-day abstinence rates at week 6 when combined with nicotine replacement therapy and behavioral counseling.
What about stimulant use disorders?
The evidence for stimulant use disorders is limited, with only one study showing a reduction in cocaine infusions selected during an operant self-administration paradigm.
Are GLP-1RAs safe to use in addiction treatment?
The safety profile of GLP-1RAs is favorable, with mild gastrointestinal symptoms being the most commonly reported adverse effects.
What are the potential limitations of using GLP-1RAs for addiction?
Potential plateau effects and rebound phenomena after treatment discontinuation suggest that long-term therapeutic strategies may be required.
Are there any real-world applications of these findings?
A retrospective TriNetX database analysis found that patients prescribed semaglutide had a significantly lower risk of incident AUD diagnoses and AUD recurrence.
What future research is needed?
Larger-scale randomized clinical trials are needed to confirm these findings and determine the optimal role of GLP-1RAs in addiction treatment. [...]
Read more...
June 3, 2026GLP-1 Agonists in Body Contouring Surgery: What the Evidence Shows
GLP-1 Receptor Agonists
Body Contouring Surgery
Wound Healing
Semaglutide
Perioperative Safety
What You’ll Learn:
How perioperative GLP-1 RA use compares to no exposure across wound-healing outcomes in 8,944 body contouring patients
Why the pooled wound dehiscence signal deserves careful scrutiny before clinical translation
Which complications showed no statistically significant difference between GLP-1 RA users and non-users
What the current evidence does — and does not — support for perioperative management decisions
TL;DR: A systematic review and meta-analysis of 8,944 patients found a statistically significant association between perioperative GLP-1 RA use and wound dehiscence (RR 1.62; 95% CI 1.09–2.42), but that signal disappears in leave-one-out sensitivity analysis when a single large cohort is removed, and no other surgical site outcomes reached significance.
STUDY TYPE: Systematic Review and Meta-Analysis
Abstract
Background: The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight management has created new considerations for plastic surgeons, particularly regarding their impact on wound healing and perioperative outcomes. Patients presenting for body contouring procedures increasingly use GLP-1 RAs, yet the safety of these agents in surgical populations remains unclear.
Methods: The authors conducted the first systematic review and meta-analysis in accordance with Cochrane’s Handbook and PRISMA reporting guidelines comparing adults undergoing body-contouring procedures with and without GLP-1 RA exposure. Primary outcomes were surgical site occurrences (SSOs), including wound dehiscence, surgical site infection (SSI), seroma, and hematoma. Secondary outcomes included readmission, emergency visits, and gastrointestinal complications. Risk of bias was assessed using ROBINS-I, and pooled risk ratios (RRs) were calculated with random-effects models. Sensitivity was evaluated with leave-one-out (LOO) analyses.
Results: From 1,479 screened records, four studies (three retrospective, one prospective) comprising 8,944 patients were included. Semaglutide was the most frequently reported agent, accounting for more than 99% of prescriptions. Meta-analysis demonstrated a significantly higher risk of wound dehiscence among GLP-1 RA users (5.2% vs. 2.9%; RR 1.62; 95% CI 1.09–2.42; p=0.017; I²=0%). No significant differences were observed for seroma (RR 0.78; 95% CI 0.30–2.05; p=0.613; I²=62.7%), hematoma (RR 1.74; 95% CI 0.72–4.24; p=0.220; I²=0%), or SSI (RR 1.16; 95% CI 0.48–2.77; p=0.746; I²=65.6%). Composite SSO analysis also showed no significant difference (RR 1.31; 95% CI 0.90–1.90; p=0.164; I²=80.7%). Leave-one-out sensitivity analysis attenuated the wound dehiscence association to non-significance (RR 1.02; 95% CI 0.46–2.26) when the largest cohort was removed. ROBINS-I assessment rated all studies at moderate or serious risk of bias.
Conclusions: GLP-1 RA use in body contouring surgery may be associated with an increased risk of wound dehiscence, although this finding appears largely driven by a single large cohort study. Other perioperative complications were not consistently elevated, but substantial heterogeneity and limited evidence reduce certainty. Further prospective studies are needed to guide perioperative management in this expanding patient population.
Source: Collaco BG, Gomez-Cabello CA, Haider SA, et al. Safety of GLP-1 receptor agonists in body contouring surgery: a systematic review and meta-analysis. BMC Plastic and Reconstructive Surgery. 2026;2:13.
DOI: https://doi.org/10.1186/s44452-026-00024-w
Study at a Glance
Design
Systematic review and meta-analysis (3 retrospective cohorts, 1 prospective comparative study)
Population
Adults undergoing body contouring procedures (abdominoplasty, panniculectomy, brachioplasty, thighplasty, lipoabdominoplasty, mastopexy, and others)
Total N
8,944 patients across 4 studies
Primary Endpoint
Surgical site occurrences (SSOs): wound dehiscence, SSI, seroma, hematoma
Key Finding
Wound dehiscence was significantly higher in GLP-1 RA users on pooled analysis (RR 1.62), but this association was not robust in sensitivity analysis; no other SSO was significantly elevated
Study Snapshot
Outcome
GLP-1 RA Rate
Control Rate
Pooled RR (95% CI)
p-value
I²
Wound Dehiscence
5.2%
2.9%
1.62 (1.09–2.42)
0.017
0%
Seroma
9.2%
12.3%
0.78 (0.30–2.05)
0.613
62.7%
Hematoma
4.6%
2.6%
1.74 (0.72–4.24)
0.220
0%
Surgical Site Infection
5.3%
3.3%
1.16 (0.48–2.77)
0.746
65.6%
Composite SSO
13.9%
9.2%
1.31 (0.90–1.90)
0.164
80.7%
LOO sensitivity: wound dehiscence RR 1.02 (0.46–2.26) after removing Lewis et al. 2025
Study Facts Table
Authors
Collaco BG, Gomez-Cabello CA, Haider SA, Genovese A, Prabha S, Rinker BD, Forte AJ, Elegbede AI
Journal
BMC Plastic and Reconstructive Surgery
Year
2026
Study Design
Systematic review and meta-analysis; 3 retrospective cohorts, 1 prospective comparative study with historical controls
Total N
8,944 patients (4 studies); largest single cohort: Lewis et al. 2025, n=8,314
Intervention
Perioperative GLP-1 RA exposure (semaglutide >99% of prescriptions across studies)
Comparator
No GLP-1 RA exposure
Primary Endpoint
SSOs: wound dehiscence, SSI, seroma, hematoma
Key Results
Wound dehiscence: RR 1.62 (1.09–2.42), p=0.017, I²=0%; attenuated to RR 1.02 (0.46–2.26) on LOO analysis removing Lewis et al. All other outcomes non-significant. Composite SSO RR 1.31 (0.90–1.90), p=0.164, I²=80.7%
Adverse Events
Lewis et al. reported nausea, vomiting, diarrhea, hypertrophic scars, and surgical site pain at higher rates in GLP-1 RA users; not systematically pooled across all studies
Funding
No external funding reported
Conflict of Interest
Authors declare no competing interests
ROBINS-I Assessment
All studies rated moderate or serious risk of bias; Albanese 2025 rated serious overall
What Researchers Actually Did
Collaco and colleagues at the Division of Plastic Surgery, Mayo Clinic Jacksonville, searched PubMed, Embase, and the Cochrane Library through August 10, 2025, for studies comparing adults undergoing body contouring procedures with and without GLP-1 RA exposure. From 1,479 screened records, four studies met inclusion criteria: three retrospective cohorts and one prospective comparative study with historical controls. The combined population comprised 8,944 patients, the overwhelming majority of whom were female and predominantly in the obese BMI range. Semaglutide accounted for more than 99% of all GLP-1 RA prescriptions across included studies, driven largely by the Lewis et al. 2025 cohort, which enrolled 4,157 matched non-diabetic post-bariatric patients exclusively treated with semaglutide.
Binary outcomes were synthesized using Mantel-Haenszel random-effects models, with between-study heterogeneity further characterized via restricted maximum likelihood estimation and I² statistics. Risk of bias was assessed using ROBINS-I across seven domains. Leave-one-out sensitivity analyses were performed for outcomes with four contributing studies; outcomes with only three contributing studies were excluded from LOO analysis given interpretability constraints. Publication bias assessment was not performed, given the limited study count.
Key Findings: Primary Outcomes
Wound dehiscence: Significantly higher in GLP-1 RA users on pooled analysis across all four studies (5.2% vs. 2.9%; RR 1.62; 95% CI 1.09–2.42; p=0.017; I²=0%). LOO sensitivity analysis removing Lewis et al. 2025 attenuated the effect to non-significance (RR 1.02; 95% CI 0.46–2.26).
Seroma: No statistically significant difference across three studies (9.2% vs. 12.3%; RR 0.78; 95% CI 0.30–2.05; p=0.613; I²=62.7%).
Hematoma: No statistically significant difference across three studies (4.6% vs. 2.6%; RR 1.74; 95% CI 0.72–4.24; p=0.220; I²=0%).
Surgical site infection: No statistically significant difference across three studies (5.3% vs. 3.3%; RR 1.16; 95% CI 0.48–2.77; p=0.746; I²=65.6%).
Composite SSO: No statistically significant difference across all four studies (13.9% vs. 9.2%; RR 1.31; 95% CI 0.90–1.90; p=0.164; I²=80.7%); heterogeneity was high throughout.
Key Findings: Secondary Outcomes and Subgroup Analyses
Lewis et al. 2025 reported higher rates of nausea, vomiting, diarrhea, delayed wound healing, hypertrophic scars, and surgical site pain in GLP-1 RA users, and recommended cautious perioperative planning, potential drug discontinuation, and nutritional optimization. These secondary outcomes were not pooled across all studies due to inconsistent reporting.
Koenig et al. 2025 restricted analysis to panniculectomy and reported lower wound dehiscence in GLP-1 RA users (1.2% vs. 2.4%), in contrast to Lewis et al. 2025.
Liang et al. 2025 reported wound dehiscence rates of 8.3% (GLP-1 RA) vs. 7.0% (controls), with a longer mean discontinuation interval of 9.6 weeks (range 0–100 weeks).
Albanese et al. 2025 was the only study to follow the ASA protocol, discontinuing GLP-1 therapy one week preoperatively.
Formal subgroup analyses by procedure type, agent, dose, or discontinuation interval were not performed; the authors cite this as a key limitation.
VTE events were infrequently reported and not pooled; no consistent differences were identified between groups.
Results: Adverse Events and Safety Profile
Gastrointestinal adverse events — nausea, vomiting, diarrhea — were reported as secondary outcomes by Lewis et al. 2025 at higher rates in GLP-1 RA users, but were not systematically captured or pooled across all four studies. Hypertrophic scarring and surgical site pain were also noted by Lewis et al. in GLP-1 RA users. The authors note that GLP-1 RAs may delay gastric emptying and increase aspiration risk during anesthesia, citing relevant anesthesiology guidance. Venous thromboembolism was infrequently reported and no consistent between-group differences were identified.
Statistical Approach and Rigor
The authors used Mantel-Haenszel random-effects models with REML for variance estimation, which is a defensible and commonly applied approach for heterogeneous observational data. I² was used as the primary heterogeneity metric, with pre-specified thresholds. LOO sensitivity analyses were correctly limited to outcomes with four contributing studies. The decision to forgo funnel plot and Egger’s test given the small number of studies is methodologically appropriate, though it leaves publication bias unquantified. Meta-analysis was conducted on event-level, unadjusted data because adjusted estimates were not consistently available across studies — a meaningful constraint that increases residual confounding in the pooled estimates. No formal assessment of small-study effects was performed.
Clinical Takeaway
Clinicians counseling patients on GLP-1 RA therapy who are pursuing body contouring procedures should be aware that the current pooled data suggest a possible but fragile signal for increased wound dehiscence. That signal is carried almost entirely by one large matched cohort of non-diabetic post-bariatric patients (Lewis et al. 2025), and disappears entirely in sensitivity analysis. No other wound-healing complication — seroma, hematoma, SSI, or composite SSO — reached statistical significance. The evidence is insufficient to mandate universal perioperative discontinuation, but coordination with anesthesiology and endocrinology, attention to nutritional status, and meticulous wound closure technique remain sound individualized management steps in the absence of higher-quality data.
Clinical Bottom Line: Based on four observational studies rated at moderate to serious risk of bias, GLP-1 RA use at the time of body contouring surgery carries a statistically significant but sensitivity-analysis-fragile association with wound dehiscence, and no consistent increase in other perioperative wound complications.
Why This Matters Clinically
The intersection of GLP-1 RA use and body contouring surgery represents one of the most rapidly expanding clinical scenarios in plastic surgery. Millions of patients are losing weight on semaglutide and related agents and subsequently presenting for panniculectomy, abdominoplasty, brachioplasty, and thighplasty. Until this systematic review, no rigorous synthesis existed to guide clinicians. The findings do not establish that GLP-1 RAs are clearly unsafe in this setting, but they identify wound dehiscence as the outcome most plausibly affected — a complication associated with prolonged recovery, increased cost, reoperation, and impaired aesthetic outcomes. Equally relevant is what the data do not show: no consistent elevation in infection, seroma, hematoma, or overall SSOs. The heterogeneity across studies, the dominant influence of a single cohort, and the observational design of all included studies mean that confident perioperative guidance cannot yet be derived from this evidence base alone.
CED Clinical Relevance
At CED Clinic, patients commonly use GLP-1 receptor agonists for weight management, metabolic optimization, and as adjuncts to comprehensive cannabis-based and integrative care plans. When these patients are also pursuing or have undergone surgical procedures — including body contouring — the perioperative safety of their GLP-1 RA regimen becomes a direct concern. This review reinforces the importance of individualized preoperative assessment, nutritional screening, and interdisciplinary coordination with surgeons and anesthesiologists when GLP-1 RA therapy is part of a patient’s active medication regimen. The absence of a robust composite SSO signal is reassuring, but the wound dehiscence data warrants a specific conversation about wound monitoring and postoperative follow-up protocols.
Clinical Insight: For patients on semaglutide approaching body contouring surgery, the most defensible current approach is individualized risk stratification: assess nutritional status, involve anesthesiology in gastric-emptying risk planning, apply meticulous wound closure, and schedule close postoperative wound surveillance. Universal mandatory discontinuation is not yet supported by the evidence reviewed here.
Fits What We Already Know
This meta-analysis situates within a sparse but emerging literature. The authors cite Wilding et al. (NEJM 2021) establishing semaglutide’s weight-loss efficacy, and several prior case series and single-center reports on GLP-1 RAs in aesthetic contexts. The ASA consensus guidance on perioperative GLP-1 RA management, referenced by the authors, focuses primarily on aspiration risk from delayed gastric emptying, not wound healing. Prior work in other surgical specialties — including spinal fusion and total knee arthroplasty, cited by the authors — has suggested either neutral or beneficial effects of GLP-1 RAs on perioperative infection rates, which is consistent with the non-significant SSI finding here. A separate, non-included cohort by Khong et al. 2025 comparing GLP-1 RA users to post-bariatric patients without GLP-1 exposure found higher wound dehiscence and SSO rates in the bariatric group, suggesting that post-bariatric surgery status itself — not GLP-1 RA use — may be the primary driver of elevated complications in Lewis et al. 2025.
What This Study Teaches Us
In plain terms: using a GLP-1 medication like semaglutide around the time of a body-reshaping surgery does not clearly raise the overall risk of wound infections, fluid collections, or bleeding. There is a possible — but fragile — signal that wounds may be more likely to open up (dehisce) in patients on these medications, but that signal is almost entirely produced by a single large study, and vanishes when that study is removed from the analysis. The takeaway
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
Study finds possible but fragile link between GLP-1 RA use and increased wound dehiscence in body contouring surgery.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: Comprehensive ReviewBadge 2: Large Patient SampleBadge 3: Sensitivity Analysis
This systematic review and meta-analysis of 8,944 patients found a statistically significant association between perioperative GLP-1 RA use and wound dehiscence. However, this signal disappears in sensitivity analysis when the largest cohort is removed.
No other surgical site outcomes reached significance, indicating that while there may be a potential risk with wound dehiscence, it is not consistently elevated across all studies.
GLP-1 RA use may increase wound dehiscence risk but this finding is sensitive to the inclusion of one large study.
No significant differences were observed for seroma, hematoma, or surgical site infection.
Further prospective studies are needed to guide perioperative management in patients using GLP-1 RAs.
Key Insight
GLP-1 RA use may increase wound dehiscence risk but this finding is not robust across all studies.
Patient Takeaway
Badge 1: Patient-CentricBadge 2: Informed Decision-MakingBadge 3: Safety First
Patients using GLP-1 RAs for weight management should be aware of the potential increased risk of wound dehiscence during body contouring surgery. However, this risk is not consistently elevated across all studies.
It’s important to discuss perioperative management options with your healthcare provider, including potential drug discontinuation and nutritional optimization, to minimize risks.
Discuss perioperative management options with healthcare providers.
Potential for increased wound dehiscence risk but not consistently elevated.
Consider nutritional status and meticulous wound closure techniques.
Patient Advice
Discuss perioperative management options with your healthcare provider to minimize risks.
Clinician’s POV
Badge 1: Evidence-BasedBadge 2: Clinical GuidanceBadge 3: Risk Management
Clinicians should be aware of the possible increased risk of wound dehiscence in patients using GLP-1 RAs undergoing body contouring surgery. However, this finding is not robust across all studies.
Coordination with anesthesiology and endocrinology, attention to nutritional status, and meticulous wound closure technique are recommended steps in managing these patients.
Possible increased risk of wound dehiscence but not consistently elevated.
Coordinate with anesthesiology and endocrinology.
Attention to nutritional status and meticulous wound closure techniques.
Clinical Guidance
Coordinate with anesthesiology and endocrinology, and focus on nutritional status and meticulous wound closure.
A Skeptical Read
Badge 1: Critical ThinkingBadge 2: Skeptical ViewpointBadge 3: Evidence Scrutiny
The study’s findings regarding increased risk of wound dehiscence with GLP-1 RA use are not robust, as the signal disappears in sensitivity analysis when a single large cohort is removed.
Further prospective studies are needed to confirm these findings and provide more definitive guidance on perioperative management for patients using GLP-1 RAs.
Increased risk of wound dehiscence not robust across all studies.
Sensitivity analysis attenuates the initial finding.
Further prospective studies needed for confirmation.
Critical Perspective
Increased risk of wound dehiscence not robust; further studies needed.
Study Critic
Badge 1: Rigorous CritiqueBadge 2: Methodological ScrutinyBadge 3: Bias Assessment
The study includes observational data with moderate to serious risk of bias, and high heterogeneity among studies limits the certainty of findings.
Formal subgroup analyses by procedure type, agent, dose, or discontinuation interval were not performed, which is a key limitation.
Observational data with moderate to serious risk of bias.
High heterogeneity among studies.
Limited subgroup analyses.
Methodological Critique
Study has limitations due to observational design and high heterogeneity.
Compared to Past Research
Badge 1: Historical ContextBadge 2: Previous ResearchBadge 3: Evolution of Knowledge
Previous research on GLP-1 RAs in surgical populations has been limited, with this study being the first systematic review and meta-analysis focusing specifically on body contouring surgery.
The findings provide initial insights into the safety profile of GLP-1 RAs in this context, highlighting the need for further investigation.
First systematic review and meta-analysis on GLP-1 RAs in body contouring.
Initial insights into safety profile.
Need for further investigation.
Historical Context
First systematic review on GLP-1 RAs in body contouring; need for further research.
Practical Considerations
Badge 1: Practical AdviceBadge 2: Real-World ApplicationBadge 3: Immediate Usefulness
Practically, clinicians should consider the potential increased risk of wound dehiscence in patients using GLP-1 RAs undergoing body contouring surgery.
Coordination with anesthesiology and endocrinology, attention to nutritional status, and meticulous wound closure technique are recommended steps to minimize risks.
Consider potential increased risk of wound dehiscence.
Coordinate with anesthesiology and endocrinology.
Attention to nutritional status and meticulous wound closure.
Practical Advice
Coordinate with specialists and focus on nutrition and wound care.
Future Directions
Badge 1: Future DirectionsBadge 2: Research NeedsBadge 3: Emerging Trends
Future research should include prospective studies to confirm the findings of this meta-analysis and provide more definitive guidance on perioperative management for patients using GLP-1 RAs.
Investigating subgroup analyses by procedure type, agent, dose, or discontinuation interval could also provide valuable insights into the safety profile of GLP-1 RAs in body contouring surgery.
Prospective studies needed for confirmation.
Subgroup analyses by various factors could be valuable.
Emerging trends in perioperative management.
Future Research
Prospective studies and subgroup analyses needed to confirm findings.
Misreadings & Bad-Faith Takes
Badge 1: Common MisunderstandingsBadge 2: Clarification NeededBadge 3: Avoiding Errors
A common misreading of the study is that GLP-1 RA use definitively increases wound dehiscence risk in body contouring surgery. However, this finding is not robust across all studies.
Another potential misunderstanding is that no other perioperative complications are elevated with GLP-1 RA use, which is accurate based on the current evidence.
GLP-1 RA use does not definitively increase wound dehiscence risk.
No other perioperative complications were consistently elevated.
Avoiding misinterpretation of study findings.
Misreadings to Avoid
Avoid misinterpreting the robustness of increased wound dehiscence risk.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What is the main finding of the study regarding GLP-1 RA use in body contouring surgery?
The study found a statistically significant association between perioperative GLP-1 RA use and wound dehiscence, but this signal disappears in sensitivity analysis when a single large cohort is removed.
Which complications showed no statistically significant difference between GLP-1 RA users and non-users?
No significant differences were observed for seroma, hematoma, surgical site infection (SSI), or composite surgical site occurrences (SSOs).
What is the significance of the leave-one-out sensitivity analysis in this study?
The leave-one-out sensitivity analysis attenuated the wound dehiscence association to non-significance when the largest cohort was removed, suggesting that the initial finding may be driven by a single large study.
Which GLP-1 RA was most frequently reported in the studies?
Semaglutide accounted for more than 99% of all GLP-1 RA prescriptions across included studies.
What are the implications of the study’s findings for clinical practice?
The evidence is insufficient to mandate universal perioperative discontinuation, but coordination with anesthesiology and endocrinology, attention to nutritional status, and meticulous wound closure technique remain sound individualized management steps.
How was the risk of bias assessed in the included studies?
Risk of bias was assessed using ROBINS-I across seven domains, with all studies rated at moderate or serious risk of bias.
What were some of the secondary outcomes reported by Lewis et al. 2025?
Lewis et al. reported higher rates of nausea, vomiting, diarrhea, delayed wound healing, hypertrophic scars, and surgical site pain in GLP-1 RA users.
What is the current evidence regarding gastrointestinal complications with GLP-1 RAs in body contouring?
Gastrointestinal adverse events such as nausea, vomiting, and diarrhea were reported at higher rates in GLP-1 RA users by Lewis et al. 2025 but were not systematically captured or pooled across all studies.
Why was a funnel plot not included in the study?
A funnel plot and Egger’s test were not performed due to the small number of studies, which is methodologically appropriate but leaves publication bias unquantified.
What are the limitations of this meta-analysis?
The study includes observational data with moderate to serious risk of bias, high heterogeneity among studies, and limited subgroup analyses by procedure type, agent, dose, or discontinuation interval. [...]
Read more...
June 3, 2026SemaGBA: How Semaglutide Regulates Appetite and Weight
Semaglutide
GLP-1 Receptor Agonist
Obesity & Type 2 Diabetes
Gut-Brain Axis
Computational Modeling
What You’ll Learn
How the SemaGBA model integrates 14 metabolic and neural variables to simulate semaglutide’s mechanisms across type 2 diabetes, obesity, and prediabetes
What the model predicts about AgRP, POMC, and dopamine neuron activity during semaglutide treatment — and why those predictions cannot yet be validated in humans
Where computational modeling adds genuine explanatory value and where its assumptions require caution
Why early intervention in prediabetes may preserve beta-cell function, and what this model’s limitations mean for clinical translation
TL;DR: The SemaGBA computational model accurately reproduces clinical weight loss and glucose outcomes for semaglutide across five phase 3 datasets, and generates hypotheses — not validated conclusions — about the neural pathways through which the drug suppresses appetite.
STUDY TYPE: Computational / System Dynamics Modeling Study
Abstract
Aims: Semaglutide is a GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity. Its clinical effects are well established, but the underlying mechanisms remain unclear. This study aimed to use computational modelling to generate hypotheses about semaglutide’s long-term metabolic (body weight, net energy intake, blood glucose, insulin, insulin sensitivity, glucotoxicity, leptin, leptin sensitivity, lipotoxicity, GLP-1, and beta-cell function) and neural (AgRP, POMC, and dopamine neural activity) effects.
Materials and Methods: The SemaGBA computational model was developed in Julia using a system dynamics approach, integrating 14 metabolic and neural variables. A version without neural variables was first constructed and validated against clinical data for blood glucose and weight loss. The model was then extended with neural variables. Baseline variable profiles were defined for people with type 2 diabetes, obesity, and a healthy condition. Simulations were performed for semaglutide treatment over periods from 30 weeks to 5 years.
Results: The reduced model accurately reproduced clinical outcomes, predicting glucose reductions of 38.0 mg/dL (clinical data: 41.0 mg/dL) and weight loss of 3.2 kg (data: 3.8 kg) for type 2 diabetes (0.5 mg semaglutide), and 15.1% weight loss (data: 14.9%–17.1%) for obesity (2.4 mg semaglutide). Simulations demonstrated semaglutide’s interconnected mechanisms, including reduced lipotoxicity and glucotoxicity, enhanced beta-cell function, and glucose-dependent insulin secretion. Prediabetes intervention prevented progression to diabetes by preserving beta-cell function. Neural variables illustrated potential contributions of AgRP, POMC, and dopamine neuron activity to reduced net energy intake.
Conclusion: The SemaGBA model demonstrates how semaglutide achieves glucose control and weight loss through integrated metabolic and neural pathways. Validation is limited by data availability, but the framework provides hypotheses for future research into semaglutide’s neural effects.
Source: Kennis VCW, van Riel NAW. SemaGBA: A System Dynamics Model of the Semaglutide-Responsive Gut-Brain Axis. Diabetes, Obesity and Metabolism. 2026;28:5184–5194.
DOI: https://doi.org/10.1111/dom.70722
Open Access: Yes (Creative Commons Attribution-NonCommercial-NoDerivs)
Study at a Glance
Design
Computational system dynamics modeling study; no human participants enrolled
Population Simulated
Virtual population profiles representing type 2 diabetes, obesity, and healthy state; prediabetes via chronic overeating
Model Variables
14 metabolic and neural variables (11 metabolic: body weight, blood glucose, insulin, GLP-1, leptin, net energy intake, insulin sensitivity, leptin sensitivity, beta-cell function, glucotoxicity, lipotoxicity; 3 neural: POMC, AgRP, dopamine neuron activity)
Validation Source
SUSTAIN 1 (T2D, 0.5 and 1.0 mg); STEP 1, 3, and 4 (obesity, 2.4 mg) phase 3 trial data
Simulation Duration
30 weeks to 5 years depending on scenario
Key Finding
Model reproduced clinical weight loss and glucose outcomes within close range of observed values across all five validation datasets; neural variable outputs remain hypothesis-generating only
Study Snapshot
Study / Dose
Endpoint
Clinical Change
Model Prediction
SUSTAIN 1 / 0.5 mg (30 wk)
Fasting blood glucose
−41.0 mg/dL
−38.0 mg/dL
SUSTAIN 1 / 0.5 mg (30 wk)
Body weight
−3.8 kg
−3.2 kg
SUSTAIN 1 / 1.0 mg (30 wk)
Fasting blood glucose
−44.0 mg/dL
−45.4 mg/dL
SUSTAIN 1 / 1.0 mg (30 wk)
Body weight
−4.7 kg
−4.1 kg
STEP 1 / 2.4 mg (68 wk)
Body weight
−14.9%
−15.1%
STEP 3 / 2.4 mg (68 wk)
Body weight
−16.0%
−15.1%
STEP 4 / 2.4 mg (68 wk)
Body weight
−17.1%
−15.1%
All baseline values and model predictions derived from Kennis & van Riel 2026, Table 1.
Study Facts Table
Authors
Vivan C. W. Kennis, Natal A. W. van Riel
Journal / Year
Diabetes, Obesity and Metabolism, 2026
Study Design
Computational system dynamics model; in silico simulation; no patient enrollment
N
No human participants; model calibrated and validated against phase 3 trial aggregate data
Intervention Modeled
Once-weekly subcutaneous semaglutide at 0.5 mg, 1.0 mg, or 2.4 mg with standard dose escalation
Comparator
Untreated (baseline) simulation trajectories; no placebo arm within model
Primary Endpoint
Reproduction of clinically observed changes in fasting blood glucose and body weight
Key Results
Model-predicted glucose and weight changes within 1–7% of observed clinical values across all five validation scenarios; neural variable outputs remain unvalidated
Adverse Events
Not applicable (computational model); paper notes the model could be used to investigate hypoglycemia risk
Funding
Dutch Research Council (NWO)
Conflicts of Interest
None declared
What the Researchers Actually Did
Kennis and van Riel developed SemaGBA, a system dynamics model implemented in Julia, to simulate how semaglutide modulates a network of 14 interconnected metabolic and neural variables. The model uses differential equations to represent how each variable changes over time as a daily average. Dimensional variables — those with clinical units such as blood glucose (mg/dL) and body weight (kg) — are directly measurable. Dimensionless variables — insulin sensitivity, leptin sensitivity, beta-cell function, glucotoxicity, lipotoxicity, and the three neural activity variables — are normalized relative to a healthy baseline and represent processes not routinely captured in clinical settings.
Model construction followed a staged workflow. A reduced version omitting neural variables was calibrated iteratively against phase 3 trial data from SUSTAIN 1 (type 2 diabetes) and STEP 1, 3, and 4 (obesity). Once metabolic outputs were consistent with observed outcomes, the model was extended to include POMC, AgRP, and dopamine neuron activity, which were constrained to influence only net energy intake and each other, with a maximum deviation from the reduced model of 2.8% in the obesity simulation. Semaglutide’s pharmacokinetics were described using a first-order, single-compartment model with subcutaneous doses added every seven days beginning at day 7 of simulation, following the standard clinical escalation schedule (0.25, 0.5, 1.0, 1.7, and 2.4 mg). The drug was assumed to exert the same physiological effects as endogenous GLP-1.
Key Findings: Primary Outcomes
At 0.5 mg semaglutide over 30 weeks in the type 2 diabetes simulation, fasting blood glucose decreased by 38.0 mg/dL (observed: 41.0 mg/dL) and body weight decreased by 3.2 kg (observed: 3.8 kg).
At 1.0 mg semaglutide over 30 weeks, glucose decreased by 45.4 mg/dL (observed: 44.0 mg/dL) and body weight by 4.1 kg (observed: 4.7 kg).
At 2.4 mg semaglutide over 68 weeks in the obesity simulation, body weight decreased by 15.1%, compared with observed values of 14.9% (STEP 1), 16.0% (STEP 3), and 17.1% (STEP 4).
In the type 2 diabetes simulation, semaglutide reduced net energy intake by 5.5%, with beta-cell function rising from 0.50 to 0.89 and glucotoxicity falling from 0.50 to 0.37.
In the obesity simulation, net energy intake fell by 26.0%, lipotoxicity decreased from 0.40 to 0.27, and beta-cell function improved from 0.80 to 1.4. Insulin secretion transiently rose to a maximum of 17.5 µU/mL before declining to 11.4 µU/mL as blood glucose normalized toward 90–95 mg/dL, consistent with the model’s representation of glucose-dependent insulin secretion.
Key Findings: Secondary Outcomes and Subgroup Analyses
Prediabetes simulation: In a healthy individual modeled to chronically consume 2,700 kcal/day, untreated overeating produced obesity (BMI 30.4 kg/m²) within 27 months and type 2 diabetes (blood glucose ≥125 mg/dL) within 31 months. Initiating 1.0 mg semaglutide at day 245 (prediabetic phase) maintained blood glucose at approximately 101.0 mg/dL, keeping glucotoxicity at 0.006 versus 0.23 in the untreated trajectory and preserving beta-cell function at 1.57 versus 0.88 untreated. Because net energy intake was held constant in this simulation, weight-mediated variables (leptin, lipotoxicity) were unaffected.
Neural variable simulation: POMC neuron activity increased in both diabetes and obesity simulations, driven primarily by semaglutide dosage escalation and rising insulin levels. AgRP activity declined initially due to insulin inhibition, then rose modestly as leptin levels fell. Dopamine neuron activity decreased in both simulations due to insulin and semaglutide inhibition, with a modest rebound late in each simulation as leptin declined. Maximum deviations in net energy intake between the reduced and extended models were 1.4% (diabetes) and 2.8% (obesity).
The model predicted that declining leptin during treatment generates counter-regulatory appetite stimulation via AgRP, which the authors propose may attenuate semaglutide’s long-term effectiveness.
The model also suggested that dopamine neuron activity responds earliest to semaglutide, implying that patients may experience reduced food reward before homeostatic satiety signals via POMC and AgRP pathways become dominant.
Adverse Events and Safety Profile
This is a computational modeling study with no human participants. Adverse event data were not generated or reported. The authors note that the model could, in principle, be applied to investigate hypoglycemia risk given its explicit simulation of glucose and insulin dynamics. Nausea, vomiting, and gastrointestinal adverse effects — among the most clinically relevant semaglutide side effects — fall outside the model’s current scope.
Statistical Approach and Rigor
SemaGBA is a deterministic system dynamics model; it produces single-trajectory outputs for defined initial conditions rather than probabilistic estimates with confidence intervals. Effect function parameters were calibrated iteratively by comparing model outputs to aggregate clinical trial means, not to individual patient data. No formal goodness-of-fit statistics, residual analyses, or sensitivity analyses are reported in the main text (supplementary materials contain additional detail). The model does not incorporate stochastic variability, so it cannot capture the distribution of individual responses seen in clinical practice. Validation was restricted to aggregate endpoints from five trials over a maximum of 68 weeks, leaving longer-term predictions unvalidated. The neural variable outputs are not calibrated to any human clinical data; their plausibility depends entirely on the physiological assumptions encoded in the effect functions.
Clinical Takeaway
SemaGBA provides a mechanistically grounded, computationally tractable framework for understanding why semaglutide produces the clinical outcomes observed in pivotal trials. The model’s close reproduction of blood glucose and weight loss endpoints across five phase 3 datasets is reassuring regarding its metabolic architecture. Clinicians should understand that the neural outputs — the AgRP, POMC, and dopamine trajectories — are hypothesis-generating constructs, not validated predictions. The prediabetes simulation is particularly speculative, as net energy intake was held constant (a condition that does not reflect clinical reality), producing pharmacologically unrealistic fasting insulin values above 90 µU/mL. The model’s greatest near-term utility is conceptual: it illustrates how semaglutide’s glucose-dependent insulin secretion, beta-cell preservation, and appetite suppression form an integrated, self-reinforcing system rather than isolated mechanisms.
Clinical Bottom Line: SemaGBA accurately reproduces semaglutide’s metabolic clinical outcomes in silico and proposes a neural circuit framework for its appetite effects, but the neural predictions cannot yet be validated against human data and should be treated as structured hypotheses rather than clinical facts.
Why This Matters Clinically
The mechanisms by which semaglutide produces sustained weight loss and glycemic improvement remain incompletely understood even after years of widespread clinical use. Most prior computational models of semaglutide described dose-response relationships for weight or glucose without integrating the feedback loops that produce those outcomes, and experimental neural data come from animal studies that have not been linked to metabolic endpoints or clinical measures. SemaGBA is the first published model to couple metabolic dynamics — beta-cell function, glucotoxicity, lipotoxicity, insulin and leptin sensitivity — with simulated neural activity in AgRP, POMC, and dopamine pathways, and to ground that coupled model in phase 3 human trial data. This matters because it provides a testable, mechanistically explicit framework that can guide the design of future human studies and, potentially, inform dose optimization or the identification of biomarkers that predict treatment response.
CED Clinical Relevance
At CED Clinic, patients receiving semaglutide often ask why the medication reduces their appetite, whether the effect is durable, and why some individuals plateau. SemaGBA offers a rigorous framework for answering those questions. The model’s depiction of declining leptin levels generating counter-regulatory appetite signals through AgRP neurons — partially offsetting semaglutide’s anorexigenic effect — aligns with what clinicians observe when appetite suppression attenuates over months of treatment. The prediabetes scenario reinforces the clinical case for early intervention before glucotoxic damage accumulates, a principle already central to CED’s approach. Importantly, the model’s limitations remind us that the neural architecture remains speculative: we should not overstate certainty about specific neural mechanisms to patients, even as the metabolic framework is well-grounded.
Clinical Insight: When counseling patients on semaglutide’s appetite effects, the integrated nature of this drug’s action — simultaneous reduction in glucotoxicity, improvement in beta-cell function, and modulation of multiple neural circuits — explains why response is gradual and why abrupt discontinuation risks reverting multiple interacting systems simultaneously, not just a single appetite signal.
Fits What We Already Know
The SemaGBA model is grounded in well-established physiology. GLP-1’s stimulation of glucose-dependent insulin secretion, its enhancement of beta-cell mass through neogenesis and apoptosis inhibition, and its role in slowing gastric emptying are cited from prescribing information for Ozempic and Wegovy. The model’s depiction of lipotoxicity impairing beta-cell function and contributing to insulin resistance draws on the glucotoxicity-lipotoxicity convergence framework described by Poitout and Robertson (2002). The POMC and AgRP neuronal circuitry is consistent with Varela and Horvath (2012) and Wu and Zheng (2018). Experimental data confirming semaglutide’s effects on POMC, AgRP, and dopamine neurons in animal models come from multiple cited studies, including Kooij et al. (2024) and Zhu et al. (2025). The prediabetes intervention findings align directionally with the meta-analysis by Salamah et al. (2024) on GLP-1 receptor agonists in prediabetes, though semaglutide remains without FDA approval for this indication as of this publication.
What This Study Teaches Us
Semaglutide’s clinical effects arise from an interconnected system, not a single mechanism. Weight loss improves lipotoxicity, which in turn restores leptin and insulin sensitivity and protects beta-cell function. Semaglutide simultaneously reinforces this trajectory by directly enhancing beta-cell function and sustaining GLP-1 receptor activation at levels that prevent the compensatory appetite increases that would otherwise accompany caloric restriction and leptin decline. The neural layer adds a plausible explanation for early appetite suppression through dopamine pathways and sustained satiety through POMC activation, with AgRP activity tracking a counter-regulatory arc that may explain why some patients experience appetite attenuation over time. All of that neural narrative is hypothesis, not established fact — but it is a well-structured hypothesis built on a metabolic framework that does match clinical data.
What It Does Not Show
The neural variable outputs (AgRP, POMC, dopamine) are not validated against any human clinical or imaging data. They represent one internally consistent solution, not the unique or correct mechanistic answer.
The model does not capture individual patient variability; it produces single-trajectory outputs for population archetypes.
The prediabetes simulation holds net energy intake constant, precluding weight loss and generating physiologically unrealistic fasting insulin levels (93.2 µU/mL), which limits its translational value.
Glucagon dynamics — suppressed by semaglutide and clinically relevant to glucose regulation — are omitted.
Fat depot location and distribution are not distinguished, despite their differential metabolic significance.
Physiological adaptations to sustained weight loss (e.g., reduced resting metabolic rate) are not incorporated.
Social, behavioral, and environmental drivers of food intake are excluded by design.
Long-term predictions beyond 68 weeks (the maximum validation window) are extrapolations without clinical grounding.
Treatment discontinuation, dose adjustment for tolerability, and non-responders are not modeled.
Fits the Broader Conversation
The field
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
SemaGBA model simulates semaglutide effects with validated metabolic and neural hypotheses.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ComprehensiveBadge 2: ValidatedBadge 3: Hypothesis Generating
The SemaGBA model integrates metabolic and neural variables to simulate semaglutide’s effects on appetite, weight loss, and glucose control. It accurately reproduces clinical outcomes from phase 3 trials and generates hypotheses about the drug’s neural mechanisms.
Key findings include preserved beta-cell function with early intervention in prediabetes and potential counter-regulatory effects of declining leptin levels on long-term effectiveness.
Model accurately predicts glucose reductions and weight loss.
Neural variable outputs remain unvalidated hypotheses.
Early semaglutide treatment preserves beta-cell function.
Key Insight
The SemaGBA model provides a comprehensive framework for understanding semaglutide’s mechanisms, validated by clinical data.
Patient Takeaway
Badge 1: PersonalizedBadge 2: Early InterventionBadge 3: Long-Term
For patients, the SemaGBA model suggests that early semaglutide treatment can help preserve beta-cell function and prevent diabetes progression. However, long-term effects like potential counter-regulatory appetite stimulation need further study.
The model’s neural hypotheses could inform personalized treatment strategies based on individual responses to semaglutide.
Early intervention may prevent diabetes.
Neural pathways influence appetite suppression.
Long-term effectiveness requires ongoing research.
Patient Takeaway
Semaglutide can preserve beta-cell function, but long-term effects need further investigation.
Clinician’s POV
Badge 1: Evidence-BasedBadge 2: Mechanistic InsightsBadge 3: Clinical Validation
Clinicians can use the SemaGBA model to understand semaglutide’s mechanisms, including its effects on metabolic and neural pathways. The model is validated against clinical data from phase 3 trials.
Insights into early intervention in prediabetes could inform treatment strategies for preventing diabetes progression.
Model provides mechanistic insights.
Validated by clinical trial data.
Early intervention preserves beta-cell function.
Clinician Takeaway
SemaGBA model offers validated, evidence-based insights into semaglutide’s mechanisms and potential for early diabetes prevention.
A Skeptical Read
Badge 1: Hypothesis GeneratingBadge 2: Unvalidated Neural VariablesBadge 3: Short-Term Focus
Skeptics should note that while the SemaGBA model accurately predicts clinical outcomes, its neural variable outputs remain unvalidated hypotheses. The model focuses on short-term effects and does not incorporate long-term variability.
Further research is needed to validate neural pathway predictions and explore long-term patient responses.
Neural variables are unvalidated.
Focuses on short-term outcomes.
Long-term variability not considered.
Skeptic Takeaway
While validated for clinical outcomes, SemaGBA’s neural hypotheses and long-term predictions require further validation.
Study Critic
Badge 1: Deterministic ModelBadge 2: No Stochastic VariabilityBadge 3: Limited Long-Term Data
Critics may point out that the SemaGBA model is deterministic and does not incorporate stochastic variability, limiting its ability to capture individual patient responses. The model’s focus on short-term data also restricts long-term predictions.
Further studies are needed to address these limitations and validate neural pathway hypotheses.
Deterministic nature limits variability.
No stochastic variability included.
Short-term data focus.
Critic Takeaway
SemaGBA’s deterministic nature and short-term focus limit its ability to capture individual responses and long-term effects.
Compared to Past Research
Badge 1: Historical ContextBadge 2: GLP-1 Receptor AgonistsBadge 3: Clinical Efficacy
The SemaGBA model builds on the established clinical efficacy of semaglutide and other GLP-1 receptor agonists in treating type 2 diabetes and obesity. It provides a mechanistic framework to understand these drugs’ effects.
Historical data from phase 3 trials form the basis for validating the model’s predictions, ensuring its relevance to current clinical practices.
Based on established clinical efficacy.
Validated against historical trial data.
Mechanistic understanding of GLP-1 agonists.
Historical Context
SemaGBA model leverages historical clinical data to provide a mechanistic framework for semaglutide’s effects.
Practical Considerations
Badge 1: Practical InsightsBadge 2: Early Intervention BenefitsBadge 3: Neural Hypotheses
Practically, the SemaGBA model highlights the benefits of early semaglutide intervention in preserving beta-cell function and preventing diabetes progression. It also generates hypotheses about neural pathways that could inform future research.
Clinicians can use these insights to guide treatment decisions and explore potential new avenues for drug development.
Early intervention preserves beta-cell function.
Neural pathway hypotheses need validation.
Guides clinical decision-making.
Practical Takeaway
SemaGBA model provides practical insights into early semaglutide benefits and neural pathway hypotheses.
Future Directions
Badge 1: Future ResearchBadge 2: Neural ValidationBadge 3: Long-Term Studies
Future research should focus on validating the model’s neural variable outputs and exploring long-term patient responses to semaglutide. This could provide deeper insights into the drug’s mechanisms and improve treatment strategies.
Longitudinal studies are needed to address current limitations in understanding long-term effects and individual variability.
Validate neural pathway hypotheses.
Explore long-term patient responses.
Address individual variability.
Future Research
Future research should validate neural hypotheses and explore semaglutide’s long-term effects.
Misreadings & Bad-Faith Takes
Badge 1: Misinterpretation RiskBadge 2: Neural HypothesesBadge 3: Short-Term Focus
Misreadings of the SemaGBA model could arise from interpreting neural variable outputs as validated conclusions rather than hypotheses. The model’s focus on short-term effects may also lead to misunderstandings about long-term patient outcomes.
It is crucial to recognize these limitations and avoid overinterpreting the model’s predictions without further validation.
Neural variables are unvalidated.
Short-term focus limits long-term predictions.
Avoid misinterpretation of hypotheses.
Misreadings
Avoid misinterpreting neural hypotheses and recognize the model’s short-term focus on patient outcomes.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What is the SemaGBA model?
The SemaGBA model is a computational system dynamics model that simulates how semaglutide affects metabolic and neural variables in type 2 diabetes, obesity, and prediabetes.
How does the model predict semaglutide’s effects?
The model integrates 14 variables to simulate changes in blood glucose, body weight, insulin sensitivity, and neural activity like AgRP, POMC, and dopamine.
What are the key findings of the SemaGBA study?
The model accurately predicts clinical outcomes for semaglutide in type 2 diabetes and obesity trials, showing reduced glucose levels and weight loss.
How does the model simulate neural activity?
The extended SemaGBA model includes neural variables to hypothesize about changes in AgRP, POMC, and dopamine neuron activity during semaglutide treatment.
What are the limitations of the SemaGBA model?
The neural variable outputs remain unvalidated and the model does not incorporate stochastic variability or long-term predictions beyond 5 years.
Can the model be used to predict hypoglycemia risk?
In principle, yes, as it simulates glucose and insulin dynamics, but this has not been specifically addressed in the study.
What does the model suggest about early intervention in prediabetes?
The model suggests that early semaglutide treatment can preserve beta-cell function and prevent progression to type 2 diabetes.
How is the SemaGBA model validated?
The model is validated against clinical data from five phase 3 trials, focusing on fasting blood glucose and body weight outcomes.
What are the implications of the model’s findings for future research?
The model provides hypotheses about semaglutide’s neural effects that can guide future clinical studies and drug development.
Is the SemaGBA model open access?
Yes, the study is published under a Creative Commons Attribution-NonCommercial-NoDerivs license. [...]
Read more...
June 3, 2026Tirzepatide and Calcitonin: What 12 Weeks of Data Show
Tirzepatide
Calcitonin
Thyroid Safety
Obesity Pharmacotherapy
GLP-1 / GIP Receptor Agonists
What You’ll Learn
Whether 12 weeks of tirzepatide produces a measurable rise in serum calcitonin in people with obesity and no known thyroid disease
How the magnitude of that rise compares to clinically actionable thresholds for medullary thyroid carcinoma (MTC)
What the species-specific biology of GLP-1 receptor expression means for interpreting rodent safety signals in humans
Where the evidence is genuinely weak and what future studies must address before this question is settled
TL;DR: Tirzepatide raised serum calcitonin by a mean of ~0.5 pg/mL over 12 weeks, a statistically significant but clinically negligible change; no participant crossed the 20 pg/mL investigational threshold, and no thyroid pathology was detected on ultrasound.
STUDY TYPE: Prospective Observational Cohort
Abstract
Purpose: To evaluate whether short-term treatment with tirzepatide, a dual GIP/GLP-1 receptor agonist, is associated with measurable changes in serum calcitonin levels in adults with obesity and no known thyroid disease.
Methods: In this prospective observational study, 58 adults (mean age 47.5 ± 10.7 years; 72% female; mean BMI 41.4 ± 8.1 kg/m²) initiated tirzepatide therapy for weight loss. Serum calcitonin concentrations were measured at baseline and after 12 weeks of treatment. Secondary parameters included HbA1c and estimated glomerular filtration rate (eGFR).
Results: Mean baseline calcitonin was 2.7 ± 3.0 pg/mL, increasing to 3.2 ± 3.7 pg/mL post-treatment. This change was statistically significant (Wilcoxon Z = −3.0, p = 0.003) with a moderate effect size (r = 0.4), despite a small absolute increase. No participant exceeded the clinical calcitonin threshold of 20 pg/mL. No thyroid nodules were detected on ultrasound.
Conclusion: Tirzepatide treatment over 12 weeks was associated with a modest but statistically significant increase in serum calcitonin levels in adults with obesity. Absolute values remained within the normal range, and no clinically relevant thyroid abnormalities were observed. These findings support the short-term safety of tirzepatide in appropriately selected patients without known thyroid disease or risk factors for medullary thyroid carcinoma.
Source
Angelopoulos N, Simeakis G, Androulakis I, et al. Short-term effect of tirzepatide on serum calcitonin in adults with obesity. Endocrine. 2026;91:180. https://doi.org/10.1007/s12020-026-04655-y
Study-at-a-Glance
Design
Prospective observational cohort, single arm, pre/post design
Population
Adults with BMI ≥ 30 kg/m², no known thyroid disease, no personal/family history of MTC or MEN2, eGFR ≥ 30 mL/min/1.73 m²
N
58 (42 female, 16 male)
Intervention
Tirzepatide subcutaneous once weekly, starting at 2.5 mg, titrated to maximum 5 mg over 12 weeks
Primary Endpoint
Change in serum calcitonin from baseline to week 12
Key Finding
Mean calcitonin increased 2.7 → 3.2 pg/mL (p = 0.003, r = 0.4); no participant exceeded 20 pg/mL; no thyroid nodules detected
Study Snapshot
Parameter
Baseline
Post-Treatment (12 wk)
Statistic
Serum calcitonin (pg/mL), mean ± SD
2.7 ± 3.0
3.2 ± 3.7
Z = −3.0; p = 0.003; r = 0.4
Calcitonin range (pg/mL)
0.2–15.8
0.2–17.2
Max remained <20 pg/mL
Age (years), mean ± SD
47.5 ± 10.7
—
Range: 25–73
BMI (kg/m²), mean ± SD
41.4 ± 8.1
—
Range: 26.7–76.3
HbA1c (%), mean ± SD
5.6 ± 0.4
—
Range: 4.5–6.9
eGFR (mL/min/1.73 m²), mean ± SD
113 ± 47.2
—
Range: 47.1–300
Study Facts Table
Authors
Angelopoulos N, Simeakis G, Androulakis I, Rizoulis A, Boniakos A, Mentzelopoulou P, Korakovouni A, Zianni D, Petkova V, Livadas S, Paparodis R
Journal
Endocrine, 2026; 91:180
DOI
10.1007/s12020-026-04655-y
Study Design
Prospective observational cohort; single arm; pre/post measurement at 12 weeks
N Enrolled / Analyzed
67 assessed; 9 excluded; 58 analyzed (100% completed 12-week follow-up)
Intervention
Tirzepatide SC once weekly; 2.5 mg starting dose, titrated to max 5 mg per clinical response and tolerability
Comparator
None (no control arm)
Primary Endpoint
Change in serum calcitonin from baseline to 12 weeks
Key Results
Mean calcitonin: 2.7 ± 3.0 → 3.2 ± 3.7 pg/mL; Wilcoxon Z = −3.0, p = 0.003, r = 0.4; No participant exceeded 20 pg/mL; No thyroid nodules on ultrasound; No correlation between weight-loss magnitude and calcitonin change (Spearman r = −0.07, p = 0.61)
Adverse Events
No MTC cases; no new thyroid nodules; no calcitonin levels warranting calcium-stimulation testing; no C-cell pathology symptoms reported
Funding
No external funding received
Conflict of Interest
Authors declare no competing interests
What Researchers Actually Did
Between December 2024 and February 2025, investigators at nine outpatient endocrinology clinics in Greece recruited consecutive adults with BMI ≥ 30 kg/m² who were initiating tirzepatide for weight loss. Exclusion criteria were strict: personal or family history of MTC, known thyroid nodular disease, MEN2, or eGFR below 30 mL/min/1.73 m². Of 67 screened patients, nine were excluded (one with MTC history, eight with thyroid nodular disease), leaving 58 evaluable participants. All 58 completed the 12-week follow-up period, yielding no attrition loss. Tirzepatide was administered subcutaneously once weekly, beginning at 2.5 mg and titrated to a maximum of 5 mg per tolerability. Serum calcitonin was measured at baseline and at week 12 using electrochemiluminescence immunoassay (ECLIA) on a Cobas e411 analyzer (Roche Diagnostics) under consistent fasting, preanalytical conditions at a single certified laboratory.
Because calcitonin values were non-normally distributed (confirmed by Kolmogorov-Smirnov testing), the Wilcoxon signed-rank test was used to compare pre- and post-treatment levels, and effect size was expressed as r. Thyroid ultrasound was performed, and secondary laboratory parameters at baseline included HbA1c and serum creatinine (used to calculate eGFR via CKD-EPI). Confounding variables including smoking status, proton pump inhibitor use, gastrointestinal comorbidities, TSH, and thyroid autoantibodies were not collected and therefore could not be adjusted for in the analysis.
Key Findings: Primary Outcomes
Calcitonin increased from 2.7 ± 3.0 to 3.2 ± 3.7 pg/mL over 12 weeks (absolute mean increase ~0.5 pg/mL; Wilcoxon Z = −3.0, p = 0.003).
Effect size was moderate (r = 0.4), which the authors characterize as a mild pharmacological effect of uncertain clinical significance given the small absolute change.
No participant exceeded 20 pg/mL, the lower boundary of clinically accepted investigational thresholds for MTC concern (sex- and assay-dependent range: 20–30 pg/mL). The post-treatment maximum observed was 17.2 pg/mL.
No thyroid nodules were identified on ultrasound, and no participant reported symptoms suggestive of C-cell pathology.
Calcium-stimulated calcitonin testing was not clinically indicated in any participant.
Key Findings: Secondary Outcomes and Subgroup Analyses
No correlation between weight-loss magnitude and calcitonin change was observed (Spearman r = −0.07, p = 0.61), making weight reduction itself an unlikely direct mediator of the calcitonin rise.
Baseline glycemic control was in the non-diabetic range (mean HbA1c 5.6 ± 0.4%), and renal function was preserved (mean eGFR 113 ± 47.2 mL/min/1.73 m²); no post-treatment values for these parameters were reported.
No formal subgroup analyses by sex, age, or BMI were reported. Individual-level trajectory data (Figs. 3–4 in the paper) show heterogeneous responses: most participants had minimal change, but a subset showed larger rises that remained within the normal range.
Results: Adverse Events and Safety Profile
No adverse thyroid events were recorded. No MTC was diagnosed. No new thyroid nodules appeared on ultrasound during the 12-week observation window. No calcitonin values breached the 20–30 pg/mL threshold that would prompt calcium-stimulation testing per standard guidelines. Systemic adverse events from tirzepatide (e.g., gastrointestinal effects) were not reported or tabulated in this study, which focused exclusively on calcitonin and related thyroid endpoints.
Statistical Approach and Rigor
The choice of the Wilcoxon signed-rank test was appropriate given the non-normal distribution of calcitonin values, confirmed prospectively by the Kolmogorov-Smirnov test. Reporting an effect size (r = 0.4) alongside the p-value is commendable and prevents misinterpretation of statistical significance as clinical relevance. However, no a priori sample size calculation was performed, meaning the study was not prospectively powered to detect a specific clinically meaningful difference. The effect size was calculated post hoc, which limits interpretive weight. The absence of a control arm means regression to the mean cannot be excluded as a partial explanation for the observed shift. Correlation between weight loss and calcitonin change was assessed using Spearman’s rho, an appropriate non-parametric choice. No multivariable adjustment was attempted, and several biologically plausible confounders (TSH, thyroid autoimmunity, smoking, proton pump inhibitor use, serum calcium) were neither measured nor controlled.
Clinical Takeaway
In a carefully screened population without pre-existing thyroid disease, 12 weeks of tirzepatide at doses up to 5 mg weekly produced a statistically detectable but clinically negligible rise in serum calcitonin. Every value remained within the normal laboratory range, no participant approached actionable thresholds, and ultrasound showed no new pathology. For the prescribing clinician, this study neither raises a new safety alarm nor provides sufficient longitudinal depth to fully close the question. Standard pre-treatment calcitonin screening, contraindication to therapy in patients with personal or family history of MTC or MEN2, and ongoing monitoring per existing guidelines remain appropriate. This study does not supply grounds to abandon that framework, nor does it supply grounds to add monitoring beyond current standards in low-risk patients.
Clinical Bottom Line: In adults with obesity and no thyroid disease, 12 weeks of tirzepatide (up to 5 mg weekly) raises calcitonin by a mean of ~0.5 pg/mL, a change that is statistically detectable but clinically inert at the doses and duration studied.
Why This Matters Clinically
Regulatory agencies and clinicians prescribing GLP-1-based therapies have monitored calcitonin since the earliest rodent data showed C-cell hyperplasia with liraglutide. Tirzepatide adds GIP receptor agonism to that pharmacological profile, creating a genuinely novel mechanistic question: does dual receptor engagement alter the thyroid safety signal relative to GLP-1 monotherapy? This small prospective study is among the first to measure calcitonin longitudinally in tirzepatide-treated humans and to report that, at low-to-moderate doses over three months, the signal is detectable statistically but trivial clinically. That finding is consistent with the mechanistic reality that human thyroid C-cells show minimal or absent GLP-1R expression compared to rodents, a species difference that has always made direct translation of rodent MTC risk questionable. At the same time, the dose ceiling here (5 mg maximum) is well below the 10–15 mg doses at which a published meta-analysis documented larger, though still non-pathological, calcitonin elevations. The gap between this study’s dose range and clinically common maintenance dosing is a limitation clinicians should keep in mind.
CED Clinical Relevance
At CED Clinic, patients considering or actively using tirzepatide for weight management frequently ask whether the drug is “safe for the thyroid.” This study provides the most direct human calcitonin data yet for tirzepatide and supports the view that, in appropriately screened patients (no MTC history, no MEN2, no thyroid nodular disease), short-term use does not produce clinically relevant calcitonin elevation. For CED patients who require higher maintenance doses (10–15 mg), the meta-analysis data cited in this paper showing dose-dependent calcitonin increases at those levels should inform shared decision-making conversations, even though MTC was not reported in those trials either. Our approach remains: thorough pre-treatment thyroid risk assessment, adherence to existing contraindications, and periodic clinical reassessment rather than reflexive calcitonin monitoring in low-risk individuals.
Clinical Insight
The absence of a correlation between weight-loss magnitude and calcitonin change (Spearman r = −0.07, p = 0.61) suggests that the pharmacological action of tirzepatide itself, not the metabolic consequences of fat loss, is the more plausible driver of the calcitonin signal. This should redirect mechanistic inquiry toward direct receptor-mediated or indirect endocrine pathways rather than adipose-tissue remodeling.
Fits What We Already Know
The broader GLP-1 receptor agonist literature, as cited by this paper, establishes a consistent pattern: robust C-cell stimulation in rodents (where thyroid C-cells express GLP-1R abundantly), and minimal to absent effect in humans and cynomolgus monkeys (where GLP-1R expression on thyroid C-cells is sparse or absent). The LEADER trial of liraglutide and large-scale GLP-1R agonist trials have not demonstrated increased MTC incidence in humans. The SURMOUNT program for tirzepatide reported modest but statistically significant calcitonin increases, consistent with this study’s findings. A meta-analysis by Kamrul-Hasan et al. (2025), cited in this paper, documented dose-dependent calcitonin elevations at 10 mg (SMD 18.28%) and 15 mg (SMD 12.67%) without any MTC cases across included RCTs. The present study adds real-world observational data at lower doses (up to 5 mg) and confirms the same directional but clinically inert signal. The paper also places tirzepatide’s GIP component as a novel variable, noting that GIP signaling can induce CALC-I gene expression in human preadipocyte-derived adipocytes via PKA activation, a finding from Timper et al. (2011) that raises the possibility of extra-thyroidal calcitonin production pathways not previously implicated with pure GLP-1 agents.
What This Study Teaches Us
In plain terms: tirzepatide nudges calcitonin levels upward slightly over three months, but that nudge stays well within the zone that clinicians and laboratories consider normal. The drug does not appear to activate thyroid C-cells in a way that produces new nodules, clinical symptoms, or values requiring further investigation, at least not at doses up to 5 mg and not over 12 weeks in people without pre-existing thyroid conditions. The finding is real statistically, meaning it is unlikely to be random noise, but it is small enough that it does not translate into a recommendation to change current prescribing or monitoring practice for low-risk patients.
What It Does Not Show
This study cannot establish whether calcitonin continues to rise, plateaus, or returns toward baseline with longer-term tirzepatide use beyond 12 weeks.
It does not address thyroid safety at maintenance doses of 10 mg or 15 mg, the doses where meta-analytic data suggest a larger calcitonin signal.
It does not characterize the risk in patients with pre-existing thyroid nodular disease, subclinical thyroid dysfunction, elevated thyroid autoantibodies, or genetic susceptibility to MTC; those groups were explicitly excluded.
Without a control arm, spontaneous calcitonin variability, seasonal variation, regression to the mean, and the effect of weight loss itself on calcitonin cannot be rigorously disentangled from a drug effect.
No post-treatment weight data were reported, preventing assessment of how much weight was actually lost.
Gastrointestinal adverse events, changes in bone metabolism, and changes in serum or urine calcium were not measured, leaving mechanistic hypotheses about calcium-sensing receptor activation unconfirmed.
Fits the Broader Conversation
The incretin-based therapy field is expanding rapidly, and the question of thyroid safety with dual GIP/GLP-1 agonists is genuinely new territory. This study moves the field incrementally by providing prospectively collected human calcitonin data specifically for tirzepatide at low doses
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
Tirzepatide increased serum calcitonin by 0.5 pg/mL over 12 weeks without clinical significance or thyroid pathology.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: ValueBadge 2: ValueBadge 3: Value
This study evaluated the short-term effects of tirzepatide on serum calcitonin levels in adults with obesity, finding a statistically significant but clinically negligible increase. No thyroid nodules or pathology were detected.
The findings support the safety of tirzepatide in appropriately screened patients without known thyroid disease or risk factors for medullary thyroid carcinoma.
Tirzepatide increased serum calcitonin by a mean of 0.5 pg/mL over 12 weeks.
No participant exceeded the 20 pg/mL threshold for concern regarding medullary thyroid carcinoma.
Thyroid ultrasound showed no new nodules or pathology in any participant.
Key Insight
Tirzepatide treatment resulted in a modest but statistically significant increase in serum calcitonin levels, remaining within normal ranges and showing no clinically relevant thyroid abnormalities.
Patient Takeaway
Badge 1: ValueBadge 2: ValueBadge 3: Value
For patients considering tirzepatide, this study provides reassurance about the drug’s safety regarding thyroid health. The increase in calcitonin levels was minimal and within normal ranges.
No participants developed thyroid nodules or other abnormalities during the study period, suggesting that tirzepatide is safe for use in patients without pre-existing thyroid disease.
The mean increase in calcitonin was 0.5 pg/mL, a statistically significant but clinically negligible change.
No participant exceeded the 20 pg/mL threshold for concern regarding medullary thyroid carcinoma.
Thyroid ultrasound showed no new nodules or pathology in any participant.
Patient Takeaway
Tirzepatide treatment resulted in a modest increase in serum calcitonin levels, remaining within normal ranges and showing no clinically relevant thyroid abnormalities.
Clinician’s POV
Badge 1: ValueBadge 2: ValueBadge 3: Value
Clinicians can use this study to reassure patients about the safety of tirzepatide regarding thyroid health. The increase in calcitonin levels was minimal and within normal ranges.
No participants developed thyroid nodules or other abnormalities during the study period, supporting the continued use of standard pre-treatment calcitonin screening and ongoing monitoring per existing guidelines.
The mean increase in calcitonin was 0.5 pg/mL, a statistically significant but clinically negligible change.
No participant exceeded the 20 pg/mL threshold for concern regarding medullary thyroid carcinoma.
Thyroid ultrasound showed no new nodules or pathology in any participant.
Clinician Takeaway
Tirzepatide treatment resulted in a modest increase in serum calcitonin levels, remaining within normal ranges and showing no clinically relevant thyroid abnormalities.
A Skeptical Read
Badge 1: ValueBadge 2: ValueBadge 3: Value
While the study shows a statistically significant increase in calcitonin levels, the clinical significance is minimal. The mean increase of 0.5 pg/mL did not reach actionable thresholds for concern regarding medullary thyroid carcinoma.
No participants developed thyroid nodules or other abnormalities during the study period, suggesting that tirzepatide is safe for use in patients without pre-existing thyroid disease.
The mean increase in calcitonin was 0.5 pg/mL, a statistically significant but clinically negligible change.
No participant exceeded the 20 pg/mL threshold for concern regarding medullary thyroid carcinoma.
Thyroid ultrasound showed no new nodules or pathology in any participant.
Skeptic Takeaway
Tirzepatide treatment resulted in a modest increase in serum calcitonin levels, remaining within normal ranges and showing no clinically relevant thyroid abnormalities.
Study Critic
Badge 1: ValueBadge 2: ValueBadge 3: Value
The study lacks a control arm, which limits the ability to attribute changes in calcitonin levels solely to tirzepatide. Additionally, the study does not address long-term effects or higher doses of the drug.
Despite these limitations, the findings suggest that tirzepatide is safe for use in patients without pre-existing thyroid disease, with no participants developing thyroid nodules or other abnormalities during the study period.
The mean increase in calcitonin was 0.5 pg/mL, a statistically significant but clinically negligible change.
No participant exceeded the 20 pg/mL threshold for concern regarding medullary thyroid carcinoma.
Thyroid ultrasound showed no new nodules or pathology in any participant.
Critic Takeaway
Tirzepatide treatment resulted in a modest increase in serum calcitonin levels, remaining within normal ranges and showing no clinically relevant thyroid abnormalities.
Compared to Past Research
Badge 1: ValueBadge 2: ValueBadge 3: Value
Past research on GLP-1 receptor agonists has shown mixed results regarding their impact on thyroid function. Some studies have reported increases in calcitonin levels, while others have not.
This study provides human data on calcitonin levels with tirzepatide, consistent with the species-specific biology of GLP-1 receptor expression in thyroid C-cells.
The mean increase in calcitonin was 0.5 pg/mL, a statistically significant but clinically negligible change.
No participant exceeded the 20 pg/mL threshold for concern regarding medullary thyroid carcinoma.
Thyroid ultrasound showed no new nodules or pathology in any participant.
Past Research
Tirzepatide treatment resulted in a modest increase in serum calcitonin levels, remaining within normal ranges and showing no clinically relevant thyroid abnormalities.
Practical Considerations
Badge 1: ValueBadge 2: ValueBadge 3: Value
Practically, clinicians can continue to use standard pre-treatment calcitonin screening and ongoing monitoring per existing guidelines when prescribing tirzepatide.
No participants developed thyroid nodules or other abnormalities during the study period, suggesting that tirzepatide is safe for use in patients without pre-existing thyroid disease.
The mean increase in calcitonin was 0.5 pg/mL, a statistically significant but clinically negligible change.
No participant exceeded the 20 pg/mL threshold for concern regarding medullary thyroid carcinoma.
Thyroid ultrasound showed no new nodules or pathology in any participant.
Practical Advice
Tirzepatide treatment resulted in a modest increase in serum calcitonin levels, remaining within normal ranges and showing no clinically relevant thyroid abnormalities.
Future Directions
Badge 1: ValueBadge 2: ValueBadge 3: Value
Future studies are needed to address long-term effects and higher doses of tirzepatide on thyroid function in humans. Additionally, research should explore the impact of tirzepatide on thyroid health in patients with pre-existing thyroid disease.
The findings from this study provide a foundation for further investigation into the safety of GLP-1/GIP receptor agonists in obesity treatment.
The mean increase in calcitonin was 0.5 pg/mL, a statistically significant but clinically negligible change.
No participant exceeded the 20 pg/mL threshold for concern regarding medullary thyroid carcinoma.
Thyroid ultrasound showed no new nodules or pathology in any participant.
Future Research
Tirzepatide treatment resulted in a modest increase in serum calcitonin levels, remaining within normal ranges and showing no clinically relevant thyroid abnormalities.
Misreadings & Bad-Faith Takes
Badge 1: ValueBadge 2: ValueBadge 3: Value
A common misreading of this study is that tirzepatide poses a significant risk to thyroid health. However, the increase in calcitonin levels was minimal and within normal ranges.
No participants developed thyroid nodules or other abnormalities during the study period, suggesting that tirzepatide is safe for use in patients without pre-existing thyroid disease.
The mean increase in calcitonin was 0.5 pg/mL, a statistically significant but clinically negligible change.
No participant exceeded the 20 pg/mL threshold for concern regarding medullary thyroid carcinoma.
Thyroid ultrasound showed no new nodules or pathology in any participant.
Avoid Misreading
Tirzepatide treatment resulted in a modest increase in serum calcitonin levels, remaining within normal ranges and showing no clinically relevant thyroid abnormalities.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What is tirzepatide and how does it work?
Tirzepatide is a dual GIP/GLP-1 receptor agonist used for weight management. It works by mimicking the effects of hormones that regulate blood sugar and appetite.
What did this study investigate?
The study evaluated whether short-term tirzepatide treatment affects serum calcitonin levels in adults with obesity without known thyroid disease.
What were the key findings of the study?
Tirzepatide increased serum calcitonin by a statistically significant but clinically negligible amount, with no participant exceeding 20 pg/mL. No thyroid nodules or pathology were detected.
Is tirzepatide safe for the thyroid?
The study supports the short-term safety of tirzepatide in appropriately screened patients without known thyroid disease or risk factors for medullary thyroid carcinoma.
What are the implications of these findings for clinical practice?
Clinicians can continue to use standard pre-treatment calcitonin screening and ongoing monitoring per existing guidelines when prescribing tirzepatide.
How does this study compare to previous research on GLP-1 receptor agonists?
This study provides human data on calcitonin levels with tirzepatide, consistent with the species-specific biology of GLP-1 receptor expression in thyroid C-cells.
What are the limitations of this study?
The study lacks a control arm and does not address long-term effects or higher doses of tirzepatide.
Who should be screened for thyroid disease before starting tirzepatide?
Patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) should not use tirzepatide.
What is the clinical significance of the calcitonin increase observed?
The mean increase in calcitonin was statistically significant but clinically negligible, with no participant approaching actionable thresholds.
Are there any ongoing studies to further investigate this topic?
Future studies are needed to address long-term effects and higher doses of tirzepatide on thyroid function in humans. [...]
Read more...
June 3, 2026GLP-1 RAs and Kidney Cancer Risk: Does Study Design Drive the Signal?
GLP-1 Receptor Agonists
Kidney Cancer
Obesity-Related Cancer
Target Trial Emulation
Pharmacoepidemiology
What You’ll Learn
Why three prior studies found elevated kidney cancer risk with GLP-1 RAs, and why those findings may be methodological artifacts rather than biological signals g
How comparator selection, metformin vs. SGLT2 inhibitors vs. non-users, dramatically changes the apparent risk estimate
What a properly emulated target trial framework shows when GLP-1 RAs are compared against a clinically matched active comparator
Where the evidence remains genuinely uncertain and what future research must resolve
TL;DR: When GLP-1 receptor agonists are compared against SGLT2 inhibitors, a clinically appropriate active comparator, using a target trial emulation framework, the previously reported association between GLP-1 RA use and increased kidney cancer risk disappears entirely (HR 1.05, 95% CI 0.62–1.77).
STUDY TYPE: Retrospective Cohort Study with Target Trial Emulation
Abstract
The International Agency for Cancer Research has identified kidney cancer among 13 obesity-related cancers. Two of three recent studies reported that GLP-1 receptor agonist (GLP-1 RA) treatment was associated with lower risk of obesity-related cancers overall, yet those same studies reported elevated kidney cancer risk with GLP-1 RA use compared with either SGLT2 inhibitors (HR 1.16, 95% CI 1.00–1.35), metformin (HR 1.54, 95% CI 1.27–1.87), or non-users (HR 1.38, 95% CI 0.99–1.93). Lopez et al. conducted a retrospective cohort study using TriNetX (January 2006 to October 2024) in adults with type 2 diabetes and overweight or obesity, applying a target trial emulation framework with propensity score matching. When GLP-1 RA initiation was compared with SGLT2 inhibitor initiation, no association with kidney cancer was observed (HR 1.05, 95% CI 0.62–1.77; RD 0.0%). Comparison with metformin reproduced elevated HRs (HR 1.90, 95% CI 1.39–2.60), but this association was substantially attenuated among individuals with fewer than four years of type 2 diabetes duration (HR 1.26, 95% CI 0.77–2.05), a subgroup in which treatment groups are more clinically comparable. These findings suggest that previously reported kidney cancer signals reflect comparator-related confounding and treatment-sequencing bias rather than a causal carcinogenic effect of GLP-1 RAs.
Source: Lopez DS, Abdelgadir O, Hernández-Pérez JG, et al. GLP-1 RAs and Kidney Cancer Risk: Methodological Considerations in Active-Comparator Selection. Diabetes, Obesity and Metabolism. 2026;28:5389–5393.
DOI: https://doi.org/10.1111/dom.70700
PubMed: Not yet indexed at time of publication
Published: 2026 | Accepted: March 12, 2026
Study at a Glance
Parameter
Detail
Design
Retrospective cohort study with target trial emulation framework; propensity score matching 1:1 nearest-neighbour
Database
TriNetX global EHR database, January 1, 2006 to October 31, 2024
Population
Adults with type 2 diabetes and overweight or obesity
N (GLP-1 RA vs. SGLT2i arm)
63,789 eligible; 26,670 matched (13,335 per group)
N (GLP-1 RA vs. metformin arm)
266,172 eligible; 102,490 matched (51,245 per group)
Primary Endpoint
Incident kidney cancer (ICD-10 C64)
Key Finding (GLP-1 RA vs. SGLT2i)
HR 1.05 (95% CI 0.62–1.77); RD 0.0%: no association
Key Finding (GLP-1 RA vs. Metformin)
HR 1.90 (95% CI 1.39–2.60) overall; attenuated to HR 1.26 (95% CI 0.77–2.05) among patients with T2D duration <4 years
Study Snapshot
Comparison
Events (GLP-1 vs. Comparator)
RD (95% CI)
RR (95% CI)
HR (95% CI)
GLP-1 RA vs. SGLT2i (Overall)
30 vs. 27
0.0% (−0.1, 0.1)
1.11 (0.66, 1.87)
1.05 (0.62, 1.77)
GLP-1 RA vs. SGLT2i (1-year)
12 vs. 21
−0.1% (−0.2, 0.0)
0.57 (0.28, 1.16)
0.54 (0.27, 1.11)
GLP-1 RA vs. SGLT2i (3-year)
27 vs. 30
0.0% (−0.1, 0.1)
0.90 (0.54, 1.51)
0.85 (0.51, 1.43)
GLP-1 RA vs. SGLT2i (5-year)
28 vs. 30
0.0% (−0.1, 0.1)
0.93 (0.56, 1.56)
0.88 (0.53, 1.48)
GLP-1 RA vs. Metformin (Overall)
95 vs. 80
0.0% (0.0, 0.1)
1.19 (0.88, 1.59)
1.90 (1.39, 2.60)
GLP-1 RA vs. Metformin (3-year)
85 vs. 46
0.1% (0.0, 0.1)
1.85 (1.29, 2.65)
2.09 (1.45, 2.99)
GLP-1 RA vs. Metformin (T2D <4 years)
32 vs. 43
0.0% (−0.1, 0.0)
0.74 (0.47, 1.18)
1.26 (0.77, 2.05)
GLP-1 RA vs. Metformin (1–3 years follow-up)
41 vs. 19
0.0% (0.0, 0.1)
2.16 (1.25, 3.72)
2.86 (1.65, 4.94)
Study Facts Table
Full Study Profile
Authors
Lopez DS, Abdelgadir O, Hernández-Pérez JG, Ernest D, Hong AS, DeSantis SM, Cowell LG, Almandoz JP, Messiah SE
Journal
Diabetes, Obesity and Metabolism
Year / Volume / Pages
2026; 28:5389–5393
DOI
10.1111/dom.70700
Study Design
Retrospective cohort study with target trial emulation; propensity score matched (1:1 nearest-neighbour, 0.1 calliper)
Database / Setting
TriNetX global EHR network, January 1, 2006 to October 31, 2024
Population
Adults with type 2 diabetes and overweight or obesity
Intervention
Initiation of GLP-1 receptor agonist therapy
Comparators
SGLT2 inhibitor initiation (Arm 1); metformin initiation (Arm 2)
Primary Endpoint
Incident kidney cancer (ICD-10 C64), harmonized with tumour registry data
Key Results (GLP-1 RA vs. SGLT2i)
HR 1.05 (95% CI 0.62–1.77); RD 0.0%; RR 1.11 (95% CI 0.66–1.87), no association across all follow-up intervals
Key Results (GLP-1 RA vs. Metformin)
HR 1.90 (95% CI 1.39–2.60) overall; HR 1.26 (95% CI 0.77–2.05) in T2D duration <4 years subgroup
Adverse Events
Not a safety reporting study; oncologic endpoint only
Funding
National Cancer Institute (P30CA142543); Cancer Prevention and Research Institute of Texas (RP210130)
Conflicts of Interest
Lopez: grants from NCI and CPRIT during study conduct. Ernest: CPRIT postdoctoral fellowship. All other authors: none reported.
What Researchers Actually Did
Lopez and colleagues designed this study as an explicit methodological challenge to three prior observational analyses that each reported an elevated kidney cancer risk among GLP-1 RA users. Using the TriNetX global EHR database spanning January 2006 through October 2024, the investigators first specified the protocol of a hypothetical randomized trial, then mapped each component to available observational data in accordance with the target trial emulation framework. Eligible participants were adults with type 2 diabetes and overweight or obesity. Treatment was defined as initiation of a GLP-1 RA versus initiation of either an SGLT2 inhibitor or metformin, with time zero anchored to the moment eligibility criteria, treatment assignment, and follow-up start all coincided. The analysis was framed as the observational analog of an intention-to-treat estimate. Propensity score matching (1:1 nearest-neighbour, 0.1 calliper) was used to adjust for baseline confounders including age, sex, race, ethnicity, socioeconomic determinants, BMI, HbA1c, CKD stage, eGFR, proteinuria, nicotine dependence, antihypertensive use, NSAID use, and others. Covariate balance was confirmed using standardized mean differences below 0.10.
The two treatment comparisons were analyzed separately because they address different methodological questions. The GLP-1 RA versus SGLT2i arm (63,789 eligible, 26,670 matched) was designed to replicate and interrogate the Xie et al. finding using a rigorous trial emulation structure. The GLP-1 RA versus metformin arm (266,172 eligible, 102,490 matched) was designed to replicate and interrogate the Wang et al. finding, with additional stratification by diabetes duration (fewer than 4 years versus 4 or more years) to probe whether channelling bias driven by treatment sequencing explains the observed signal. Reporting adhered to both STROBE and TARGET guidelines.
Key Findings: Primary Outcomes
GLP-1 RA vs. SGLT2i, no association: In the fully matched cohort of 26,670 adults, 30 kidney cancer events occurred in the GLP-1 RA group versus 27 in the SGLT2i group. The overall HR was 1.05 (95% CI 0.62–1.77), the RR was 1.11 (95% CI 0.66–1.87), and the absolute risk difference was 0.0% (95% CI −0.1 to 0.1). No association was detected at 1-, 3-, or 5-year follow-up intervals.
GLP-1 RA vs. Metformin, elevated HR overall, attenuated in early T2D subgroup: In the matched cohort of 102,490 adults, the overall HR was 1.90 (95% CI 1.39–2.60). The RR was 1.19 (95% CI 0.88–1.59), substantially lower than the HR, indicating that the hazard signal is temporally front-loaded and that cumulative incidence differences are modest. Absolute risk difference remained 0.0% (95% CI 0.0–0.1), reflecting the low baseline incidence of kidney cancer.
Attenuation in T2D duration <4 years subgroup: Among the 52,104 matched individuals with fewer than four years of type 2 diabetes at treatment initiation, the HR fell to 1.26 (95% CI 0.77–2.05), no longer reaching statistical significance. The RR in this subgroup was 0.74 (95% CI 0.47–1.18). This subgroup represents the population in which GLP-1 RA and metformin initiators are most clinically comparable.
1–3 year follow-up window, GLP-1 RA vs. Metformin: HR was 2.86 (95% CI 1.65–4.94), with RR 2.16 (95% CI 1.25–3.72), suggesting the excess hazard is concentrated early in the follow-up, a pattern more consistent with detection bias or pre-existing subclinical disease than with a causal carcinogenic effect.
Key Findings: Secondary Outcomes and Subgroup Analyses
GLP-1 RA vs. SGLT2i at 1 year: HR 0.54 (95% CI 0.27–1.11), RR 0.57 (95% CI 0.28–1.16), a numerically lower point estimate for the GLP-1 RA group, though confidence intervals cross 1.0.
GLP-1 RA vs. Metformin, T2D duration 4 or more years: HR 1.68 (95% CI 0.66–4.23), based on 11 versus 10 events (n=7,535 per group). Wide confidence intervals preclude meaningful interpretation; this reflects low statistical power from sparse events.
Stratified analyses, GLP-1 RA vs. SGLT2i by T2D duration: Models did not converge due to insufficient event counts in both the <4-year and 4-or-more-year subgroups. Results were not reported for these strata.
Divergence between HR and RR in the metformin comparison: The overall HR of 1.90 versus an RR of 1.19 indicates temporal non-proportionality. Hazard excess is concentrated early in follow-up, and cumulative cancer burden over the study period is modest, a pattern the authors interpret as consistent with detection or surveillance differences rather than sustained carcinogenic exposure.
Results: Adverse Events and Safety Profile
This study was designed exclusively to evaluate kidney cancer incidence as an oncologic safety signal, not to characterize the broader adverse event profile of GLP-1 receptor agonists. No additional safety or tolerability outcomes were reported. The outcome of interest, incident kidney cancer (ICD-10 C64), was identified using TriNetX data harmonized with tumour registry data to enhance diagnostic validity. Residual misclassification was expected to be non-differential and to bias results toward the null.
Statistical Approach and Rigor
The analytic strategy was appropriate for its stated purpose. Propensity score matching on a broad set of clinically relevant confounders, including markers of renal risk (CKD stages 1–3, proteinuria, eGFR) and metabolic severity (HbA1c, BMI), was a methodological strength. Standardized mean differences below 0.10 confirmed acceptable post-match balance. Reporting HR alongside RR for each comparison was a deliberate and informative choice: divergence between these metrics is diagnostic of front-loaded risk, which the authors appropriately flag as a marker of possible detection bias. Stratification by diabetes duration was prespecified and directly addressed the channelling bias hypothesis. Conditional Cox proportional hazards models accounted for within-match clustering. Limitations of the analytic approach include the ITT framing, which estimates initiation effects and may attenuate associations dependent on sustained exposure; the lack of cumulative dose or persistence data; and the inherently limited power to detect associations for a rare outcome in subgroup strata, as evidenced by model non-convergence in two SGLT2i subgroups and wide confidence intervals throughout.
Clinical Takeaway
Three prior studies raised a signal that GLP-1 receptor agonists may increase kidney cancer risk, a biologically counterintuitive finding given that obesity is a primary driver of renal cell carcinoma and GLP-1 RAs are first-line therapies for obesity management. This target trial emulation, the most methodologically rigorous of the four studies now in this literature, shows that the signal dissolves when the comparator group is clinically appropriate. Comparing GLP-1 RAs to SGLT2 inhibitors, drugs prescribed for overlapping indications at similar points in the treatment pathway, produced no kidney cancer association across any follow-up interval. The elevated HRs seen against metformin are substantially explained by channelling bias from treatment sequencing: GLP-1 RA initiators in real-world data tend to have longer disease duration and greater comorbidity burden than metformin initiators, and when that gap
Evidence Watch Reading Tool
Read This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEW
Study finds no increased kidney cancer risk with GLP-1 RAs vs. SGLT2 inhibitors.
OverviewWhy this paper matters
Patient TakeawayReal-world implications
Clinician’s POVClinical decision-making
A Skeptical ReadAlternative explanations
Study CriticMethodology audit
Compared to Past ResearchHistorical context
Practical ConsiderationsImplementation barriers
Future DirectionsWhat comes next
Misreadings & Bad-Faith TakesCommon distortions
Overview
Badge 1: MethodologyBadge 2: Target Trial EmulationBadge 3: Comparator Selection
This study challenges prior findings of elevated kidney cancer risk with GLP-1 receptor agonists by using a target trial emulation framework. It found no increased risk when comparing GLP-1 RAs to SGLT2 inhibitors, highlighting the impact of comparator selection on risk estimates.
The research underscores the importance of methodological rigor in observational studies and suggests that previous signals may have been influenced by biases rather than a causal effect.
No increased kidney cancer risk with GLP-1 RAs compared to SGLT2 inhibitors.
Comparator selection significantly impacts risk estimates.
Target trial emulation provides a robust framework for comparing treatments in observational studies.
Key Insight
GLP-1 RAs do not show increased kidney cancer risk when compared to SGLT2 inhibitors using target trial emulation.
Patient Takeaway
Badge 1: Patient SafetyBadge 2: Treatment OptionsBadge 3: Risk Assessment
For patients, this study suggests that using GLP-1 receptor agonists may not increase the risk of kidney cancer when compared to SGLT2 inhibitors. This information can help in making informed decisions about diabetes management options.
The findings highlight the importance of considering methodological rigor in studies assessing treatment risks and benefits.
No increased kidney cancer risk with GLP-1 RAs vs. SGLT2 inhibitors.
Comparator selection affects risk estimates.
Target trial emulation provides a robust framework for comparing treatments.
Patient Takeaway
Using GLP-1 RAs may not increase the risk of kidney cancer compared to SGLT2 inhibitors.
Clinician’s POV
Badge 1: Clinical PracticeBadge 2: Treatment GuidelinesBadge 3: Risk Management
Clinicians can use this study’s findings to better understand the risk profile of GLP-1 receptor agonists compared to SGLT2 inhibitors. The research emphasizes the importance of methodological rigor in assessing treatment risks and supports informed decision-making.
These insights can help clinicians provide more accurate information to patients about potential risks and benefits of different diabetes treatments.
No increased kidney cancer risk with GLP-1 RAs vs. SGLT2 inhibitors.
Comparator selection affects risk estimates.
Target trial emulation provides a robust framework for comparing treatments.
Clinician Takeaway
GLP-1 RAs do not show increased kidney cancer risk compared to SGLT2 inhibitors, based on target trial emulation.
A Skeptical Read
Badge 1: Skeptical ViewBadge 2: Critical AnalysisBadge 3: Methodological Rigor
This study challenges previous findings of increased kidney cancer risk with GLP-1 receptor agonists by using a more rigorous methodological approach. The results suggest that prior signals may have been influenced by biases rather than a causal effect.
For skeptics, this research underscores the importance of critical analysis and robust methodologies in observational studies to ensure accurate risk assessments.
No increased kidney cancer risk with GLP-1 RAs vs. SGLT2 inhibitors.
Comparator selection affects risk estimates.
Target trial emulation provides a robust framework for comparing treatments.
Skeptic Takeaway
Prior signals of increased kidney cancer risk with GLP-1 RAs may have been influenced by biases rather than a causal effect.
Study Critic
Badge 1: Critical EvaluationBadge 2: Methodological CritiqueBadge 3: Risk Assessment
Critics can evaluate this study’s use of target trial emulation to assess the risk of kidney cancer with GLP-1 receptor agonists. The research provides a methodologically rigorous approach that challenges previous findings and highlights the importance of comparator selection in observational studies.
This critique emphasizes the need for robust methodologies in assessing treatment risks and benefits.
No increased kidney cancer risk with GLP-1 RAs vs. SGLT2 inhibitors.
Comparator selection affects risk estimates.
Target trial emulation provides a robust framework for comparing treatments.
Critic Takeaway
The study challenges previous findings of increased kidney cancer risk with GLP-1 RAs using target trial emulation.
Compared to Past Research
Badge 1: Historical ContextBadge 2: Previous StudiesBadge 3: Methodological Evolution
This study builds on and challenges previous findings of increased kidney cancer risk with GLP-1 receptor agonists. It highlights the evolution of methodological approaches in observational studies, particularly the use of target trial emulation to address biases.
The research underscores the importance of continuous evaluation and improvement in study design to ensure accurate risk assessments.
No increased kidney cancer risk with GLP-1 RAs vs. SGLT2 inhibitors.
Comparator selection affects risk estimates.
Target trial emulation provides a robust framework for comparing treatments.
Historical Takeaway
This study challenges previous findings of increased kidney cancer risk with GLP-1 RAs using target trial emulation.
Practical Considerations
Badge 1: Practical ImplicationsBadge 2: Clinical ApplicationBadge 3: Risk Management
Practically, this study’s findings can inform clinical decision-making regarding the use of GLP-1 receptor agonists versus SGLT2 inhibitors. The research emphasizes the importance of considering methodological rigor in assessing treatment risks and supports informed patient care.
Clinicians can use these insights to provide more accurate information about potential risks and benefits to patients.
No increased kidney cancer risk with GLP-1 RAs vs. SGLT2 inhibitors.
Comparator selection affects risk estimates.
Target trial emulation provides a robust framework for comparing treatments.
Practical Takeaway
GLP-1 RAs do not show increased kidney cancer risk compared to SGLT2 inhibitors, based on target trial emulation.
Future Directions
Badge 1: Future ResearchBadge 2: Long-term StudiesBadge 3: Mechanistic Insights
Future research should focus on understanding the mechanisms behind early detection bias and exploring long-term effects with more detailed exposure data. This study’s findings highlight the need for continued evaluation of treatment risks using robust methodologies.
Further studies can provide deeper insights into the safety profile of GLP-1 receptor agonists in diabetes management.
No increased kidney cancer risk with GLP-1 RAs vs. SGLT2 inhibitors.
Comparator selection affects risk estimates.
Target trial emulation provides a robust framework for comparing treatments.
Future Takeaway
Future research should explore long-term effects and mechanisms behind early detection bias in GLP-1 RA use.
Misreadings & Bad-Faith Takes
Badge 1: Common MisunderstandingsBadge 2: Clarification NeededBadge 3: Methodological Nuances
Common misinterpretations of this study may include assuming a causal effect without considering methodological nuances. The research emphasizes the importance of comparator selection and robust methodologies in assessing treatment risks.
Critics should be aware that the findings challenge previous signals of increased kidney cancer risk, suggesting these were likely influenced by biases rather than a causal effect.
No increased kidney cancer risk with GLP-1 RAs vs. SGLT2 inhibitors.
Comparator selection affects risk estimates.
Target trial emulation provides a robust framework for comparing treatments.
Misreading Takeaway
Previous signals of increased kidney cancer risk with GLP-1 RAs were likely influenced by biases rather than a causal effect.
Have thoughts on this? Share it:
X Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
RELATED READING AT CED CLINIC
Continue exploring the evidence
How CED Clinic Approaches Metabolic Care
An overview of the physician-led metabolic program at CED Clinic, including how GLP-1 therapies fit into a whole-person treatment framework.
Explore evidence
GLP-1 Medications and Weight Loss: What Patients Need to Know
A clinical overview of GLP-1 receptor agonists, their mechanisms, expected outcomes, and what individualized care looks like in practice.
Read article
Cannabis for Pain Management: Matching Products to Symptoms
A practical guide to cannabinoid selection for pain, relevant for patients managing overlapping metabolic and pain concerns.
Continue reading
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
What is the main finding of the study regarding GLP-1 RAs and kidney cancer risk?
The study found no increased risk of kidney cancer with GLP-1 receptor agonists when compared to SGLT2 inhibitors using a target trial emulation framework.
How does comparator selection affect the results in studies on GLP-1 RAs and kidney cancer?
The choice of comparator (e.g., metformin vs. SGLT2 inhibitors) significantly impacts the risk estimates, with different comparators yielding varying hazard ratios.
What is target trial emulation and why was it used in this study?
Target trial emulation is a method that maps observational data to the design of an ideal randomized controlled trial, allowing for more accurate risk comparisons.
How does diabetes duration affect the relationship between GLP-1 RAs and kidney cancer risk?
The study found that the hazard ratio was attenuated in patients with fewer than four years of type 2 diabetes, suggesting channelling bias may influence results.
What does the divergence between HR and RR indicate in this study?
The divergence suggests that any excess risk is concentrated early in follow-up, which could be due to detection or surveillance differences rather than a sustained carcinogenic effect.
Why was metformin used as a comparator in this study?
Metformin was used to replicate and interrogate the findings of previous studies, particularly those that reported elevated kidney cancer risk with GLP-1 RAs.
What are the limitations of using an intention-to-treat (ITT) approach in this study?
The ITT approach may attenuate associations dependent on sustained exposure and lacks cumulative dose or persistence data, which could affect risk estimates.
How does the study address potential biases related to treatment sequencing?
The study stratified analyses by diabetes duration to probe whether channelling bias driven by treatment sequencing explains the observed signal.
What is the significance of the absolute risk difference (RD) in this study?
The RD remained 0.0% across all comparisons, indicating that the cumulative incidence differences are modest despite elevated hazard ratios.
What future research is needed based on this study’s findings?
Future research should focus on understanding the mechanisms behind early detection bias and exploring long-term effects with more detailed exposure data. [...]
Read more...
Cannabis News
June 8, 2026Cannabis News✦ New
CED Clinical Relevance
#70
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
⚒ Policy Watch | Federal Register
cannabis_policyfederal_lawDEA_schedulingrescheduling_marijuanaFDA_approved_productsSchedule_I_to_Schedule_IIIstate_regulation
Why This Matters
This rescheduling from Schedule I to Schedule III would enable clinicians to prescribe FDA-approved cannabis products with reduced regulatory burden and allow insurance reimbursement, potentially improving patient access to evidence-based cannabinoid therapies. The change would facilitate clinical research by simplifying DEA licensing requirements for researchers studying cannabis, generating the evidence base clinicians need to make informed prescribing decisions. Patients could benefit from standardized dosing, quality assurance, and documented efficacy data that are currently unavailable for Schedule I substances.
Clinical Summary
The U.S. Drug Enforcement Administration has announced a rescheduling of FDA-approved cannabis products from Schedule I to Schedule III of the Controlled Substances Act, a significant regulatory shift that reflects the agency’s recognition of accepted medical utility in FDA-approved formulations. This rescheduling applies specifically to products like dronabinol and nabilone that have completed the full FDA approval process and demonstrated therapeutic benefit, rather than whole-plant cannabis. The change simplifies prescribing and dispensing requirements for these medications, reducing administrative burdens on clinicians and improving patient access by allowing Schedule III controlled substance handling procedures rather than the more restrictive Schedule I requirements. Clinicians should note that this rescheduling does not affect state-level regulations, CBD products, or non-FDA-approved cannabis preparations, which remain subject to varying state laws and federal restrictions. The practical consequence for prescribers is streamlined documentation and fewer barriers when prescribing FDA-approved cannabinoid medications for patients with qualifying conditions such as chemotherapy-induced nausea, vomiting, or wasting disorders.
Dr. Caplan’s Take
“The DEA’s rescheduling of FDA-approved cannabis products from Schedule I to III is fundamentally a regulatory correction that removes an absurd barrier to evidence-based practice, not a philosophical endorsement of cannabis as medicine. My patients with intractable seizures or chemotherapy-induced nausea deserve the same access to rigorous pharmacokinetic data and drug interaction screening that we provide for any other medication, and Schedule III status finally makes that possible without requiring us to practice in a legal gray zone.”
Clinical Perspective
⚕️ The potential rescheduling of FDA-approved cannabis products from Schedule I to Schedule III represents a significant regulatory shift that could facilitate clinical research and patient access, though practitioners should recognize that rescheduling alone does not establish efficacy or clinical superiority for any given cannabis product. While moving approved medications to Schedule III would reduce prescribing restrictions and potentially increase insurance coverage, the heterogeneity of cannabis formulations, variable cannabinoid profiles, and limited long-term safety data in specific patient populations mean that clinical evidence supporting particular indications remains sparse. Importantly, rescheduling status does not equate to robust clinical validation; many approved drugs still require careful patient selection and monitoring regardless of their schedule. Clinicians should maintain a cautious, evidence-based stance when considering cannabis-derived products for patients, focusing on FDA-approved formulations with demonstrated benefit for specific conditions such as chemotherapy-induced nausea and vellus
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Related Articles
Schedules of Controlled Substances: Placement of Diphenidine in Schedule IPolicy Watch: 20 Regulatory Updates — June 06, 2026Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
📰 Source: https://www.federalregister.gov/documents/2026/04/28/2026-08176/schedules-of-controlled-substances-rescheduling-of-food-and-drug-administration-approved-products
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 8, 2026Cannabis News✦ New
CED Clinical Relevance
#70
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
⚒ Policy Watch | Federal Register
cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesSchedule_Imarijuana_regulationstate_legislation
Clinical Summary
The Drug Enforcement Administration has placed four synthetic cannabinoids (4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA) into Schedule I, recognizing their high abuse potential and lack of accepted medical use. These compounds represent an emerging class of illicit designer cannabinoids that have appeared in unregulated products marketed as “herbal incense” or “K2/spice,” often with potency and pharmacological profiles substantially different from cannabis itself. Schedule I placement increases legal penalties for possession and distribution while signaling to healthcare providers that these substances carry significant public health risks distinct from regulated cannabis. Clinicians should be aware that patients presenting with acute cannabinoid toxicity, psychiatric symptoms, or cardiovascular events may have used these synthetic products rather than conventional cannabis, which can manifest more severe adverse effects due to their higher receptor affinity and unpredictable composition. The continued emergence of novel synthetic cannabinoids underscores the importance of detailed substance use screening in clinical practice, as routine drug testing may not detect these designer compounds. Providers should counsel patients about the particular dangers of unregulated synthetic cannabinoid products and remain alert to atypical presentations of cannabinoid-related toxicity that may warrant consideration of synthetic cannabinoid exposure.
Dr. Caplan’s Take
“We’re watching synthetic cannabinoids evolve faster than our regulatory apparatus can classify them, and meanwhile patients who could benefit from legitimate cannabis medicine are caught in the collateral damage of these scheduling decisions. The real clinical issue isn’t the chemistry of novel synthetics, it’s that we’ve criminalized the entire category instead of building a rational framework that distinguishes between research-grade compounds and street drugs.”
Clinical Perspective
? The DEA’s emergency scheduling of four synthetic cannabinoids (4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA) reflects the ongoing challenge of regulating novel psychoactive substances that evade existing legal frameworks through structural modification. While scheduling decisions aim to protect public health by restricting access to compounds associated with adverse events, clinicians should recognize that emergency scheduling typically occurs after these substances have already circulated in communities, meaning patients may present with exposures and toxidromes unfamiliar to standard toxicology protocols. The lack of human pharmacology data for these specific analogs complicates clinical management, as case reports and animal studies may not reliably predict human effects, potency variations, or contaminant-related harms. Clinicians encountering patients with suspected novel synthetic cannabinoid
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Related Articles
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule ISchedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule ISchedules of Controlled Substances: Placement of Diphenidine in Schedule I
📰 Source: https://www.federalregister.gov/documents/2026/05/01/2026-08517/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 8, 2026Cannabis News✦ New
CED Clinical Relevance
#70
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
⚒ Policy Watch | Federal Register
cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesCUMYL-PEGACLONESchedule_Istate_regulation
Why This Matters
I don’t see an article summary provided in your message. Please share the summary text so I can write the 2-3 sentences explaining its clinical relevance.
Clinical Summary
The Drug Enforcement Administration has placed cumyl-pegaclone, a synthetic cannabinoid, into Schedule I of the Controlled Substances Act, recognizing it as having high abuse potential and no accepted medical use. This regulatory action reflects the ongoing challenge of synthetic cannabinoid proliferation, as manufacturers continuously develop novel compounds to evade existing drug laws and circumvent controlled substance schedules. For clinicians, this scheduling underscores the distinction between illicit synthetic cannabinoids and approved cannabis-derived or cannabinoid medications, which remains clinically relevant as patients may present with acute toxicity from these unregulated substances. The placement in Schedule I means that cumyl-pegaclone has no role in evidence-based clinical practice and carries legal penalties for possession or distribution. Clinicians should remain aware that synthetic cannabinoid use continues to pose public health risks distinct from cannabis itself, with reports of severe psychiatric and cardiovascular adverse effects that differ from natural cannabis toxidrome. Practitioners encountering patients with suspected synthetic cannabinoid use should be prepared to provide supportive care and toxicology screening, while educating patients about the dangers of these unregulated compounds compared to the more predictable pharmacology of regulated cannabis products.
Dr. Caplan’s Take
I don’t see an article provided for me to reference. Could you please share the article text or details about CUMYL-PEGACLONE and the DEA scheduling decision? Once you provide that, I’ll write an appropriate clinical quote from Dr. Caplan that responds directly to the content.
Clinical Perspective
⚕️ The DEA’s scheduling of CUMYL-PEGACLONE as a Schedule I controlled substance reflects ongoing regulatory efforts to address novel synthetic cannabinoids that evade existing drug laws. While this action aims to prevent proliferation of an uncharacterized compound with unknown safety and abuse potential, clinicians should recognize that scheduling decisions often lag behind street availability and chemical innovation, meaning patients may present with exposure to this or similar compounds before regulatory action occurs. The lack of published toxicology, pharmacology, or clinical case reports for CUMYL-PEGACLONE itself limits our ability to anticipate specific harms or manage acute intoxication effectively. Clinicians should maintain vigilance for synthetic cannabinoid toxidromes in patients with acute psychiatric, cardiovascular, or neurological symptoms, particularly those with substance use histories, while recognizing that routine drug screening will not detect most novel synthetic cannabinoids. In practice, this
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Related Articles
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule ISchedules of Controlled Substances: Placement of Diphenidine in Schedule ISchedules of Controlled Substances: Placement of Diphenidine in Schedule I
📰 Source: https://www.federalregister.gov/documents/2026/05/13/2026-09566/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 8, 2026Cannabis News✦ New
CED Clinical Relevance
#70
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
⚒ Policy Watch | Federal Register
cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesSchedule_I2-Fluorodeschloroketaminestate_regulation
Why This Matters
I don’t see a summary provided for this article about 2-Fluorodeschloroketamine scheduling. To write clinically relevant sentences, I would need the article’s summary or key details about the regulatory action, its implications for clinical use, or its effects on research/treatment access.Could you please provide the article summary so I can complete this accurately?
Clinical Summary
This notice announces the Drug Enforcement Administration’s temporary placement of 2-fluorodeschloroketamine (2-FDCK), a synthetic ketamine analog, into Schedule I of the Controlled Substances Act. The action reflects regulatory efforts to control emerging designer drugs that may be marketed as legal alternatives to controlled substances but pose potential health risks. While this specific compound is not cannabis-related, it exemplifies the regulatory framework and scheduling mechanisms that govern controlled substance classification, which directly parallels how cannabinoids and cannabis derivatives are evaluated and regulated. Clinicians should be aware that novel synthetic compounds continue to emerge in unregulated markets, and patients may present with adverse effects or exposure to these substances, requiring awareness of evolving drug scheduling. This regulatory action underscores the importance of staying informed about newly controlled substances and maintaining vigilance regarding patient substance use, particularly among populations seeking alternatives to prescription medications or recreational drugs. Clinicians should counsel patients about the health risks of unregulated synthetic compounds and emphasize that temporary scheduling is often a precursor to permanent control measures.
Clinical Perspective
? The DEA’s emergency scheduling of 2-fluorodeschloroketamine highlights the ongoing challenge of regulating novel psychoactive substances that emerge faster than traditional legislative processes can address, particularly as illicit chemists modify existing drugs to circumvent legal restrictions. While this regulatory action protects public health by restricting a ketamine analogue with unknown safety and abuse potential, clinicians should recognize that the appearance of such designer drugs in community settings may indicate evolving patterns of substance use that differ from traditional ketamine misuse, potentially affecting how we screen for and counsel patients about emerging drugs of concern. The limited published literature on 2-fluorodeschloroketamine means we lack clinical data on overdose presentation, physiologic effects, and addiction potential compared to ketamine, creating diagnostic and management uncertainty for emergency and primary care providers. Additionally, emergency scheduling may simply displace users toward other untested analogues rather than addressing underlying drivers of drug seeking
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Related Articles
Policy Watch: 20 Regulatory Updates — June 06, 2026Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule ISchedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
📰 Source: https://www.federalregister.gov/documents/2026/05/22/2026-10253/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 8, 2026Cannabis News✦ New
CED Clinical Relevance
#70
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
⚒ Policy Watch | Federal Register
cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesdiphenidine_schedule_Istate_regulationmarijuana_legislation
Clinical Summary
The Drug Enforcement Administration has moved diphenidine, a synthetic dissociative drug chemically related to ketamine, into Schedule I controlled substance status due to its high abuse potential and lack of recognized medical use. This regulatory action reflects ongoing federal efforts to address emerging synthetic drugs that pose public health risks, particularly among vulnerable populations seeking alternatives to traditional substances of abuse. While diphenidine itself has not been developed as a pharmaceutical agent, this scheduling decision provides clarity for clinicians and law enforcement by formally prohibiting its manufacture, distribution, and possession, thereby preventing potential diversion or misuse in clinical settings. The placement of diphenidine in Schedule I also has implications for any future research that might investigate dissociative compounds as potential therapeutics, as such work would require additional regulatory approval and oversight. For clinicians managing patients with substance use disorders or dissociative experiences, this scheduling clarifies that diphenidine cannot be considered a legitimate treatment option and that patients presenting with diphenidine use should be evaluated and managed as cases of illicit drug use. Clinicians should remain aware that synthetic dissociative drugs continue to emerge in unregulated markets, necessitating vigilance in screening for novel substance use and counseling patients about the risks of these compounds.
Clinical Perspective
I don’t see the article summary provided in your message. To write an accurate clinical perspective paragraph on the DEA scheduling decision regarding diphenidine, I would need the full summary or additional details about the rationale, evidence, and public health considerations presented in the article. Could you please provide the article summary so I can create an informed clinical perspective for healthcare providers?
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Related Articles
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule IPolicy Watch: 20 Regulatory Updates — June 06, 2026Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
📰 Source: https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 8, 2026Cannabis News✦ New
CED Clinical Relevance
#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
ResearchPainSafetyCBDTHCAnxietyMental Health
Dr. Caplan’s Take
“When we look at the evidence for cannabis in chronic pain, what matters clinically is that we’re finally seeing rigorous data that validates what patients have been telling us for years, and this allows us to move beyond ideology on either side and make real treatment decisions based on outcomes.”
Clinical Perspective
? While emerging research suggests cannabis may provide symptom relief for certain chronic pain conditions, clinicians should approach these findings with appropriate caution given the current evidence limitations and heterogeneity in study designs, dosing protocols, and patient populations. The therapeutic potential must be weighed against individual risk factors including psychiatric comorbidities, substance use history, driving safety, and potential drug interactions, particularly in older adults or those on multiple medications. Publication patterns and funding sources in cannabis research merit scrutiny, as positive findings may be overrepresented in the literature compared to null or negative results. For patients with refractory chronic pain where conventional analgesics have failed or pose unacceptable risks, a cautious discussion about cannabis as an adjunctive option may be warranted in jurisdictions where it is legal, with clear documentation of the uncertainty regarding efficacy and safety. Ultimately, individualized assessment and shared decision-making remain essential until higher-quality comparative
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
Related Articles
Lancet Unveils Medicinal Cannabis Effectiveness Study | Mirage NewsCED Digest: 436 Items — March 14, 2026CED Digest: 405 Items — March 12, 2026
📰 Source: https://www.nugmag.com/new-research-unveils-health-benefits-of-medical-cannabis/
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 8, 2026Cannabis News✦ New
CED Clinical Relevance
#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
CBDNeurologyResearchSafetyMental HealthPainAnxiety
Why This Matters
Clinicians treating patients with traumatic brain injury should be aware of emerging preclinical evidence suggesting CBD may modulate neuroinflammatory pathways, though clinical trials are needed before recommending it as standard therapy. Patients seeking alternative or adjunctive treatments for TBI-related cognitive symptoms and inflammation should understand the current evidence gap between promising laboratory findings and proven clinical efficacy. This research direction is clinically relevant because post-TBI neuroinflammation contributes to long-term disability, making anti-inflammatory approaches a logical therapeutic target if CBD efficacy can be demonstrated in human trials.
Clinical Summary
Preclinical evidence increasingly indicates that cannabidiol (CBD) may modulate neuroinflammatory responses in the context of traumatic brain injury (TBI), a mechanism that could theoretically limit secondary brain damage and improve functional recovery. While these laboratory findings are encouraging, the translation from animal models to clinical efficacy in TBI patients remains uncertain, and robust human trials are needed to establish safety, optimal dosing, and whether CBD offers benefits beyond standard of care interventions. Current evidence does not yet support routine CBD prescription for acute or chronic TBI management in clinical practice. Clinicians should remain cautious about recommending CBD to TBI patients outside of research settings, while acknowledging the scientific rationale for continued investigation. For patients with TBI interested in CBD, clinicians should discuss the experimental nature of this application and advise against substituting proven rehabilitation and neuroprotective strategies with unproven cannabis-based interventions until clinical evidence matures.
Dr. Caplan’s Take
“The neuroinflammatory cascade after TBI is a legitimate therapeutic target, and the preclinical data on CBD’s anti-inflammatory mechanisms warrants rigorous clinical trials, but we need to be honest with patients that we’re still in the early stages and shouldn’t oversell what we don’t yet understand about dosing, timing, and real-world efficacy.”
Clinical Perspective
? Preclinical evidence for cannabidiol’s potential neuroprotective effects through neuroinflammation reduction is intriguing, yet clinicians should recognize that in vitro and animal models often fail to translate to human efficacy and safety profiles. The mechanistic plausibility is noteworthy, but we currently lack robust randomized controlled trials specifically examining CBD as an adjunctive or primary therapy for traumatic brain injury in humans, making evidence-based recommendations premature. Important confounders include variable CBD formulations and bioavailability, potential drug interactions with standard TBI management protocols, and unknown optimal dosing parameters in this population. Until rigorous clinical trials establish safety and efficacy in humans with TBI, practitioners should counsel patients seeking CBD for head injury that this remains experimental and may delay evidence-based rehabilitation and monitoring. For now, maintaining focus on guideline-directed acute and subacute TBI care remains the standard of practice
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
Related Articles
WNBA Removes Marijuana From Banned Substances List And Sets Rules For Player …WNBA Removes Marijuana From Banned Substances List And Sets Rules For Player …CBD may calm the brain’s runaway immune response behind Alzheimer’s – MSN
📰 Source: https://x.com/drcaplan/status/2063342428812153159
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 8, 2026Cannabis News✦ New
CED Clinical Relevance
#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
PolicyIndustryResearchSafetyCBDTHCPain
Why This Matters
Clinicians need to understand that cannabis product quality and manufacturer financial stability directly affect medication availability and consistency for their patients, as companies with poor cash flow may struggle to maintain supply chains or meet regulatory standards. As Australia’s medicinal cannabis market matures beyond speculative investment phases, practitioners should prioritize prescribing products from financially viable manufacturers with demonstrated quality control, ensuring their patients receive reliable, standardized treatment rather than experiencing interruptions or substandard preparations.
Clinical Summary
Australia’s medicinal cannabis industry is transitioning from speculative growth toward sustainable operations, with investors and regulators now prioritizing product quality and financial stability over market hype. This shift reflects the maturation of the sector under the Therapeutic Goods Administration’s oversight, where companies must demonstrate consistent manufacturing standards, reliable supply chains, and viable business models to remain competitive. For clinicians, this consolidation means greater reliability in sourcing quality-assured cannabis products for patients, reduced risk of supply disruptions, and more transparent information about product composition and efficacy data. Companies with strong cash flow and quality controls are better positioned to invest in clinical research and standardization, ultimately supporting evidence-based prescribing practices. The emphasis on fundamentals over speculation also encourages pharmaceutical-grade standards that facilitate integration of cannabis into mainstream medical practice. Clinicians should evaluate cannabis suppliers based on demonstrated product consistency, regulatory compliance, and financial stability rather than marketing claims, ensuring their patients receive dependable, quality-controlled medications.
Dr. Caplan’s Take
“What we’re seeing in the Australian market is exactly what should happen when cannabis moves from hype to healthcare: companies that can demonstrate consistent product quality and sustainable operations will survive, while those chasing investor euphoria will fail, and that’s good news for patients who deserve standardized medicine, not speculation.”
Clinical Perspective
? The Australian medicinal cannabis market’s increasing focus on product quality and financial sustainability reflects a maturation that should reassure clinicians considering cannabis therapeutics for their patients. As commercial operators face greater scrutiny around manufacturing standards and business viability, this regulatory pressure may ultimately improve the consistency and reliability of cannabis products available for clinical use—a critical factor given the historically variable potency and composition of cannabis medicines. However, clinicians should remain cautious about conflating commercial success with clinical efficacy, as market dynamics and product standardization do not automatically resolve outstanding questions about optimal dosing, long-term safety, or comparative effectiveness against established alternatives. The shift away from speculative hype toward demonstrable cash flow and quality metrics does suggest a maturing industry better positioned to support robust pharmacovigilance and supply chain transparency. For practitioners, this evolution means the cannabis products reaching Australian patients are increasingly subject to manufacturing oversight, but clinical decision-making should still be grounded in
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
Related Articles
Europe’s Medical Marijuana Market Positioned for Explosive Multi-Billion Dollar Growth …Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety DisorderWhy Tilray and other cannabis stocks just had their best week of 2026 – MSN
📰 Source: https://kalkinemedia.com/au/stocks/cannabis/asx-cannabis-stocks-why-product-quality-and-cash-flow-now-matter-more-than-hype
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis NewsDr. Benjamin Caplan, MD |
Board-Certified Family Physician | CMO, CED Clinic |
Cannabis Science
Clinical Insight
A University of Colorado Boulder study of 171 anxious adults found that a person’s baseline level of systemic inflammation predicts how well cannabis works for anxiety and sleep quality. CBD-rich products reduced negative affect consistently across all inflammation levels. THC-dominant products helped only in people with average inflammation, not those at either extreme. No cannabis product of any type improved sleep in people with low baseline inflammation.
Why Your Inflammation Level May Predict How Cannabis Works for Anxiety and Sleep
A peer-reviewed study in Frontiers in Behavioral Neuroscience adds a precision-medicine dimension to cannabis care that most patients and clinicians have not yet heard about. Your body’s baseline inflammatory state may be quietly shaping whether the cannabis you use for anxiety or sleep is actually working, and which type of product is most likely to work for you specifically.
CED Clinical Relevance
77 / 100
Strong Clinical Relevance
This study directly addresses one of the most common patient complaints in clinical cannabis practice: inconsistent response. The moderation finding by inflammation state offers a plausible, biologically grounded explanation and points toward CBD-rich formulations as a more reliable starting point.
Cannabis Science
Anxiety
CBD vs. THC
Sleep
Inflammation
What You’ll Learn
Why baseline inflammation may explain inconsistent cannabis results in people using it for anxiety and sleep
How CBD-rich and THC-dominant products behave differently depending on your inflammatory state
What the study’s 4-week design, 171 participants, and three chemovar groups actually showed
How these findings apply to a clinical cannabis conversation in Massachusetts and beyond
What the study cannot tell us yet, including dose specificity, route of administration, and long-term effects
TL;DR
In 171 adults with anxiety, those who used CBD-rich cannabis improved on anxiety and sleep measures at every level of baseline inflammation.
THC-dominant products only produced consistent mood improvements in people with average systemic inflammation, not at the high or low extremes.
Cannabis use did not change cytokine concentrations over 4 weeks, but existing inflammation shaped how well it worked.
The non-cannabis group did not improve sleep quality at any inflammation level, which strengthens the interpretation that cannabis was responsible for sleep changes in those who used it.
Study at a Glance
Study type
Randomized observational study with ad libitum cannabis use; four-group longitudinal design
Sample size
171 adults with mild-to-severe anxiety (147 cannabis users, 24 non-users)
Duration
4 weeks (baseline and week-4 visits)
Interventions
THC+CBD flower (12%/12%), THC-dominant (24%/<1% CBD), CBD-dominant (<1% THC/24%), or no cannabis
Primary outcomes
DASS-21 (depression, anxiety, stress), Pittsburgh Sleep Quality Index (PSQI), plasma cytokines (IL-1a, IL-1b, IL-6, IL-8, IL-12, TNFα)
Key finding
Baseline cytokine levels moderated cannabis effects on anxiety (p<0.001) and sleep (p=0.04); CBD-rich products consistently improved both outcomes regardless of inflammation
Institution
University of Colorado Boulder, Institute of Cognitive Science and Department of Psychology and Neuroscience
Journal
Frontiers in Behavioral Neuroscience, Vol. 19, July 2025
Limitations
No placebo control; ad libitum use without dose standardization; predominantly White Colorado sample; 4-week window only; flower products only
Why This Matters
One of the most frustrating conversations in clinical cannabis practice is with a patient who says “it just doesn’t work for me.” Until recently, there was little scientific scaffolding to explain why two people with similar anxiety levels could have such different responses to the same product. This paper offers a biologically grounded mechanism: systemic inflammation, measured through circulating cytokine concentrations, may quietly determine whether a cannabis product does what a patient hopes it will do. CBD-rich products appear to sidestep this constraint. THC-dominant products do not. That distinction has real implications for how clinicians should approach product selection, particularly for patients who have tried cannabis and reported no benefit.
What the Study Found
Researchers at the University of Colorado Boulder enrolled 171 adults who met criteria for mild or greater anxiety (GAD-7 score of 5 or above, mean 11.8). Participants were randomly assigned to use one of three commercially available cannabis flower products for four weeks: a balanced THC+CBD formulation (12% THC / 12% CBD), a THC-dominant product (24% THC / less than 1% CBD), or a CBD-dominant product (less than 1% THC / 24% CBD). A fourth group of 24 individuals with anxiety used no cannabis during the study. Products were purchased by participants at a local Colorado dispensary, reflecting real-world use patterns. Participants were free to use as much or as little as they chose. Blood was collected at baseline and at week four to measure plasma cytokine concentrations and cannabinoid levels.
The central finding is a three-way interaction: cannabis chemovar, time, and baseline cytokine concentration all together determine the trajectory of anxiety and sleep outcomes. CBD-rich products, whether CBD-dominant or balanced THC+CBD, produced significant improvements in DASS-21 total scores at low, average, and high baseline inflammation levels. The CBD group specifically outperformed the non-cannabis group in the rate of negative-affect reduction at every inflammatory tier. THC-dominant products were a different story. They produced significant reductions in anxiety and depression only at average cytokine levels. When inflammation was very low or very high, THC-dominant use was not associated with significant improvements. For sleep, no cannabis product moved the needle in people with low baseline inflammation. At average and high inflammation levels, all three cannabis groups improved Pittsburgh Sleep Quality Index scores compared to baseline, with CBD-containing products showing a tendency to outperform THC-dominant products. Importantly, cannabis use did not change cytokine concentrations during the four weeks, ruling out a simple anti-inflammatory mechanism as the explanation for symptom improvement.
What This Paper Does Not Show
The study does not establish that measuring cytokines before starting cannabis will reliably predict outcomes in a clinical setting. The inflammation measure used here is a composite z-score across six cytokines, not a single, clinically accessible biomarker. The study also does not show which THC dose, frequency, or delivery method would produce different results. Products were flower-based; whether edibles, tinctures, or concentrates would follow the same moderation pattern is not addressed. The sample was predominantly White adults in Colorado with legal access to cannabis, which limits generalizability to populations with different baseline inflammatory profiles, health histories, or access to regulated products.
The four-week window does not speak to what happens at six months or a year. The absence of a placebo control means expectation effects cannot be ruled out, particularly given that participants knew their product type via the required label. The non-cannabis group did show some improvement in DASS total at average and high inflammation levels, which introduces some regression-to-the-mean interpretation. Finally, the study was not powered to compare specific subscales of anxiety, depression, and stress with the same confidence as the composite score.
How This Fits With the Broader Clinical Conversation
The inconsistency of cannabis outcomes across patients is one of the most persistent challenges in this field. Researchers have attempted to explain variability through dosing, frequency, delivery method, endocannabinoid system genetics, and prior cannabis experience. Inflammation as a moderator is a newer hypothesis, but it has biological plausibility. CBD has been shown in preclinical work to suppress inflammatory cytokine release through mechanisms that do not require CB1 or CB2 activation, including suppression of the NF-kappaB pathway and upregulation of STAT3 in immune cells. THC, by contrast, appears to have more receptor-dependent and dose-sensitive immunomodulatory effects. If those preclinical findings hold at real-world blood concentrations, they would predict exactly what this study found: CBD provides a more consistent anti-inflammatory signal across a wider inflammatory range, while THC’s effects are narrower.
This connects to a broader trend in cannabis research toward stratified or personalized medicine. The Lancet Psychiatry meta-analysis published in March 2026 found limited evidence for medicinal cannabis in anxiety and depression broadly. But meta-analyses pool heterogeneous populations, which can obscure the effects that exist for specific subgroups. A finding like this one suggests that a subgroup defined by inflammatory state might respond very differently from the pooled average. That doesn’t mean the Lancet analysis was wrong. It means the question of “does cannabis work for anxiety” may be less useful than “for whom, with what product, and at what baseline biological state.”
In clinical practice, many of the patients who report the most benefit from medical cannabis are those dealing with chronic pain, autoimmune conditions, or post-viral syndromes, populations often carrying elevated inflammatory burden. This study’s finding that people with higher baseline cytokines showed greater improvements in sleep quality from cannabis is consistent with what clinicians using cannabis with these patients have reported observationally for years. It does not prove causation, but it adds structure to a clinical intuition that has been hard to quantify.
Dr. Caplan’s Take
When a patient tells me cannabis stopped working, or that it never worked for them at all, I used to have to say something vague about individual variability. Now I have a better starting point for the conversation. The finding that THC-dominant products lose their effect at extremes of inflammation is clinically important. It suggests that for patients who already have significant systemic inflammation, or conversely, patients who have very low baseline inflammation perhaps well-regulated, active, healthy adults, THC-only cannabis may not be the right first choice. CBD or a balanced CBD/THC product covers more ground.
I also want to name what this study does carefully: it measures flower-based ad libitum use in Colorado adults at commercially available concentrations. These are real-world doses and real-world habits, not the locked-down clinical trial doses that sometimes make cannabis research feel irrelevant to actual patients. That external validity matters. At the same time, the lack of a placebo, the four-week cap, and the mostly White Colorado sample are genuine constraints. I would not read this paper and immediately shift all anxiety patients to CBD-only products. I would read it as one more piece of evidence that CBD-rich formulations are more forgiving, and that THC-dominant options deserve more individualized assessment before recommending them as a primary approach. For the many Massachusetts patients I see who have tried cannabis and felt nothing, or felt worse, their inflammatory state is now on my checklist of things worth considering.
What a Careful Reader Should Take Away
This paper offers a genuinely new angle on a persistent clinical problem, but it does not change the evidence base overnight. CBD-rich cannabis products continue to accumulate support as a more consistent and forgiving choice across populations. THC-dominant products appear to have a narrower window of effectiveness that may depend on biological factors patients cannot easily know without lab work. The practical implication is not “get a cytokine panel before starting cannabis,” but rather “CBD-containing products are a lower-risk starting point for anxiety and sleep in most patients, and THC-heavy products warrant more individualized assessment.”
What this paper does not do is establish proof of benefit for any cannabis product in clinical anxiety disorders, revise the conclusions of large systematic reviews, or provide enough information to use cytokine levels as a clinical decision-making tool. The finding is mechanistically interesting, biologically plausible, and clinically suggestive. It is an invitation to design better-controlled, longer-term studies that account for inflammatory state at baseline. For now, it adds a useful dimension to the clinician-patient conversation, and that alone is worth reading carefully.
Evidence Watch Reading Tool
Read This Paper Through Eight Different Lenses
A single study can mean different things depending on who is reading it. This card separates the patient takeaway, clinical meaning, skepticism, study critique, prior research context, practical implications, future directions, and likely public misreadings.
How to use this: Choose a lens above to see how the same paper reads from a different evidence, clinical, or practical angle.
Patient Takeaway
Clinician’s POV
A Skeptical Read
Study Critic
Compared to Past Research
Practical Considerations
Future Directions (Expected)
Misreadings & Bad-Faith Takes
Select a lens above to reveal a focused interpretation of the paper. Each view is prepared in advance, evidence-calibrated, and designed to keep the claims tied to what the work actually shows.
Patient Takeaway
If you have tried cannabis for anxiety or sleep and found it either hit-or-miss or entirely ineffective, this research suggests your body’s inflammatory state might be part of the explanation. In this study, people using CBD-rich products improved their anxiety scores and sleep quality at every level of baseline inflammation measured. People using THC-heavy products only improved when their inflammation was at an average level, not when it was unusually low or unusually high. The non-cannabis group did not improve sleep quality at all, which gives some weight to the idea that cannabis was genuinely doing something for sleep in those who used it. What this does not mean: you should not try to guess your inflammatory state, nor should you switch products without talking to a clinician. What it does mean: if you have found CBD-containing products more consistently helpful than THC-heavy ones, there is now biological research consistent with that experience. This study also does not mean cannabis works for everyone with anxiety. It is a four-week study of 171 adults in Colorado using specific flower products, and it cannot tell you whether a given product will help you specifically. These findings are most useful as a starting point for a conversation with a clinician about product type, your health history, and what you have already tried.
Clinician’s POV
The clinically actionable dimension of this paper is the THC moderation finding. CBD-rich and balanced products produced consistent improvements across the inflammatory spectrum, which supports what many clinicians using cannabis therapeutically have observed: CBD formulations are more predictable in their response profile. The THC-only window being restricted to average inflammation levels raises a practical question about how to identify patients who may not respond well to THC-dominant products before they try them. The study cannot answer that directly, but it gives clinicians a new domain to ask about: chronic inflammatory conditions, recent infections, immunological history, and even lifestyle factors known to affect cytokine levels. There is no validated clinical test to run before product selection, but the concept of inflammatory status as a moderating variable is now supported by a prospectively designed study. For patients who have tried THC-heavy cannabis and felt nothing or felt worse, this paper offers a framing that goes beyond “you just didn’t respond.” For product selection counseling in Massachusetts and other regulated markets where CBD-rich flower is accessible, this finding provides an additional reason to lean toward balanced or CBD-dominant formulations as first-line options for anxiety and sleep, particularly in patients with known inflammatory conditions.
A Skeptical Read
The absence of a placebo control is the most significant limitation in this design, and it is one the authors acknowledge directly. Participants knew which product they were assigned to because Colorado regulations require cannabinoid content on the label. Someone who believes CBD is calming may report less anxiety because they believe they received the calming product. The magnitude of the effect size in the CBD group at low inflammation is large enough that placebo alone is unlikely to fully account for it, but the possibility cannot be excluded. The cannabis non-use group also showed improvement in DASS total at average and high inflammation, which complicates interpretation. The authors invoke regression to the mean as a possible explanation for that, which is plausible but not conclusively established. The predominantly White Colorado sample introduces demographic specificity that makes generalizing to a Boston patient population non-trivial. Many patients seeking medical cannabis in Massachusetts are older, carry more chronic disease burden, and may have inflammatory profiles that differ systematically from healthy Colorado adults in their early thirties. This study does not tell you what happens in those populations, and extrapolating directly from this sample would outrun the data.
Study Critic
The core statistical finding is a three-way generalized estimating equations interaction: time, group, and baseline cytokine z-score. The DASS moderation reached p less than 0.001 and the PSQI moderation p equals 0.04, which is statistically significant but notably weaker for the sleep outcome. In a study with several outcomes and multiple comparisons, a p-value of 0.04 for the sleep moderation warrants caution. The post hoc power analysis showed adequate power for a Cohen’s f as small as 0.17, which is a modest effect. The cytokine composite used in the analysis averages z-scores across six pro-inflammatory cytokines, which reduces individual specificity. It is possible that individual cytokines such as IL-6 or TNFa are driving the moderation while others are noise, but the study design cannot separate those contributions. The ad libitum use design, while realistic, means the statistical models could not include frequency of use or blood cannabinoid concentration because the non-use group had zero values for both, introducing a structural constraint that limits what can be attributed to dose. The 24-hour abstinence period before each visit means blood cannabinoids at the week-4 visit reflect stable trough concentrations, not acute peak exposure, which affects interpretation of the cannabinoid verification data.
Compared to Past Research
This paper extends previous work from the same research group at the University of Colorado Boulder. Prior analyses from the same longitudinal dataset (Bidwell et al. 2023 and 2024) reported improvements in sleep and anxiety from cannabis use, with CBD-containing products generally outperforming THC-dominant ones on anxiety measures. This paper adds the inflammatory moderation layer to that foundation, which is genuinely new. The broader literature on cannabis for anxiety has been mixed, with the March 2026 Lancet Psychiatry meta-analysis finding limited evidence across the pooled literature for cannabinoids in anxiety and depression. This study does not contradict those findings; rather, it suggests that pooling heterogeneous samples may obscure meaningful subgroup effects. The preclinical literature on CBD’s immunosuppressive mechanisms through the NF-kappaB pathway and STAT3 upregulation provides biological scaffolding for the moderation hypothesis, though the study did not observe cannabis-mediated changes in cytokine concentrations directly. The comparison to prior literature is constrained here because few previous studies assessed inflammatory status as a moderator of cannabis outcomes; the authors note only one prior study examined cytokines in the context of anxiety treatment and it used a non-pharmacological intervention. This paper is, to their knowledge, the first to examine this moderation in a cannabis chemovar context.
Practical Considerations
Colorado’s regulated market provided access to standardized, ISO-certified flower products, which is a far cry from what patients in many markets face. Massachusetts has a regulated medical and adult-use market, which provides some comparability, but product variability in THC-to-CBD ratios is real, and what a product label says does not always match what a patient consumes or absorbs. The ad libitum use pattern, while realistic, also means some patients may have used products in ways that differ significantly from others in the same group. In practice, a CBD-rich flower product at 24% CBD does not translate straightforwardly to a CBD tincture or an edible, and the sleep and anxiety benefits observed in this study may not replicate with other delivery methods. The practical implication that clinicians can act on today is modest but real: when a patient with anxiety asks whether to try cannabis, and the choice is between a THC-heavy product and a CBD-containing one, this paper adds evidence-based support for recommending a CBD-containing option first. For patients who have already tried THC-dominant products without benefit, this research offers a biologically coherent explanation that may help them understand their experience and stay open to trying a different formulation.
Future Directions (Expected)
The most important next step is a placebo-controlled design. Federal scheduling constraints have made this difficult in the United States, but the April 2026 rescheduling of state-licensed medical cannabis to Schedule III may open new research pathways that were previously blocked. A follow-up study should measure individual cytokines rather than a composite z-score to identify which inflammatory markers carry the most predictive weight. A study that stratifies participants by clinically accessible proxies of inflammation, such as high-sensitivity CRP or standard metabolic markers, would be far more translatable to clinical practice than a research-grade cytokine panel. Longer follow-up is needed: four weeks is enough to see an initial signal but not enough to determine whether the inflammatory moderation persists or reverses at six months or a year. Expansion beyond flower products to edibles, oils, and sublingual preparations would address the route-of-administration gap. A replication in a clinically defined population with DSM-5 generalized anxiety disorder, rather than the broader screening threshold used here, would sharpen the clinical relevance considerably. And a racially and geographically diverse sample is essential to assess whether the finding holds across different baseline inflammatory profiles.
Misreadings & Bad-Faith Takes
One likely misreading: “Study proves CBD cures anxiety.” This is a distortion. The paper found that CBD-rich products were associated with improvements in anxiety scores over four weeks in adults with mild-to-severe self-reported anxiety. Correlation across four weeks is not proof of cure, and anxiety scores improving in a study does not translate to clinical remission of an anxiety disorder. Another predictable distortion: “Cannabis does not work for anxiety unless your inflammation is just right.” This misreads the THC finding as a finding about all cannabis. CBD-rich products worked across every inflammation level in this study; the inflammation sensitivity was specific to THC-dominant products. A third misreading, from the opposite direction: “This study shows inflammation testing should be part of cannabis consultations.” The study does not support that conclusion. The cytokine panel used is a research tool, not a clinical one, and there is no validated protocol for translating composite cytokine z-scores into product recommendations. Finally: “CBD is now proven to be better than THC for anxiety.” The study found CBD-rich products to be more consistent, not categorically superior in all patients for all outcomes. THC-containing products, including the balanced THC+CBD group, also showed significant improvements in this study. The distinction is about consistency and range, not a binary verdict.
Related Reading at CED Clinic
Continue exploring the evidence
Understanding the Effects of Cannabis on Inflammation
A broader look at how cannabinoids interact with the immune system, providing useful background for the cytokine moderation findings in this study.
Explore evidence
Endocannabinoid System Research: Cannabis for Anxiety
A review of ECS-focused research on anxiety, placing the CBD vs. THC question in its broader neurobiological context.
Explore evidence
The Unsettling Truth About Medical Cannabis and Mental Health
A candid clinical discussion of where the evidence for cannabis in mental health remains genuinely uncertain, and why that matters for patients.
Explore evidence
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care
Have thoughts on this? Share it:
? Share on X
in Share on LinkedIn
? Share on BlueSky
? Follow on Instagram
? Read more on Substack
? Subscribe via RSS
Source
Lisano JK, Skrzynski CJ, Giordano G, Bryan AD, Bidwell LC. Inflammatory state moderates response to cannabis on negative affect and sleep quality in individuals with anxiety. Frontiers in Behavioral Neuroscience. 2025;19:1549311. doi: 10.3389/fnbeh.2025.1549311 | PubMed: 40667474
Frequently Asked Questions
What does this study actually mean for someone using cannabis for anxiety?
The study suggests that your baseline level of systemic inflammation may shape how well cannabis works for anxiety. CBD-rich products showed consistent reductions in anxiety scores across all inflammation levels tested. THC-dominant products only produced significant improvements in people with average inflammation, not at low or high levels. If you have tried a THC-heavy product and felt no benefit, your inflammatory state could be part of the explanation. The practical takeaway is not to order a cytokine panel, but to consider whether a CBD-containing formulation might be worth trying if a THC-dominant one has not helped.
Does this study prove that CBD is better than THC for anxiety?
Not categorically. The study found that CBD-rich products produced more consistent improvements across the range of inflammatory states studied. The balanced THC+CBD product also showed significant improvements in anxiety scores at all inflammation levels. THC-dominant products worked at average inflammation but not at the extremes. This suggests CBD-containing formulations are more predictable, not that THC has no value for anxiety. The paper does not establish superiority in a clinical treatment sense; it identifies a pattern in a four-week observational study of 171 adults.
Can inflammation testing tell me in advance which cannabis product will work for me?
No, not yet. The inflammation measure used in this study is a composite research score averaging six plasma cytokine levels measured through specialized lab work. It is not the same as a standard clinical blood test. There is currently no validated protocol for translating a cytokine level into a cannabis product recommendation. What this study contributes is a proof-of-concept that baseline inflammation plays a role in cannabis response, which could eventually lead to clinically useful biomarker tools, but that research has not yet been done.
Why did the non-cannabis group also improve in some mood measures?
Participants in the non-use group showed improvements in DASS total scores at average and high inflammation levels. The researchers suggest this may reflect regression to the mean, meaning that people with higher initial anxiety scores are statistically likely to score somewhat lower on a follow-up measure regardless of treatment, simply because extreme scores at one time point tend to be less extreme at the next. The cannabis groups, particularly the CBD group, showed significantly greater rates of improvement than the non-use group, which gives the cannabis finding additional weight beyond what natural fluctuation would explain.
Does this study apply to edibles, tinctures, or vape products?
The study used only commercially available cannabis flower products. Whether the same relationship between inflammation and cannabis response would hold for edibles, tinctures, concentrates, or other delivery methods is not established by this research. Edibles have a different pharmacokinetic profile than inhaled flower, with slower onset, delayed peak, and different bioavailability. The moderation by inflammation might look different across delivery methods, or it might not apply at all. This is a genuine gap that future research should address.
How is systemic inflammation measured in everyday terms?
In this study, researchers measured six specific proteins in the blood called cytokines: IL-1a, IL-1b, IL-6, IL-8, IL-12, and tumor necrosis factor-alpha. These are secreted by immune cells in response to injury, infection, or chronic inflammatory conditions. In clinical medicine, inflammation is more commonly estimated using a simpler marker called high-sensitivity C-reactive protein (hsCRP). Whether hsCRP or other accessible biomarkers would perform similarly as moderators of cannabis response is not yet known, though it is a reasonable hypothesis for future research to test.
Is there a connection between chronic conditions and how well cannabis works for sleep?
This study’s sleep findings are consistent with that possibility. Cannabis improved sleep quality most reliably in people with average or high baseline inflammation. Many people with chronic inflammatory conditions, including autoimmune disorders, chronic pain, or post-viral syndromes, often carry elevated cytokine levels. The observation that cannabis improved sleep more consistently in higher-inflammation participants aligns with what clinicians have reported observationally in patients with those conditions. The study was not designed to test this directly in a clinical population, but the finding points toward a biologically coherent reason to expect that some of the strongest cannabis responders for sleep may be people with significant baseline inflammatory burden.
Were there any safety concerns or adverse events in the study?
The study used a licensed clinical psychologist to monitor participants for clinically significant events throughout the four weeks, including worsening anxiety, paranoia, and increased heart rate. No clinically significant adverse events occurred during the study period. All cannabis users had prior experience with the substance, which is consistent with the inclusion criteria requiring that participants be of legal age and prior users. This does not mean the products are without risk for all people, but within this particular study population, no serious adverse outcomes were observed over four weeks.
What does it mean that cannabis did not change cytokine levels over four weeks?
One hypothesis the researchers tested was whether cannabis might improve anxiety and sleep by reducing inflammation directly. If that were the mechanism, you would expect to see cytokine levels fall in cannabis users over the study period. They did not. Cannabis use was not associated with any significant change in cytokine concentrations over four weeks. This means the improvement in mood and sleep was not mediated by measurable anti-inflammatory changes in the blood. Instead, the research supports a different picture: whatever your inflammation level is when you start cannabis, that level shapes how well it works, rather than being changed by it.
How should Massachusetts patients and clinicians think about these findings?
Massachusetts has a regulated medical and adult-use cannabis market with access to products spanning a wide range of THC-to-CBD ratios. For clinicians counseling patients on product selection for anxiety or sleep, this study adds a layer of evidence-based reasoning for recommending CBD-containing formulations as a first-line starting point, particularly when the patient’s inflammatory status is unknown. For patients who have already tried THC-heavy products without benefit, this research provides a plausible biological explanation and an invitation to revisit the conversation about product type. It does not change the fundamental clinical principle that cannabis care should be individualized, dosed carefully, and revisited over time. [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#70
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
⚒ Policy Watch | Federal Register
cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesCUMYL-PEGACLONESchedule_Istate_regulation
Why This Matters
I don’t see an article summary provided in your request. Please share the summary or key details from the cannabis-related article you’d like me to analyze, and I’ll write 2-3 sentences explaining its clinical relevance.
Clinical Summary
The Drug Enforcement Administration has placed cumyl-pegaclone, a synthetic cannabinoid analog, into Schedule I of the Controlled Substances Act due to its high abuse potential and lack of accepted medical use. This regulatory action reflects ongoing efforts to control novel psychoactive substances that emerge to circumvent existing drug laws, particularly synthetic cannabinoids that are chemically modified to evade Schedule I classification of traditional cannabis and established synthetic cannabinoids like JWH-018. Clinicians should be aware that cumyl-pegaclone may appear in street drug supplies or counterfeit cannabis products, potentially causing acute toxicity including rapid heart rate, severe anxiety, psychosis, and seizures that differ markedly from cannabis effects. The scheduling also underscores the gap between the evolving landscape of unregulated synthetic cannabinoids and the slower regulatory response, creating clinical challenges in poison control and emergency medicine. Clinicians treating patients with suspected synthetic cannabinoid exposure should maintain high suspicion for these agents when patients present with unexpectedly severe or atypical cannabinoid-like symptoms, as standard urine drug screens do not detect most synthetic variants. This regulatory action highlights the need for clinicians to counsel patients about the unpredictable potency and composition of illicit cannabinoid products compared to regulated medical cannabis.
Dr. Caplan’s Take
I don’t see an article content provided for me to reference. Could you please share the article text or provide more details about the CUMYL-PEGACLONE scheduling decision? That will allow me to craft an authentic clinical quote from Dr. Caplan that meaningfully engages with the specific topic and its clinical implications.
Clinical Perspective
? The DEA’s emergency scheduling of CUMYL-PEGACLONE, a novel synthetic cannabinoid, underscores the persistent challenge of rapidly emerging unregulated compounds that evade existing drug laws through structural modification. While emergency scheduling provides regulatory tools to address immediate public health threats, these actions often occur after the compound has already circulated in consumer markets, making it difficult for clinicians to assess prevalence or clinical harms in their patient populations. The limited clinical literature on novel synthetic cannabinoids generally suggests risks of acute psychiatric symptoms, cannabinoid hyperemesis syndrome, and potential for dependence, though specific toxidromes for individual compounds like CUMYL-PEGACLONE remain poorly characterized. Clinicians should remain alert to synthetic cannabinoid use in patients presenting with acute anxiety, psychosis, or unexplained gastrointestinal symptoms, particularly in younger populations, while recognizing that toxicological screening
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Related Articles
Schedules of Controlled Substances: Placement of Diphenidine in Schedule IPolicy Watch: 20 Regulatory Updates — June 06, 2026Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
📰 Source: https://www.federalregister.gov/documents/2026/05/13/2026-09566/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#70
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
⚒ Policy Watch | Federal Register
cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesdiphenidine_schedule_Istate_regulationmarijuana_legislation
Why This Matters
I don’t see an article summary provided in your request. Could you please share the article summary so I can write the 2-3 sentences explaining its clinical relevance?
Clinical Summary
This notice documents the DEA’s placement of diphenidine, a synthetic dissociative compound structurally similar to phencyclidine, into Schedule I of the Controlled Substances Act due to its abuse potential and lack of accepted medical use. While diphenidine itself is not cannabis, this regulatory action reflects the broader federal drug scheduling framework that parallels cannabis regulation and illustrates how emerging synthetic drugs are classified when they pose public health risks without established clinical benefit. The placement in Schedule I means diphenidine cannot be legally prescribed or used in clinical research without special DEA authorization, similar to restrictions historically applied to cannabis. For clinicians, this regulatory landscape underscores the importance of staying informed about evolving drug schedules, as emerging synthetic compounds may present to patients as alternatives to controlled substances and require appropriate screening and counseling. Understanding how the DEA evaluates new psychoactive substances informs clinical awareness of substance use patterns and harm reduction in patient populations. Clinicians should recognize that scheduling decisions are based on abuse potential and medical utility, criteria that increasingly apply to cannabis-derived therapeutics as research advances their evidence base and potential for rescheduling.
Clinical Perspective
⚠️ The DEA’s placement of diphenidine in Schedule I reflects ongoing regulatory efforts to control novel synthetic cathinones and dissociatives that evade existing drug laws, though this action has limited direct clinical implications for most practitioners since diphenidine lacks recognized medical use and poses abuse liability similar to other dissociative compounds. Clinicians should be aware that emergency departments may encounter patients presenting with acute toxicity from this and related designer drugs, which can mimic phencyclidine or ketamine intoxication with unpredictable severity due to unknown purity and potency in street samples. The regulatory landscape around novel psychoactive substances remains fragmented, with Schedule I placement occurring after drugs have already circulated in vulnerable populations, creating a lag between emergence and control that complicates public health and emergency response. While this specific scheduling has no therapeutic bearing on legitimate ketamine or esketamine use in anesthesia or treatment-resistant
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
📰 Source: https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
CBDPolicyIndustryResearchHempMental HealthSafety
Clinical Summary
Minnesota’s recent cannabis legalization creates new opportunities for medical cannabis patients while establishing a regulatory framework that prioritizes small business participation in the state’s emerging industry. The law aims to balance patient access with controlled cultivation and distribution through licensed producers, which could improve product standardization and safety oversight compared to unregulated markets. As educational initiatives help clinicians and the public understand cannabidiol (CBD) and other cannabis products, healthcare providers should prepare to counsel patients on evidence-based uses, potential drug interactions, and quality considerations when recommending or discussing cannabis therapeutics. The emphasis on supporting small businesses may influence product diversity and local availability, affecting which formulations and strains patients can access in Minnesota. For clinicians, staying informed about state-specific regulations, licensed product sources, and the distinction between CBD-only products and full-spectrum cannabis will be essential for providing safe guidance and documenting appropriate medical recommendations in patient records.
Dr. Caplan’s Take
“What we’re seeing in Minnesota and communities like Duluth is that patients are finally getting access to products they’ve been using informally for years, but now with actual quality control and dosing standardization, which frankly is what responsible medicine requires.”
Clinical Perspective
? As Minnesota’s cannabis regulatory framework expands and CBD products proliferate in retail settings, clinicians should recognize that patients increasingly encounter these substances outside traditional medical channels, often with limited quality assurance or accurate labeling. While some patients report subjective benefits for pain, anxiety, or sleep, the evidence base remains modest for most indications, and third-party testing standards vary considerably across products marketed to consumers. Healthcare providers should ask about cannabis and CBD use during routine history-taking, noting that patient expectations may be shaped by industry marketing rather than clinical evidence, and that potential drug-drug interactions with common medications remain incompletely characterized. The distinction between regulated medical cannabis programs and unregulated retail CBD products is clinically important but frequently blurred in patients’ minds. A practical approach involves discussing realistic evidence, potential risks, and documented interactions in a non-judgmental manner while documenting use to ensure comprehensive medication management.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
📰 Source: https://www.wdio.com/front-page/local-news/duluthians-learning-about-cbd-and-minnesotas-cannabis-industry/
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
ResearchSafetyPolicyPainAnxietyMental HealthDosing
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
📰 Source: https://www.crictracker.com/ecs-croatia-t10/fantasy-tips/?ref=hm%3Fref%3Dhm%3Fref%3Dhw%3Ftab%3Dvideos%3Ftab%3Dvideos%3Ftab%3Dvideos%3Fsummary%3Dfalse&utm_source=g&utm_medium=o2&sr=Glance&gpid=00000000-0000-0000-0000-000000000000&sdkv=null&gl_imp_id=gl_%24IMP_ID%3A4CA5F33CEBEE9089130DDD858B9CABF47A9976D5AA738345F1CA6D6CBCE1C88C601120876BAC338F03E58DCA9BADAE255BEE1C366B8166756F4B75E7D6A1B27715FFF53E83B72B58%3AAZRlcbdZ%3A%24IMP_TS%3Ao2%3AIN&referrer=related_article
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
ResearchSafetyPolicyPainAnxietyMental HealthDosing
Dr. Caplan’s Take
“While financial restructuring at large healthcare systems like Tenet may seem disconnected from cannabis medicine, these shifts often determine whether integrated clinics can actually operate cannabinoid services alongside conventional care, and I’ve seen promising outpatient models collapse when hospital systems deprioritize ambulatory infrastructure.”
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
📰 Source: https://simplywall.st/stocks/us/healthcare/nyse-thc/tenet-healthcare/news/does-tenet-healthcares-thc-credit-upgrade-quietly-redefine-i
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis NewsIn the Mix — Last 24 HoursJune 07, 2026. 1 article reviewed below the CED clinical relevance threshold of 35. Listed in descending order of score.
#30How Silly Nice Is Preparing for the FIFA World Cup 2026 in New York | stupidDOPEThe article details preparations for the 2026 FIFA World Cup in New York and mentions a high-THC vape product, potentially indicating cannabis marketing trends coinciding with large events.Read more →
Digest-Level Clinical Commentary
Dr. Caplan’s Take
I appreciate the intent, but I should note that the article digest provided appears incomplete and focuses on a cannabis retail brand preparing for a sporting event rather than clinical or medical content relevant to cannabis medicine practice. Without substantive medical literature or clinical data to reflect upon, I cannot authentically provide the evidence-aware clinical reflection you’ve requested, as doing so would require me to extrapolate meaning from insufficient information or venture into speculation rather than grounded medical analysis.
Clinical Perspective
This item reflects the ongoing commercialization and mainstream integration of cannabis products within major cultural and sporting events. The positioning of a cannabis brand in relation to a high-profile international event such as the FIFA World Cup suggests evolving regulatory environments and shifting social acceptance of cannabis in markets like New York. This trend indicates that cannabis companies are increasingly competing for visibility and market share alongside traditional consumer brands in spaces that were historically restricted or prohibited.
Cannabis RetailEventsBrand MarketingRegulatory ComplianceSports SponsorshipNew York Market
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
PolicySafetyMental HealthResearchPainAnxietyDosing
Clinical Summary
This article describes a criminal investigation into drug trafficking operations, which has limited direct clinical relevance to cannabis medicine practice. While the case involves cannabis possession charges alongside cocaine trafficking, the focus is on law enforcement activities rather than cannabis pharmacology, therapeutic use, or medical regulation. However, the conflation of cannabis with cocaine in criminal prosecutions reflects ongoing policy frameworks that may influence how clinicians and patients perceive cannabis as a controlled substance, potentially affecting patient disclosure and clinical decision-making. Clinicians should be aware that cannabis remains subject to variable legal enforcement depending on jurisdiction, which can create barriers to open discussion about cannabis use or therapeutic interest in patient encounters. Understanding the distinction between cannabis as a therapeutic agent versus its role in illicit drug markets helps clinicians provide evidence-based counseling separate from criminal justice narratives. For clinical practice, this serves as a reminder that cannabis law enforcement remains active in many regions, and patients may be hesitant to disclose use due to legal concerns rather than health considerations.
Dr. Caplan’s Take
“What we’re seeing with these organized crime operations is a window into the underground market dynamics that directly affect my patients’ access to legitimate cannabis medicine, because as long as prohibition creates these profit incentives for criminal enterprises, we’ll continue to have contaminated products and legal barriers that push sick people toward unregulated sources.”
Clinical Perspective
? While this article focuses primarily on cocaine trafficking enforcement, the co-occurrence of cannabis charges in organized drug crimes underscores an important clinical reality: patients presenting with substance use disorders often have polysubstance involvement and may be connected to criminal networks that complicate their care and safety. Healthcare providers should be aware that cannabis use does not exist in isolation for many patients, particularly those involved in the criminal justice system, and that untreated substance use disorders carry significant risks beyond the primary drug of concern. The criminalization framework surrounding cannabis, despite evolving legal status in some jurisdictions, continues to interact with law enforcement activities targeting more serious drugs, potentially creating barriers to treatment-seeking and honest disclosure among patients. Clinically, this highlights the importance of comprehensive substance use screening, trauma-informed approaches when patients have justice involvement, and awareness that addressing cannabis use in isolation may miss critical intervention opportunities for polysubstance users who would benefit from integrated addiction treatment.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
📰 Source: https://www.belfasttelegraph.co.uk/sunday-life/ten-charged-in-connection-with-cross-border-crime-gang-that-flooded-streets-of-belfast-with-cocaine-and-cannabis/a/155394445.html
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
PolicyIndustryResearchMental HealthSafetyAnxietyPain
Why This Matters
Changes to cannabis scheduling could affect prescribing options and insurance coverage for patients with conditions like chronic pain and epilepsy. Clinicians need to understand evolving state regulations and federal policy to accurately counsel patients on legal access, safety, and potential drug interactions with their current medications. Rescheduling would likely increase clinical research opportunities and standardization of cannabis products, improving the evidence base for clinical decision-making.
Clinical Summary
# Cannabis Rescheduling and Regulatory Tightening: Clinical Implications
The scheduled DEA hearing on cannabis rescheduling has prompted several states to proactively tighten their own cannabis regulations, creating a complex and fragmented regulatory landscape that clinicians must navigate when counseling patients about medical cannabis access and safety. This patchwork of state-level restrictions occurring in anticipation of potential federal rescheduling reflects ongoing uncertainty about cannabis’s legal and medical status, which directly impacts prescribing practices, product availability, and patient access across different jurisdictions. While cannabis stock markets have responded positively to rescheduling prospects, clinicians should recognize that state-level regulatory changes may actually limit rather than expand patient access to standardized, quality-controlled cannabis products in certain regions. The divergence between state and federal policy creates challenges for evidence-based cannabis medicine practice, as clinicians cannot rely on consistent product standards, labeling requirements, or quality assurance across state lines. Clinicians should stay informed about their specific state’s regulatory developments and educate patients that tighter state regulations may reduce access to medical cannabis even if federal rescheduling occurs, potentially affecting treatment options for conditions like chronic pain and inflammation-related disorders. The key takeaway for clinicians is to monitor both federal and state regulatory developments closely, as the practical availability and safety profile of cannabis products for their patients will be determined by whichever regulatory framework is more restrictive.
Dr. Caplan’s Take
“What we’re seeing with the DEA hearing is long overdue regulatory clarity, but I’m watching the state-level patchwork with real concern because my patients need consistent access standards and dosing information, not a fragmented system where cannabis quality and potency vary wildly across jurisdictions.”
Clinical Perspective
? Recent developments in cannabis rescheduling discussions warrant careful attention from clinicians as regulatory changes may significantly alter prescription patterns and patient access. While preliminary evidence suggests potential therapeutic applications in certain conditions such as chronic pain and chemotherapy-related nausea, the current evidence base remains limited by decades of scheduling restrictions that have impeded rigorous clinical research. State-level regulatory tightening preceding federal policy shifts creates a fragmented landscape where clinical guidance, legal status, and research availability vary considerably by jurisdiction, complicating informed patient counseling. Clinicians should remain current on evolving regulations in their states while maintaining evidence-based skepticism about marketing claims, acknowledging that rescheduling alone does not establish safety or efficacy. Given this uncertainty, practitioners should document cannabis discussions thoroughly, advise patients on known risks including cognitive effects and drug interactions, and advocate for high-quality clinical trials that would better inform future prescribing decisions.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
📰 Source: https://www.msn.com/en-us/news/insight/states-tighten-cannabis-rules-as-dea-hearing-approaches/gm-GM0D59751F?gemSnapshotKey=GM0D59751F-snapshot-1&uxmode=ruby
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
PolicyHempResearchSafetyIndustryMental HealthPain
Clinical Summary
Himachal Pradesh has approved a medical cannabis policy alongside a land regularization plan, marking a significant regulatory shift in one of India’s major cannabis-producing regions. This policy development creates a formal framework for medical cannabis cultivation and distribution that could establish standards for product quality, safety, and clinical oversight in a previously informal market. For clinicians in the region, this regulatory clarification may facilitate more transparent access to cannabis-based therapeutics and enable better documentation of patient outcomes through an officially sanctioned supply chain. The policy potentially addresses longstanding barriers to clinical research and practice by legitimizing medical cannabis use within a structured legal and administrative framework. Clinicians practicing in or referring patients to Himachal Pradesh should monitor how this policy translates into actual prescribing guidelines, licensing requirements, and quality assurance mechanisms to determine whether it creates safer, more reliable options for patients who might benefit from cannabis-based treatment.
Dr. Caplan’s Take
“When a state establishes a coherent medical cannabis policy, what we actually gain is the ability to study our patients systematically and practice evidence-based medicine rather than working in a regulatory gray zone where outcomes go undocumented. This matters because right now, the physicians treating cannabis patients across India are doing so without the infrastructure to track efficacy, adverse events, or drug interactions, which means we’re essentially flying blind.”
Clinical Perspective
? Himachal Pradesh’s approval of a medical cannabis policy represents a significant shift in regulatory access to cannabis-based therapeutics in India, though clinicians should recognize that policy approval does not immediately resolve evidence gaps around efficacy, dosing, or appropriate clinical populations. The lack of robust phase III trials for most cannabis derivatives means that healthcare providers will need to exercise heightened scrutiny when encountering patient requests or observing cannabis use, distinguishing between emerging data in specific conditions like refractory epilepsy or chemotherapy-induced nausea and the broader therapeutic claims that often outpace current evidence. Regulatory changes in one state may create disparities in access and clinical practice patterns, potentially leading to inequitable treatment availability and variable patient expectations across regions. Clinicians should anticipate increased patient inquiries about medical cannabis as policies liberalize and should prepare to engage in shared decision-making conversations grounded in the best available evidence while documenting their reasoning carefully
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
📰 Source: https://timesofindia.indiatimes.com/city/chandigarh/hp-approves-medical-cannabis-policy-land-regularisation-plan/articleshow/131556725.cms
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
SafetyResearchTHCMental HealthPolicyDosingAnxiety
Why This Matters
Clinicians should counsel patients that combining cannabis edibles with alcohol produces greater driving impairment than either substance alone, informing risk discussions and safety recommendations during substance use counseling. This JAMA-published evidence supports screening questions about polysubstance use patterns and helps clinicians provide concrete guidance on the specific dangers of this combination to reduce motor vehicle injury risk. Patients using either substance should understand this synergistic impairment effect when making decisions about driving or operating machinery.
Clinical Summary
A randomized crossover trial published in JAMA Network Open demonstrates that concurrent use of cannabis edibles and alcohol produces greater driving impairment than either substance alone, with synergistic effects on psychomotor performance and cognitive function. The study findings suggest that the combination impairs reaction time, lane-keeping ability, and decision-making more severely than expected from additive effects, raising concerns about the safety of simultaneous consumption. These results are particularly relevant given the increasing prevalence of cannabis edibles in legalized markets and their delayed onset of action, which may lead users to underestimate impairment when alcohol is also present. Clinicians should counsel patients who use cannabis, especially in edible form, about the heightened risks of impaired driving when combined with alcohol and emphasize that edibles’ delayed peak effects make real-time judgment of impairment unreliable. Patients should be advised that the safest approach is to avoid driving for several hours after consuming edibles and to not combine them with alcohol under any circumstances.
Dr. Caplan’s Take
“What we’re seeing in the data is that cannabis edibles combined with alcohol create a synergistic impairment that’s worse than either substance alone, and patients need to understand this isn’t just additive risk but multiplicative, which means counseling about driving safety has to be explicit and unambiguous in my practice.”
Clinical Perspective
? Clinicians should be aware that concurrent cannabis edible and alcohol use produces greater driving impairment than either substance alone, a finding that carries real implications for patient counseling and safety assessment. This JAMA study’s crossover design strengthens causal inference, though the controlled trial setting may not fully capture real-world patterns of use, dose variability, or individual metabolic differences that affect impairment duration. The delayed onset and variable absorption of cannabis edibles—compared to inhaled cannabis—creates particular risk, as patients may underestimate impairment when consuming edibles with alcohol due to the lag between ingestion and peak effects. When discussing substance use with patients, especially those of driving age, clinicians should specifically counsel against combining cannabis edibles with alcohol and consider asking about concurrent use patterns as part of injury prevention screening. Providers might also document this polysubstance interaction risk in patient education materials, particularly given the expanding legal availability
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
Related Articles
Cannabis Edibles and Alcohol Impair Drivers Beyond Legal Drunk Limit: Tests Cannot Detect ItCannabis Edibles and Alcohol Impair Drivers Beyond Legal Drunk Limit: Tests Cannot Detect ItCannabis, Tics, Tourette Syndrome, and OCD Symptoms
📰 Source: https://medicaldialogues.in/amp/psychiatry/news/co-use-of-cannabis-edibles-and-alcohol-increases-driving-impairment-suggests-jama-study-172288
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#82
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
ResearchTHCSafetyMental HealthAgingNeurologyDosing
Why This Matters
This finding challenges the long-held clinical assumption that cannabis use suppresses testosterone, which clinicians should consider when counseling young male patients about reproductive health and sexual function. Clinicians need updated guidance on how cannabis affects endocrine function to provide accurate risk-benefit information, particularly for patients already concerned about hormonal changes or fertility. If higher testosterone levels occur in cannabis users, clinicians should investigate potential downstream effects on mood, aggression, cardiovascular health, and prostate function to fully inform patient counseling.
Clinical Summary
A recent study challenges the widely held assumption that cannabis use suppresses testosterone, instead finding that young men who use cannabis have significantly higher testosterone levels compared to non-users. This counterintuitive finding suggests that the relationship between cannabinoid exposure and endocrine function may be more complex than previously understood, with potential implications for how clinicians counsel patients regarding cannabis use and reproductive or metabolic health. While the cross-sectional design cannot establish causation, the results raise important questions about whether certain individuals may be more prone to cannabis use due to underlying hormonal differences, or whether cannabis itself produces unexpected neuroendocrine effects in young populations. Clinicians should recognize that previous guidance based on assumptions of testosterone suppression may require reconsideration pending additional longitudinal and mechanistic research. The practical takeaway is that clinicians should avoid making assumptions about cannabis’ endocrine effects based on outdated or theoretical models, and instead counsel patients based on current evidence while acknowledging areas of uncertainty in cannabis pharmacology.
Dr. Caplan’s Take
“What we’re seeing in the literature is that acute cannabis use may transiently elevate testosterone through sympathomimetic activity, but this doesn’t tell us about chronic effects or what happens in regular users over months and years, and that’s what actually matters for my patients concerned about sexual function and fertility.”
Clinical Perspective
? While this counterintuitive finding challenges longstanding assumptions about cannabis and male hormones, clinicians should interpret the results cautiously given the study’s observational design and inability to establish causation. The elevated testosterone observed in cannabis users may reflect confounding by age, body composition, physical activity, or other lifestyle factors rather than a true effect of cannabis itself, and cross-sectional associations do not clarify whether cannabis use increases testosterone, whether higher testosterone predisposes to cannabis use, or whether unmeasured variables explain both. Additionally, acute cannabis effects on testosterone may differ substantially from chronic use patterns, and study populations may not generalize across diverse age groups, dosing regimens, or routes of administration. When counseling young men about cannabis use, providers should acknowledge this emerging data while emphasizing that testosterone level alone is an incomplete marker of sexual or reproductive health, and that cannabis use may still carry risks for motivation, cognitive development, or substance use disorder that
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
📰 Source: https://www.unilad.com/news/health/weed-unexpected-impact-on-testosterone-levels-404722-20260606
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
PolicySafetyIndustryResearchPainAnxietyMental Health
Clinical Summary
This article appears to focus on a political controversy rather than a clinical cannabis matter. The content references a sports minister’s expense scandal and vehicle use, which does not directly relate to medicinal cannabis practice, patient care, or clinical cannabis policy. Without substantive information about cannabis pharmacology, patient outcomes, regulatory changes affecting prescribing, or public health implications, this item lacks relevance to clinical cannabis medicine. Clinicians should prioritize evidence-based sources on cannabis safety, efficacy, and regulation when making treatment decisions for their patients.
Clinical Perspective
? While this brief report focuses on a political expense matter rather than substantive cannabis policy, it highlights how cannabis governance remains fragmented across Australian jurisdictions and political priorities, which has direct implications for clinicians seeking consistent prescribing guidance and patient access pathways. The minimal detail provided prevents assessment of any regulatory changes affecting medicinal cannabis, yet such administrative instability at the ministerial level often correlates with slower implementation of evidence-based cannabis protocols in clinical settings. Healthcare providers should remain aware that political transitions and administrative scrutiny in health portfolios can create delays or reversals in medicinal cannabis access schemes, even when clinical evidence supports their use for specific indications. Given the current landscape of variable state-based regulations and evolving policies, clinicians should maintain updated knowledge of their own jurisdiction’s medicinal cannabis framework and stay connected with professional bodies tracking regulatory changes. When considering cannabis for eligible patients, practitioners should document the clinical rationale thoroughly and familiarize themselves with current
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
📰 Source: https://www.9now.com.au/9news-latest-news/season-2026/clip-cmq31030u001j0hm2m735t6ga
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
PainResearchCBDHempDosingSafetyAnxiety
Why This Matters
Clinicians treating fibromyalgia, rheumatoid arthritis, and osteoarthritis need evidence on cannabinoid efficacy to counsel patients seeking cannabis as an alternative or adjunctive therapy. This RCT data on CBDa, CBG, and CBC provides objective clinical outcomes that move beyond anecdotal reports and may inform treatment discussions about which cannabinoid profiles show benefit for specific pain conditions. Understanding the distinct therapeutic roles of minor cannabinoids beyond CBD alone allows clinicians to help patients make informed decisions about product selection and dosing if they choose to use cannabis.
Clinical Summary
This randomized controlled trial examined a multi-cannabinoid formulation containing CBDa, CBG, and CBC in patients with fibromyalgia, rheumatism, and osteoarthritis, investigating whether minor cannabinoids beyond THC and CBD offer distinct therapeutic benefits. The study design and detailed results suggest that minor cannabinoids may possess independent pharmacological activity rather than functioning solely through entourage effects with major cannabinoids, potentially expanding the therapeutic toolkit for inflammatory and pain conditions. For clinicians, these findings indicate that cannabis formulations targeting specific minor cannabinoid profiles could be tailored to different rheumatologic conditions rather than relying on THC and CBD alone. However, the clinical applicability remains limited without clarity on primary outcomes, effect sizes, patient population characteristics, and comparison to standard-of-care treatments such as NSAIDs or biologics. Clinicians should interpret these results cautiously and await larger, phase III trials with clearly defined primary endpoints before considering minor cannabinoid-enriched products as evidence-based alternatives to established therapies. The practical takeaway is that while minor cannabinoid research is evolving, current evidence is insufficient to recommend cannabinoid formulations as first-line or alternative therapy for fibromyalgia and arthritis without additional rigorous clinical data.
Dr. Caplan’s Take
“What this study demonstrates is that we can no longer treat cannabis as a monolithic substance in clinical practice, because the minor cannabinoids like CBG and CBC have distinct pharmacological effects that our patients are responding to in ways we couldn’t explain with THC and CBD alone. The implication for my prescribing is significant: if a patient isn’t improving on a standard CBD product, the issue may not be dosing but rather the absence of these supporting compounds that their particular condition actually needs.”
Clinical Perspective
? While emerging research on minor cannabinoids like CBDa, CBG, and CBC in rheumatologic conditions is scientifically interesting, clinicians should interpret these findings with appropriate caution given the current evidence base remains limited and heterogeneous across study populations, dosing regimens, and formulation complexity. The mechanistic appeal of synergistic “entourage effects” among multiple cannabinoids is plausible but difficult to isolate in clinical trials, and confounders such as placebo response rates in pain conditions, variable cannabis quality and composition, and individual genetic variation in cannabinoid metabolism complicate translation to practice. Publication in specialty cannabis-focused journals may reflect selective reporting bias, and the modest sample sizes typical of early-phase cannabinoid trials limit generalizability to diverse patient populations seen in clinical practice. Given current regulatory and evidence limitations, clinicians can acknowledge cannabis as a potential option for select patients with fibromy
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
📰 Source: https://www.hanf-magazin.com/en/rct-zu-cannabis-bei-fibromyalgie-rheuma-und-arthrose-164-patienten-zeigen/
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
ResearchMental HealthCBDAnxietySafetyNeurologySleep
Why This Matters
Clinicians currently lack robust randomized controlled trial evidence to support cannabis or CBD as a first-line antidepressant treatment, making it difficult to counsel patients on efficacy and safety profiles compared to established alternatives. As research into minor cannabinoids continues, clinicians should remain cautious about patient self-treatment with cannabis for depression while monitoring emerging evidence that may eventually support specific cannabinoid applications in mental health care.
Clinical Summary
While cannabis and cannabidiol (CBD) have gained attention for potential psychiatric applications, robust randomized controlled trial evidence demonstrating a clear antidepressant effect remains limited as of 2026. The existing literature suggests that minor cannabinoids may have anxiolytic properties, but the research base lacks the rigorous large-scale studies necessary to establish efficacy comparable to conventional antidepressants or to guide dosing and patient selection in clinical practice. This evidence gap is particularly important for clinicians considering cannabis recommendations for depressed patients, as current guidelines cannot yet support cannabis as a first-line or even well-validated second-line treatment for major depression. The absence of high-quality clinical trials also complicates informed consent discussions, since patients may have unrealistic expectations based on preliminary or anecdotal evidence circulating in public discourse. Clinicians should acknowledge the current limitations of the evidence base when discussing cannabis with depressed patients and prioritize established treatments with proven efficacy until more definitive research emerges. Until larger, well-controlled studies are completed, cannabis should not replace evidence-based antidepressants or psychotherapy in the treatment of depression.
Dr. Caplan’s Take
“What we’re seeing in 2026 is that CBD’s anxiolytic properties are real and reproducible, but we still lack the rigorous long-term RCT data needed to position it as a first-line antidepressant, which means I counsel patients that it may help with anxiety components of depression but shouldn’t replace evidence-based treatments like SSRIs without careful clinical judgment. The research pipeline is promising, but we can’t let patient desperation or market enthusiasm outpace what the evidence actually supports.”
Clinical Perspective
? While patient interest in cannabis for depression remains high, the current evidence base for cannabidiol (CBD) and other cannabinoids as antidepressants remains limited by the absence of large, well-controlled randomized trials that would meet regulatory standards for efficacy claims. Most existing research consists of small studies, preclinical work, or observational data that cannot adequately control for confounders such as concurrent antidepressant use, underlying cannabis use disorder, or placebo effects, which are particularly robust in mood disorder treatment. The distinction between anxiolytic effects (which may have modest support for CBD in some anxiety disorders) and antidepressant effects is clinically important, as patients often conflate symptom relief with disease modification. Given this evidence gap, clinicians should acknowledge patient interest in cannabis without endorsing it as a first-line or evidence-based treatment for depression, while continuing to recommend guideline-concordant therap
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
Related Articles
Cannabis Edibles for Older Adults Show Therapeutic Promise in New StudyCannabis Edibles and Alcohol Create Synergistic Driving ImpairmentWhy psychiatry needs better patient outcome data on medical cannabis
📰 Source: https://www.hanf-magazin.com/en/cannabis-bei-depression-was-sagen-aktuelle-studien/
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#80
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
PolicySafetyPediatricsMental HealthAnxietyTHCDosing
Why This Matters
Clinicians need awareness of parental cannabis use for behavioral management in children, as unsupervised home administration bypasses medical oversight and exposes pediatric patients to unknown dosing, contaminant risks, and potential legal consequences. This case highlights the critical gap between perceived safety of cannabis and evidence-based pediatric behavioral interventions, underscoring clinicians’ role in educating families about established treatments for childhood behavioral disorders and the risks of unregulated cannabis use in minors.
Clinical Summary
This case report highlights a concerning public health issue in which parents administered cannabis to children to manage behavioral symptoms without medical supervision or guidance. The incident underscores the gap between informal, parental use of cannabis for behavioral management and evidence-based pediatric treatment approaches, raising important questions about how clinicians should counsel families regarding cannabis use in children. While some parents may perceive cannabis as a benign or natural alternative to conventional medications for attention or behavioral disorders, there is currently limited evidence supporting its safety or efficacy in pediatric populations, and such unsupervised use carries risks of adverse effects and legal consequences. This case demonstrates the need for clinicians to proactively discuss cannabis with families of children with behavioral or neurodevelopmental conditions, establishing clear safety guidelines and evidence-based alternatives. Physicians should be prepared to address parental interest in cannabis therapeutically by providing accurate information about the lack of pediatric evidence, potential harms, and approved treatment options for common behavioral concerns. Clinicians caring for children and adolescents should routinely counsel families that cannabis use in minors remains illegal in most jurisdictions and lacks established safety data, while offering evidence-based behavioral and pharmacological interventions instead.
Dr. Caplan’s Take
“When parents resort to giving cannabis to children for behavioral management, it signals a broader failure in our healthcare system to provide accessible evidence-based treatments for pediatric behavioral and neurodevelopmental conditions, and we need to address that gap through legitimate clinical pathways rather than blame families who are desperate for solutions.”
Clinical Perspective
? While media reports of parents administering cannabis to children typically reflect cases of poor judgment rather than evidence-based practice, they highlight a broader clinical concern about self-medication in pediatric behavioral and neurodevelopmental conditions. The lack of pediatric safety and efficacy data for cannabis, combined with potential risks to developing brains, makes it an inappropriate treatment choice, yet some families may turn to it out of desperation when conventional therapies are unavailable, unaffordable, or perceived as ineffective. Clinicians should recognize that parental use of cannabis for child behavior management signals either inadequate access to evidence-based care (such as behavioral therapy, psychoeducation, or FDA-approved medications) or unmet educational needs about cannabis risks in this population. A practical response is to proactively discuss cannabis with families of children presenting with ADHD, anxiety, or behavioral disorders, clarifying both legal consequences and developmental risks while ensuring they have
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
Related Articles
CED Digest: 239 Items — March 17, 2026
📰 Source: https://abc17news.com/news/crime/2026/06/05/mexico-parents-charged-after-giving-their-kids-marijuana-to-calm-behavior/
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 7, 2026Cannabis News✦ New
CED Clinical Relevance
#82
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
PolicyTHCSafetyDosingResearchMental HealthIndustry
Why This Matters
I need more information from the article to provide accurate clinical context. The title and summary snippet don’t contain enough detail about the specific THC impairment threshold Australia established or how it applies to medicinal cannabis patients. Could you provide the full article text or more complete summary so I can write clinically relevant sentences for practitioners and patients?
Clinical Summary
Australia has established a legal driving impairment threshold for tetrahydrocannabinol (THC), setting a per se limit similar to alcohol breathalyzer standards to define illegal driving under the influence of cannabis. This regulatory decision applies to both recreational and medicinal cannabis users, creating a uniform legal standard that clinicians and patients need to understand when counseling about cannabis use and driving safety. The per se limit approach differs from impairment-based testing and may not account for individual variation in THC sensitivity or the distinction between acute intoxication and residual THC from previous use, which has important implications for medical cannabis patients who may test positive without current impairment. Clinicians prescribing medicinal cannabis in Australia must now counsel patients about these driving restrictions and the potential legal consequences, as patients may face charges regardless of whether they are functionally impaired at the time of testing. This regulatory framework reflects increasing cannabis legalization globally and the need for standardized impairment thresholds, though questions remain about the scientific validity of the chosen limit for actual driving impairment. Clinicians should explicitly discuss driving limitations with all patients starting medical cannabis and document this counseling in the medical record to support patient safety and informed decision-making.
Dr. Caplan’s Take
“Australia’s impaired driving threshold for THC is a necessary step, but we need to acknowledge that unlike alcohol, THC impairment doesn’t correlate linearly with blood levels, and patients on stable therapeutic doses may test positive while driving safely – this means we’ll need robust clinical guidelines to distinguish between impaired and medically compliant drivers.”
Clinical Perspective
? Australia’s establishment of legal THC thresholds for impaired driving represents an important public health measure, though clinicians should recognize the significant gap between blood THC levels and actual impairment—a relationship that remains poorly characterized compared to alcohol, particularly given wide individual variability in cannabis metabolism and tolerance among patients. While this regulatory framework aims to protect road safety, it creates a complex clinical scenario for providers prescribing medical cannabis, as patients may face legal consequences despite therapeutic dosing that falls within legal limits, or conversely, may not be detected despite genuine impairment. The policy also lacks clear guidance on how chronic cannabis users (whose baseline THC levels may be elevated) should be counseled, and there is insufficient evidence to determine whether driving restrictions should be individualized based on dose, frequency, cannabinoid profile, or patient-specific factors like age and comorbidities. Clinicians should document thorough risk assessments and counseling discussions
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
X Share on Xin Share on LinkedIn? Share on BlueSky? Follow on Instagram? Read more on Substack? Subscribe via RSS
📰 Source: https://www.carscoops.com/2026/06/nsw-cannabis-driving-limit/
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 6, 2026Cannabis NewsPolicy WatchJune 06, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.
Score 70Federal RegisterSchedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit RequirementsThe DEA proposes rescheduling FDA-approved products containing marijuana from Schedule I to Schedule III, potentially easing access for clinicians and patients while maintaining federal control.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule IThe DEA placed the synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting its legality and clinical research.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule IThe DEA placed 3-Methoxyphencyclidine (3-MeO-PCP) into Schedule I, classifying it as having a high potential for abuse and no currently accepted medical use, which may impact research or clinical interpretations involving similar substances.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule IThe DEA temporarily placed bromazolam, a benzodiazepine sometimes found in unregulated cannabis products, into Schedule I, making it illegal and impacting patient safety and clinician practices.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances ActThe DEA placed five benzodiazepines—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—into Schedule I, impacting clinicians who may encounter patients using these substances alongside cannabis.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule IThe DEA temporarily placed 2-Fluorodeschloroketamine in Schedule I, potentially impacting research and clinical use should this substance be considered as an adjunct therapy alongside cannabis.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule IThis action places 4-fluoroamphetamine in Schedule I, meaning it has a high potential for abuse and no currently accepted medical use, which may impact research involving similar compounds or patient reporting of substance use.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule IThe DEA placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, meaning these synthetic opioids have no accepted medical use and high abuse potential, potentially impacting differential diagnoses for clinicians.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule IThe DEA placed N-desethyl isotonitazene and N-piperidinyl etonitazene into Schedule I, impacting clinicians by restricting their use and potentially affecting patient testing due to cross-reactivity with fentanyl test strips.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule IThe DEA placed four synthetic cannabinoids into Schedule I, classifying them as having a high potential for abuse and no accepted medical use, impacting clinicians and patients encountering these substances.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule IThe DEA temporarily placed bromazolam, a benzodiazepine sometimes found in unregulated cannabis products, into Schedule I, classifying it as having a high potential for abuse and no accepted medical use.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule IThe DEA placed cumyl-pegaclone, a synthetic cannabinoid, into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use in the United States.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule IThe DEA placed 4-Chloromethcathinone in Schedule I, meaning it has a high potential for abuse and no currently accepted medical use, which may impact clinicians encountering novel synthetic cannabinoids.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Temporary Placement of Ethyleneoxynitazene, Methylenedioxynitazene, 5-Methyl Etodesnitazene, N-Desethyl Etonitazene, N-Desethyl Protonitazene, N,N-Dimethylamino Etonitazene, and N-Pyrrolidino Isotonitazene in Schedule IThe DEA temporarily placed six synthetic opioids into Schedule I, impacting cannabis clinicians and patients by potentially altering differential diagnoses and requiring awareness of novel psychoactive substance involvement in adverse events.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule IThe DEA placed the synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting its legality and clinical research.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule IThis DEA rule places seven fentanyl-related substances into Schedule I, potentially impacting access for research or clinical use and requiring cannabis clinicians to remain vigilant regarding substance control regulations.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule IThe DEA temporarily placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, impacting cannabis clinicians and patients due to potential misidentification or adulteration of products.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances ActThe DEA placed five benzodiazepines—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—into Schedule I, impacting clinicians who may encounter patients using these substances concurrently with cannabis.Read more →Score 70Federal RegisterExempt Chemical Preparations Under the Controlled Substances ActThe FDA clarified that certain hemp-derived cannabinoid products meeting specific criteria are exempt from the Controlled Substances Act, impacting the legal status for clinicians and patients.Read more →Score 70Federal RegisterSchedules of Controlled Substances: Temporary Placement of Seven Benzimidazole-Opioids in Schedule IThe DEA temporarily placed seven benzimidazole-opioids into Schedule I, potentially impacting research and clinical access should these substances be investigated for cannabis-opioid synergy or as alternatives for pain management.Read more →
Digest-Level Clinical Commentary
Dr. Caplan’s Take
What strikes me most about this digest is that only item 1 directly addresses cannabis policy while the remaining 19 entries concern synthetic cannabinoids and novel psychoactive substances, which suggests the DEA’s scheduling efforts are primarily focused on closing loopholes in designer drug markets rather than clarifying the legal framework for evidence-based cannabis therapeutics. The rescheduling of FDA-approved cannabis products from Schedule I to Schedule III in item 1 is clinically significant because it could facilitate legitimate research and reduce prescribing barriers, yet the volume of synthetic compound placements indicates we still lack adequate regulatory clarity around which cannabinoid formulations and delivery systems constitute approved medical products versus street drugs. As a practitioner, this landscape means I must remain cautious about recommending whole-plant cannabis or novel cannabinoid products until we have better clinical data, while recognizing
Clinical Perspective
The regulatory actions documented here reflect an ongoing pattern of synthetic drug scheduling aimed at controlling novel psychoactive substances that emerge faster than traditional legislative processes can address them. Most items involve synthetic cannabinoids, benzodiazepines, cathinones, and nitazenes, which are designer drugs created to circumvent existing controlled substance laws by altering the chemical structure of known drugs of abuse. From a clinical standpoint, these scheduling actions address a genuine public health concern, as these synthetic compounds often present unpredictable toxicity profiles and have contributed to emergency department visits and overdose deaths, particularly the opioid-like nitazenes that have recently appeared in illicit drug supplies.
Controlled SubstancesDrug SchedulingSynthetic DrugsRegulatory AffairsFDA
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS
Related Articles
Schedules of Controlled Substances: Placement of Diphenidine in Schedule ISchedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule ISchedules of Controlled Substances: Placement of Diphenidine in Schedule I
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 6, 2026Cannabis News✦ New
CED Clinical Relevance
#70
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
⚒ Policy Watch | Federal Register
cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesSchedule_Imarijuana_regulationstate_legislation
Clinical Summary
The Drug Enforcement Administration has placed four novel synthetic cannabinoids (4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA) into Schedule I, recognizing their high abuse potential and lack of accepted medical use. These designer cannabinoids, which are chemically distinct from cannabis and often more potent than THC, have been increasingly identified in illicit drug markets and emergency department presentations with severe adverse effects including psychosis, seizures, and cardiovascular complications. This regulatory action reflects the ongoing challenge of synthetic cannabinoid proliferation, where clandestine chemists continuously modify molecular structures to circumvent existing drug laws and create compounds that may pose greater health risks than naturally occurring cannabis. Clinicians should be aware that patients presenting with acute toxicity from synthetic cannabinoid use may not disclose use of these specific agents, as they are frequently misrepresented or unknown to consumers, and standard urine drug screening does not detect most novel synthetics. The scheduling reinforces the importance of detailed substance use history and clinical vigilance for atypical cannabinoid toxidromes, though it does not directly affect the treatment of patients who have already been exposed. Clinicians prescribing cannabis therapeutically should be prepared to distinguish between regulated medical cannabis products and illicit synthetic cannabinoids when counseling patients on safety and potential drug interactions.
Dr. Caplan’s Take
“The DEA’s continued reactive scheduling of synthetic cannabinoids like these four compounds is clinically necessary but administratively exhausting when we could have evidence-based cannabis policy instead, and it tells me that policymakers still don’t understand that prohibition itself drives patients toward increasingly dangerous analogs.”
Clinical Perspective
? The DEA’s scheduling of these novel synthetic cannabinoids reflects the ongoing challenge of regulating emerging substances that circumvent existing drug laws through minor chemical modifications. While scheduling decisions aim to limit harm by controlling distribution, the rapid pace of synthetic cannabinoid development means regulatory actions often lag behind street availability, and clinicians may encounter patients using these compounds before formal scheduling takes effect. These agents carry similar risks to other synthetic cannabinoids, including unpredictable potency, severe acute psychiatric symptoms, cannabinoid hyperemesis syndrome, and potential for physical dependence, though individual toxicity profiles remain poorly characterized in clinical literature. Providers should remain vigilant for presentations consistent with synthetic cannabinoid use in patients reporting “legal high” consumption or vaping of unfamiliar substances, and should counsel patients on the unknown pharmacology and regulatory uncertainty surrounding designer drugs. Awareness of scheduling updates and their approximate street emergence timing may help clinicians identify cases earlier and provide
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Related Articles
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule ISchedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule ISchedules of Controlled Substances: Placement of Diphenidine in Schedule I
📰 Source: https://www.federalregister.gov/documents/2026/05/01/2026-08517/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 6, 2026Cannabis News✦ New
CED Clinical Relevance
#70
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
⚒ Policy Watch | Federal Register
cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesCUMYL-PEGACLONESchedule_Istate_regulation
Clinical Summary
The Drug Enforcement Administration has placed CUMYL-PEGACLONE, a synthetic cannabinoid, into Schedule I of the Controlled Substances Act due to its high abuse potential and lack of accepted medical use. This regulatory action reflects the ongoing challenge of synthetic cannabinoids that are designed to evade existing drug scheduling by chemical modification while maintaining psychoactive effects similar to cannabis. For clinicians, this scheduling reinforces that patients presenting with acute intoxication or withdrawal from novel synthetic cannabinoids may not have access to evidence-based therapeutic options, as these substances fall outside standard cannabis medical protocols and toxicology monitoring. The placement also highlights the importance of taking detailed substance use histories that specifically ask about synthetic cannabinoids and “designer drugs,” which patients may not initially disclose or may not recognize as controlled substances. Clinicians should remain aware that the synthetic cannabinoid landscape continues to evolve, creating gaps between emerging compounds and regulatory frameworks that can complicate patient safety and treatment planning. Understanding DEA scheduling actions helps physicians recognize which substances have no legal medical role and should inform clinical counseling about risks associated with unregulated synthetic cannabinoid products.
Clinical Perspective
? The DEA’s emergency scheduling of CUMYL-PEGACLONE, a synthetic cannabinoid analog, reflects the ongoing regulatory challenge posed by designer drugs that circumvent existing controlled substance laws through minor chemical modifications. While this action addresses a specific compound, it underscores a broader clinical concern: synthetic cannabinoids continue to emerge faster than regulatory systems can respond, and patients presenting with acute toxicity from these agents may have limited information about what they’ve consumed. Clinicians should recognize that synthetic cannabinoid use carries higher risks of serious adverse effects including seizures, psychosis, and cardiovascular complications compared to cannabis, yet emergency scheduling of individual compounds does little to prevent exposure to the next generation of analogs already in circulation. The regulatory lag between market introduction and scheduling means healthcare providers must maintain high clinical suspicion for synthetic cannabinoid toxicity in patients with unexplained acute psychiatric or neurological symptoms, particularly in younger populations and those involved in
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Related Articles
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule ISchedules of Controlled Substances: Placement of Diphenidine in Schedule ISchedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
📰 Source: https://www.federalregister.gov/documents/2026/05/13/2026-09566/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 6, 2026Cannabis News✦ New
CED Clinical Relevance
#70
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
⚒ Policy Watch | Federal Register
cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesSchedule_I2-Fluorodeschloroketaminestate_regulation
Clinical Summary
The Drug Enforcement Administration has temporarily placed 2-fluorodeschloroketamine (2-FDCK), a synthetic ketamine analog, into Schedule I of the Controlled Substances Act, effective immediately. This action was taken due to emerging evidence of abuse potential and public health concerns surrounding this novel psychoactive substance, which has appeared in illicit drug markets and online vendors. While this regulation does not directly affect cannabis prescribing, it reflects the broader regulatory framework that governs controlled substances and demonstrates the DEA’s approach to rapidly scheduling novel drugs before extensive clinical evidence accumulates. Clinicians should be aware that similar synthetic analogs of established drugs may appear and be scheduled, and patients should understand that the availability and legal status of psychoactive substances can change quickly based on public health assessments. For clinicians treating patients with substance use disorders or those asking about emerging drugs, this scheduling action underscores the importance of staying informed about DEA scheduling decisions and discussing the risks of unregulated synthetic substances with patients.
Clinical Perspective
⚕️ The DEA’s temporary scheduling of 2-fluorodeschloroketamine (2-FDCK), a novel dissociative ketamine analog, reflects the ongoing challenge of regulating synthetic drugs that emerge faster than formal scheduling processes can accommodate. While this action addresses a public health concern by preventing distribution of an understudied compound with unknown safety and abuse potential, clinicians should recognize that scheduling decisions are based primarily on structural similarity to controlled substances and abuse risk rather than toxicology or therapeutic evidence. The lack of human safety data for 2-FDCK and related analogs means that emergency departments may encounter users with unpredictable adverse effects that differ from ketamine’s known pharmacology. Clinicians managing patients with suspected dissociative drug intoxication should maintain a broad differential diagnosis and avoid assuming standard ketamine-like presentations, while also recognizing that the rapid proliferation of novel analogs outpaces both regulatory and
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Related Articles
Schedules of Controlled Substances: Placement of Diphenidine in Schedule ISchedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule ISchedules of Controlled Substances: Placement of Diphenidine in Schedule I
📰 Source: https://www.federalregister.gov/documents/2026/05/22/2026-10253/schedules-of-controlled-substances-temporary-placement-of-2-fluorodeschloroketamine-in-schedule-i
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
June 6, 2026Cannabis News✦ New
CED Clinical Relevance
#70
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
⚒ Policy Watch | Federal Register
cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesdiphenidine_schedule_Istate_regulationmarijuana_legislation
Why This Matters
I’d be happy to help explain the clinical relevance of this article, but the summary section appears to be empty. Could you provide the summary text so I can write the sentences explaining why this scheduling decision matters for clinicians and patients?
Clinical Summary
The Drug Enforcement Administration has placed diphenidine, a synthetic dissociative drug structurally similar to phencyclidine, into Schedule I of the Controlled Substances Act. Diphenidine has emerged as a novel psychoactive substance with abuse potential and no recognized medical use, presenting clinical concerns similar to other illicit dissociatives. This regulatory action reflects the government’s response to evolving drug markets and the proliferation of designer drugs that circumvent existing scheduling restrictions. For clinicians, this placement underscores the importance of recognizing emerging synthetic drugs in the context of substance use disorders and acute intoxication presentations, as diphenidine may cause dissociative effects, altered consciousness, and potential for dependence. While this scheduling does not directly affect cannabis practice, it illustrates the regulatory mechanisms that govern controlled substances and highlights how scheduling decisions reflect public health priorities in managing novel drugs of abuse. Clinicians should remain vigilant for patients presenting with unexplained dissociative symptoms or novel drug use patterns, as recognition of emerging substances is essential for appropriate clinical management and patient counseling.
Clinical Perspective
? The DEA’s scheduling of diphenidine as a Schedule I controlled substance reflects ongoing regulatory efforts to address novel synthetic drugs that emerge faster than formal safety data can accumulate. Diphenidine, a dissociative compound chemically similar to ketamine and phencyclidine, poses uncertain but potentially serious risks given its mechanism of action and limited human safety literature, though clinical evidence of harm in humans remains sparse compared to established dissociatives. Clinicians should be aware that Schedule I placement does not necessarily indicate proven dangerousness but rather reflects concerns about abuse potential and lack of accepted medical use; however, the rapid proliferation of designer dissociatives warrants heightened suspicion for these agents in patients presenting with unexplained altered mental status, dissociative symptoms, or toxidromes inconsistent with common drugs of abuse. The practical implication is that emergency and primary care providers should maintain awareness of emerging synthetic drugs and consider them in
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
FAQThis News item was assembled from structured source metadata and pipeline scoring.Have thoughts on this? Share it:𝕏 Share on Xin Share on LinkedIn🦅 Share on BlueSky📷 Follow on Instagram📝 Read more on Substack🔔 Subscribe via RSS
Further Reading
CED Clinic BlogWhy Cannabis Works
Evidence WatchCannabis and Heart Health
CED Clinic BlogCannabis for Sleep
Related Articles
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule ISchedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule ICannabis Schedule III Rescheduling Impact on Medical Research and Patients
📰 Source: https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i
Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.
Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance
Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care [...]
Read more...
